2021-01-18 16:49:09 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': False, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': '/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_fr_comma/checkpoint_best.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out_fp32_best/fr_comma_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_comma', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=False, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_fr_comma/checkpoint_best.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out_fp32_best/fr_comma_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-18 16:49:10 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-18 16:49:10 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-18 16:49:10 | INFO | fairseq_cli.generate | loading model(s) from /global/lv71502/clang/fairseq/mBART_termeval/checkpoint_fr_comma/checkpoint_best.pt
2021-01-18 16:49:48 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.src
2021-01-18 16:49:48 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.label
2021-01-18 16:49:48 | INFO | fairseq.tasks.translation | ./postprocessed/en_comma test src-label 2024 examples
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise ; cardiovascular
H-1900	-0.35464897751808167	▁benefits ▁; ▁cardiovascular ▁system
D-1900	-0.35464897751808167	benefits ; cardiovascular system
P-1900	-1.0828 -0.3047 -0.2774 -0.2423 -0.1039 -0.1169
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse events
H-1988	-0.2158854752779007	
D-1988	-0.2158854752779007	
P-1988	-0.3676 -0.0641
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox proportional hazards models
H-712	-0.6213999390602112	
D-712	-0.6213999390602112	
P-712	-1.0962 -0.1466
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-0.6229628324508667	
D-1451	-0.6229628324508667	
P-1451	-1.0906 -0.1554
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.09823453426361084	▁EH
D-1528	-0.09823453426361084	EH
P-1528	-0.0418 -0.1030 -0.1499
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.4725989103317261	
D-664	-0.4725989103317261	
P-664	-0.8431 -0.1021
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.07203199714422226	
D-133	-0.07203199714422226	
P-133	-0.1028 -0.0412
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-1.0691990852355957	▁young ▁woman ▁; ▁family
D-1685	-1.0691990852355957	young woman ; family
P-1685	-3.8819 -0.7172 -0.7443 -0.8363 -0.0920 -0.1436
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.3618329167366028	
D-228	-0.3618329167366028	
P-228	-0.6674 -0.0562
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient ; hf
H-364	-0.7877270579338074	▁ HF
D-364	-0.7877270579338074	HF
P-364	-2.6929 -0.1089 -0.1288 -0.2204
S-949	No major complications occurred during follow-up.<unk>
T-949	complications ; follow-up
H-949	-0.3158878684043884	▁complica tions
D-949	-0.3158878684043884	complications
P-949	-0.9336 -0.0915 -0.1369 -0.1016
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting ; cell ; anand
H-1037	-0.3808538019657135	▁cell ▁; ▁Anand
D-1037	-0.3808538019657135	cell ; Anand
P-1037	-1.0611 -0.6364 -0.0009 -0.1570 -0.0489
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin ; injected
H-957	-0.1779112070798874	▁do xor ubi cin
D-957	-0.1779112070798874	doxorubicin
P-957	-0.2730 -0.0222 -0.0503 -0.1561 -0.4089 -0.1570
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors ; blood transfusions
H-1684	-1.025493860244751	▁blood ▁trans fusion s
D-1684	-1.025493860244751	blood transfusions
P-1684	-5.2606 -0.0399 -0.0251 -0.2711 -0.2322 -0.3240
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.3609149158000946	▁FM
D-18	-0.3609149158000946	FM
P-18	-0.8838 -0.1231 -0.0758
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse events
H-1916	-0.4576127529144287	
D-1916	-0.4576127529144287	
P-1916	-0.7631 -0.1522
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart failure
H-1066	-0.8329440355300903	▁devices ▁; ▁heart ▁failure
D-1066	-0.8329440355300903	devices ; heart failure
P-1066	-1.8971 -1.6525 -0.7282 -0.3703 -0.1406 -0.2090
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.8461799025535583	▁d XA
D-1496	-0.8461799025535583	dXA
P-1496	-1.0195 -0.6428 -1.4542 -0.2683
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver disease
H-233	-0.4530108571052551	▁Live r ▁disease
D-233	-0.4530108571052551	Liver disease
P-233	-1.1720 -0.0211 -0.4182 -0.5464 -0.1074
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.1543399542570114	
D-307	-0.1543399542570114	
P-307	-0.2292 -0.0795
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf ; pna
H-1699	-0.578094482421875	▁ HF ▁; ▁p na
D-1699	-0.578094482421875	HF ; pna
P-1699	-1.8452 -0.3083 -0.2872 -0.7163 -0.5820 -0.2175 -0.0902
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise ; cardiovascular ; health
H-1897	-1.3089377880096436	
D-1897	-1.3089377880096436	
P-1897	-2.4595 -0.1584
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal artery stenosis
H-1592	-0.16569620370864868	▁Ren al ▁arter y ▁sten osis
D-1592	-0.16569620370864868	Renal artery stenosis
P-1592	-0.0563 -0.1906 -0.1512 -0.2279 -0.0732 -0.1342 -0.3493 -0.1428
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective cohort study
H-1712	-0.5772733688354492	
D-1712	-0.5772733688354492	
P-1712	-1.0430 -0.1115
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute care surgery ; heart transplant
H-1279	-1.1866521835327148	▁surgery ▁; ▁heart ▁transplant
D-1279	-1.1866521835327148	surgery ; heart transplant
P-1279	-2.4823 -0.6010 -0.1525 -0.1388 -3.5617 -0.1836
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary end point ; inhospital ; mortality
H-190	-0.30043989419937134	hospital ▁mortal ity
D-190	-0.30043989419937134	hospital mortality
P-190	-0.9138 -0.1246 -0.1778 -0.1281 -0.1579
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.2545507848262787	▁molecular ▁mechanism
D-1607	-0.2545507848262787	molecular mechanism
P-1607	-0.2190 -0.5619 -0.1031 -0.1342
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.20280897617340088	▁tertia ry ▁refer ral ▁centre
D-1497	-0.20280897617340088	tertiary referral centre
P-1497	-0.0948 -0.0880 -0.0628 -0.0905 -0.7078 -0.2814 -0.0943
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-0.6886453628540039	▁EC
D-256	-0.6886453628540039	EC
P-256	-1.8091 -0.1529 -0.1040
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.4749661087989807	▁ HF
D-346	-0.4749661087989807	HF
P-346	-1.3382 -0.1117 -0.2431 -0.2069
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate models
H-241	-0.3890366554260254	
D-241	-0.3890366554260254	
P-241	-0.5776 -0.2005
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.07995046675205231	
D-1944	-0.07995046675205231	
P-1944	-0.1095 -0.0504
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.5687081217765808	
D-1982	-0.5687081217765808	
P-1982	-0.9719 -0.1655
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.45877817273139954	▁mortal ity
D-589	-0.45877817273139954	mortality
P-589	-1.3360 -0.2609 -0.1027 -0.1355
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic breathing ; heart beat
H-1345	-0.7442905902862549	▁breath ing ▁; ▁heart ▁beat
D-1345	-0.7442905902862549	breathing ; heart beat
P-1345	-3.3818 -0.4485 -0.3161 -0.5170 -0.2431 -0.1777 -0.1258
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.5694460272789001	
D-796	-0.5694460272789001	
P-796	-1.0003 -0.1386
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective cohort
H-211	-0.7055140137672424	▁DESIGN
D-211	-0.7055140137672424	DESIGN
P-211	-1.4000 -0.5362 -0.1803
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart failure ; latin america
H-1788	-0.5780104398727417	▁heart ▁failure ▁; ▁Latin ▁America
D-1788	-0.5780104398727417	heart failure ; Latin America
P-1788	-2.0105 -0.4441 -0.6011 -0.2773 -0.2719 -0.2353 -0.2059
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational cohort study
H-811	-0.4691329896450043	
D-811	-0.4691329896450043	
P-811	-0.8343 -0.1039
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.5486301183700562	
D-44	-0.5486301183700562	
P-44	-0.9190 -0.1783
S-422	Heart rate was minimally altered.<unk>
T-422	heart rate
H-422	-0.7080363035202026	▁Heart
D-422	-0.7080363035202026	Heart
P-422	-0.3571 -1.5223 -0.2447
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.2413623183965683	
D-1846	-0.2413623183965683	
P-1846	-0.3818 -0.1009
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.1833312064409256	▁doctor s
D-1686	-0.1833312064409256	doctors
P-1686	-0.2875 -0.1342 -0.2557 -0.0559
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart failure
H-1356	-0.6236114501953125	▁Nutrition ▁; ▁heart ▁failure
D-1356	-0.6236114501953125	Nutrition ; heart failure
P-1356	-1.3798 -1.4687 -0.2867 -0.3218 -0.1189 -0.1658
S-1620	SETTING: Northwest United States.<unk>
T-1620	united states
H-1620	-0.5270978808403015	▁nord west ▁United ▁States
D-1620	-0.5270978808403015	nordwest United States
P-1620	-1.8674 -0.2149 -0.6034 -0.1804 -0.2375 -0.0590
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.4007405638694763	▁Cross - sec tional
D-795	-0.4007405638694763	Cross-sectional
P-795	-1.1958 -0.0869 -0.1253 -0.6807 -0.1583 -0.1574
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.21601121127605438	▁unilateral
D-1595	-0.21601121127605438	unilateral
P-1595	-0.3848 -0.1196 -0.1437
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.5277631282806396	▁surgery
D-363	-0.5277631282806396	surgery
P-363	-1.4145 -0.0491 -0.1197
S-1683	She is going into heart failure.<unk>
T-1683	heart failure
H-1683	-0.44139713048934937	▁heart ▁failure
D-1683	-0.44139713048934937	heart failure
P-1683	-0.9646 -0.4634 -0.1232 -0.2144
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.30865368247032166	▁INTER ven tions
D-798	-0.30865368247032166	INTERventions
P-798	-0.7392 -0.4476 -0.1618 -0.1406 -0.0542
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.2546684443950653	
D-1249	-0.2546684443950653	
P-1249	-0.2791 -0.2302
S-979	Heart failure in the young.<unk>
T-979	heart failure
H-979	-0.5327451229095459	▁Heart ▁failure
D-979	-0.5327451229095459	Heart failure
P-979	-0.3665 -0.5088 -1.0176 -0.2382
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.20785392820835114	
D-1687	-0.20785392820835114	
P-1687	-0.3491 -0.0666
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.2937007546424866	▁c lin
D-1246	-0.2937007546424866	clin
P-1246	-0.6200 -0.0680 -0.3967 -0.0901
S-1248	Sci.<unk>
T-1248	
H-1248	-0.42056259512901306	▁Sci
D-1248	-0.42056259512901306	Sci
P-1248	-0.6131 -0.5099 -0.1387
S-1247	Trans.<unk>
T-1247	
H-1247	-0.6047834753990173	▁trans
D-1247	-0.6047834753990173	trans
P-1247	-0.2527 -1.4555 -0.1061
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.21634890139102936	
D-1963	-0.21634890139102936	
P-1963	-0.2528 -0.1799
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.3666832447052002	▁CHF
D-222	-0.3666832447052002	CHF
P-222	-0.0536 -0.9747 -0.0718
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic balance
H-1375	-0.1640263944864273	▁autonomi c ▁balance
D-1375	-0.1640263944864273	autonomic balance
P-1375	-0.3277 -0.2497 -0.0291 -0.0814 -0.1322
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral growth
H-511	-1.179314136505127	▁dynamique ▁; ▁competitive
D-511	-1.179314136505127	dynamique ; competitive
P-511	-2.8439 -0.5669 -1.4378 -0.8487 -0.1993
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.38757193088531494	▁inter media te ▁fra il ty
D-1005	-0.38757193088531494	intermediate frailty
P-1005	-0.3890 -0.0757 -0.2367 -0.1086 -0.2874 -1.7933 -0.0979 -0.1120
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.33424144983291626	▁ HF p EF
D-1078	-0.33424144983291626	HFpEF
P-1078	-1.2032 -0.2548 -0.0168 -0.2623 -0.1951 -0.0734
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 ; functional capacity
H-702	-1.0767908096313477	
D-702	-1.0767908096313477	
P-702	-2.0358 -0.1177
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end point
H-1763	-0.3629785478115082	
D-1763	-0.3629785478115082	
P-1763	-0.6574 -0.0685
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.18358121812343597	▁do d son
D-205	-0.18358121812343597	dodson
P-205	-0.3402 -0.0313 -0.1483 -0.3288 -0.0693
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.22123153507709503	
D-392	-0.22123153507709503	
P-392	-0.3242 -0.1183
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv fibrosis
H-280	-0.3550914227962494	▁LV ▁fibro sis ▁; ▁ ANS ▁mi ce
D-280	-0.3550914227962494	LV fibrosis ; ANS mice
P-280	-0.0672 -0.0738 -0.3167 -0.2758 -1.5933 -0.3118 -0.5670 -0.0990 -0.1672 -0.0789
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.3887569308280945	
D-126	-0.3887569308280945	
P-126	-0.6488 -0.1287
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness ; anemia
H-1679	-0.915292501449585	▁Jehovah s ▁Wit ness ▁; ▁an emia
D-1679	-0.915292501449585	Jehovahs Witness ; anemia
P-1679	-0.0332 -3.6150 -0.0248 -0.6338 -0.5345 -2.5823 -0.4918 -0.1598 -0.1624
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient ; medical ; conditions
H-1688	-0.21888293325901031	▁in patient ▁medical ▁conditions
D-1688	-0.21888293325901031	inpatient medical conditions
P-1688	-0.4389 -0.0145 -0.5270 -0.0100 -0.1022 -0.2207
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient ; hospital ; heart failure
H-1960	-1.1591451168060303	▁hospital ▁; ▁heart ▁failure
D-1960	-1.1591451168060303	hospital ; heart failure
P-1960	-2.6477 -0.7401 -3.0648 -0.2650 -0.0972 -0.1401
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended criteria cardiac transplantation
H-707	-0.17055194079875946	▁cardiac ▁transplant ation
D-707	-0.17055194079875946	cardiac transplantation
P-707	-0.2708 -0.3049 -0.0478 -0.1127 -0.1165
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated ; mixed linear models
H-325	-0.806501567363739	▁CO
D-325	-0.806501567363739	CO
P-325	-1.1350 -1.0862 -0.1984
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty ; hf
H-624	-1.0806845426559448	▁impact ▁; ▁ HF
D-624	-1.0806845426559448	impact ; HF
P-624	-2.1562 -0.9262 -2.6322 -0.0779 -0.5382 -0.1533
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary outcomes ; quality of life
H-1654	-0.9290091395378113	▁cognitive ▁function
D-1654	-0.9290091395378113	cognitive function
P-1654	-1.1320 -1.2355 -1.2120 -0.1365
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart failure ; mortality
H-204	-0.1951177716255188	▁Heart ▁failure ▁; ▁cognitive ▁im pair ment ▁; ▁mortal ity
D-204	-0.1951177716255188	Heart failure ; cognitive impairment ; mortality
P-204	-0.2554 -0.1195 -0.1522 -0.1459 -0.0207 -0.0098 -0.0443 -1.1127 -0.0708 -0.1612 -0.1194 -0.1294
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf ; hf
H-1309	-0.8408051133155823	▁ HF ▁; ▁ HF
D-1309	-0.8408051133155823	HF ; HF
P-1309	-2.0694 -0.2322 -1.0900 -1.6596 -0.1231 -0.4923 -0.2190
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up duration
H-495	-0.34334081411361694	▁media n ▁follow - up
D-495	-0.34334081411361694	median follow-up
P-495	-0.7593 -0.0537 -0.8372 -0.2799 -0.0138 -0.3515 -0.1079
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology ; hospital
H-812	-0.8265572190284729	▁card i ology ▁; ▁university ▁hospital
D-812	-0.8265572190284729	cardiology ; university hospital
P-812	-3.4454 -1.1082 -0.7581 -0.6450 -0.3060 -0.1467 -0.1343 -0.0686
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.28738293051719666	
D-575	-0.28738293051719666	
P-575	-0.5130 -0.0618
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart rate variability ; risk stratification ; cardiac ; patients
H-1584	-1.2084815502166748	▁Heart ▁rate ▁variabil ity ▁; ▁cardiac
D-1584	-1.2084815502166748	Heart rate variability ; cardiac
P-1584	-0.5349 -2.6295 -1.3995 -0.4726 -0.2987 -0.2839 -3.7411 -0.3076
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote ischemic conditioning ; patients ; heart failure
H-53	-0.6529385447502136	▁Remote ▁ ische mic ▁condition ing ▁; ▁heart ▁failure
D-53	-0.6529385447502136	Remote ischemic conditioning ; heart failure
P-53	-1.2768 -0.5441 -1.0593 -0.1014 -0.0212 -0.6151 -0.4178 -2.4561 -0.3496 -0.1547 -0.1863
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air ; heart failure
H-1805	-0.11365234851837158	▁air ▁pollution ▁; ▁heart ▁failure
D-1805	-0.11365234851837158	air pollution ; heart failure
P-1805	-0.0107 -0.0340 -0.2119 -0.0917 -0.1113 -0.1373 -0.1986
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.5500618815422058	
D-1399	-0.5500618815422058	
P-1399	-0.9540 -0.1461
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.9332372546195984	▁Sham - opera ted
D-1339	-0.9332372546195984	Sham-operated
P-1339	-0.2189 -0.1626 -0.0684 -2.2266 -2.6116 -0.3112
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.1994270384311676	
D-885	-0.1994270384311676	
P-885	-0.2974 -0.1015
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.10813914984464645	
D-311	-0.10813914984464645	
P-311	-0.1313 -0.0850
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-0.7141376733779907	▁policy
D-312	-0.7141376733779907	policy
P-312	-1.3715 -0.6959 -0.0750
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-0.7200618386268616	
D-749	-0.7200618386268616	
P-749	-1.3891 -0.0510
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.7593952417373657	
D-1754	-0.7593952417373657	
P-1754	-1.4080 -0.1108
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-0.9441124796867371	▁tax ono my
D-1125	-0.9441124796867371	taxonomy
P-1125	-3.7827 -0.0832 -0.5855 -0.1355 -0.1336
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.9856082201004028	▁rates ▁; ▁CHF
D-673	-0.9856082201004028	rates ; CHF
P-673	-1.5444 -0.2350 -2.8629 -0.1171 -0.1686
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart failure
H-1886	-0.9686676859855652	▁Heart ▁failure ▁; ▁uk
D-1886	-0.9686676859855652	Heart failure ; uk
P-1886	-1.0181 -0.6328 -0.5975 -2.8108 -0.5210 -0.2318
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients ; followed up
H-825	-0.39163583517074585	
D-825	-0.39163583517074585	
P-825	-0.6810 -0.1022
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients ; cardiovascular disease
H-247	-0.5819502472877502	▁cardiovascular ▁disease
D-247	-0.5819502472877502	cardiovascular disease
P-247	-1.4913 -0.6273 -0.0882 -0.1210
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf ; mi
H-1101	-0.7819020748138428	▁ HF ▁; ▁MI
D-1101	-0.7819020748138428	HF ; MI
P-1101	-3.1371 -0.1627 -0.2937 -0.4693 -0.4388 -0.1898
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal support
H-1296	-0.35029852390289307	
D-1296	-0.35029852390289307	
P-1296	-0.6187 -0.0819
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart failure ; disease ; therapeutics
H-1073	-0.6823373436927795	▁Heart ▁failure ▁; ▁disease
D-1073	-0.6823373436927795	Heart failure ; disease
P-1073	-0.3933 -0.3405 -0.9102 -0.7945 -1.5511 -0.1045
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary outcomes ; hemostasis
H-1116	-0.3021499514579773	▁hemos tas is
D-1116	-0.3021499514579773	hemostasis
P-1116	-0.9999 -0.2736 -0.0524 -0.0601 -0.1247
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective matched cohort study
H-1619	-0.2765670418739319	
D-1619	-0.2765670418739319	
P-1619	-0.4561 -0.0970
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 ; gene expression ; heart failure
H-169	-1.6674432754516602	▁cas pas e ▁; ▁heart
D-169	-1.6674432754516602	caspase ; heart
P-169	-3.7058 -0.0941 -0.4497 -0.3397 -1.4710 -5.3308 -0.2811
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic ; heart failure ; outcomes
H-1198	-0.5565100312232971	▁di ure tic ▁use ▁; ▁heart ▁failure
D-1198	-0.5565100312232971	diuretic use ; heart failure
P-1198	-0.2868 -0.0265 -1.3606 -1.8566 -0.4401 -0.1708 -0.4795 -0.1947 -0.1930
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute right heart failure ; pulmonary hypertension
H-1090	-0.5363012552261353	▁right ▁heart ▁failure ▁; ▁pulmonar y ▁hyper tension
D-1090	-0.5363012552261353	right heart failure ; pulmonary hypertension
P-1090	-3.9286 -0.7708 -0.1393 -0.1587 -0.0026 -0.0562 -0.0104 -0.0641 -0.1115 -0.1210
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart failure ; patients ; bisphosphonates
H-1534	-1.1471483707427979	▁Heart ▁; ▁bis phos phon ates
D-1534	-1.1471483707427979	Heart ; bisphosphonates
P-1534	-0.4255 -7.2323 -0.2064 -0.0252 -0.0322 -0.6407 -0.3493 -0.2655
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients ; functional capacity ; symptoms
H-550	-0.7649394273757935	
D-550	-0.7649394273757935	
P-550	-1.3313 -0.1986
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology ; diagnosed
H-352	-0.21862336993217468	▁MR ▁; ▁MS
D-352	-0.21862336993217468	MR ; MS
P-352	-0.3286 -0.3984 -0.1007 -0.1959 -0.0696
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients ; hypertension
H-1889	-0.38644587993621826	▁hyper tension
D-1889	-0.38644587993621826	hypertension
P-1889	-1.0359 -0.2196 -0.0645 -0.2258
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american ; hf
H-1843	-0.8990541696548462	▁ HF
D-1843	-0.8990541696548462	HF
P-1843	-2.5078 -0.4052 -0.5723 -0.1109
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart rate ; arterial pressure
H-424	-0.41902562975883484	▁Heart ▁rate ▁; ▁arterial ▁pressure
D-424	-0.41902562975883484	Heart rate ; arterial pressure
P-424	-0.3782 -0.8678 -0.2391 -0.1081 -0.9583 -0.2341 -0.1475
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up ; patients
H-1009	-0.2850834131240845	
D-1009	-0.2850834131240845	
P-1009	-0.4816 -0.0886
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic hf ; death
H-1796	-0.18348312377929688	▁Chro nic ▁ HF
D-1796	-0.18348312377929688	Chronic HF
P-1796	-0.0637 -0.0733 -0.1484 -0.0175 -0.6473 -0.1506
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac amyloidosis
H-997	-0.16160131990909576	▁Card iac ▁a my lo idos is
D-997	-0.16160131990909576	Cardiac amyloidosis
P-997	-0.2200 -0.0330 -0.0285 -0.2105 -0.3052 -0.1635 -0.2043 -0.2003 -0.0892
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training ; heart failure ; patients
H-1911	-0.616012454032898	▁Robot - assist ed ▁training ▁; ▁heart ▁failure
D-1911	-0.616012454032898	Robot-assisted training ; heart failure
P-1911	-0.6432 -0.2318 -0.0021 -0.1344 -2.0566 -0.5652 -0.4949 -0.4033 -1.3609 -0.2676
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.2528323233127594	
D-1616	-0.2528323233127594	
P-1616	-0.4224 -0.0833
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.6479816436767578	▁Interna l ▁reli ability ▁; ▁cro n bach
D-786	-0.6479816436767578	Internal reliability ; cronbach
P-786	-2.7686 -0.2007 -1.1531 -0.3833 -0.4267 -0.1943 -0.0453 -0.0471 -1.1083 -0.1525
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients ; hfpef
H-787	-0.5310571193695068	▁ HF p EF
D-787	-0.5310571193695068	HFpEF
P-787	-2.2959 -0.1476 -0.0484 -0.3851 -0.1202 -0.1890
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection fraction ; bnp
H-194	-0.20286910235881805	▁e je ction ▁ fraction ▁; ▁sex ▁; ▁b NP
D-194	-0.20286910235881805	ejection fraction ; sex ; bNP
P-194	-0.6266 -0.2921 -0.0132 -0.1656 -0.0029 -0.1204 -0.3338 -0.2031 -0.0540 -0.1679 -0.2640 -0.1909
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic ; medication ; death
H-507	-0.26370882987976074	▁Pig s ▁; ▁anti ar rhythm ic ▁medication
D-507	-0.26370882987976074	Pigs ; antiarrhythmic medication
P-507	-0.3571 -0.0493 -0.7361 -0.0820 -0.4172 -0.0260 -0.3041 -0.0906 -0.3387 -0.2360
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients ; therapy ; beta blockade
H-1736	-0.7322584390640259	▁beta ▁block ade
D-1736	-0.7322584390640259	beta blockade
P-1736	-3.0645 -0.3025 -0.1143 -0.0757 -0.1042
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf ; patients ; intubated
H-219	-0.6721005439758301	▁CHF
D-219	-0.6721005439758301	CHF
P-219	-0.0198 -1.8213 -0.1752
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical ; hypothermic circulatory arrest
H-598	-0.3825199007987976	▁sur g ical ▁tac tics ▁; ▁circula tory ▁arrest
D-598	-0.3825199007987976	surgical tactics ; circulatory arrest
P-598	-0.5890 -0.2044 -0.2629 -1.5381 -0.6312 -0.1590 -0.3329 -0.1844 -0.0504 -0.1041 -0.1513
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary outcomes ; functional capacity ; quality of life
H-616	-1.0866860151290894	
D-616	-1.0866860151290894	
P-616	-2.0407 -0.1327
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end point
H-266	-0.33869460225105286	
D-266	-0.33869460225105286	
P-266	-0.6131 -0.0643
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected ; patients ; systolic dysfunction
H-1069	-0.9089736342430115	▁sy sto lic ▁dys function
D-1069	-0.9089736342430115	systolic dysfunction
P-1069	-3.0664 -0.4628 -2.0647 -0.0207 -0.5264 -0.1158 -0.1059
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.4750045835971832	▁Literatur e
D-32	-0.4750045835971832	Literature
P-32	-1.4878 -0.1561 -0.1393 -0.1168
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.4402581751346588	
D-804	-0.4402581751346588	
P-804	-0.7507 -0.1299
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise ; quality of life ; heart failure
H-612	-1.822266697883606	▁heart ▁failure
D-612	-1.822266697883606	heart failure
P-612	-6.4761 -0.5236 -0.1231 -0.1662
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.1912900060415268	▁implant ed ▁monitoring ▁devices
D-156	-0.1912900060415268	implanted monitoring devices
P-156	-0.0016 -0.1929 -0.4376 -0.3202 -0.1051 -0.0903
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.3742977976799011	
D-1469	-0.3742977976799011	
P-1469	-0.6904 -0.0582
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient ; conditions
H-0	-0.6705090403556824	▁patient ▁safety ▁; ▁conditions
D-0	-0.6705090403556824	patient safety ; conditions
P-0	-1.7271 -0.8414 -1.0379 -0.0374 -0.1322 -0.2471
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea ; afterload
H-518	-1.2363204956054688	▁HR ▁; ▁after load ▁burde n
D-518	-1.2363204956054688	HR ; afterload burden
P-518	-4.0745 -0.6575 -4.2104 -0.0317 -0.4298 -0.0448 -0.1998 -0.2419
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths ; strokes
H-778	-0.5685009360313416	▁stroke s
D-778	-0.5685009360313416	strokes
P-778	-2.1065 -0.0490 -0.0492 -0.0693
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.5675745010375977	▁Media n ▁age
D-677	-0.5675745010375977	Median age
P-677	-0.4705 -0.0503 -1.2516 -0.9336 -0.1320
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras ; atherosclerosis
H-1594	-0.5218517184257507	▁ RAS ▁; ▁at hero sc ler osis
D-1594	-0.5218517184257507	RAS ; atherosclerosis
P-1594	-1.3300 -0.0325 -0.3041 -0.2066 -0.2825 -1.1690 -1.4014 -0.1848 -0.1254 -0.1821
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty ; heart failure
H-1000	-1.1829876899719238	▁fra il ty ▁in ▁heart ▁failure
D-1000	-1.1829876899719238	frailty in heart failure
P-1000	-4.1339 -1.1405 -1.4977 -0.9156 -0.6499 -0.2464 -0.6443 -0.2356
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas ; heart failure ; disease
H-1479	-0.41364428400993347	▁micro RNA s ▁in ▁heart ▁failure ▁; ▁disease ▁management
D-1479	-0.41364428400993347	microRNAs in heart failure ; disease management
P-1479	-0.9654 -0.0051 -0.0376 -0.8922 -0.6413 -0.5537 -0.7872 -0.2059 -0.0708 -0.2747 -0.1162
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard ratios ; cox regression analysis
H-1770	-0.47392967343330383	▁co x ▁re gression
D-1770	-0.47392967343330383	cox regression
P-1770	-1.0512 -0.0543 -0.1627 -0.1861 -1.1436 -0.2457
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss ; exercise ; training ; outcomes
H-1932	-0.39468419551849365	▁PS SS
D-1932	-0.39468419551849365	PSSS
P-1932	-0.4618 -0.3890 -0.6196 -0.1084
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart failure with preserved ejection fraction
H-1885	-0.43297672271728516	▁management ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1885	-0.43297672271728516	management ; heart failure ; ejection fraction
P-1885	-1.4184 -1.0360 -0.2572 -0.2156 -0.1487 -1.0457 -0.4001 -0.1376 -0.0931 -0.0005 -0.1890 -0.2539
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology ; bromodomain ; halts ; heart failure
H-1033	-0.5946745276451111	▁Card i ology ▁; ▁inhibi tion ▁; ▁heart ▁failure
D-1033	-0.5946745276451111	Cardiology ; inhibition ; heart failure
P-1033	-0.3639 -0.6819 -0.6369 -0.2514 -2.4989 -0.0513 -1.1785 -0.4129 -0.2048 -0.1707 -0.0901
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.7144129872322083	
D-1759	-0.7144129872322083	
P-1759	-1.2208 -0.2080
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin ; congestive heart failure
H-633	-0.21022608876228333	▁vaso press in ▁; ▁con ges tive ▁heart ▁failure
D-633	-0.21022608876228333	vasopressin ; congestive heart failure
P-633	-0.0547 -0.0632 -0.7303 -0.2933 -0.1789 -0.0459 -0.1707 -0.3334 -0.2092 -0.1266 -0.1063
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral stenosis ; medical treatment ; heart failure
H-332	-0.5718621611595154	▁Mit ral ▁sten osis ▁rever sed ▁; ▁medical ▁treatment ▁; ▁heart ▁failure
D-332	-0.5718621611595154	Mitral stenosis reversed ; medical treatment ; heart failure
P-332	-1.0908 -0.0378 -0.5101 -0.3089 -1.4183 -1.3437 -0.3256 -0.8219 -0.4677 -0.5404 -0.0579 -0.5574 -0.3319 -0.1935
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart failure ; hospitalization ; cardiovascular death
H-410	-0.600736141204834	▁heart ▁failure ▁hospital ization ▁; ▁cardiovascular ▁death
D-410	-0.600736141204834	heart failure hospitalization ; cardiovascular death
P-410	-0.5842 -0.5733 -1.5451 -1.3136 -0.5604 -0.0106 -0.4811 -0.1937 -0.1446
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity ; patients ; breast cancer
H-669	-0.18764132261276245	▁Tras tuz um ab - related ▁cardio toxic ity ▁; ▁breast ▁cancer
D-669	-0.18764132261276245	Trastuzumab-related cardiotoxicity ; breast cancer
P-669	-0.2831 -0.0049 -0.0257 -0.2255 -0.1270 -0.1842 -0.0419 -0.1608 -0.3581 -0.3436 -0.2866 -0.2420 -0.1959 -0.1477
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart failure ; hf ; therapy
H-1067	-0.8350062966346741	▁implant s ▁; ▁heart ▁failure ▁; HF
D-1067	-0.8350062966346741	implants ; heart failure ;HF
P-1067	-2.8875 -0.7671 -0.3285 -1.5331 -0.4025 -0.1733 -0.0692 -1.1916 -0.1622
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality ; sts
H-159	-1.2527246475219727	▁beneficia l ▁effect ▁; ▁mortal ity
D-159	-1.2527246475219727	beneficial effect ; mortality
P-159	-5.5147 -0.1628 -0.5707 -0.9034 -0.0496 -0.3522 -2.3244 -0.1438
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 ; hf
H-1211	-0.17663228511810303	▁p de 2 ▁; ▁ HF
D-1211	-0.17663228511810303	pde2 ; HF
P-1211	-0.4898 -0.0210 -0.0530 -0.1779 -0.3374 -0.1333 -0.0818 -0.1189
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital ; coprimary outcome
H-1651	-0.515425443649292	▁Night s ▁spent ▁; ▁hospital
D-1651	-0.515425443649292	Nights spent ; hospital
P-1651	-0.5496 -0.0343 -1.5447 -1.0023 -0.0717 -0.2414 -0.1640
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart failure ; public ; health
H-1606	-0.8173369765281677	▁Heart ▁failure ▁; ▁public ▁health
D-1606	-0.8173369765281677	Heart failure ; public health
P-1606	-1.2554 -0.6814 -0.2569 -0.0194 -0.4983 -2.7948 -0.2152
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative ; albumin
H-539	-0.9299129247665405	▁implant e ▁; ▁album in
D-539	-0.9299129247665405	implante ; albumin
P-539	-3.7168 -0.7093 -0.8315 -0.2109 -0.5366 -0.4041 -0.1003
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet ; aortic pressure
H-581	-0.6548901200294495	▁a or tic ▁pressure ▁cur ve
D-581	-0.6548901200294495	aortic pressure curve
P-581	-1.8826 -0.2850 -0.9879 -1.2964 -0.3364 -0.0327 -0.1851 -0.2331
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician ; outcomes ; discharge
H-1414	-0.44913509488105774	▁physician ▁continu ity
D-1414	-0.44913509488105774	physician continuity
P-1414	-0.0707 -0.0109 -0.0915 -1.9371 -0.1356
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication ; sst2
H-403	-0.5629234910011292	▁Medica tion ▁; ▁s ST 2
D-403	-0.5629234910011292	Medication ; sST2
P-403	-0.1854 -0.0498 -1.7634 -0.0223 -1.3710 -0.1909 -0.6702 -0.2503
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-0.6593595743179321	▁réseau ▁meta - analys is
D-150	-0.6593595743179321	réseau meta-analysis
P-150	-1.4840 -2.5071 -0.1676 -0.1070 -0.1248 -0.1149 -0.1101
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac ; symptoms ; congenital ; lesions
H-983	-0.7781997919082642	▁Card iac
D-983	-0.7781997919082642	Cardiac
P-983	-0.6242 -0.1689 -2.1759 -0.1438
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone ; systolic heart failure
H-437	-0.308808833360672	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-437	-0.308808833360672	spironolactone ; systolic heart failure
P-437	-0.6917 -0.0226 -0.0487 -0.0268 -0.1616 -0.7517 -0.1404 -0.9263 -0.3826 -0.2635 -0.1523 -0.1375
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular scaffolds ; heart ; pathology
H-989	-0.6190525889396667	▁e RK ▁; ▁molecular ▁sc af fold s ▁; ▁heart ▁path ologie
D-989	-0.6190525889396667	eRK ; molecular scaffolds ; heart pathologie
P-989	-1.9067 -0.0181 -0.8648 -0.2238 -0.8189 -0.7832 -0.1239 -0.0188 -0.4361 -0.0977 -1.6618 -1.3049 -0.1775 -0.2305
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional ms ; reported ; patients ; degenerative mr
H-339	-0.5561513900756836	▁fonction al ▁MS ▁; ▁de genera tive ▁MR
D-339	-0.5561513900756836	fonctional MS ; degenerative MR
P-339	-4.2323 -0.0563 -0.0664 -0.3208 -0.5211 -0.1244 -0.0218 -0.0095 -0.1245 -0.0843
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology ; chronic heart failure ; bisoprolol
H-645	-0.6572539806365967	▁chronic ▁heart ▁failure ▁; ▁bis o pro lol
D-645	-0.6572539806365967	chronic heart failure ; bisoprolol
P-645	-4.0663 -1.4050 -0.3323 -0.0845 -0.0502 -0.1672 -0.0267 -0.0823 -0.1866 -0.1717
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart failure ; hf ; leading ; mortality ; society
H-1034	-0.3952913284301758	▁Heart ▁failure ▁; HF ▁; ▁mortal ity
D-1034	-0.3952913284301758	Heart failure ;HF ; mortality
P-1034	-0.6123 -0.1014 -0.1245 -0.2854 -0.5919 -0.5887 -0.1688 -0.9293 -0.1552
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate adjustment ; cox proportional hazards models
H-785	-0.3419288396835327	▁co x ▁proportion al ▁hazard s
D-785	-0.3419288396835327	cox proportional hazards
P-785	-0.3245 -0.0986 -0.0378 -0.0525 -0.2369 -0.4054 -1.3972 -0.1823
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician ; hospital ; physician
H-1726	-0.6832934021949768	▁physician ▁; ▁hospital ▁; ▁physician ▁special ty
D-1726	-0.6832934021949768	physician ; hospital ; physician specialty
P-1726	-0.3358 -2.1393 -0.1353 -2.2562 -0.0415 -0.4637 -0.5044 -0.1271 -0.1463
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan ; vasopressin type 2 receptor antagonist
H-1195	-0.34505146741867065	▁Tol va p tan ▁; ▁vaso press in ▁; ▁receptor
D-1195	-0.34505146741867065	Tolvaptan ; vasopressin ; receptor
P-1195	-0.1023 -0.0052 -0.0905 -0.0533 -0.1313 -0.0262 -0.0628 -0.9081 -0.7892 -0.0036 -1.8503 -0.1179
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs ; expenditures
H-1238	-0.4251036047935486	▁Ar rhythm ia - related ▁costs
D-1238	-0.4251036047935486	Arrhythmia-related costs
P-1238	-1.0784 -0.1653 -0.6994 -0.0720 -0.0818 -0.7932 -0.3602 -0.1505
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.595445990562439	▁ metric ▁choice ▁; ▁read mission ▁metri cs
D-134	-0.595445990562439	metric choice ; readmission metrics
P-134	-0.8473 -0.2064 -1.8721 -0.2524 -1.1395 -0.4620 -0.2415 -0.6369 -0.1490 -0.1475
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.5096448659896851	▁read mission ▁ metric
D-145	-0.5096448659896851	readmission metric
P-145	-1.4295 -0.2238 -0.2354 -0.0768 -0.9944 -0.0978
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.6104055643081665	
D-1998	-0.6104055643081665	
P-1998	-1.1081 -0.1127
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.7064957618713379	▁Media n
D-1758	-0.7064957618713379	Median
P-1758	-0.3821 -0.0675 -2.2464 -0.1301
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.2544400095939636	
D-1261	-0.2544400095939636	
P-1261	-0.3926 -0.1162
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-0.43283891677856445	
D-958	-0.43283891677856445	
P-958	-0.7458 -0.1198
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-1.1287344694137573	▁black ▁patients
D-1634	-1.1287344694137573	black patients
P-1634	-1.2492 -2.8672 -0.1820 -0.2165
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-0.9170909523963928	▁ET ▁; ▁CHF
D-261	-0.9170909523963928	ET ; CHF
P-261	-3.2019 -0.4358 -0.6060 -0.2000 -0.1418
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable hf
H-481	-0.7296651005744934	▁reli ability ▁; ▁ HF
D-481	-0.7296651005744934	reliability ; HF
P-481	-2.5110 -0.0970 -0.3881 -1.8892 -0.0518 -0.0953 -0.0753
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.6063748598098755	
D-1839	-0.6063748598098755	
P-1839	-1.1120 -0.1007
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality of life
H-1919	-0.8686728477478027	
D-1919	-0.8686728477478027	
P-1919	-1.6316 -0.1057
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.15106233954429626	▁pro pens ity
D-1837	-0.15106233954429626	propensity
P-1837	-0.2219 -0.0256 -0.2642 -0.1114 -0.1322
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb ; correlated ; baseline ; hrqol
H-840	-0.33749380707740784	▁h gb ▁; ▁base line ▁HR Qo L
D-840	-0.33749380707740784	hgb ; baseline HRQoL
P-840	-0.0231 -0.0342 -0.2306 -1.3781 -0.0630 -0.2672 -0.0194 -0.9979 -0.1901 -0.1715
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved ejection fraction ; outcomes
H-1464	-0.5509657859802246	▁e je ction ▁ fraction
D-1464	-0.5509657859802246	ejection fraction
P-1464	-1.2710 -0.5585 -0.0561 -0.1607 -0.0020 -1.5473 -0.2611
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic ; biomarkers ; chronic heart failure
H-1471	-0.2793116271495819	▁bio mark ers ▁; ▁chronic ▁heart ▁failure
D-1471	-0.2793116271495819	biomarkers ; chronic heart failure
P-1471	-0.2946 -0.0040 -0.1142 -0.4040 -0.2893 -0.8374 -0.2733 -0.1294 -0.1677
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated hf ; cardiovascular ; hospitalization
H-1797	-0.5086567997932434	▁ HF ▁; ▁cardiovascular ▁hospital ization
D-1797	-0.5086567997932434	HF ; cardiovascular hospitalization
P-1797	-2.0978 -0.0738 -0.2711 -0.2941 -0.4773 -0.5668 -0.1245 -0.1639
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients ; cardiac ; inflammatory ; biomarkers
H-1914	-0.2053183913230896	▁cardiac ▁; ▁infla mma tory ▁bio mark ers
D-1914	-0.2053183913230896	cardiac ; inflammatory biomarkers
P-1914	-0.0809 -0.9440 -0.0520 -0.2523 -0.2320 -0.0170 -0.0035 -0.0784 -0.1226 -0.2705
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed ; mortality ; random-effects models
H-64	-0.4287989139556885	▁mortal ity
D-64	-0.4287989139556885	mortality
P-64	-0.0482 -0.2820 -1.1608 -0.2242
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes ; patients ; heart failure ; emergency department
H-461	-1.1204495429992676	▁heart ▁failure ▁; ▁emergency ▁department
D-461	-1.1204495429992676	heart failure ; emergency department
P-461	-3.2460 -0.9775 -1.8687 -0.3006 -0.3254 -0.8892 -0.2357
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological ; acute heart failure
H-1465	-0.5222862958908081	▁Pharma c ological ▁treatment ▁; ▁a cute ▁heart ▁failure
D-1465	-0.5222862958908081	Pharmacological treatment ; acute heart failure
P-1465	-2.3756 -0.0178 -0.1703 -0.9560 -0.5300 -0.0394 -0.0248 -1.0001 -0.2070 -0.2678 -0.1562
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping ; baseline ; heart failure
H-1059	-1.1340216398239136	▁heart ▁failure
D-1059	-1.1340216398239136	heart failure
P-1059	-3.2658 -0.5537 -0.5225 -0.1941
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal ; heartmate ii
H-772	-0.45714330673217773	▁off - pump ▁ster nal ▁spar ing ▁approach ▁; ▁Heart Mate ▁II ▁exchange
D-772	-0.45714330673217773	off-pump sternal sparing approach ; HeartMate II exchange
P-772	-0.2045 -0.0426 -0.0344 -2.1735 -0.0295 -0.0740 -0.0738 -2.0024 -0.1394 -0.3804 -0.0834 -1.2380 -0.0176 -0.2196 -0.1440
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis ; patients ; implantation
H-913	-0.2683735191822052	▁di al ysis ▁; ▁implant ation
D-913	-0.2683735191822052	dialysis ; implantation
P-913	-0.1009 -0.0527 -0.0934 -1.0172 -0.5313 -0.0295 -0.1661 -0.1559
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary angiography ; lesions
H-349	-0.36343836784362793	▁Corona ry ▁ang i ography
D-349	-0.36343836784362793	Coronary angiography
P-349	-0.0320 -0.2262 -0.0270 -1.4504 -0.2021 -0.4999 -0.1064
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic phenotype ; fontan
H-223	-0.4248824417591095	▁Hem o dynamic ▁; ▁fail ing ▁Font an
D-223	-0.4248824417591095	Hemodynamic ; failing Fontan
P-223	-0.2007 -0.1057 -0.0094 -0.9250 -1.3865 -0.2742 -0.1435 -0.4992 -0.6210 -0.0837
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient ; surgery ; echocardiography
H-358	-0.5816126465797424	▁MS ▁; ▁e cho card i ography
D-358	-0.5816126465797424	MS ; echocardiography
P-358	-0.3586 -0.6843 -3.0643 -0.1168 -0.1190 -0.5740 -0.1693 -0.0847 -0.0635
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise ; life expectancy
H-1902	-0.3435570299625397	
D-1902	-0.3435570299625397	
P-1902	-0.5231 -0.1641
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate analyses
H-826	-0.36851948499679565	
D-826	-0.36851948499679565	
P-826	-0.6223 -0.1148
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart failure ; cox proportional hazard analyses
H-1537	-1.145721197128296	▁co x ▁proportion al ▁hazard
D-1537	-1.145721197128296	cox proportional hazard
P-1537	-5.9045 -0.0094 -0.5717 -0.0175 -0.0980 -1.1756 -0.2433
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized ; walking ; patients ; severe heart failure
H-567	-1.6165494918823242	▁Nordic ▁walking
D-567	-1.6165494918823242	Nordic walking
P-567	-0.4636 -1.6768 -4.0919 -0.2339
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric ; self-care of heart failure index version 6.2
H-1503	-0.4912082552909851	▁Psycho metric ▁testing ▁; ▁Self - Car e ▁of ▁Heart ▁Fail ure ▁Index
D-1503	-0.4912082552909851	Psychometric testing ; Self-Care of Heart Failure Index
P-1503	-1.4048 -0.0157 -0.6574 -0.1724 -0.2788 -0.0198 -1.5793 -0.0597 -0.8437 -0.2476 -0.0315 -0.0467 -1.4248 -0.4053 -0.1805
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient ; postoperatively ; multiorgan failure ; sepsis
H-551	-0.41047778725624084	▁multi organ ▁failure ▁; ▁se psis
D-551	-0.41047778725624084	multiorgan failure ; sepsis
P-551	-2.1930 -0.0253 -0.1807 -0.6638 -0.0186 -0.0025 -0.0777 -0.1222
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients ; acute kidney injury ; postoperatively
H-975	-0.31256628036499023	▁a cute ▁ki dne y ▁injury
D-975	-0.31256628036499023	acute kidney injury
P-975	-0.9015 -0.0075 -0.3697 -0.4082 -0.0430 -0.2549 -0.3296 -0.1861
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max ; significance
H-1255	-0.28535592555999756	▁VO 2 max
D-1255	-0.28535592555999756	VO2max
P-1255	-0.5531 -0.1173 -0.0140 -0.5718 -0.1706
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive statistics ; cox proportional hazards models
H-675	-0.28885865211486816	▁co x ▁proportion al ▁hazard s ▁models
D-675	-0.28885865211486816	cox proportional hazards models
P-675	-0.3339 -0.0131 -0.0319 -0.0327 -0.1854 -0.3688 -1.3130 -0.1244 -0.1964
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle heart failure model
H-2011	-0.41827327013015747	▁Seattle ▁Heart ▁Fail ure ▁Model
D-2011	-0.41827327013015747	Seattle Heart Failure Model
P-2011	-1.9404 -0.4239 -0.0346 -0.0222 -0.2364 -0.1674 -0.1031
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-1.3364390134811401	▁health care ▁programme s
D-603	-1.3364390134811401	healthcare programmes
P-603	-7.0693 -0.2637 -0.3083 -0.0926 -0.1695 -0.1151
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart failure
H-1204	-0.9984695315361023	▁heart ▁failure
D-1204	-0.9984695315361023	heart failure
P-1204	-3.0298 -0.6827 -0.1293 -0.1520
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.1863965541124344	
D-1854	-0.1863965541124344	
P-1854	-0.2954 -0.0774
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.14363765716552734	
D-1923	-0.14363765716552734	
P-1923	-0.2185 -0.0687
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.3959192633628845	
D-800	-0.3959192633628845	
P-800	-0.7000 -0.0918
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.4895574152469635	▁ab normal ▁cardiac
D-746	-0.4895574152469635	abnormal cardiac
P-746	-0.7972 -0.0138 -0.0342 -1.4851 -0.1174
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.39149025082588196	
D-1028	-0.39149025082588196	
P-1028	-0.7105 -0.0725
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.7227055430412292	
D-1206	-0.7227055430412292	
P-1206	-1.3316 -0.1138
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated ; hf
H-608	-0.42810308933258057	▁HR ▁; ▁ HF
D-608	-0.42810308933258057	HR ; HF
P-608	-0.3523 -0.4693 -1.4593 -0.0297 -0.1404 -0.1176
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.4481109082698822	
D-591	-0.4481109082698822	
P-591	-0.7212 -0.1750
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug ; japan
H-1197	-0.7883976697921753	▁drug ▁; ▁Japan
D-1197	-0.7883976697921753	drug ; Japan
P-1197	-1.6071 -1.3721 -0.8068 -0.0723 -0.0837
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.2345239520072937	▁bio mark ers
D-70	-0.2345239520072937	biomarkers
P-70	-0.9169 -0.0084 -0.0536 -0.0651 -0.1286
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome ; tug test
H-799	-0.9306836128234863	▁m AIN ▁o UTC OME ▁ME as ure ▁; ▁tu g
D-799	-0.9306836128234863	mAIN oUTCOME MEasure ; tug
P-799	-1.0979 -0.0615 -2.1740 -0.0027 -0.0804 -1.8210 -0.4054 -1.4648 -0.3357 -1.5289 -1.6679 -1.3843 -0.0743
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients ; esrd
H-394	-0.5953960418701172	▁ES RD
D-394	-0.5953960418701172	ESRD
P-394	-1.3437 -0.3006 -0.4043 -0.3331
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart failure with preserved left ventricular ejection fraction
H-1299	-0.35602661967277527	▁Heart ▁failure ▁; ▁vent ri cular ▁e je ction ▁ fraction
D-1299	-0.35602661967277527	Heart failure ; ventricular ejection fraction
P-1299	-0.2075 -0.2487 -0.0732 -1.3552 -0.9285 -0.1324 -0.1432 -0.3692 -0.4611 -0.2059 -0.0005 -0.3139 -0.1892
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome ; all-cause readmissions
H-1580	-0.8623233437538147	▁m AIN ▁o UTC OME
D-1580	-0.8623233437538147	mAIN oUTCOME
P-1580	-0.7582 -0.1587 -3.1401 -0.0097 -0.2568 -1.6249 -0.0878
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence ; systolic hf
H-1798	-0.4717964231967926	▁sy sto lic ▁ HF
D-1798	-0.4717964231967926	systolic HF
P-1798	-2.0278 -0.3078 -0.4105 -0.2319 -0.0439 -0.1697 -0.1109
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary outcome ; patient ; post
H-617	-0.7560643553733826	▁patient ▁satisfaction
D-617	-0.7560643553733826	patient satisfaction
P-617	-1.5025 -0.4375 -0.9539 -0.1304
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients ; lvad ; implantation
H-545	-0.24339988827705383	▁implant ation
D-545	-0.24339988827705383	implantation
P-545	-0.5349 -0.0406 -0.2660 -0.1321
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation ; postsystolic function
H-331	-0.8510342836380005	▁posts y sto lic
D-331	-0.8510342836380005	postsystolic
P-331	-1.5197 -0.1532 -0.8154 -1.2269 -1.2615 -0.1295
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication ; resting hemodynamics
H-828	-0.2318723201751709	▁medication ▁; ▁rest ing ▁hem o dynamic s
D-828	-0.2318723201751709	medication ; resting hemodynamics
P-828	-0.5286 -0.2658 -0.1320 -0.0982 -0.6919 -0.2974 -0.0438 -0.0422 -0.1270 -0.0919
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis ; pathophysiological
H-1276	-0.5624745488166809	▁pat ho phy si ological ▁origin
D-1276	-0.5624745488166809	pathophysiological origin
P-1276	-1.7262 -0.0848 -0.1474 -0.3096 -0.3759 -1.6084 -0.1140 -0.1336
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac ; cardiac hypertrophy
H-1782	-0.46845537424087524	▁a ac ▁; ▁cardiac ▁hyper trop hy
D-1782	-0.46845537424087524	aac ; cardiac hypertrophy
P-1782	-0.4602 -2.5289 -0.1236 -0.4798 -0.1417 -0.0075 -0.0980 -0.1710 -0.2054
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha ; esc
H-1908	-0.45758193731307983	AHA ▁; ▁ESC
D-1908	-0.45758193731307983	AHA ; ESC
P-1908	-0.6964 -0.1515 -0.2866 -0.9970 -0.1564
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician ; outcomes ; patients ; heart failure
H-1720	-0.9795448184013367	▁Physic ian ▁; ▁heart ▁failure
D-1720	-0.9795448184013367	Physician ; heart failure
P-1720	-1.3990 -0.5649 -1.2078 -2.7603 -0.5000 -0.1713 -0.2535
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal muscle ; exercise capacity ; fontan circulation
H-1491	-0.8720902800559998	▁s kelet al ▁muscle ▁ab normal ities ▁; ▁circulation
D-1491	-0.8720902800559998	skeletal muscle abnormalities ; circulation
P-1491	-4.7133 -0.0294 -0.0962 -0.2285 -0.1269 -0.0275 -0.6884 -0.1421 -3.2136 -0.2066 -0.1206
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission ; hospital ; heart failure ; discharge
H-147	-0.6361765265464783	▁hospital ▁; ▁heart ▁failure
D-147	-0.6361765265464783	hospital ; heart failure
P-147	-1.7774 -0.9912 -0.3683 -0.2467 -0.2660 -0.1675
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease ; lead ; hypertension ; kidney failure
H-1598	-0.3426770567893982	▁progressive ▁disease ▁; ▁hyper tension ▁; ▁ki dne y ▁failure
D-1598	-0.3426770567893982	progressive disease ; hypertension ; kidney failure
P-1598	-0.7944 -1.2884 -0.1364 -0.4169 -0.0579 -0.0996 -0.9612 -0.0607 -0.0581 -0.0668 -0.0853 -0.0864
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients ; chronic kidney disease ; ckd
H-898	-0.5782091021537781	▁chronic ▁ki dne y ▁disease ▁; CK d
D-898	-0.5782091021537781	chronic kidney disease ;CKd
P-898	-0.7900 -1.1647 -0.5986 -0.2722 -0.8611 -0.3363 -0.1524 -1.0987 -0.2933 -0.2147
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income ; expenditure ; health
H-1792	-1.411060094833374	▁gross ▁income ▁; ▁health ▁per ▁capita
D-1792	-1.411060094833374	gross income ; health per capita
P-1792	-6.6922 -0.4107 -0.0912 -2.8956 -0.6435 -0.0018 -0.3894 -0.1641
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations ; hospital ; longitudinal ; change
H-143	-0.3057647943496704	▁hospital ▁longitud in al ▁change
D-143	-0.3057647943496704	hospital longitudinal change
P-143	-0.7393 -0.7093 -0.1974 -0.1294 -0.0306 -0.1011 -0.2333
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr variability ; cardiac death
H-1589	-0.8781576156616211	▁HR ▁; ▁sud den ▁; ▁cardiac ▁death
D-1589	-0.8781576156616211	HR ; sudden ; cardiac death
P-1589	-2.1604 -1.9296 -0.5943 -0.0354 -2.0363 -0.2168 -0.6226 -0.1085 -0.1994
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient ; circulation
H-1824	-0.3435547649860382	▁circulation
D-1824	-0.3435547649860382	circulation
P-1824	-0.7956 -0.0830 -0.1521
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic blood pressure
H-1048	-0.5927218198776245	▁ toxic ity ▁; ▁system ic ▁blood ▁pressure
D-1048	-0.5927218198776245	toxicity ; systemic blood pressure
P-1048	-0.0864 -0.1902 -0.2494 -0.1225 -2.7786 -0.4051 -0.6929 -1.1052 -0.1447 -0.1523
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.1555720716714859	
D-1881	-0.1555720716714859	
P-1881	-0.2224 -0.0887
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.3173621892929077	
D-1576	-0.3173621892929077	
P-1576	-0.5167 -0.1180
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.42461517453193665	▁ therapy
D-1965	-0.42461517453193665	therapy
P-1965	-1.4938 -0.0552 -0.0506 -0.0989
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north america
H-75	-0.9004121422767639	▁en roll ment
D-75	-0.9004121422767639	enrollment
P-75	-2.8225 -0.0048 -0.0772 -1.5225 -0.0751
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.25628623366355896	▁c PG s
D-1848	-0.25628623366355896	cPGs
P-1848	-0.5746 -0.3454 -0.0506 -0.1558 -0.1550
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.5841048359870911	▁MS
D-372	-0.5841048359870911	MS
P-372	-1.1114 -0.5793 -0.0616
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity ; outcomes
H-709	-0.3864090144634247	
D-709	-0.3864090144634247	
P-709	-0.6753 -0.0976
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute heart failure
H-1014	-0.45326220989227295	▁a cute ▁heart ▁failure
D-1014	-0.45326220989227295	acute heart failure
P-1014	-0.6800 -0.0151 -0.3752 -0.0996 -1.4008 -0.1489
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients ; heart failure
H-1821	-0.7510988116264343	▁patients ▁; ▁heart ▁failure
D-1821	-0.7510988116264343	patients ; heart failure
P-1821	-1.8377 -1.6240 -0.4292 -0.2727 -0.1985 -0.1444
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic ; hf
H-1072	-1.1587053537368774	▁ HF
D-1072	-1.1587053537368774	HF
P-1072	-3.8831 -0.4670 -0.1310 -0.1537
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end stage heart failure
H-1669	-0.9990484714508057	▁end ▁stage ▁heart ▁failure
D-1669	-0.9990484714508057	end stage heart failure
P-1669	-4.4722 -0.5122 -0.6960 -0.1812 -0.0692 -0.0634
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician ; hf
H-1732	-0.8298337459564209	▁ HF
D-1732	-0.8298337459564209	HF
P-1732	-2.4024 -0.1556 -0.6657 -0.0957
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial function ; flow-mediated dilatation
H-253	-0.3660229444503784	▁en dot heli al ▁function ▁; ▁flow - media ted ▁di la tation
D-253	-0.3660229444503784	endothelial function ; flow-mediated dilatation
P-253	-0.3836 -0.3974 -0.1018 -0.0149 -1.7043 -0.4954 -0.2304 -0.0096 -0.0423 -1.0717 -0.0801 -0.6142 -0.0113 -0.1837 -0.1496
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone ; severe heart failure
H-1701	-0.41399216651916504	▁Race ▁; ▁spi rono lac tone ▁; ▁heart ▁failure
D-1701	-0.41399216651916504	Race ; spironolactone ; heart failure
P-1701	-1.3461 -0.3382 -0.7916 -0.0341 -0.1401 -0.0850 -0.3604 -0.8186 -0.3102 -0.1468 -0.1829
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients ; heart failure ; cardiac rehabilitation
H-568	-0.6546941995620728	▁heart ▁failure ▁; ▁cardiac ▁rehabilita tion
D-568	-0.6546941995620728	heart failure ; cardiac rehabilitation
P-568	-3.1332 -0.5451 -0.6788 -0.3358 -0.1373 -0.0629 -0.1962 -0.1482
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control ; outcomes
H-1232	-0.6174705028533936	▁ Rhythm - ▁; ▁rate - control
D-1232	-0.6174705028533936	Rhythm- ; rate-control
P-1232	-0.2098 -0.0546 -0.0925 -3.8869 -0.0781 -0.1181 -0.3437 -0.5474 -0.2262
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise ; training ; outcomes
H-1640	-0.8044884204864502	▁race ▁; ▁exercise
D-1640	-0.8044884204864502	race ; exercise
P-1640	-1.5970 -1.6877 -0.1300 -0.4787 -0.1291
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia ; patients ; heart disease
H-39	-1.2552818059921265	▁an emia ▁; ▁heart ▁disease
D-39	-1.2552818059921265	anemia ; heart disease
P-39	-3.4295 -0.5296 -1.4512 -1.8397 -1.2599 -0.1032 -0.1738
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians ; patients ; hf
H-1724	-0.837748110294342	▁physician s ▁; ▁ HF
D-1724	-0.837748110294342	physicians ; HF
P-1724	-1.8907 -0.0546 -0.4349 -3.1679 -0.0441 -0.1634 -0.1087
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial infarction
H-1137	-0.4199487864971161	▁My o card ial ▁in far ction ▁; ▁Wi star ▁rat s
D-1137	-0.4199487864971161	Myocardial infarction ; Wistar rats
P-1137	-0.1529 -0.1278 -0.0570 -0.3510 -0.0132 -1.1666 -0.0903 -0.2847 -2.7670 -0.2347 -0.1988 -0.0322 -0.2420 -0.1611
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad ai
H-543	-1.0475472211837769	▁l VAD ▁AI
D-543	-1.0475472211837769	lVAD AI
P-543	-4.2712 -0.1144 -0.6206 -0.1110 -0.1206
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients ; surgical
H-547	-1.0954484939575195	▁AI
D-547	-1.0954484939575195	AI
P-547	-2.3740 -0.7724 -0.1400
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus rhythm ; adverse outcomes
H-1644	-0.3474244177341461	▁sinus ▁ rhythm ▁; ▁AF
D-1644	-0.3474244177341461	sinus rhythm ; AF
P-1644	-1.0162 -0.0661 -0.0883 -0.5480 -0.5638 -0.0659 -0.0837
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public reporting ; patients ; hospitals
H-1689	-0.819942831993103	▁public ▁report ing
D-1689	-0.819942831993103	public reporting
P-1689	-0.3993 -0.2661 -0.1241 -3.2127 -0.0975
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative ; operative ; outcomes
H-299	-0.1386277973651886	
D-299	-0.1386277973651886	
P-299	-0.1800 -0.0973
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth ; longitudinal ; medicare
H-1617	-0.810060441493988	▁services ▁management ▁; ▁tele health ▁; ▁medica re
D-1617	-0.810060441493988	services management ; telehealth ; medicare
P-1617	-5.9267 -0.1481 -0.2488 -0.1201 -0.2164 -0.4946 -0.0370 -0.0181 -0.7367 -0.1541
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal ; diagnostic ; filling pressures
H-490	-0.8862178325653076	▁fill ing ▁pressure s
D-490	-0.8862178325653076	filling pressures
P-490	-3.7757 -0.2075 -0.9138 -0.1565 -0.1570 -0.1068
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity pathway analysis
H-875	-0.39247673749923706	▁ingen u ity ▁path way
D-875	-0.39247673749923706	ingenuity pathway
P-875	-0.2114 -0.2590 -0.1629 -1.4135 -0.1288 -0.4046 -0.1671
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf ; chromatin hyperacetylation
H-1036	-0.6131596565246582	▁ HF ▁; ▁chr omat in ▁hyper ace ty lation
D-1036	-0.6131596565246582	HF ; chromatin hyperacetylation
P-1036	-2.3580 -0.0592 -0.3468 -0.0252 -0.0134 -1.3964 -0.0320 -0.1228 -2.7440 -0.0235 -0.1301 -0.1065
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing ; nursing
H-1397	-0.9069870710372925	▁nur sing
D-1397	-0.9069870710372925	nursing
P-1397	-1.2674 -0.3969 -1.8229 -0.1408
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute heart failure
H-468	-0.4592283368110657	▁a cute ▁heart ▁failure
D-468	-0.4592283368110657	acute heart failure
P-468	-0.9082 -0.0286 -1.1414 -0.1452 -0.2903 -0.2416
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse events
H-1263	-0.18612153828144073	
D-1263	-0.18612153828144073	
P-1263	-0.3229 -0.0493
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-0.5864288210868835	▁ms
D-370	-0.5864288210868835	ms
P-370	-1.0092 -0.6549 -0.0953
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-0.9267706274986267	▁gr LS ▁; ▁CV ▁; ▁AF
D-810	-0.9267706274986267	grLS ; CV ; AF
P-810	-0.5694 -2.1295 -0.2112 -0.9339 -1.8481 -1.4584 -0.1581 -0.1055
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit index
H-1006	-0.3418006896972656	▁deficit ▁index
D-1006	-0.3418006896972656	deficit index
P-1006	-0.2461 -0.3449 -0.6735 -0.1026
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.08711390942335129	
D-1855	-0.08711390942335129	
P-1855	-0.1060 -0.0682
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.20714221894741058	
D-1165	-0.20714221894741058	
P-1165	-0.3550 -0.0593
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-0.27166908979415894	▁mortal ity
D-1696	-0.27166908979415894	mortality
P-1696	-0.6063 -0.2965 -0.0576 -0.1263
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients ; hospitals
H-3	-0.6091253757476807	▁hospital s
D-3	-0.6091253757476807	hospitals
P-3	-2.0814 -0.2000 -0.0695 -0.0857
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs duration
H-888	-0.7106232643127441	▁QR s
D-888	-0.7106232643127441	QRs
P-888	-0.2554 -1.3472 -1.0831 -0.1568
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort study
H-1829	-0.7834245562553406	
D-1829	-0.7834245562553406	
P-1829	-1.4506 -0.1162
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf ; unilateral renal dnx ; cardiac ; autonomic balance
H-1372	-0.18379032611846924	▁CHF ▁; ▁unilateral ▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance
D-1372	-0.18379032611846924	CHF ; unilateral renal DNx ; cardiac autonomic balance
P-1372	-0.0117 -0.1235 -0.3929 -0.0543 -0.4788 -0.0021 -0.2783 -0.0566 -0.1962 -0.4710 -0.0577 -0.1585 -0.1077
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral regurgitation ; hf ; symptoms ; surgery
H-362	-0.4291647672653198	▁Mit ral ▁re gur gi tation ▁; ▁ HF
D-362	-0.4291647672653198	Mitral regurgitation ; HF
P-362	-2.1038 -0.0895 -0.0600 -0.1135 -0.6023 -0.1603 -0.3403 -0.6570 -0.0348 -0.3318 -0.2275
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone system inhibitors ; heart failure
H-1486	-0.4112864136695862	▁re nin - angi oten sin - al do ster one ▁system ▁inhibi tors ▁; ▁heart ▁failure
D-1486	-0.4112864136695862	renin-angiotensin-aldosterone system inhibitors ; heart failure
P-1486	-0.1247 -0.2759 -0.0309 -0.0075 -0.1233 -1.6928 -0.0673 -0.0181 -0.4208 -0.1261 -1.1518 -0.3782 -0.1216 -1.3293 -0.5963 -0.0575 -0.9038 -0.1886 -0.1999
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic ; anaerobic threshold ; heart failure
H-1752	-0.37008675932884216	▁ana ero bic ▁thre s hold ▁; ▁heart ▁failure
D-1752	-0.37008675932884216	anaerobic threshold ; heart failure
P-1752	-0.8455 -0.6547 -0.5376 -0.5431 -0.0383 -0.2309 -0.5063 -0.0909 -0.3733 -0.1230 -0.1273
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical ; patients ; functional ms
H-373	-0.6811248064041138	▁MS
D-373	-0.6811248064041138	MS
P-373	-1.8473 -0.0911 -0.1049
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients ; patients ; echocardiographic
H-813	-0.6583320498466492	▁af ▁; ▁e cho car dio graphic ▁examina tion
D-813	-0.6583320498466492	af ; echocardiographic examination
P-813	-0.6518 -2.4957 -0.6269 -0.2026 -0.0912 -0.9651 -0.5592 -1.1685 -0.1897 -0.1578 -0.1330
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses ; patients ; disease
H-2020	-1.1057076454162598	▁Nur ses
D-2020	-1.1057076454162598	Nurses
P-2020	-2.7150 -0.1104 -1.4957 -0.1017
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic ; accounting ; cost
H-1582	-0.5595962405204773	▁économique ▁sav ings ▁; ▁coût
D-1582	-0.5595962405204773	économique savings ; coût
P-1582	-0.8297 -0.3862 -0.4489 -0.6873 -0.8962 -0.5914 -0.0774
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf ; pb
H-1349	-0.45265212655067444	▁PV f ▁; ▁ PB ▁; ▁amplitud e
D-1349	-0.45265212655067444	PVf ; PB ; amplitude
P-1349	-0.0446 -0.1448 -0.1062 -1.9739 -0.0226 -1.7867 -0.2131 -0.0404 -0.1179 -0.0764
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life ; patients
H-161	-0.5017421841621399	
D-161	-0.5017421841621399	
P-161	-0.8057 -0.1978
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital ; heart ; lesions
H-985	-0.2446432262659073	▁con geni tal ▁heart ▁les ions
D-985	-0.2446432262659073	congenital heart lesions
P-985	-1.0349 -0.0161 -0.0839 -0.4224 -0.2049 -0.0415 -0.0558 -0.0976
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf ; surgical
H-353	-0.2596805989742279	▁MS ▁; HF ▁; ▁sur g ical ▁indica tion ▁; ▁MS
D-353	-0.2596805989742279	MS ;HF ; surgical indication ; MS
P-353	-0.7256 -0.2269 -0.5335 -0.2266 -0.2789 -0.0699 -0.1096 -0.0087 -0.0321 -0.7384 -0.2384 -0.0903 -0.0972
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu ; mortality
H-582	-0.3132408857345581	▁ ICU ▁mortal ity
D-582	-0.3132408857345581	ICU mortality
P-582	-0.3376 -0.0195 -0.3318 -0.1655 -0.9060 -0.1190
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray ; genes ; heart failure
H-1605	-0.5928441286087036	▁bio informati c ▁; ▁micro arra y ▁; ▁heart ▁failure
D-1605	-0.5928441286087036	bioinformatic ; microarray ; heart failure
P-1605	-0.3392 -0.0097 -0.1772 -1.1513 -0.4762 -0.1333 -0.0690 -0.9500 -2.9037 -0.5450 -0.1923 -0.1671
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up ; cardiovascular events ; deaths
H-974	-0.37237316370010376	▁cardiovascular ▁events
D-974	-0.37237316370010376	cardiovascular events
P-974	-0.2852 -0.5898 -0.5062 -0.1083
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic ; outcomes ; hf
H-1202	-0.8200922012329102	▁di ure tic ▁use ▁; HF
D-1202	-0.8200922012329102	diuretic use ;HF
P-1202	-0.2451 -0.0461 -1.3707 -2.0131 -0.3097 -2.4049 -0.0758 -0.0954
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad ; systolic hf ; prognostic
H-1183	-0.2643805146217346	▁CAD ▁; ▁cause ▁; ▁sy sto lic ▁ HF
D-1183	-0.2643805146217346	CAD ; cause ; systolic HF
P-1183	-0.2216 -0.1210 -0.3362 -0.9866 -0.2494 -0.1867 -0.3258 -0.1805 -0.0170 -0.2118 -0.0715
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin ; inflammation ; metabolism ; heart disease
H-940	-0.412322074174881	▁ inflammation ▁; ▁metabolism ▁; ▁heart ▁disease
D-940	-0.412322074174881	inflammation ; metabolism ; heart disease
P-940	-1.0494 -0.2151 -0.1823 -0.0683 -0.2456 -0.2019 -1.3799 -0.1471 -0.2214
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 ; therapy
H-401	-0.5682992339134216	▁BB ▁ therapy
D-401	-0.5682992339134216	BB therapy
P-401	-2.0792 -0.3698 -0.0383 -0.1832 -0.1709
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart block ; pulmonary artery ; bivp
H-322	-0.2841542661190033	▁Heart ▁block ▁; ▁pulmonar y ▁arter y ▁snar ed ▁; ▁Bi VP
D-322	-0.2841542661190033	Heart block ; pulmonary artery snared ; BiVP
P-322	-0.9227 -0.3557 -0.1949 -0.0096 -0.0546 -0.0303 -0.3502 -0.2918 -0.1018 -0.2483 -1.0236 -0.0477 -0.2275 -0.1195
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance ; attrition
H-1319	-0.8300202488899231	
D-1319	-0.8300202488899231	
P-1319	-1.5907 -0.0693
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt ; patients
H-905	-0.5112185478210449	▁c rte ▁; ▁di al ysis - dependent ▁patients
D-905	-0.5112185478210449	crte ; dialysis-dependent patients
P-905	-0.4592 -1.9262 -0.4327 -0.5356 -0.1062 -0.0951 -0.1072 -0.1312 -1.4785 -0.1839 -0.1675
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.21727703511714935	▁beta - block ers
D-865	-0.21727703511714935	beta-blockers
P-865	-0.5143 -0.0519 -0.1083 -0.1227 -0.3862 -0.1202
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf ; patients
H-217	-0.4501904547214508	▁CHF
D-217	-0.4501904547214508	CHF
P-217	-0.1910 -1.0209 -0.1387
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-1.1307538747787476	▁RM
D-163	-1.1307538747787476	RM
P-163	-3.0978 -0.1201 -0.1744
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.8059573769569397	▁ HF
D-556	-0.8059573769569397	HF
P-556	-2.9421 -0.0989 -0.1145 -0.0684
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac function ; catheter
H-1143	-0.34568899869918823	▁Card iac ▁function ▁; ▁pressure - volu me ▁conduct ance ▁cat heter ▁system
D-1143	-0.34568899869918823	Cardiac function ; pressure-volume conductance catheter system
P-1143	-0.1644 -0.1723 -2.1527 -0.1845 -0.3360 -0.0285 -0.0070 -0.0448 -0.2116 -0.0609 -0.5910 -0.0080 -0.7171 -0.3978 -0.1089
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence ; idiopathic dilated cardiomyopathy
H-1741	-0.1928374171257019	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1741	-0.1928374171257019	idiopathic dilated cardiomyopathy
P-1741	-0.6167 -0.0164 -0.0137 -0.1168 -0.1230 -0.2473 -0.0993 -0.5363 -0.2733 -0.0150 -0.1452 -0.1110
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded protein response ; cardiac sodium ; systolic ; heart failure
H-1079	-0.8710898756980896	▁un fold ed ▁protein ▁; ▁cardiac ▁so dium ▁current ▁; ▁sy sto lic ▁human ▁heart ▁failure
D-1079	-0.8710898756980896	unfolded protein ; cardiac sodium current ; systolic human heart failure
P-1079	-5.7033 -0.0002 -0.0555 -0.6446 -1.5507 -0.8520 -1.0396 -0.0131 -0.4241 -0.1622 -2.6484 -0.0654 -0.2705 -1.2076 -0.4678 -0.2024 -0.1975 -0.1746
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia ; prognostic ; patients ; heart failure
H-529	-0.7384455800056458	▁hypo album in emia
D-529	-0.7384455800056458	hypoalbuminemia
P-529	-0.9971 -0.0767 -0.4543 -0.0901 -2.5752 -0.2373
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient ; diagnosed ; hypertensive lv dysfunction
H-350	-0.15936803817749023	▁hyper tensi ve ▁LV ▁dys function ▁; ▁MR ▁; ▁MS
D-350	-0.15936803817749023	hypertensive LV dysfunction ; MR ; MS
P-350	-0.1251 -0.0504 -0.0479 -0.0106 -0.0216 -0.0795 -0.1129 -0.3750 -0.1500 -0.7840 -0.0887 -0.0667
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis ; hf ; etiologies
H-1795	-0.6324796676635742	▁c d ▁ HF
D-1795	-0.6324796676635742	cd HF
P-1795	-1.3125 -0.7548 -1.0010 -0.1584 -0.4359 -0.1322
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin receptor neprilysin inhibitor ; heart failure
H-1461	-0.40357813239097595	▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁; ▁heart ▁failure
D-1461	-0.40357813239097595	angiotensin receptor neprilysin inhibitor ; heart failure
P-1461	-0.2618 -1.3360 -0.1155 -0.5624 -0.0548 -1.0808 -0.0457 -0.2536 -0.1056 -0.1289 -1.0119 -0.1491 -0.6024 -0.1999 -0.1454
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western blot ; immunohistochemistry ; electron microscopy
H-1252	-0.20881472527980804	▁Western ▁blot ▁; ▁immun oh isto che mist ry ▁; ▁electro n ▁micro s copy
D-1252	-0.20881472527980804	Western blot ; immunohistochemistry ; electron microscopy
P-1252	-0.9433 -0.0136 -0.8407 -0.0013 -0.0228 -0.2285 -0.1134 -0.1233 -0.0441 -0.1785 -0.0005 -0.0150 -0.0970 -0.3579 -0.0512 -0.2883 -0.2306
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic dysfunction ; patients ; peripheral artery disease
H-1566	-0.37839141488075256	▁dia sto lic ▁dys function ▁; ▁per i pher al ▁arter y ▁disease
D-1566	-0.37839141488075256	diastolic dysfunction ; peripheral artery disease
P-1566	-0.0632 -0.4036 -1.5339 -0.0230 -0.2083 -0.1765 -0.5509 -0.4354 -0.0276 -0.2025 -0.0807 -0.6997 -0.9582 -0.1736 -0.1387
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic cardiomyopathy ; mortality
H-67	-0.6223581433296204	▁i sche mic ▁cardio my o pathy ▁; ▁mortal ity
D-67	-0.6223581433296204	ischemic cardiomyopathy ; mortality
P-67	-1.4713 -0.0097 -0.0517 -0.0490 -0.2424 -0.3654 -0.0131 -0.1802 -4.4748 -0.3085 -0.0985 -0.2036
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical ; hfpef
H-943	-0.4582035541534424	▁h f f
D-943	-0.4582035541534424	hff
P-943	-1.4386 -0.2310 -0.2635 -0.2565 -0.1013
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients ; heart transplant ; ecct
H-714	-1.0522581338882446	▁implant ▁; ▁EC CT
D-714	-1.0522581338882446	implant ; ECCT
P-714	-3.5063 -0.9284 -1.3780 -0.1948 -0.1463 -0.1598
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome ; hdl
H-254	-0.6213399171829224	▁prote ome ▁; ▁HD L ▁parti cles ▁; ▁shot gun ▁ LC - MS ▁; MS
D-254	-0.6213399171829224	proteome ; HDL particles ; shotgun LC-MS ;MS
P-254	-1.0367 -0.9697 -0.4257 -0.5472 -2.1714 -0.0569 -0.0327 -0.3044 -0.0874 -0.0362 -2.9483 -0.2368 -0.0277 -0.1113 -1.5194 -0.4026 -0.1502 -0.1195
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty ; hf
H-632	-0.7410637736320496	▁Fra il ty ▁; ▁ HF
D-632	-0.7410637736320496	Frailty ; HF
P-632	-1.4397 -0.6490 -1.3646 -0.0748 -1.3930 -0.0342 -0.8629 -0.1103
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota ; hf
H-1003	-0.46954312920570374	▁South e a stern ▁Minnesota ▁residents ▁; ▁ HF
D-1003	-0.46954312920570374	Southeastern Minnesota residents ; HF
P-1003	-2.6978 -0.0276 -0.1377 -0.0212 -0.0329 -0.9847 -0.3192 -0.5541 -0.0373 -0.2277 -0.1248
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left bundle branch block
H-1153	-1.038907527923584	▁bran ch ▁; ▁block ▁electric al ▁activa tion
D-1153	-1.038907527923584	branch ; block electrical activation
P-1153	-4.7031 -0.3678 -1.2356 -1.5527 -0.3457 -0.0532 -0.7753 -0.0879 -1.1070 -0.1608
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4 inhibitors ; drugs
H-1834	-0.3998589813709259	▁h HF ▁; ▁d p -4 ▁inhibi tors ▁; ▁drugs
D-1834	-0.3998589813709259	hHF ; dp-4 inhibitors ; drugs
P-1834	-0.0049 -0.7763 -0.1177 -0.3518 -1.0410 -0.1014 -0.1359 -0.6827 -0.6046 -0.7914 -0.0945 -0.0959
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins ; tac
H-872	-0.7791693806648254	▁ TAC ▁; ▁path ways
D-872	-0.7791693806648254	TAC ; pathways
P-872	-2.6133 -0.2491 -1.4949 -0.7555 -0.0922 -0.1314 -0.1177
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac cachexia
H-9	-0.3909437656402588	▁Card iac ▁cache xia ▁; cc
D-9	-0.3909437656402588	Cardiac cachexia ;cc
P-9	-0.7430 -0.0274 -0.0614 -0.0915 -0.2046 -0.5427 -1.3605 -0.0964
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling pathways ; cardiac remodelling
H-992	-0.5408498644828796	▁signal ling ▁; ▁adapt ive ▁; ▁mal adapt ive ▁cardiac ▁remodel ling
D-992	-0.5408498644828796	signalling ; adaptive ; maladaptive cardiac remodelling
P-992	-2.2674 -1.0841 -0.9544 -1.2310 -0.0106 -0.8446 -0.2625 -0.0348 -0.0134 -0.1974 -0.0721 -0.2136 -0.1831 -0.2028
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications ; dialysis ; patients
H-908	-0.34049302339553833	▁di al ysis
D-908	-0.34049302339553833	dialysis
P-908	-0.8413 -0.0742 -0.0997 -0.5324 -0.1549
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end point ; neurological ; cardiovascular events
H-1872	-1.4230332374572754	▁neurologi cal ▁; ▁cardiovascular
D-1872	-1.4230332374572754	neurological ; cardiovascular
P-1872	-3.9186 -0.3407 -1.7798 -0.0107 -2.3760 -0.1125
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary disease ; leading ; heart failure
H-981	-0.48271697759628296	▁corona ry ▁disease ▁; ▁heart ▁failure
D-981	-0.48271697759628296	coronary disease ; heart failure
P-981	-0.7518 -0.2577 -0.5008 -0.1115 -1.7803 -0.2232 -0.1470 -0.0894
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ; ffm ; stable
H-20	-0.5979189872741699	f f ▁; ▁FM ▁; ▁body ▁weight ▁; ▁CC
D-20	-0.5979189872741699	ff ; FM ; body weight ; CC
P-20	-0.9858 -0.1969 -0.2183 -0.6416 -0.1067 -3.3046 -0.1167 -0.2647 -0.4755 -0.1530 -0.1133
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart failure ; nurse
H-84	-0.8231460452079773	▁multi hospital ▁study ▁; ▁heart ▁failure
D-84	-0.8231460452079773	multihospital study ; heart failure
P-84	-1.0091 -0.0070 -1.3828 -0.2769 -0.6335 -0.2268 -2.8233 -0.2257
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise ; training ; endothelial function
H-248	-0.6056920886039734	▁ Protect ive ▁effects ▁; ▁ed ▁; ▁en dot heli al ▁function
D-248	-0.6056920886039734	Protective effects ; ed ; endothelial function
P-248	-1.6024 -0.1214 -0.0160 -0.5902 -0.2175 -2.9295 -0.5187 -0.0770 -0.9364 -0.0623 -0.0182 -1.1479 -0.1176 -0.1248
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery ; mva
H-361	-0.5552239418029785	▁MS ▁; ▁m va
D-361	-0.5552239418029785	MS ; mva
P-361	-0.7838 -1.2202 -0.7848 -0.1880 -0.2188 -0.1357
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise ; exercise
H-1931	-0.817069947719574	▁social ▁support ▁; ▁barrier s ▁; ▁exercise
D-1931	-0.817069947719574	social support ; barriers ; exercise
P-1931	-0.5880 -0.5719 -0.1541 -2.5462 -0.0184 -0.8912 -1.1150 -1.3520 -0.1169
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart rate
H-1446	-1.4625827074050903	▁heart ▁rate
D-1446	-1.4625827074050903	heart rate
P-1446	-3.1564 -1.5384 -0.9801 -0.1755
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.32071295380592346	▁c RF
D-1769	-0.32071295380592346	cRF
P-1769	-0.7533 -0.2435 -0.1989 -0.0871
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.4056378901004791	▁Mediterrane an ▁; ▁DAS h
D-688	-0.4056378901004791	Mediterranean ; DASh
P-688	-0.1697 -0.0169 -0.1868 -0.0238 -0.3247 -1.9349 -0.1827
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.6836578845977783	▁re hospital ization
D-1711	-0.6836578845977783	rehospitalization
P-1711	-2.7364 -0.0133 -0.4714 -0.0825 -0.1147
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl ; hno ; acute ; heart failure
H-412	-0.4950568675994873	▁ni tro x yl ▁; ▁h no ▁; ▁heart ▁failure
D-412	-0.4950568675994873	nitroxyl ; hno ; heart failure
P-412	-1.3954 -0.0075 -0.0194 -0.1075 -0.1288 -0.2378 -0.4735 -0.3902 -2.6976 -0.2847 -0.0998 -0.0985
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization therapy ; heart failure ; narrow qrs complex
H-844	-0.41018423438072205	▁Card iac - re syn chron ization ▁ therapy ▁; ▁heart ▁failure
D-844	-0.41018423438072205	Cardiac-resynchronization therapy ; heart failure
P-844	-0.4648 -0.1455 -0.0299 -0.1519 -0.0622 -0.0032 -0.9567 -1.3962 -0.0488 -0.3314 -0.2655 -0.8690 -0.8797 -0.1378
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate models ; odds ratios ; accounting ; hospital
H-191	-1.187757968902588	▁odds ▁; ▁hospital ▁cluster ing
D-191	-1.187757968902588	odds ; hospital clustering
P-191	-1.2473 -6.2510 -0.1359 -0.1217 -0.2584 -0.1408 -0.1594
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change ; lvet ; admission ; follow-up ; outcome
H-588	-0.4055868089199066	▁change ▁; ▁l VET ▁; ▁follow - up
D-588	-0.4055868089199066	change ; lVET ; follow-up
P-588	-0.4762 -0.4271 -1.2046 -0.4848 -0.7440 -0.2124 -0.0679 -0.0062 -0.2978 -0.1347
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute walk distance ; peak vo2 ; baseline
H-1636	-0.5581375956535339	▁Black s ▁; ▁VO 2
D-1636	-0.5581375956535339	Blacks ; VO2
P-1636	-1.3274 -0.0691 -0.5527 -1.3444 -0.1088 -0.2461 -0.2585
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician ; death ; readmission ; discharge ; patients ; heart failure
H-1412	-0.663407564163208	▁physician ▁continu ity ▁; ▁urgent ▁read mission ▁; ▁dis charge ▁; ▁heart ▁failure
D-1412	-0.663407564163208	physician continuity ; urgent readmission ; discharge ; heart failure
P-1412	-0.3228 -0.0087 -0.1001 -0.3354 -3.1171 -1.2067 -0.0695 -0.8211 -1.3423 -0.0132 -0.5777 -1.3691 -0.3524 -0.1893 -0.1255
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref ; hfpef ; patients ; regression line
H-497	-0.5098280310630798	▁h f ▁; ▁ HF p EF
D-497	-0.5098280310630798	hf ; HFpEF
P-497	-0.1784 -1.1319 -0.2759 -0.6773 -0.2324 -0.0669 -0.8586 -0.9473 -0.2198
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home ; hospital ; readmission ; congestive heart failure
H-1573	-0.6238173842430115	▁hospital - to - Home ▁; ▁hospital ▁read mission ▁re duction ▁program ▁; ▁con ges tive ▁heart ▁failure
D-1573	-0.6238173842430115	hospital-to-Home ; hospital readmission reduction program ; congestive heart failure
P-1573	-0.1891 -2.6347 -0.4384 -0.0584 -0.1283 -0.5185 -1.9170 -2.3960 -0.2977 -0.0115 -0.0115 -2.0175 -0.4699 -0.0485 -0.0569 -0.1796 -0.3092 -0.3095 -0.3253 -0.1587
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk stratification ; death ; all-cause hospitalization ; heart failure ; clinic ; outpatients
H-377	-1.0330952405929565	▁risk ▁; ▁hospital ization ▁; ▁heart ▁failure ▁clinic
D-377	-1.0330952405929565	risk ; hospitalization ; heart failure clinic
P-377	-3.7801 -0.6151 -1.3548 -0.7896 -0.4160 -0.0670 -0.3024 -1.0051 -1.7223 -0.2784
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients ; diabetes ; eo-cfus ; functional capacity
H-132	-0.5985237956047058	▁diabetes ▁; ▁ EO - c FU s
D-132	-0.5985237956047058	diabetes ; EO-cFUs
P-132	-0.2697 -0.2342 -2.2263 -0.0100 -0.0367 -2.0049 -0.2362 -0.2005 -0.5608 -0.2059
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-0.5486690402030945	▁patient ▁safety
D-1	-0.5486690402030945	patient safety
P-1	-1.5737 -0.4047 -0.0717 -0.1446
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients ; transplants
H-2000	-0.32039201259613037	▁transplant s
D-2000	-0.32039201259613037	transplants
P-2000	-1.0251 -0.0638 -0.1273 -0.0654
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy ; engage ; exercise
H-1903	-1.2725733518600464	▁Health y ▁; ▁aero bic ▁exercise
D-1903	-1.2725733518600464	Healthy ; aerobic exercise
P-1903	-3.2267 -0.0826 -1.6260 -3.2911 -0.0709 -1.5117 -0.1457 -0.2258
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals ; outcome
H-1690	-0.6474295258522034	
D-1690	-0.6474295258522034	
P-1690	-1.1708 -0.1241
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf ; patients
H-671	-0.27575811743736267	▁tras tuz um ab - related ▁CHF
D-671	-0.27575811743736267	trastuzumab-related CHF
P-671	-0.9252 -0.0096 -0.0907 -0.3463 -0.1669 -0.2620 -0.1498 -0.3126 -0.2187
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.16980436444282532	▁hospital s
D-1694	-0.16980436444282532	hospitals
P-1694	-0.2832 -0.1162 -0.2213 -0.0586
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak vo2
H-1498	-0.325824111700058	▁Peak ▁VO 2
D-1498	-0.325824111700058	Peak VO2
P-1498	-0.6696 -0.1692 -0.1018 -0.5320 -0.1566
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.6673901081085205	▁ pharma ce ut ically
D-948	-0.6673901081085205	pharmaceutically
P-948	-0.3747 -0.0147 -0.1925 -1.0033 -0.3532 -2.5913 -0.1421
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-0.6796253323554993	▁FIN DING s
D-1955	-0.6796253323554993	FINDINGs
P-1955	-0.9073 -1.0965 -0.4824 -0.8203 -0.0917
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary artery disease ; cad ; systolic heart failure ; hf
H-1182	-0.349414199590683	▁Corona ry ▁arter y ▁disease ▁; CAD ▁; ▁sy sto lic ▁heart ▁failure ▁; HF
D-1182	-0.349414199590683	Coronary artery disease ;CAD ; systolic heart failure ;HF
P-1182	-0.0617 -0.1031 -0.0924 -0.1592 -0.5279 -0.0944 -1.2174 -0.1535 -1.5595 -0.0277 -0.9982 -0.1917 -0.1874 -0.3607 -0.0337 -0.1051 -0.0664
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative ; hypoalbuminemia ; prognosis ; lvad ; surgery
H-538	-0.3675515055656433	▁hypo album in emia ▁; ▁l VAD ▁surgery
D-538	-0.3675515055656433	hypoalbuminemia ; lVAD surgery
P-538	-0.9791 -0.0955 -0.2355 -0.1173 -0.3219 -0.8251 -0.0368 -0.8905 -0.0482 -0.1256
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis ; atherosclerosis ; cardiovascular events ; rotterdam study
H-1554	-0.4356120526790619	▁p sori asis ▁; ▁at hero sc ler osis ▁; ▁incident ▁cardiovascular ▁events ▁; ▁Rotterdam
D-1554	-0.4356120526790619	psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam
P-1554	-1.0987 -0.0202 -0.2085 -0.0769 -0.0800 -0.0875 -0.6170 -1.1292 -0.0518 -0.1667 -1.1335 -0.0550 -0.2495 -0.7164 -0.0199 -1.5775 -0.1171
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality ; hf ; hospital ; admissions ; transplant ; ventricular assist device
H-125	-0.30443015694618225	▁mortal ity ▁; HF ▁hospital ▁ad missions ▁; ▁transplant ▁; ▁vent ri cular ▁assist ▁device
D-125	-0.30443015694618225	mortality ;HF hospital admissions ; transplant ; ventricular assist device
P-125	-0.8874 -0.2376 -0.1374 -1.1308 -0.5387 -0.1089 -0.0072 -0.0789 -0.0696 -0.3656 -0.0023 -0.8521 -0.1068 -0.1932 -0.1517 -0.2005 -0.1067
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart failure ; patients ; rheumatoid arthritis ; tnf antagonist
H-600	-0.5460765361785889	▁Heart ▁failure ▁; ▁rhe um ato id ▁ar thri tis ▁; ▁t NF ▁anta gon ist
D-600	-0.5460765361785889	Heart failure ; rheumatoid arthritis ; tNF antagonist
P-600	-0.4588 -0.7579 -0.2747 -0.5237 -0.1165 -0.6365 -0.7469 -1.7785 -0.2292 -0.9097 -0.4087 -0.7743 -0.1018 -0.9435 -0.0393 -0.6049 -0.2989 -0.2256
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade ; holosystolic murmur ; third heart sound ; apex
H-342	-0.6044813990592957	▁holo sy sto lic ▁mur mur ▁; ▁heart ▁sound
D-342	-0.6044813990592957	holosystolic murmur ; heart sound
P-342	-0.0788 -0.1100 -0.4599 -0.8870 -0.1505 -0.0320 -0.2607 -3.3960 -1.0159 -0.1340 -0.1245
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death ; stroke ; hospitalisation ; heart failure
H-815	-0.6153513789176941	▁CV ▁death ▁; ▁non - fa tal ▁stroke ▁; ▁heart ▁failure
D-815	-0.6153513789176941	CV death ; non-fatal stroke ; heart failure
P-815	-0.7335 -3.4926 -0.1461 -1.5341 -0.0245 -0.0279 -0.0686 -0.0608 -0.2077 -1.1670 -0.1995 -0.1572 -0.1800
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling ; hf ; haemodynamic ; neuronal stressors
H-1039	-0.3650679886341095	▁remodel ling ▁; HF ▁; ▁ha emo dynamic ▁; ▁neuron al ▁stress ors
D-1039	-0.3650679886341095	remodelling ;HF ; haemodynamic ; neuronal stressors
P-1039	-0.9430 -0.6664 -0.1041 -1.7365 -0.1691 -0.0644 -0.0654 -0.0265 -0.4392 -0.2644 -0.0445 -0.4000 -0.2155 -0.2119 -0.1254
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit index ; biological phenotype ; mortality
H-1012	-0.6060929298400879	▁deficit ▁; ▁bi ological ▁ph eno type ▁; ▁mortal ity
D-1012	-0.6060929298400879	deficit ; biological phenotype ; mortality
P-1012	-2.3768 -1.4060 -0.0138 -0.1767 -1.7314 -0.4846 -0.0164 -0.5417 -0.0294 -0.2967 -0.0575 -0.1419
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right ventricular function ; prognosis ; heart failure
H-1157	-1.1714963912963867	▁vent ri cular ▁function ▁; ▁body ▁composition ▁; ▁heart ▁failure
D-1157	-1.1714963912963867	ventricular function ; body composition ; heart failure
P-1157	-0.7330 -1.5815 -0.3477 -4.0716 -0.3030 -2.7205 -0.8046 -0.2037 -2.2930 -0.6908 -0.1258 -0.1827
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia ; right ventricle ; heart failure
H-1457	-0.6003481149673462	▁Fat ▁; ▁cache xia ▁; ▁right ▁vent ric le ▁; ▁heart ▁failure
D-1457	-0.6003481149673462	Fat ; cachexia ; right ventricle ; heart failure
P-1457	-0.8612 -0.2686 -0.3589 -0.0357 -0.1129 -1.3203 -0.0220 -2.4099 -0.7989 -0.9616 -0.2229 -0.2994 -0.5763 -0.1561
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial fibrillation ; patients ; heart failure
H-1231	-0.2239028513431549	▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure
D-1231	-0.2239028513431549	atrial fibrillation ;AF ; heart failure
P-1231	-0.6889 -0.0486 -0.3920 -0.0234 -0.0243 -0.3177 -0.0956 -0.3062 -0.2821 -0.2465 -0.1554 -0.1060
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct ; heart failure ; therapy ; patients
H-718	-0.43786412477493286	▁EC CT ▁; ▁advanced ▁heart ▁failure ▁ therapy
D-718	-0.43786412477493286	ECCT ; advanced heart failure therapy
P-718	-0.6601 -1.3142 -0.2247 -0.7585 -0.6074 -0.1724 -0.2458 -0.0247 -0.2370 -0.1337
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart transplantation ; left ventricular assist device
H-306	-0.847399115562439	▁heart ▁transplant ation ▁; ▁left ▁vent ri cular ▁assist ▁device
D-306	-0.847399115562439	heart transplantation ; left ventricular assist device
P-306	-2.2234 -1.0236 -0.0729 -0.2296 -0.9318 -0.0229 -1.9674 -0.2367 -0.8573 -0.8010 -1.6636 -0.1387
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise intolerance ; chronic heart failure ; prognosis
H-1273	-0.4763182997703552	▁Exerci se ▁in tolerance ▁; ▁chronic ▁heart ▁failure
D-1273	-0.4763182997703552	Exercise intolerance ; chronic heart failure
P-1273	-2.3532 -0.0802 -0.0096 -0.1081 -0.2104 -0.4833 -0.7894 -0.3297 -0.2501 -0.1491
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd ; vvd ; free wall rs
H-328	-0.5384802222251892	▁av d ▁; ▁VVD ▁; ▁co ▁; ▁free ▁wall ▁RS
D-328	-0.5384802222251892	avd ; VVD ; co ; free wall RS
P-328	-0.6999 -0.3903 -0.0470 -0.6001 -0.1068 -2.5494 -0.2460 -0.4240 -0.1900 -0.9595 -0.1434 -0.1053
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical ; connected ; elevated ; resistin ; heart failure
H-929	-0.9467194080352783	▁resist in ▁; ▁heart ▁failure
D-929	-0.9467194080352783	resistin ; heart failure
P-929	-4.1273 -1.1153 -0.4422 -0.4150 -0.3500 -0.0898 -0.0874
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ; ecgs ; electrocardiographers
H-884	-0.32975929975509644	▁base line ▁E CG s ▁; ▁electro car dio graph ers
D-884	-0.32975929975509644	baseline ECGs ; electrocardiographers
P-884	-1.1639 -0.1258 -1.0423 -0.1084 -0.0779 -0.3702 -0.0399 -0.0409 -0.6580 -0.0523 -0.2251 -0.2310 -0.1512
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left ventricular assist device ; right ventricular support
H-293	-0.4717082977294922	▁vent ri cular ▁assist ▁device ▁; ▁right ▁vent ri cular ▁support
D-293	-0.4717082977294922	ventricular assist device ; right ventricular support
P-293	-0.0944 -0.7214 -0.1505 -0.5411 -0.4930 -0.1771 -1.4688 -0.0099 -1.1377 -0.0988 -0.8189 -0.2827 -0.1379
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence ; esrd ; outpatients ; hf
H-388	-0.4526360034942627	▁ES RD ▁; ▁out patient s ▁; ▁ HF
D-388	-0.4526360034942627	ESRD ; outpatients ; HF
P-388	-1.0471 -0.3302 -0.2159 -0.7612 -0.0144 -0.0239 -0.4958 -1.7701 -0.0271 -0.1244 -0.1689
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon matched-pairs signed-rank tests
H-923	-0.3230969309806824	▁Wil co xon
D-923	-0.3230969309806824	Wilcoxon
P-923	-0.4216 -0.0052 -0.0807 -0.8871 -0.2209
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical ; atherosclerosis ; linear models
H-1557	-0.5580559372901917	▁sub clin ical ▁at hero sc ler osis
D-1557	-0.5580559372901917	subclinical atherosclerosis
P-1557	-0.6716 -0.0603 -0.3423 -0.2375 -0.4101 -0.6922 -1.7983 -0.1270 -1.0266 -0.2148
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal artery stenosis ; ras ; peripheral arterial disease
H-1593	-0.13505816459655762	▁Ren al ▁arter y ▁sten osis ▁; RAS ▁; ▁per i pher al ▁arterial ▁disease
D-1593	-0.13505816459655762	Renal artery stenosis ;RAS ; peripheral arterial disease
P-1593	-0.0814 -0.0718 -0.0791 -0.1549 -0.0412 -0.1020 -0.1592 -0.0115 -0.3542 -0.0772 -0.1812 -0.0160 -0.0510 -0.0662 -0.5884 -0.1187 -0.1420
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline ; outcomes ; ecct ; cardiac transplant
H-711	-0.3565860688686371	▁EC CT ▁; ▁cardiac ▁transplant ▁recipient s
D-711	-0.3565860688686371	ECCT ; cardiac transplant recipients
P-711	-0.7139 -0.8381 -0.1696 -0.1090 -0.2332 -0.7219 -0.1444 -0.1372 -0.1421
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone ; primary composite endpoint
H-1227	-0.43370234966278076	▁e pler en one
D-1227	-0.43370234966278076	eplerenone
P-1227	-0.4656 -0.0130 -0.0954 -1.3717 -0.5092 -0.1473
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient ; asymptomatic ; follow-up
H-599	-0.45185586810112	
D-599	-0.45185586810112	
P-599	-0.8077 -0.0960
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients ; extubated ; blood ; transfusion
H-777	-1.3030105829238892	▁trans fusion
D-777	-1.3030105829238892	transfusion
P-777	-4.3265 -0.1283 -0.5897 -0.1676
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate ii ; lvads ; patients
H-776	-0.5320684313774109	▁technique ▁; ▁mal function ing ▁Heart Mate ▁; ▁l VAD s
D-776	-0.5320684313774109	technique ; malfunctioning HeartMate ; lVADs
P-776	-1.0675 -0.4891 -1.1536 -0.3148 -0.2434 -0.4872 -0.0484 -1.3666 -1.0908 -0.0337 -0.1582 -0.2590 -0.2046
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart failure ; hf ; cardiovascular ; hospitalization
H-1074	-0.39657512307167053	▁Heart ▁failure ▁; HF ▁; ▁cardiovascular ▁hospital ization
D-1074	-0.39657512307167053	Heart failure ;HF ; cardiovascular hospitalization
P-1074	-0.7230 -0.1254 -0.1473 -0.0959 -0.4127 -0.1976 -0.6255 -0.6433 -0.8480 -0.1470
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf inhibition ; cardiac function ; remodeling
H-458	-0.5815591812133789	▁VE GF ▁inhibi tion ▁; ▁b ▁; ▁cardiac ▁; ▁remodel ing
D-458	-0.5815591812133789	VEGF inhibition ; b ; cardiac ; remodeling
P-458	-0.3546 -0.2005 -0.5729 -0.0293 -0.0428 -0.1540 -0.4919 -0.1550 -5.2982 -0.0158 -0.0603 -0.1165 -0.0685
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing ; β-blocker ; sst2
H-400	-0.31241676211357117	▁β - block er ▁; BB ▁; ▁s ST 2
D-400	-0.31241676211357117	β-blocker ;BB ; sST2
P-400	-0.6116 -0.0442 -0.0959 -0.0696 -0.2197 -0.3817 -0.7378 -0.1066 -0.9064 -0.0706 -0.3561 -0.1489
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas ; cardiac ; pathogenesis
H-1484	-0.531810462474823	▁mi RNA s ▁; ▁cardiac
D-1484	-0.531810462474823	miRNAs ; cardiac
P-1484	-0.6446 -0.0299 -0.0367 -0.3318 -0.0657 -2.5085 -0.1055
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet ; exercise rehabilitation ; patients ; chf
H-1884	-0.4567663073539734	▁c PET ▁gu iding ▁exercise ▁rehabilita tion ▁; ▁CHF
D-1884	-0.4567663073539734	cPET guiding exercise rehabilitation ; CHF
P-1884	-0.3351 -2.0957 -1.1096 -0.0216 -0.5739 -0.1899 -0.0181 -0.3213 -0.1612 -0.1255 -0.0725
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient ; heart failure with reduced ejection fraction
H-1203	-0.7010707259178162	▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1203	-0.7010707259178162	heart failure ; ejection fraction
P-1203	-4.3055 -0.4477 -0.2549 -0.9069 -0.3179 -0.1825 -0.1948 -0.0011 -0.2397 -0.1598
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients ; heart failure ; diagnostic ; medication ; follow-up
H-732	-1.012058973312378	▁Patient s ▁; ▁heart ▁failure
D-732	-1.012058973312378	Patients ; heart failure
P-732	-2.9282 -0.1437 -1.4962 -0.4909 -0.5855 -1.2343 -0.2057
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart failure ; hf ; morbidity ; mortality
H-199	-0.392729252576828	▁Pediatri c ▁heart ▁failure ▁; HF
D-199	-0.392729252576828	Pediatric heart failure ;HF
P-199	-0.6328 -0.0250 -0.6474 -0.1651 -0.1482 -0.0810 -1.2957 -0.1468
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression ; type i regulatory subunit ; ri ; hf
H-1429	-0.30602777004241943	▁regulator y ▁sub un it ▁; RI ▁; ▁ HF
D-1429	-0.30602777004241943	regulatory subunit ;RI ; HF
P-1429	-1.3323 -0.0679 -0.0292 -0.2545 -0.0739 -0.2348 -0.0660 -0.3634 -0.8524 -0.1641 -0.0961 -0.1377
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients ; discharge ; follow-up ; medication
H-730	-0.6165679097175598	▁dis charge ▁; ▁medication
D-730	-0.6165679097175598	discharge ; medication
P-730	-0.8530 -0.0158 -0.6171 -1.7838 -0.3152 -0.1146
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain proteins
H-1042	-0.8689091205596924	bro modo main ▁protein s
D-1042	-0.8689091205596924	bromodomain proteins
P-1042	-4.9881 -0.0424 -0.0131 -0.7189 -0.0232 -0.1753 -0.1214
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative ; clinical ; mortality
H-532	-0.5567075610160828	
D-532	-0.5567075610160828	
P-532	-1.0029 -0.1106
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart failure ; readmission ; outcome
H-1030	-0.9590831398963928	▁heart ▁failure
D-1030	-0.9590831398963928	heart failure
P-1030	-0.7636 -0.2343 -2.6809 -0.1576
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt ; dt ; implantation
H-315	-0.26837021112442017	▁b t ▁; ▁ DT
D-315	-0.26837021112442017	bt ; DT
P-315	-0.0991 -0.3195 -0.1888 -0.3306 -0.1935 -0.6585 -0.0886
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes ; hospitalization
H-566	-0.5419540405273438	
D-566	-0.5419540405273438	
P-566	-0.9502 -0.1337
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse event ; hypotension
H-1970	-0.17576318979263306	▁hypo tension
D-1970	-0.17576318979263306	hypotension
P-1970	-0.1968 -0.2349 -0.1794 -0.0920
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers ; hf
H-1475	-0.27377697825431824	▁bio mark ers ▁; ▁ HF
D-1475	-0.27377697825431824	biomarkers ; HF
P-1475	-0.0961 -0.0049 -0.0774 -0.2554 -1.4398 -0.0657 -0.1075 -0.1435
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up ; hf
H-288	-0.5216372609138489	▁incident ▁ HF
D-288	-0.5216372609138489	incident HF
P-288	-1.3448 -1.0194 -0.0748 -0.0896 -0.0796
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 ; patients ; plasma
H-699	-0.7538721561431885	▁ST 2
D-699	-0.7538721561431885	ST2
P-699	-1.3899 -0.2207 -1.3088 -0.0961
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients ; condition ; economic
H-1575	-0.4362230598926544	▁économique
D-1575	-0.4362230598926544	économique
P-1575	-0.8972 -0.3002 -0.1112
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing ; medications ; heart failure
H-1121	-0.9967142343521118	▁medication s ▁; ▁heart ▁failure
D-1121	-0.9967142343521118	medications ; heart failure
P-1121	-3.0311 -0.0622 -0.6833 -2.5468 -0.2782 -0.1875 -0.1879
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient ; mortality ; therapeutic
H-1667	-0.7353876829147339	▁mortal ity
D-1667	-0.7353876829147339	mortality
P-1667	-1.8406 -0.2676 -0.7333 -0.1001
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary heart disease ; stroke ; heart failure
H-1564	-0.2860925793647766	▁corona ry ▁heart ▁disease ▁; ▁stroke ▁; ▁heart ▁failure
D-1564	-0.2860925793647766	coronary heart disease ; stroke ; heart failure
P-1564	-0.1707 -0.1367 -0.5484 -1.2632 -0.1436 -0.0136 -0.1730 -0.1270 -0.3564 -0.1078 -0.1066
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality of life ; mlhf questionnaire
H-1991	-0.9380304217338562	▁ ML HF
D-1991	-0.9380304217338562	MLHF
P-1991	-1.9970 -0.5377 -1.3247 -0.6625 -0.1682
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions ; septal ; surgical
H-984	-0.3308757543563843	▁sept al ▁defect s
D-984	-0.3308757543563843	septal defects
P-984	-0.1280 -0.0585 -0.0568 -0.0368 -1.6189 -0.0863
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis ; mortality ; patients
H-61	-0.4211631417274475	▁mortal ity ▁; ▁i CD - HF
D-61	-0.4211631417274475	mortality ; iCD-HF
P-61	-1.3425 -0.4617 -0.2519 -0.3594 -0.1034 -0.0225 -0.0307 -0.9004 -0.3177
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral renal denervation ; autonomic balance ; chronic heart failure
H-1369	-0.7128389477729797	▁Uni lateral ▁renal ▁den er va tion ▁; ▁autonomi c ▁balance ▁; ▁rabbi ts ▁; ▁chronic ▁heart ▁failure
D-1369	-0.7128389477729797	Unilateral renal denervation ; autonomic balance ; rabbits ; chronic heart failure
P-1369	-4.1790 -0.0229 -0.1572 -0.8260 -0.0233 -0.0892 -0.0571 -0.2010 -0.6842 -0.4026 -0.0308 -0.2766 -1.0216 -0.0324 -0.1713 -3.9711 -1.2948 -0.4479 -0.2166 -0.1512
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient ; clinical ; symptoms
H-1468	-0.5607877969741821	
D-1468	-0.5607877969741821	
P-1468	-1.0459 -0.0757
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients ; trastuzumab
H-676	-0.06971240043640137	▁tras tuz um ab
D-676	-0.06971240043640137	trastuzumab
P-676	-0.1122 -0.0151 -0.0274 -0.0721 -0.0796 -0.1119
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna ; genotyped
H-1454	-0.5929362177848816	▁h CT ▁germ line ▁DNA
D-1454	-0.5929362177848816	hCT germline DNA
P-1454	-0.3305 -1.7234 -0.2616 -0.0636 -0.4087 -1.2027 -0.1600
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart failure ; disease ; medical
H-2008	-0.7092151641845703	▁Heart ▁failure ▁disease ▁management ▁; ▁medical ▁resource
D-2008	-0.7092151641845703	Heart failure disease management ; medical resource
P-2008	-0.5900 -0.4872 -0.7731 -0.3225 -1.3631 -0.4166 -0.3148 -1.9766 -0.1390
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal dnx ; plasma
H-1381	-0.4165646433830261	▁Ren al ▁DN x ▁; ▁circula ting ▁plasma ▁NE ▁; ▁CHF - IN v ▁rabbi ts
D-1381	-0.4165646433830261	Renal DNx ; circulating plasma NE ; CHF-INv rabbits
P-1381	-0.0868 -0.0222 -0.1612 -0.0030 -0.1133 -0.1467 -2.5780 -0.0574 -1.4151 -0.1748 -0.2168 -0.0106 -1.2133 -0.8423 -0.0704 -0.0359 -0.2182 -0.1321
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow up ; hf
H-627	-0.7426342368125916	▁ HF
D-627	-0.7426342368125916	HF
P-627	-2.6272 -0.1342 -0.1035 -0.1056
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients ; blood ; medication
H-729	-0.9179764986038208	▁blood ▁work ▁; ▁medication
D-729	-0.9179764986038208	blood work ; medication
P-729	-2.8383 -0.5728 -1.2171 -0.1946 -0.4802 -0.2048
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses ; patients
H-1021	-0.6332182884216309	▁ NP ▁assessment ▁; ▁ED
D-1021	-0.6332182884216309	NP assessment ; ED
P-1021	-0.7147 -0.0110 -2.2066 -0.4902 -0.2946 -0.5815 -0.1339
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac hypertrophy ; energy metabolism
H-1778	-0.18727253377437592	▁Card iac ▁hyper trop hy ▁; ▁energy ▁metabolism
D-1778	-0.18727253377437592	Cardiac hypertrophy ; energy metabolism
P-1778	-0.9028 -0.0896 -0.0177 -0.0081 -0.1448 -0.1150 -0.3109 -0.0533 -0.1194 -0.1111
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients ; lvad ; implantation
H-531	-0.3089641332626343	▁implant ation
D-531	-0.3089641332626343	implantation
P-531	-0.5039 -0.0255 -0.5631 -0.1433
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.35169699788093567	▁HD L - bound ▁malo ndi alde hy de ▁; ▁HD L - indu ced ▁; ▁EC
D-252	-0.35169699788093567	HDL-bound malondialdehyde ; HDL-induced ; EC
P-252	-0.2670 -1.3708 -0.0226 -0.0324 -0.1172 -0.2645 -0.0908 -0.5846 -0.0531 -0.0958 -0.1201 -1.4464 -0.0146 -0.0276 -0.5508 -0.3532 -0.8528 -0.2095 -0.2083
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal dysfunction ; morbidity
H-719	-0.579524576663971	▁renal ▁dys function ▁; ▁long - term ▁survival ▁; ▁trans plant ▁morbi d ity
D-719	-0.579524576663971	renal dysfunction ; long-term survival ; transplant morbidity
P-719	-2.4860 -0.0648 -0.6317 -0.5382 -1.0813 -0.0098 -1.1038 -0.5574 -0.2521 -1.1716 -0.2487 -0.2242 -0.2948 -0.3980 -0.0783 -0.1317
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients ; cad ; cad
H-1189	-1.191773533821106	▁CAD ▁; ▁severe ▁CAD
D-1189	-1.191773533821106	CAD ; severe CAD
P-1189	-3.5645 -0.8586 -2.3410 -0.1985 -0.0980 -0.0900
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.5190439820289612	▁valid ity
D-154	-0.5190439820289612	validity
P-154	-1.3359 -0.5326 -0.1187 -0.0889
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients ; randomized
H-1874	-0.416155070066452	
D-1874	-0.416155070066452	
P-1874	-0.7292 -0.1031
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital ; discharge
H-302	-0.5209804773330688	▁sur vi val ▁; ▁hospital ▁dis charge
D-302	-0.5209804773330688	survival ; hospital discharge
P-302	-1.1387 -0.0297 -0.8136 -1.8132 -0.2647 -0.3359 -0.0356 -0.1215 -0.1360
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.2810111939907074	▁hospital s
D-1713	-0.2810111939907074	hospitals
P-1713	-0.4149 -0.2996 -0.2945 -0.1151
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia ; heart disease
H-40	-1.0154204368591309	▁an emia ▁; ▁heart ▁disease
D-40	-1.0154204368591309	anemia ; heart disease
P-40	-3.4046 -0.5233 -0.2764 -1.9518 -0.7204 -0.1141 -0.1174
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right atrial myxoma ; pulmonary embolism ; right heart failure
H-592	-0.3484475016593933	▁Right ▁at rial ▁my xo ma ▁; ▁pulmonar y ▁e mbol ism ▁; ▁right ▁heart ▁failure
D-592	-0.3484475016593933	Right atrial myxoma ; pulmonary embolism ; right heart failure
P-592	-0.1565 -0.0686 -0.2115 -1.4231 -0.0315 -0.1119 -0.8486 -0.0064 -0.0481 -0.0655 -0.0026 -1.1317 -0.2929 -0.6268 -0.3746 -0.5664 -0.2030 -0.1024
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
H-638	-0.5009939670562744	▁N fat ▁; ▁mi r -25 ▁; ▁tran scription ▁factor ▁; ▁Hand 2 ▁in ▁heart ▁failure
D-638	-0.5009939670562744	Nfat ; mir-25 ; transcription factor ; Hand2 in heart failure
P-638	-3.3706 -0.2292 -0.0671 -0.2453 -0.5277 -0.0950 -0.2442 -0.2925 -0.0351 -0.4463 -0.6127 -0.2752 -0.0504 -0.7737 -0.5197 -0.5694 -0.3631 -0.3008
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation ; resistin ; correlated ; ejection fraction
H-938	-0.31375008821487427	▁resist in ▁; ▁decline ▁; ▁e je ction ▁ fraction
D-938	-0.31375008821487427	resistin ; decline ; ejection fraction
P-938	-0.3721 -0.5411 -0.1769 -0.8014 -0.4190 -0.1264 -0.2709 -0.2060 -0.0723 -0.0013 -0.5649 -0.2126
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic heart transplantation ; oht ; end-stage heart failure
H-1280	-0.27097320556640625	▁Ort ho topic ▁heart ▁transplant ation ▁; ▁o HT ▁; ▁end - s tage ▁heart ▁failure
D-1280	-0.27097320556640625	Orthotopic heart transplantation ; oHT ; end-stage heart failure
P-1280	-0.5232 -0.0189 -0.0185 -0.7335 -0.3020 -0.0236 -0.1676 -0.0241 -0.9948 -0.2903 -0.9638 -0.0304 -0.2099 -0.0013 -0.2732 -0.1198 -0.1021 -0.0802
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas ; right atrium ; embolize ; pulmonary arterial vasculature
H-594	-0.23967859148979187	▁My xo mas ▁; ▁right ▁at rium ▁; ▁pulmonar y ▁arterial ▁vas cula ture
D-594	-0.23967859148979187	Myxomas ; right atrium ; pulmonary arterial vasculature
P-594	-0.6555 -0.0111 -0.1863 -0.4179 -0.5840 -0.0973 -0.0307 -0.3416 -0.0036 -0.0901 -0.0551 -0.5477 -0.2808 -0.1529 -0.1939 -0.1863
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change ; readmissions ; follow-up ; heart failure ; readmission
H-720	-1.3936560153961182	▁change ▁in ▁read missions ▁; ▁heart ▁failure
D-720	-1.3936560153961182	change in readmissions ; heart failure
P-720	-3.9703 -2.0375 -0.6808 -0.0106 -0.1279 -1.6592 -0.3356 -3.5469 -0.1742
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas ; bridge to transplantation ; destination therapy
H-1999	-0.5972321033477783	▁l VAS ▁; ▁ bridge ▁to ▁transplant ation
D-1999	-0.5972321033477783	lVAS ; bridge to transplantation
P-1999	-0.9069 -0.2572 -1.4438 -0.4571 -0.0707 -0.6147 -0.0847 -0.0186 -2.0210 -0.0976
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac overexpression ; mammalian enabled ; mena ; heart failure
H-1809	-0.33123186230659485	▁Card iac ▁; ▁Mamma lian ▁enabled ▁; Men a ▁; ▁heart ▁failure ▁; ▁mi ce
D-1809	-0.33123186230659485	Cardiac ; Mammalian enabled ;Mena ; heart failure ; mice
P-1809	-0.3635 -0.0942 -0.2424 -0.0445 -0.2896 -0.3676 -0.0881 -1.4037 -0.0603 -0.1717 -0.3249 -0.2342 -1.5650 -0.0760 -0.0318 -0.1497 -0.1237
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs ; functional capacity ; peak vo2
H-123	-0.4550892114639282	▁c PC s ▁; ▁functional ▁capacity ▁; ▁VO 2
D-123	-0.4550892114639282	cPCs ; functional capacity ; VO2
P-123	-0.1485 -0.4967 -0.0440 -0.3096 -0.6894 -0.4566 -0.2477 -0.6788 -1.5716 -0.1516 -0.2115
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction ; pump ; driveline ; pump ; curative
H-774	-0.5152159333229065	▁dys function ▁; ▁pump ▁failure ▁; ▁drive line ▁injury
D-774	-0.5152159333229065	dysfunction ; pump failure ; driveline injury
P-774	-0.9970 -0.0940 -0.2165 -0.1526 -0.5094 -0.0830 -0.1040 -0.0891 -0.0827 -3.2518 -0.0873
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis ; chronic heart failure ; tachycardia
H-164	-0.5272812247276306	▁can ine ▁; ▁chronic ▁heart ▁failure ▁; ▁ta chy car dia
D-164	-0.5272812247276306	canine ; chronic heart failure ; tachycardia
P-164	-1.1393 -0.0522 -1.0209 -1.1692 -0.9034 -0.4634 -0.6166 -0.7887 -0.0880 -0.0197 -0.2427 -0.2156 -0.1350
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil ; orally ; doxorubicin
H-959	-0.22077932953834534	▁Nico rand il ▁; ▁do xor ubi cin
D-959	-0.22077932953834534	Nicorandil ; doxorubicin
P-959	-0.0067 -0.0297 -0.3325 -0.2272 -0.2192 -0.0240 -0.0344 -0.2849 -0.9576 -0.0917
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical ; outcomes ; hfpef
H-1525	-0.5194397568702698	▁EH ▁; ▁h p EF
D-1525	-0.5194397568702698	EH ; hpEF
P-1525	-0.0960 -0.6098 -1.8024 -0.0138 -0.8370 -0.1291 -0.1480
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east ; rhythm control therapy ; cardiovascular ; complications
H-1648	-0.3429160714149475	▁e AST ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1648	-0.3429160714149475	eAST ; rhythm control therapy ; cardiovascular complications ; AF
P-1648	-0.6980 -0.4713 -0.1537 -0.4358 -0.4887 -0.0744 -0.1057 -0.0185 -0.3777 -0.3914 -0.0401 -0.0197 -1.6836 -0.2528 -0.1166 -0.1586
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients ; clinical ; radiological ; hf ; hospitalization
H-560	-0.722898542881012	▁radi ological ▁sign s ▁; HF
D-560	-0.722898542881012	radiological signs ;HF
P-560	-1.3024 -0.3935 -0.6152 -0.0406 -0.6912 -2.4868 -0.1038 -0.1497
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics ; symptoms ; patients ; heart failure ; hf
H-1199	-0.6104416847229004	▁di ure tics ▁; ▁con ges tive ▁symptoms ▁; ▁heart ▁failure
D-1199	-0.6104416847229004	diuretics ; congestive symptoms ; heart failure
P-1199	-0.1827 -0.0551 -0.4038 -0.4286 -2.5610 -0.0454 -0.1035 -0.6379 -0.2025 -0.3840 -0.2227 -2.5559 -0.1527
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based ; therapies ; patients ; fes
H-1333	-1.1034826040267944	▁fe es
D-1333	-1.1034826040267944	fees
P-1333	-3.6976 -0.5484 -0.0658 -0.1022
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 ; prognosis ; heart failure
H-399	-1.3257029056549072	▁heart ▁failure
D-399	-1.3257029056549072	heart failure
P-399	-4.2575 -0.8667 -0.1006 -0.0780
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham heart study ; hf ; ef
H-1103	-0.3453890383243561	▁Fram ing ham ▁Heart ▁Study ▁; ▁ HF ▁; ▁EF
D-1103	-0.3453890383243561	Framingham Heart Study ; HF ; EF
P-1103	-0.0593 -0.1109 -0.0174 -0.2838 -0.0439 -0.3929 -0.5710 -0.0476 -0.2180 -2.1618 -0.1683 -0.0698
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up ; hf ; deaths
H-1771	-0.5747965574264526	▁ HF
D-1771	-0.5747965574264526	HF
P-1771	-1.5652 -0.0951 -0.4543 -0.1846
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations ; acr ; cms
H-140	-0.6411086916923523	▁a CR ▁; ▁CMS
D-140	-0.6411086916923523	aCR ; CMS
P-140	-0.2078 -2.7285 -0.2199 -0.0334 -0.5154 -0.1416
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase ; myocardium
H-171	-0.5379360318183899	▁cas pas e ▁; ▁pace d ▁my o car dium
D-171	-0.5379360318183899	caspase ; paced myocardium
P-171	-2.7914 -0.1432 -0.2898 -0.1727 -1.6012 -0.0787 -0.7867 -0.1068 -0.0097 -0.1791 -0.1968 -0.0992
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty ; heart failure ; health
H-621	-0.715817391872406	▁Fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; ▁ aging ▁; ▁body ▁composition
D-621	-0.715817391872406	Frailty ; risk ; heart failure ; aging ; body composition
P-621	-2.6235 -0.0430 -1.0839 -0.1344 -1.7219 -0.1883 -0.3794 -0.5763 -0.2072 -2.2025 -0.5804 -0.8721 -0.2290 -0.2662 -0.2123 -0.1327
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin ; sitagliptin
H-1828	-0.2599218189716339	▁h f ▁; ▁sax ag lip tin ▁; ▁si tag lip tin
D-1828	-0.2599218189716339	hf ; saxagliptin ; sitagliptin
P-1828	-0.0019 -1.2863 -0.0862 -0.4960 -0.1273 -0.2464 -0.4765 -0.2111 -0.0929 -0.0008 -0.0568 -0.2720 -0.1627 -0.1219
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart ; heart failure ; arrhythmias
H-747	-1.5917937755584717	▁Heart ▁t 2 ▁; ▁heart ▁failure
D-747	-1.5917937755584717	Heart t2 ; heart failure
P-747	-1.0438 -4.2465 -0.0154 -0.4458 -1.8861 -0.5585 -4.3854 -0.1529
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic ; inflammatory ; abdominal
H-1285	-1.1205618381500244	▁ ische mic ▁; ▁in flam ma tory ▁abdominal
D-1285	-1.1205618381500244	ischemic ; inflammatory abdominal
P-1285	-0.6763 -1.6438 -0.2521 -2.6926 -0.3419 -0.2633 -0.6370 -0.8531 -0.5927 -4.0609 -0.3123
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations ; congestive heart failure
H-208	-0.25266700983047485	▁ED ▁; ▁in tuba tions ▁; ▁con ges tive ▁heart ▁failure
D-208	-0.25266700983047485	ED ; intubations ; congestive heart failure
P-208	-0.7886 -1.1199 -0.0101 -0.0734 -0.0174 -0.2439 -0.0528 -0.0220 -0.1106 -0.3153 -0.2111 -0.1631 -0.1565
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline ; embase ; cinahl
H-62	-0.4138580858707428	▁Med Line ▁; ▁ EMBA se ▁; ▁c INA HL
D-62	-0.4138580858707428	MedLine ; EMBAse ; cINAHL
P-62	-0.4206 -0.1917 -0.1806 -0.2537 -0.0122 -0.9817 -0.1482 -0.5347 -1.0619 -0.8786 -0.2319 -0.0706
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence ; acp ; clinical practice guidelines
H-35	-0.39553824067115784	▁a CP ▁; ▁clinic al ▁practice ▁guidelines
D-35	-0.39553824067115784	aCP ; clinical practice guidelines
P-35	-0.2992 -0.1272 -0.9431 -0.3192 -0.0312 -0.0646 -0.6471 -1.0072 -0.1211
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise ; adverse events ; coronary artery disease ; cad
H-1899	-0.536370575428009	▁corona ry ▁arter y ▁disease ▁; CAD
D-1899	-0.536370575428009	coronary artery disease ;CAD
P-1899	-2.5056 -0.1076 -0.0603 -0.1491 -0.5729 -0.4262 -0.7840 -0.1076 -0.1140
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.23293854296207428	
D-1852	-0.23293854296207428	
P-1852	-0.3889 -0.0770
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical ; change
H-792	-0.606906533241272	▁responsive ness ▁; ▁clinic al ▁change
D-792	-0.606906533241272	responsiveness ; clinical change
P-792	-1.8018 -1.1710 -1.5951 -0.1663 -0.0210 -0.0121 -0.0344 -0.0536
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-0.4476180374622345	▁ED ▁visit s ▁; ▁CHF
D-216	-0.4476180374622345	ED visits ; CHF
P-216	-1.3600 -1.3519 -0.0405 -0.1572 -0.0359 -0.1038 -0.0839
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-0.9741116762161255	▁QR s
D-892	-0.9741116762161255	QRs
P-892	-1.9182 -1.4439 -0.4498 -0.0846
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare ; policy
H-1716	-0.5459349751472473	▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1716	-0.5459349751472473	Medicare ; post-acute care transfer policy
P-1716	-0.1304 -0.0069 -0.3958 -0.5041 -0.0128 -0.1754 -0.0134 -2.6282 -0.2186 -1.1497 -1.1591 -0.1570
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-1.0068494081497192	▁vegetables ▁; ▁nu ts ▁; ▁whole ▁grain ▁in take
D-692	-1.0068494081497192	vegetables ; nuts ; whole grain intake
P-692	-4.8197 -0.2598 -0.0749 -0.0294 -0.3090 -1.8895 -0.2315 -0.1856 -1.0346 -2.0362 -0.2052
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-0.8464341163635254	
D-1508	-0.8464341163635254	
P-1508	-1.5467 -0.1462
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs ; osprey
H-1611	-0.47888869047164917	▁de g s ▁; ▁o spre y ▁; ▁réseau s
D-1611	-0.47888869047164917	degs ; osprey ; réseaus
P-1611	-0.6164 -2.2458 -0.0754 -0.2958 -0.0398 -0.0115 -0.0867 -0.9676 -0.9971 -0.2048 -0.1259 -0.0799
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis ; therapy
H-1467	-0.5305061340332031	
D-1467	-0.5305061340332031	
P-1467	-0.9500 -0.1110
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world health organization ; hf
H-1791	-0.785848081111908	▁electronic ▁database s ▁; ▁World ▁health ▁Organization ▁; ▁ HF ▁; ▁LA
D-1791	-0.785848081111908	electronic databases ; World health Organization ; HF ; LA
P-1791	-4.1364 -0.9169 -0.0206 -0.0788 -0.3666 -1.2588 -0.1856 -0.7808 -1.0268 -0.0752 -1.0078 -0.7377 -0.3452 -0.0647
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit index
H-1008	-0.5295815467834473	▁deficit ▁index
D-1008	-0.5295815467834473	deficit index
P-1008	-0.3736 -0.4277 -1.1885 -0.1285
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients ; implantation ; crt
H-848	-0.5428647398948669	▁implant ation ▁; ▁c RT
D-848	-0.5428647398948669	implantation ; cRT
P-848	-0.2083 -0.0261 -0.3276 -0.3951 -1.6598 -1.0528 -0.1303
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-0.35373440384864807	▁benefit
D-619	-0.35373440384864807	benefit
P-619	-0.8267 -0.1378 -0.0967
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.6932264566421509	▁ir on
D-49	-0.6932264566421509	iron
P-49	-0.4222 -0.1592 -2.0770 -0.1145
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote monitoring ; hospital ; discharge ; patients ; heart failure ; meta-analysis
H-146	-0.7104076743125916	▁hospital ▁dis charge ▁; ▁patients ▁; ▁heart ▁failure
D-146	-0.7104076743125916	hospital discharge ; patients ; heart failure
P-146	-2.0079 -0.5392 -0.0242 -0.4455 -1.5212 -1.6798 -0.1982 -0.2658 -0.2739 -0.1485
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv filling pressure ; stable ; severe systolic hf
H-489	-0.6820298433303833	▁LV ▁fill ing ▁pressure ▁; ▁ HF
D-489	-0.6820298433303833	LV filling pressure ; HF
P-489	-0.1667 -1.9926 -0.1127 -0.5643 -0.1356 -2.8010 -0.1185 -0.1477 -0.0991
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ; ambulatory ; patients ; heart failure ; functional capacity ; outcomes
H-695	-0.47151196002960205	▁Solu ble ▁ST 2 ▁; ▁ambula tory ▁patients ▁; ▁heart ▁failure
D-695	-0.47151196002960205	Soluble ST2 ; ambulatory patients ; heart failure
P-695	-0.4299 -0.0305 -0.4874 -0.0617 -0.6441 -1.5750 -0.3029 -0.7789 -0.6796 -0.2791 -0.3040 -0.4168 -0.1398
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline ; echocardiograms ; evidence ; reverse remodeling
H-907	-1.2591966390609741	▁implant ing
D-907	-1.2591966390609741	implanting
P-907	-3.6037 -1.1271 -0.1440 -0.1620
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin hypophosphorylation ; myocardial dd
H-771	-0.2642248272895813	▁Tit in ▁hypo phos phor y lation ▁; ▁my o card ial ▁ DD
D-771	-0.2642248272895813	Titin hypophosphorylation ; myocardial DD
P-771	-0.0653 -0.8316 -0.1225 -0.0265 -0.1455 -0.4670 -0.0159 -0.1142 -1.1086 -0.1780 -0.0983 -0.1478 -0.5075 -0.0204 -0.1764 -0.2021
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic ; right ventricular contractile reserve ; patients ; pulmonary hypertension
H-821	-0.3014054298400879	▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension
D-821	-0.3014054298400879	ventricular contractile reserve ; pulmonary hypertension
P-821	-0.1155 -0.9957 -0.1595 -0.0448 -1.3305 -0.1483 -0.2317 -0.4540 -0.1207 -0.0301 -0.0815 -0.0930 -0.1130
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck stent ; chronic myocardial ischemia ; heart failure
H-502	-0.2938043475151062	▁bottle ne ck ▁sten t ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure ▁; ▁pig s
D-502	-0.2938043475151062	bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
P-502	-0.4805 -0.0029 -0.1557 -0.1150 -0.0403 -0.6117 -0.3694 -0.7849 -0.2300 -0.1158 -0.2461 -0.0579 -0.8828 -0.6373 -0.2076 -0.1109 -0.0978 -1.0154 -0.0141 -0.0240 -0.1594 -0.1042
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt intervals ; sd of all qt intervals ; sdqt
H-1439	-0.9570651054382324	▁ QT ▁interval s ▁; ▁SD ▁; ▁ QT
D-1439	-0.9570651054382324	QT intervals ; SD ; QT
P-1439	-0.6254 -0.4548 -0.5162 -0.0615 -0.1888 -0.0259 -0.7433 -0.9805 -0.5908 -6.0985 -0.2420
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal bleeding ; patients ; ventricular assist devices ; cardiac ; nurse
H-1656	-0.2852477729320526	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse
D-1656	-0.2852477729320526	Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
P-1656	-0.1300 -0.0111 -0.3029 -0.3140 -0.0862 -0.3290 -0.4103 -0.2372 -0.0102 -0.8114 -0.1319 -0.5711 -0.3622 -0.8975 -0.0218 -0.1489 -0.2069 -0.1518
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker ; uptitration ; hfpef
H-183	-0.3633785843849182	▁benefit ▁; ▁ RAS - ▁; ▁β - block er ▁up tit ration ▁; ▁ HF p EF
D-183	-0.3633785843849182	benefit ; RAS- ; β-blocker uptitration ; HFpEF
P-183	-1.3161 -0.0719 -1.4730 -0.0149 -0.1543 -1.2433 -0.2224 -0.0154 -0.0374 -0.0662 -0.0671 -0.4583 -0.0774 -0.2853 -0.8543 -0.1671 -0.0147 -0.4761 -0.1047 -0.1477
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition ; compliance ; exercise ; injections ; patients
H-1321	-0.5982091426849365	▁inject ions
D-1321	-0.5982091426849365	injections
P-1321	-2.1942 -0.0508 -0.0791 -0.0687
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump ; pump ; pump thrombosis ; hemolysis
H-2004	-0.3377688229084015	▁pump ▁exchange s ▁; ▁pump ▁mal function s ▁; ▁pump ▁ thro mbo sis ▁; ▁hem ol ysis
D-2004	-0.3377688229084015	pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis
P-2004	-0.0777 -0.3158 -0.0884 -0.3264 -0.2341 -0.7577 -0.0935 -0.1035 -0.2400 -0.5677 -0.2655 -0.1301 -0.1906 -1.2628 -0.3949 -0.3061 -0.0240 -0.1194 -1.1519 -0.1053
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac resynchronization therapy ; patients ; heart failure
H-903	-0.4203260540962219	▁cardiac ▁re syn chron ization ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure
D-903	-0.4203260540962219	cardiac resynchronization ; dialysis-dependent patients ; heart failure
P-903	-0.4513 -0.0192 -0.0733 -0.0092 -0.8851 -1.8853 -0.3836 -0.0624 -0.0893 -0.0808 -0.0915 -1.5126 -0.5903 -0.1835 -0.3849 -0.2210 -0.2222
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc ; outcomes ; outcome ; admission ; discharge
H-1401	-1.0780733823776245	▁NO c ▁; ▁ad mission
D-1401	-1.0780733823776245	NOc ; admission
P-1401	-0.9844 -1.3101 -0.9132 -1.3017 -0.0349 -2.8330 -0.1691
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol ; exercise ; training ; baseline ; hgb
H-843	-0.5734262466430664	▁HR Qo L ▁; ▁h gb
D-843	-0.5734262466430664	HRQoL ; hgb
P-843	-1.2409 -0.0229 -0.7593 -0.4477 -1.6336 -0.1975 -0.1799 -0.1056
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient ; patients ; discharged ; hf
H-1400	-0.5683482885360718	▁in patient ▁records ▁; ▁ HF
D-1400	-0.5683482885360718	inpatient records ; HF
P-1400	-0.1912 -0.0792 -0.8625 -0.2842 -2.6965 -0.1017 -0.1559 -0.1756
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal muscle ; correlated ; vo2 max
H-1500	-0.4760810434818268	▁skelet al ▁muscle ▁mass ▁; ▁VO 2
D-1500	-0.4760810434818268	skeletal muscle mass ; VO2
P-1500	-0.6125 -0.1868 -0.9518 -0.7935 -0.4733 -1.0328 -0.0517 -0.1075 -0.0749
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac catheterization ; patient ; extubated ; transferred
H-1297	-0.6445610523223877	▁cardiac ▁cat heter ization
D-1297	-0.6445610523223877	cardiac catheterization
P-1297	-1.5275 -0.3721 -0.0170 -0.9771 -0.9003 -0.0734
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial ; exercise ; training ; heart failure ; hf ; patients
H-1925	-0.6605962514877319	▁psycho social ▁factors ▁; ▁exercise ▁; ▁heart ▁failure ▁; HF
D-1925	-0.6605962514877319	psychosocial factors ; exercise ; heart failure ;HF
P-1925	-1.0879 -0.0806 -0.7126 -0.4847 -2.1623 -1.5908 -0.3162 -0.2757 -0.2975 -0.1351 -0.6222 -0.1615
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis ; medical ; heart failure ; canadian cardiovascular society
H-198	-0.8599390983581543	▁heart ▁failure ▁; ▁Canadian ▁Card io vas cular ▁Society ▁guidelines
D-198	-0.8599390983581543	heart failure ; Canadian Cardiovascular Society guidelines
P-198	-4.7431 -0.4249 -0.1378 -1.6957 -0.5183 -1.1749 -0.1014 -0.2758 -0.0946 -0.8585 -0.1560 -0.1383
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized ; double-blind ; active ; placebo
H-77	-0.83073490858078	▁active ▁treatment
D-77	-0.83073490858078	active treatment
P-77	-0.7476 -2.1001 -0.3720 -0.1033
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report ; aric ; hf
H-290	-0.5302709341049194	▁a RIC ▁ HF
D-290	-0.5302709341049194	aRIC HF
P-290	-0.6246 -1.2624 -0.2686 -0.1320 -0.7482 -0.1457
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients ; atrial fibrillation ; pacemaker
H-883	-0.38914379477500916	▁at rial ▁fi bril lation ▁; ▁pace maker
D-883	-0.38914379477500916	atrial fibrillation ; pacemaker
P-883	-1.5893 -0.0950 -0.3392 -0.0282 -0.0433 -0.3273 -1.2012 -0.0304 -0.1363 -0.1012
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis ; mortality ; patients
H-68	-0.4138408899307251	▁mortal ity ▁; ▁i CD - HF
D-68	-0.4138408899307251	mortality ; iCD-HF
P-68	-1.0020 -0.3455 -0.7031 -0.2805 -0.1225 -0.0095 -0.0358 -1.0437 -0.1820
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients ; therapy ; hospitalized ; cardiovascular
H-1223	-0.8433923125267029	▁cardiovascular ▁reason
D-1223	-0.8433923125267029	cardiovascular reason
P-1223	-2.2277 -0.8999 -0.0714 -0.1747
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter ablation ; sinus rhythm
H-945	-0.45171019434928894	▁AF - free ▁probabil ity ▁; ▁cat heter ▁ab lation ▁; ▁sinus ▁ rhythm
D-945	-0.45171019434928894	AF-free probability ; catheter ablation ; sinus rhythm
P-945	-0.4146 -0.0490 -0.1997 -2.8185 -0.1845 -0.3906 -0.1474 -0.0100 -0.0287 -0.0369 -0.1180 -2.1068 -0.0988 -0.2130 -0.1868 -0.2240
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body mass index ; crf ; exercise
H-1768	-0.41444963216781616	▁body ▁mass ▁index ▁; ▁c RF ▁; ▁tre ad m ill ▁exercise ▁testing
D-1768	-0.41444963216781616	body mass index ; cRF ; treadmill exercise testing
P-1768	-1.1419 -0.5787 -0.0434 -0.0627 -0.1132 -0.0973 -0.0982 -0.6910 -0.0124 -0.0281 -0.1305 -1.8593 -0.9596 -0.2222 -0.1783
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial tissue ; pka
H-1426	-0.3844396471977234	▁human ▁my o card ial ▁tissu e ▁; ▁p KA ▁sub un its
D-1426	-0.3844396471977234	human myocardial tissue ; pKA subunits
P-1426	-1.3315 -1.1698 -0.1518 -0.1319 -0.1835 -0.0978 -0.3561 -0.2117 -0.6074 -0.9755 -0.2719 -0.0403 -0.0502 -0.1067 -0.0804
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease ; accounting ; cardiac transplants
H-982	-0.43063992261886597	▁pa e dia tric ▁cardiac ▁transplant s
D-982	-0.43063992261886597	paediatric cardiac transplants
P-982	-1.4142 -0.0723 -1.1341 -0.1164 -0.0120 -0.1387 -0.0729 -0.7807 -0.1344
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ; ventricular-arterial coupling
H-526	-0.2232353687286377	▁vent ri cular - arte rial ▁coup ling ▁; ▁SV
D-526	-0.2232353687286377	ventricular-arterial coupling ; SV
P-526	-0.0080 -0.7248 -0.0682 -0.0320 -0.0036 -0.0464 -0.0227 -1.0687 -0.4238 -0.0141 -0.0883 -0.1782
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic failure ; cardiomyopathic
H-986	-0.32148727774620056	▁dia sto lic ▁failure ▁; ▁cardio my o pathi c ▁restriction
D-986	-0.32148727774620056	diastolic failure ; cardiomyopathic restriction
P-986	-0.6944 -0.1424 -0.9597 -0.0480 -0.2188 -0.0466 -0.3267 -0.2952 -0.0042 -0.0811 -0.0887 -1.1705 -0.1029
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic nervous system ; activity ; qtv
H-1436	-0.36596032977104187	▁autonomi c ▁ner vous ▁system ▁activity ▁; ▁Q TV
D-1436	-0.36596032977104187	autonomic nervous system activity ; QTV
P-1436	-0.1087 -0.2996 -0.4045 -0.9041 -0.2551 -0.8794 -0.2876 -0.4788 -0.2392 -0.0809 -0.0877
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients ; pneumonia ; surgical ; conditions
H-5	-0.23936614394187927	▁pneu monia ▁; ▁sur g ical ▁conditions
D-5	-0.23936614394187927	pneumonia ; surgical conditions
P-5	-0.0349 -0.5667 -0.6904 -0.0334 -0.3890 -0.2333 -0.0063 -0.0751 -0.1252
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1 mapping ; clinically ; myocardial fibrosis
H-1065	-0.7277247309684753	▁ma pping ▁; ▁my o card ial ▁fibro sis
D-1065	-0.7277247309684753	mapping ; myocardial fibrosis
P-1065	-1.4759 -0.3534 -0.2983 -3.9117 -0.2584 -0.3057 -0.4114 -0.0126 -0.7789 -0.0950 -0.1035
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.37047135829925537	
D-1862	-0.37047135829925537	
P-1862	-0.6571 -0.0838
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients ; prognosis
H-1315	-0.678101122379303	
D-1315	-0.678101122379303	
P-1315	-1.2765 -0.0797
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-0.8053125143051147	SD
D-1983	-0.8053125143051147	SD
P-1983	-1.2541 -0.9765 -0.1854
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-0.6672038435935974	
D-626	-0.6672038435935974	
P-626	-1.2126 -0.1218
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics rounds
H-1681	-0.3089437484741211	▁e thi cs ▁Round s
D-1681	-0.3089437484741211	ethics Rounds
P-1681	-1.0380 -0.0163 -0.1454 -0.3427 -0.0329 -0.5054 -0.0819
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.21650588512420654	
D-2013	-0.21650588512420654	
P-2013	-0.3549 -0.0781
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
H-13	-0.12884806096553802	▁bio mark ers ▁; ▁neuro hormon al ▁stimul ation ▁; ▁ inflammation ▁; ▁en dot heli al ▁dys function
D-13	-0.12884806096553802	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
P-13	-0.2963 -0.0120 -0.0221 -0.3631 -0.0549 -0.0207 -0.0873 -0.0705 -0.0217 -0.1598 -0.0185 -0.0805 -0.1275 -0.0278 -0.7869 -0.0597 -0.0131 -0.0038 -0.2182 -0.1077 -0.1539
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart failure ; pathophysiology ; diagnosis ; medical treatment ; nursing
H-2018	-0.44765833020210266	▁Heart ▁Fail ure ▁; ▁Path o phy si ology ▁; ▁Medical ▁Treatment ▁; ▁Nur sing ▁Management
D-2018	-0.44765833020210266	Heart Failure ; Pathophysiology ; Medical Treatment ; Nursing Management
P-2018	-0.2438 -0.0327 -0.0396 -0.4253 -0.1645 -0.7951 -0.0135 -0.3974 -0.4118 -0.2982 -0.4666 -0.1091 -3.6356 -0.1257 -0.0728 -0.5934 -0.1320 -0.1009
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia ; patients ; heart disease ; clinical practice guideline ; american college of physicians
H-29	-0.567600667476654	▁an emia ▁; ▁heart ▁disease ▁; ▁clinic al ▁practice ▁guide line ▁; ▁American ▁College ▁of ▁Physic ians
D-29	-0.567600667476654	anemia ; heart disease ; clinical practice guideline ; American College of Physicians
P-29	-1.4865 -0.1647 -0.3462 -1.1585 -0.9949 -0.7035 -2.7003 -0.0402 -0.0335 -0.0946 -0.0135 -0.7920 -1.4639 -0.0969 -0.2675 -0.0183 -0.1225 -0.1791 -0.1075
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart rate reduction ; ivabradine ; left ventricle ; heart failure ; patients
H-515	-0.7198059558868408	▁heart ▁rate ▁re duction ▁; ▁i va bra dine ▁un load s ▁; ▁left ▁vent ric le ▁; ▁heart ▁failure
D-515	-0.7198059558868408	heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
P-515	-1.7448 -1.8914 -0.3398 -0.0291 -0.3667 -0.0235 -0.0164 -0.6286 -0.0352 -1.2424 -0.0087 -0.1277 -0.7836 -0.3032 -0.0876 -2.9198 -2.0301 -0.6931 -0.4462 -0.6826 -1.0925 -0.3427
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence ; end-stage renal disease ; outpatients ; systolic heart failure
H-386	-0.384881854057312	▁end - s tage ▁renal ▁disease ▁; ▁out patient s ▁; ▁sy sto lic ▁heart ▁failure
D-386	-0.384881854057312	end-stage renal disease ; outpatients ; systolic heart failure
P-386	-0.3999 -0.0853 -0.2821 -0.0029 -0.0297 -0.3543 -0.1017 -2.8227 -0.0077 -0.0196 -0.2866 -0.2215 -0.0686 -1.5006 -0.2835 -0.1617 -0.1537 -0.1458
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo ; bivp ; correlated ; rs synchrony
H-327	-0.4382312595844269	▁ RV PO ▁; ▁Bi VP ▁; ▁CO ▁; ▁RS ▁synchron y ▁; ▁CS
D-327	-0.4382312595844269	RVPO ; BiVP ; CO ; RS synchrony ; CS
P-327	-0.4273 -0.8439 -1.8906 -0.0992 -1.1197 -0.1031 -0.1017 -1.0003 -0.1101 -0.4675 -0.0012 -0.1719 -0.3500 -0.0124 -0.1360 -0.1770
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal dnx ; cardiac ; autonomic balance ; chf ; sympathetic tone
H-1382	-0.2243233472108841	▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance ▁; ▁CHF ▁; ▁sympa the tic ▁tone
D-1382	-0.2243233472108841	renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
P-1382	-0.1663 -0.3019 -0.0039 -0.2122 -0.0592 -0.1877 -0.2315 -0.0279 -0.2540 -0.0041 -0.4280 -0.0525 -0.5825 -1.0270 -0.0220 -0.1628 -0.0900
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin ; acute ; anthracycline-induced cardiotoxicity
H-931	-0.18832413852214813	▁resist in ▁; ▁a cute ▁an thra cycli ne - indu ced ▁cardio toxic ity
D-931	-0.18832413852214813	resistin ; acute anthracycline-induced cardiotoxicity
P-931	-0.3834 -0.2539 -0.1019 -0.3265 -0.0129 -0.0589 -0.0545 -0.4190 -0.2049 -0.0481 -0.0065 -0.4957 -0.0152 -0.1248 -0.2861 -0.1986 -0.2107
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute ; autonomic nervous system ; qtv ; hf ; patients
H-1447	-0.4572257697582245	▁a cute ▁autonomi c ▁ner vous ▁system ▁modul ation ▁; ▁Q TV ▁; ▁ HF
D-1447	-0.4572257697582245	acute autonomic nervous system modulation ; QTV ; HF
P-1447	-0.9012 -0.0184 -1.1499 -0.4746 -0.4047 -1.6324 -0.3159 -0.1726 -0.0298 -0.1766 -0.5395 -0.2002 -0.2367 -1.0840 -0.0629 -0.2595 -0.1139
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart rate ; aortic ; blood flow ; doxorubicin
H-960	-0.34886664152145386	▁Heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁do xor ubi cin
D-960	-0.34886664152145386	Heart rate ; aortic blood flow ; doxorubicin
P-960	-0.6823 -1.2929 -0.1822 -0.0128 -0.0711 -0.9916 -0.1785 -0.3180 -0.8128 -0.0667 -0.0249 -0.0652 -0.2661 -0.1445 -0.1234
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical ; outcomes ; hospitalisations ; readmissions ; mortality
H-1850	-0.5294655561447144	▁hospital isation s ▁; ▁read missions
D-1850	-0.5294655561447144	hospitalisations ; readmissions
P-1850	-1.9885 -0.0233 -0.0812 -0.5892 -0.4638 -0.0252 -0.9173 -0.1472
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial ; pde2 ; expression ; activity ; hf
H-1213	-0.5684143304824829	▁My o card ial ▁p de 2 ▁expression ▁; ▁ HF
D-1213	-0.5684143304824829	Myocardial pde2 expression ; HF
P-1213	-1.2052 -0.1113 -0.0510 -0.2302 -2.0268 -0.0416 -0.0806 -0.1713 -0.2663 -2.4580 -0.3985 -0.1865 -0.1621
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat ; sympathetic outflow ; parasympathetic activity
H-1869	-0.8163084387779236	▁BAT ▁; ▁sympa the tic ▁out flow ▁; ▁para sy mpa the
D-1869	-0.8163084387779236	BAT ; sympathetic outflow ; parasympathe
P-1869	-0.1424 -0.8258 -0.1354 -0.3560 -0.8755 -0.3194 -0.1385 -0.2268 -0.0775 -0.1330 -0.0748 -1.3413 -6.6281 -0.1536
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
H-426	-0.27139636874198914	▁e cho car dio graphic ▁; ▁rever se ▁remodel ing ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-426	-0.27139636874198914	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
P-426	-0.5211 -0.2314 -0.0656 -0.4558 -0.1876 -1.0218 -0.1206 -0.0086 -0.0182 -0.1996 -0.3045 -0.0253 -0.0154 -0.0113 -0.0017 -0.4822 -1.2923 -0.0330 -0.2531 -0.1788
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular death ; hf ; hospitalization ; exercise ; training ; patients ; btes
H-1933	-0.5665984153747559	▁cardiovascular ▁death ▁; HF ▁; ▁b tes
D-1933	-0.5665984153747559	cardiovascular death ;HF ; btes
P-1933	-0.5467 -0.8816 -0.0501 -0.5232 -1.4007 -1.0916 -0.3532 -0.1492 -0.1029
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise ; training ; patients ; chronic heart failure ; high-density lipoprotein
H-245	-1.4791595935821533	▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁lipo prote in ▁functional ▁properties
D-245	-1.4791595935821533	patients ; chronic heart failure ; lipoprotein functional properties
P-245	-7.1906 -0.6202 -1.1179 -1.2150 -0.6084 -0.2162 -3.1603 -0.1926 -1.2741 -2.2337 -1.0023 -0.2253 -0.1726
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal ; pathophysiology ; congestive heart failure ; chf
H-634	-0.3680039048194885	▁Neuro hormon al ▁ab normal ities ▁; ▁pat ho phy si ology ▁; ▁con ges tive ▁heart ▁failure ▁; CH f
D-634	-0.3680039048194885	Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
P-634	-0.9987 -0.0146 -0.0250 -0.0442 -0.0278 -0.8610 -0.0855 -2.6206 -0.0119 -0.0786 -0.3750 -0.7200 -0.5178 -0.0608 -0.0504 -0.2017 -0.5810 -0.1407 -0.4283 -0.3314 -0.0833 -0.0994 -0.1064
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic neurotransmission ; acetylcholinesterase inhibition
H-1135	-0.21292735636234283	▁para sy mpa the tic ▁neuro trans mission ▁; ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.21292735636234283	parasympathetic neurotransmission ; acetylcholinesterase inhibition
P-1135	-0.0291 -0.0809 -0.0971 -0.6730 -0.9762 -0.0407 -0.0204 -0.1222 -0.2220 -0.0203 -0.0363 -0.1692 -0.2170 -0.1077 -0.1526 -0.7704 -0.1187 -0.1304 -0.1443 -0.1300
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential effect ; lvef ; mortality
H-118	-0.27777886390686035	▁LV EF ▁; ▁long - term ▁mortal ity
D-118	-0.27777886390686035	LVEF ; long-term mortality
P-118	-0.4840 -0.3151 -0.3816 -0.0419 -0.0503 -0.7157 -0.0694 -0.1932 -0.3663 -0.1604
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash ; mortality ; heart failure ; health
H-684	-0.49363917112350464	▁Mediterrane an ▁; ▁DAS h ▁; ▁mortal ity ▁; ▁women ▁; ▁heart ▁failure ▁; ▁Women s ▁Health ▁Initiative
D-684	-0.49363917112350464	Mediterranean ; DASh ; mortality ; women ; heart failure ; Womens Health Initiative
P-684	-0.1763 -0.0196 -0.2783 -0.0095 -0.5666 -0.9478 -0.0475 -0.1480 -0.1045 -2.1997 -0.5493 -0.1502 -0.3900 -0.3080 -0.5906 -1.6959 -1.2833 -0.1224 -0.1504 -0.1353
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness ; sickle cell disease ; anemia
H-1682	-0.4385318458080292	▁Jehovah ' s ▁Wit ness ▁; ▁sick le ▁cell ▁disease ▁; ▁an emia
D-1682	-0.4385318458080292	Jehovah's Witness ; sickle cell disease ; anemia
P-1682	-0.0060 -3.5879 -0.6519 -0.0236 -0.2561 -0.2036 -0.0305 -0.2612 -0.0364 -0.1619 -0.5262 -0.3734 -0.1222 -0.1369 -0.2001
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas ; therapeutic ; heart failure
H-1485	-0.49843573570251465	▁mi RNA s ▁; ▁heart ▁failure
D-1485	-0.49843573570251465	miRNAs ; heart failure
P-1485	-0.9763 -0.0205 -0.0380 -0.4192 -2.1131 -0.2434 -0.0767 -0.1003
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine ; furosemide ; outcome
H-586	-0.46997255086898804	▁do bu tamine ▁; ▁fur os em ide ▁; ▁oxygen ▁flow
D-586	-0.46997255086898804	dobutamine ; furosemide ; oxygen flow
P-586	-0.3237 -0.2573 -0.1361 -0.2892 -0.1859 -0.8478 -0.0249 -0.0096 -2.0149 -0.4719 -1.3253 -0.1318 -0.0911
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health buddy program ; hospital ; hospitalized
H-1626	-0.4187304675579071	▁Health ▁Budd y ▁Program ▁; ▁ED
D-1626	-0.4187304675579071	Health Buddy Program ; ED
P-1626	-1.1106 -0.0092 -0.0418 -0.5185 -0.1244 -0.2848 -1.1549 -0.1056
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad variant ; congestive heart failure
H-1670	-0.71876460313797	▁ca 2 ▁; ▁current s ▁; ▁rad ▁; ▁con ges tive ▁heart ▁failure
D-1670	-0.71876460313797	ca2 ; currents ; rad ; congestive heart failure
P-1670	-2.4022 -0.1751 -1.3329 -3.7765 -0.1303 -0.0898 -0.8937 -0.3684 -0.3610 -0.0474 -0.1119 -0.3536 -0.4200 -0.1895 -0.1290
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs ; outcomes ; patients ; diabetes
H-130	-0.3408154249191284	▁c PC s ▁; ▁diabetes
D-130	-0.3408154249191284	cPCs ; diabetes
P-130	-0.4357 -0.5978 -0.0620 -0.3795 -0.5716 -0.1262 -0.2130
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin ; breast cancer ; patients ; cardiotoxicity
H-936	-0.3522413671016693	▁resist in ▁; ▁an thra cycli ne - tre ated ▁breast ▁cancer ▁; ▁cardio toxic ity
D-936	-0.3522413671016693	resistin ; anthracycline-treated breast cancer ; cardiotoxicity
P-936	-1.0669 -0.6103 -0.6620 -0.0355 -0.0305 -0.7960 -0.2566 -0.0809 -0.0236 -0.5609 -0.0357 -0.2088 -1.0409 -0.0814 -0.0645 -0.4140 -0.2067 -0.1650
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left pulmonary artery ; right pulmonary artery
H-597	-0.3477180302143097	▁pulmonar y ▁arter y ▁; ▁right ▁pulmonar y ▁arter y
D-597	-0.3477180302143097	pulmonary artery ; right pulmonary artery
P-597	-0.8909 -0.0705 -0.0691 -0.3716 -0.6281 -1.0853 -0.0317 -0.0756 -0.0652 -0.3164 -0.4205 -0.1477
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri scanner ; baseline ; heart failure
H-1057	-0.7637072801589966	▁m RI ▁scanner ▁; ▁heart ▁failure
D-1057	-0.7637072801589966	mRI scanner ; heart failure
P-1057	-1.7077 -1.0984 -0.5364 -0.6277 -1.0740 -0.6145 -0.2123 -0.2386
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical ; therapeutic
H-1368	-0.44925710558891296	
D-1368	-0.44925710558891296	
P-1368	-0.8177 -0.0808
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive heart failure ; chf
H-209	-0.2557826638221741	▁con ges tive ▁heart ▁failure ▁; CH f
D-209	-0.2557826638221741	congestive heart failure ;CHf
P-209	-1.0776 -0.0360 -0.0623 -0.2864 -0.1051 -0.2739 -0.4637 -0.0869 -0.0808 -0.0852
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome ; heart failure ; fontan
H-1493	-0.330828458070755	▁muscle - was ting ▁syndrome ▁; ▁acquire d ▁heart ▁failure
D-1493	-0.330828458070755	muscle-wasting syndrome ; acquired heart failure
P-1493	-0.6801 -0.0550 -0.2550 -0.3458 -0.1803 -0.0905 -0.6408 -0.0206 -0.3356 -0.1875 -1.0767 -0.1020
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty ; health ; outcomes
H-623	-0.6884024143218994	▁Fra il ty ▁; ▁el der ly
D-623	-0.6884024143218994	Frailty ; elderly
P-623	-1.0755 -0.5121 -1.9325 -0.2322 -0.0700 -0.2251 -0.2922 -1.7749 -0.0811
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf ; intubation
H-221	-0.5635783672332764	▁ed ▁; ▁CHF ▁; ▁in tub ation
D-221	-0.5635783672332764	ed ; CHF ; intubation
P-221	-1.1489 -2.0189 -0.1942 -0.3569 -0.0030 -0.0099 -0.0145 -1.2215 -0.1045
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol ; mortality
H-650	-0.3391251564025879	▁bis o pro lol ▁; ▁mortal ity
D-650	-0.3391251564025879	bisoprolol ; mortality
P-650	-0.5100 -0.1301 -0.0277 -0.4667 -1.0487 -0.4116 -0.2938 -0.0570 -0.1065
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health buddy program ; telehealth
H-1622	-0.34623268246650696	▁Health ▁Budd y ▁Program ▁; ▁content - driv en ▁tele health ▁system ▁; ▁care ▁management
D-1622	-0.34623268246650696	Health Buddy Program ; content-driven telehealth system ; care management
P-1622	-1.2698 -0.0122 -0.0342 -1.0300 -0.1632 -1.2042 -0.0124 -0.0087 -0.0481 -0.3054 -0.0910 -0.2142 -0.7439 -0.3130 -0.0270 -0.2943 -0.1144
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare ; hospitalizations
H-1714	-0.3061302900314331	▁Medica re ▁fee - for - service ▁beneficiar ies
D-1714	-0.3061302900314331	Medicare fee-for-service beneficiaries
P-1714	-0.0473 -0.0091 -0.1699 -0.0326 -0.3270 -0.0261 -0.0426 -1.4548 -0.1359 -1.0212 -0.1009
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician ; conditions ; hospital ; discharge
H-1422	-0.18849007785320282	▁physician ▁continu ity ▁; ▁conditions ▁; ▁hospital ▁dis charge
D-1422	-0.18849007785320282	physician continuity ; conditions ; hospital discharge
P-1422	-0.1565 -0.0111 -0.0753 -0.7635 -0.0093 -0.5056 -0.2733 -0.1016 -0.0065 -0.0671 -0.1037
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic ; patients ; heart failure
H-1740	-1.4026973247528076	▁patients ▁; ▁heart ▁failure
D-1740	-1.4026973247528076	patients ; heart failure
P-1740	-6.2257 -1.4165 -0.3400 -0.2722 -0.0687 -0.0931
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss ; btes ; exercise
H-1928	-0.4247754216194153	▁PS SS ▁; ▁social ▁support ▁; ▁b tes
D-1928	-0.4247754216194153	PSSS ; social support ; btes
P-1928	-0.8352 -0.6800 -0.1202 -0.0256 -0.5973 -0.2960 -0.1354 -0.2453 -1.1828 -0.1300
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac stress ; β-ar ; drive
H-1219	-0.7480430603027344	▁cardiac ▁stress ▁; ▁β - AR ▁drive
D-1219	-0.7480430603027344	cardiac stress ; β-AR drive
P-1219	-2.6853 -1.1472 -0.2958 -1.9438 -0.0227 -0.1344 -0.2784 -0.1027 -0.1220
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin subproteome ; diseased ; heart
H-99	-0.4657546281814575	▁chr omat in ▁sub prote ome ▁; ▁mouse ▁heart
D-99	-0.4657546281814575	chromatin subproteome ; mouse heart
P-99	-0.7128 -0.0060 -1.1000 -0.0305 -0.0198 -0.1674 -0.1545 -2.2474 -0.5309 -0.0729 -0.0809
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated ; septal ; wall ; avd ; free wall cs ; vvd
H-329	-0.6029359102249146	▁sept al ▁wall ▁CS ▁; ▁av d ▁; ▁free ▁wall ▁CS ▁; ▁VVD
D-329	-0.6029359102249146	septal wall CS ; avd ; free wall CS ; VVD
P-329	-1.6023 -0.1478 -0.1141 -2.1422 -0.1355 -0.2909 -0.3981 -0.1745 -0.6953 -0.1440 -1.7942 -0.2284 -0.8966 -0.1580 -0.1220
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv strain ; strain ; echocardiography ; baseline ; ablation
H-946	-0.7716189026832581	▁LV ▁; ▁e cho card i ography
D-946	-0.7716189026832581	LV ; echocardiography
P-946	-0.2678 -2.1966 -2.6115 -0.2753 -0.2002 -0.4286 -0.3239 -0.4824 -0.1582
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed up ; adverse events ; death ; transplantation ; circulatory assist device
H-1162	-0.39976760745048523	▁implant ation ▁; ▁circula tory ▁assist ▁device
D-1162	-0.39976760745048523	implantation ; circulatory assist device
P-1162	-2.5785 -0.0067 -0.2664 -0.0319 -0.1379 -0.1423 -0.1906 -0.1503 -0.0933
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular pacing ; left heart twist ; strain ; right heart failure
H-318	-0.4405045807361603	▁bi ven tri cular ▁pa cing ▁; ▁left ▁heart ▁twist ▁; ▁strain ▁; ▁por cine ▁model ▁of ▁right ▁heart ▁failure
D-318	-0.4405045807361603	biventricular pacing ; left heart twist ; strain ; porcine model of right heart failure
P-318	-0.4316 -0.2081 -0.5919 -0.2726 -0.2495 -0.1604 -0.3383 -1.0507 -1.0127 -0.8166 -0.1046 -0.1689 -0.1195 -0.6421 -0.0934 -0.9339 -1.2657 -0.4054 -0.2325 -0.2188 -0.2313 -0.1427
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic ; acute rv failure ; left ventricular dysfunction
H-1092	-0.5983868837356567	▁et i ologic ▁causes ▁; ▁ RV ▁failure ▁; ▁left ▁vent ri cular ▁dys function
D-1092	-0.5983868837356567	etiologic causes ; RV failure ; left ventricular dysfunction
P-1092	-2.8966 -0.2979 -0.2122 -1.1088 -0.3090 -0.8235 -0.3217 -0.6568 -0.1689 -0.1993 -0.0343 -2.1381 -0.1648 -0.0307 -0.4266 -0.1963 -0.1872
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs ; functional capacity ; outcomes ; heart failure ; hf
H-121	-0.24851004779338837	▁c PC s ▁; ▁functional ▁capacity ▁; ▁heart ▁failure ▁; HF
D-121	-0.24851004779338837	cPCs ; functional capacity ; heart failure ;HF
P-121	-0.0761 -0.3365 -0.0850 -0.1676 -0.6900 -0.4899 -0.1355 -0.2258 -0.1835 -0.4345 -0.1075 -0.1436 -0.1550
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein kinase a ; guanylate cyclase ; contractile response
H-418	-0.560845136642456	▁inhibi tion ▁; ▁protein ▁kina se ▁; ▁solu ble ▁gua ny late ▁cy cla se
D-418	-0.560845136642456	inhibition ; protein kinase ; soluble guanylate cyclase
P-418	-0.5025 -0.0390 -0.7364 -0.1449 -0.1300 -0.1028 -0.2325 -1.0018 -0.0985 -0.0895 -0.1888 -1.6571 -1.9225 -0.0991 -0.3757 -1.9720 -0.2414
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating progenitor cells ; outcome ; heart failure ; patients ; longitudinal
H-119	-0.5601144433021545	▁circula ting ▁pro gen itor ▁cell s ▁; ▁heart ▁failure
D-119	-0.5601144433021545	circulating progenitor cells ; heart failure
P-119	-1.0065 -2.2915 -0.5004 -0.1908 -0.2009 -0.3289 -0.0490 -0.3360 -0.4544 -0.2184 -0.9812 -0.1634
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress doppler echocardiography ; prognostic ; pulmonary hypertension ; patients
H-832	-0.31096509099006653	▁Stress ▁do pp ler ▁e cho card i ography ▁; ▁pulmonar y ▁hyper tension
D-832	-0.31096509099006653	Stress doppler echocardiography ; pulmonary hypertension
P-832	-0.6972 -1.4693 -0.0408 -0.2197 -0.0315 -0.5254 -0.1511 -0.4222 -0.1929 -0.3654 -0.0311 -0.0570 -0.0196 -0.2191 -0.3939 -0.1394
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic ; diastolic mitral leaflet motions ; organic ; lesion
H-351	-0.552641749382019	▁sy sto lic ▁; ▁dia sto lic ▁mit ral ▁le a flet
D-351	-0.552641749382019	systolic ; diastolic mitral leaflet
P-351	-0.9577 -0.1028 -0.3626 -0.4847 -0.1179 -0.4490 -0.5121 -1.6602 -0.0857 -0.3046 -0.3206 -0.0071 -2.2025 -0.1695
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity ; mortality ; quality of life ; patients ; hf
H-2023	-0.5898645520210266	▁morbi d ity ▁; ▁mortal ity
D-2023	-0.5898645520210266	morbidity ; mortality
P-2023	-0.2319 -0.1851 -0.3029 -0.2877 -0.0147 -0.1819 -3.4023 -0.1123
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt ; nt-probnp ; hf
H-291	-0.23434413969516754	▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF
D-291	-0.23434413969516754	ctnt ; NT-probNP ; HF
P-291	-0.0649 -0.0788 -0.0934 -0.1375 -0.0402 -0.0685 -0.0139 -0.0043 -0.5767 -0.0843 -0.1298 -0.4559 -0.1512 -1.4336 -0.1823
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student t test ; confidence intervals ; cis ; regression analyses
H-215	-1.0076688528060913	▁confidence ▁interval s ▁; CI s
D-215	-1.0076688528060913	confidence intervals ;CIs
P-215	-4.0461 -0.5144 -0.0287 -0.1906 -2.7474 -0.0645 -0.3346 -0.1351
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical ; radiological ; hf ; quality of life
H-565	-0.9980916976928711	▁radi ological ▁sign s
D-565	-0.9980916976928711	radiological signs
P-565	-0.5373 -0.4752 -0.7486 -0.0413 -4.0541 -0.1322
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital ; mortality ; patients ; bnp ; mortality
H-195	-0.34539511799812317	▁in hospital ▁mortal ity ▁; ▁b NP
D-195	-0.34539511799812317	inhospital mortality ; bNP
P-195	-0.4172 -0.0066 -0.1910 -0.1190 -0.2969 -0.1162 -0.4720 -1.3648 -0.1249
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality ; deaths ; acs ; consultation ; operation
H-1287	-0.5579617619514465	▁Mor t ality ▁; ▁a CS
D-1287	-0.5579617619514465	Mortality ; aCS
P-1287	-0.6625 -0.0281 -0.0247 -0.7828 -0.3405 -1.3786 -1.0929 -0.1536
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right ventricle ; rv ; cardiac function ; medical
H-1091	-0.8272120356559753	▁vent ric le ▁; RV ▁; ▁cardiac ▁function
D-1091	-0.8272120356559753	ventricle ;RV ; cardiac function
P-1091	-0.2565 -1.4313 -1.0021 -0.2582 -0.7100 -0.5307 -0.1169 -2.9936 -0.8532 -0.1196
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes ; costs ; patients ; heart failure ; hf
H-1721	-0.9007744193077087	▁coût ▁; ▁patients ▁; ▁heart ▁failure ▁; HF
D-1721	-0.9007744193077087	coût ; patients ; heart failure ;HF
P-1721	-2.7454 -0.6180 -2.0622 -1.5713 -0.7722 -0.2297 -0.6661 -0.1419 -0.1140 -0.0871
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv dysfunction ; correlated ; lean body mass
H-1164	-0.8019616007804871	▁ RV ▁dys function ▁; ▁weight ▁loss ▁; ▁fat ▁; lean ▁body ▁mass ▁ratio
D-1164	-0.8019616007804871	RV dysfunction ; weight loss ; fat ;lean body mass ratio
P-1164	-0.8182 -0.4094 -0.1977 -0.5961 -0.1662 -0.7428 -1.9737 -0.1937 -1.6456 -1.7102 -1.3088 -1.7801 -0.7777 -0.1372 -0.1842 -0.1897
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr reduction ; beta blockers ; exercise capacity ; hfref
H-1937	-0.2888750433921814	▁HR ▁re duction ▁; ▁beta ▁block ers ▁; ▁h Fr EF
D-1937	-0.2888750433921814	HR reduction ; beta blockers ; hFrEF
P-1937	-0.4909 -0.1140 -0.0078 -0.1397 -0.0864 -0.1386 -0.0231 -0.3691 -0.3496 -1.4067 -0.4080 -0.1298 -0.0917
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary ; exercise ; prognostically ; heart failure
H-1274	-0.9193432927131653	▁cardio pul mon ary ▁; ▁heart ▁failure
D-1274	-0.9193432927131653	cardiopulmonary ; heart failure
P-1274	-0.3675 -0.0854 -2.0357 -0.2356 -2.9704 -2.0269 -0.3417 -0.1056 -0.1053
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle cohort study ; canada
H-1951	-0.6598274111747742	
D-1951	-0.6598274111747742	
P-1951	-1.2455 -0.0742
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary outcome ; sympathetic activity ; myocardial washout
H-1115	-1.142408847808838	▁i - mi g ▁my o card ial ▁was hout
D-1115	-1.142408847808838	i-mig myocardial washout
P-1115	-1.0955 -2.1182 -1.0933 -2.3744 -2.8717 -0.3504 -0.2384 -0.0552 -2.9872 -0.0555 -0.1819 -0.2872
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial diastolic dysfunction ; dd ; collagen deposition ; titin
H-761	-0.3112609088420868	▁my o card ial ▁dia sto lic ▁dys function ▁; DD
D-761	-0.3112609088420868	myocardial diastolic dysfunction ;DD
P-761	-0.3827 -0.1056 -0.0900 -0.2864 -0.1118 -0.3202 -0.9924 -0.0059 -0.4246 -0.3595 -0.0736 -0.7797 -0.1140
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome ; death ; hospitalization ; heart failure
H-849	-1.2310237884521484	▁heart ▁failure
D-849	-1.2310237884521484	heart failure
P-849	-4.3610 -0.3874 -0.0490 -0.1267
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline ; st2 ; interquartile range
H-701	-1.2394249439239502	▁base line ▁ST 2
D-701	-1.2394249439239502	baseline ST2
P-701	-2.7798 -0.0667 -1.2194 -0.0330 -3.1998 -0.1379
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up ; outcomes ; mortality
H-1637	-0.7776853442192078	▁black ▁race
D-1637	-0.7776853442192078	black race
P-1637	-0.1067 -0.4772 -2.3907 -0.1361
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome ; change ; hospitalized ; heart failure
H-1395	-0.6269205808639526	▁Nur sing - sensitiv e ▁outcome ▁change ▁; ▁hospital ized ▁older ▁adults ▁; ▁heart ▁failure
D-1395	-0.6269205808639526	Nursing-sensitive outcome change ; hospitalized older adults ; heart failure
P-1395	-0.4019 -0.1733 -0.0298 -0.0415 -0.2332 -1.5742 -0.7567 -0.9646 -1.5029 -0.8079 -1.3291 -1.0522 -0.7057 -0.2970 -0.3674 -0.2047 -0.2155
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic ; diagnostic ; fluid overload
H-1071	-0.7931658029556274	▁ therapeut ic ▁; ▁fluid ▁over load
D-1071	-0.7931658029556274	therapeutic ; fluid overload
P-1071	-0.6379 -0.0278 -0.2250 -2.8853 -0.6244 -2.1135 -0.3786 -0.1330 -0.1130
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin ; heart failure ; breast cancer
H-927	-0.4202117919921875	▁Human ▁resist in ▁; ▁che mo therapy - indu ced ▁heart ▁failure ▁; ▁human ized ▁male ▁mi ce ▁; ▁breast ▁cancer
D-927	-0.4202117919921875	Human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
P-927	-1.1680 -0.6582 -0.2339 -0.4477 -0.2708 -0.0640 -0.0067 -0.1094 -0.0062 -0.1574 -0.1628 -0.0546 -0.2003 -3.0678 -0.4597 -0.3337 -0.2533 -0.0332 -0.2003 -1.1354 -0.2292 -0.2646 -0.1476
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise ; clinical ; outcomes
H-1926	-0.46838465332984924	▁social ▁support ▁; ▁barrier s
D-1926	-0.46838465332984924	social support ; barriers
P-1926	-0.1472 -0.3616 -0.6172 -1.0058 -0.0594 -0.9702 -0.1172
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure ulcers ; surgical ; patients
H-6	-0.715779721736908	▁pressure ▁ul cer s ▁; ▁sur g ical
D-6	-0.715779721736908	pressure ulcers ; surgical
P-6	-1.6199 -0.1121 -0.7852 -0.1491 -0.4837 -0.0836 -0.0933 -0.2056 -3.4253 -0.2002
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf ; valve plasty ; mva
H-369	-0.3244897127151489	▁ HF ▁; ▁val ve ▁plast y ▁; ▁MS ▁; ▁m va
D-369	-0.3244897127151489	HF ; valve plasty ; MS ; mva
P-369	-1.8455 -0.0435 -0.0800 -0.4171 -0.0477 -0.0184 -0.2383 -0.1278 -0.5014 -0.3058 -0.2370 -0.2816 -0.2951 -0.1037
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd ; congestive heart failure ; chf
H-902	-0.22874902188777924	▁p ▁; ▁re frac tory ▁; ▁end - s tage ▁con ges tive ▁heart ▁failure ▁; CH f
D-902	-0.22874902188777924	p ; refractory ; end-stage congestive heart failure ;CHf
P-902	-0.9411 -0.4647 -0.3100 -0.0249 -0.1849 -0.4528 -0.3356 -0.0233 -0.1610 -0.0010 -0.0385 -0.0748 -0.0639 -0.4427 -0.1220 -0.2486 -0.3516 -0.0736 -0.1528 -0.1070
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression models ; comorbidities
H-662	-0.8865060806274414	▁insurance ▁status ▁; ▁como rbi di ties
D-662	-0.8865060806274414	insurance status ; comorbidities
P-662	-3.3747 -1.4758 -1.2773 -0.0959 -0.0031 -0.1639 -1.2511 -0.1115 -0.2253
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta blockers ; mortality ; patients ; heart failure
H-649	-0.739878237247467	▁beta ▁block ers ▁; ▁heart ▁failure
D-649	-0.739878237247467	beta blockers ; heart failure
P-649	-1.0050 -0.6019 -0.1143 -0.5365 -2.8865 -0.5809 -0.0850 -0.1089
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter ; invasive ; surgery
H-553	-0.2812269628047943	▁trans cat heter
D-553	-0.2812269628047943	transcatheter
P-553	-0.0109 -0.0871 -0.0195 -1.1988 -0.0898
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-1.2771656513214111	▁fut ility ▁; ▁data ▁; ▁safety
D-850	-1.2771656513214111	futility ; data ; safety
P-850	-2.1966 -0.1978 -0.2098 -1.0711 -1.2068 -0.7346 -4.4955 -0.1053
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic ; complication
H-1661	-0.1496826410293579	▁complica tion
D-1661	-0.1496826410293579	complication
P-1661	-0.2845 -0.1727 -0.0387 -0.1028
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation ; heart iron
H-748	-0.7294313907623291	▁che lation ▁regime ns ▁; ▁heart ▁ir on
D-748	-0.7294313907623291	chelation regimens ; heart iron
P-748	-1.8568 -0.0107 -1.7858 -0.2664 -0.1310 -2.1908 -0.1149 -0.0723 -0.7607 -0.1051
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients ; consultation ; abdominal
H-1284	-0.8893844485282898	▁MT ▁; ▁abdominal ▁problems
D-1284	-0.8893844485282898	MT ; abdominal problems
P-1284	-1.2209 -0.8105 -0.8638 -2.1521 -0.1202 -0.1688
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients ; chronic organ failure
H-793	-0.8220686316490173	▁Time d ▁up ▁; ▁Go ▁test ▁; ▁patients ▁; ▁chronic ▁organ ▁failure
D-793	-0.8220686316490173	Timed up ; Go test ; patients ; chronic organ failure
P-793	-2.4160 -0.1193 -0.3675 -0.8685 -0.6433 -1.2641 -0.1676 -2.2254 -0.5224 -2.2097 -0.0306 -0.3615 -0.1115 -0.2015
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms ; patients ; nyha
H-1893	-0.9540927410125732	▁NY HA
D-1893	-0.9540927410125732	NYHA
P-1893	-1.0370 -1.0270 -1.6359 -0.1165
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.5438259840011597	
D-727	-0.5438259840011597	
P-727	-1.0076 -0.0801
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.3469776213169098	▁mortal ity
D-2001	-0.3469776213169098	mortality
P-2001	-0.7247 -0.1927 -0.3744 -0.0962
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
H-576	-0.26219266653060913	▁vent ri cular ▁e je ction ▁; ▁a cute ▁heart ▁failure ▁; ▁pre cap illa ry ▁pulmonar y ▁hyper tension
D-576	-0.26219266653060913	ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
P-576	-0.0337 -1.2646 -0.0892 -0.0954 -0.1295 -0.0531 -1.6534 -0.5651 -0.0221 -0.4571 -0.2618 -0.3999 -0.0899 -0.0485 -0.0029 -0.0370 -0.0151 -0.0490 -0.0249 -0.0500 -0.2279 -0.1983
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical ; aortic valve insufficiency ; left ventricular assist device ; implantation
H-541	-0.36855223774909973	▁a or tic ▁val ve ▁insu ffi cie ncy ▁; ▁vent ri cular ▁assist ▁device ▁implant ation
D-541	-0.36855223774909973	aortic valve insufficiency ; ventricular assist device implantation
P-541	-1.3338 -0.0707 -1.1317 -0.1369 -0.0584 -0.3607 -0.0289 -0.4972 -0.0123 -0.1509 -0.5649 -0.6344 -0.0404 -0.9070 -0.7211 -0.0023 -0.0298 -0.2147 -0.1065
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection fraction ; clinical ; cardiac resynchronization therapy ; mild heart failure
H-750	-0.22153446078300476	▁e je ction ▁ fraction ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁mild ▁heart ▁failure
D-750	-0.22153446078300476	ejection fraction ; cardiac resynchronization therapy ; mild heart failure
P-750	-0.7141 -0.1026 -0.0197 -0.1008 -0.0004 -0.1464 -0.1017 -0.0172 -0.0668 -0.0059 -0.6056 -0.5656 -0.0217 -0.3350 -0.5025 -0.2980 -0.2944 -0.1673 -0.1435
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary outcome ; functional capacity ; 6-minute walk test ; 6mwt
H-571	-1.0716264247894287	▁functional ▁capacity ▁; ▁mw t
D-571	-1.0716264247894287	functional capacity ; mwt
P-571	-3.2970 -1.9705 -0.4559 -1.4130 -0.1014 -0.1280 -0.1355
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef ; sodium ; ventricular ; vascular stiffness
H-917	-0.4404301047325134	▁h f f ▁; ▁dieta ry ▁so dium ▁restriction ▁; ▁vent ri cular ▁; ▁vas cular ▁sti ff ness
D-917	-0.4404301047325134	hff ; dietary sodium restriction ; ventricular ; vascular stiffness
P-917	-0.1937 -0.5578 -0.3125 -0.1722 -2.7816 -0.0197 -0.3011 -0.0331 -0.3399 -0.0677 -0.0024 -0.7955 -0.1346 -0.7247 -0.7300 -0.2377 -0.3052 -0.4795 -0.4759 -0.4634 -0.1207
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully magnetically levitated left ventricular assist system ; hf
H-1992	-0.5154651403427124	▁magnet ically ▁Lev ité d ▁le ft ▁vent ri cular ▁Assist ▁System ▁; ▁Tre ating ▁Advanced ▁ HF
D-1992	-0.5154651403427124	magnetically Levitéd left ventricular Assist System ; Treating Advanced HF
P-1992	-0.3559 -0.1292 -0.3344 -0.6723 -0.5173 -0.8682 -0.0328 -0.6854 -2.4252 -0.1783 -0.1046 -0.6415 -0.3687 -2.1766 -0.0351 -0.0576 -0.1283 -0.0343 -0.4525 -0.1111
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf ; atrial explants ; cells ; explants
H-1341	-0.5235810875892639	▁CHF ▁at rial ▁ex plant s ▁; ▁c - K it ▁; ▁implant s
D-1341	-0.5235810875892639	CHF atrial explants ; c-Kit ; implants
P-1341	-0.0210 -0.7667 -0.1971 -0.3021 -0.0892 -0.1092 -0.2500 -0.0636 -0.0985 -0.2619 -0.0063 -0.7271 -4.9897 -0.0830 -0.2855 -0.1263
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic heart failure ; chf ; sympathetic tone ; autonomic imbalance
H-1370	-0.3793160617351532	▁chronic ▁heart ▁failure ▁; CH f ▁; ▁sympa the tic ▁tone ▁; ▁autonomi c ▁im balance
D-1370	-0.3793160617351532	chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
P-1370	-1.2034 -1.0858 -0.2522 -0.1093 -0.7338 -0.0513 -0.4088 -0.6337 -0.2755 -0.7886 -0.1335 -0.2151 -0.0433 -0.4335 -0.0990 -0.0244 -0.1677 -0.1689
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart failure ; leading ; mortality ; western ; society ; cardiovascular diseases
H-1480	-0.6670666933059692	▁Heart ▁failure ▁; ▁mortal ity ▁; ▁Western ▁society ▁; ▁cardiovascular ▁disease s
D-1480	-0.6670666933059692	Heart failure ; mortality ; Western society ; cardiovascular diseases
P-1480	-1.0297 -0.2708 -0.1956 -2.7080 -0.2565 -0.2177 -2.9265 -0.1540 -0.2168 -0.2786 -0.7619 -0.0500 -0.1643 -0.1085
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal membrane oxygenation ; refractory right heart failure
H-1290	-0.28955337405204773	▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ bridge ▁to ▁recovery ▁; ▁in far ction - related ▁re frac tory ▁right ▁heart ▁failure
D-1290	-0.28955337405204773	extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
P-1290	-1.6729 -0.0033 -0.3311 -0.0360 -0.0019 -0.0713 -0.1197 -0.0226 -0.2023 -0.3376 -0.0177 -1.3979 -0.0721 -0.5976 -0.0180 -0.4363 -0.0396 -0.0891 -0.0423 -0.0108 -0.0067 -0.3434 -1.0690 -0.2203 -0.3051 -0.2355 -0.1179
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical ; echocardiographic ; invasive ; hemodynamic ; outcome
H-1527	-0.2030647099018097	▁e cho car dio graphic ▁; ▁invasi ve ▁hem o dynamic
D-1527	-0.2030647099018097	echocardiographic ; invasive hemodynamic
P-1527	-0.3404 -0.0788 -0.0619 -0.5886 -0.1575 -0.3309 -0.0157 -0.0693 -0.4152 -0.1865 -0.0095 -0.2881 -0.0973
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac catheterization ; thrombotic obstruction ; right coronary artery
H-1292	-0.3143203556537628	▁cardiac ▁cat heter ization ▁; ▁ thro mbo tic ▁ob struct ion ▁; ▁right ▁corona ry ▁arter y
D-1292	-0.3143203556537628	cardiac catheterization ; thrombotic obstruction ; right coronary artery
P-1292	-1.2045 -0.1303 -0.0101 -0.5345 -0.1077 -0.0850 -0.0610 -0.1576 -1.9111 -0.1632 -0.0397 -0.0080 -0.2592 -0.3689 -0.1718 -0.1562 -0.0217 -0.6064 -0.1810 -0.1083
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california office of statewide health planning and development patient discharge data nonpublic file
H-136	-0.6588361263275146	▁California ▁office ▁of ▁State wide ▁Health ▁Plan ning ▁; ▁Development ▁Patient ▁Dis charge ▁Data
D-136	-0.6588361263275146	California office of Statewide Health Planning ; Development Patient Discharge Data
P-136	-1.4877 -0.0838 -1.0445 -0.7210 -0.0853 -1.1853 -0.7738 -0.0471 -0.5870 -0.8145 -0.3173 -1.0851 -0.0044 -1.2818 -0.9385 -0.0842
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan failure ; systolic ventricular function ; liver disease
H-224	-0.852692186832428	▁Font an ▁failure ▁; ▁vent ri cular ▁; ▁ liver ▁disease
D-224	-0.852692186832428	Fontan failure ; ventricular ; liver disease
P-224	-0.1224 -0.7087 -0.8372 -0.1402 -1.6539 -1.2013 -0.1219 -3.4086 -0.1220 -0.2240 -2.3183 -0.1245 -0.1020
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing ; outcomes ; hospitalized ; hf
H-1402	-1.0246554613113403	▁hospital ized ▁older ▁adults ▁; ▁ HF
D-1402	-1.0246554613113403	hospitalized older adults ; HF
P-1402	-5.0374 -0.7944 -0.9101 -0.2123 -0.4564 -1.6173 -0.0174 -0.0752 -0.1014
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis ; pacing-induced dilated cardiomyopathy
H-165	-0.42214736342430115	▁pa cing - indu ced ▁dil ated ▁cardio my o pathy
D-165	-0.42214736342430115	pacing-induced dilated cardiomyopathy
P-165	-1.3074 -1.7186 -0.0457 -0.0161 -0.4987 -0.3606 -0.3566 -0.0550 -0.3960 -0.4092 -0.0295 -0.0973 -0.1972
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical delay ; dyssynchronous heart failure
H-1146	-0.30255424976348877	▁electro me chan ical ▁de lay ▁; ▁dys syn chron ous ▁heart ▁failure
D-1146	-0.30255424976348877	electromechanical delay ; dyssynchronous heart failure
P-1146	-1.7507 -0.0052 -0.1253 -0.1364 -0.0201 -0.1234 -0.5205 -0.0241 -0.0050 -0.0019 -0.5902 -0.3783 -0.1975 -0.3803 -0.2796
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients ; trastuzumab ; cardiac ; comorbidities
H-682	-0.5839095115661621	▁tras tuz um ab ▁; ▁cardiac
D-682	-0.5839095115661621	trastuzumab ; cardiac
P-682	-0.4057 -0.0086 -0.0148 -0.1247 -0.4001 -0.0233 -3.5291 -0.1649
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype ; perioperative ; deaths
H-279	-0.2407914400100708	
D-279	-0.2407914400100708	
P-279	-0.3898 -0.0918
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic ; patients ; heart failure ; québec ; canada
H-1233	-0.6566062569618225	▁économique ▁impact ▁; ▁af ▁; ▁heart ▁failure ▁; ▁Québec ▁; ▁Canada
D-1233	-0.6566062569618225	économique impact ; af ; heart failure ; Québec ; Canada
P-1233	-0.2896 -1.8180 -0.2440 -0.7399 -0.6978 -0.7628 -0.2191 -0.9440 -1.2183 -0.7631 -0.6179 -0.1447 -0.0767
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac ; mena deletion ; cardiac dysfunction ; hypertrophy
H-1811	-0.15008169412612915	▁cardiac ▁Men a ▁dele tion ▁; ▁cardiac ▁dys function ▁; ▁hyper trop hy
D-1811	-0.15008169412612915	cardiac Mena deletion ; cardiac dysfunction ; hypertrophy
P-1811	-0.1590 -0.3500 -0.2872 -0.0438 -0.0334 -0.1729 -0.0852 -0.0522 -0.2322 -0.3647 -0.0344 -0.0032 -0.2051 -0.0998 -0.1279
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left bundle-branch block ; lbbb
H-886	-0.30619630217552185	▁bund le - bran ch ▁block ▁; LB BB ▁; LB BB
D-886	-0.30619630217552185	bundle-branch block ;LBBB ;LBBB
P-886	-0.0081 -0.2031 -0.0167 -0.0005 -0.0977 -0.1826 -0.3455 -0.1338 -0.4465 -0.2969 -0.7763 -0.4215 -1.2602 -0.0973
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein ; genes ; western blot ; dna fragmentation ; tunel
H-167	-0.4994850754737854	▁protein ▁; ▁Western ▁blot ▁; ▁DNA ▁fragment ation ▁; ▁TU nel
D-167	-0.4994850754737854	protein ; Western blot ; DNA fragmentation ; TUnel
P-167	-1.4603 -0.7776 -1.3504 -0.0045 -0.1304 -0.2551 -0.1838 -0.0185 -0.2659 -0.5624 -0.6729 -0.7006 -0.1108
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine ; dilated cardiomyopathy ; patients ; heart failure
H-1257	-0.42173025012016296	▁Chinese ▁herbal ▁medicine ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure
D-1257	-0.42173025012016296	Chinese herbal medicine ; dilated cardiomyopathy ; heart failure
P-1257	-1.5474 -0.3715 -0.3468 -0.1187 -1.0677 -0.2934 -0.1049 -0.5269 -0.3112 -0.0184 -0.2319 -0.4880 -0.4505 -0.2411 -0.2075
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient ; implantable cardioverter-defibrillator
H-1856	-0.23320189118385315	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1856	-0.23320189118385315	implantable cardioverter-defibrillator deactivation
P-1856	-0.0004 -0.0494 -0.5343 -0.0918 -0.0553 -0.0162 -0.0782 -1.2933 -0.6496 -0.0049 -0.0675 -0.0614 -0.0401 -0.1563 -0.4224 -0.2102
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated ; cardiac filling pressures ; adverse outcomes
H-1532	-0.5796611309051514	▁EH ▁; ▁CH ▁; ▁cardiac ▁fill ing ▁pressure s
D-1532	-0.5796611309051514	EH ; CH ; cardiac filling pressures
P-1532	-0.2139 -0.1048 -1.6385 -0.3301 -0.2853 -0.6691 -0.1754 -2.4002 -0.1455 -0.2818 -0.1318
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right atrium ; prolapse ; tricuspid valve ; stenotic physiology
H-596	-0.2734137177467346	▁right ▁at rium ▁mass ▁; ▁pro lapse ▁; ▁tri cus pid ▁val ve ▁; ▁ste no tic ▁physio log y
D-596	-0.2734137177467346	right atrium mass ; prolapse ; tricuspid valve ; stenotic physiology
P-596	-1.4707 -0.1686 -0.0447 -0.4798 -0.0724 -0.1308 -0.0729 -0.3882 -0.6003 -0.1719 -0.0115 -0.3185 -0.0973 -0.4670 -0.0011 -0.0297 -0.7570 -0.1385 -0.0804 -0.3035 -0.1293 -0.0809
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp ; sensitivity
H-271	-0.3435959815979004	▁NT - pro b NP
D-271	-0.3435959815979004	NT-probNP
P-271	-0.8005 -0.0127 -0.0098 -0.6121 -0.2082 -0.5629 -0.1989
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart failure ; protein kinase a ; expression
H-1423	-0.627665102481842	▁heart ▁failure ▁; ▁alter ed ▁protein ▁kina se
D-1423	-0.627665102481842	heart failure ; altered protein kinase
P-1423	-2.4527 -0.6203 -0.1879 -1.7611 -0.0165 -0.1416 -0.0428 -0.0596 -0.7795 -0.2147
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up ; patients ; hf
H-1106	-0.786926805973053	▁ HF
D-1106	-0.786926805973053	HF
P-1106	-2.6075 -0.0790 -0.3078 -0.1533
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality of life ; seattle heart failure model
H-2012	-0.5416697859764099	▁temps - var ying ▁Seattle ▁Heart ▁Fail ure
D-2012	-0.5416697859764099	temps-varying Seattle Heart Failure
P-2012	-3.9375 -0.0188 -0.0792 -0.1481 -0.0514 -0.3464 -0.0499 -0.0338 -0.6105 -0.1413
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized ; dopamine ; nesiritide
H-76	-0.4185822606086731	▁dop amine ▁; ▁nesi riti de
D-76	-0.4185822606086731	dopamine ; nesiritide
P-76	-0.7117 -0.3963 -0.4726 -0.0208 -0.0097 -0.0284 -1.5795 -0.1298
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical ; nitrite ; vascular
H-414	-0.4233783185482025	▁chemical ▁in st ability ▁; ▁co genera tion ▁; ▁nit rite
D-414	-0.4233783185482025	chemical instability ; cogeneration ; nitrite
P-414	-1.9975 -0.0165 -0.2895 -0.0663 -0.1110 -0.0710 -0.1422 -0.0424 -1.2075 -0.0292 -0.2971 -1.1353 -0.0982
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological ; cardiovascular ; bound
H-1875	-0.558322548866272	▁neurologi cal ▁; ▁cardiovascular
D-1875	-0.558322548866272	neurological ; cardiovascular
P-1875	-0.2497 -0.2440 -0.7286 -0.0509 -1.9691 -0.1076
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox regression ; cardiovascular events ; psoriasis
H-1558	-0.20331650972366333	▁co x ▁re gression ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
D-1558	-0.20331650972366333	cox regression ; cardiovascular events ; psoriasis
P-1558	-0.2448 -0.0323 -0.0341 -0.0637 -0.1951 -0.5046 -0.4718 -0.1952 -0.0083 -0.3348 -0.1519
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective studies ; cpg ; hf
H-1845	-0.8341947793960571	▁c PG ▁; ▁ HF
D-1845	-0.8341947793960571	cPG ; HF
P-1845	-1.9325 -0.6443 -1.3646 -1.5459 -0.1321 -0.1072 -0.1127
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation ; flow-mediated dilatation
H-259	-0.48868998885154724	▁HD L - indu ced ▁; ▁production ▁; ▁flow - media ted ▁di la tation ▁; ▁ET
D-259	-0.48868998885154724	HDL-induced ; production ; flow-mediated dilatation ; ET
P-259	-0.8990 -1.7412 -0.1756 -0.0234 -0.1669 -0.6379 -1.0342 -0.1616 -0.8108 -0.0191 -0.1307 -1.9866 -0.1089 -0.3801 -0.0243 -0.4952 -0.1888 -0.1564 -0.1443
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ; ahf ; risk stratification
H-58	-0.6034435033798218	▁a HF
D-58	-0.6034435033798218	aHF
P-58	-1.3408 -0.2804 -0.6242 -0.1684
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients ; systolic function ; therapeutic
H-1070	-1.1805237531661987	▁sy sto lic ▁function
D-1070	-1.1805237531661987	systolic function
P-1070	-3.7740 -0.2049 -0.8512 -1.6673 -0.4822 -0.1036
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets ; tac ; hf
H-1050	-0.44778352975845337	BET s ▁; ▁mouse ▁ TAC ▁model ▁; ▁human ▁ HF
D-1050	-0.44778352975845337	BETs ; mouse TAC model ; human HF
P-1050	-0.6414 -0.2107 -0.1200 -0.4770 -0.4200 -0.0161 -1.1382 -0.3155 -1.8424 -0.3829 -0.0446 -0.1152 -0.0971
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-0.8152987957000732	▁coût - effect ive ▁; ▁participa tory ▁; ▁population - specific ▁health ▁intervention s
D-614	-0.8152987957000732	coût-effective ; participatory ; population-specific health interventions
P-614	-1.1672 -0.0248 -0.0232 -0.0112 -0.4619 -2.2024 -0.0408 -0.7843 -2.9109 -0.0236 -0.0987 -1.1911 -2.0208 -0.0219 -1.9448 -0.1171
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac ; nurses
H-1662	-0.20585080981254578	▁cardiac ▁nurse s
D-1662	-0.20585080981254578	cardiac nurses
P-1662	-0.0721 -0.4738 -0.0645 -0.3305 -0.0883
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations ; patients ; patients
H-1282	-0.1534762978553772	▁consultation s
D-1282	-0.1534762978553772	consultations
P-1282	-0.0740 -0.0469 -0.4090 -0.0840
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion ; mortality
H-50	-0.4390121102333069	▁trans fusion ▁; ▁mortal ity
D-50	-0.4390121102333069	transfusion ; mortality
P-50	-0.0471 -0.3200 -1.5812 -0.0463 -0.1824 -0.7226 -0.1734
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech republic
H-1972	-0.32356297969818115	▁Czech ▁Republic
D-1972	-0.32356297969818115	Czech Republic
P-1972	-0.2957 -0.0828 -0.7548 -0.1610
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients ; madit-crt
H-858	-0.6603133082389832	▁MAD it - c RT ▁; ▁device
D-858	-0.6603133082389832	MADit-cRT ; device
P-858	-0.0907 -1.3021 -0.0104 -1.1848 -1.4665 -1.3169 -0.3348 -0.1044 -0.1322
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients ; randomization
H-851	-0.8606330156326294	
D-851	-0.8606330156326294	
P-851	-1.5987 -0.1226
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c statistics
H-383	-0.9154602885246277	▁UM / va / va - RT
D-383	-0.9154602885246277	UM/va/va-RT
P-383	-0.5915 -1.6390 -0.4518 -2.3239 -0.3900 -0.2670 -2.1550 -0.2838 -0.1372
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart failure
H-1539	-0.9599728584289551	▁risk ▁; ▁heart ▁failure
D-1539	-0.9599728584289551	risk ; heart failure
P-1539	-3.7364 -0.9151 -0.2176 -0.5493 -0.2091 -0.1323
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; hf
H-1431	-0.3856991231441498	▁Western ▁blot s ▁; ▁mono clo nal ▁anti bo dies ▁; ▁Ser 83 ▁ phos phor y lation ▁; ▁ HF
D-1431	-0.3856991231441498	Western blots ; monoclonal antibodies ; Ser83 phosphorylation ; HF
P-1431	-0.0963 -0.0066 -0.0339 -0.1724 -0.6727 -0.0199 -0.2190 -0.0047 -0.3522 -1.8166 -0.1281 -0.6041 -0.4114 -0.1987 -0.0837 -0.7623 -1.1484 -0.0237 -0.8381 -0.8716 -0.0330 -0.1822 -0.1914
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative ; serum albumin ; patients ; left ventricular assist device ; implantation
H-528	-0.7040941119194031	▁vent ri cular ▁assist ▁device ▁implant ation
D-528	-0.7040941119194031	ventricular assist device implantation
P-528	-2.8172 -1.4711 -0.0865 -0.8481 -0.7457 -0.0031 -0.0317 -0.1630 -0.1704
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new york heart association classification ; 6-min walk test ; quality-of-life
H-2005	-0.8563531041145325	▁New ▁York ▁Heart ▁Association ▁; ▁quality - of - life
D-2005	-0.8563531041145325	New York Heart Association ; quality-of-life
P-2005	-1.8107 -0.4495 -1.0475 -0.8808 -1.1184 -3.8829 -0.0142 -0.2228 -0.0553 -0.0279 -0.5825 -0.1837
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional ms ; ring annuloplasty ; ischemic mr ; lv dilatation
H-366	-0.19696645438671112	▁functional ▁MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁MR ▁; ▁LV ▁di la tation
D-366	-0.19696645438671112	functional MS ; ring annuloplasty ; ischemic MR ; LV dilatation
P-366	-1.3551 -0.1070 -0.1168 -0.1092 -0.1878 -0.2032 -0.0152 -0.2013 -0.1085 -0.2883 -0.3918 -0.0447 -0.0258 -0.1826 -0.0161 -0.2126 -0.1272 -0.0060 -0.1678 -0.0723
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change ; paco2 ; cerebral ; blood flow ; perfusion ; carotid
H-1350	-0.2765790522098541	▁Paco 2 ▁; ▁cerebral ▁blood ▁flow ▁; ▁caro tid ▁bo dies
D-1350	-0.2765790522098541	Paco2 ; cerebral blood flow ; carotid bodies
P-1350	-0.2322 -0.0522 -1.0741 -0.0751 -0.3514 -0.3376 -0.1182 -0.5644 -0.1825 -0.1133 -0.2554 -0.1167 -0.1222
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin receptor antagonist ; tolvaptan ; heart failure ; patients
H-1194	-0.370929479598999	▁vaso press in ▁receptor ▁anta gon ist ▁; ▁to lv ap tan ▁; ▁Japanese ▁heart ▁failure
D-1194	-0.370929479598999	vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
P-1194	-0.0391 -0.0280 -0.9177 -0.0260 -0.2016 -0.0932 -1.7347 -0.2093 -0.2840 -0.1486 -0.0278 -0.0135 -0.2237 -0.8460 -0.7464 -0.1870 -0.8430 -0.1070
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology ; hf ; diagnosis ; medical ; nursing
H-2021	-0.5095341801643372	▁pat ho phy si ology ▁; ▁ HF ▁; ▁medical ▁management
D-2021	-0.5095341801643372	pathophysiology ; HF ; medical management
P-2021	-1.0390 -0.1009 -0.1187 -0.8378 -0.8457 -0.3158 -0.8681 -0.0612 -0.6527 -0.3338 -0.0297 -1.2892 -0.1314
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients ; physicians ; hospitals ; new jersey ; new york
H-212	-0.6826449036598206	▁ED ▁; ▁subur ban ▁hospital s ▁; ▁New ▁Jersey ▁; ▁New ▁York
D-212	-0.6826449036598206	ED ; suburban hospitals ; New Jersey ; New York
P-212	-1.9435 -2.2474 -1.9257 -0.0263 -0.4396 -0.0702 -0.4256 -0.7160 -0.0956 -0.7292 -0.2882 -0.2302 -0.3313 -0.0884
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis ; patients ; diastolic blood pressure ; body mass index
H-1560	-0.45954611897468567	▁p sori asis ▁; ▁smo ked ▁; ▁dia sto lic ▁blood ▁pressure ▁; ▁body ▁mass ▁index
D-1560	-0.45954611897468567	psoriasis ; smoked ; diastolic blood pressure ; body mass index
P-1560	-1.0363 -0.0073 -0.4666 -0.7411 -1.3060 -0.5177 -0.1485 -0.3186 -0.1701 -0.9432 -0.3187 -1.0814 -0.2142 -0.1276 -0.3592 -0.0443 -0.3263 -0.1445
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise intolerance ; heart failure ; exercise ; diagnosis ; prognosis ; therapeutic
H-1272	-0.5258334875106812	▁Exerci se ▁in tolerance ▁; ▁heart ▁failure
D-1272	-0.5258334875106812	Exercise intolerance ; heart failure
P-1272	-1.7714 -0.3558 -0.0097 -0.0337 -1.2769 -0.3156 -0.3023 -0.5387 -0.1285
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients ; clinical ; echocardiography ; baseline ; shunt ; implantation
H-1954	-0.5129826664924622	▁e cho card i ography ▁; ▁implant ation
D-1954	-0.5129826664924622	echocardiography ; implantation
P-1954	-0.5749 -0.0649 -0.0974 -0.3829 -0.2632 -1.1395 -2.2850 -0.0259 -0.1151 -0.1811
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
H-1383	-0.32185134291648865	▁vent ri cular ▁assist ▁device ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁renal ▁function ▁; ▁pediatr ic ▁heart ▁failure
D-1383	-0.32185134291648865	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
P-1383	-0.0021 -0.7824 -0.1419 -0.3591 -0.4795 -0.1013 -0.1627 -0.0043 -0.2967 -0.0240 -0.0031 -0.1108 -0.2472 -0.0575 -0.2673 -0.1079 -2.9695 -0.2864 -0.1776 -0.0975 -0.3633 -0.3964 -0.1508 -0.1353
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations ; cox models ; st2 ; functional capacity ; outcomes
H-700	-0.9144524931907654	▁co x ▁models ▁; ▁ST 2
D-700	-0.9144524931907654	cox models ; ST2
P-700	-1.5797 -0.0088 -0.5982 -0.4739 -1.5004 -0.0858 -2.9430 -0.1258
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause hospitalisations ; sts
H-160	-0.8534970879554749	▁TM ▁intervention s ▁; ▁s ts
D-160	-0.8534970879554749	TM interventions ; sts
P-160	-0.9778 -2.3151 -0.0411 -0.2927 -0.9246 -1.4354 -0.6748 -0.1664
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol ; linear mixed models ; intention-to-treat
H-838	-0.8968187570571899	▁HR Qo L
D-838	-0.8968187570571899	HRQoL
P-838	-3.2745 -0.0085 -0.6657 -0.4371 -0.0983
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp ; circulation ; hf ; patients
H-1513	-0.35608091950416565	▁NT - pro b NP ▁; ▁circulation ▁; ▁ HF
D-1513	-0.35608091950416565	NT-probNP ; circulation ; HF
P-1513	-0.1299 -0.0254 -0.0065 -0.9451 -0.1246 -0.2512 -0.4546 -0.8016 -0.4539 -0.0775 -0.7686 -0.2342
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy metabolism ; heart failure ; hypertrophied ; heart
H-1779	-0.3442762792110443	▁energy ▁metabolism ▁; ▁heart ▁failure ▁; ▁hyper trop hi ed ▁heart
D-1779	-0.3442762792110443	energy metabolism ; heart failure ; hypertrophied heart
P-1779	-2.2013 -0.1299 -0.1325 -0.4094 -0.6263 -0.1482 -0.0120 -0.0066 -0.0050 -0.1860 -0.4304 -0.0620 -0.1261
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional ms ; lv dilatation ; functional ms
H-368	-0.9838417768478394	▁MS ▁; ▁LV ▁di la tation ▁; ▁MS
D-368	-0.9838417768478394	MS ; LV dilatation ; MS
P-368	-2.9360 -0.2359 -0.3777 -0.6395 -0.2607 -0.0048 -0.3702 -4.5576 -0.3042 -0.1519
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients ; pad ; ankle-brachial index
H-1568	-0.37425497174263	PAD ▁; ▁an kle - bra chi al ▁index
D-1568	-0.37425497174263	PAD ; ankle-brachial index
P-1568	-1.5910 -0.4679 -1.0352 -0.2148 -0.0575 -0.1443 -0.1427 -0.0657 -0.0249 -0.2238 -0.1491
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr reduction ; ivabradine ; tac ; ea
H-525	-0.4009284973144531	▁HR ▁re duction ▁; ▁i va bra dine ▁; ▁ TAC
D-525	-0.4009284973144531	HR reduction ; ivabradine ; TAC
P-525	-1.6311 -0.4512 -0.0103 -0.2268 -0.0144 -0.0185 -0.4155 -0.0333 -0.1097 -0.8557 -0.0447 -1.2122 -0.1886
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline ; mechanical cardiac support ; renal function
H-1388	-0.7783357501029968	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function
D-1388	-0.7783357501029968	mechanical cardiac support ; renal function
P-1388	-1.3282 -0.0372 -0.3760 -0.9349 -0.2601 -0.0198 -3.7276 -0.1626 -0.1586
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ; ecmo ; patients ; vad ; ecmo ; vad
H-1390	-0.874082624912262	▁EC mo ▁; ▁ VAD ▁; ▁EC mo + VAD
D-1390	-0.874082624912262	ECmo ; VAD ; ECmo+VAD
P-1390	-1.7787 -0.7375 -1.1453 -0.5947 -0.0530 -0.2857 -1.4908 -1.9513 -1.4832 -0.1165 -0.5716 -0.2808
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality ; morbidity ; health-care ; budget
H-1075	-0.19993682205677032	▁mortal ity ▁; ▁morbi d ity ▁; ▁cancer s ▁; ▁budget
D-1075	-0.19993682205677032	mortality ; morbidity ; cancers ; budget
P-1075	-0.1816 -0.3192 -0.1477 -0.0643 -0.1296 -0.4083 -0.1483 -0.0943 -0.0560 -0.2540 -0.5490 -0.1208 -0.1260
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation ; therapy ; heart disease ; rate control
H-1652	-0.4925179183483124	▁antico ag ulation ▁; ▁ therapy ▁; ▁under ly ing ▁heart ▁disease
D-1652	-0.4925179183483124	anticoagulation ; therapy ; underlying heart disease
P-1652	-0.6330 -0.4595 -0.0283 -0.1187 -1.0659 -0.0107 -0.2848 -2.2984 -0.0570 -0.0936 -0.2430 -0.6726 -0.8017 -0.1280
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic effect ; beta blockers ; heart failure
H-648	-0.6722981929779053	▁in o tropi c ▁effect ▁; ▁beta ▁block ers
D-648	-0.6722981929779053	inotropic effect ; beta blockers
P-648	-0.6396 -0.3502 -0.0302 -0.1120 -0.4735 -0.2483 -0.1671 -0.5114 -0.0845 -4.6381 -0.1405
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin receptor ; st2 ; beta-blocker ; therapy ; chronic heart failure
H-398	-0.5279541015625	▁inter le u kin ▁receptor ▁family ▁; ▁ST 2 ▁; ▁beta - block er ▁ therapy ▁; ▁chronic ▁heart ▁failure
D-398	-0.5279541015625	interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
P-398	-0.0088 -0.8433 -0.1520 -3.7762 -0.0332 -1.1539 -1.4533 -0.3085 -0.0318 -0.1621 -0.1003 -0.0188 -0.0500 -0.0240 -0.1189 -0.0187 -0.4417 -1.1861 -0.7872 -0.6553 -0.1877 -0.1032
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients ; heart failure ; systolic heart failure
H-725	-1.5879768133163452	▁implant s ▁; ▁heart ▁failure
D-725	-1.5879768133163452	implants ; heart failure
P-725	-5.2003 -0.5592 -0.6086 -1.4387 -0.3403 -2.8051 -0.1635
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline ; rhythm-control ; rate-control
H-1237	-0.28910839557647705	▁ rhythm - control ▁; ▁rate - control
D-1237	-0.28910839557647705	rhythm-control ; rate-control
P-1237	-0.1817 -0.4118 -0.1639 -0.2185 -0.5067 -0.4295 -0.1183 -0.2257 -0.3978 -0.2372
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin ; health ; outcomes
H-43	-0.795227587223053	▁hem o glob in
D-43	-0.795227587223053	hemoglobin
P-43	-1.5321 -0.1013 -0.0773 -0.7515 -2.2004 -0.1087
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional ms ; medical treatment ; surgical
H-376	-0.543036699295044	▁Fun ction al ▁MS
D-376	-0.543036699295044	Functional MS
P-376	-0.2928 -0.0057 -0.0143 -0.0824 -2.7549 -0.1080
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf ; epidemiology ; health ; hf
H-1790	-0.6307128071784973	▁ HF ▁epidemi ology ▁; ▁health ▁service ▁provision ▁; ▁ HF ▁; ▁LA
D-1790	-0.6307128071784973	HF epidemiology ; health service provision ; HF ; LA
P-1790	-1.0478 -0.0486 -1.6021 -1.3071 -0.1347 -1.0568 -0.0681 -1.1138 -0.2978 -0.3895 -0.0537 -0.8998 -1.0175 -0.2535 -0.1699
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart failure ; hf ; chronic ; disease
H-2019	-0.22841423749923706	▁Heart ▁failure ▁; HF ▁; ▁de bilitat ing ▁chronic ▁disease
D-2019	-0.22841423749923706	Heart failure ;HF ; debilitating chronic disease
P-2019	-0.5924 -0.1140 -0.1288 -0.2544 -0.6449 -0.2307 -0.0009 -0.1064 -0.0633 -0.1681 -0.3050 -0.1323
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes ; heart failure ; hf
H-555	-0.8739712834358215	▁heart ▁failure ▁; HF
D-555	-0.8739712834358215	heart failure ;HF
P-555	-3.8776 -0.2346 -0.7680 -0.1319 -0.0913 -0.1404
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up ; lvad ; patients ; heart failure
H-548	-0.6019926071166992	▁CF ▁l VAD ▁; ▁AI ▁; ▁heart ▁failure
D-548	-0.6019926071166992	CF lVAD ; AI ; heart failure
P-548	-0.1098 -2.0100 -0.0757 -0.4237 -2.0972 -0.3248 -0.3692 -0.3520 -0.1430 -0.1145
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade ; evidence ; anemia ; patients ; heart disease
H-38	-0.8843304514884949	▁an emia ▁; ▁heart ▁disease
D-38	-0.8843304514884949	anemia ; heart disease
P-38	-2.6244 -0.4508 -0.2153 -1.3048 -1.2645 -0.1502 -0.1803
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients ; left ventricular dilatation ; dysfunction
H-1746	-0.49101969599723816	▁vent ri cular ▁di la tation
D-1746	-0.49101969599723816	ventricular dilatation
P-1746	-0.3956 -1.3875 -0.2594 -0.4590 -0.4137 -0.0422 -0.8411 -0.1297
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular assist devices ; therapies
H-203	-0.2061046063899994	▁vent ri cular ▁assist ▁devices ▁; ▁device ▁ therapie s
D-203	-0.2061046063899994	ventricular assist devices ; device therapies
P-203	-0.0104 -0.5443 -0.0705 -0.3632 -0.2805 -0.7274 -0.0851 -0.0303 -0.0488 -0.0350 -0.1457 -0.1320
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted ; patients ; adverse events ; follow-up
H-1956	-0.5060669183731079	▁implant ed
D-1956	-0.5060669183731079	implanted
P-1956	-0.0218 -0.7519 -1.1387 -0.1119
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal dysfunction ; mechanical cardiac support
H-1394	-0.26987695693969727	▁renal ▁dys function ▁; ▁mechanic al ▁cardiac ▁support
D-1394	-0.26987695693969727	renal dysfunction ; mechanical cardiac support
P-1394	-0.4473 -0.1028 -0.3097 -0.1932 -0.6525 -0.0212 -0.1283 -0.6809 -0.0846 -0.0783
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-0.6908887624740601	▁ HF
D-1002	-0.6908887624740601	HF
P-1002	-2.0960 -0.1355 -0.4024 -0.1297
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions ; hospital
H-144	-0.3726698160171509	▁computing ▁read missions ▁; ▁hospital ▁ranking s ▁; ▁pay - for - per form ance
D-144	-0.3726698160171509	computing readmissions ; hospital rankings ; pay-for-performance
P-144	-2.0354 -1.3361 -0.0172 -0.1162 -0.3605 -0.3371 -0.0200 -0.1023 -0.1858 -0.0168 -0.6095 -0.0455 -0.0959 -0.7566 -0.0130 -0.1383 -0.1492
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory factor analysis ; cfa
H-1506	-0.6936413049697876	▁c fa
D-1506	-0.6936413049697876	cfa
P-1506	-1.6388 -0.7454 -0.2093 -0.1810
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb ; patients ; hf
H-1351	-0.8491195440292358	PB ▁; ▁ HF ▁; ▁pattern ▁generator
D-1351	-0.8491195440292358	PB ; HF ; pattern generator
P-1351	-0.2813 -0.1833 -1.7012 -0.2298 -0.6937 -3.9962 -0.1618 -0.2489 -0.1459
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic ; clinicians ; patients
H-1124	-0.6505863666534424	▁Reason s
D-1124	-0.6505863666534424	Reasons
P-1124	-1.1121 -0.0572 -1.3423 -0.0907
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates ; coagulability
H-1113	-1.1421654224395752	
D-1113	-1.1421654224395752	
P-1113	-2.1880 -0.0963
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd ; patients
H-65	-0.4547199308872223	▁i CD
D-65	-0.4547199308872223	iCD
P-65	-0.3295 -0.7508 -0.5728 -0.1658
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients ; patients
H-267	-0.5573663115501404	
D-267	-0.5573663115501404	
P-267	-0.9992 -0.1155
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp ; nt-probnp ; diagnostic ; prognostic ; biomarkers ; patients ; heart failure
H-1365	-0.5619403123855591	▁b NP ▁; ▁NT - pro b NP ▁; ▁bio mark ers
D-1365	-0.5619403123855591	bNP ; NT-probNP ; biomarkers
P-1365	-0.0526 -0.1940 -0.1074 -0.2774 -0.0161 -0.0030 -0.6231 -0.1359 -0.3795 -1.5295 -0.0073 -0.0589 -4.3206 -0.1620
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory fitness ; body mass index ; heart failure ; mortality ; cooper center longitudinal study
H-1765	-0.6001215577125549	▁Card i spira tory ▁fitness ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁mortal ity ▁; ▁Cooper ▁Center ▁long itud in al ▁Study
D-1765	-0.6001215577125549	Cardispiratory fitness ; body mass index ; heart failure mortality ; Cooper Center longitudinal Study
P-1765	-0.3915 -1.4531 -3.6942 -0.2316 -0.7742 -0.0979 -0.3295 -0.5198 -0.0447 -0.1188 -0.2909 -0.9190 -0.5573 -0.1169 -0.6040 -0.4209 -0.8754 -1.7162 -0.1339 -0.2834 -0.1880 -0.3318 -0.1744 -0.1355
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse correlation ; pro-adrenomedullin ; mr-proadm ; ffm
H-15	-0.3371080160140991	▁pro - ad re nom edu llin ▁; MR - pro AD m ▁; ▁f f
D-15	-0.3371080160140991	pro-adrenomedullin ;MR-proADm ; ff
P-15	-0.7777 -0.0192 -0.0109 -0.0526 -0.3432 -0.6943 -0.3664 -0.1976 -0.0240 -0.0023 -0.0040 -0.7467 -0.0667 -0.2821 -1.1803 -0.6194 -0.5616 -0.1190
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-0.7513311505317688	
D-1979	-0.7513311505317688	
P-1979	-1.3936 -0.1090
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart failure ; hf ; elevated ; sympathetic activity ; parasympathetic control ; heart
H-1133	-0.4281475245952606	▁Heart ▁failure ▁; HF ▁; ▁sympa the tic ▁activity ▁; ▁para sy mpa the tic ▁control ▁; ▁heart
D-1133	-0.4281475245952606	Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
P-1133	-0.6676 -0.1356 -0.1250 -0.1488 -0.4805 -0.7819 -0.5025 -1.3148 -0.1479 -0.0787 -0.4249 -0.0928 -0.0279 -0.8222 -0.6486 -0.0733 -0.8925 -0.8040 -0.2178 -0.1754
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality ; patients ; implantable cardiac defibrillator ; meta-analysis
H-59	-0.2385048121213913	▁implant able ▁cardiac ▁de fi br illa tor
D-59	-0.2385048121213913	implantable cardiac defibrillator
P-59	-0.0258 -0.0689 -0.0548 -0.0540 -1.3046 -0.3737 -0.0102 -0.1158 -0.2280 -0.1493
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp ; xo-mediated ros ; mitochondrial respiration ; contractile function
H-471	-0.2848344147205353	▁ATP ▁demand ▁; ▁ XO - media ted ▁ ROS ▁; ▁mito cho ndri al ▁respira tion ▁; ▁contract ile
D-471	-0.2848344147205353	ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile
P-471	-0.1367 -0.5250 -0.0524 -0.9388 -0.0544 -0.0062 -0.0361 -0.1051 -0.0816 -0.1767 -0.2540 -0.0923 -0.2679 -0.0777 -0.0394 -0.1323 -0.0333 -0.4609 -0.0102 -0.4875 -2.1815 -0.1162
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical ; activity ; cardiovascular ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
H-1898	-0.8706891536712646	▁cardiovascular ▁; ▁diabetes ▁mell itus ▁; ▁hyper tension
D-1898	-0.8706891536712646	cardiovascular ; diabetes mellitus ; hypertension
P-1898	-2.2615 -2.2606 -0.2826 -0.0234 -0.0660 -0.1707 -0.0033 -0.8540 -2.6448 -0.1399
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients ; systolic hf ; etiology ; coronary angiography
H-1184	-0.356993168592453	▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology ▁; ▁corona ry ▁ang i ography
D-1184	-0.356993168592453	systolic HF ; unclear etiology ; coronary angiography
P-1184	-3.0468 -0.0823 -0.3912 -0.2378 -0.0095 -0.1222 -0.5890 -0.0111 -0.0337 -0.1288 -0.3670 -0.2276 -0.0690 -0.2278 -0.0386 -0.7793 -0.1211 -0.1766 -0.1234
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
H-1230	-0.2768934965133667	▁at rial ▁fi bril lation ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ rhythm - control ▁; ▁rate - control
D-1230	-0.2768934965133667	atrial fibrillation ; congestive heart failure ; rhythm-control ; rate-control
P-1230	-0.9625 -0.0206 -0.2835 -0.0129 -0.0106 -0.1117 -0.0942 -0.0342 -0.0495 -0.1646 -0.1461 -0.6157 -0.5253 -0.8142 -0.0405 -0.1723 -0.5245 -0.1218 -0.0910 -0.1590 -0.9528 -0.1842
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection fraction ; ef ; infarct ; collateral growth ; myocardial perfusion
H-506	-0.23110388219356537	▁e je ction ▁ fraction ▁; EF ▁; ▁in far ct ▁; ▁col lateral ▁growth ▁; ▁my o card ial ▁per fusion
D-506	-0.23110388219356537	ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
P-506	-0.3686 -0.2328 -0.0300 -0.1108 -0.0010 -0.1988 -0.4761 -0.0932 -0.4860 -0.6382 -0.0728 -0.8030 -0.0675 -0.0005 -0.1750 -0.1264 -0.4089 -0.2572 -0.0823 -0.2577 -0.1990 -0.1156 -0.1472 -0.1981
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure ; patients
H-1510	-0.548029899597168	▁Circula ting ▁; ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti des ▁; ▁plasma ▁; ▁heart ▁failure
D-1510	-0.548029899597168	Circulating ; N-terminal pro-B-type natriuretic peptides ; plasma ; heart failure
P-1510	-0.5726 -0.7788 -1.2902 -2.2590 -0.0311 -0.0073 -0.0130 -1.1491 -0.0192 -0.3858 -0.0649 -0.0209 -0.0081 -0.0406 -0.0167 -3.0211 -0.2317 -0.2597 -0.2927 -0.3147 -1.2062 -0.7770 -0.1552 -0.2015 -0.9198 -0.2119
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients ; heart failure ; hf ; preserved left ventricular ejection fraction ; hfpef
H-1300	-0.4652904272079468	▁heart ▁failure ▁; HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; HF p EF
D-1300	-0.4652904272079468	heart failure ;HF ; left ventricular ejection fraction ;HFpEF
P-1300	-2.1384 -0.3151 -0.0701 -0.1251 -0.1247 -1.7974 -0.0265 -1.3034 -0.2743 -0.0751 -0.3268 -0.6858 -0.2135 -0.0018 -0.3510 -0.9100 -0.0088 -0.1430 -0.2698 -0.1452
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients ; end-stage heart failure ; implantation ; ventricular assist device
H-1657	-0.4704628884792328	▁implant ation ▁; ▁long - term ▁vent ri cular ▁assist ▁device
D-1657	-0.4704628884792328	implantation ; long-term ventricular assist device
P-1657	-1.0184 -0.0094 -0.2668 -0.6372 -0.0395 -0.4980 -0.0231 -2.2380 -0.1866 -0.3199 -0.3165 -0.3020 -0.2606
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf ; symptom ; cardiac murmurs ; blood pressure
H-356	-0.6912481188774109	▁ HF ▁; ▁cardiac ▁mur mur s ▁; ▁blood ▁pressure ▁; ▁h g
D-356	-0.6912481188774109	HF ; cardiac murmurs ; blood pressure ; hg
P-356	-1.7037 -0.0575 -0.3660 -0.2499 -0.2461 -0.0378 -0.1150 -0.2736 -2.6468 -2.0359 -2.0513 -0.0837 -0.0077 -0.2232 -0.2703
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors ; adenylyl cyclase ; g-protein coupling
H-1406	-0.42279624938964844	▁a den yl yl ▁cy cla se ▁; ▁g - prote in ▁coup ling
D-1406	-0.42279624938964844	adenylyl cyclase ; g-protein coupling
P-1406	-0.2490 -0.0397 -0.0742 -0.1697 -0.1776 -0.0098 -0.2233 -0.2073 -2.1741 -0.0505 -0.0962 -1.2696 -0.0123 -1.6083 -0.2328 -0.1703
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients ; hf ; spontaneous vt ; qt intervals
H-1445	-0.5507264137268066	▁ HF ▁; ▁spontane ous ▁ VT ▁; ▁beat - to - beat ▁ QT
D-1445	-0.5507264137268066	HF ; spontaneous VT ; beat-to-beat QT
P-1445	-2.2240 -0.0679 -0.0583 -2.9616 -0.1671 -0.2205 -0.0115 -0.2849 -0.2204 -0.0276 -0.3912 -0.0358 -0.0404 -0.8409 -0.3927 -1.1773 -0.2400
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular dysfunction ; outcome ; patients ; heartmate ii
H-305	-0.8249956965446472	▁bi ven tri cular ▁dys function ▁; ▁Heart Mate ▁II
D-305	-0.8249956965446472	biventricular dysfunction ; HeartMate II
P-305	-0.1975 -0.2581 -1.2812 -0.8099 -0.0596 -1.3995 -0.3225 -3.4564 -0.0662 -1.7263 -0.1581 -0.1648
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug test ; patients ; copd ; chf ; crf
H-806	-0.7223179936408997	▁TU g ▁test ▁; ▁patients ▁; ▁advanced ▁COP d ▁; ▁CHF ▁; ▁c RF
D-806	-0.7223179936408997	TUg test ; patients ; advanced COPd ; CHF ; cRF
P-806	-0.9962 -1.8932 -1.3035 -0.1210 -3.8936 -0.2209 -1.0909 -0.1027 -1.0636 -0.0587 -0.0074 -0.0686 -0.2495 -0.2296 -0.1683 -0.0894
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling pathways ; pressure-overload-induced heart failure
H-877	-0.7502270340919495	▁passage s ▁; ▁pressure - over load - indu ced ▁heart ▁failure
D-877	-0.7502270340919495	passages ; pressure-overload-induced heart failure
P-877	-5.5152 -1.7019 -0.1824 -0.7743 -0.0329 -0.0738 -0.1223 -0.0782 -0.0735 -0.9661 -0.3025 -0.2929 -0.1842 -0.2030
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing ; mandate ; accountable ; outcomes ; nursing
H-1396	-0.7434117794036865	▁social ▁mandat e
D-1396	-0.7434117794036865	social mandate
P-1396	-1.1857 -0.0024 -0.0847 -2.2373 -0.2070
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical ; patient ; hemodynamically ; cpr
H-1294	-0.48326757550239563	▁hem o dynamic ally ▁uns table ▁; ▁c PR
D-1294	-0.48326757550239563	hemodynamically unstable ; cPR
P-1294	-2.8080 -0.0790 -0.0345 -0.3179 -1.0021 -0.0319 -0.3507 -0.2549 -0.2417 -0.1202 -0.0750
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol ; cxl-1020 ; myocytes ; hearts
H-419	-0.6815409064292908	▁iso prot eren ol ▁; ▁c XL -10 20 ▁; ▁my o cy tes ▁; ▁heart s
D-419	-0.6815409064292908	isoproterenol ; cXL-1020 ; myocytes ; hearts
P-419	-0.4662 -0.0659 -2.1527 -0.0597 -0.2741 -0.5815 -0.6466 -0.2522 -0.1125 -1.0905 -1.5154 -0.1761 -0.0651 -0.0578 -0.7214 -4.0564 -0.1055 -0.3267 -0.2228
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
H-454	-0.32388022541999817	▁cardiac ▁ang io gene sis ▁; ▁in ▁vivo ▁corona ry ▁per fusion ▁; ▁cardiac ▁fibro sis
D-454	-0.32388022541999817	cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
P-454	-0.3940 -0.1699 -1.1256 -0.1654 -1.5753 -0.0941 -0.6801 -0.0079 -0.3405 -0.0564 -0.3511 -0.0215 -0.2196 -0.0665 -0.0215 -0.2721 -0.1885 -0.0800
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization ; patients ; heart failure ; ventricular tachycardia
H-1434	-0.5771609544754028	▁implant ation ▁; ▁heart ▁failure ▁; ▁vent ri cular ▁ta chy car dia
D-1434	-0.5771609544754028	implantation ; heart failure ; ventricular tachycardia
P-1434	-2.5751 -0.0554 -0.5201 -0.9382 -0.4025 -0.3363 -0.0179 -1.3149 -0.0894 -1.3196 -0.1525 -0.0210 -0.3585 -0.3884 -0.1676
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine ; myocyte ; collagen ; left ventricle
H-1141	-0.20571236312389374	▁Pyr ido stig mine ▁; ▁my o cy te ▁diameter ▁; ▁collage n ▁den s ity ▁; ▁vent ric le
D-1141	-0.20571236312389374	Pyridostigmine ; myocyte diameter ; collagen density ; ventricle
P-1141	-0.0030 -0.0407 -0.0003 -0.0268 -0.0497 -0.3760 -0.1045 -0.0377 -0.0646 -0.3393 -0.0515 -0.0201 -0.0205 -0.1027 -0.1606 -0.1696 -0.1448 -0.7231 -0.8652 -0.9487 -0.1811 -0.0953
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise intolerance ; symptom ; chronic hfpef ; quality of life ; qol
H-1975	-0.703624427318573	▁Exerci se ▁in tolerance ▁; ▁h f f ▁; q ol
D-1975	-0.703624427318573	Exercise intolerance ; hff ;qol
P-1975	-1.6246 -0.1010 -0.0059 -0.0334 -0.1515 -0.9057 -0.5392 -0.6112 -0.2437 -3.8297 -0.8089 -0.1799 -0.1124
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy substrate metabolism ; hearts ; aac
H-1781	-0.7189861536026001	▁energy ▁substrat e ▁metabolism
D-1781	-0.7189861536026001	energy substrate metabolism
P-1781	-1.2753 -0.0434 -0.1099 -0.1551 -2.6107 -0.1196
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence ; schfi v.6.2 ; clinical
H-1509	-0.8188260793685913	▁structure ▁; ▁ SCH FI
D-1509	-0.8188260793685913	structure ; SCHFI
P-1509	-1.7519 -0.4669 -0.6282 -0.0721 -2.0086 -0.7301 -0.0740
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule ; patients ; cad ; patients ; cad
H-1191	-1.2847939729690552	▁CAD
D-1191	-1.2847939729690552	CAD
P-1191	-1.9460 -1.8076 -0.1007
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes mellitus ; cardiovascular disease ; baseline
H-630	-0.41833430528640747	▁diabetes ▁mell itus ▁; ▁cardiovascular ▁disease
D-630	-0.41833430528640747	diabetes mellitus ; cardiovascular disease
P-630	-1.1372 -0.0079 -0.1163 -0.3321 -0.0160 -1.4416 -0.1071 -0.1884
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd ; psoriasis ; hazard ratio ; confidence interval
H-1563	-0.4547733664512634	▁CV d ▁; ▁psoriasis
D-1563	-0.4547733664512634	CVd ; psoriasis
P-1563	-1.3390 -0.5694 -0.1622 -0.0200 -0.4639 -0.1741
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise ; haemodynamic ; pulmonary
H-1277	-0.23833738267421722	▁ha emo dynamic ▁; ▁pulmonar y
D-1277	-0.23833738267421722	haemodynamic ; pulmonary
P-1277	-0.1733 -0.0631 -0.0110 -0.2853 -0.0040 -0.0578 -1.1387 -0.1734
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic ; rule ; prospectively
H-1188	-0.551594078540802	▁predict ion ▁rule
D-1188	-0.551594078540802	prediction rule
P-1188	-2.2967 -0.0135 -0.1784 -0.1588 -0.1105
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam study ; psoriasis ; cardiovascular ; outcomes
H-1556	-0.6164097785949707	▁Rotterdam ▁; ▁psoriasis ▁; ▁cardiovascular ▁outcome s
D-1556	-0.6164097785949707	Rotterdam ; psoriasis ; cardiovascular outcomes
P-1556	-2.0087 -2.0364 -0.1600 -0.5276 -0.0125 -0.6427 -0.0172 -0.0843 -0.0583
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf antagonists ; nbdmard
H-607	-0.3939090669155121	▁HR ▁; ▁t NF ▁anta gon ists ▁; ▁n b DM ARD
D-607	-0.3939090669155121	HR ; tNF antagonists ; nbDMARD
P-607	-0.2334 -0.0852 -0.3465 -0.3149 -1.0174 -0.0561 -0.2891 -0.1539 -0.2000 -0.0156 -2.0226 -0.2880 -0.3569 -0.1352
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications ; acs ; patients ; patients ; vad
H-1286	-0.5395727157592773	▁a CS ▁; ▁MT ▁; ▁ VAD
D-1286	-0.5395727157592773	aCS ; MT ; VAD
P-1286	-0.1466 -0.8723 -0.9521 -1.5140 -0.1210 -0.8944 -0.0191 -0.1667 -0.1700
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital ; cardiac ; hospital ; south dakota
H-1577	-0.5909033417701721	▁hospital ▁; ▁cardiac ▁special ty ▁hospital ▁; ▁rural ▁South ▁da kota
D-1577	-0.5909033417701721	hospital ; cardiac specialty hospital ; rural South dakota
P-1577	-0.8596 -0.2249 -0.0219 -0.1972 -0.1697 -0.3327 -0.6314 -2.8201 -1.0296 -1.1201 -0.0126 -0.1685 -0.0935
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-0.9416492581367493	▁structure ▁; ▁medical ▁records
D-1131	-0.9416492581367493	structure ; medical records
P-1131	-1.9557 -2.0827 -0.4665 -0.4112 -0.6322 -0.1016
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo ; egfr ; egfr
H-1392	-0.7600106000900269	▁EC mo ▁; ▁e g FR ▁; ▁e g FR
D-1392	-0.7600106000900269	ECmo ; egFR ; egFR
P-1392	-0.3304 -0.7553 -0.9225 -0.2880 -1.6780 -0.6636 -0.3131 -0.8513 -2.0650 -0.6905 -0.4063 -0.1561
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration ; chf
H-683	-0.5625792145729065	▁tras tuz um ab - related ▁CHF
D-683	-0.5625792145729065	trastuzumab-related CHF
P-683	-4.4396 -0.0099 -0.0377 -0.0991 -0.1690 -0.0523 -0.0509 -0.1071 -0.0976
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute hf
H-1018	-0.26262983679771423	▁a cute ▁ HF
D-1018	-0.26262983679771423	acute HF
P-1018	-0.9537 -0.0103 -0.2063 -0.0358 -0.2269 -0.1427
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.5171545147895813	▁bio mark er - guide d ▁clinic al
D-1476	-0.5171545147895813	biomarker-guided clinical
P-1476	-0.0552 -0.0052 -0.0224 -0.0246 -0.0051 -0.1445 -0.2367 -0.0979 -4.4220 -0.1580
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.33313700556755066	▁hospital s
D-142	-0.33313700556755066	hospitals
P-142	-0.5751 -0.1255 -0.4110 -0.2210
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.3172803521156311	▁long - term ▁survival
D-272	-0.3172803521156311	long-term survival
P-272	-0.3917 -0.1106 -0.7202 -0.3023 -0.2846 -0.0943
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac death
H-1905	-0.46917495131492615	▁sud den ▁cardiac ▁death
D-1905	-0.46917495131492615	sudden cardiac death
P-1905	-0.3914 -0.0543 -0.0860 -0.7209 -1.4035 -0.1590
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia ; rv function
H-1159	-0.47382527589797974	HF - related ▁cache xia ▁; ▁ RV ▁; ▁body ▁composition
D-1159	-0.47382527589797974	HF-related cachexia ; RV ; body composition
P-1159	-2.0771 -0.0721 -0.3357 -0.1507 -0.0952 -0.1995 -0.2394 -0.1463 -1.6426 -0.5712 -0.3674 -0.1568 -0.1058
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital ; mortality
H-1692	-0.3227245509624481	▁hospital ▁mortal ity
D-1692	-0.3227245509624481	hospital mortality
P-1692	-1.0586 -0.1445 -0.1823 -0.0738 -0.1544
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital ; rehospitalization
H-1719	-0.6853148341178894	▁hospital ▁; ▁re hospital ization
D-1719	-0.6853148341178894	hospital ; rehospitalization
P-1719	-1.4880 -2.5020 -0.0284 -0.0263 -0.5877 -0.0586 -0.1061
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality ; readmission
H-207	-0.23774932324886322	▁cognitive ▁im pair ment ▁; ▁mortal ity
D-207	-0.23774932324886322	cognitive impairment ; mortality
P-207	-0.4847 -0.0333 -0.1009 -0.0510 -0.4207 -0.3210 -0.3096 -0.2925 -0.1261
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic ; histological ; gastrointestinal
H-1359	-0.4954511821269989	▁sono graphic ▁; ▁his t ological ▁; ▁functional ▁ab normal ities
D-1359	-0.4954511821269989	sonographic ; histological ; functional abnormalities
P-1359	-0.4063 -0.5842 -0.8774 -0.9695 -0.0861 -0.1622 -0.5706 -0.2440 -0.0737 -0.0171 -0.8413 -1.4380 -0.1703
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic peptide ; biomarkers ; point of care ; poc
H-1023	-0.3926619589328766	▁na tri ure tic ▁pe pti de ▁; ▁bio mark ers
D-1023	-0.3926619589328766	natriuretic peptide ; biomarkers
P-1023	-0.1315 -0.0346 -0.0245 -1.6668 -0.3846 -0.0826 -0.0495 -0.7799 -0.1802 -0.0034 -0.0440 -1.6265 -0.0966
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
H-1352	-0.2541654407978058	▁antico a gul ants ▁; ▁anti plate let ▁drugs ▁; ▁heart ▁failure ▁; ▁at rial ▁fi bril lation
D-1352	-0.2541654407978058	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
P-1352	-1.0970 -0.3538 -0.1234 -0.0153 -0.1306 -0.0107 -0.0773 -0.0420 -0.2531 -0.1869 -1.1090 -0.3420 -0.1935 -0.1866 -0.1569 -0.4608 -0.0263 -0.0355 -0.1536 -0.1291
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone ; hyperkalemia ; acute kidney injury
H-445	-0.1553879678249359	▁Spir ono lac tone ▁; ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury
D-445	-0.1553879678249359	Spironolactone ; hyperkalemia ; acute kidney injury
P-445	-0.1380 -0.0922 -0.0343 -0.0400 -0.1287 -0.0511 -0.2466 -0.2879 -0.1735 -0.2403 -0.0171 -0.3379 -0.4403 -0.0548 -0.1797 -0.0810 -0.0980
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence ; bnp ; patients ; pad ; bnp ; hf
H-1572	-0.4294814467430115	▁b NP ▁; PAD ▁; ▁b NP ▁; ▁ HF
D-1572	-0.4294814467430115	bNP ;PAD ; bNP ; HF
P-1572	-0.4004 -0.1434 -0.3241 -1.0696 -0.1040 -0.2894 -0.2237 -0.3670 -1.5652 -0.4514 -0.1080 -0.1075
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic ; parasympathetic activity ; hf ; symptoms ; disease
H-1868	-0.4615689218044281	▁sympa the tic ▁; ▁para sy mpa the tic ▁activity ▁; ▁ HF
D-1868	-0.4615689218044281	sympathetic ; parasympathetic activity ; HF
P-1868	-0.6235 -0.4498 -0.8921 -0.1519 -0.2150 -0.1968 -0.0536 -1.1125 -1.1020 -0.3089 -0.1704 -0.4804 -0.0630 -1.0004 -0.1031
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients ; systolic blood pressure ; renal impairment ; hypertension
H-1529	-0.7455755472183228	▁EH ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁renal ▁im pair ment ▁; ▁hyper tension
D-1529	-0.7455755472183228	EH ; systolic blood pressure ; renal impairment ; hypertension
P-1529	-1.2401 -0.1347 -6.0600 -0.1686 -2.0665 -0.4063 -1.4725 -0.0842 -0.0458 -0.0332 -0.0056 -0.0376 -0.3501 -0.1169 -0.2091 -0.1077 -0.1359
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes ; exercise ; training ; patients ; ambulatory ; hf
H-1631	-1.1364378929138184	▁race ▁; ▁ HF
D-1631	-1.1364378929138184	race ; HF
P-1631	-2.3203 -0.3708 -3.7931 -0.0676 -0.1089 -0.1580
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf ; transition ; compensated lv hypertrophy ; hf ; hhd
H-283	-0.36213138699531555	▁mouse ▁ HF ▁; ▁transition ▁; ▁compensa ted ▁LV ▁hyper trop hy ▁; ▁ HF ▁; ▁h HD
D-283	-0.36213138699531555	mouse HF ; transition ; compensated LV hypertrophy ; HF ; hHD
P-283	-1.0489 -0.4240 -0.0852 -0.4911 -0.4444 -0.4235 -0.4404 -0.5671 -0.1255 -0.0936 -0.0097 -0.1286 -0.1791 -0.6947 -0.0466 -0.1705 -0.0868 -1.5389 -0.1647 -0.0796
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global left ventricular longitudinal systolic strain ; cardiovascular events ; patients ; atrial fibrillation
H-808	-0.3804090619087219	▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation
D-808	-0.3804090619087219	ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
P-808	-0.5043 -1.1346 -0.1321 -0.3017 -0.1597 -0.0490 -1.2755 -0.1118 -0.2502 -0.9290 -0.2818 -0.0946 -0.7733 -0.2573 -0.4432 -0.1877 -0.5673 -0.0436 -0.0682 -0.2437 -0.1799
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up ; deaths ; heart transplantations ; lv assist device implantations ; heart failure ; admissions
H-434	-0.4311400055885315	▁heart ▁transplant ations ▁; LV ▁assist ▁device ▁implant ations ▁; ▁heart ▁failure
D-434	-0.4311400055885315	heart transplantations ;LV assist device implantations ; heart failure
P-434	-1.6306 -0.3966 -0.1613 -0.1214 -0.2577 -1.0838 -0.1827 -0.0024 -0.1027 -0.4742 -0.2350 -0.2581 -0.9735 -0.1559
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic myocardial ischemia ; heart failure ; therapeutic
H-503	-0.658420979976654	▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure
D-503	-0.658420979976654	chronic myocardial ischemia ; heart failure
P-503	-3.3903 -2.0382 -0.2028 -0.1402 -0.3829 -0.0674 -0.9747 -0.6331 -0.2681 -0.0722 -0.0811 -0.1871 -0.1213
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients ; hfpef ; adverse outcomes
H-237	-0.505985677242279	▁ HF p EF
D-237	-0.505985677242279	HFpEF
P-237	-2.0492 -0.0697 -0.0165 -0.1395 -0.5967 -0.1645
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical cardiac support ; renal function ; end-stage heart failure
H-1384	-0.615720808506012	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function ▁; ▁end - s tage ▁heart ▁failure
D-1384	-0.615720808506012	mechanical cardiac support ; renal function ; end-stage heart failure
P-1384	-0.7285 -0.0281 -0.3974 -1.0951 -0.4730 -0.1033 -2.2301 -0.2027 -3.0249 -0.0538 -0.1874 -0.0021 -0.6924 -0.3428 -0.1430 -0.1469
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical ; revascularization ; revascularization
H-1603	-0.5746577978134155	▁sur g ical ▁re vas cular ization
D-1603	-0.5746577978134155	surgical revascularization
P-1603	-0.4011 -0.5774 -1.7715 -0.0216 -0.1763 -0.3809 -0.5032 -1.2038 -0.1361
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline ; hgb ; exercise ; training ; kccq
H-841	-0.901715099811554	▁h gb ▁; ▁k cc q
D-841	-0.901715099811554	hgb ; kccq
P-841	-0.4751 -0.1099 -0.2332 -4.5303 -0.0477 -1.1339 -0.5084 -0.1753
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based ; nucleolin ; protein expression
H-96	-0.2847016751766205	▁Mor pho lino - based ▁knock down ▁; ▁nucleo lin ▁; ▁protein ▁expression
D-96	-0.2847016751766205	Morpholino-based knockdown ; nucleolin ; protein expression
P-96	-0.2397 -0.0558 -0.2418 -0.0730 -0.3346 -0.1333 -0.0398 -0.3921 -0.1125 -0.9098 -0.4239 -0.5459 -0.0981 -0.5445 -0.1258
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical ; rule ; cad ; systolic hf
H-1185	-0.30283647775650024	▁clinic al ▁predict ion ▁rule ▁; ▁CAD ▁; ▁cause ▁of ▁sy sto lic ▁ HF
D-1185	-0.30283647775650024	clinical prediction rule ; CAD ; cause of systolic HF
P-1185	-1.0960 -0.0326 -0.2162 -0.0085 -0.4620 -0.1457 -0.0550 -0.1069 -0.0663 -1.7614 -0.2017 -0.3196 -0.2627 -0.1284 -0.0144 -0.1893 -0.0814
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo sternotomy ; cardiopulmonary bypass
H-775	-0.42267465591430664	▁pump - ex change ▁technique ▁; ▁redo ▁ster no to my ▁; ▁cardio pul mon ary ▁by pass
D-775	-0.42267465591430664	pump-exchange technique ; redo sternotomy ; cardiopulmonary bypass
P-775	-3.0753 -0.0232 -0.1171 -0.0051 -0.0335 -0.1959 -0.0619 -0.1826 -0.0126 -0.1012 -0.7842 -0.2334 -0.0349 -0.0669 -1.2401 -0.1583 -1.6647 -0.0267 -0.2562 -0.1797
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical treatment ; hf ; functional ms ; medical treatment
H-354	-0.9033289551734924	▁MS ▁; ▁ HF ▁; ▁functional ▁MS
D-354	-0.9033289551734924	MS ; HF ; functional MS
P-354	-0.5525 -0.2757 -2.8000 -0.0324 -0.3829 -2.2210 -0.1518 -1.6459 -0.0678
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence ; parasympathetic ; therapeutic ; hf
H-1134	-0.7625910043716431	▁para sy mpa the tic ▁function ▁; ▁ HF ▁e volution
D-1134	-0.7625910043716431	parasympathetic function ; HF evolution
P-1134	-0.7560 -0.2054 -0.0886 -0.5900 -1.1318 -2.2700 -0.2760 -0.2122 -2.4803 -1.7074 -0.0172 -0.0873 -0.0917
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical treatment ; hf ; hf ; symptom ; mva
H-371	-0.699347972869873	▁ HF ▁; ▁ HF ▁; ▁ms ▁; ▁m va
D-371	-0.699347972869873	HF ; HF ; ms ; mva
P-371	-2.7038 -0.1745 -0.2500 -1.4378 -0.1357 -0.2517 -1.1130 -0.7927 -0.6943 -0.3079 -0.3738 -0.1570
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular venous pressure ; peripheral oedema ; patient
H-1895	-0.22993458807468414	▁jugu lar ▁ve nous ▁pressure ▁; ▁per i pher al ▁oed ema
D-1895	-0.22993458807468414	jugular venous pressure ; peripheral oedema
P-1895	-0.0167 -0.1605 -0.1857 -0.3998 -0.5589 -0.0943 -0.2032 -0.1802 -0.0092 -0.0330 -0.1098 -0.0231 -1.1445 -0.1001
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart failure ; hf ; condition ; morbidity ; mortality
H-1487	-0.5140884518623352	▁Heart ▁failure ▁; HF
D-1487	-0.5140884518623352	Heart failure ;HF
P-1487	-0.9052 -0.1222 -0.1610 -0.1933 -1.5973 -0.1056
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported ; functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-333	-0.28814345598220825	▁functional ▁mit ral ▁sten osis ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation
D-333	-0.28814345598220825	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
P-333	-1.0581 -1.9771 -0.0725 -0.0576 -0.0605 -0.1525 -0.2467 -0.1695 -0.1899 -0.0236 -0.1209 -0.2490 -0.3886 -0.1791 -0.0551 -0.8145 -0.1260 -0.0066 -0.0163 -0.1596 -0.0434 -0.3050 -0.1549
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients ; fontan circulation ; svr ; cardiac index
H-232	-0.33895543217658997	▁Font an ▁circulation ▁; ▁s VR ▁index ▁; ▁cardiac ▁index
D-232	-0.33895543217658997	Fontan circulation ; sVR index ; cardiac index
P-232	-1.0559 -0.4691 -0.0135 -0.0889 -1.2096 -0.2110 -0.2004 -0.0575 -0.0248 -0.1623 -0.4908 -0.0837
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients ; lvad ; patients ; biventricular support
H-297	-0.4537982642650604	▁l VAD ▁; ▁bi ven tri cular ▁support
D-297	-0.4537982642650604	lVAD ; biventricular support
P-297	-2.2622 -0.0851 -0.5148 -0.1791 -0.1793 -0.3217 -0.1348 -0.6461 -0.0924 -0.1225
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid receptor antagonists
H-1709	-0.4166266620159149	▁mineral o cor tico id ▁receptor ▁anta gon ists
D-1709	-0.4166266620159149	mineralocorticoid receptor antagonists
P-1709	-1.5452 -0.0535 -0.3050 -0.7068 -0.3643 -0.0680 -0.2540 -0.0854 -0.5097 -0.5442 -0.1467
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary ; congenital ; heart ; death
H-1906	-1.0693325996398926	▁her edit ary ▁; ▁con geni tal ▁ab normal ities ▁; ▁heart
D-1906	-1.0693325996398926	hereditary ; congenital abnormalities ; heart
P-1906	-6.5347 -0.0861 -0.3612 -0.7289 -1.7416 -0.0239 -0.0721 -0.0514 -0.1354 -1.3644 -0.3174 -0.4309 -2.8049 -0.3179
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan circulation ; skeletal muscle ; metabolic
H-1494	-0.24094226956367493	▁Font an ▁circulation ▁; ▁skelet al ▁muscle ▁mass ▁; ▁metabol ic ▁ab normal ities
D-1494	-0.24094226956367493	Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
P-1494	-0.3033 -0.3400 -0.0211 -0.1376 -0.1662 -0.1172 -0.5523 -0.3787 -0.8996 -0.0176 -0.0979 -0.0551 -0.0624 -0.5172 -0.1075 -0.0814
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients ; heartmate ii ; lvad
H-303	-0.7327805757522583	▁Heart Mate ▁II ▁l VAD
D-303	-0.7327805757522583	HeartMate II lVAD
P-303	-2.4119 -0.1503 -0.9878 -1.1850 -0.0390 -0.2059 -0.1496
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based ; patient ; outcomes
H-85	-0.8361080288887024	
D-85	-0.8361080288887024	
P-85	-1.5872 -0.0850
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health ; health ; u.s. ; drug ; administration
H-1830	-0.8696345686912537	▁health ▁insurance ▁; ▁health ▁system ▁data ▁; ▁u e s ▁; ▁Food ▁and ▁Drug ▁Administration ▁; ▁Mini - S enti nel ▁program
D-1830	-0.8696345686912537	health insurance ; health system data ; ues ; Food and Drug Administration ; Mini-Sentinel program
P-1830	-0.4390 -0.2766 -0.1666 -0.2382 -0.1812 -2.5559 -0.4234 -0.3139 -0.9717 -3.7899 -1.0947 -0.4869 -3.2476 -0.1459 -0.3770 -1.7471 -0.8813 -0.0048 -1.4298 -0.0084 -0.0033 -1.6772 -0.2529 -0.1579
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp ; patients ; acute heart failure
H-262	-0.45998579263687134	▁NT - pro b NP ▁; ▁ED ▁; ▁a cute ▁heart ▁failure
D-262	-0.45998579263687134	NT-probNP ; ED ; acute heart failure
P-262	-0.2843 -0.0102 -0.0037 -0.8476 -0.0769 -0.8513 -2.2699 -0.6743 -0.2941 -0.0668 -0.4871 -0.2794 -0.1253 -0.1690
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension ; diabetes ; ischemic ; etiology
H-1635	-0.3086022734642029	▁black s ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁ ische mic ▁et i ology ▁; ▁socio economic ▁status ▁; ▁white s
D-1635	-0.3086022734642029	blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
P-1635	-1.9841 -0.0744 -0.1134 -0.0195 -0.1056 -0.1000 -0.0334 -0.1012 -0.0419 -0.1900 -0.0345 -0.0111 -0.3223 -0.8534 -0.3162 -0.0491 -0.0963 -0.5882 -1.5674 -0.1851 -0.0434 -0.1523 -0.1151
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin ; lvad ; postoperative
H-536	-0.9672778248786926	▁album in ▁; ▁l VAD
D-536	-0.9672778248786926	albumin ; lVAD
P-536	-2.0880 -0.9385 -1.2095 -0.6763 -0.0978 -1.5547 -0.2062
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape ; functional enrichment analysis ; david
H-1612	-0.5726533532142639	▁réseau ▁; ▁Cy to scape ▁; ▁functional ▁en rich ment
D-1612	-0.5726533532142639	réseau ; Cytoscape ; functional enrichment
P-1612	-0.8776 -0.2042 -0.0720 -0.0308 -0.1064 -0.1958 -0.9995 -0.0347 -0.0015 -0.0289 -4.2042 -0.1162
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular ; conditions ; patients ; hf
H-694	-0.8124009966850281	▁cardiovascular ▁conditions ▁; HF
D-694	-0.8124009966850281	cardiovascular conditions ;HF
P-694	-1.5188 -0.0502 -0.2824 -2.8545 -0.0649 -0.1036
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-0.731709897518158	▁patient ▁safety
D-7	-0.731709897518158	patient safety
P-7	-0.8163 -0.6250 -1.3569 -0.1287
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling ; emd
H-1151	-0.19881372153759003	▁ HF - indu ced ▁remodel ing ▁; ▁EM d ▁prolong ation
D-1151	-0.19881372153759003	HF-induced remodeling ; EMd prolongation
P-1151	-0.5442 -0.0565 -0.0577 -0.0219 -0.2403 -0.0084 -0.1048 -0.8377 -0.1982 -0.2315 -0.2410 -0.0572 -0.0862 -0.0978
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right heart circulation ; right heart failure
H-1459	-1.0102934837341309	▁right ▁heart ▁circulation ▁; ▁right ▁heart ▁failure
D-1459	-1.0102934837341309	right heart circulation ; right heart failure
P-1459	-4.2596 -0.9852 -0.0891 -0.3218 -2.3842 -0.5132 -0.3079 -0.1142 -0.1175
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling pathway ; remodelling
H-994	-0.4819510281085968	▁Raf - MEK 1/2 - ER k 1/2 ▁signal ling ▁; ▁remodel ling
D-994	-0.4819510281085968	Raf-MEK1/2-ERk1/2 signalling ; remodelling
P-994	-0.0685 -0.0359 -0.0117 -0.8427 -0.1215 -0.5047 -0.5594 -0.5272 -0.4716 -0.4284 -1.8834 -1.0979 -0.3896 -0.1721 -0.1146
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi ; mi ; hf
H-1104	-0.8052058219909668	▁MI ▁; ▁late - ons et ▁; ▁MI ▁; ▁ HF
D-1104	-0.8052058219909668	MI ; late-onset ; MI ; HF
P-1104	-2.1285 -0.5596 -2.7133 -0.0401 -0.2036 -0.2929 -0.2228 -1.5066 -0.4327 -1.8324 -0.1445 -0.1664 -0.2243
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate ; heart failure
H-1544	-0.5284198522567749	▁Bis phos phon ate ▁; ▁heart ▁failure
D-1544	-0.5284198522567749	Bisphosphonate ; heart failure
P-1544	-1.0655 -0.0112 -0.0523 -1.1133 -0.7430 -0.7414 -0.4595 -0.4623 -0.1073
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs ; outcomes
H-2009	-1.0241321325302124	▁coût ▁; ▁survival
D-2009	-1.0241321325302124	coût ; survival
P-2009	-1.9682 -1.4804 -1.4386 -0.1521 -0.0814
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary outcomes
H-620	-0.6381250023841858	▁sustain ability ▁; ▁commission ing ▁; ▁hospital - based ▁programme s
D-620	-0.6381250023841858	sustainability ; commissioning ; hospital-based programmes
P-620	-0.0579 -0.1462 -0.2490 -0.0411 -0.0976 -0.4064 -0.0222 -0.0904 -5.9526 -0.8618 -0.0644 -0.1881 -0.1181
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.5552306175231934	▁mal adapt ive ▁molecular
D-1473	-0.5552306175231934	maladaptive molecular
P-1473	-0.7082 -0.0402 -0.0073 -0.2587 -2.2437 -0.0733
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine oxidase inhibition ; left ventricular ; systolic ; diastolic function ; cardiac volume overload
H-469	-0.5917550921440125	▁Xan thi ne ▁oxid ase ▁inhibi tion ▁; ▁vent ri cular ▁sy sto lic ▁; ▁dia sto lic ▁; ▁cardiac
D-469	-0.5917550921440125	Xanthine oxidase inhibition ; ventricular systolic ; diastolic ; cardiac
P-469	-0.0013 -0.0548 -0.1069 -0.0207 -1.5713 -0.3966 -0.0964 -0.1426 -0.0199 -1.5104 -0.2507 -1.3002 -0.1656 -0.6455 -0.3502 -0.0698 -0.1716 -0.2756 -2.1850 -0.5463 -2.9965 -0.1407
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis ; heart failure with preserved ejection fraction ; clinical ; doppler echocardiography
H-21	-0.35568079352378845	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁clinic al ▁do pp ler ▁e cho card i ography
D-21	-0.35568079352378845	heart failure ; preserved ejection fraction ; clinical doppler echocardiography
P-21	-1.4729 -0.4019 -0.1735 -1.0373 -0.0113 -0.2222 -0.0363 -0.2984 -0.0942 -0.1095 -0.0002 -0.2724 -1.5577 -0.0251 -0.4921 -0.0188 -0.6100 -0.0542 -0.4896 -0.1204 -0.5639 -0.1728 -0.1805 -0.1211
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients ; heart failure ; hf ; heart failure adherence and retention trial ; hart
H-238	-0.3908144533634186	▁heart ▁failure ▁; HF ▁; ▁Heart ▁Fail ure ▁Ad her ence ▁; ▁re tention ▁Tri al ▁; HAR t
D-238	-0.3908144533634186	heart failure ;HF ; Heart Failure Adherence ; retention Trial ;HARt
P-238	-2.0228 -0.2711 -0.1490 -0.0905 -0.1885 -0.9893 -0.1213 -0.0476 -1.0868 -0.1608 -0.0046 -0.4011 -0.9813 -0.0069 -0.3571 -0.0118 -0.5829 -0.0115 -0.4565 -0.1421 -0.1237
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf with preserved ejection fraction ; hfpef ; hypertension
H-1076	-0.37910547852516174	HF ▁; ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁hyper tension
D-1076	-0.37910547852516174	HF ; ejection fraction ;HFpEF ; hypertension
P-1076	-0.4784 -0.4587 -2.1577 -0.6074 -0.1374 -0.2064 -0.0016 -0.1520 -0.8699 -0.0184 -0.1671 -0.2876 -0.0796 -0.1271 -0.1369 -0.1795
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end points ; nyha functional class ; quality-of-life ; 6-minute hall walk
H-1873	-0.5277765393257141	▁NY ha ▁functional ▁class ▁; ▁quality - of - life ▁score
D-1873	-0.5277765393257141	NYha functional class ; quality-of-life score
P-1873	-1.3219 -0.6604 -1.0164 -0.0466 -0.2461 -0.5181 -0.0163 -0.3022 -0.0598 -0.0423 -0.4981 -1.8534 -0.2795
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial infarction ; left anterior descending coronary artery occlusion
H-1338	-0.40256690979003906	▁My o card ial ▁in far ction ▁; ▁left ▁anterior ▁descend ing ▁corona ry ▁arter y ▁oc clusi on
D-1338	-0.40256690979003906	Myocardial infarction ; left anterior descending coronary artery occlusion
P-1338	-1.1014 -0.2138 -0.0723 -0.2866 -0.0162 -1.7249 -0.0638 -0.4007 -1.0771 -1.5204 -0.0089 -0.0567 -0.5190 -0.0952 -0.0205 -0.5545 -0.0453 -0.0091 -0.2450 -0.2932 -0.1292
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical ; symptoms ; hfpef ; symptoms ; breathlessness ; fluid retention
H-1891	-0.8609351515769958	▁ HF p EF ▁; ▁breath less ness ▁; ▁fatigue
D-1891	-0.8609351515769958	HFpEF ; breathlessness ; fatigue
P-1891	-1.9926 -0.4450 -0.0617 -0.8272 -0.4706 -0.9741 -0.0185 -1.0666 -0.4147 -0.1518 -3.7442 -0.1642
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection ; nt-probnp ; antibodies ; terminal
H-1521	-0.22048868238925934	▁immun o det ection ▁; ▁NT - pro b NP ▁; ▁anti bo dies
D-1521	-0.22048868238925934	immunodetection ; NT-probNP ; antibodies
P-1521	-0.0884 -0.0983 -0.0347 -0.0413 -0.2400 -0.0249 -0.0210 -0.0044 -0.7799 -0.0939 -0.8405 -0.0090 -0.1056 -0.8128 -0.2269 -0.1063
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; heart failure
H-574	-0.7848092913627625	▁Nordic ▁walking ▁; ▁cardiac ▁rehabilita tion ▁; ▁heart ▁failure
D-574	-0.7848092913627625	Nordic walking ; cardiac rehabilitation ; heart failure
P-574	-0.1867 -1.1503 -0.2573 -0.1502 -0.1138 -0.0196 -1.1089 -5.0509 -0.3380 -0.1473 -0.1098
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
H-1132	-0.29079511761665344	▁para sy mpa the tic ▁tone ▁; ▁py rido stig mine ▁; ▁vent ri cular ▁dys function ▁; ▁heart ▁failure
D-1132	-0.29079511761665344	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
P-1132	-0.4104 -0.3920 -0.0436 -0.6276 -0.7698 -0.1631 -0.1458 -0.2016 -0.0165 -0.0006 -0.0545 -0.1409 -0.0034 -1.1822 -0.2910 -0.0340 -0.2389 -0.3491 -0.4623 -0.5260 -0.1900 -0.1538
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade ; cardiac angiogenesis ; heart failure ; vegf signaling pathway
H-459	-0.5819911956787109	▁β - Block ade ▁; ▁cardiac ▁ang io gene sis ▁; ▁heart ▁failure ▁; ▁VE GF ▁signal ing ▁path way
D-459	-0.5819911956787109	β-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
P-459	-2.2522 -0.0759 -0.1047 -1.0474 -0.4338 -0.0918 -0.0877 -2.0947 -0.4525 -2.1233 -0.3890 -0.1754 -0.5151 -0.2075 -0.5423 -0.0651 -0.7751 -0.4025 -0.3321 -0.1233 -0.3357 -0.1770
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes ; myocardial ischemic events ; patients ; cardiac resynchronization therapy
H-101	-0.3380917012691498	▁my o card ial ▁ ische mic ▁events ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-101	-0.3380917012691498	myocardial ischemic events ; cardiac resynchronization therapy
P-101	-1.8666 -0.2679 -0.0995 -0.4826 -0.0705 -0.6326 -0.0872 -0.5350 -0.2188 -0.0512 -0.0301 -0.0253 -0.0047 -0.8513 -0.5047 -0.0263 -0.1391 -0.1924
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report ; patients ; aortic valve ; surgery ; post-lvad ai
H-544	-0.4614090323448181	▁a or tic ▁val ve ▁surgery ▁; ▁new - ons et ▁; ▁l VAD ▁AI
D-544	-0.4614090323448181	aortic valve surgery ; new-onset ; lVAD AI
P-544	-0.1263 -0.0155 -0.9370 -0.0752 -0.0146 -0.0786 -0.1518 -1.9473 -0.0564 -0.0703 -0.1924 -1.9139 -0.9296 -0.0430 -1.1329 -0.0788 -0.0804
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart ; hr reduction ; patients ; systolic heart failure
H-527	-0.5209500193595886	▁un load ing ▁; ▁heart ▁; ▁HR ▁re duction ▁; ▁sy sto lic ▁heart ▁failure
D-527	-0.5209500193595886	unloading ; heart ; HR reduction ; systolic heart failure
P-527	-0.8568 -0.0664 -0.0982 -0.9557 -1.4049 -0.2288 -0.6169 -0.1659 -0.0027 -0.3003 -1.3291 -0.1639 -1.8012 -0.5035 -0.1394 -0.1096 -0.1129
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone ; diagnosed ; systolic heart failure ; clinical
H-439	-0.37973690032958984	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-439	-0.37973690032958984	spironolactone ; systolic heart failure
P-439	-0.6152 -0.0150 -0.0429 -0.0497 -0.1558 -1.4836 -0.1858 -1.0501 -0.5442 -0.1625 -0.1668 -0.0853
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart failure ; clinical ; medicine ; prevalence ; coronary disease
H-980	-0.48168689012527466	▁Heart ▁failure ▁; ▁medicine ▁; ▁a ther omat ous ▁corona ry ▁disease
D-980	-0.48168689012527466	Heart failure ; medicine ; atheromatous coronary disease
P-980	-0.7205 -0.1686 -0.1838 -3.3636 -0.1480 -0.0116 -0.0068 -0.0108 -0.8487 -0.1322 -0.3036 -0.4836 -0.2121 -0.1497
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart failure ; hf ; latin america ; health ; hf
H-1789	-0.38914427161216736	▁Heart ▁failure ▁; HF ▁; ▁Latin ▁America ▁; LA ▁; ▁health ▁service ▁planning ▁; ▁ HF
D-1789	-0.38914427161216736	Heart failure ;HF ; Latin America ;LA ; health service planning ; HF
P-1789	-0.8091 -0.1231 -0.1270 -0.3134 -0.2354 -1.3228 -0.2367 -0.1830 -0.5445 -0.5692 -1.4179 -0.0465 -0.2466 -0.1701 -0.3736 -0.0371 -0.1410 -0.1075
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization ; medicare ; discharged ; nursing
H-1710	-0.42705416679382324	▁medica re ▁fee - for - service ▁beneficiar ies ▁; ▁skille d ▁nur sing ▁facilities
D-1710	-0.42705416679382324	medicare fee-for-service beneficiaries ; skilled nursing facilities
P-1710	-1.2650 -0.0059 -0.1161 -0.0640 -0.9448 -0.0143 -0.0273 -2.3257 -0.0410 -0.8767 -0.1286 -0.0358 -0.3183 -0.4173 -0.4000 -0.1708 -0.1083
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death ; hf ; hospitalization ; crt ; hazard ratio
H-755	-0.8142251968383789	▁ HF ▁; ▁c rte ▁; haz ard ▁ratio
D-755	-0.8142251968383789	HF ; crte ;hazard ratio
P-755	-2.1672 -0.1377 -1.2656 -0.7044 -2.2398 -1.6442 -0.0683 -0.0285 -0.0594 -0.3975 -0.2439
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative care ; patients ; terminal ; disease ; therapeutic
H-1820	-1.0652797222137451	▁palli ative
D-1820	-1.0652797222137451	palliative
P-1820	-0.1735 -0.2139 -3.7941 -0.0796
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic ; hfpef ; medical history ; physical examination
H-1892	-0.7180668711662292	▁ HF p EF
D-1892	-0.7180668711662292	HFpEF
P-1892	-1.5625 -0.2379 -0.0546 -0.3369 -2.0195 -0.0970
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative stress ; gtpase ; rac1 ; activity ; hearts
H-281	-0.5739619135856628	▁o xi da tive ▁stress ▁; ▁GT Pas e ▁Rac 1 ▁activity ▁; ▁heart s ▁; ▁ ANS ▁mi ce
D-281	-0.5739619135856628	oxidative stress ; GTPase Rac1 activity ; hearts ; ANS mice
P-281	-2.4937 -0.0539 -0.0710 -0.0296 -0.3333 -0.1177 -2.3882 -0.1560 -0.0439 -0.1439 -0.1765 -1.0663 -0.2162 -0.6840 -0.0326 -0.4660 -1.8169 -0.7783 -1.0395 -0.2172 -0.1578 -0.1446
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin ; insulin resistance ; monocytes ; inflammatory
H-928	-0.4626322388648987	▁circula ting ▁media tor ▁of ▁insulin ▁resist ance ▁; ▁human ▁mono cy tes ▁; ▁infla mma tory ▁stimul i
D-928	-0.4626322388648987	circulating mediator of insulin resistance ; human monocytes ; inflammatory stimuli
P-928	-2.8292 -1.4547 -0.1382 -0.1247 -0.5947 -0.1164 -0.1808 -0.0197 -0.1632 -2.2391 -0.0835 -0.0143 -0.0296 -0.3190 -0.3165 -0.3532 -0.1574 -0.0301 -0.1810 -0.1334 -0.2365
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end point ; cardiovascular death ; cardiac transplant ; secondary end point ; death
H-1757	-0.43526268005371094	▁cardiovascular ▁death ▁; ▁urgent ▁cardiac ▁transplant
D-1757	-0.43526268005371094	cardiovascular death ; urgent cardiac transplant
P-1757	-1.0574 -1.1500 -0.0822 -0.0715 -0.0222 -0.0562 -0.9321 -0.1106
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications ; outpatients ; heart failure ; ncdr pinnacle
H-658	-0.6032093167304993	▁medication s ▁; ▁heart ▁failure ▁; ▁NC DR ▁PIN NA CLE
D-658	-0.6032093167304993	medications ; heart failure ; NCDR PINNACLE
P-658	-1.6227 -0.0545 -0.5233 -1.2678 -0.3687 -0.8485 -0.0620 -0.2584 -0.2071 -0.8462 -0.6178 -0.9666 -0.1980
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; patients ; heart failure
H-1110	-0.7735235095024109	▁beta - block ers ▁; ▁cardiac ▁sympa the tic ▁activity ▁; ▁hemos tas is ▁; ▁heart ▁failure
D-1110	-0.7735235095024109	beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
P-1110	-5.0088 -0.0538 -0.1128 -0.1205 -0.5361 -0.0476 -0.9311 -0.7436 -3.2975 -0.1012 -0.3561 -1.2791 -0.0775 -0.1691 -0.5879 -0.5918 -0.3347 -0.1830 -0.1647
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission ; patients
H-1581	-0.8757411241531372	
D-1581	-0.8757411241531372	
P-1581	-1.5880 -0.1635
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.3006958067417145	▁transform ed
D-86	-0.3006958067417145	transformed
P-86	-0.3395 -0.6903 -0.0823 -0.0907
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous ; symptoms ; patients ; heart failure
H-51	-0.2965497374534607	▁Intra ven ous ▁ir on ▁; ▁heart ▁failure ▁; ▁ir on ▁de fici en cy
D-51	-0.2965497374534607	Intravenous iron ; heart failure ; iron deficiency
P-51	-0.1365 -0.0069 -1.6054 -0.1131 -0.2067 -0.3736 -0.9897 -0.3362 -0.2840 -0.0443 -0.1267 -0.1885 -0.0507 -0.2476 -0.1090 -0.0871 -0.1356
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart failure ; emergency department ; patient ; outcomes
H-462	-0.5868968367576599	▁he art ▁failure ▁; ▁Emer gen cy ▁Department ▁; ED ▁; ▁ED
D-462	-0.5868968367576599	heart failure ; Emergency Department ;ED ; ED
P-462	-2.3036 -0.1117 -0.0768 -0.1543 -0.6153 -0.0478 -0.0113 -0.1623 -0.4072 -0.7878 -0.3975 -1.4930 -1.5064 -0.1416
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions ; remodelling ; leading ; heart failure
H-991	-0.4190152883529663	▁conditions ▁; ▁mal adapt ive ▁remodel ling ▁; ▁heart ▁failure
D-991	-0.4190152883529663	conditions ; maladaptive remodelling ; heart failure
P-991	-2.8826 -0.3915 -0.4120 -0.0302 -0.0064 -0.0188 -0.2304 -0.3351 -0.2598 -0.2531 -0.0872 -0.1211
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ; ischemic heart failure
H-1613	-0.5578189492225647	▁de g s ▁; ▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure
D-1613	-0.5578189492225647	degs ; non-ischemic ; ischemic heart failure
P-1613	-1.7864 -2.0264 -0.0819 -0.2973 -0.5140 -0.0430 -1.0785 -0.0665 -0.9900 -0.1019 -0.4884 -0.2087 -0.6119 -0.2381 -0.2241 -0.1680
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis ; systemic ; followed up
H-1559	-0.6717288494110107	▁psoriasis ▁; ▁system ic / UV
D-1559	-0.6717288494110107	psoriasis ; systemic/UV
P-1559	-0.0250 -0.3833 -0.7346 -0.3095 -1.6769 -0.0026 -2.1270 -0.1149
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv dysfunction ; prognosis ; hf
H-1160	-0.647607684135437	▁ RV ▁dys function ▁; ▁weight ▁loss ▁; ▁ab normal ▁body ▁composition ▁; ▁ HF
D-1160	-0.647607684135437	RV dysfunction ; weight loss ; abnormal body composition ; HF
P-1160	-1.6242 -0.2774 -0.0840 -0.4127 -0.1876 -0.4279 -1.6107 -0.2027 -2.3933 -0.0233 -0.4596 -0.1880 -0.4050 -2.4069 -0.0653 -0.0644 -0.1764
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-0.83940190076828	
D-609	-0.83940190076828	
P-609	-1.5204 -0.1584
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.3099904954433441	
D-158	-0.3099904954433441	
P-158	-0.5350 -0.0850
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis ; clinical ; prognostic ; diastolic dysfunction ; leading ; hfpef
H-26	-0.620935320854187	▁dia sto lic ▁dys function ▁; ▁h FP EF
D-26	-0.620935320854187	diastolic dysfunction ; hFPEF
P-26	-2.5411 -0.2508 -1.2511 -0.0137 -0.1805 -0.2163 -0.2473 -1.5071 -0.3600 -0.1046 -0.1578
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic receptor blockade ; mortality ; all-cause hospitalizations ; patients ; heart failure ; hf
H-1424	-0.5516777038574219	▁ad r energi c ▁receptor ▁block ade ▁; ▁heart ▁failure ▁; HF
D-1424	-0.5516777038574219	adrenergic receptor blockade ; heart failure ;HF
P-1424	-2.0251 -0.0449 -0.1084 -0.0438 -0.0147 -0.7117 -0.3023 -0.2645 -2.0747 -0.4888 -1.1960 -0.0608 -0.1659 -0.2220
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right ventricle ; leads ; stroke volume ; shortens ; left ventricular ejection time ; lvet
H-578	-0.5934112668037415	▁vent ric le ▁over load ▁; ▁stroke ▁volume ▁; ▁vent ri cular ▁e je ction ▁time ▁; ▁l VET
D-578	-0.5934112668037415	ventricle overload ; stroke volume ; ventricular ejection time ; lVET
P-578	-0.2692 -1.9581 -1.2091 -2.2834 -0.0599 -0.1289 -0.1549 -0.6572 -0.1413 -0.3352 -1.3522 -0.0761 -0.0721 -0.4868 -0.2517 -1.5685 -0.5380 -0.2865 -0.3368 -0.2053 -0.0905
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp ; hf ; patient ; plasma ; immunoprecipitation ; mass spectrometric analysis
H-1515	-0.4896000027656555	▁NT - pro b NP ▁; ▁ HF ▁patient ▁plasma ▁; ▁immun o preci pit ation
D-1515	-0.4896000027656555	NT-probNP ; HF patient plasma ; immunoprecipitation
P-1515	-0.0726 -0.0368 -0.0143 -0.6663 -0.1631 -0.2335 -1.7614 -0.0825 -2.7758 -0.8642 -0.3068 -0.0058 -0.2009 -0.1159 -0.0316 -0.0480 -1.2499 -0.1835
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated proteins ; chromatin structure ; changing ; dna ; gene expression profile
H-90	-0.4437546730041504	▁Chro mat in - as soci ated ▁protein s ▁; ▁chr omat in ▁structure ▁; ▁DNA
D-90	-0.4437546730041504	Chromatin-associated proteins ; chromatin structure ; DNA
P-90	-0.7138 -0.0169 -0.9231 -0.2164 -0.0896 -0.0021 -0.3506 -0.9899 -0.0694 -0.2381 -0.0244 -0.0208 -1.2771 -1.4993 -0.1543 -0.4066 -0.8715 -0.1238
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd ; clinical ; hospitalizations ; complications ; therapy ; end-stage hf
H-895	-0.9182570576667786	▁PD ▁; ▁ therapy ▁; ▁ HF
D-895	-0.9182570576667786	PD ; therapy ; HF
P-895	-1.3755 -0.3256 -2.3445 -0.0795 -0.4079 -3.3366 -0.1786 -0.0961 -0.1201
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive ; patients ; pulmonary hypertension ; heart failure
H-577	-0.29366037249565125	▁pulmonar y ▁hyper tension ▁; PH ▁; ▁heart ▁failure
D-577	-0.29366037249565125	pulmonary hypertension ;PH ; heart failure
P-577	-2.2123 -0.0434 -0.0102 -0.1147 -0.1077 -0.0279 -0.2353 -0.1908 -0.0764 -0.1033 -0.1082
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait ; therapy ; lokomat ; heart failure ; patients
H-1912	-0.31178367137908936	▁robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ® ▁system ▁in ▁heart ▁failure
D-1912	-0.31178367137908936	robot-assisted gait therapy ; Lokomat® system in heart failure
P-1912	-1.0498 -0.0706 -0.0046 -0.0484 -0.1666 -0.0944 -0.0609 -0.0152 -0.1414 -0.0480 -0.0337 -1.1080 -0.3296 -0.9156 -0.2922 -0.1703 -0.9545 -0.1084
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
H-1647	-0.12481290102005005	▁cat heter ▁ab lation ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁ rhythm ▁control ▁ therapy
D-1647	-0.12481290102005005	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
P-1647	-0.0509 -0.0052 -0.0136 -0.0167 -0.0482 -0.0149 -0.4002 -0.1245 -0.2539 -0.0469 -0.3016 -0.0739 -0.3205 -0.0980 -0.0998 -0.0154 -0.1723 -0.1899
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy ; hdl ; chf-nyha-iiib ; hdl
H-258	-0.86949622631073	▁ET ▁; ▁HD L ▁function ▁; ▁ET ▁; ▁CHF - NY ha - III b ▁; ▁HD L
D-258	-0.86949622631073	ET ; HDL function ; ET ; CHF-NYha-IIIb ; HDL
P-258	-2.2512 -0.1894 -1.6869 -1.5290 -2.1220 -0.2354 -2.2394 -0.1123 -0.2125 -0.0354 -0.4152 -0.6552 -0.1196 -0.2226 -0.0358 -0.2177 -1.1578 -1.8174 -2.0489 -0.0863
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac failure ; death ; patients ; type 2 diabetes ; diabetes ; heart failure
H-652	-0.4750515818595886	▁Card iac ▁failure ▁; ▁diabetes ▁; ▁diabetes ▁; ▁heart ▁failure
D-652	-0.4750515818595886	Cardiac failure ; diabetes ; diabetes ; heart failure
P-652	-1.0955 -0.2114 -0.0731 -0.1342 -0.5304 -0.2093 -2.1217 -0.2656 -0.5498 -0.3040 -0.0797 -0.1259
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient ; symptomatic ; therapeutic ; exercise ; hemodynamic
H-1179	-1.3315061330795288	▁implant ation ▁; ▁hem o dynamic ▁status
D-1179	-1.3315061330795288	implantation ; hemodynamic status
P-1179	-4.8542 -1.2911 -0.5110 -3.6392 -0.1928 -0.0432 -1.2025 -0.1341 -0.1154
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet ; sensitivity ; specificity ; death ; icu
H-584	-0.8076385855674744	▁l VET ▁; ▁ ICU
D-584	-0.8076385855674744	lVET ; ICU
P-584	-1.4376 -1.4611 -0.5634 -1.4569 -0.4070 -0.1774 -0.1501
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients ; diagnosis ; congestive heart failure
H-1578	-0.2542848587036133	▁con ges tive ▁heart ▁failure
D-1578	-0.2542848587036133	congestive heart failure
P-1578	-0.7892 -0.0344 -0.1656 -0.4356 -0.1606 -0.0831 -0.1115
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient ; implantable cardioverter-defibrillator
H-1859	-0.39072588086128235	▁a im ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1859	-0.39072588086128235	aim ; implantable cardioverter-defibrillator deactivation
P-1859	-0.9123 -0.9662 -0.2437 -0.0019 -0.0394 -0.4604 -0.1221 -0.0525 -0.0103 -0.0759 -2.8346 -0.9442 -0.0100 -0.0616 -0.1117 -0.0236 -0.0659 -0.3189 -0.1688
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial structure ; sarcomeric microstructure
H-1250	-0.7440717220306396	▁mito cho ndri al ▁structure
D-1250	-0.7440717220306396	mitochondrial structure
P-1250	-0.2068 -0.6578 -0.0767 -0.0576 -0.3430 -3.7403 -0.1264
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients ; heart failure and reduced ejection fraction
H-668	-0.7318142652511597	▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-668	-0.7318142652511597	heart failure ; ejection fraction
P-668	-4.7808 -0.2594 -0.2002 -0.7781 -0.7032 -0.0817 -0.0878 -0.0012 -0.1660 -0.2597
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut ; inflammation ; heart failure ; patients ; heart failure
H-1363	-0.6961180567741394	▁gut ▁; ▁ inflammation ▁; ▁heart ▁failure
D-1363	-0.6961180567741394	gut ; inflammation ; heart failure
P-1363	-0.9786 -0.1361 -0.0351 -0.1036 -0.1395 -2.4618 -0.1401 -2.0987 -0.1716
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr ; acr ; cms ; correlated
H-141	-0.6280128955841064	▁p PR ▁; ▁a CR ▁; ▁CMS
D-141	-0.6280128955841064	pPR ; aCR ; CMS
P-141	-0.6520 -1.4041 -0.0701 -0.0581 -2.4377 -0.1350 -0.0663 -0.6915 -0.1373
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality ; lcx ; lad ; disease
H-513	-0.5349503755569458	▁ LC x ▁; ▁ LAD ▁; ▁two - ves sel ▁disease ▁model
D-513	-0.5349503755569458	LCx ; LAD ; two-vessel disease model
P-513	-1.9150 -0.0873 -0.2371 -0.2150 -0.2564 -0.0140 -0.8781 -2.2383 -0.0980 -0.0334 -0.0126 -0.3297 -1.4509 -0.1396 -0.1189
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf ; patients ; emergency department ; intubated
H-210	-0.48484259843826294	▁CHF ▁; ▁emergency ▁department ▁; ED ▁; ▁in tuba ted
D-210	-0.48484259843826294	CHF ; emergency department ;ED ; intubated
P-210	-0.0184 -1.2759 -0.6292 -0.1852 -0.3558 -0.6608 -0.8687 -0.0418 -0.0673 -1.3516 -0.2245 -0.1388
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis ; patients ; chf ; therapeutic ; neurohormonal systems
H-635	-0.38795918226242065	▁CHF ▁; ▁ therapeut ic ▁interrupt ion ▁; ▁activa ted ▁neuro hormon al ▁systems
D-635	-0.38795918226242065	CHF ; therapeutic interruption ; activated neurohormonal systems
P-635	-0.8338 -0.6138 -0.9412 -0.0661 -0.2342 -0.0032 -0.0093 -0.5666 -0.8076 -0.4659 -0.1511 -0.0863 -0.0453 -1.0453 -0.2313 -0.1063
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese ; zsf1 ; heart failure with preserved ejection fraction
H-770	-0.3508913516998291	▁z f 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-770	-0.3508913516998291	zf1 rats ; heart failure ; preserved ejection fraction
P-770	-0.7699 -1.4112 -0.2032 -0.5034 -0.0482 -0.5987 -0.4660 -0.3871 -0.1967 -0.6936 -0.0044 -0.1612 -0.0658 -0.3855 -0.1046 -0.0943 -0.0020 -0.3264 -0.2446
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician ; follow-up ; discharge ; death ; readmission ; patients ; heart failure
H-1413	-0.9190472364425659	▁physician ▁follow - up ▁; ▁dis charge ▁; ▁death ▁; ▁read mission ▁; ▁heart ▁failure
D-1413	-0.9190472364425659	physician follow-up ; discharge ; death ; readmission ; heart failure
P-1413	-0.4196 -2.8055 -0.0562 -0.0193 -0.9241 -2.5933 -0.0209 -0.2805 -3.8366 -0.2255 -1.3513 -0.0487 -0.4024 -2.2149 -0.2335 -0.1032 -0.0884
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart magnetic resonance imaging ; chelation ; compliance ; heart disease ; patients ; thalassaemia major
H-744	-0.5235015153884888	▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁heart ▁disease ▁; ▁tha lassa emia
D-744	-0.5235015153884888	heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
P-744	-1.0418 -0.1150 -0.4693 -0.4334 -0.0774 -0.3053 -0.1253 -0.2571 -1.8571 -0.0043 -0.9194 -0.0327 -0.1612 -1.6920 -0.9340 -0.3645 -0.0468 -0.3870 -0.7794 -0.8849 -0.1055
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial tonometry ; lvet ; prognostic ; patients ; precapillary ph ; heart failure
H-579	-0.2765427529811859	▁arterial ▁ton ometr y ▁; ▁l VET ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-579	-0.2765427529811859	arterial tonometry ; lVET ; precapillary PH ; heart failure
P-579	-0.4572 -0.5490 -0.0372 -0.0720 -0.4201 -1.1273 -0.6081 -0.0700 -0.2644 -0.0776 -0.0075 -0.0554 -0.1668 -0.3301 -0.2916 -0.1589 -0.1525 -0.1321
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk ; heart ; adipose tissue ; cachectic heart failure ; patients ; prospective study
H-8	-0.6092501282691956	▁Cross - talk ▁; ▁heart ▁; ▁adi pose ▁tissu e ▁; ▁cache ctic ▁heart ▁failure
D-8	-0.6092501282691956	Cross-talk ; heart ; adipose tissue ; cachectic heart failure
P-8	-3.0735 -0.0804 -0.0227 -0.8470 -1.1988 -0.2515 -0.0161 -0.2090 -0.3917 -0.1764 -0.3208 -0.1100 -0.4315 -0.3253 -0.1262 -2.6010 -0.1753
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 ; healthy ; heart muscle ; cells ; phenotype ; pathological ; hypertrophy
H-641	-0.48071661591529846	▁mu tant ▁mi ce ▁; ▁Hand 2 ▁; ▁heart ▁muscle ▁cell s ▁; ▁path ological ▁hyper trop hy
D-641	-0.48071661591529846	mutant mice ; Hand2 ; heart muscle cells ; pathological hypertrophy
P-641	-0.0452 -0.2889 -0.1140 -0.0953 -0.1334 -2.8267 -0.3749 -0.2092 -1.9242 -0.9628 -0.6303 -0.0566 -1.1270 -0.2215 -0.2551 -0.0206 -0.0012 -0.1242 -0.0813 -0.1218
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal echocardiography ; shunts ; thrombosis
H-1957	-0.40159109234809875	▁trans o es op hage al ▁e cho card i ography
D-1957	-0.40159109234809875	transoesophageal echocardiography
P-1957	-0.0696 -0.2637 -0.1140 -0.6802 -0.0365 -0.2196 -0.0343 -0.0711 -0.0401 -0.3029 -0.1509 -3.1218 -0.1160
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients ; uptitration ; heart rate ; renal function ; spironolactone
H-180	-1.0285965204238892	▁heart ▁rate ▁; ▁renal ▁function ▁; ▁spi rono lac tone
D-180	-1.0285965204238892	heart rate ; renal function ; spironolactone
P-180	-5.7777 -1.7205 -0.0587 -0.1461 -3.3579 -0.6627 -0.0877 -0.0181 -0.0476 -0.0509 -0.1372 -0.2781
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis ; patients ; adverse events ; echocardiographic ; outcomes
H-914	-0.5537886023521423	▁di al ysis ▁; ▁e cho car dio graphic
D-914	-0.5537886023521423	dialysis ; echocardiographic
P-914	-0.1996 -0.0819 -0.1250 -1.6175 -0.4518 -0.4141 -0.1018 -0.4236 -0.8552 -1.6399 -0.1813
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence ; micrornas ; mirnas ; pathogenesis ; heart failure
H-1481	-0.28130680322647095	▁micro RNA s ▁; mi RNA s ▁; ▁heart ▁failure
D-1481	-0.28130680322647095	microRNAs ;miRNAs ; heart failure
P-1481	-0.2514 -0.0168 -0.0273 -0.3446 -0.1779 -0.0178 -0.0182 -0.3735 -1.5037 -0.4075 -0.1238 -0.1132
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf ; shift ; chronic heart failure ; chronic heart failure ; cardiology
H-1964	-0.7377686500549316	▁PARA DIG m - HF ▁; ▁paradigm ▁shift ▁; ▁chronic ▁heart ▁failure ▁; ▁Chro nic ▁heart ▁failure ▁; ▁card i ology
D-1964	-0.7377686500549316	PARADIGm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
P-1964	-3.6692 -0.0550 -0.1434 -0.0152 -0.0135 -0.1179 -3.8040 -0.0889 -0.1430 -1.7579 -0.4452 -0.1666 -0.3040 -3.4664 -0.1560 -0.2435 -0.0711 -0.4388 -0.6495 -0.4254 -0.5577 -0.1215 -0.1151
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory ; hf ; patients ; left ventricular ejection fraction
H-122	-0.5520366430282593	▁consenti ng ▁ambula tory ▁ HF ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction
D-122	-0.5520366430282593	consenting ambulatory HF ; left ventricular ejection fraction
P-122	-2.8342 -0.1725 -0.1108 -0.1666 -0.2147 -0.0380 -1.1669 -1.2477 -0.1879 -0.0188 -2.1815 -0.2193 -0.1178 -0.2502 -0.6096 -0.3507 -0.0010 -0.4632 -0.1372
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new zealand ; renal dnx ; pacing-induced chf
H-1373	-0.44495511054992676	▁New ▁Zealand ▁White ▁rabbi ts ▁; ▁renal ▁DN x ▁; ▁pa cing - indu ced ▁CHF
D-1373	-0.44495511054992676	New Zealand White rabbits ; renal DNx ; pacing-induced CHF
P-1373	-5.9380 -0.0094 -0.6296 -0.0373 -0.0243 -0.1403 -0.1366 -0.0746 -0.0016 -0.2118 -0.2034 -0.1653 -0.0220 -0.0041 -0.1452 -0.0101 -0.1428 -0.1129
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt variability ; qtv ; repolarization ; qtv ; cardiac death
H-1435	-0.5443776249885559	▁ QT ▁variabil ity ▁; ▁q TV ▁; ▁repo lar ization ▁la bility ▁; ▁Q TV ▁; ▁risk ▁predict or ▁; ▁sud den ▁cardiac ▁death
D-1435	-0.5443776249885559	QT variability ; qTV ; repolarization lability ; QTV ; risk predictor ; sudden cardiac death
P-1435	-1.8921 -0.2321 -1.2729 -0.2670 -0.0713 -1.7653 -0.8454 -0.2595 -2.0822 -0.2963 -0.1404 -0.0109 -0.0219 -0.1340 -0.6888 -0.6331 -0.1628 -1.9797 -0.6670 -0.0724 -0.3346 -0.1043 -0.0414 -0.0137 -0.4127 -0.1435 -0.1527
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker ; patients ; resting hr ; bpm ; p value
H-1941	-0.6477336287498474	▁Beta - block er
D-1941	-0.6477336287498474	Beta-blocker
P-1941	-0.1696 -0.0354 -0.0214 -0.0819 -3.4827 -0.0953
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping ; mri ; tidal respiration ; myocardial t1 ; heart failure
H-1054	-0.3747904896736145	▁m RI ▁; ▁tid al ▁respira tion ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁; ▁heart ▁failure
D-1054	-0.3747904896736145	mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
P-1054	-0.4500 -1.6796 -0.2880 -1.0117 -0.0149 -0.0653 -0.0140 -0.0968 -0.2071 -0.2390 -0.0402 -0.0175 -1.7415 -0.0362 -0.5382 -0.3821 -0.3483 -0.1209 -0.4945 -0.2492 -0.1769 -0.2358 -0.1724
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular disease ; baseline
H-1767	-1.1474424600601196	▁cardiovascular ▁disease
D-1767	-1.1474424600601196	cardiovascular disease
P-1767	-2.9057 -1.4259 -0.1319 -0.1263
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage ; poc
H-1029	-1.5703601837158203	▁technologies
D-1029	-1.5703601837158203	technologies
P-1029	-4.4216 -0.1434 -0.1460
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis ; cardiovascular disease ; cvd
H-1555	-0.5003126263618469	▁psoriasis ▁; ▁cardiovascular ▁disease ▁; CV d
D-1555	-0.5003126263618469	psoriasis ; cardiovascular disease ;CVd
P-1555	-1.8626 -0.4410 -0.3378 -1.1540 -0.1286 -0.0261 -0.2875 -0.1415 -0.1238
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital compare ; ami ; mortality
H-1697	-0.6313993334770203	▁Hospital ▁Compar e ▁; ▁ AMI ▁mortal ity ▁rates
D-1697	-0.6313993334770203	Hospital Compare ; AMI mortality rates
P-1697	-1.9510 -1.3549 -0.0570 -0.3744 -0.5651 -0.0626 -0.2552 -0.0917 -1.8374 -0.1927 -0.2033
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause readmissions
H-726	-0.570220410823822	
D-726	-0.570220410823822	
P-726	-1.0635 -0.0770
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins ; subproteome
H-94	-1.404919981956482	▁protein s
D-94	-1.404919981956482	proteins
P-94	-3.0160 -0.0487 -2.5068 -0.0481
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm control therapy
H-1645	-0.2150559425354004	▁ Rhythm ▁control ▁ therapy
D-1645	-0.2150559425354004	Rhythm control therapy
P-1645	-0.0867 -0.0720 -0.0563 -0.1485 -0.0230 -1.0150 -0.1039
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal ; likelihood ratio
H-487	-1.2919100522994995	▁e - sept al
D-487	-1.2919100522994995	e-septal
P-487	-1.8710 -5.2533 -0.0029 -0.0273 -0.4189 -0.1782
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs ; clinical
H-2015	-1.2803462743759155	
D-2015	-1.2803462743759155	
P-2015	-2.4647 -0.0960
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
H-1546	-0.20841839909553528	▁cardiac ▁dys function ▁; ▁sub cel lular ▁altera tions ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1546	-0.20841839909553528	cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
P-1546	-0.1515 -0.0453 -0.4323 -0.1269 -0.0401 -0.0439 -0.0112 -0.3017 -0.0176 -0.2928 -0.0366 -0.1087 -0.0100 -0.1230 -0.5821 -0.2000 -0.1725 -0.2586 -0.5738 -0.2428 -0.1981 -0.2403 -0.0130 -0.6599 -0.3487 -0.2101 -0.1859
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv diastolic dysfunction ; filling pressures ; non-invasively ; doppler echocardiography
H-28	-0.3809607923030853	▁LV ▁dia sto lic ▁dys function ▁; ▁fill ing ▁pressure s ▁; ▁do pp ler ▁e cho card i ography
D-28	-0.3809607923030853	LV diastolic dysfunction ; filling pressures ; doppler echocardiography
P-28	-0.3115 -1.6563 -0.3651 -1.0759 -0.0070 -0.2074 -0.0928 -0.2113 -0.0491 -0.9479 -0.0580 -0.3747 -0.5732 -0.0322 -0.3742 -0.0786 -0.7232 -0.1766 -0.4782 -0.2427 -0.1641 -0.1813
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac magnetic resonance postcontrast t1 time ; outcome ; patients ; heart failure ; preserved ejection fraction
H-733	-0.33913904428482056	▁Card iac ▁magnetic ▁res on ance ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-733	-0.33913904428482056	Cardiac magnetic resonance ; heart failure ; ejection fraction
P-733	-0.3248 -0.1574 -0.0636 -0.1709 -0.2953 -0.0338 -0.7634 -1.9539 -0.3603 -0.2332 -0.6063 -0.3635 -0.0956 -0.0880 -0.0008 -0.1306 -0.1239
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial collagen ; collagen cross-linking ; titin ; isoforms ; phosphorylation
H-764	-0.33546775579452515	▁My o card ial ▁collage n ▁; ▁collage n ▁; ▁titi n ▁iso form s ▁; ▁ phos phor y lation
D-764	-0.33546775579452515	Myocardial collagen ; collagen ; titin isoforms ; phosphorylation
P-764	-0.5472 -0.0751 -0.0806 -0.6137 -0.1123 -0.1562 -0.3656 -0.4912 -0.0450 -1.8595 -0.3598 -0.0397 -0.4280 -0.4407 -0.0779 -0.7730 -0.0704 -0.0260 -0.2019 -0.6180 -0.0242 -0.1456 -0.1641
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker ; uptitration ; clinical ; outcome ; patients ; hfref ; hfpef
H-185	-0.3439193069934845	RAS - block er ▁up tit ration ▁; ▁h Fr EF ▁; ▁ HF p EF
D-185	-0.3439193069934845	RAS-blocker uptitration ; hFrEF ; HFpEF
P-185	-0.1902 -0.0278 -0.0943 -0.1671 -0.5158 -0.2077 -0.0369 -0.2128 -0.2295 -1.5342 -0.4728 -0.2366 -1.3910 -0.2073 -0.0690 -0.2779 -0.1640 -0.1556
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin ; exercise ; training ; health ; patients ; chronic heart failure ; hf-action ; randomized
H-833	-0.7167872786521912	▁Hem o glob in ▁; ▁health ▁status ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁ HF - AC tion
D-833	-0.7167872786521912	Hemoglobin ; health status ; patients ; chronic heart failure ; HF-ACtion
P-833	-0.1205 -0.0833 -0.0260 -0.9988 -0.3720 -2.7269 -0.4551 -0.1921 -2.4123 -0.7442 -0.6837 -0.7395 -1.2342 -0.5286 -1.1258 -0.0319 -0.0186 -1.0085 -0.9496 -0.3351 -0.2660
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
H-88	-0.466726690530777	▁Systems ▁prote o mics ▁; ▁cardiac ▁chr omat in ▁; ▁nucleo lin ▁; ▁regulator ▁of ▁growth ▁; ▁cel lular ▁plastic ity ▁; ▁cardio my o cy tes
D-88	-0.466726690530777	Systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
P-88	-1.1319 -0.4449 -1.2812 -0.0056 -0.4502 -0.0697 -0.0259 -0.0069 -0.8337 -0.1654 -0.1323 -0.3546 -0.1607 -1.8070 -0.7105 -0.4063 -0.1539 -3.1702 -0.0260 -0.0566 -0.1157 -0.4971 -0.0127 -0.1929 -0.7090 -0.0869 -0.2549 -0.1672 -0.1049
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma ; collected ; hf ; patients
H-1514	-0.735764741897583	▁Plas ma ▁; ▁ HF
D-1514	-0.735764741897583	Plasma ; HF
P-1514	-0.1352 -0.2625 -1.4575 -1.4777 -0.0504 -1.6571 -0.1099
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes ; hypertrophic
H-1217	-0.3410521447658539	▁p de 2- over express ing ▁cardio my o cy tes ▁; ▁no re pine ph rine - indu ced ▁hyper trop hic
D-1217	-0.3410521447658539	pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic
P-1217	-1.2987 -0.0168 -0.4588 -0.4538 -0.0458 -0.0461 -0.0752 -0.1534 -0.3978 -0.1634 -0.2451 -0.2316 -0.0450 -0.0216 -0.0812 -0.7535 -0.0594 -0.0377 -0.0423 -0.7954 -0.0043 -0.0011 -0.0703 -2.7451 -0.2831
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported ; heart failure ; clcnka ; snp
H-1804	-0.9564641118049622	▁heart ▁failure ▁; ▁CL CN KA ▁s NP
D-1804	-0.9564641118049622	heart failure ; CLCNKA sNP
P-1804	-4.6325 -0.4599 -0.0923 -0.9923 -0.4811 -0.6783 -1.7421 -0.0407 -0.3306 -0.1148
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt ; gdmt ; bat
H-1871	-0.6207332015037537	▁GD MT ▁; ▁GD MT ▁; ▁BAT
D-1871	-0.6207332015037537	GDMT ; GDMT ; BAT
P-1871	-0.2398 -0.0883 -0.3514 -3.1572 -0.0664 -0.2938 -1.1152 -0.1890 -0.0856
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline ; patients ; resting hr ; bpm
H-1940	-0.9992026686668396	▁h z
D-1940	-0.9992026686668396	hz
P-1940	-2.0587 -1.5287 -0.3090 -0.1005
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction pathways ; engage ; signalling proteins
H-993	-0.7075650095939636	▁trans duction ▁; ▁signal ling ▁protein s
D-993	-0.7075650095939636	transduction ; signalling proteins
P-993	-0.0390 -0.2446 -3.0069 -0.9575 -0.9356 -0.9661 -0.0441 -0.0849 -0.0894
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate ; alendronate ; heart failure
H-1545	-1.0493483543395996	▁ale ndr onate ▁; ▁risk ▁; ▁heart ▁failure
D-1545	-1.0493483543395996	alendronate ; risk ; heart failure
P-1545	-0.5655 -0.2453 -0.5249 -0.2634 -5.6032 -0.7108 -1.6880 -0.7017 -0.0791 -0.1114
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients ; cardiovascular disease ; drs
H-1838	-0.8104385733604431	▁cardiovascular ▁disease ▁; ▁d RS
D-1838	-0.8104385733604431	cardiovascular disease ; dRS
P-1838	-1.4024 -0.6476 -0.8374 -0.2643 -0.5907 -1.8104 -0.1202
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician ; patient ; admission ; admission
H-1417	-0.8572428822517395	▁index ▁ad mission
D-1417	-0.8572428822517395	index admission
P-1417	-3.6462 -0.0546 -0.0447 -0.3067 -0.2340
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy ; patients ; follow-up
H-861	-0.5793153047561646	
D-861	-0.5793153047561646	
P-861	-1.0524 -0.1062
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients ; beta-blocker ; therapy
H-1939	-0.4538363814353943	▁beta - block er ▁ therapy
D-1939	-0.4538363814353943	beta-blocker therapy
P-1939	-2.9166 -0.0165 -0.0673 -0.0326 -0.1778 -0.0272 -0.1127 -0.2799
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart failure ; patients ; bisphosphonates
H-1535	-0.3269706666469574	▁heart ▁failure ▁; ▁bis phos phon ates
D-1535	-0.3269706666469574	heart failure ; bisphosphonates
P-1535	-1.5103 -0.2463 -0.2566 -0.1464 -0.0130 -0.0683 -0.3605 -0.1634 -0.1779
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty ; heart failure ; hf
H-622	-0.5563485026359558	▁fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; HF
D-622	-0.5563485026359558	frailty ; risk ; heart failure ;HF
P-622	-1.6874 -0.4814 -1.8420 -0.0816 -0.6403 -0.3638 -0.2239 -0.2110 -0.1920 -0.2953 -0.5563 -0.1012
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas ; cardiac remodeling ; heart failure
H-1483	-0.17535237967967987	▁mi RNA s ▁; ▁cardiac ▁remodel ing ▁; ▁heart ▁failure
D-1483	-0.17535237967967987	miRNAs ; cardiac remodeling ; heart failure
P-1483	-0.8786 -0.0079 -0.0225 -0.1181 -0.0840 -0.0314 -0.0988 -0.2070 -0.1321 -0.1742 -0.2656 -0.0841
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis ; medical ; hf
H-200	-1.0534281730651855	▁ HF
D-200	-1.0534281730651855	HF
P-200	-2.9360 -0.2859 -0.8431 -0.1487
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical ; diastolic dysfunction ; mortality
H-25	-0.5475440621376038	▁dia sto lic ▁dys function ▁; ▁cause ▁mortal ity
D-25	-0.5475440621376038	diastolic dysfunction ; cause mortality
P-25	-2.0203 -0.2331 -1.6806 -0.0305 -0.2761 -1.4064 -0.0644 -0.0248 -0.1583 -0.0476 -0.0810
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa ; immunoassays ; nt-probnp
H-1516	-0.5434410572052002	▁Alpha LIS a ▁; ▁immun o assa ys ▁; ▁NT - pro b NP
D-1516	-0.5434410572052002	AlphaLISa ; immunoassays ; NT-probNP
P-1516	-3.7628 -0.3989 -0.8383 -1.2091 -0.0037 -0.1406 -0.0287 -0.8252 -0.3603 -0.0933 -0.0090 -0.0056 -0.6951 -0.0494 -0.1656 -0.1094
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic adult fontan ; saf ; patients ; catheterization
H-226	-0.44456735253334045	▁Font an ▁; SAF
D-226	-0.44456735253334045	Fontan ;SAF
P-226	-1.0699 -0.3016 -0.5704 -0.0186 -0.5542 -0.1529
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death ; c-statistics ; biological phenotype ; deficit index
H-1011	-0.44711190462112427	▁c - stat istic s ▁; ▁bi ological ▁ph eno type
D-1011	-0.44711190462112427	c-statistics ; biological phenotype
P-1011	-1.1714 -0.2131 -0.0181 -0.0795 -0.0091 -0.2949 -0.0133 -0.1649 -0.5589 -0.1178 -0.0226 -2.9986 -0.1501
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients ; sinus rhythm ; antiplatelet agents ; anticoagulants
H-1354	-0.3204512298107147	▁sinus ▁ rhythm ▁; ▁anti plate let ▁agents ▁; ▁antico a gul ants
D-1354	-0.3204512298107147	sinus rhythm ; antiplatelet agents ; anticoagulants
P-1354	-2.7175 -0.0763 -0.1250 -0.3331 -0.0073 -0.0595 -0.1015 -0.0846 -0.2314 -0.0505 -0.5934 -0.1262 -0.0129 -0.1505 -0.1371
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported ; patient ; implantable cardioverter-defibrillator
H-1858	-0.2367059737443924	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1858	-0.2367059737443924	implantable cardioverter-defibrillator deactivation
P-1858	-0.0025 -0.0332 -0.3309 -0.0990 -0.0355 -0.0096 -0.0679 -1.7977 -0.8086 -0.0057 -0.0568 -0.0540 -0.0209 -0.1103 -0.2259 -0.1288
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients ; heart failure ; left ventricular ; ejection fraction
H-22	-0.7914676070213318	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction
D-22	-0.7914676070213318	heart failure ; left ventricular ;LV ; ejection fraction
P-22	-5.0936 -0.6188 -0.1236 -3.3998 -0.0346 -1.6565 -0.1661 -0.2761 -0.0518 -1.0755 -0.1142 -0.2003 -0.0815 -0.0598 -0.0005 -0.2640 -0.2383
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity ; doxorubicin ; anti-neoplastic agent
H-955	-0.2444421350955963	▁cardio toxic ity ▁; ▁do xor ubi cin ▁; ▁anti - neo plast ic ▁agent
D-955	-0.2444421350955963	cardiotoxicity ; doxorubicin ; anti-neoplastic agent
P-955	-0.0372 -0.1464 -0.4889 -0.1584 -0.0217 -0.0039 -0.0178 -0.1003 -0.2714 -0.0152 -0.1164 -0.0190 -0.0359 -0.0703 -0.2028 -2.3433 -0.1066
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs ; patients ; oht ; transplant ; vad
H-1288	-0.46706923842430115	▁a CS ▁; ▁o HT ▁; ▁transplant ▁; ▁MT ▁; ▁ VAD
D-1288	-0.46706923842430115	aCS ; oHT ; transplant ; MT ; VAD
P-1288	-0.1113 -1.3270 -0.9485 -0.4723 -1.3566 -0.6342 -0.3493 -0.4549 -0.3536 -0.2125 -0.1059 -0.0076 -0.1136 -0.0917
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic peptides ; point of care ; ambulatory
H-1019	-0.5789165496826172	▁na tri ure tic ▁pe pti des
D-1019	-0.5789165496826172	natriuretic peptides
P-1019	-0.0196 -0.0862 -0.0331 -2.0510 -0.3092 -0.0389 -0.1091 -2.4451 -0.1181
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients ; β-blocker ; patients ; uptitration
H-179	-0.5357378125190735	▁ RAS - ▁; ▁β - block er
D-179	-0.5357378125190735	RAS- ; β-blocker
P-179	-0.7958 -0.0164 -0.1156 -1.8383 -0.1314 -0.0289 -0.0432 -0.0537 -2.1336 -0.2004
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac angiogenesis ; therapy ; cardiac function ; remodeling
H-460	-0.5903737545013428	▁β - Block er - indu ced ▁enhance ment ▁; ▁cardiac ▁ang io gene sis ▁; ▁ therapy ▁; ▁cardiac ▁function
D-460	-0.5903737545013428	β-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
P-460	-1.3644 -0.0952 -0.1133 -0.0438 -0.0728 -0.0539 -1.1360 -1.3024 -0.0207 -0.3994 -0.0137 -0.0704 -1.3521 -0.1628 -0.8042 -0.3132 -1.4501 -0.0383 -0.7942 -0.0599 -2.9336 -0.8680 -0.1161
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf ; patients ; rheumatoid arthritis ; ra
H-602	-0.6560155749320984	▁ HF ▁; ▁rhe um ato id ▁ar thri tis ▁; RA
D-602	-0.6560155749320984	HF ; rheumatoid arthritis ;RA
P-602	-2.4397 -0.0567 -0.2389 -2.6653 -0.1041 -0.4753 -0.6400 -0.6372 -0.0789 -0.5221 -0.6337 -0.3365 -0.1888 -0.1672
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression ; bax ; bcl-2 ; proteins ; pacing
H-170	-0.39139604568481445	▁Bax ▁; ▁b cl -2 ▁protein s ▁; ▁dog s
D-170	-0.39139604568481445	Bax ; bcl-2 proteins ; dogs
P-170	-0.1759 -0.1114 -0.0449 -0.0258 -0.3049 -0.5882 -0.0533 -0.7830 -1.6584 -0.0654 -0.7199 -0.1657
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal ; hospital ; hf ; patients ; cms ; conditions
H-139	-0.6241311430931091	▁PRI n ci PAL ▁FIN DING s ▁; ▁hospital ▁rates ▁; ▁ HF ▁; ▁CMS ▁; ▁conditions
D-139	-0.6241311430931091	PRInciPAL FINDINGs ; hospital rates ; HF ; CMS ; conditions
P-139	-1.5863 -0.5368 -1.3314 -0.5411 -0.2467 -0.5162 -0.3966 -0.4424 -1.6426 -0.3325 -0.0913 -0.5392 -0.0177 -1.1063 -0.2395 -1.8374 -0.0144 -0.3024 -0.1378
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation ; anti-inflammatory ; chf
H-1362	-0.5269708633422852	▁regula tion ▁of ▁feed ing ▁; ▁anti - in flam ma tory ▁effects ▁; ▁CHF
D-1362	-0.5269708633422852	regulation of feeding ; anti-inflammatory effects ; CHF
P-1362	-1.5054 -0.0170 -0.6123 -0.1681 -0.1373 -0.1886 -1.9723 -0.0380 -1.8199 -0.0316 -0.7743 -0.3766 -0.8430 -0.2100 -0.0709 -0.0955 -0.0978
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs ; hf with reduced ejection fraction ; hfref
H-1077	-0.49238961935043335	▁life sa ving ▁drugs ▁; HF ▁; ▁e je ction ▁ fraction ▁; HF r EF
D-1077	-0.49238961935043335	lifesaving drugs ;HF ; ejection fraction ;HFrEF
P-1077	-2.2343 -0.2912 -0.7265 -0.1696 -0.0448 -1.3961 -0.1274 -1.6116 -0.2901 -0.0405 -0.0862 -0.0012 -0.2517 -1.0976 -0.0614 -0.1482 -0.1997 -0.0851
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia ; acute kidney injury ; spironolactone ; clinical
H-444	-0.3654341995716095	▁hyper kal emia ▁; ▁ki dne y ▁injury ▁; ▁spi rono lac tone
D-444	-0.3654341995716095	hyperkalemia ; kidney injury ; spironolactone
P-444	-0.6345 -0.2331 -0.1281 -0.1053 -2.4975 -0.2234 -0.0768 -0.3560 -0.2931 -0.0158 -0.0088 -0.0475 -0.0261 -0.6922 -0.1432
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal denervation ; dnx ; chf ; patients ; symptomatic
H-1371	-0.21762609481811523	▁Ren al ▁den er va tion ▁; DN x ▁; ▁CHF
D-1371	-0.21762609481811523	Renal denervation ;DNx ; CHF
P-1371	-0.2673 -0.1012 -0.3075 -0.1386 -0.1752 -0.1276 -0.2276 -0.3088 -0.0109 -0.1829 -0.0170 -0.8445 -0.1200
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence ; vad ; acs ; consultations ; operations ; mortality ; morbidity
H-1289	-0.5475131869316101	▁MT ▁; ▁ VAD ▁; ▁a CS
D-1289	-0.5475131869316101	MT ; VAD ; aCS
P-1289	-0.3126 -0.1935 -0.1315 -0.0299 -1.0399 -0.2263 -1.2657 -1.5950 -0.1332
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
H-893	-0.2430136799812317	▁re frac tory ▁con ges tive ▁heart ▁failure ▁; ▁per ito ne al ▁di al ysis
D-893	-0.2430136799812317	refractory congestive heart failure ; peritoneal dialysis
P-893	-0.4507 -0.0370 -0.8375 -0.4917 -0.1194 -0.1043 -0.5974 -0.0965 -0.2414 -0.0428 -0.4211 -0.1194 -0.0522 -0.3305 -0.0730 -0.0520 -0.1282 -0.1793
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ; hf
H-1810	-0.3331785500049591	▁Mamma lian ▁enabled ▁; Men a ▁; ▁cy tos kelet al ▁act in ▁dynamic s ▁; ▁heart ▁failure ▁; HF
D-1810	-0.3331785500049591	Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ;HF
P-1810	-0.3689 -0.2421 -0.1154 -0.1744 -1.0077 -0.0204 -0.2392 -1.9498 -0.2536 -0.1426 -0.0305 -0.1117 -1.0872 -0.4264 -0.0120 -0.1714 -0.0869 -0.2472 -0.4273 -0.0497 -0.0819 -0.0835
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients ; heart failure ; elevated ; left atrial pressure ; symptoms ; hospital ; admission
H-1949	-0.9431169033050537	▁heart ▁failure ▁; ▁left ▁at rial ▁pressure
D-1949	-0.9431169033050537	heart failure ; left atrial pressure
P-1949	-1.4301 -0.2387 -0.2485 -3.2981 -0.5899 -0.6561 -0.9997 -0.9063 -0.1206
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart failure with preserved ejection fraction ; hfpef ; cardiovascular reserve
H-916	-0.29984161257743835	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f f ▁; ▁cardiovascular ▁reserve
D-916	-0.29984161257743835	Heart failure ; preserved ejection fraction ; hff ; cardiovascular reserve
P-916	-0.9527 -0.4045 -0.1604 -0.6643 -0.0139 -0.2209 -0.0351 -0.5325 -0.1131 -0.1330 -0.0006 -0.1281 -0.0892 -0.3037 -0.5853 -0.2540 -0.9832 -0.1426 -0.1725 -0.1074
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv diastolic dysfunction ; combination ; figure ; hfpef
H-24	-0.5041182041168213	▁LV ▁dia sto lic ▁dys function ▁; ▁h f f
D-24	-0.5041182041168213	LV diastolic dysfunction ; hff
P-24	-0.2019 -1.6232 -0.2834 -1.3748 -0.0056 -0.2471 -0.2495 -0.3615 -0.7680 -0.6680 -0.1362 -0.1305
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician ; follow-up ; discharge ; physician ; outcomes ; patients ; heart failure
H-1421	-0.5047484040260315	▁physician ▁follow - up ▁; ▁physician ▁continu ity ▁; ▁heart ▁failure
D-1421	-0.5047484040260315	physician follow-up ; physician continuity ; heart failure
P-1421	-0.1648 -1.8642 -0.0738 -0.0142 -1.0501 -0.2672 -0.0084 -0.0736 -0.3549 -2.1901 -0.2847 -0.1053 -0.1103
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory ; icd ; patients ; mortality ; multivariable regression
H-63	-0.5083574652671814	▁ambula tory ▁i CD ▁patients ▁; ▁predict or ▁; ▁mortal ity
D-63	-0.5083574652671814	ambulatory iCD patients ; predictor ; mortality
P-63	-0.0479 -0.1881 -0.8541 -0.2229 -1.0752 -0.2416 -0.9608 -0.0268 -0.9704 -0.0059 -0.1668 -1.6584 -0.1898
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni inhibitors ; angiotensin-receptor neprilysin inhibitors
H-1966	-0.34827813506126404	▁AR NI ▁inhibi tors ▁; angi oten sin - recept or ▁nepri ly sin ▁inhibi tors
D-1966	-0.34827813506126404	ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
P-1966	-1.0059 -0.6304 -0.2002 -0.4362 -0.1142 -0.0344 -0.0548 -1.2485 -0.0932 -0.0111 -0.0993 -0.2873 -0.1564 -0.2372 -0.3114 -1.0758 -0.1426 -0.1302
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal bleeding ; reported ; patients ; ventricular assist devices
H-1659	-0.24547357857227325	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices
D-1659	-0.24547357857227325	Gastrointestinal bleeding ; ventricular assist devices
P-1659	-0.3059 -0.0192 -0.2633 -0.1570 -0.1268 -0.3218 -0.3233 -0.3130 -0.0123 -0.8901 -0.0918 -0.4281 -0.2112 -0.0896 -0.1289
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil ; cytotoxic ; doxorubicin ; ehrlich carcinoma
H-966	-0.21597769856452942	▁nic oran dil ▁; ▁cy to toxic ▁effect ▁; ▁do xor ubi cin ▁; ▁Eh r lich ▁car cino ma
D-966	-0.21597769856452942	nicorandil ; cytotoxic effect ; doxorubicin ; Ehrlich carcinoma
P-966	-0.1169 -0.0131 -0.1382 -0.1506 -0.6712 -0.0232 -0.0246 -0.2832 -0.2324 -0.0209 -0.0108 -0.0098 -0.1663 -0.4071 -1.5192 -0.0160 -0.2983 -0.0925 -0.1304 -0.1592 -0.1671 -0.1007
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas ; cardiac ; benign tumors ; left atrium ; right atrium
H-593	-0.4044573903083801	▁My xo mas ▁; ▁cardiac ▁benign ▁tumor s ▁; ▁left ▁at rium
D-593	-0.4044573903083801	Myxomas ; cardiac benign tumors ; left atrium
P-593	-1.6806 -0.0108 -0.0691 -0.3278 -0.1323 -0.0150 -0.0355 -0.0308 -0.9402 -0.5560 -0.1224 -0.0079 -1.5934 -0.1405
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes ; patients ; preserved ejection fraction ; hfpef
H-1328	-0.4309235215187073	▁f es ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1328	-0.4309235215187073	fes ; preserved ejection fraction ;HFpEF
P-1328	-3.2880 -0.2777 -0.1076 -0.8268 -0.0085 -0.2839 -0.0521 -0.6679 -0.1838 -0.0722 -0.0015 -0.3210 -0.7406 -0.0090 -0.1606 -0.1868 -0.1377
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic ; bnp ; nt-probnp ; patients ; coronary artery disease ; cad
H-1366	-0.2894999384880066	▁b NP ▁; ▁NT - pro b NP ▁; ▁corona ry ▁arter y ▁disease ▁; CAD
D-1366	-0.2894999384880066	bNP ; NT-probNP ; coronary artery disease ;CAD
P-1366	-0.0744 -0.3251 -0.0727 -0.1387 -0.0115 -0.0031 -0.9109 -0.1399 -0.1103 -0.2358 -0.2040 -0.1051 -0.4451 -0.8835 -0.2377 -1.0085 -0.1888 -0.1159
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant ; exercise
H-1883	-0.24346405267715454	
D-1883	-0.24346405267715454	
P-1883	-0.4024 -0.0846
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.4099941551685333	▁NT - pro b NP
D-1512	-0.4099941551685333	NT-probNP
P-1512	-1.6426 -0.0167 -0.0048 -0.7114 -0.1178 -0.2366 -0.1402
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ; ecct
H-713	-1.0691779851913452	▁EC CT
D-713	-1.0691779851913452	ECCT
P-713	-3.6294 -0.4751 -0.0557 -0.1165
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.5471994876861572	▁aero bic ▁capacity ▁; ▁left - hand ▁grip ▁strength ▁; ▁body ▁weight ▁; ▁wa ist ▁circum ferenc e
D-573	-0.5471994876861572	aerobic capacity ; left-hand grip strength ; body weight ; waist circumference
P-573	-1.7500 -0.1200 -0.5827 -0.2236 -0.3307 -0.0097 -0.0676 -0.3424 -2.0565 -0.1099 -0.5840 -0.1425 -0.2667 -0.8989 -0.3357 -0.0156 -0.0202 -0.0430 -2.8852 -0.1593
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.7438282370567322	▁Process ▁re design
D-1851	-0.7438282370567322	Process redesign
P-1851	-1.2022 -0.9498 -0.1283 -1.3570 -0.0818
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial ; irs1 ; irs2 ; heart failure ; p38alpha ; mapk ; insulin resistance
H-651	-0.3471212685108185	▁My o card ial ▁loss ▁; ▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart ▁failure ▁; ▁ma PK ▁; ▁insulin ▁resist ance
D-651	-0.3471212685108185	Myocardial loss ; iRS1 ; iRS2 ; heart failure ; maPK ; insulin resistance
P-651	-1.3505 -0.1112 -0.0527 -0.2003 -0.1599 -0.1163 -0.9630 -0.1613 -0.2525 -0.2080 -0.5548 -0.5362 -0.0749 -0.2906 -0.5825 -0.2667 -0.1295 -1.0047 -0.3787 -0.4794 -0.0380 -0.3278 -0.0077 -0.1880 -0.2428
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart failure ; hypertensive heart disease ; angiotensin ii ; infusion ; nephrectomy ; salt loading
H-273	-0.30374839901924133	▁heart ▁failure ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁ang io ten sin ▁II ▁in fusion ▁; ▁nep hr ecto my ▁; ▁salt ▁load ing
D-273	-0.30374839901924133	heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
P-273	-0.6640 -0.1944 -1.6864 -0.0308 -0.1353 -0.1052 -0.7231 -0.9560 -0.1422 -0.0057 -0.3614 -0.0663 -0.2587 -0.7050 -0.0129 -0.0194 -0.2544 -0.0400 -0.2031 -0.0821 -0.1881 -0.7042 -0.0038 -0.0376 -0.0197 -0.4032 -0.1980
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-337	-0.37121251225471497	▁Fun ction al ▁mit ral ▁sten osis ▁; MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation ▁; MR
D-337	-0.37121251225471497	Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
P-337	-0.6841 -0.0145 -0.1837 -4.0366 -0.0585 -0.1315 -0.2365 -0.1789 -0.1354 -0.3051 -0.5931 -0.1405 -0.2005 -0.0135 -0.0814 -0.2433 -0.1974 -0.2029 -0.0737 -1.3122 -0.1219 -0.0083 -0.0395 -0.1664 -0.0184 -1.0359 -0.0017 -0.2207 -0.1290
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened ; lvet ; icu ; admission ; prognostic ; patients ; precapillary ph ; heart failure
H-590	-0.33223670721054077	▁ ICU ▁ad mission ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-590	-0.33223670721054077	ICU admission ; precapillary PH ; heart failure
P-590	-1.8290 -0.2828 -0.9519 -0.0185 -0.1182 -0.2779 -0.0860 -0.0111 -0.0801 -0.1565 -0.4204 -0.2452 -0.1452 -0.2054 -0.1551
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart ; hospitalization ; death ; patients ; preserved left ventricular ejection fraction
H-235	-0.6718628406524658	▁heart ▁failure - related ▁hospital ization ▁; ▁vent ri cular ▁e je ction ▁ fraction
D-235	-0.6718628406524658	heart failure-related hospitalization ; ventricular ejection fraction
P-235	-1.1279 -0.9140 -0.5301 -0.2867 -0.3492 -1.1521 -0.1906 -1.4565 -1.9538 -0.2827 -0.4522 -0.8360 -0.6846 -0.4306 -0.0020 -0.3370 -0.4357
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart failure with preserved ejection fraction ; hfpef ; cardiovascular morbidity ; mortality
H-236	-0.2781376838684082	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁cardiovascular ▁morbi d ity
D-236	-0.2781376838684082	Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
P-236	-0.5160 -0.1801 -0.2396 -1.4207 -0.0143 -0.2572 -0.0262 -0.5189 -0.0719 -0.1584 -0.0009 -0.1347 -0.2839 -0.0094 -0.2337 -0.2750 -0.1232 -0.0527 -0.1488 -0.1969 -1.1058 -0.1507
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue doppler ; left ventricular filling pressure ; patients ; stable ; severe systolic heart failure
H-479	-0.6898967623710632	▁tissu e ▁do pp ler ▁imagin g ▁; ▁left ▁vent ri cular ▁fill ing ▁pressure ▁; ▁sy sto lic ▁heart ▁failure
D-479	-0.6898967623710632	tissue doppler imaging ; left ventricular filling pressure ; systolic heart failure
P-479	-1.5638 -0.1895 -1.0975 -0.0200 -0.3237 -0.1926 -0.0334 -0.1055 -0.7555 -0.0319 -2.0360 -0.1178 -1.1099 -0.1927 -2.3647 -0.1801 -2.9793 -0.2235 -1.3014 -0.4721 -0.2439 -0.2075 -0.1251
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 ; hypertensive ; obese ; zsf1 ; hypertensive ; diabetic
H-766	-0.6536358594894409	▁lean ▁Z SF 1 ▁group ▁; ▁hyper tensi ve ▁; ▁obes e ▁Z SF 1 ▁; ▁diabet ic
D-766	-0.6536358594894409	lean ZSF1 group ; hypertensive ; obese ZSF1 ; diabetic
P-766	-0.6751 -1.5792 -0.1032 -0.3585 -1.4933 -0.2861 -1.3723 -0.0429 -0.0703 -0.3450 -0.1739 -0.0741 -1.7718 -0.1078 -0.1405 -2.1900 -1.9081 -0.1533 -0.1331 -0.0942
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence ; heart failure with preserved ejection fraction ; hfpef ; prognosis
H-23	-0.2654167115688324	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f f
D-23	-0.2654167115688324	heart failure ; preserved ejection fraction ; hff
P-23	-0.9235 -0.2435 -0.1254 -0.4588 -0.0084 -0.2051 -0.0381 -0.3970 -0.1136 -0.1223 -0.0009 -0.1443 -0.0951 -0.3114 -0.5967 -0.5900 -0.1379
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas city cardiomyopathy questionnaire ; patients ; heart failure ; reduced ejection fraction
H-779	-0.33684274554252625	▁Kansas ▁City ▁Card i om yo pathy ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-779	-0.33684274554252625	Kansas City Cardiomyopathy ; heart failure ; ejection fraction
P-779	-0.0321 -0.1830 -0.6087 -0.1336 -0.1146 -1.2611 -0.0426 -1.1522 -0.8838 -0.1460 -0.5123 -0.2462 -0.2119 -0.0685 -0.1128 -0.0007 -0.1326 -0.2205
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial ; pde2 ; intracellular ; antiadrenergic ; therapeutic ; hf
H-1220	-0.4608295261859894	▁my o card ial ▁p de 2 ▁; ▁intra cel lular ▁anti ad r energi c ▁ therapeut ic ▁strategy ▁; ▁ HF
D-1220	-0.4608295261859894	myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ; HF
P-1220	-2.5455 -0.1308 -0.0521 -0.3207 -1.8115 -0.0396 -0.0537 -0.2120 -0.6581 -0.1590 -0.0105 -0.0085 -0.0822 -0.1321 -0.0919 -0.1947 -0.2425 -0.2249 -0.8833 -1.7008 -0.8627 -0.6719 -0.0874 -0.1292 -0.2151
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone ; clinical ; medications
H-447	-0.5827188491821289	▁benefits ▁; ▁spi rono lac tone
D-447	-0.5827188491821289	benefits ; spironolactone
P-447	-2.4778 -0.3765 -0.1299 -0.0234 -0.0482 -0.0648 -1.4022 -0.1389
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up ; hf ; hospitalization
H-690	-0.7266486287117004	▁ HF
D-690	-0.7266486287117004	HF
P-690	-1.5783 -0.0482 -1.1243 -0.1558
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart failure ; hf ; death ; crt-d
H-105	-0.5601551532745361	▁IE ▁; ▁heart ▁failure ▁; HF ▁; ▁c RT - d
D-105	-0.5601551532745361	IE ; heart failure ;HF ; cRT-d
P-105	-2.7514 -0.1451 -0.9766 -0.1349 -0.0867 -0.3692 -0.1083 -0.6920 -0.8953 -0.0329 -0.5248 -0.4124 -0.1523
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic ; clinical ; pharmacologic
H-1470	-0.4767049551010132	▁ pharma c ologic ▁treatment ▁; ▁clinic al ▁trial s
D-1470	-0.4767049551010132	pharmacologic treatment ; clinical trials
P-1470	-0.1262 -0.0181 -0.2045 -0.0838 -0.9285 -0.7410 -0.5274 -0.0591 -0.3146 -0.0236 -2.5770 -0.1166
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients ; narrow qrs complex ; crt ; patients
H-846	-0.3741965889930725	▁Mechanic al ▁dys syn chron y ▁; ▁QR S ▁complex ▁; ▁c RT
D-846	-0.3741965889930725	Mechanical dyssynchrony ; QRS complex ; cRT
P-846	-0.2503 -0.0156 -0.0096 -0.0043 -0.0009 -0.2839 -0.1928 -0.6422 -2.1007 -0.1263 -0.2578 -0.3441 -1.0575 -0.1708 -0.1562
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary occlusion ; collateral growth ; stent
H-510	-0.30901896953582764	▁corona ry ▁oc clusi on ▁; ▁col lateral ▁growth
D-510	-0.30901896953582764	coronary occlusion ; collateral growth
P-510	-0.3692 -0.1698 -0.0066 -0.0549 -0.3350 -0.3546 -0.1254 -0.0015 -0.5540 -1.3310 -0.0973
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid intima-media thickness ; psoriasis
H-1561	-0.5389925241470337	▁caro tid ▁intim a - media ▁; ▁psoriasis
D-1561	-0.5389925241470337	carotid intima-media ; psoriasis
P-1561	-0.2085 -0.1037 -1.1667 -0.0842 -0.0661 -0.0236 -3.4014 -0.0424 -0.1475 -0.1458
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions ; patients ; heart disease
H-48	-0.26557251811027527	▁trans fusion s ▁; ▁heart ▁disease
D-48	-0.26557251811027527	transfusions ; heart disease
P-48	-0.0468 -0.0484 -0.0307 -0.3577 -0.4216 -0.8863 -0.2068 -0.1262
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination ; exercise ; peak vo2 ; joint
H-1985	-0.8713135719299316	▁VO 2 ▁; jo int ▁effect
D-1985	-0.8713135719299316	VO2 ;joint effect
P-1985	-3.9582 -0.0432 -1.4125 -0.9006 -0.0178 -0.0664 -0.4322 -0.1397
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf ; pb ; bp
H-1348	-0.42875394225120544	▁PV f ▁; ▁ PB ▁cycle ▁; ▁BP
D-1348	-0.42875394225120544	PVf ; PB cycle ; BP
P-1348	-0.0578 -0.1090 -0.1187 -0.5926 -0.0265 -1.1400 -0.1986 -1.8023 -0.1476 -0.0944
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence ; chronic heart failure ; hungary
H-646	-1.1570734977722168	▁chronic ▁heart ▁failure ▁; ▁Hungary
D-646	-1.1570734977722168	chronic heart failure ; Hungary
P-646	-3.0477 -1.7974 -0.3219 -0.5711 -1.4595 -0.7257 -0.1763
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv dysfunction ; cardiac cachexia
H-1168	-0.30142155289649963	▁ RV ▁dys function ▁; ▁cardiac ▁cache xia
D-1168	-0.30142155289649963	RV dysfunction ; cardiac cachexia
P-1168	-1.1727 -0.6494 -0.0214 -0.2192 -0.0593 -0.0166 -0.1279 -0.1825 -0.4062 -0.1589
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote monitoring ; rm ; heart failure
H-148	-0.5996802449226379	▁Remote ▁monitoring ▁; RM ▁; ▁heart ▁failure
D-148	-0.5996802449226379	Remote monitoring ;RM ; heart failure
P-148	-0.1909 -0.2490 -0.2227 -0.0134 -0.6699 -3.3179 -0.1410 -0.5195 -0.0728
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg ; crt ; clinical
H-881	-0.6031129956245422	▁e CG ▁; ▁c RT
D-881	-0.6031129956245422	eCG ; cRT
P-881	-0.8815 -0.1722 -0.3866 -0.9232 -1.4840 -0.2623 -0.1120
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients ; sst2 ; cardiovascular event
H-407	-0.9848039746284485	▁s ST 2 ▁; ▁b ▁; ▁cardiovascular ▁event
D-407	-0.9848039746284485	sST2 ; b ; cardiovascular event
P-407	-0.2184 -2.4407 -0.2648 -0.3698 -2.7786 -0.9012 -0.3327 -1.2057 -1.1990 -0.1371
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast cancer ; patients ; chf ; reported ; clinical
H-681	-0.3864712715148926	▁breast ▁cancer ▁patients ▁; ▁tras tuz um b - related ▁CHF
D-681	-0.3864712715148926	breast cancer patients ; trastuzumb-related CHF
P-681	-1.5553 -0.2084 -2.0543 -0.1675 -0.4279 -0.0044 -0.0175 -0.0148 -0.1007 -0.0363 -0.0742 -0.2671 -0.0957
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf ; remodeling ; emd ; dyssynchronous failing heart
H-1150	-0.2675080895423889	▁ HF ▁remodel ing ▁; ▁EM d ▁; ▁dys syn chron ous ▁fail ing ▁heart
D-1150	-0.2675080895423889	HF remodeling ; EMd ; dyssynchronous failing heart
P-1150	-0.5335 -0.0624 -0.0810 -0.0232 -0.9592 -0.7914 -0.2339 -0.0822 -0.0235 -0.0063 -0.0064 -0.8218 -0.0920 -0.0906 -0.3541 -0.2047 -0.1815
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute heart failure ; ahf ; symptoms ; heart failure ; hf
H-1466	-0.5226498246192932	▁a cute ▁heart ▁failure ▁; ▁a HF ▁; ▁heart ▁failure ▁; HF
D-1466	-0.5226498246192932	acute heart failure ; aHF ; heart failure ;HF
P-1466	-0.2562 -0.0676 -0.5781 -0.1270 -0.1506 -0.4131 -0.3348 -0.3188 -3.1112 -0.4315 -0.5538 -0.7519 -0.0779 -0.1446
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis ; post-myocardial infarction ; heart ; heart failure
H-449	-0.5391286015510559	▁ang io gene sis ▁; ▁post - my o card ial ▁in far ction ▁heart ▁; ▁heart ▁failure
D-449	-0.5391286015510559	angiogenesis ; post-myocardial infarction heart ; heart failure
P-449	-0.2162 -2.8292 -0.1897 -1.8597 -0.1693 -0.7212 -0.0098 -0.2262 -0.5760 -0.1558 -0.2352 -0.0653 -0.6058 -0.2510 -0.9199 -0.2721 -1.0363 -0.2089 -0.1229 -0.1121
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical ; clinical ; outcomes ; aldosterone antagonist ; heart failure
H-1734	-0.43871062994003296	▁al do ster one ▁anta gon ist ▁; ▁heart ▁failure
D-1734	-0.43871062994003296	aldosterone antagonist ; heart failure
P-1734	-0.7604 -0.0924 -0.1031 -1.2865 -0.1323 -0.0646 -1.3797 -0.4695 -0.3908 -0.3831 -0.1146 -0.0876
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery ; medical treatment ; hf ; hypertension ; vasodilators ; diuretics
H-355	-0.42618298530578613	▁surgery ▁; ▁ HF ▁; ▁hyper tension ▁; ▁vaso dila tors ▁; ▁di ure tics
D-355	-0.42618298530578613	surgery ; HF ; hypertension ; vasodilators ; diuretics
P-355	-1.5826 -0.1837 -2.4734 -0.0168 -0.1507 -0.0318 -0.0993 -0.2053 -0.0181 -0.0201 -0.8484 -0.5482 -0.0802 -0.0567 -0.5616 -0.2667 -0.1014
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic ; congestive heart failure ; haematopoietic cell transplantation
H-1448	-0.30179187655448914	▁Gene tic ▁sus cept i bility ▁; ▁an thra cycli ne - related ▁con ges tive ▁heart ▁failure ▁; ▁ha e mato po ie tic ▁cell ▁transplant ation
D-1448	-0.30179187655448914	Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
P-1448	-1.9385 -0.1354 -0.1884 -0.0069 -0.2343 -0.0552 -0.2332 -0.0177 -0.0735 -1.2121 -0.2431 -0.2336 -0.0990 -0.1757 -0.0314 -0.1140 -0.4495 -0.2050 -0.1910 -0.1151 -0.0574 -0.0176 -0.0975 -0.4188 -1.9510 -0.0662 -0.0498 -0.0319 -0.2337 -0.1772
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration ; patients ; hr reduction ; beta-blocker ; therapy
H-1947	-0.322429358959198	▁HR ▁re duction ▁; ▁beta - block er ▁ therapy
D-1947	-0.322429358959198	HR reduction ; beta-blocker therapy
P-1947	-2.8146 -0.1284 -0.0037 -0.2085 -0.0739 -0.0251 -0.0718 -0.0393 -0.1992 -0.0347 -0.0977 -0.1724
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 ; hearts ; acute ; β-ar
H-1218	-0.69336998462677	▁p de 2 ▁; ▁fail ing ▁heart s ▁; ▁β - AR
D-1218	-0.69336998462677	pde2 ; failing hearts ; β-AR
P-1218	-0.8247 -0.0125 -0.0757 -0.4710 -0.4459 -0.2472 -0.3176 -0.0292 -0.2743 -3.6145 -0.0049 -0.0816 -3.0836 -0.2244
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis ; patients ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
H-1565	-0.7946639060974121	▁psoriasis ▁; ▁at hero sc ler osis ▁; ▁cardiovascular ▁events
D-1565	-0.7946639060974121	psoriasis ; atherosclerosis ; cardiovascular events
P-1565	-0.4794 -1.2377 -2.3691 -0.1138 -0.7217 -0.6374 -0.0779 -0.3035 -0.0588 -0.9887 -2.3488 -0.1994
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians ; patient ; anemic ; patients ; heart disease
H-34	-0.6541408896446228	▁a ne mic ▁; ▁ir on - d eficient ▁adult ▁patients ▁; ▁heart ▁disease
D-34	-0.6541408896446228	anemic ; iron-deficient adult patients ; heart disease
P-34	-2.4835 -0.0435 -0.1487 -0.5502 -0.0926 -0.0430 -0.0481 -0.1643 -0.4057 -2.1427 -1.8845 -0.5889 -0.3962 -1.2061 -0.1050 -0.1633
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence ; prevalence ; heart failure ; leading ; death ; hospitalisation
H-1664	-0.6852383017539978	▁heart ▁failure ▁; ▁hospital isation
D-1664	-0.6852383017539978	heart failure ; hospitalisation
P-1664	-1.1122 -0.3542 -0.8057 -0.9438 -0.0264 -1.3986 -0.1558
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr ; diuretics ; hypertension ; patients ; esrd
H-397	-0.33685705065727234	▁e g FR ▁; ▁di ure tics ▁; ▁hyper tension ▁; ▁ES RD
D-397	-0.33685705065727234	egFR ; diuretics ; hypertension ; ESRD
P-397	-0.3353 -1.7888 -0.4882 -0.1118 -0.3266 -0.0288 -0.4869 -0.1217 -0.3180 -0.0835 -0.1230 -0.3662 -0.1258 -0.1852 -0.1630
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab ; chf ; nontrastuzumab users
H-678	-0.2901851534843445	▁tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab
D-678	-0.2901851534843445	trastuzumab ; CHF ; nontrastuzumab
P-678	-0.2701 -0.0071 -0.0326 -0.0750 -0.6302 -0.0410 -0.2217 -1.2425 -0.0185 -0.0091 -0.0214 -0.1449 -1.2441 -0.1043
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus ; mortality ; hazard ratio ; confidence interval
H-129	-0.7764557600021362	▁e - c FU s ▁; ▁mortal ity
D-129	-0.7764557600021362	e-cFUs ; mortality
P-129	-1.5375 -0.1979 -1.3877 -1.6037 -0.2210 -0.4654 -1.0216 -0.2907 -0.8620 -0.1770
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care ; outpatient ; acute heart failure
H-1026	-0.7660840749740601	▁point - of - care ▁systems ▁; NP ▁; ▁ED ▁; ▁community ▁out patient s ▁; ▁a cute ▁heart ▁failure
D-1026	-0.7660840749740601	point-of-care systems ;NP ; ED ; community outpatients ; acute heart failure
P-1026	-0.6938 -0.1871 -3.8262 -0.1982 -0.1081 -1.1413 -0.2319 -1.1294 -0.2354 -1.3980 -0.1085 -3.7823 -0.1833 -0.0167 -2.3134 -0.3058 -0.2152 -0.0394 -0.3187 -0.0933 -0.1693 -0.1586
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart failure ; preserved ejection fraction ; myocardial infarction
H-1098	-0.384417325258255	▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁my o card ial ▁in far ction
D-1098	-0.384417325258255	heart failure ; ejection fraction ; myocardial infarction
P-1098	-1.2730 -0.3788 -0.0941 -0.3080 -0.1633 -0.0617 -0.0823 -0.0005 -0.8437 -1.0288 -0.3348 -0.1959 -0.4203 -0.0186 -0.9859 -0.2763 -0.2794 -0.1743
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective ; lvas
H-1995	-0.9302825331687927	▁l VAS
D-1995	-0.9302825331687927	lVAS
P-1995	-3.0888 -0.4648 -0.0696 -0.0979
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf ; hospitalization ; cardiovascular mortality
H-1639	-0.4860883951187134	▁black ▁race ▁; ▁ HF ▁hospital ization ▁; ▁cardiovascular ▁mortal ity
D-1639	-0.4860883951187134	black race ; HF hospitalization ; cardiovascular mortality
P-1639	-1.0786 -0.4228 -0.2303 -1.4371 -0.0182 -1.3476 -0.5510 -0.1585 -0.5594 -0.0191 -0.1675 -0.1409 -0.1882
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise ; health ; cardiac disease ; heart failure
H-1904	-1.0783902406692505	▁cardiac ▁disease ▁; ▁heart ▁failure
D-1904	-1.0783902406692505	cardiac disease ; heart failure
P-1904	-5.3274 -1.3436 -0.1807 -0.2341 -0.2753 -0.0887 -0.0989
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients ; hfpef ; prospective
H-736	-0.3289133608341217	▁h f f
D-736	-0.3289133608341217	hff
P-736	-0.2280 -0.3401 -0.4717 -0.5105 -0.0943
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician ; hf ; cpgs
H-1853	-0.41058096289634705	▁physician ▁ad her ence ▁; ▁ HF ▁c PG s
D-1853	-0.41058096289634705	physician adherence ; HF cPGs
P-1853	-0.9382 -0.0437 -0.5016 -0.0111 -0.4336 -0.8976 -0.0393 -1.5462 -0.0927 -0.0472 -0.1718 -0.2041
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf ; hf ; mortality
H-1774	-0.7444077134132385	▁ HF ▁; ▁ HF ▁; ▁ HF ▁mortal ity
D-1774	-0.7444077134132385	HF ; HF ; HF mortality
P-1774	-0.8270 -0.0501 -0.7807 -1.3065 -0.1032 -1.1491 -1.6752 -0.2558 -0.7015 -0.3374 -1.5666 -0.1798
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl ; chf ; vascular
H-260	-0.5840967893600464	▁HD L ▁function ▁; ▁CHF ▁; ▁ET ▁; ▁HD L - media ted ▁vas cular ▁effects
D-260	-0.5840967893600464	HDL function ; CHF ; ET ; HDL-mediated vascular effects
P-260	-1.0066 -1.6088 -2.3236 -0.1758 -0.0312 -0.0717 -0.7853 -0.1190 -0.7206 -1.9093 -0.0400 -0.0765 -0.5792 -0.3266 -0.0524 -0.4375 -0.1541 -0.0956
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical ; coronary artery disease ; patients ; systolic heart failure ; etiology
H-1181	-0.3391745984554291	▁corona ry ▁arter y ▁disease ▁; ▁sy sto lic ▁heart ▁failure
D-1181	-0.3391745984554291	coronary artery disease ; systolic heart failure
P-1181	-0.4058 -0.1759 -0.1095 -0.2083 -0.7867 -0.1079 -0.2709 -0.0905 -0.9850 -0.2934 -0.1074 -0.7771 -0.0909
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt ; implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
H-1953	-0.29704996943473816	▁Shu nt ▁implant s ▁; ▁trans sept al ▁cat heter isation ▁; ▁trans o es op hage al ▁e cho car dio graphic ▁guidance
D-1953	-0.29704996943473816	Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic guidance
P-1953	-0.5008 -0.0183 -0.0024 -0.0365 -0.4525 -0.0025 -0.0883 -0.3724 -0.0384 -0.0040 -0.0859 -0.2508 -0.0012 -1.1964 -0.1110 -0.2136 -0.0115 -0.1955 -0.0653 -0.2643 -0.0572 -0.3605 -0.8433 -0.8884 -1.4530 -0.2093
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea ; total arterial compliance ; tac ; end-systolic elastance ; ees ; baseline
H-520	-0.24219639599323273	▁arterial ▁compliance ▁; TAC ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es
D-520	-0.24219639599323273	arterial compliance ;TAC ; end-systolic elastance ; ees
P-520	-1.0951 -0.2091 -0.0443 -0.0547 -0.0470 -0.4422 -0.0194 -0.3435 -0.2324 -0.6077 -0.0195 -0.0738 -0.2139 -0.2746 -0.0054 -0.3046 -0.1300
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular support ; heartmate ii ; lvad ; centrimag ; rvad ; mortality ; hospital ; discharge
H-304	-0.6304046511650085	▁bi ven tri cular ▁support ▁; ▁Heart Mate ▁; ▁l VAD ▁; ▁Centri Mag ▁R VAD
D-304	-0.6304046511650085	biventricular support ; HeartMate ; lVAD ; CentriMag RVAD
P-304	-1.0326 -0.2733 -1.0227 -0.3267 -0.2461 -0.2007 -1.5854 -0.0512 -1.4258 -0.8376 -0.0268 -0.0971 -0.2519 -0.2462 -2.1396 -0.0286 -1.3668 -0.1885
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal dysfunction ; mortality ; myocardial infarction ; coronary artery bypass grafting ; cabg
H-969	-0.38103121519088745	▁Ren al ▁dys function ▁; ▁long - term ▁mortal ity ▁; ▁my o card ial ▁in far ction ▁; ▁corona ry ▁arter y ▁by pass ▁graf ting ▁; CA BG
D-969	-0.38103121519088745	Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ;CABG
P-969	-0.0959 -0.1229 -0.0367 -0.2719 -0.1938 -1.1443 -0.0124 -0.3053 -0.0528 -0.2839 -0.1084 -0.3866 -0.1363 -0.0308 -0.1144 -0.0145 -0.4120 -0.0664 -0.3809 -0.0692 -0.0785 -0.0267 -0.7256 -2.5385 -0.0939 -0.0073 -2.3229 -0.5933 -1.1393 -0.1331 -0.1607 -0.1339
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hfpef
H-1890	-0.3887506127357483	▁cardiovascular ▁; ▁diabetes ▁mell itus ▁; ▁at rial ▁fi bril lation ▁; ▁corona ry ▁arter y ▁disease ▁; ▁ HF p EF
D-1890	-0.3887506127357483	cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
P-1890	-0.2808 -2.3074 -0.2494 -0.0225 -0.1400 -0.0730 -0.0562 -0.0304 -0.4357 -0.0123 -0.0102 -0.1700 -0.0636 -0.1471 -0.0621 -0.9492 -1.6519 -0.9104 -0.9285 -0.0517 -0.0163 -0.1469 -0.4326 -0.1817
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline ; isoprenaline ; infusion ; sdqt ; hf ; patients
H-1443	-0.3978160619735718	▁iso pren a line ▁in fusion ▁; ▁SD QT ▁; ▁h Nor m ▁; ▁ HF
D-1443	-0.3978160619735718	isoprenaline infusion ; SDQT ; hNorm ; HF
P-1443	-0.2946 -0.0359 -0.4248 -0.0951 -0.0422 -0.0636 -0.1235 -0.0290 -0.7498 -0.1973 -0.0991 -2.9083 -0.0059 -0.3201 -1.0654 -0.1149 -0.4091 -0.1819
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal dysfunction ; all-cause mortality ; cardiovascular events ; postoperative ; cabg
H-978	-0.38623204827308655	▁Ren al ▁dys function ▁; ▁cardiovascular ▁events ▁; ▁ca BG
D-978	-0.38623204827308655	Renal dysfunction ; cardiovascular events ; caBG
P-978	-0.1018 -0.0998 -0.0230 -0.3664 -0.2242 -0.5520 -0.7909 -0.6088 -1.1832 -0.4500 -0.1018 -0.1330
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
H-1142	-0.45830783247947693	▁Pyr ido stig mine ▁; ▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ▁vent ric le ▁; ▁my o card ial ▁ang io gene sis
D-1142	-0.45830783247947693	Pyridostigmine ; vascular endothelial growth factor ; ventricle ; myocardial angiogenesis
P-1142	-0.0233 -0.0499 -0.0001 -0.0422 -0.1331 -0.1869 -0.0983 -0.0336 -0.7157 -0.0339 -0.0268 -0.4209 -1.0354 -0.6374 -1.4284 -1.7423 -1.2272 -0.3317 -0.9414 -0.1221 -0.2094 -0.2887 -0.0488 -1.6927 -0.1500 -0.8782 -0.1724 -0.1616
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr ; vad ; ecmo ; vad ; ecmo
H-1393	-0.860930860042572	▁e g FR ▁; ▁ VAD ▁; ▁EC mo + VAD ▁group ▁; ▁EC mo
D-1393	-0.860930860042572	egFR ; VAD ; ECmo+VAD group ; ECmo
P-1393	-0.1723 -1.3665 -1.3446 -0.0711 -0.2982 -0.0378 -0.7163 -1.3446 -1.3659 -2.3858 -0.1166 -1.3640 -0.4524 -0.4739 -0.9155 -1.9989 -0.2113
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients ; chf ; international classification of diseases
H-213	-0.38424286246299744	▁CHF ▁; ▁international ▁Classifica tion ▁of ▁Disease s
D-213	-0.38424286246299744	CHF ; international Classification of Diseases
P-213	-0.4682 -0.3250 -1.2249 -0.1131 -0.0095 -0.3506 -0.0206 -0.0149 -1.1863 -0.1295
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv dysfunction ; body mass index ; fat mass ; cachexia
H-1163	-0.5955040454864502	▁ RV ▁dys function ▁; ▁body ▁mass ▁index ▁; ▁fat ▁mass ▁index ▁; ▁cache xia
D-1163	-0.5955040454864502	RV dysfunction ; body mass index ; fat mass index ; cachexia
P-1163	-0.5535 -0.3953 -0.0945 -0.4325 -0.1314 -3.3939 -0.5169 -0.1263 -0.1309 -1.9053 -0.8110 -0.0451 -0.5009 -0.4383 -0.1587 -0.3378 -0.1513
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline ; crf ; hf ; mortality ; hf
H-1775	-0.5035637617111206	▁base line ▁c RF ▁; ▁ HF ▁mortal ity ▁; ▁ HF
D-1775	-0.5035637617111206	baseline cRF ; HF mortality ; HF
P-1775	-1.0233 -0.0468 -1.3279 -0.3363 -0.0621 -0.4202 -0.0963 -0.1387 -0.0679 -1.0145 -0.6223 -0.1385 -1.6260 -0.1290
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait ; therapy ; lokomat ; heart failure ; patients
H-1921	-0.29146072268486023	▁Robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ® ▁System ▁; ▁heart ▁failure
D-1921	-0.29146072268486023	Robot-assisted gait therapy ; Lokomat® System ; heart failure
P-1921	-0.3722 -0.0709 -0.0061 -0.0959 -0.1436 -0.1118 -0.0558 -0.0196 -0.1232 -0.0601 -0.0404 -1.4547 -0.8998 -0.3549 -0.2676 -0.1664 -0.9006 -0.1028
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests ; cardiac growth ; disease ; chromatin ; remodeling
H-92	-0.29633909463882446	▁cardiac ▁growth ▁; ▁plastic ity ▁; ▁disease ▁recap it ulat es ▁; ▁chr omat in ▁remodel ing
D-92	-0.29633909463882446	cardiac growth ; plasticity ; disease recapitulates ; chromatin remodeling
P-92	-0.1194 -1.7958 -0.2166 -0.0810 -0.1351 -0.1935 -0.3301 -0.1197 -0.0052 -0.0043 -0.0912 -0.1364 -0.0882 -0.0083 -0.7291 -0.0115 -0.0687 -1.4108 -0.0857
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis ; idiopathic dilated cardiomyopathy
H-1742	-0.27495071291923523	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1742	-0.27495071291923523	idiopathic dilated cardiomyopathy
P-1742	-0.7111 -0.0733 -0.0383 -0.2744 -0.1909 -0.2199 -0.1200 -0.7118 -0.3179 -0.0263 -0.4346 -0.1809
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine ; nesiritide ; placebo
H-78	-0.20860542356967926	▁dop amine ▁; ▁nesi riti de
D-78	-0.20860542356967926	dopamine ; nesiritide
P-78	-0.0164 -0.0914 -0.0567 -0.0387 -0.0108 -0.0211 -1.3313 -0.1024
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline ; embase ; cochrane ; clinical
H-41	-0.35613682866096497	▁MED line ▁; ▁ EMBA se ▁; ▁co ch rane ▁database s ▁; ▁clinic al ▁trial ▁registri es
D-41	-0.35613682866096497	MEDline ; EMBAse ; cochrane databases ; clinical trial registries
P-41	-0.1502 -1.3491 -0.1162 -0.2864 -0.0090 -0.4834 -0.0801 -0.1293 -0.0317 -0.0087 -0.9746 -0.0861 -0.0651 -0.1155 -0.0483 -0.5301 -0.1961 -0.0736 -2.2477 -0.1416
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician ; nonprescribing ; patient
H-1127	-1.0634785890579224	▁Clinic ian
D-1127	-1.0634785890579224	Clinician
P-1127	-1.4035 -0.8044 -1.9297 -0.1162
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients ; severe hf ; prognostic ; hf
H-1764	-0.7177066802978516	▁ HF
D-1764	-0.7177066802978516	HF
P-1764	-1.4899 -0.0874 -1.1230 -0.1706
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ; ea ; tac ; ees ; patients
H-522	-0.37757372856140137	▁Ea ▁; ▁ TAC ▁; ▁HR ▁; ▁e es ▁; ▁i va bra dine -
D-522	-0.37757372856140137	Ea ; TAC ; HR ; ees ; ivabradine-
P-522	-1.2203 -0.2000 -0.5383 -0.0299 -0.0847 -0.1131 -0.2085 -0.4441 -0.0178 -0.2015 -0.0161 -0.0113 -0.2926 -0.0233 -0.2073 -2.6579 -0.1521
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth ; health ; outcomes ; medicare
H-1628	-0.39531126618385315	▁Care ▁management ▁couple d ▁; ▁content - driv en ▁tele health ▁technology ▁; ▁health ▁outcome s ▁; ▁high - co st ▁Medica re ▁beneficiar ies
D-1628	-0.39531126618385315	Care management coupled ; content-driven telehealth technology ; health outcomes ; high-cost Medicare beneficiaries
P-1628	-1.6625 -0.0319 -0.7925 -0.0473 -0.2214 -1.3919 -0.0094 -0.0114 -0.0536 -0.5284 -0.0951 -1.4895 -0.1550 -1.0859 -0.3954 -0.0198 -0.1076 -1.3097 -0.0117 -0.0410 -0.0557 -0.0210 -0.0074 -0.7585 -0.0318 -0.2240 -0.1136
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant ; erc ; epicatechin ; muscle
H-1256	-0.40208593010902405	▁ ERC ▁; ▁pure ▁epi cate chin
D-1256	-0.40208593010902405	ERC ; pure epicatechin
P-1256	-0.6070 -0.0399 -0.0754 -0.3713 -0.1330 -0.0028 -0.1770 -2.0682 -0.1443
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical ; nonprescribing ; patients
H-1128	-0.4279704689979553	▁bio medic al ▁reasons
D-1128	-0.4279704689979553	biomedical reasons
P-1128	-0.0238 -0.0072 -0.0029 -0.1675 -2.2332 -0.1332
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium ; expression ; pka ; downstream signaling
H-1433	-0.5917569994926453	▁my o car dium ▁; ▁p ka ▁sub un its ▁; ▁down stream ▁signal ing
D-1433	-0.5917569994926453	myocardium ; pka subunits ; downstream signaling
P-1433	-1.1727 -0.0490 -0.0257 -0.0534 -0.4781 -2.1036 -1.3301 -2.1260 -0.3748 -0.0844 -0.6362 -0.8226 -0.0041 -0.1740 -0.2844 -0.1959 -0.1447
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-867	-0.35912346839904785	▁ therapy ▁; ▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-867	-0.35912346839904785	therapy ; atrial fibrillation ; carvedilol ; metoprolol
P-867	-2.6210 -0.1669 -0.4806 -0.1162 -0.1308 -0.5949 -0.0440 -0.0432 -0.3601 -0.6445 -0.0821 -0.0950 -0.5928 -0.1633 -0.2151 -0.0129 -0.1060 -0.2123 -0.1417
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect ; heart failure ; patients ; implantable cardioverter-defibrillator
H-1860	-0.2621142268180847	▁implant able ▁cardio ver ter - de fi br illa tor
D-1860	-0.2621142268180847	implantable cardioverter-defibrillator
P-1860	-0.6420 -0.0454 -0.2456 -0.1156 -0.0534 -0.0183 -0.0991 -1.1132 -0.5101 -0.0087 -0.0930 -0.3372 -0.1259
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-367	-0.2515582740306854	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV
D-367	-0.2515582740306854	functional MS ; valve plasty ; degenerative MR ; LV
P-367	-1.1504 -0.0421 -0.1352 -0.8178 -0.0135 -0.0238 -0.1832 -0.2624 -0.0422 -0.1074 -0.0166 -0.0637 -0.2091 -0.0522 -0.8392 -0.0660
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients ; heartmate ii ; biventricular support ; heartmate ii ; implantation
H-300	-0.4950520992279053	▁Heart Mate ▁II ▁ insertion ▁; ▁bi ven tri cular ▁support ▁; ▁implant ation
D-300	-0.4950520992279053	HeartMate II insertion ; biventricular support ; implantation
P-300	-1.7645 -0.1199 -0.5478 -0.3806 -0.0130 -0.1169 -0.1604 -0.1429 -0.6325 -0.1077 -0.3428 -0.2822 -2.8123 -0.0257 -0.2956 -0.1761
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end stage heart failure ; heart failure ; public ; health ; patient ; europe ; north america
H-1663	-0.9437230825424194	▁management ▁; ▁end ▁stage ▁heart ▁failure ▁Heart ▁failure ▁; ▁public ▁health ▁; ▁ europe ▁; ▁nord ▁America
D-1663	-0.9437230825424194	management ; end stage heart failure Heart failure ; public health ; europe ; nord America
P-1663	-2.2045 -0.9583 -0.6970 -0.3672 -1.0386 -0.1589 -3.6385 -0.1368 -0.2135 -0.0340 -0.3515 -2.3147 -2.5648 -0.1072 -0.4460 -1.1877 -1.0925 -0.2683 -0.1506
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient ; st-segment-elevation mis ; killip class ; comorbid ; conditions
H-1105	-0.30721554160118103	▁st - seg ment - elevat ion ▁MI s ▁; ▁Kill ip ▁class
D-1105	-0.30721554160118103	st-segment-elevation MIs ; Killip class
P-1105	-1.6124 -0.0517 -0.0015 -0.0166 -0.0137 -0.0014 -0.0066 -0.3884 -0.0384 -0.1135 -0.8655 -0.1248 -0.0346 -1.1870 -0.1521
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart failure ; cardiology-cardiovascular surgery consensus report ; heart failure ; disease
H-1818	-0.4512997567653656	▁heart ▁failure ▁; ▁mechanic al ▁support ▁devices ▁; ▁Card i ology - car dio vas cular ▁Sur ger y ▁Cons en sus ▁; ▁Heart ▁failure ▁; ▁progressive ▁disease
D-1818	-0.4512997567653656	heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus ; Heart failure ; progressive disease
P-1818	-1.4585 -0.2854 -0.0772 -0.1578 -0.0073 -0.0865 -0.0757 -0.2018 -0.4040 -0.2620 -0.5274 -0.0145 -0.8598 -0.6703 -0.1801 -0.0654 -1.1482 -0.0967 -0.1213 -2.7931 -0.0111 -0.0204 -0.9512 -1.0788 -0.3142 -0.9066 -0.0864 -0.3729 -0.1549 -0.1498
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 ; n2bus ; s12884 ; pevk
H-769	-0.7181423306465149	▁elastic ▁N 2 Bu s ▁segment ▁; ▁PE v k ▁segment
D-769	-0.7181423306465149	elastic N2Bus segment ; PEvk segment
P-769	-0.3615 -1.4190 -0.0787 -0.9142 -0.0550 -0.7208 -0.2207 -0.6431 -1.4870 -1.3836 -1.7616 -0.1394 -0.1513
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care of heart failure index version 6.2 ; schfi v.6.2 ; psychometric
H-1504	-0.4183836579322815	▁Self - Car e ▁of ▁Heart ▁Fail ure ▁Index ▁; SCH FI ▁; ▁psycho metric ▁profile
D-1504	-0.4183836579322815	Self-Care of Heart Failure Index ;SCHFI ; psychometric profile
P-1504	-0.2546 -0.0182 -1.5592 -0.0470 -0.3065 -0.2805 -0.0556 -0.0670 -1.5088 -0.1570 -0.2179 -1.4216 -1.3120 -0.0299 -0.0150 -0.0697 -0.1150 -0.0955
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics ; chromatin-associated proteins ; disease
H-93	-0.37698259949684143	▁prote o mics ▁; ▁chr omat in - as soci ated ▁protein s ▁; ▁detergent
D-93	-0.37698259949684143	proteomics ; chromatin-associated proteins ; detergent
P-93	-0.4788 -0.8173 -0.0087 -0.3494 -0.1146 -0.0073 -0.7572 -0.0479 -0.0449 -0.0007 -0.3105 -0.8536 -0.0320 -0.7298 -0.2952 -1.4675 -0.0934
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate ; left ventricular assist system ; lvas ; patients ; heart failure
H-1993	-0.6612646579742432	▁Heart Mate ▁; ▁left ▁vent ri cular ▁assist ▁system ▁; ▁l VAS ▁; ▁patients ▁; ▁advanced ▁heart ▁failure
D-1993	-0.6612646579742432	HeartMate ; left ventricular assist system ; lVAS ; patients ; advanced heart failure
P-1993	-0.5788 -0.2201 -0.4598 -0.7500 -0.0409 -2.1536 -0.6102 -0.5736 -0.4842 -0.3921 -0.2246 -0.2509 -0.6752 -2.3584 -0.7809 -1.5522 -0.4600 -0.3867 -0.1633 -0.1098
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil ; mitochondrial dysfunction ; heart failure ; cardioprotection
H-954	-0.2663646340370178	▁Nico rand il ▁a meli orat es ▁mito cho ndri al ▁dys function ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁cardio protec tion
D-954	-0.2663646340370178	Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; cardioprotection
P-954	-0.0024 -0.2089 -0.1767 -1.9936 -0.0010 -0.0147 -0.0649 -0.0288 -1.0823 -0.1715 -0.0564 -0.0088 -0.1324 -0.1937 -0.0380 -0.0059 -0.0075 -0.2638 -0.0227 -0.0158 -0.5354 -0.3656 -0.4526 -0.3293 -0.1842 -0.0176 -1.1601 -0.2691 -0.3819 -0.0390 -0.1596 -0.1396
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic ; acute hf ; adverse event ; chronic hf
H-1016	-0.31166136264801025	▁ pharma c ologic ▁management ▁; ▁a cute ▁ HF ▁; ▁chronic ▁ HF
D-1016	-0.31166136264801025	pharmacologic management ; acute HF ; chronic HF
P-1016	-0.3008 -0.0582 -0.0819 -0.1133 -0.0808 -0.1660 -0.0305 -0.0100 -0.1979 -0.0190 -0.4487 -2.9362 -0.2519 -0.0286 -0.1568 -0.1061
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
H-517	-0.5481325387954712	▁arterial ▁elastan ce ▁; ▁pulsa tile ▁after load ▁; ▁heart ▁; ▁pressure
D-517	-0.5481325387954712	arterial elastance ; pulsatile afterload ; heart ; pressure
P-517	-0.5994 -0.1410 -0.2311 -0.0802 -0.5844 -0.0266 -2.5485 -0.0466 -0.2581 -0.3008 -0.2079 -0.6231 -1.9391 -0.0868
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 ; hno ; cxl-1051 ; t1
H-416	-0.45302948355674744	▁c XL -10 20 ▁convert s ▁; ▁h no ▁; ▁in active ▁; ▁c XL -10 51
D-416	-0.45302948355674744	cXL-1020 converts ; hno ; inactive ; cXL-1051
P-416	-1.5640 -1.1633 -0.1633 -0.3716 -0.0643 -0.2852 -0.3636 -0.1447 -0.3317 -0.1003 -0.0291 -0.0561 -1.1551 -1.0621 -0.9057 -0.1429 -0.2300 -0.3089 -0.1655
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf antagonists ; hf ; hospital ; admissions ; nbdmards ; ra
H-611	-0.24239978194236755	▁t NF ▁anta gon ists ▁; ▁ HF ▁hospital ▁ad missions ▁; ▁n b DM ARD s ▁; ▁RA
D-611	-0.24239978194236755	tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
P-611	-0.4135 -0.2289 -0.3675 -0.1361 -0.3522 -0.1032 -0.7075 -0.0262 -1.1447 -0.0440 -0.0178 -0.1033 -0.1235 -0.0111 -0.3797 -0.0562 -0.0338 -0.3374 -0.1743 -0.2115 -0.1180
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ; ejection fraction
H-1236	-0.5412634611129761	▁e je ction ▁ fraction
D-1236	-0.5412634611129761	ejection fraction
P-1236	-1.8705 -0.8774 -0.1525 -0.1569 -0.0016 -0.4909 -0.2390
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate analysis ; gls
H-817	-0.9677239060401917	▁gr s ▁; ▁h ▁; ▁CV
D-817	-0.9677239060401917	grs ; h ; CV
P-817	-0.4285 -1.8573 -0.1533 -1.3264 -1.1221 -2.1574 -0.4483 -0.2486
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized ; exercise ; exercise
H-1981	-0.9347105622291565	
D-1981	-0.9347105622291565	
P-1981	-1.7737 -0.0958
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality ; hospitals
H-1695	-0.6066709160804749	▁risk - ad just ed ▁mortal ity
D-1695	-0.6066709160804749	risk-adjusted mortality
P-1695	-3.5612 -0.0110 -0.0098 -0.0011 -0.0192 -0.0108 -0.1387 -1.5436 -0.1646
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses ; magnet
H-87	-1.3879873752593994	▁nurse s
D-87	-1.3879873752593994	nurses
P-87	-2.4549 -0.0306 -2.9725 -0.0938
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician ; evidence
H-1842	-0.3341488540172577	▁physician ▁ad her ence ▁; ▁class ▁I ▁recommendations
D-1842	-0.3341488540172577	physician adherence ; class I recommendations
P-1842	-0.2979 -0.0514 -0.3664 -0.0113 -0.5299 -0.1524 -0.5184 -0.2869 -1.0066 -0.1203
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed ; patients ; hf ; drug treatment ; paf ; biosynthetic enzymes ; lyso-paf-at
H-1271	-0.42680323123931885	▁ HF ▁; ▁PA f ▁bio syn the tic ▁enzym es ▁; ▁lys o - pa f - AT
D-1271	-0.42680323123931885	HF ; PAf biosynthetic enzymes ; lyso-paf-AT
P-1271	-1.9870 -0.0359 -0.1479 -2.8121 -0.2976 -0.1009 -0.0019 -0.3773 -0.9656 -0.0977 -0.0476 -0.2687 -0.0693 -0.0418 -0.0068 -0.8633 -0.1748 -0.0550 -0.1436 -0.3062 -0.1621
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology ; myocardial infarction ; mi ; outcomes ; heart failure ; hf
H-1099	-0.3980464041233063	▁my o card ial ▁in far ction ▁; MI ▁; ▁heart ▁failure ▁; HF
D-1099	-0.3980464041233063	myocardial infarction ;MI ; heart failure ;HF
P-1099	-2.4365 -0.1934 -0.1367 -0.2899 -0.0250 -0.7921 -0.1195 -0.1939 -1.0602 -0.1781 -0.1469 -0.1720 -0.3399 -0.0279 -0.1376 -0.1194
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic ; tests ; cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments ; baseline
H-737	-0.2620277404785156	▁cardiac ▁magnetic ▁res on ance ▁imagin g ▁; ▁ma pping ▁; ▁invasi ve ▁hem o dynamic ▁assessment s
D-737	-0.2620277404785156	cardiac magnetic resonance imaging ; mapping ; invasive hemodynamic assessments
P-737	-0.0876 -0.2039 -0.3894 -0.2513 -0.0459 -0.2424 -0.0727 -0.1120 -1.0086 -0.1339 -0.2082 -0.1718 -0.1018 -0.3726 -0.3440 -0.0230 -0.9671 -0.1476 -0.2268 -0.1301
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart rate reduction ; exercise ; heart failure with reduced ejection fraction ; beta-blocker
H-1935	-0.37599503993988037	▁Heart ▁rate ▁re duction ▁; ▁exercise ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁beta - block er ▁hypo - respons e
D-1935	-0.37599503993988037	Heart rate reduction ; exercise ; heart failure ; ejection fraction ; beta-blocker hypo-response
P-1935	-0.8725 -1.9922 -0.0988 -0.0464 -0.1523 -1.7401 -0.7332 -0.9490 -0.2817 -0.1440 -0.7662 -0.1006 -0.0300 -0.0904 -0.0004 -0.5109 -0.4286 -0.0147 -0.1624 -0.0310 -0.2001 -0.0472 -0.0002 -0.0854 -0.1434 -0.1543
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ; ras ; asymptomatic ; clinically ; hypertension ; nephropathy ; congestive heart failure
H-1597	-0.8829653859138489	RAS ▁; ▁hyper tension ▁; ▁nep hro pathy
D-1597	-0.8829653859138489	RAS ; hypertension ; nephropathy
P-1597	-1.0748 -0.4209 -0.0325 -0.0455 -0.1501 -0.0120 -0.0164 -0.0243 -6.9219 -0.1313
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic ; admission ; brain natriuretic peptide ; bnp ; creatinine ; natremia
H-585	-0.5000273585319519	▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁creati nine ▁; ▁na trem ia
D-585	-0.5000273585319519	brain natriuretic peptide ; bNP ; creatinine ; natremia
P-585	-3.7967 -0.0145 -0.1166 -0.0122 -2.4387 -0.0684 -0.1511 -0.0910 -0.2394 -0.1446 -0.2512 -0.3549 -0.0159 -0.1210 -0.5217 -0.0683 -0.0527 -1.1540 -0.1932 -0.1945
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-868	-0.38704240322113037	▁m ADI t - c rte ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-868	-0.38704240322113037	mADIt-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
P-868	-0.5168 -0.9622 -0.0936 -0.0083 -0.9316 -1.5112 -0.1915 -0.0589 -0.0084 -0.6934 -0.0360 -0.6049 -0.2188 -0.0843 -0.0516 -0.1279 -0.0186 -0.2014 -0.2685 -0.0620 -0.8633 -0.0425 -0.0035 -0.6523 -0.1835 -1.9459 -0.1096
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated ; baseline ; nt-probnp ; mr-proanp ; mr-proadm
H-17	-0.27344459295272827	▁NT - pro b NP ▁; ▁MR - pro an p ▁; ▁MR - pro ad m
D-17	-0.27344459295272827	NT-probNP ; MR-proanp ; MR-proadm
P-17	-0.7633 -0.0110 -0.0064 -0.8643 -0.2956 -0.0791 -0.1005 -0.0065 -0.0049 -1.3777 -0.1866 -0.1847 -0.0851 -0.0088 -0.0223 -0.9230 -0.0198 -0.1094 -0.1464
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric focusing ; riα ; ser77 ; ser83 ; in vivo ; phosphorylation
H-1430	-0.7047070860862732	▁iso electric ▁focus ing ▁; ▁RI α ▁; ▁ser 77 ▁; ▁ser 83 ▁; ▁ phos phor y lation ▁sites
D-1430	-0.7047070860862732	isoelectric focusing ; RIα ; ser77 ; ser83 ; phosphorylation sites
P-1430	-1.7987 -0.3510 -2.0059 -0.0607 -0.2493 -0.1642 -0.6025 -0.2624 -0.9293 -0.7316 -0.3657 -0.7817 -1.2703 -1.2072 -1.2139 -0.1809 -0.7561 -1.1329 -0.0396 -1.0644 -0.1859 -0.1496
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt ; sd of rr intervals ; sdrr ; qtv ; heart rate variability
H-1440	-0.7180187106132507	▁SD QT ▁; ▁SD ▁; ▁ RR ▁; SD RR ▁; ▁Q TV ▁; ▁heart ▁rate ▁variabil ity
D-1440	-0.7180187106132507	SDQT ; SD ; RR ;SDRR ; QTV ; heart rate variability
P-1440	-0.0786 -0.4015 -0.1255 -0.0330 -0.4716 -0.9996 -0.6815 -0.3705 -0.9937 -1.9916 -0.2343 -2.0460 -1.0439 -0.1611 -1.2010 -2.1221 -0.5330 -0.2821 -0.3210 -0.2690
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs ; septal ; qrs ; resynchronization
H-486	-0.7746283411979675	▁a UC s ▁; ▁e sept al ▁; ▁e eme an ▁; sept al ▁; ▁QR s ▁ width
D-486	-0.7746283411979675	aUCs ; eseptal ; eemean ;septal ; QRs width
P-486	-1.6637 -0.4741 -0.1431 -0.2810 -0.3411 -2.5234 -0.0697 -0.1901 -0.6375 -4.6957 -0.1172 -0.2684 -0.1897 -0.0511 -0.4532 -0.0649 -1.4219 -1.4388 -0.0784 -0.9366 -0.2276
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic regression ; primary outcome ; secondary outcome ; death
H-973	-0.5256099104881287	▁Log istic ▁re gression ▁models
D-973	-0.5256099104881287	Logistic regression models
P-973	-0.1546 -0.0732 -0.0290 -0.0115 -0.8002 -2.4959 -0.1148
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc occlusion ; correlated ; rs ; rs synchrony
H-326	-0.23983851075172424	▁IV c ▁oc clusi on ▁; ▁CO ▁cor related ▁; ▁twist ▁; ▁ap ical ▁ro tation ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁CS
D-326	-0.23983851075172424	IVc occlusion ; CO correlated ; twist ; apical rotation ; RS ; RS synchrony ; CS
P-326	-0.1463 -1.1759 -0.1359 -0.0341 -0.3733 -0.0882 -1.0633 -0.1429 -0.1564 -0.3022 -0.1876 -0.1003 -0.1581 -0.0795 -0.0075 -0.0036 -0.0854 -0.0852 -0.2198 -0.5486 -0.0031 -0.0861 -0.7838 -0.0483 -0.0851 -0.1355
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission ; hospital ; congestive heart failure ; united states
H-1574	-0.46999019384384155	▁hospital ▁stay ▁; ▁con ges tive ▁heart ▁failure
D-1574	-0.46999019384384155	hospital stay ; congestive heart failure
P-1574	-2.5005 -0.7459 -0.2092 -0.0209 -0.0185 -0.0806 -0.2318 -0.1115 -0.6599 -0.1211
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective ; diuretics ; morbidity ; mortality
H-1200	-0.24594052135944366	▁di ure tics ▁; ▁modul ate ▁ HF - related ▁morbi d ity
D-1200	-0.24594052135944366	diuretics ; modulate HF-related morbidity
P-1200	-0.1230 -0.0299 -0.4946 -0.3375 -0.3177 -0.4519 -0.1295 -0.0217 -0.1075 -0.1523 -0.0602 -0.2448 -0.2696 -0.8096 -0.1392
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital ; readmission ; patients ; heart failure ; follow-up
H-731	-1.331353783607483	▁hospital ▁; ▁patients ▁; ▁heart ▁failure
D-731	-1.331353783607483	hospital ; patients ; heart failure
P-731	-1.9986 -0.6664 -6.2921 -0.8883 -0.1857 -0.1927 -0.2680 -0.1591
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health care ; clinically ; gastrointestinal bleeding
H-1658	-0.5668140053749084	▁devices ▁; ▁gastro inte stin al ▁ble ed ing
D-1658	-0.5668140053749084	devices ; gastrointestinal bleeding
P-1658	-2.9257 -0.3826 -1.6135 -0.0194 -0.2595 -0.0762 -0.0547 -0.3709 -0.2424 -0.2002 -0.0897
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients ; t1 times ; cardiac events
H-740	-0.7177098989486694	▁cardiac ▁events
D-740	-0.7177098989486694	cardiac events
P-740	-1.9189 -0.7099 -0.1445 -0.0975
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr ; vad ; ecmo ; vad ; renal function
H-1391	-0.8998034000396729	▁e g FR ▁; ▁ VAD ▁group ▁; ▁EC mo + VAD ▁group ▁; ▁renal ▁function
D-1391	-0.8998034000396729	egFR ; VAD group ; ECmo+VAD group ; renal function
P-1391	-0.1530 -1.2726 -1.0301 -0.0948 -0.5849 -0.0165 -2.1129 -0.2269 -0.9536 -1.3676 -1.4662 -0.0505 -1.4681 -0.6207 -0.5506 -3.8581 -0.1920 -0.1775
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 ; sst2 ; outcomes
H-406	-0.6503229141235352	▁s ST 2/ low - dos e ▁BB ▁; ▁s ST 2/ high - dos e ▁BB
D-406	-0.6503229141235352	sST2/low-dose BB ; sST2/high-dose BB
P-406	-0.8391 -1.6250 -1.0215 -1.3023 -0.0081 -0.5303 -0.0573 -0.2683 -0.2879 -2.0284 -1.7016 -0.6159 -0.5149 -0.0085 -0.7152 -0.0296 -0.4382 -0.1798 -0.1844
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf ; chf ; patients ; intubated
H-214	-0.5628350973129272	▁CHF ▁visit ▁; ▁ED ▁visit s ▁; ▁CHF ▁patients ▁in tuba ted
D-214	-0.5628350973129272	CHF visit ; ED visits ; CHF patients intubated
P-214	-0.1206 -1.3842 -1.0565 -1.6416 -1.0903 -0.1023 -0.1994 -0.2078 -1.2591 -0.0543 -0.0142 -0.4340 -0.2180 -0.0973
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician ; mortality ; hf ; physicians
H-1731	-0.4821588695049286	▁Physic ian ▁volume ▁; ▁mortal ity ▁; ▁ HF ▁; ▁non car dio logist ▁physician s
D-1731	-0.4821588695049286	Physician volume ; mortality ; HF ; noncardiologist physicians
P-1731	-0.8553 -0.4819 -0.3837 -0.1476 -1.1097 -0.2733 -0.0770 -1.6434 -0.0180 -0.2325 -1.7497 -0.0292 -0.4246 -0.0997 -0.8754 -0.0468 -0.1533 -0.0776
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin ; genomic reprogramming ; disease
H-100	-0.4015144407749176	▁zebra fish ▁; ▁nu cle olin ▁; ▁genom ic ▁re programm ing ▁events
D-100	-0.4015144407749176	zebrafish ; nucleolin ; genomic reprogramming events
P-100	-0.7328 -0.0254 -0.0978 -0.7530 -0.0025 -0.3126 -0.7706 -0.1229 -0.1977 -0.0063 -0.1040 -0.0455 -1.3680 -1.4061 -0.0776
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv ejection fraction ; pcwp
H-483	-0.5047457814216614	▁LV ▁e je ction ▁ fraction ▁; ▁PC WP
D-483	-0.5047457814216614	LV ejection fraction ; PCWP
P-483	-0.2851 -1.4547 -0.3414 -0.1007 -0.2064 -0.0012 -0.3742 -1.4638 -0.0717 -1.0903 -0.1627
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence ; hf ; ami ; mortality
H-1314	-0.4176654517650604	▁ HF ▁complicat ing ▁ AMI ▁; ▁mortal ity
D-1314	-0.4176654517650604	HF complicating AMI ; mortality
P-1314	-1.7130 -0.0372 -0.4887 -0.0992 -0.2259 -0.0295 -0.4812 -1.1723 -0.1738 -0.0797 -0.0938
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency department ; acute heart failure ; clinical ; patient ; collins
H-56	-0.5126383900642395	▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁clinic al ▁trial s
D-56	-0.5126383900642395	emergency department ; acute heart failure clinical trials
P-56	-1.0763 -0.1653 -0.1643 -0.0308 -0.0056 -0.7847 -0.2337 -1.4788 -0.0696 -0.3675 -0.0465 -2.0964 -0.1447
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary exercise test ; quality of life ; muscular ; peak quadriceps force
H-1915	-0.662643313407898	▁cardio pul mon ary ▁exercise ▁; ▁muscular ▁strength ▁; ▁pe ak ▁quadri cep s ▁force
D-1915	-0.662643313407898	cardiopulmonary exercise ; muscular strength ; peak quadriceps force
P-1915	-0.0639 -0.0617 -1.3416 -0.3626 -2.0127 -0.4305 -3.5491 -1.3082 -0.1087 -1.2584 -0.0635 -0.2164 -0.0090 -0.0442 -0.0555 -0.1999 -0.1791
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians ; public ; health ; air ; cardiovascular ; health ; lead ; hospitalisation ; death
H-1808	-0.780936062335968	▁public ▁health ▁; ▁air ▁pollution ▁; ▁urban ▁; ▁industrial ▁areas ▁; ▁cardiovascular ▁health
D-1808	-0.780936062335968	public health ; air pollution ; urban ; industrial areas ; cardiovascular health
P-1808	-0.6891 -0.6044 -0.2904 -0.0057 -0.0246 -0.2158 -3.1260 -2.3683 -0.4950 -1.3681 -0.5861 -0.6634 -0.4055 -0.7262 -0.1455
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg ; congenital ; accessory ; ion channelopathies ; cardiomyopathy
H-1909	-0.5282855033874512	▁e CG ▁; ▁ion ▁channel o pathi es ▁; ▁cardio my o pathy
D-1909	-0.5282855033874512	eCG ; ion channelopathies ; cardiomyopathy
P-1909	-0.4213 -0.3954 -0.3144 -3.6636 -0.8253 -0.9360 -0.0404 -0.0498 -0.2604 -0.1698 -0.4175 -0.1383 -0.0422 -0.1231 -0.1269
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients ; idiopathic dilated cardiomyopathy ; tuscany ; evidence-based
H-1739	-0.2864029109477997	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁tu sca ny
D-1739	-0.2864029109477997	idiopathic dilated cardiomyopathy ; tuscany
P-1739	-1.3923 -0.0378 -0.0411 -0.1776 -0.1940 -0.3618 -0.0880 -0.6349 -0.2928 -0.0239 -0.3518 -0.2800 -0.0013 -0.0984 -0.4958 -0.1111
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf ; pyridostigmine ; basal heart rate ; sympathetic control of heart rate
H-1140	-0.41991424560546875	▁ HF ▁; ▁py rido stig mine ▁; ▁bas al ▁heart ▁rate ▁; ▁va gal ▁; ▁sympa the tic ▁control ▁; ▁heart ▁rate
D-1140	-0.41991424560546875	HF ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
P-1140	-1.8471 -0.2522 -1.1956 -0.5864 -0.0103 -0.0006 -0.0391 -0.0705 -0.0212 -0.0802 -0.8737 -0.6600 -0.1650 -0.0200 -0.0165 -0.2942 -0.7425 -0.3409 -0.3209 -0.0635 -1.2390 -0.5159 -0.7723 -0.1906 -0.1794
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity ; mortality ; hfpef ; patients ; hf ; reduced ef
H-1301	-0.39230531454086304	▁Morbi d ity ▁; ▁mortal ity ▁; HF p EF ▁; ▁ HF ▁; ▁EF
D-1301	-0.39230531454086304	Morbidity ; mortality ;HFpEF ; HF ; EF
P-1301	-0.0616 -0.0577 -0.3761 -0.2499 -0.0377 -0.2511 -0.1129 -1.1172 -0.0217 -0.0715 -0.2194 -1.8870 -0.0517 -0.2372 -1.3605 -0.4757 -0.0804
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf ; heart failure ; t2d ; type 2 diabetes ; skm ; skeletal muscle
H-1244	-0.4153759777545929	HF ▁; heart ▁failure ▁; ▁t 2 d ▁; ▁diabetes ▁; ▁Sk m ▁; s kelet al ▁muscle
D-1244	-0.4153759777545929	HF ;heart failure ; t2d ; diabetes ; Skm ;skeletal muscle
P-1244	-0.4144 -0.4052 -0.1960 -0.0803 -0.0973 -0.6316 -0.0324 -0.3151 -0.0774 -1.0600 -0.2783 -0.1050 -0.1371 -0.3751 -3.4461 -0.0206 -0.0380 -0.1201 -0.3656 -0.1118
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart failure ; hf ; risk stratification ; inpatient ; outpatient
H-378	-0.5668665170669556	▁heart ▁failure ▁; HF ▁; ▁in patient ▁; ▁out patient ▁models
D-378	-0.5668665170669556	heart failure ;HF ; inpatient ; outpatient models
P-378	-0.3469 -0.4103 -0.1539 -0.0624 -0.5714 -1.0742 -0.0160 -3.3577 -0.0919 -0.0194 -0.9498 -0.1758 -0.1397
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence ; biomarkers ; pathophysiology ; chronic hf ; therapeutic
H-1474	-0.2692326009273529	▁molecular ▁bio mark ers ▁; ▁pat ho phy si ology ▁; ▁chronic ▁ HF
D-1474	-0.2692326009273529	molecular biomarkers ; pathophysiology ; chronic HF
P-1474	-0.6552 -0.0390 -0.0115 -0.0566 -0.1556 -0.8356 -0.0294 -0.1029 -0.5770 -0.5593 -0.3036 -0.2053 -0.1642 -0.0316 -0.4291 -0.1517
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol ; metoprolol ; therapy ; heart failure ; patients
H-857	-0.40009844303131104	▁car vedi lol ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁devices
D-857	-0.40009844303131104	carvedilol ; metoprolol ; heart failure ; devices
P-857	-0.5029 -0.0541 -0.0749 -0.3609 -0.0641 -0.1444 -0.0109 -0.1814 -0.5085 -1.2969 -0.2687 -2.1482 -0.1773 -0.0598 -0.1484
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating agents ; patients ; anemia ; heart disease
H-52	-0.5198297500610352	▁Er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁heart ▁disease
D-52	-0.5198297500610352	Erythropoiesis-stimulating agents ; anemia ; heart disease
P-52	-3.9439 -0.0485 -0.2322 -0.3439 -0.1536 -0.1199 -0.0784 -0.0193 -0.5906 -0.1432 -0.2404 -1.1843 -0.1138 -0.1841 -0.2749 -1.3614 -0.1609 -0.1637
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence ; intravenous ; exercise tolerance ; quality of life ; patients ; heart failure
H-46	-1.0916759967803955	▁intra ven ous ▁ir on ▁; ▁heart ▁failure
D-46	-1.0916759967803955	intravenous iron ; heart failure
P-46	-2.1918 -0.0116 -1.7701 -0.1055 -0.0806 -0.2036 -6.0934 -0.2869 -0.0878 -0.0853
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report ; mitral valve plasty ; degenerative mitral regurgitation
H-335	-0.23945483565330505	▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁mit ral ▁re gur gi tation
D-335	-0.23945483565330505	mitral valve plasty ; degenerative mitral regurgitation
P-335	-2.3884 -0.0370 -0.1660 -0.0480 -0.0424 -0.1054 -0.1971 -0.0472 -0.1145 -0.0347 -0.6284 -0.0849 -0.0071 -0.0097 -0.1180 -0.0384 -0.1368 -0.1063
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs ; québec health insurance board ; costs ; ontario case costing initiative
H-1235	-0.4122507870197296	▁in - t rial ▁resource ▁utiliza tion ▁; ▁coût ▁; ▁Québec ▁Health ▁Insurance ▁Board ▁; ▁disease - specific ▁costs ▁; ▁Ontario ▁Case ▁Cost ing ▁Initiative
D-1235	-0.4122507870197296	in-trial resource utilization ; coût ; Québec Health Insurance Board ; disease-specific costs ; Ontario Case Costing Initiative
P-1235	-0.1747 -1.6959 -0.2381 -0.0445 -0.3725 -0.2275 -0.0208 -0.1081 -0.9762 -0.7552 -0.2809 -1.3732 -0.2252 -0.0878 -0.3235 -2.6182 -0.0100 -0.0510 -0.2506 -0.1164 -0.2890 -0.1505 -0.0909 -0.1426 -0.2051 -0.2122 -0.0902
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet ; bromodomain-containing protein 4 ; brd4 ; cardiac
H-1045	-0.4492437541484833	▁ BET ▁bro modo main - conta ining ▁protein ▁; BR d 4) ▁; ▁cardiac ▁tissu es
D-1045	-0.4492437541484833	BET bromodomain-containing protein ;BRd4) ; cardiac tissues
P-1045	-1.8863 -0.0246 -0.9985 -0.0208 -0.0594 -0.0400 -0.0235 -0.1021 -0.1424 -0.7341 -0.2577 -0.2717 -0.8584 -1.2710 -0.0231 -1.4012 -0.1472 -0.1366 -0.1371
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras ; neprilysin inhibition ; change ; stable ; chronic heart failure ; systolic dysfunction
H-1971	-0.5521405935287476	▁ RAS ▁; ▁nepri ly sin ▁inhibi tion ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function
D-1971	-0.5521405935287476	RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction
P-1971	-0.9943 -0.0200 -0.4699 -0.4184 -0.1769 -0.2646 -0.1753 -0.0405 -0.3392 -3.3578 -0.6011 -0.4534 -0.2634 -0.3411 -0.2288 -1.9147 -0.0177 -0.1074 -0.6468 -0.2114
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change ; readmission ; follow-up ; follow-up
H-724	-1.1394660472869873	
D-724	-1.1394660472869873	
P-724	-2.1454 -0.1336
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage heart failure ; mechanical cardiac support
H-1386	-0.5123665928840637	▁end - s tage ▁heart ▁failure ▁; ▁pediatr ic ▁mechanic al ▁cardiac ▁support
D-1386	-0.5123665928840637	end-stage heart failure ; pediatric mechanical cardiac support
P-1386	-4.4643 -0.0669 -0.2950 -0.0037 -0.6063 -0.1554 -0.4193 -0.1250 -0.2040 -0.2137 -0.0118 -0.0342 -0.7958 -0.1898 -0.1002
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence ; economic ; lvad ; outcomes
H-317	-0.6881500482559204	▁économique ▁models ▁; ▁l VAD
D-317	-0.6881500482559204	économique models ; lVAD
P-317	-0.2609 -0.3241 -0.1621 -3.1676 -0.0764 -0.7326 -0.0933
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic ; crt
H-428	-0.5902882814407349	▁e cho car dio graphic ▁score ▁; ▁c RT
D-428	-0.5902882814407349	echocardiographic score ; cRT
P-428	-2.4057 -0.5334 -0.0535 -0.2580 -0.1363 -0.3235 -0.1848 -0.3484 -1.6573 -0.4021 -0.1902
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection fraction ; patients
H-909	-0.9240396618843079	▁e je ction ▁ fraction
D-909	-0.9240396618843079	ejection fraction
P-909	-3.5346 -0.9275 -0.2795 -0.0978 -0.0009 -1.4412 -0.1867
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized ; af ablation
H-953	-0.4784581661224365	▁AF ▁ab lation
D-953	-0.4784581661224365	AF ablation
P-953	-1.9844 -0.0656 -0.0372 -0.1655 -0.1396
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel inhibition ; hemodynamic ; exercise tolerance ; heart failure with preserved ejection fraction ; randomized
H-1170	-0.38445767760276794	▁If - chan nel ▁inhibi tion ▁; ▁hem o dynamic ▁status ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1170	-0.38445767760276794	If-channel inhibition ; hemodynamic status ; heart failure ; preserved ejection fraction
P-1170	-3.8794 -0.0202 -0.0204 -0.0369 -0.2609 -0.0965 -0.2934 -0.1971 -0.1666 -0.0172 -0.2957 -0.1004 -1.5896 -0.3471 -0.2573 -0.7455 -0.0105 -0.3213 -0.0722 -0.2599 -0.1006 -0.1645 -0.0009 -0.2172 -0.1400
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping ; tidal respiration ; administration ; gadolinium-chelate contrast agent
H-1058	-0.5074313282966614	▁tid al ▁respira tion ▁; ▁ gado lini um - che late ▁contrast ▁agent
D-1058	-0.5074313282966614	tidal respiration ; gadolinium-chelate contrast agent
P-1058	-4.4995 -0.0259 -0.1824 -0.0272 -0.2328 -0.5592 -0.0566 -0.2795 -0.1348 -0.0279 -0.0423 -1.0562 -0.3852 -0.1884 -0.2233 -0.1977
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
H-1777	-0.19094863533973694	▁Card iac ▁insulin - re si stance ▁; ▁mito cho ndri al ▁energy ▁production ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁pressure - over load ▁hyper trop hy
D-1777	-0.19094863533973694	Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
P-1777	-0.3246 -0.0266 -0.6968 -0.0234 -0.1021 -0.4009 -0.0013 -0.0339 -0.0500 -0.4023 -0.0423 -0.0355 -0.1452 -0.2187 -0.0902 -0.6020 -0.0517 -0.7886 -0.3319 -0.2557 -0.2527 -0.1980 -0.0299 -0.1622 -0.0641 -0.0118 -0.0005 -0.0726 -0.1462 -0.1670
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare ; inpatient ; hf ; admissions ; acute ; hospitals ; united states
H-1723	-0.4208436608314514	▁Medica re ▁in patient ▁; ▁ HF ▁ad missions ▁; ▁a cute ▁care ▁hospital s ▁; ▁United ▁States
D-1723	-0.4208436608314514	Medicare inpatient ; HF admissions ; acute care hospitals ; United States
P-1723	-0.0333 -0.0044 -0.0187 -0.0198 -0.7865 -1.4772 -0.0703 -0.3949 -0.0092 -0.6208 -0.0150 -0.0287 -2.0948 -0.3547 -0.0418 -1.4151 -0.4117 -0.3265 -0.1929 -0.1008
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes ; catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction
H-941	-0.21749016642570496	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-941	-0.21749016642570496	catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection fraction
P-941	-0.1908 -0.0189 -0.0639 -0.0170 -0.3554 -0.0678 -0.3142 -0.5561 -0.0305 -0.0123 -0.1331 -0.3732 -0.2334 -0.2872 -0.7968 -0.0127 -0.2877 -0.0770 -0.5578 -0.2277 -0.1029 -0.0004 -0.2596 -0.2433
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; rose ; acute heart failure ; randomized
H-71	-0.27222174406051636	▁dop amine ▁; ▁nesi riti de ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁RO se ▁a cute ▁heart ▁failure
D-71	-0.27222174406051636	dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; ROse acute heart failure
P-71	-1.0839 -0.1238 -0.0594 -0.5340 -0.0126 -0.0241 -0.3131 -0.0711 -0.0116 -0.4761 -0.2135 -0.2634 -0.1353 -0.0833 -0.3061 -0.2997 -0.4492 -0.4927 -0.1152 -0.0359 -0.6011 -0.2033 -0.4505 -0.1745
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report ; dapc ; dystrophin-associated protein complex ; sarcomeric microstructure ; baseline
H-1253	-0.2552943825721741	▁DAP c ▁; dys trop hin - as soci ated ▁protein ▁complex ▁; ▁sar come ric ▁micro structure
D-1253	-0.2552943825721741	DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
P-1253	-0.1568 -1.0161 -0.2079 -0.1948 -0.0050 -0.4480 -0.0208 -0.0307 -0.0002 -0.3078 -0.1230 -0.0424 -0.5395 -0.0217 -0.5055 -0.9371 -0.2258 -0.1523 -0.0703 -0.1002
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf ; hhd ; salt loading ; uninephrectomy ; ang ii infusion
H-275	-0.3049744963645935	▁mouse ▁ HF ▁; ▁h h ▁; ▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion
D-275	-0.3049744963645935	mouse HF ; hh ; salt loading ; uninephrectomy ; ANG II infusion
P-275	-0.2403 -0.7019 -0.0327 -0.3654 -0.0871 -1.0134 -0.1218 -1.3712 -0.0762 -0.0431 -0.1744 -0.0789 -0.0451 -1.2731 -0.1283 -0.0362 -0.4495 -0.1426 -0.0792 -0.5491 -0.0075 -0.0373 -0.1643 -0.1007
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf with preserved ejection fraction ; pef ; uptitration ; hospitalization
H-176	-0.4717319905757904	▁Bene fit s ▁; ▁ HF ▁; ▁e je ction ▁ fraction ▁; ▁p EF ▁; ▁up tit ration
D-176	-0.4717319905757904	Benefits ; HF ; ejection fraction ; pEF ; uptitration
P-176	-1.9226 -0.0241 -0.0188 -0.1177 -1.2832 -0.0786 -0.0889 -1.1068 -0.7834 -0.2287 -0.1112 -0.0015 -0.1730 -0.5763 -0.2697 -1.0867 -0.4343 -0.1507 -0.0160 -1.2561 -0.1783
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial ; titin hypophosphorylation ; heart failure with preserved ejection fraction ; metabolic
H-759	-0.26635128259658813	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁rat ▁metabol ic ▁risk
D-759	-0.26635128259658813	Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk
P-759	-0.4762 -0.0595 -0.0445 -0.2560 -0.3994 -0.0688 -0.1136 -0.0250 -0.2146 -0.7024 -0.0118 -0.1303 -0.1223 -0.2094 -0.1819 -0.9429 -0.0978 -0.0272 -0.0769 -0.0008 -0.2407 -0.0360 -0.3532 -0.0442 -0.3135 -1.7958 -0.2468
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic ; cardiac resynchronization therapy ; crt
H-427	-0.37248703837394714	▁e cho car dio graphic ▁predict ors ▁; ▁response ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-427	-0.37248703837394714	echocardiographic predictors ; response ; cardiac resynchronization therapy ; cRT
P-427	-0.0531 -0.1545 -0.0611 -0.5303 -0.0971 -1.1511 -0.2115 -0.2134 -0.9018 -1.0088 -0.0326 -0.0167 -0.0490 -0.0079 -0.9966 -0.3341 -0.0288 -0.2022 -0.4420 -1.4167 -0.1677 -0.1177
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients ; baseline ; serum creatinine ; serum potassium
H-441	-0.5298138856887817	▁base line ▁se rum ▁creati nine ▁; ▁se rum ▁po tas s ium
D-441	-0.5298138856887817	baseline serum creatinine ; serum potassium
P-441	-2.7104 -0.0879 -0.3319 -0.2831 -0.2445 -0.1943 -0.3099 -2.0540 -0.1267 -0.0361 -0.3278 -0.3583 -0.1126 -0.6095 -0.1603
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin subproteomes ; heart failure ; proteins ; chromatin structure
H-91	-0.5258910059928894	▁chr omat in ▁sub prote om es ▁; ▁heart ▁failure ▁; ▁chr omat in ▁structure
D-91	-0.5258910059928894	chromatin subproteomes ; heart failure ; chromatin structure
P-91	-1.3985 -0.0103 -0.8548 -0.2164 -0.0391 -0.4521 -0.1490 -0.2435 -0.1840 -0.2954 -0.3873 -2.8110 -0.0421 -1.1308 -0.4698 -0.1210 -0.1349
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac mrna ; inflammatory ; cell adhesion genes ; retn
H-934	-0.4422233998775482	▁Hum - ▁re t n ▁mi ce ▁; ▁cardiac ▁m RNA ▁; ▁infla mma tory ▁; ▁cell ▁a dhe sion ▁; ▁Ret n ▁; ▁mi ce
D-934	-0.4422233998775482	Hum- retn mice ; cardiac mRNA ; inflammatory ; cell adhesion ; Retn ; mice
P-934	-0.2424 -0.1395 -1.5131 -0.0698 -0.0210 -1.1127 -0.1019 -0.1291 -0.5293 -0.0082 -0.0129 -0.3280 -1.6430 -0.1638 -0.1627 -0.9233 -0.0996 -0.0638 -0.0015 -0.0124 -2.1030 -0.0372 -0.0159 -1.2681 -1.2738 -0.0981 -0.1522 -0.1560
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia ; patients ; chronic heart failure ; hf ; prevalence ; outcomes
H-834	-0.5745832920074463	▁an emia ▁; ▁chronic ▁heart ▁failure ▁; HF
D-834	-0.5745832920074463	anemia ; chronic heart failure ;HF
P-834	-1.0949 -0.0317 -0.3228 -1.4772 -1.0272 -0.3045 -0.2126 -0.0613 -1.0664 -0.1473
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university of connecticut heart failure center ; heart failure ; nurse practitioner
H-728	-0.17777694761753082	▁University ▁of ▁Connect i cut ▁Heart ▁Fail ure ▁Center ▁; ▁cardio logist ▁; ▁heart ▁failure ▁nurse ▁prac ti tioner
D-728	-0.17777694761753082	University of Connecticut Heart Failure Center ; cardiologist ; heart failure nurse practitioner
P-728	-0.4321 -0.0419 -0.2680 -0.0598 -0.2120 -0.2657 -0.0427 -0.0308 -0.2945 -0.1717 -0.0160 -0.0299 -0.1115 -0.1045 -0.1416 -0.4460 -0.2794 -0.0418 -0.4097 -0.2040 -0.1296
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp ; antibodies ; nonterminal epitopes
H-1519	-0.3906767666339874	▁NT - pro b NP ▁; ▁anti bo dies ▁; ▁non gly cos yla ted
D-1519	-0.3906767666339874	NT-probNP ; antibodies ; nonglycosylated
P-1519	-0.6560 -0.0216 -0.0061 -0.8816 -0.1142 -0.5102 -0.0084 -0.1246 -0.5992 -0.6102 -0.2075 -0.1469 -0.0232 -0.1619 -1.4336 -0.9731 -0.1631
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv failure ; diagnostic ; left ventricular dysfunction
H-1093	-0.4944172203540802	▁ RV ▁failure ▁; ▁intr in sic ▁left ▁vent ri cular ▁dys function
D-1093	-0.4944172203540802	RV failure ; intrinsic left ventricular dysfunction
P-1093	-0.4025 -0.5298 -0.7217 -0.2242 -2.5802 -0.1143 -0.0419 -0.2632 -0.0196 -1.7856 -0.1458 -0.0127 -0.2599 -0.1275 -0.1874
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd ; diuretic ; peripheral edema ; functional class
H-899	-0.5484381914138794	▁PD ▁; ▁di ure tic ▁response ▁; ▁ed ema ▁; ▁functional ▁class
D-899	-0.5484381914138794	PD ; diuretic response ; edema ; functional class
P-899	-0.9345 -0.6021 -1.7249 -0.0309 -1.0072 -0.5684 -0.3128 -0.7086 -0.0200 -1.2079 -0.0448 -0.3263 -0.0784 -0.1114
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic heart failure ; yield ; atrial ; cells
H-1334	-0.3875928521156311	▁Chro nic ▁heart ▁failure ▁; ▁transform ing ▁growth ▁factor ▁beta - dependent ▁yi eld ▁; ▁functional ▁decline ▁; ▁at rial ▁ex plant - der i ved ▁c - K it
D-1334	-0.3875928521156311	Chronic heart failure ; transforming growth factor beta-dependent yield ; functional decline ; atrial explant-derived c-Kit
P-1334	-0.1253 -0.1188 -0.7232 -0.1706 -0.0962 -0.0727 -0.0489 -0.5950 -0.5138 -1.6200 -0.0037 -0.0554 -1.9015 -0.0021 -0.0752 -2.9396 -0.4005 -0.1695 -0.1392 -0.1241 -0.8190 -0.0181 -0.0287 -0.1384 -0.1360 -0.0766 -0.1369 -0.0815 -0.3312 -0.0126 -0.6164 -0.1120
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients ; hfpef ; kccq ; health ; prognostic
H-791	-0.6277410387992859	▁ HF p EF ▁; ▁k cc q
D-791	-0.6277410387992859	HFpEF ; kccq
P-791	-1.6579 -0.1094 -0.0429 -0.3032 -0.0594 -0.4763 -0.0330 -0.7348 -2.7422 -0.1184
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients ; heartmate ii ; lvad ; centrimag ; rvad
H-298	-0.5722508430480957	▁Heart Mate ▁II ▁l VAD ▁; ▁temporar y ▁Centri Mag ▁R VAD
D-298	-0.5722508430480957	HeartMate II lVAD ; temporary CentriMag RVAD
P-298	-0.8129 -0.0972 -0.9130 -0.9907 -0.0208 -0.1812 -2.1564 -0.0957 -0.0597 -0.2890 -2.0748 -0.0098 -0.1734 -0.1369
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods study ; exercise ; patients ; heart failure
H-615	-1.3475643396377563	▁implant ation ▁; ▁heart ▁failure
D-615	-1.3475643396377563	implantation ; heart failure
P-615	-3.2122 -1.7979 -0.5038 -3.4189 -0.2341 -0.1282 -0.1379
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf ; mi ; reduced ejection fraction ; ef
H-1100	-0.47114086151123047	▁h ▁; ▁MI ▁; ▁pres er ved ▁; ▁reduce d ▁e je ction ▁ fraction ▁; EF
D-1100	-0.47114086151123047	h ; MI ; preserved ; reduced ejection fraction ;EF
P-1100	-0.8720 -0.4966 -2.2798 -0.1511 -0.8448 -0.0061 -0.2396 -0.4517 -1.4529 -0.0658 -0.0670 -0.4524 -0.1557 -0.1525 -0.0032 -0.6090 -0.1675 -0.2440 -0.2401
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality ; inpatient ; admissions ; hospital ; emergency department
H-1623	-0.2581442594528198	▁Mor t ality ▁; ▁in patient ▁ad missions ▁; ▁hospital ▁days ▁; ▁emergency ▁department ▁; ED
D-1623	-0.2581442594528198	Mortality ; inpatient admissions ; hospital days ; emergency department ;ED
P-1623	-0.3814 -0.0264 -0.1350 -0.3922 -0.5255 -0.0367 -0.2062 -0.0094 -0.2825 -0.1270 -0.2715 -0.1306 -0.0740 -0.0476 -0.6843 -0.7665 -0.4175 -0.1323
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard ; tnf antagonist ; baseline ; covariates
H-606	-0.42388880252838135	▁n b DM ARD ▁; ▁t NF ▁anta gon ist
D-606	-0.42388880252838135	nbDMARD ; tNF antagonist
P-606	-0.1708 -0.0307 -1.7319 -0.4924 -0.0900 -1.0318 -0.3575 -0.1376 -0.0705 -0.5455 -0.2756 -0.1523
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab ; adjuvant ; outcomes ; cardiotoxicity ; congestive heart failure ; chf
H-670	-0.13879433274269104	▁tras tuz um ab ▁; ▁cardio toxic ity ▁; ▁con ges tive ▁heart ▁failure ▁; CH f
D-670	-0.13879433274269104	trastuzumab ; cardiotoxicity ; congestive heart failure ;CHf
P-670	-0.0990 -0.0088 -0.0128 -0.1454 -0.0692 -0.1497 -0.1251 -0.2493 -0.0985 -0.0443 -0.0192 -0.1478 -0.3178 -0.1297 -0.3760 -0.3476 -0.1092 -0.0913 -0.0965
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine ; administration ; methylatropine ; propranolol ; cardiac ; sympathovagal balance
H-1138	-0.2518309950828552	▁py rido stig mine ▁administration ▁; ▁met hy la tropi ne ▁; ▁propra no lol ▁; ▁cardiac ▁sympa t hova gal ▁balance
D-1138	-0.2518309950828552	pyridostigmine administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
P-1138	-0.1565 -0.0132 -0.0011 -0.0352 -0.5194 -0.1072 -0.0934 -0.0475 -0.5888 -0.0194 -0.7932 -0.1805 -0.0128 -0.0045 -0.0530 -0.7598 -0.0748 -1.6207 -0.2861 -0.1252 -0.1843 -0.0845 -0.1583 -0.1247
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr ; protein kinase r-like er kinase ; perk ; calreticulin ; chop ; hf
H-1084	-0.38532277941703796	▁u PR ▁; ▁protein ▁kina se ▁; ▁ER ▁kina se ▁; per k ▁; ▁cal ret icul in ▁; ▁CHO p ▁; ▁ HF
D-1084	-0.38532277941703796	uPR ; protein kinase ; ER kinase ;perk ; calreticulin ; CHOp ; HF
P-1084	-0.2412 -0.0665 -0.5809 -0.3983 -0.1015 -0.0289 -0.4498 -1.2663 -0.3102 -0.0108 -0.1519 -1.3937 -0.9405 -0.0728 -0.0105 -0.1816 -0.0016 -0.7752 -0.2409 -0.0171 -0.2281 -0.3509 -0.9360 -0.2239 -0.9326 -0.1068
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin ; protein-c ; phosphorylation ; troponin i ; phosphorylation ; hf
H-1427	-0.5479453802108765	▁my os in ▁ binding ▁protein - C ▁ phos phor y lation ▁; ▁Ser 23 /24 ▁trop onin ▁I ▁ phos phor y lation ▁; ▁ HF
D-1427	-0.5479453802108765	myosin binding protein-C phosphorylation ; Ser23/24 troponin I phosphorylation ; HF
P-1427	-1.7122 -0.6448 -1.5563 -0.1392 -0.0912 -0.5663 -0.0638 -0.9560 -0.4385 -0.0469 -0.4508 -1.4149 -0.0273 -0.1875 -1.5556 -0.4879 -0.0359 -0.0344 -0.1089 -2.2849 -0.1885 -0.0373 -0.4560 -1.3928 -0.0382 -0.5883 -0.5744 -0.0392 -0.1164 -0.2038
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory
H-1324	-0.43526074290275574	▁e cho car dio graphic ▁; ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s
D-1324	-0.43526074290275574	echocardiographic ; N-terminal pro-brain natriuretic peptide ; inflammatory markers
P-1324	-1.0832 -1.5690 -0.3644 -0.3204 -0.1268 -0.9621 -3.7711 -0.0081 -0.0059 -0.0036 -0.1340 -0.0234 -0.1029 -0.2496 -0.0229 -0.0174 -0.0124 -1.7835 -0.2660 -0.1010 -0.0540 -0.5193 -0.0137 -0.2290 -0.4084 -0.1141 -0.0405 -0.0893 -0.2265
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
H-1207	-0.3393200933933258	▁Pho s pho dies tera se -2 ▁; ▁fail ing ▁heart s ▁; ▁blu nts ▁beta - ad r energi c ▁response s ▁; ▁cardio my o cy tes
D-1207	-0.3393200933933258	Phosphodiesterase-2 ; failing hearts ; blunts beta-adrenergic responses ; cardiomyocytes
P-1207	-0.2170 -0.0514 -0.1671 -0.5633 -0.0453 -0.2055 -0.2641 -0.4376 -4.1278 -0.2646 -0.4193 -0.0413 -0.1695 -0.1581 -0.0104 -0.5599 -0.0041 -0.0771 -0.1508 -0.1627 -0.0780 -0.3105 -0.0267 -0.5641 -0.0177 -0.2442 -0.2874 -0.1243 -0.2436 -0.2301 -0.2955
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol ; thromboembolic events ; patients ; heart failure ; β2-receptor haplotype
H-1120	-0.35457319021224976	▁car vedi lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure ▁; ▁β 2- recept or ▁ha plo type
D-1120	-0.35457319021224976	carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype
P-1120	-0.3649 -0.0545 -0.3170 -0.4467 -0.2639 -0.0923 -0.6725 -0.5708 -0.0194 -0.8658 -0.7141 -0.1613 -0.4999 -0.3692 -0.6090 -0.1384 -0.1715 -0.0128 -0.0553 -0.3267 -0.0491 -0.1019 -1.4827 -0.1500
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref ; exercise ; resting hr ; bpm ; beta-blocker ; therapy
H-1946	-0.4587844908237457	▁h Fr EF ▁; ▁exercise ▁performance ▁; ▁rest ing ▁HR ▁; ▁beta - block er ▁ therapy
D-1946	-0.4587844908237457	hFrEF ; exercise performance ; resting HR ; beta-blocker therapy
P-1946	-0.1104 -1.7393 -0.8758 -0.1144 -2.0415 -0.6653 -0.0999 -1.5407 -0.0446 -0.1643 -0.1793 -0.6728 -0.0138 -0.0565 -0.0156 -0.0710 -0.0114 -0.1732 -0.1270
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline ; follow-up ; paf ; activity ; metabolic ; enzymes ; patients ; heart failure ; healthy
H-1266	-0.3342313766479492	▁PA f ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure
D-1266	-0.3342313766479492	PAf ; metabolic enzymes ; heart failure
P-1266	-1.1207 -0.1451 -0.1391 -0.2288 -0.1042 -0.1101 -0.0415 -0.2798 -0.6481 -0.2660 -0.7573 -0.1701
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo inhibition ; cardiomyocyte bioenergetics ; lv function ; chronic acf
H-472	-0.3194120228290558	XO ▁inhibi tion ▁; ▁cardio my o cy te ▁bio ener ge tics ▁; ▁LV ▁; ▁chronic ▁a CF ▁; ▁rat
D-472	-0.3194120228290558	XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic aCF ; rat
P-472	-1.8469 -0.4624 -0.0427 -0.0367 -0.0094 -0.1318 -0.2412 -0.1094 -0.2267 -0.0133 -0.0832 -0.3963 -0.5973 -0.0724 -0.0346 -0.1449 -0.8640 -0.7816 -0.4338 -0.5900 -0.0042 -0.1329 -0.0905
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled trials ; rcts ; observational cohort studies ; contemporaneous control group
H-152	-0.4116598069667816	▁random ised - control led ▁trial s ▁; rc s
D-152	-0.4116598069667816	randomised-controlled trials ;rcs
P-152	-1.2979 -0.7930 -0.0182 -0.1375 -0.3236 -0.3936 -0.0255 -0.3437 -0.7361 -0.1904 -0.5510 -0.1294
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox hazard models ; esrd ; death ; composite end point ; esrd ; death ; esrd
H-391	-0.8016225695610046	▁co x ▁hazard ▁models ▁; ▁temps ▁; ▁ES RD ▁; ▁death ▁; ▁ES RD ▁; ▁death ▁; ▁ES RD
D-391	-0.8016225695610046	cox hazard models ; temps ; ESRD ; death ; ESRD ; death ; ESRD
P-391	-1.7106 -0.0015 -0.4374 -0.2761 -0.1218 -1.5236 -0.1810 -0.3415 -0.4403 -0.1419 -3.7655 -0.2057 -1.1298 -0.4372 -0.3498 -3.5674 -0.6902 -0.6484 -0.4647 -0.2156 -0.1839
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative ; renal dysfunction ; stroke ; myocardial infarction ; heart failure ; cabg
H-970	-0.31637808680534363	▁renal ▁dys function ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁CA BG
D-970	-0.31637808680534363	renal dysfunction ; stroke ; myocardial infarction ; heart failure ; CABG
P-970	-1.3119 -0.0121 -0.1288 -0.0583 -0.7919 -0.0887 -0.7439 -0.3001 -0.0827 -0.3257 -0.0164 -0.7169 -0.1745 -0.1194 -0.2074 -0.1088 -0.4059 -0.7897 -0.0892 -0.0655 -0.1062
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients ; heart failure ; hf ; cardiopulmonary exercise test ; anaerobic threshold
H-1753	-0.4326317310333252	▁heart ▁failure ▁; HF ▁; ▁cardio pul mon ary ▁exercise ▁; ▁ana ero bic ▁thre s hold
D-1753	-0.4326317310333252	heart failure ;HF ; cardiopulmonary exercise ; anaerobic threshold
P-1753	-0.9381 -0.3919 -0.1213 -0.0352 -0.1268 -0.1785 -0.0271 -1.0843 -0.3441 -1.2055 -0.7362 -0.0359 -0.0683 -0.6040 -0.3737 -0.0323 -0.4010 -1.3620 -0.1537
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients ; heart failure ; heart failure ; nurses ; follow-up ; cardiology ; mortality
H-1896	-0.5644723176956177	▁Patient s ▁; ▁heart ▁failure ▁; ▁heart ▁failure ▁nurse s ▁; ▁card i ology ▁services
D-1896	-0.5644723176956177	Patients ; heart failure ; heart failure nurses ; cardiology services
P-1896	-2.3063 -0.1024 -0.9744 -0.2270 -0.2018 -0.3498 -1.4010 -0.1618 -0.4806 -0.0273 -0.1990 -0.9507 -0.4321 -0.6978 -0.0812 -0.8379 -0.1648
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
H-1144	-0.47211018204689026	▁h f ▁; ▁py rido stig mine ▁; ▁stroke ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁output ▁; ▁contract ility ▁; ▁left ▁vent ric le
D-1144	-0.47211018204689026	hf ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility ; left ventricle
P-1144	-0.8624 -1.5265 -0.2857 -1.5943 -0.0095 -0.0008 -0.0799 -0.0660 -1.4758 -0.6443 -0.1913 -0.1977 -0.0453 -0.0533 -0.0003 -0.1079 -0.0357 -0.1677 -0.1134 -0.7450 -0.3728 -0.3238 -0.6802 -0.0269 -1.4180 -1.8997 -0.1759 -0.1192
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac deaths ; atherosclerotic cad
H-1907	-0.5546756386756897	▁recrea tional ▁ath letes ▁; ▁sud den ▁cardiac ▁death s ▁; ▁a ther os cle ro tic ▁CAD
D-1907	-0.5546756386756897	recreational athletes ; sudden cardiac deaths ; atherosclerotic CAD
P-1907	-5.5030 -0.3389 -2.1506 -0.0342 -0.2890 -0.0883 -0.0294 -0.0151 -0.5023 -0.0484 -0.3774 -0.3159 -0.0104 -0.6374 -0.0670 -0.0617 -0.3128 -0.0218 -0.1167 -0.1734
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery ; rheumatic ; surgery ; mva
H-359	-0.7480979561805725	▁rhe u matic ▁; ▁MS
D-359	-0.7480979561805725	rheumatic ; MS
P-359	-3.2380 -0.0199 -0.0173 -0.1192 -0.9070 -0.8206 -0.1147
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health ; followed up ; hf ; hospitalization ; death ; contact
H-687	-0.7157772183418274	▁Women s ▁Health ▁Initiative ▁; ▁ HF
D-687	-0.7157772183418274	Womens Health Initiative ; HF
P-687	-1.5410 -1.7623 -0.7139 -0.2359 -0.5500 -0.6072 -0.0511 -0.8160 -0.1646
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted ; left ventricle end-diastolic pressure
H-1340	-0.5385941863059998	▁CHF ▁; ▁in far cted ▁animals ▁; ▁left ▁vent ric le ▁end - dia sto lic ▁pressure ▁; ▁h g
D-1340	-0.5385941863059998	CHF ; infarcted animals ; left ventricle end-diastolic pressure ; hg
P-1340	-0.0040 -1.2975 -0.1167 -0.1279 -0.8016 -0.7840 -0.2374 -0.5143 -0.0235 -1.0745 -1.3036 -0.8400 -0.0342 -0.1269 -0.5810 -0.8492 -1.2098 -0.6599 -0.0329 -0.0117 -1.1092 -0.1092
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv ; pathophysiologic ; rv dysfunction
H-1094	-0.38404786586761475	▁ RV ▁; ▁pat ho phy si ologic ▁mechanism s ▁; ▁ RV ▁dys function
D-1094	-0.38404786586761475	RV ; pathophysiologic mechanisms ; RV dysfunction
P-1094	-0.4493 -0.4899 -0.6005 -1.3967 -0.0565 -0.4015 -0.4797 -0.1099 -0.7404 -0.0233 -0.8354 -0.2090 -0.1283 -0.0384 -0.3018 -0.0935 -0.1748
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients ; hf ; crt ; implantation ; complications
H-912	-0.3700123727321625	▁di al ysis - dependent ▁patients ▁; ▁ HF ▁; ▁implant ation
D-912	-0.3700123727321625	dialysis-dependent patients ; HF ; implantation
P-912	-0.1398 -0.0292 -0.0544 -0.0318 -0.0510 -0.9809 -0.1449 -1.1465 -0.0208 -0.1034 -1.9970 -0.0313 -0.3621 -0.0871
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak oxygen consumption ; pulse ; patients
H-1918	-0.5522811412811279	▁Peak ▁oxygen ▁; ▁oxygen ▁puls e
D-1918	-0.5522811412811279	Peak oxygen ; oxygen pulse
P-1918	-0.6226 -0.5259 -1.9121 -0.7465 -0.1614 -0.1180 -0.2185 -0.1132
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic ; nhs ; chronic ; disease ; exercise ; acute ; hospital
H-613	-0.581892728805542	▁économique ▁climate ▁; ▁NH s ▁; ▁behaviour al - change ▁; ▁chronic ▁disease
D-613	-0.581892728805542	économique climate ; NHs ; behavioural-change ; chronic disease
P-613	-0.4872 -1.7079 -0.1229 -0.4155 -1.0060 -0.2338 -1.0857 -0.0349 -0.0244 -0.0064 -0.5736 -0.1549 -0.2555 -2.4541 -0.1655
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf ; patients ; hct ; city of hope
H-1452	-0.7212952971458435	▁h CT ▁CHF ▁; ▁h CT ▁; ▁City ▁of ▁Hope
D-1452	-0.7212952971458435	hCT CHF ; hCT ; City of Hope
P-1452	-0.3518 -1.2200 -1.1635 -0.3216 -1.7380 -0.9268 -0.2464 -1.8281 -0.2006 -0.3192 -0.2517 -0.0877
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.45211851596832275	
D-557	-0.45211851596832275	
P-557	-0.7976 -0.1067
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior vena cava ; ivc
H-321	-0.6516631245613098	▁pig s ▁; ▁inferior ▁ve na ▁ca va ▁; IV c ▁; ▁CO
D-321	-0.6516631245613098	pigs ; inferior vena cava ;IVc ; CO
P-321	-3.3131 -0.0225 -0.1366 -0.2163 -0.6500 -0.1344 -0.0084 -0.0351 -0.1926 -0.5059 -0.5288 -0.2169 -3.2222 -0.5030 -0.0892
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin ; resistin
H-932	-0.3255108594894409	▁do xor ubi cin ▁; ▁i p ▁; ▁se rum ▁resist in ▁; ▁Hum - re t n ▁mi ce
D-932	-0.3255108594894409	doxorubicin ; ip ; serum resistin ; Hum-retn mice
P-932	-0.0066 -0.0249 -0.0460 -0.1134 -0.0765 -0.2289 -0.0078 -0.2763 -0.4762 -0.1683 -0.1959 -0.6058 -0.5825 -0.0955 -0.0847 -2.6524 -0.1259 -0.0317 -0.6475 -0.1870 -0.3172 -0.2103
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs ; physicians ; hospital
H-1729	-0.6469670534133911	▁costs ▁; ▁high - volu me ▁physician s ▁; ▁hospital
D-1729	-0.6469670534133911	costs ; high-volume physicians ; hospital
P-1729	-1.4759 -0.1806 -0.7329 -0.0310 -0.0152 -0.0319 -0.7422 -0.0610 -0.4903 -0.8819 -3.0095 -0.1113
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf ; proteins
H-1361	-1.0861085653305054	▁nutrition al ▁ab normal ities ▁; ▁CHF
D-1361	-1.0861085653305054	nutritional abnormalities ; CHF
P-1361	-3.7561 -0.0401 -0.0111 -0.0111 -0.3100 -0.2180 -0.0759 -5.2636 -0.0890
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.23308102786540985	▁de activa tion
D-1864	-0.23308102786540985	deactivation
P-1864	-0.6413 -0.0116 -0.0388 -0.3782 -0.0954
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone receptor antagonists ; randomized ; morbidity ; mortality ; symptomatic systolic heart failure
H-438	-0.39989757537841797	▁al do ster one ▁receptor ▁anta gon ists ▁; ▁morbi d ity ▁; ▁mortal ity ▁; ▁sy sto lic ▁heart ▁failure
D-438	-0.39989757537841797	aldosterone receptor antagonists ; morbidity ; mortality ; systolic heart failure
P-438	-0.4171 -0.0547 -0.0786 -1.1374 -0.0148 -0.1481 -0.1352 -0.8598 -0.3548 -0.9465 -0.0727 -0.4139 -0.3119 -0.0330 -0.1045 -0.1886 -1.4060 -0.1143 -1.5304 -0.4456 -0.1956 -0.1282 -0.1061
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a ; upr ; downregulation ; cardiac ; genes ; hf
H-1089	-0.5093163847923279	▁s CN 5 a ▁tran script ▁; ▁u PR ▁; ▁down regul ation ▁; ▁cardiac ▁gene s ▁; ▁ HF
D-1089	-0.5093163847923279	sCN5a transcript ; uPR ; downregulation ; cardiac genes ; HF
P-1089	-1.5454 -0.6484 -0.0763 -0.3535 -0.7246 -0.0153 -0.0671 -0.0454 -0.4908 -0.1999 -2.6832 -0.0691 -0.0083 -0.4777 -1.5080 -1.4581 -0.0208 -0.3143 -0.2381 -0.0492 -0.1025 -0.1090
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east ; rhythm control therapy ; diagnosis ; cardiovascular ; complications
H-1655	-0.3546488583087921	▁e AST ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁AF ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1655	-0.3546488583087921	eAST ; rhythm control therapy ; AF ; cardiovascular complications ; AF
P-1655	-1.7874 -0.9893 -0.1686 -0.0332 -0.1625 -0.0340 -0.0472 -0.0134 -0.1746 -1.1934 -0.2785 -0.0815 -0.0203 -0.0184 -0.8008 -0.3821 -0.0802 -0.1182
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin ; inflammation ; hepatic ; prognosis ; patients ; lvad ; implantation
H-540	-0.3222658634185791	▁album in ▁; ▁ inflammation ▁; ▁he pati c ▁function ▁; ▁implant ation
D-540	-0.3222658634185791	albumin ; inflammation ; hepatic function ; implantation
P-540	-0.3157 -0.4666 -0.4588 -0.2912 -0.2489 -0.1451 -0.1069 -0.0940 -0.1642 -1.2335 -0.4450 -0.4755 -0.0263 -0.1924 -0.1702
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right ventricular ; rv ; left ventricular assist device ; lvad ; outcomes
H-294	-0.5171974301338196	▁Right ▁vent ri cular ▁; RV ▁; ▁ insertion ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-294	-0.5171974301338196	Right ventricular ;RV ; insertion ; left ventricular assist device ; lVAD
P-294	-1.2569 -0.0246 -1.4564 -0.2408 -0.5514 -0.2837 -0.2954 -1.8406 -0.0172 -0.2554 -0.2168 -0.0202 -1.9592 -0.1963 -0.4666 -0.7576 -0.3009 -0.2888 -0.0369 -0.2947 -0.1009
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse ; pasp ; downward ; regression line ; shift ; pasp ; tapse
H-496	-1.1619070768356323	▁t AP se ▁; ▁PAS p ▁; ▁t AP se
D-496	-1.1619070768356323	tAPse ; PASp ; tAPse
P-496	-3.1697 -0.8425 -1.5529 -0.1410 -0.5034 -0.8798 -0.4344 -4.5303 -0.8443 -0.8240 -0.1293 -0.0914
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox proportional hazards models ; health ; health ; hazard ratios ; confidence intervals
H-689	-0.6008566617965698	▁co x ▁proportion al ▁hazard s ▁models ▁; ▁health ▁behavior s ▁; ▁health ▁status
D-689	-0.6008566617965698	cox proportional hazards models ; health behaviors ; health status
P-689	-1.1822 -0.0105 -0.2056 -0.0494 -0.2113 -0.1509 -1.9947 -0.2426 -1.0143 -0.7510 -0.0388 -0.2076 -0.8910 -0.8506 -1.7002 -0.1127
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis ; expenditure ; b natriuretic peptides ; nps
H-10	-0.5297749042510986	▁li poly sis ▁; ▁energy ▁ex pendi ture ▁; ▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁CC
D-10	-0.5297749042510986	lipolysis ; energy expenditure ; natriuretic peptides ;NPs ; CC
P-10	-1.1704 -0.1300 -0.9428 -0.0933 -0.7657 -0.1827 -0.0066 -0.1816 -0.2597 -4.0384 -0.1298 -0.0299 -1.9573 -0.0876 -0.1315 -0.1430 -0.2542 -0.0156 -0.0058 -0.5795 -0.8459 -0.0999 -0.1335
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths ; stroke ; hospitalisations ; heart failure ; follow-up
H-816	-0.4186755120754242	▁CV ▁death s ▁; ▁non - fa tal ▁stroke ▁; ▁heart ▁failure
D-816	-0.4186755120754242	CV deaths ; non-fatal stroke ; heart failure
P-816	-1.0278 -2.1116 -0.0388 -0.1359 -0.5191 -0.0205 -0.0254 -0.1413 -0.0697 -0.1599 -1.1514 -0.2364 -0.1007 -0.1229
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts ; mena ; cardiac injury ; mena ; hf ; pathophysiology
H-1817	-0.427334189414978	▁heart s ▁; ▁Men a ▁; ▁cardiac ▁injury ▁; ▁Men a ▁; ▁ HF ▁pat ho phy si ology
D-1817	-0.427334189414978	hearts ; Mena ; cardiac injury ; Mena ; HF pathophysiology
P-1817	-0.9077 -0.0701 -0.1251 -1.2205 -0.3429 -0.3637 -0.3770 -0.5049 -0.1300 -0.8236 -0.3233 -0.3320 -0.2099 -0.0808 -0.8781 -0.0809 -0.1900 -0.4354 -1.1761 -0.2443 -0.1575
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic ; biomarkers ; molecular dysfunction ; chronic hf
H-1477	-0.7809123396873474	▁bio mark ers ▁; ▁molecular ▁dys function
D-1477	-0.7809123396873474	biomarkers ; molecular dysfunction
P-1477	-1.5829 -0.0109 -0.0695 -0.2412 -0.0327 -0.0037 -0.1318 -4.8620 -0.0935
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 ; c statistic ; net reclassification improvement ; integrated discrimination improvement
H-705	-0.9111253023147583	▁ST 2 ▁; ▁risk ▁; ▁c ▁statistic ▁; ▁discrimina tion
D-705	-0.9111253023147583	ST2 ; risk ; c statistic ; discrimination
P-705	-2.3561 -0.0682 -0.2903 -3.2291 -0.0774 -0.5733 -1.0277 -0.1918 -2.0284 -0.0692 -0.8766 -0.1455
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome ; gls ; beat ; cox proportional hazards analyses
H-814	-0.48143115639686584	▁gr s ▁; ▁index ▁beat ▁; ▁CV ▁; ▁co x ▁proportion al ▁hazard s
D-814	-0.48143115639686584	grs ; index beat ; CV ; cox proportional hazards
P-814	-2.5242 -1.7697 -0.0978 -0.1702 -0.0434 -0.4842 -0.5647 -1.1764 -0.2749 -0.0048 -0.0782 -0.0134 -0.0355 -0.0927 -0.2459 -0.1270
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ; ischemic heart failure ; biomarkers ; heart failure
H-1615	-0.55491703748703	▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁bio mark ers ▁; ▁heart ▁failure
D-1615	-0.55491703748703	non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
P-1615	-4.6729 -0.0252 -1.0872 -0.0990 -0.6396 -0.1587 -0.3313 -0.1887 -1.0126 -0.1421 -0.4526 -0.3918 -0.0029 -0.0276 -0.3699 -0.5451 -0.1404 -0.1059 -0.1499
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients ; vad ; patients ; ecmo ; vad ; patients ; ecmo
H-1389	-0.8332297801971436	▁ VAD ▁; ▁EC mo + VAD ▁group ▁; ▁EC mo ▁group
D-1389	-0.8332297801971436	VAD ; ECmo+VAD group ; ECmo group
P-1389	-0.7117 -0.0238 -0.6757 -0.8227 -1.2147 -1.5737 -0.0406 -1.4660 -0.4366 -0.6956 -0.9709 -2.5987 -0.2568 -0.1777
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air ; cardiovascular ; health ; acute myocardial infarction
H-1806	-0.4139941334724426	▁air ▁pollution ▁; ▁cardiovascular ▁health ▁; ▁a cute ▁my o card ial ▁in far ction
D-1806	-0.4139941334724426	air pollution ; cardiovascular health ; acute myocardial infarction
P-1806	-0.7262 -0.0361 -0.1153 -0.4980 -0.5534 -0.3877 -0.5918 -0.0088 -2.1585 -0.4361 -0.1575 -0.1516 -0.0096 -0.5258 -0.4506 -0.0966 -0.1346
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq ; kaplan-meier curves ; death ; all-cause hospitalization
H-784	-0.5390709042549133	▁k cc q ▁; ▁Ka plan - Me ier ▁cur ves ▁; ▁death
D-784	-0.5390709042549133	kccq ; Kaplan-Meier curves ; death
P-784	-0.9752 -0.0318 -0.6792 -0.2320 -0.3478 -0.0650 -0.0042 -0.9774 -0.0984 -1.1691 -0.1605 -0.4727 -1.1002 -1.5534 -0.2192
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ; ras ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
H-1599	-0.23668447136878967	RAS ▁; ▁do pp ler ▁ultra son ography ▁; ▁com put ed ▁to mo graphic ▁ang i ography ▁; ▁magnetic ▁res on ance ▁ang i ography
D-1599	-0.23668447136878967	RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
P-1599	-1.0646 -0.2678 -0.4715 -0.0505 -0.5987 -0.1209 -0.1480 -0.2198 -0.0964 -0.8591 -0.0116 -0.0483 -0.1013 -0.1053 -0.2188 -0.0191 -0.3169 -0.1361 -0.3260 -0.0603 -0.1973 -0.2109 -0.0839 -0.0192 -0.3410 -0.1272 -0.2502 -0.1562
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone ; double-blind ; randomized
H-1316	-0.780195951461792	▁Test o ster one ▁ therapy ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁testosteron e
D-1316	-0.780195951461792	Testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone
P-1316	-1.1179 -0.0756 -0.0481 -0.9743 -0.6013 -0.0324 -0.6360 -4.1519 -0.1033 -0.0402 -0.2657 -3.8157 -0.5308 -0.9009 -0.7169 -0.3264 -0.2684 -0.3630 -0.0363 -1.2507 -0.1284
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic ; renal underperfusion ; renin- angiotensin-aldosterone pathway
H-1596	-0.5973987579345703	▁renal ▁under per fusion ▁; ▁re nin - ▁ang io ten sin - al do ster one
D-1596	-0.5973987579345703	renal underperfusion ; renin- angiotensin-aldosterone
P-1596	-2.3513 -2.3610 -0.2794 -0.1380 -0.1374 -0.0175 -0.2402 -0.0091 -0.0307 -0.7362 -0.0590 -0.6091 -0.0583 -0.0244 -0.3867 -0.0540 -0.7961 -2.7959 -0.2662
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ; ami ; complications ; heart failure ; kidney infection ; uti ; complications ; rehospitalization
H-1718	-0.3154769837856293	AMI ▁; ▁heart ▁failure ▁; ▁ki dne y ▁infection ▁; ▁ UTI
D-1718	-0.3154769837856293	AMI ; heart failure ; kidney infection ; UTI
P-1718	-1.2313 -0.3300 -0.5052 -0.1198 -0.1222 -0.4964 -0.0597 -0.0507 -0.4723 -0.0899 -0.5244 -0.0122 -0.2424 -0.1601
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
H-869	-0.22123587131500244	▁prote o mics ▁; ▁pressure - over load - indu ced ▁heart ▁failure ▁; ▁mito cho ndri al - tar get ed ▁pe pti des
D-869	-0.22123587131500244	proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
P-869	-1.7792 -0.7520 -0.0045 -0.0769 -0.3118 -0.0258 -0.0471 -0.0644 -0.0903 -0.0687 -0.7527 -0.3836 -0.1730 -0.2136 -0.0290 -0.4538 -0.0887 -0.0248 -0.0150 -0.0157 -0.0605 -0.0237 -0.0819 -0.0311 -0.0921 -0.1406 -0.1729
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil ; cardioprotection ; apoptotic signaling pathway ; dna fragmentation ; mitochondrial
H-965	-0.16542093455791473	▁nic oran dil ▁; ▁cardio protec tion ▁; ▁apo pto tic ▁signal ing ▁path way ▁; ▁DNA ▁fragment ation ▁; ▁mito cho ndri al ▁ultra struct ural ▁changes
D-965	-0.16542093455791473	nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
P-965	-0.1674 -0.0119 -0.1606 -0.2237 -0.1692 -0.1895 -0.0343 -0.2325 -0.0869 -0.0107 -0.3457 -0.0123 -0.3065 -0.2674 -0.1329 -0.2616 -0.0392 -0.1575 -0.0153 -0.2337 -0.0093 -0.5866 -0.0321 -0.0210 -0.5561 -0.1358 -0.0143 -0.3048 -0.1301 -0.1137
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ; ic ; multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy
H-103	-0.26588717103004456	▁IC ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁implant ation ▁; ▁Tri al - Card iac ▁re syn chron ization ▁Therapy
D-103	-0.26588717103004456	IC ; multicenter Automatic Defibrillator implantation ; Trial-Cardiac resynchronization Therapy
P-103	-1.2113 -0.1796 -0.0877 -0.0144 -0.4598 -0.0277 -0.6896 -0.3414 -0.0882 -0.0545 -0.1550 -0.0182 -0.9044 -0.6936 -0.0145 -0.0115 -0.1227 -0.1564 -0.7788 -0.0041 -0.0009 -0.2858 -0.0877 -0.1349 -0.1246
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted county ; minnesota ; mi ; diagnosed ; hf ; followed-up
H-1102	-0.2814400792121887	▁Ol m sted ▁County ▁; ▁Minnesota ▁; ▁MI ▁; ▁ HF
D-1102	-0.2814400792121887	Olmsted County ; Minnesota ; MI ; HF
P-1102	-0.2879 -0.0065 -0.1372 -0.0551 -0.5231 -0.0353 -0.1520 -0.6079 -0.6578 -0.9114 -0.0526 -0.1412 -0.0907
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health buddy program ; admissions ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
H-1627	-0.2607840299606323	▁Health ▁Budd y ▁Program ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁mortal ity ▁; ▁con ges tive ▁heart ▁failure
D-1627	-0.2607840299606323	Health Buddy Program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
P-1627	-0.9438 -0.0090 -0.0202 -1.0771 -0.2635 -0.5897 -0.2978 -0.0834 -0.0189 -0.0053 -0.0759 -0.7776 -0.1399 -0.4284 -0.1659 -0.1117 -0.1145 -0.0126 -0.0634 -0.3726 -0.1437 -0.1717 -0.1115
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected ; clinical ; death ; medical ; hospitalization ; hf ; clinic ; outpatients
H-379	-1.2999292612075806	▁ HF
D-379	-1.2999292612075806	HF
P-379	-4.1991 -0.1715 -0.5886 -0.2405
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence ; adjusted odds ratio ; hazard ratio ; death ; hf ; ami ; admission ; discharge
H-1308	-0.7331123948097229	▁odds ▁ratio ▁; haz ard ▁ratio ▁; ▁death ▁; ▁ HF ▁; AMI
D-1308	-0.7331123948097229	odds ratio ;hazard ratio ; death ; HF ;AMI
P-1308	-1.8338 -0.4309 -2.1888 -0.0078 -0.0113 -0.0060 -0.4518 -1.2683 -0.1512 -2.2058 -0.0498 -0.1013 -1.7253 -0.3922 -0.1724
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration ; neurohumoral blockers ; hf ; hospitalization ; patients ; co-morbidity
H-184	-0.30817726254463196	▁neuro hu moral ▁block ers ▁; ▁ HF ▁; ▁co - mor bid ity ▁burde n
D-184	-0.30817726254463196	neurohumoral blockers ; HF ; co-morbidity burden
P-184	-0.2531 -0.0592 -0.4096 -0.6428 -0.1420 -0.1683 -0.8365 -0.0098 -1.4952 -0.7772 -0.0262 -0.0797 -0.1495 -0.0788 -0.0746 -0.0566 -0.1459 -0.1422
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left ventricular ejection fraction ; mortality ; patients ; heart failure ; heart failure survey ; israel
H-110	-0.5604662299156189	▁vent ri cular ▁e je ction ▁ fraction ▁; ▁long - term ▁mortal ity ▁; ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁Survey ▁; ▁IS ra el
D-110	-0.5604662299156189	ventricular ejection fraction ; long-term mortality ; heart failure ; Heart Failure Survey ; ISrael
P-110	-3.6677 -1.8787 -0.3365 -0.3158 -0.1907 -0.1656 -0.5010 -0.0012 -0.2359 -2.1511 -0.0396 -0.6596 -0.0291 -0.1042 -0.1570 -0.4790 -0.3679 -0.2817 -1.9963 -0.1390 -0.0547 -0.2631 -0.8469 -0.2866 -0.0049 -0.0033 -0.3052 -0.2307
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular endothelial growth factor ; vegf ; transition ; compensatory hypertrophy ; cardiac failure
H-450	-0.38847750425338745	▁vas cular ▁en dot heli al ▁growth ▁factor ▁; VE GF ▁; ▁transition ▁; ▁compensa tory ▁hyper trop hy ▁; ▁cardiac ▁failure
D-450	-0.38847750425338745	vascular endothelial growth factor ;VEGF ; transition ; compensatory hypertrophy ; cardiac failure
P-450	-2.4862 -0.1668 -0.0267 -1.1430 -0.0483 -0.0189 -0.3797 -0.7253 -0.2400 -0.7517 -0.3152 -0.5807 -0.1184 -0.8689 -0.0148 -0.1036 -0.0068 -0.0023 -0.0994 -0.8547 -0.0054 -0.1969 -0.0884 -0.0812
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective ; patients ; rule ; sensitivity ; specificity ; cad ; sensitivity ; cad
H-1192	-0.9640438556671143	▁ sensitiv ity ▁; ▁CAD ▁; ▁severe ▁CAD
D-1192	-0.9640438556671143	sensitivity ; CAD ; severe CAD
P-1192	-4.2567 -1.4450 -0.0823 -0.1238 -0.1417 -0.5947 -2.5197 -0.2862 -0.0979 -0.0924
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia ; postoperative ; mortality ; patients ; left ventricular assist device ; lvad ; implantation
H-530	-0.3762873411178589	▁hypo album in emia ▁; ▁post operativ e ▁mortal ity ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-530	-0.3762873411178589	hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
P-530	-0.0282 -0.0676 -0.3042 -0.1027 -0.1350 -1.3949 -0.0579 -0.1401 -0.0102 -0.0916 -0.1659 -0.5202 -0.0170 -2.4002 -0.1056 -0.4373 -0.6016 -0.3506 -0.4383 -0.0205 -0.7250 -0.1638
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis ; pathogenesis ; heart failure
H-173	-0.6748204827308655	▁apo pto sis ▁; ▁heart ▁failure
D-173	-0.6748204827308655	apoptosis ; heart failure
P-173	-2.1085 -0.1169 -1.0131 -0.1701 -1.0997 -0.2151 -0.5526 -0.1225
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients ; terminal ; diagnostic ; follow-up
H-1819	-0.7641632556915283	
D-1819	-0.7641632556915283	
P-1819	-1.4258 -0.1025
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic ; neurohormonal ; symptoms ; fluid overload
H-1201	-0.4061519503593445	▁di ure tic ▁ef fica cy ▁; ▁neuro hormon al ▁activa tion ▁; ▁fluid
D-1201	-0.4061519503593445	diuretic efficacy ; neurohormonal activation ; fluid
P-1201	-0.1618 -0.0254 -1.4129 -0.0678 -0.0026 -0.3022 -0.1861 -0.1223 -0.0381 -0.0418 -0.9297 -0.0457 -0.5004 -0.9930 -1.5692 -0.0994
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr ; mrna splice ; cardiac ; hf
H-1088	-0.7433733344078064	▁u PR ▁; ▁na + ▁channel ▁m RNA ▁sp lice ▁; ▁cardiac ▁; ▁na + ▁current ▁; ▁h z
D-1088	-0.7433733344078064	uPR ; na+ channel mRNA splice ; cardiac ; na+ current ; hz
P-1088	-0.0803 -0.8191 -0.1543 -0.4885 -3.0189 -0.1634 -0.0139 -0.2017 -0.0087 -0.0052 -0.3737 -1.2873 -1.3799 -1.1974 -2.7109 -1.1529 -0.2304 -0.8213 -1.0610 -0.3279 -0.1142
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients ; preserved lvef ; lvef
H-114	-0.24572408199310303	▁LV EF ▁; ▁LV EF
D-114	-0.24572408199310303	LVEF ; LVEF
P-114	-0.1539 -0.1508 -0.5989 -0.4412 -0.0967 -0.1887 -0.0899
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence ; lvad ; transplantation ; patients ; budget
H-316	-0.5009710788726807	▁l VAD ▁; ▁transplant ation ▁e ligi bility ▁status
D-316	-0.5009710788726807	lVAD ; transplantation eligibility status
P-316	-0.9557 -0.1223 -1.2586 -0.4751 -0.0285 -0.3073 -0.0057 -0.1702 -0.3430 -1.7587 -0.0855
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets ; transcriptional pause release ; pathological
H-1052	-0.46819132566452026	BET s ▁; ▁tran scription al ▁pause ▁release ▁; ▁re - activa tion ▁tran scription ▁; ▁path ological ▁stress
D-1052	-0.46819132566452026	BETs ; transcriptional pause release ; re-activation transcription ; pathological stress
P-1052	-0.7988 -0.8436 -0.4160 -0.5899 -0.0570 -0.0905 -0.3297 -0.2430 -0.1620 -1.6543 -0.0736 -0.0111 -2.0241 -0.2476 -0.0287 -1.0821 -0.4549 -0.1949 -0.2552 -0.1446 -0.1306
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg ; atherosclerotic cad ; cardiac death
H-1910	-0.27721288800239563	▁e CG ▁; ▁a ther os cle ro tic ▁CAD ▁; ▁sud den ▁cardiac ▁death
D-1910	-0.27721288800239563	eCG ; atherosclerotic CAD ; sudden cardiac death
P-1910	-0.9708 -0.2408 -0.1548 -0.6060 -0.0121 -0.6179 -0.0841 -0.0616 -0.3596 -0.0433 -0.8278 -0.0421 -0.0484 -0.0042 -0.3003 -0.1640 -0.1748
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ; ami ; hazard ratio ; mortality
H-1313	-0.8088516592979431	▁ HF ▁; ▁index ▁ AMI ▁; ▁hazard ▁ratio ▁; ▁mortal ity
D-1313	-0.8088516592979431	HF ; index AMI ; hazard ratio ; mortality
P-1313	-2.4495 -0.2135 -0.1043 -0.1460 -0.6713 -0.0304 -0.3801 -2.8137 -0.0322 -0.6503 -2.0398 -0.4362 -1.1855 -0.1713
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d ; therapy
H-107	-0.37302958965301514	▁c RT - d ▁; ▁IE ▁; ▁de fi br illa tor - on ly ▁ therapy
D-107	-0.37302958965301514	cRT-d ; IE ; defibrillator-only therapy
P-107	-0.3487 -1.8196 -0.0461 -0.6913 -0.1244 -0.2500 -0.9787 -0.4628 -0.6605 -0.2783 -0.0157 -0.0466 -0.0390 -0.1744 -0.3785 -0.0996 -0.0606 -0.4468 -0.1660
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr variability ; risk stratification
H-1587	-0.4738054871559143	▁HR ▁dynamic s ▁; ▁temps - doma in ▁; ▁HR ▁variabil ity ▁; ▁risk ▁strat ification
D-1587	-0.4738054871559143	HR dynamics ; temps-domain ; HR variability ; risk stratification
P-1587	-0.2606 -0.5349 -0.0323 -0.2024 -1.8726 -0.0169 -0.0041 -0.1294 -0.1376 -2.0225 -0.3246 -0.4242 -0.6938 -0.4253 -0.9791 -0.0794 -0.1764 -0.2125
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary exercise testing ; echocardiographic ; myocardial function ; left ventricular filling ; exercise
H-1174	-0.4986667335033417	▁Card io pul mon ary ▁exercise ▁; ▁e cho car dio graphic ▁assessment ▁; ▁my o card ial ▁; ▁vent ri cular ▁fill ing
D-1174	-0.4986667335033417	Cardiopulmonary exercise ; echocardiographic assessment ; myocardial ; ventricular filling
P-1174	-0.2142 -1.2821 -0.0184 -1.1433 -0.2831 -1.3677 -0.1753 -0.1451 -0.0327 -0.0167 -0.0646 -0.1513 -1.6064 -0.2747 -0.2036 -0.1194 -0.0797 -0.3460 -3.5826 -0.4189 -0.8312 -0.0495 -0.1671 -0.0477 -0.2290 -0.1151
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle tracking echocardiography ; ste ; bivp ; acute ; right ventricular pressure overload ; rvpo
H-320	-0.41267129778862	▁spec kle ▁track ing ▁e cho card i ography ▁; ▁ste ▁; ▁bi VP ▁; ▁vent ri cular ▁pressure ▁over load ▁; RV PO
D-320	-0.41267129778862	speckle tracking echocardiography ; ste ; biVP ; ventricular pressure overload ;RVPO
P-320	-1.3359 -0.4110 -0.0512 -0.0711 -0.0218 -0.1328 -0.0287 -0.2580 -0.1047 -0.1572 -0.2277 -0.2746 -0.6818 -0.2895 -0.2152 -2.1854 -0.7866 -0.1148 -0.2226 -1.5207 -0.0294 -0.3207 -0.1968 -0.8048 -0.1437 -0.1428
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary endpoints ; therapy ; atrial fibrillation ; atrial tachyarrhythmias ; atp ; shock therapy
H-860	-0.33272475004196167	▁at rial ▁fi bril lation ▁; ▁at rial ▁ta chy ar rhythm ias ▁; ▁ATP ▁; ▁shock ▁ therapy
D-860	-0.33272475004196167	atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
P-860	-2.3864 -0.0398 -0.2113 -0.0076 -0.0182 -0.1697 -0.0715 -0.0591 -1.5863 -0.2320 -0.2742 -0.0688 -0.5961 -0.4015 -0.0090 -0.3905 -0.0091 -0.1232 -0.0094 -0.1723 -0.1513
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous ; coronary revascularization ; hemodynamically ; stable ; patient ; intensive care unit ; icu
H-1293	-0.6599825620651245	▁corona ry ▁re vas cular ization ▁; ▁hem o dynamic ally
D-1293	-0.6599825620651245	coronary revascularization ; hemodynamically
P-1293	-2.9274 -0.1568 -0.0182 -0.0915 -0.2733 -0.5180 -0.5073 -0.2808 -0.0572 -0.0142 -0.4569 -3.1833 -0.0950
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity ; diabetes mellitus ; metabolic ; comorbidities ; heart failure with preserved ejection fraction
H-760	-0.45619988441467285	▁obes ity ▁; ▁diabetes ▁mell itus ▁; ▁metabol ic ▁risk ▁factors ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-760	-0.45619988441467285	obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; preserved ejection fraction
P-760	-2.2283 -1.1245 -0.0765 -0.0624 -0.0148 -0.0915 -0.2297 -0.3079 -0.0436 -0.6970 -0.7962 -0.0996 -2.2343 -0.3513 -0.4147 -1.4882 -0.0116 -0.2063 -0.0698 -0.2445 -0.1188 -0.0887 -0.0009 -0.1848 -0.2190
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef ; bnp ; hf ; patients ; prognostic ; significance ; bnp ; ef
H-188	-0.6427172422409058	▁sex ▁; ▁EF ▁; ▁b NP ▁; ▁ HF ▁; ▁b NP ▁; ▁sex ▁; ▁EF
D-188	-0.6427172422409058	sex ; EF ; bNP ; HF ; bNP ; sex ; EF
P-188	-2.9865 -0.0972 -0.1919 -0.0777 -0.0868 -0.3970 -0.1134 -2.0831 -0.0911 -0.3666 -0.2568 -0.5442 -0.2015 -2.2909 -0.3533 -1.0341 -0.2424 -0.1545
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk ; scn5a ; kv4.3 ; mrna ; mrna splice
H-1087	-0.632585883140564	▁per k ▁inhibi tion ▁; ▁s CN 5 a ▁; ▁kv 4.3 ▁m RNA ▁; ▁m RNA ▁; ▁na + ▁channel ▁m RNA ▁sp lice
D-1087	-0.632585883140564	perk inhibition ; sCN5a ; kv4.3 mRNA ; mRNA ; na+ channel mRNA splice
P-1087	-1.9171 -1.1714 -0.5660 -0.0253 -0.1013 -1.9526 -0.7951 -0.3004 -0.3594 -0.1004 -0.3803 -0.6349 -0.0065 -0.0533 -0.5634 -1.6998 -0.2443 -0.8560 -0.5517 -3.1834 -0.0865 -0.0075 -0.1237 -0.0268 -0.0097 -1.2505 -0.1125
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential effect ; lvef ; mortality ; hospitalization ; acute ; decompensated hf
H-112	-0.21026867628097534	▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁a cute ▁de com pensa ted ▁ HF
D-112	-0.21026867628097534	LVEF ; long-term mortality ; acute decompensated HF
P-112	-0.2364 -0.3901 -0.2858 -0.1575 -0.0234 -0.4275 -0.0283 -0.1737 -0.2504 -0.3622 -0.0187 -0.0187 -0.1388 -0.0036 -0.9387 -0.1547 -0.0354 -0.1864 -0.1648
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated ; mena expression ; correlates ; hf ; mena ; cardiac ; pathophysiology
H-1812	-0.577637255191803	▁Men a ▁expression ▁; ▁ HF ▁; ▁men a ▁; ▁cardiac ▁pat ho phy si ology
D-1812	-0.577637255191803	Mena expression ; HF ; mena ; cardiac pathophysiology
P-1812	-0.9500 -0.2457 -0.0774 -0.0505 -0.6680 -0.0475 -0.0827 -3.7025 -0.4769 -0.4451 -0.0954 -1.2912 -0.1716 -0.2287 -0.7630 -0.7695 -0.1512 -0.1806
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt loading ; uninephrectomy ; ang ii infusion ; cardiac function ; hf
H-282	-0.443413108587265	▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion ▁mouse ▁; ▁cardiac ▁function ▁; ▁mi ce ▁; ▁ HF
D-282	-0.443413108587265	salt loading ; uninephrectomy ; ANG II infusion mouse ; cardiac function ; mice ; HF
P-282	-0.2272 -0.1038 -0.0443 -0.1197 -0.0472 -0.0276 -0.6130 -0.0726 -0.0295 -0.6840 -0.0728 -0.4000 -0.6960 -0.0243 -0.0701 -1.1491 -1.1483 -0.0734 -2.6838 -0.4984 -1.2329 -0.0344 -0.5585 -1.1890 -0.0264 -0.0705 -0.0754
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination ; echocardiographic ; lv reverse remodeling ; sensitivity ; specificity
H-433	-0.17343778908252716	▁e cho car dio graphic ▁score ▁; ▁LV ▁rever se ▁remodel ing
D-433	-0.17343778908252716	echocardiographic score ; LV reverse remodeling
P-433	-0.1410 -0.1326 -0.0612 -0.2091 -0.1307 -0.3209 -0.1143 -0.0181 -0.3343 -0.0160 -0.0194 -0.1434 -0.6015 -0.1856
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients ; atrial fibrillation ; heart failure ; hf ; stroke ; anticoagulation ; patients
H-1353	-0.3306777775287628	▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; HF ▁; ▁stroke ▁; ▁antico ag ulation
D-1353	-0.3306777775287628	atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
P-1353	-1.0516 -0.1184 -0.4397 -0.0147 -0.0237 -0.2745 -0.0981 -0.0995 -0.0819 -0.2069 -0.1314 -0.1378 -0.3288 -0.5240 -0.7406 -1.2758 -0.6014 -0.0250 -0.3361 -0.1035
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration ; hr reduction ; bpm ; p value
H-1942	-0.6208246946334839	▁HR ▁re duction
D-1942	-0.6208246946334839	HR reduction
P-1942	-2.0236 -0.2718 -0.0185 -0.6019 -0.1883
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck stent ; myocardial infarction ; antiplatelet medication
H-508	-0.23672787845134735	▁bottle ne ck ▁sten t ▁; ▁my o card ial ▁in far ction ▁; ▁anti plate let ▁medication
D-508	-0.23672787845134735	bottleneck stent ; myocardial infarction ; antiplatelet medication
P-508	-0.4417 -0.0141 -0.1943 -0.0440 -0.0497 -0.0872 -1.8630 -0.2447 -0.1449 -0.1623 -0.0107 -0.5265 -0.0429 -0.2923 -0.0043 -0.0400 -0.0538 -0.2129 -0.1613 -0.1441
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv fractional shortening ; lung ; incidence
H-278	-0.8185916543006897	▁ ANS ▁; ▁LV ▁; ▁ fraction al ▁short en ing ▁; ▁lung ▁weight
D-278	-0.8185916543006897	ANS ; LV ; fractional shortening ; lung weight
P-278	-3.4640 -1.1336 -1.3575 -2.5993 -0.9261 -1.6464 -0.0022 -0.0611 -0.3267 -0.1085 -0.1969 -0.1589 -0.1586 -0.6492 -0.1917 -0.1168
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan failure ; circulatory ; hemodynamic ; portal hypertension ; cardiac output
H-234	-0.19813162088394165	▁Font an ▁failure ▁; ▁circula tory ▁de rang ement ▁; ▁hem o dynamic ▁; ▁portal ▁hyper tension ▁; ▁cardiac ▁output
D-234	-0.19813162088394165	Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
P-234	-0.1481 -0.1874 -0.0761 -0.1232 -0.3099 -0.1667 -0.0330 -0.0375 -0.0329 -0.1956 -0.1877 -0.0983 -0.0078 -1.2227 -0.1161 -0.0129 -0.0816 -0.3341 -0.5414 -0.2658 -0.1069 -0.0732
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab ; chf ; nontrastuzumab users ; hazard ratio
H-679	-0.5825715065002441	▁Tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab ▁; haz ard ▁ratio
D-679	-0.5825715065002441	Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio
P-679	-0.7128 -0.0095 -0.0328 -0.1015 -0.5096 -0.0305 -0.1537 -3.9046 -0.0065 -0.0055 -0.0180 -0.2154 -2.0245 -0.5645 -0.0116 -0.0191 -1.9492 -0.2171
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic heart failure ; spironolactone ; hospitalization ; death
H-446	-0.4734797179698944	▁sy sto lic ▁heart ▁failure ▁; ▁spi rono lac tone
D-446	-0.4734797179698944	systolic heart failure ; spironolactone
P-446	-2.6506 -0.1042 -1.5400 -0.3914 -0.1574 -0.1698 -0.0546 -0.0049 -0.0254 -0.0408 -0.4105 -0.1322
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction ; rad variant ; q66p ; congestive heart failure
H-1673	-0.48900553584098816	▁dys function ▁; ▁rad ▁variant ▁; Q 66 p ▁; ▁con ges tive ▁heart ▁failure
D-1673	-0.48900553584098816	dysfunction ; rad variant ;Q66p ; congestive heart failure
P-1673	-2.4931 -0.1396 -0.1431 -0.4416 -0.6975 -0.1746 -2.4240 -0.1647 -0.1915 -0.1351 -0.0571 -0.0303 -0.0624 -0.2552 -0.0771 -0.7552 -0.0709
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional enrichment analysis ; regulation ; cell death ; degs
H-1614	-0.6713571548461914	▁implant ation ▁; ▁programme d ▁cell ▁death ▁; ▁de g s
D-1614	-0.6713571548461914	implantation ; programmed cell death ; degs
P-1614	-3.7369 -0.0124 -0.7512 -0.0893 -0.0302 -0.0641 -0.1835 -1.1109 -0.5549 -1.9172 -0.0571 -0.0970 -0.1230
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes ; patients ; atrial fibrillation ; early treatment of atrial fibrillation for stroke prevention trial
H-1642	-0.4789678156375885	▁at rial ▁fi bril lation ▁; ▁implant ation ▁; ▁at rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁Tri al
D-1642	-0.4789678156375885	atrial fibrillation ; implantation ; atrial fibrillation ; Stroke prevention Trial
P-1642	-1.9531 -0.1945 -0.4660 -0.0583 -0.0363 -0.2428 -2.5230 -1.5311 -0.2144 -1.8077 -0.1914 -0.3072 -0.0458 -0.0295 -0.2207 -0.0083 -0.4211 -0.1484 -0.0053 -0.3589 -0.0331 -0.1123 -0.1071
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology ; comorbidities ; patients ; outcomes
H-564	-0.5847955942153931	
D-564	-0.5847955942153931	
P-564	-1.1078 -0.0618
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence ; intestinal ; patients ; chf
H-1358	-0.44158369302749634	▁REC ENT ▁FIN DING s ▁; ▁intestinal ▁ morph ology ▁; ▁per me ability ▁; ▁ab sor p tion ▁function ▁; ▁CHF
D-1358	-0.44158369302749634	RECENT FINDINGs ; intestinal morphology ; permeability ; absorption function ; CHF
P-1358	-0.4185 -0.4698 -0.1641 -0.5524 -0.3369 -0.5012 -3.3217 -0.0429 -0.0204 -1.2103 -0.2145 -0.1195 -0.0147 -0.1577 -0.3138 -0.0367 -0.0096 -0.1244 -0.0654 -1.6367 -0.4136 -0.2061 -0.1368 -0.1103
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients ; exercise ; anaerobic metabolism ; peak respiratory quotient
H-1756	-0.6184847354888916	▁ana ero bic ▁metabolism ▁; ▁respirator y
D-1756	-0.6184847354888916	anaerobic metabolism ; respiratory
P-1756	-3.3728 -0.2829 -0.1326 -0.1104 -0.4818 -0.6788 -0.0599 -0.3089 -0.1382
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni ; cardiovascular mortality ; hospitalization ; heart failure ; quality of life
H-1969	-0.5858625173568726	▁AR NI ▁; ▁cardiovascular ▁mortal ity ▁; ▁hospital ization ▁; ▁heart ▁failure
D-1969	-0.5858625173568726	ARNI ; cardiovascular mortality ; hospitalization ; heart failure
P-1969	-3.6705 -0.9521 -0.1920 -0.1350 -0.0377 -0.1186 -0.1242 -0.5119 -0.4969 -0.9509 -0.1106 -0.2600 -0.4756 -0.1660
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial dd ; muscle ; titin hypophosphorylation
H-768	-0.420093297958374	▁my o card ial ▁ DD ▁; ▁muscle ▁strip ▁sti ff ness ▁; ▁titi n ▁hypo phos phor y lation
D-768	-0.420093297958374	myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
P-768	-1.8480 -0.0917 -0.0477 -0.1222 -0.2105 -0.0259 -0.2042 -3.1337 -0.4877 -0.4380 -0.2465 -0.8210 -0.2265 -0.0889 -0.0350 -0.0407 -0.0220 -0.1536 -0.6742 -0.0185 -0.1564 -0.1492
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined training ; peak work rate ; peak quadriceps force
H-1917	-0.8482911586761475	▁quadri cep s ▁force
D-1917	-0.8482911586761475	quadriceps force
P-1917	-4.4271 -0.0058 -0.0329 -0.0786 -0.3532 -0.1921
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins ; expression ; cardiac hypertrophy ; proteins ; nucleolin
H-95	-0.5753674507141113	▁cardiac ▁hyper trop hy ▁; ▁nu cle olin
D-95	-0.5753674507141113	cardiac hypertrophy ; nucleolin
P-95	-1.5882 -0.0220 -0.0053 -0.0862 -0.3042 -3.1039 -0.0075 -0.2870 -0.1873 -0.1622
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based ; prognosis ; idiopathic dilated cardiomyopathy
H-1750	-0.2674592435359955	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1750	-0.2674592435359955	idiopathic dilated cardiomyopathy
P-1750	-1.1647 -0.3925 -0.0484 -0.1399 -0.1982 -0.2671 -0.0899 -0.4443 -0.2095 -0.0249 -0.1264 -0.1038
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients ; physicians ; readmission ; hospital
H-1728	-1.057717204093933	▁high - volu me ▁physician s ▁; ▁read mission
D-1728	-1.057717204093933	high-volume physicians ; readmission
P-1728	-4.5572 -0.0336 -0.0107 -0.0279 -0.7170 -0.0614 -0.4635 -2.3603 -0.2328 -3.0347 -0.1358
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc ; nps ; clinical
H-1024	-0.7741660475730896	▁ NP ▁; ▁PO c ▁; ▁ NP s
D-1024	-0.7741660475730896	NP ; POc ; NPs
P-1024	-1.1295 -0.0168 -0.6566 -1.4025 -2.2115 -0.2770 -1.1148 -0.0107 -0.1273 -1.4410 -0.1281
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized ; follow-up
H-1751	-0.7275605797767639	▁benefits ▁; ▁control led ▁random ized ▁trial s
D-1751	-0.7275605797767639	benefits ; controlled randomized trials
P-1751	-0.7138 -0.4505 -2.5977 -0.1769 -0.1587 -0.8001 -0.6064 -0.0201 -1.6426 -0.1090
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas city cardiomyopathy questionnaire ; kccq ; hf with reduced ef ; patients ; hfpef
H-781	-0.32410481572151184	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁k cc q ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-781	-0.32410481572151184	Kansas City Cardiomyopathy Questionnaire ; kccq ; HF ; EF ; HFpEF
P-781	-0.0067 -0.1797 -1.0314 -0.1914 -0.0891 -1.1517 -0.0425 -0.5302 -0.0018 -0.1030 -0.4724 -0.0300 -0.6045 -0.0448 -0.3735 -0.0923 -0.0431 -1.0392 -0.1111 -1.3793 -0.1441 -0.0169 -0.1684 -0.1542 -0.1010
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; right ventricular contractile function ; prognosis
H-491	-0.4970228970050812	▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; ▁heart ▁failure ▁; ▁vent ri cular ▁contract ile
D-491	-0.4970228970050812	annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; ventricular contractile
P-491	-3.2971 -0.0132 -0.1791 -0.7318 -0.2585 -0.8929 -0.3503 -0.0157 -0.0853 -0.0037 -0.0296 -0.0774 -0.4557 -0.0597 -0.2903 -1.4453 -0.1779 -0.2956 -0.4736 -0.3345 -0.7903 -1.1834 -0.1014 -0.0522 -0.5406 -1.1103 -0.1741
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients ; biventricular support ; heartmate ii ; lvad ; centrimag ; right ventricular assist device ; rvad
H-296	-0.47683262825012207	▁bi ven tri cular ▁support ▁; ▁Heart Mate ▁; ▁l VAD ▁; ▁Centri Mag ▁right ▁vent ri cular ▁assist ▁device ▁; ▁rad VAD
D-296	-0.47683262825012207	biventricular support ; HeartMate ; lVAD ; CentriMag right ventricular assist device ; radVAD
P-296	-0.2184 -0.1616 -0.5684 -0.3168 -0.3477 -0.2093 -1.9214 -0.0899 -1.3915 -0.9494 -0.0221 -0.0742 -0.1537 -0.1186 -0.6269 -0.0058 -1.0048 -0.1121 -0.2302 -0.2014 -0.2722 -2.5629 -0.1136 -0.1315 -0.1165
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume ; echocardiography
H-521	-0.34330064058303833	▁Blood ▁pressure ▁; ▁arm ▁cu ff ▁; ▁stroke ▁volume ▁; ▁v ▁; ▁e je ction ▁ fraction ▁; ▁end - dia sto lic ▁volume ▁; ▁e cho card i ography
D-521	-0.34330064058303833	Blood pressure ; arm cuff ; stroke volume ; v ; ejection fraction ; end-diastolic volume ; echocardiography
P-521	-0.2765 -0.4119 -0.0981 -0.1676 -0.1487 -0.1296 -0.0251 -0.0752 -1.3048 -0.0974 -2.3160 -1.0718 -0.2516 -0.1382 -0.0205 -0.0206 -0.0002 -0.2543 -0.6257 -0.0212 -0.2198 -0.5584 -0.8123 -0.2824 -0.4855 -0.0512 -0.2163 -0.0904 -0.2864 -0.2460 -0.1584 -0.1237
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis ; heart failure ; myocardial tissue ; left ventricular ; trichrome blue histologic analysis
H-1060	-0.6056435108184814	▁fibro sis ▁; ▁heart ▁failure ▁; ▁my o card ial ▁tissu e ▁; ▁left ▁vent ri cular ▁tissu e ▁; ▁tri ch rom e ▁blue
D-1060	-0.6056435108184814	fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue
P-1060	-0.0148 -0.4361 -0.4044 -0.2701 -0.3273 -0.4685 -3.8796 -0.2644 -0.0988 -0.3601 -0.6837 -0.4461 -0.2051 -0.9262 -0.0194 -1.3272 -0.1910 -0.8887 -0.3005 -0.4611 -1.2871 -0.0152 -0.0130 -0.0230 -0.0198 -2.8286 -0.1926
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped ; snp ; rs10927887 ; ka renal chloride channel gene ; clcnka
H-1802	-0.607082188129425	▁Cau ca sian ▁; ▁s NP ▁rs 109 27 887 ▁; ▁Ka ▁renal ▁chlor ide ▁channel ▁gene ▁; CL CN KA
D-1802	-0.607082188129425	Caucasian ; sNP rs10927887 ; Ka renal chloride channel gene ;CLCNKA
P-1802	-4.3103 -0.0058 -0.4417 -0.1789 -1.6210 -0.0773 -1.0831 -0.0606 -0.5253 -0.1161 -0.2509 -0.8538 -0.0220 -0.1728 -0.0295 -0.0993 -0.3505 -0.3567 -1.2016 -1.1619 -0.6294 -0.2648 -0.1494
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise ; training ; outcomes ; hf ; patients ; exercise ; training ; therapy ; clinical
H-1934	-1.1653565168380737	▁ HF
D-1934	-1.1653565168380737	HF
P-1934	-2.8244 -0.0316 -1.6667 -0.1387
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile function ; lv dilatation ; lv end-diastolic pressure ; wall stress ; lung
H-476	-0.4473777711391449	▁contract ile ▁function ▁; ▁LV ▁di la tation ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight
D-476	-0.4473777711391449	contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
P-476	-0.0376 -1.0195 -1.5965 -0.1461 -0.0939 -0.4333 -0.4158 -0.0104 -0.1146 -1.4352 -0.6739 -1.4950 -0.0092 -0.1694 -0.4954 -0.6090 -0.5228 -0.2934 -0.5704 -0.4595 -0.1045 -0.0702 -0.1038 -0.1846 -0.1203
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp ; plasma ; patients ; dyspnea ; left ventricular dysfunction ; admission
H-265	-0.3914668560028076	▁NT - pro b NP ▁; ▁plasma ▁; ▁dys pne a ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ed
D-265	-0.3914668560028076	NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; ed
P-265	-0.2008 -0.0165 -0.0059 -0.7586 -0.1575 -0.5004 -0.8711 -0.2272 -0.1486 -0.0981 -0.2247 -0.2057 -0.3290 -0.0280 -2.2095 -0.2868 -0.0286 -0.4286 -0.3859 -0.9873 -0.3939 -0.1195
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological ; remodelling ; heart ; cardiac hypertrophy ; hf ; death ; fibrosis ; inflammation
H-1035	-0.35002070665359497	▁path ological ▁remodel ling ▁; ▁heart ▁; ▁cardiac ▁hyper trop hy ▁; ▁ HF ▁; ▁fibro sis ▁; ▁ inflammation
D-1035	-0.35002070665359497	pathological remodelling ; heart ; cardiac hypertrophy ; HF ; fibrosis ; inflammation
P-1035	-2.8339 -0.2347 -0.0075 -0.7437 -0.3016 -0.3029 -0.1869 -0.0882 -0.0149 -0.0021 -0.0680 -0.0722 -0.6253 -0.0322 -0.1946 -0.9521 -0.1862 -0.4384 -0.0080 -0.0514 -0.2254 -0.1300
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action ; correlation ; baseline ; hgb ; baseline ; hrqol ; kccq
H-842	-0.3766435384750366	▁ HF - AC tion ▁co hor t ▁; ▁h gb ▁; ▁base line ▁HR Qo L ▁; ▁k cc q
D-842	-0.3766435384750366	HF-ACtion cohort ; hgb ; baseline HRQoL ; kccq
P-842	-1.6944 -0.1110 -0.0110 -1.1821 -0.7185 -1.1347 -0.0267 -0.0688 -0.0807 -0.1101 -0.0531 -0.0386 -0.3101 -0.0203 -0.9989 -0.0101 -0.5792 -0.1077 -0.2352 -0.0724 -0.7102 -0.2649 -0.1243
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating progenitor cells ; cpcs ; endothelial ; prognostic ; cardiovascular diseases
H-120	-0.2810164988040924	▁Circula ting ▁pro gen itor ▁cell s ▁; ▁c PC s ▁; ▁en dot heli al ▁repair ▁; ▁cardiovascular ▁disease s
D-120	-0.2810164988040924	Circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular diseases
P-120	-0.3267 -1.9134 -0.1177 -0.2714 -0.1027 -0.0715 -0.0223 -0.1785 -0.0786 -0.2364 -0.0382 -0.2214 -0.0915 -0.5861 -0.0609 -0.0095 -0.0874 -0.2852 -0.0813 -1.4340 -0.0410 -0.1193 -0.0884
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right ventricular ; rv ; prognosis ; patients ; heart failure ; hf
H-1158	-0.7935148477554321	▁vent ri cular ▁; RV ▁; ▁patients ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1158	-0.7935148477554321	ventricular ;RV ; patients ; advanced heart failure ;HF
P-1158	-2.3980 -1.1768 -0.1151 -0.5466 -0.3204 -0.3569 -4.8645 -0.4726 -0.3640 -0.3766 -0.2258 -0.4462 -0.0314 -0.0893 -0.1184
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular assist device ; vad ; extracorporeal membrane oxygenation ; ecmo ; renal function
H-1385	-0.32903850078582764	▁vent ri cular ▁assist ▁device ▁; VAD ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁e mo ▁; ▁renal ▁function
D-1385	-0.32903850078582764	ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; emo ; renal function
P-1385	-0.0020 -0.6692 -0.1107 -0.2416 -0.4550 -0.1490 -0.0084 -0.0865 -0.0372 -0.0115 -0.7482 -0.0609 -0.0014 -0.2161 -0.0829 -0.0415 -0.2113 -0.7998 -0.7539 -0.4251 -0.0139 -2.1866 -0.4687 -0.1153
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american college of cardiology ; american heart association ; patients ; ras ; patients ; ras
H-1604	-0.5169801712036133	▁American ▁College ▁of ▁Card i ology ▁; American ▁Heart ▁Association ▁; ▁ RAS
D-1604	-0.5169801712036133	American College of Cardiology ;American Heart Association ; RAS
P-1604	-2.1590 -0.0914 -0.1526 -0.2495 -0.3658 -0.3158 -0.1547 -0.4471 -0.2754 -0.9783 -0.6513 -1.3770 -0.0349 -0.3875 -0.1145
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-375	-0.2665988802909851	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV
D-375	-0.2665988802909851	functional MS ; valve plasty ; degenerative MR ; LV
P-375	-0.8634 -0.0539 -0.1606 -0.9986 -0.0140 -0.0291 -0.2135 -0.3273 -0.0348 -0.1580 -0.0137 -0.0333 -0.2214 -0.0329 -1.0439 -0.0670
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus ; cells ; functional capacity ; mortality ; nondiabetic ; patients
H-131	-1.0484576225280762	▁ EO - c FU s ▁; ▁CD 34 ▁; ve g FR 2 ▁; ▁cell s ▁; ▁mortal ity
D-131	-1.0484576225280762	EO-cFUs ; CD34 ;vegFR2 ; cells ; mortality
P-131	-2.8495 -0.0580 -0.0392 -1.9904 -0.7327 -0.1243 -0.0509 -0.9869 -0.1171 -1.6063 -2.5689 -1.0270 -1.9979 -0.2350 -1.1323 -2.0105 -0.0594 -0.6019 -3.2040 -0.4450 -1.0816 -0.1473
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable cardioverter-defibrillator ; physicians ; heart failure ; patients
H-1857	-0.4824019968509674	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁heart ▁failure
D-1857	-0.4824019968509674	implantable cardioverter-defibrillator deactivation ; heart failure
P-1857	-0.0007 -0.0360 -0.4502 -0.0952 -0.0529 -0.0149 -0.0568 -2.5297 -1.2319 -0.0065 -0.0934 -0.0364 -0.0421 -0.1735 -0.6807 -2.1705 -0.2123 -1.0906 -0.1912
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional ms ; patients ; valve plasty ; degenerative mr ; dilated ; disease
H-340	-0.18682131171226501	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁ann ular ▁size ▁re duction ▁; ▁de genera tive ▁MR ▁; ▁LV
D-340	-0.18682131171226501	functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
P-340	-0.4421 -0.0387 -0.1861 -1.0236 -0.0215 -0.0215 -0.1669 -0.1000 -0.0470 -0.0027 -0.4541 -0.0099 -0.0013 -0.2362 -0.0529 -0.1919 -0.0127 -0.0365 -0.1327 -0.0338 -0.8346 -0.0633
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty ; prognostic ; heart failure ; hf ; biological phenotype
H-1001	-0.5818108320236206	▁Fra il ty ▁; ▁heart ▁failure ▁; HF ▁; ▁bi ological ▁ph eno type
D-1001	-0.5818108320236206	Frailty ; heart failure ;HF ; biological phenotype
P-1001	-2.4882 -0.4112 -1.3734 -0.1099 -1.6506 -0.2156 -0.1310 -0.3056 -0.5158 -0.0345 -0.1673 -0.7874 -0.1331 -0.0106 -0.8564 -0.1183
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv remodeling ; diastolic ; xo inhibition ; symptoms ; hospitalizations ; patients ; severe heart failure
H-478	-0.34541383385658264	▁LV ▁remodel ing ▁; ▁dia sto lic ▁properties ▁; ▁ XO ▁inhibi tion
D-478	-0.34541383385658264	LV remodeling ; diastolic properties ; XO inhibition
P-478	-0.0262 -0.2032 -0.0512 -0.2608 -0.0873 -0.3377 -0.3251 -0.0783 -0.3215 -0.4710 -0.0188 -0.2514 -0.0366 -2.5617 -0.1504
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt ; atrial pacing
H-1442	-0.5456318259239197	▁SD QT ▁; ▁ HF VT ▁; ▁ HF VT ▁; ▁h n m ▁group ▁; ▁fixed - rate ▁at rial ▁pa cing
D-1442	-0.5456318259239197	SDQT ; HFVT ; HFVT ; hnm group ; fixed-rate atrial pacing
P-1442	-0.0255 -0.3786 -0.0781 -0.8596 -0.1531 -0.2953 -0.1313 -0.8958 -0.2056 -0.4762 -0.1365 -0.1381 -4.0107 -0.2209 -1.8519 -0.5433 -0.3623 -0.0322 -0.1053 -0.3554 -0.3627 -0.1492 -1.2771 -0.4129 -0.1830
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ; ef
H-192	-1.3018708229064941	
D-192	-1.3018708229064941	
P-192	-2.4569 -0.1468
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping ; myocardial ; heart failure
H-1063	-0.4459114074707031	▁diffuse ▁my o card ial ▁changes ▁; ▁heart ▁failure ▁; ▁contrast ▁agent ▁; ▁breath - hold ing
D-1063	-0.4459114074707031	diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
P-1063	-3.9313 -0.7131 -0.2186 -0.1309 -0.1510 -0.8043 -0.1235 -0.1665 -0.4405 -0.2372 -0.3452 -0.0563 -0.6354 -0.0290 -0.0267 -0.0263 -0.0566 -0.2010 -0.1788
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical ; bnp ; inhospital ; mortality
H-196	-0.2408168911933899	▁b NP ▁; ▁in hospital ▁mortal ity
D-196	-0.2408168911933899	bNP ; inhospital mortality
P-196	-0.0874 -0.7998 -0.4808 -0.1141 -0.0197 -0.1749 -0.1399 -0.2498 -0.1009
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies ; crt-d ; heart failure ; death
H-108	-0.6982788443565369	▁temps - dependent ▁analysis ▁; ▁IE s ▁; ▁c RT - d ▁; ▁heart ▁failure
D-108	-0.6982788443565369	temps-dependent analysis ; IEs ; cRT-d ; heart failure
P-108	-2.3605 -0.1166 -0.0724 -1.4585 -0.2020 -0.6596 -0.2877 -0.1069 -0.2504 -0.8879 -0.0416 -0.7033 -0.3568 -2.5199 -0.4783 -1.2341 -0.1341
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure ; health ; income ; hf
H-1800	-0.6547483205795288	▁ex pendi ture ▁; ▁health ▁per ▁capita ▁; ▁gross ▁national ▁income ▁; ▁ HF ▁; ▁LA
D-1800	-0.6547483205795288	expenditure ; health per capita ; gross national income ; HF ; LA
P-1800	-1.6907 -0.0101 -0.0838 -0.3483 -0.9070 -2.2065 -0.0058 -0.0775 -1.5018 -0.7463 -0.0712 -0.5752 -1.3847 -0.1602 -0.9294 -0.7266 -0.2611 -0.0994
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt ; dt ; btt ; patients
H-314	-0.507723331451416	▁b t ▁; ▁ DT ▁; ▁coût - effect ive ness ▁; ▁b t
D-314	-0.507723331451416	bt ; DT ; coût-effectiveness ; bt
P-314	-0.1084 -0.5647 -0.0639 -0.6229 -0.1068 -0.2450 -1.7788 -0.0968 -0.1425 -0.1235 -1.0033 -0.5549 -0.1986 -0.4668 -1.9295 -0.1172
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals ; patients ; hfpef
H-952	-0.36078885197639465	▁af ▁; ▁ pharma ce u tical s ▁; ▁h f f
D-952	-0.36078885197639465	af ; pharmaceuticals ; hff
P-952	-0.7440 -0.3502 -1.1756 -0.0166 -0.0859 -0.0791 -0.6805 -0.0307 -0.3142 -0.1370 -0.5771 -0.4299 -0.2832 -0.1471
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood pressure ; therapy ; patients ; ras
H-1600	-0.20777103304862976	▁blood ▁pressure ▁control ▁; ▁lipid - lo wering ▁ therapy ▁; ▁smoking ▁ces s ation ▁; ▁ RAS
D-1600	-0.20777103304862976	blood pressure control ; lipid-lowering therapy ; smoking cessation ; RAS
P-1600	-0.6674 -0.5074 -0.3530 -0.0678 -0.1312 -0.0261 -0.1701 -0.0189 -0.2063 -0.0416 -0.1661 -0.0202 -0.1036 -0.0229 -0.0368 -0.5453 -0.8391 -0.0140 -0.0699 -0.1476
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-1.1896721124649048	▁coût - effect ive ness
D-2014	-1.1896721124649048	coût-effectiveness
P-2014	-5.4360 -0.7221 -0.1340 -0.0310 -0.8997 -0.9743 -0.1306
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac magnetic resonance ; amyloidotic ; diagnosis ; multiple myeloma ; osteomedullary biopsy
H-999	-0.21537260711193085	▁cardiac ▁magnetic ▁res on ance ▁; ▁a my lo ido tic ▁pattern ▁; ▁multiple ▁mye loma ▁; ▁osteo me dulla ry ▁bio psy
D-999	-0.21537260711193085	cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
P-999	-0.0132 -0.0192 -0.0517 -0.1002 -0.0173 -0.1489 -0.0130 -0.1240 -0.2250 -0.0944 -2.1245 -0.3676 -0.2605 -0.4305 -0.0758 -0.1309 -0.7234 -0.0106 -0.0240 -0.0363 -0.1141 -0.0026 -0.0132 -0.1775 -0.0859
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable cardioverter-defibrillators ; icds ; mortality ; cardiac resynchronization therapy ; crt ; symptoms ; mortality
H-1068	-0.4003308415412903	▁implant able ▁cardio ver ter - de fi br illa tors ▁; IC d s ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-1068	-0.4003308415412903	implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ; cRT
P-1068	-0.0076 -0.0415 -1.1605 -0.0780 -0.2049 -0.0228 -0.1155 -1.9727 -1.0379 -0.0161 -1.4644 -0.1995 -0.2066 -0.1917 -0.0675 -0.2603 -0.1913 -0.0187 -0.0255 -0.0069 -0.8646 -0.4107 -0.0329 -0.2218 -0.4704 -1.3037 -0.4693 -0.1459
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular endothelial growth factor blockade ; beta-blocker ; therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
H-448	-0.43686094880104065	▁Vas cular ▁en dot heli al ▁growth ▁factor ▁block ade ▁; ▁beta - block er ▁ therapy ▁; ▁cardiac ▁function ▁; ▁ang io gene sis ▁; ▁remodel ing ▁in ▁heart ▁failure
D-448	-0.43686094880104065	Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling in heart failure
P-448	-0.0961 -0.0505 -0.0485 -0.6535 -0.0696 -0.0211 -0.4637 -0.9437 -2.3501 -0.6157 -0.1099 -0.3906 -0.0054 -0.0563 -0.0522 -0.1461 -0.0205 -0.2367 -0.0258 -2.7475 -0.4006 -0.0182 -1.1790 -0.1458 -1.1149 -0.3327 -0.3023 -0.0275 -1.1038 -0.1249 -0.2358 -0.1986 -0.1289
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure with preserved ejection fraction
H-915	-0.35966750979423523	▁DAS h ▁; ▁dia sto lic ▁function ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-915	-0.35966750979423523	DASh ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
P-915	-2.6833 -0.7632 -0.4717 -0.2264 -0.1235 -0.6231 -2.0688 -0.0635 -0.0019 -0.5175 -0.0363 -0.0232 -0.0120 -0.0764 -0.0080 -0.8394 -0.2180 -0.0120 -0.0856 -0.1072 -0.2694 -0.1330 -0.3393 -0.4756 -0.1881 -0.0739 -0.0455 -0.0002 -0.1680 -0.1362
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis ; hfpef ; clinical ; echo-doppler cardiography ; invasive haemodynamic assessment
H-1303	-0.3051641881465912	▁ HF p EF ▁; ▁e cho - D opp ler ▁card i ography ▁; ▁invasi ve ▁ha emo dynamic ▁assessment
D-1303	-0.3051641881465912	HFpEF ; echo-Doppler cardiography ; invasive haemodynamic assessment
P-1303	-1.5766 -0.1747 -0.0264 -0.4347 -0.1750 -0.3488 -0.0473 -0.0113 -1.8199 -0.0027 -0.1262 -0.2984 -0.2757 -0.1432 -0.3080 -0.1295 -0.0822 -0.0996 -0.3411 -0.0136 -0.3224 -0.1628 -0.0988
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker ; uptitrations ; patients ; hfref ; hfpef ; hospital ; admission
H-177	-0.3797442615032196	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁h Fr EF ▁; ▁ HF p EF
D-177	-0.3797442615032196	RAS- ; β-blocker uptitrations ; hFrEF ; HFpEF
P-177	-0.9662 -0.0145 -0.1746 -2.1116 -0.2112 -0.0162 -0.0542 -0.0328 -0.2445 -0.1070 -0.1195 -0.0676 -0.2038 -0.1642 -0.9631 -1.0526 -0.1344 -0.8959 -0.2168 -0.0444 -0.3594 -0.3691 -0.2103
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients ; exercise-induced pasp ; pasp ; patients ; pasp
H-827	-0.6896756887435913	▁exercise - indu ced ▁PAS p ▁; ▁h g ▁; ▁PAS p
D-827	-0.6896756887435913	exercise-induced PASp ; hg ; PASp
P-827	-4.2784 -0.0257 -0.0082 -0.1787 -0.2169 -0.6402 -0.1672 -0.0355 -0.0122 -0.1569 -2.2821 -0.4914 -1.0729 -0.0892
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal muscle ; sarcomere ; patients ; heart failure ; type 2 diabetes
H-1243	-0.3158835172653198	▁skelet al ▁muscle ▁sar com ere ▁structure ▁; ▁heart ▁failure ▁; ▁diabetes ▁; ▁e pica tech in - rich ▁coco a
D-1243	-0.3158835172653198	skeletal muscle sarcomere structure ; heart failure ; diabetes ; epicatechin-rich cocoa
P-1243	-0.6735 -0.1622 -0.3814 -0.1410 -0.2938 -0.9749 -1.1284 -0.1847 -0.5903 -0.3955 -0.0780 -0.1291 -0.3952 -0.4532 -0.0046 -0.0336 -0.2380 -0.0569 -0.0003 -0.4955 -0.1299 -0.1852 -0.1401
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician ; outcomes ; patients ; outcomes ; medically ; diseases ; hf
H-1722	-0.4347880482673645	▁Physic ian ▁volume ▁; ▁patients ▁; ▁med ically ▁managed ▁disease s ▁; ▁ HF
D-1722	-0.4347880482673645	Physician volume ; patients ; medically managed diseases ; HF
P-1722	-0.1614 -0.2954 -0.4703 -0.3003 -2.6133 -0.4928 -0.3448 -0.1041 -0.0363 -0.3555 -0.0214 -0.4168 -1.1119 -0.0197 -0.1080 -0.1048
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal flow pump ; hemocompatibility ; blood-flow ; pulse
H-1994	-0.33863565325737	▁centri fu gal ▁flow ▁pump ▁; ▁hem o com pati bility ▁; ▁magnet ically ▁le vita ted ▁ro tor ▁; ▁blood - flow ▁path s ▁; ▁artificial ▁puls e
D-1994	-0.33863565325737	centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
P-1994	-0.1219 -0.0613 -0.0526 -0.7027 -0.5943 -0.2131 -0.9150 -0.0594 -0.2482 -0.0314 -0.0562 -0.1590 -0.0048 -0.1389 -0.0080 -0.0261 -0.6018 -0.0198 -0.0166 -0.2785 -2.7397 -0.0178 -0.0702 -1.8029 -0.0255 -0.3444 -0.5688 -0.1845 -0.2174 -0.1077 -0.1094
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone ; patients ; hf-ref ; hyperkalemia ; patients
H-1224	-0.40091800689697266	▁e pler en one ▁; ▁ HF - re f ▁; ▁hyper kal emia ▁; ▁w RF
D-1224	-0.40091800689697266	eplerenone ; HF-ref ; hyperkalemia ; wRF
P-1224	-0.1908 -0.1982 -0.2562 -2.1185 -0.1802 -0.8231 -0.0394 -0.0043 -0.7577 -0.2030 -0.1710 -0.1597 -0.2117 -0.2492 -0.1763 -1.1604 -0.3475 -0.2123 -0.1579
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial complex v activity ; phosphocreatine ; atp
H-1786	-0.5037972927093506	▁mito cho ndri al ▁complex ▁V ▁activity ▁; ▁a ac ▁; ▁ phos pho creati ne ▁; ▁ATP
D-1786	-0.5037972927093506	mitochondrial complex V activity ; aac ; phosphocreatine ; ATP
P-1786	-0.5935 -1.1789 -0.0807 -0.0771 -0.1121 -1.5524 -0.6484 -0.2121 -0.3490 -1.5187 -0.2186 -0.8719 -0.0253 -0.4547 -0.4404 -0.7465 -0.7214 -0.0217 -0.1285 -0.1241
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients ; sst2 ; sst2 ; odds ratios ; cardiovascular events
H-409	-0.7890483140945435	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁; ▁cardiovascular ▁events
D-409	-0.7890483140945435	sst2/low-dose BB ; sst2/high-dose ; cardiovascular events
P-409	-1.0256 -2.2166 -0.9667 -1.4030 -0.0120 -0.3106 -0.0978 -1.9349 -0.1055 -1.9267 -2.0996 -0.2933 -0.3927 -0.0087 -0.3670 -0.0396 -0.8172 -1.0643 -1.1810 -0.1259 -0.1813
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients ; frail ; frail ; biological phenotype
H-1007	-0.9049904346466064	▁fra il ▁; ▁bi ological
D-1007	-0.9049904346466064	frail ; biological
P-1007	-2.3737 -0.2562 -0.5839 -0.6025 -0.5240 -1.9045 -0.0901
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs morphology ; cardiac resynchronization therapy ; crt
H-880	-0.31181785464286804	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-880	-0.31181785464286804	QRs morphology ; cardiac resynchronization therapy ; cRT
P-880	-0.0834 -0.5131 -0.1431 -0.0350 -0.9195 -0.0924 -0.5714 -0.0162 -0.1460 -0.0124 -0.9707 -0.3403 -0.0326 -0.2321 -0.4237 -0.8254 -0.1350 -0.1205
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients ; hfpef ; longitudinal ; cardiac event
H-738	-0.5008962750434875	▁h f f ▁; ▁cardiac ▁event
D-738	-0.5008962750434875	hff ; cardiac event
P-738	-0.1138 -0.2486 -0.4314 -0.2901 -1.4274 -1.2458 -0.1324 -0.1176
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm ; outcomes ; discharged ; admission ; heart failure
H-149	-1.1009831428527832	▁RM ▁; ▁implant s ▁; ▁heart ▁failure
D-149	-1.1009831428527832	RM ; implants ; heart failure
P-149	-0.3062 -1.1818 -3.4914 -1.4978 -0.4173 -2.6839 -0.1320 -0.0797 -0.1188
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient ; emergency department ; acute heart failure ; ahf ; clinical
H-57	-0.4581829309463501	▁a cute ▁heart ▁failure ▁; ▁a HF
D-57	-0.4581829309463501	acute heart failure ; aHF
P-57	-1.9241 -0.0339 -0.8462 -0.1826 -0.2427 -0.1261 -0.2777 -0.3387 -0.1516
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene ; pathological ; heart disease ; transcription factors ; driving ; gene
H-639	-0.6017141342163086	▁em bry o nic ▁gene ▁programs ▁; ▁path ological ▁heart ▁disease ▁; ▁tran scription ▁factors
D-639	-0.6017141342163086	embryonic gene programs ; pathological heart disease ; transcription factors
P-639	-0.6316 -0.0744 -0.1025 -1.5445 -2.0215 -0.6397 -0.1729 -0.1696 -0.2145 -0.4715 -0.6536 -1.0715 -0.1091 -0.0109 -0.2816 -1.8307 -0.2290
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard error of measurement ; mdc ; clinical ; change
H-807	-0.6631735563278198	▁m d
D-807	-0.6631735563278198	md
P-807	-0.5903 -0.5371 -1.3955 -0.1298
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients ; lbbb ; implantable ; primary outcome ; primary outcome
H-887	-0.3915916681289673	LB BB ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT
D-887	-0.3915916681289673	LBBB ; implantable cardioverter defibrillator-CRT
P-887	-0.6314 -0.8001 -0.2155 -0.0012 -0.0253 -0.2750 -0.1337 -0.0474 -0.0266 -1.1796 -0.4896 -0.0070 -0.0551 -0.0834 -1.5142 -0.7440 -0.7101 -0.1097
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart rate ; ivabradine ; afterload ; patients ; systolic heart failure
H-516	-0.6089718341827393	▁heart ▁rate ▁; HR ▁; ▁i va bra dine ▁; ▁patients ▁; ▁sy sto lic ▁heart ▁failure
D-516	-0.6089718341827393	heart rate ;HR ; ivabradine ; patients ; systolic heart failure
P-516	-2.3918 -0.7367 -0.1101 -0.1026 -0.1763 -0.0290 -0.0080 -0.2389 -0.0112 -0.1776 -4.4211 -0.5492 -0.2384 -0.1382 -1.3671 -0.4481 -0.1008 -0.1895 -0.1356
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients ; followed up ; composite primary outcome ; cardiovascular death ; stroke ; heart failure ; myocardial infarction
H-1650	-0.2926529049873352	▁cardiovascular ▁death ▁; ▁stroke ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1650	-0.2926529049873352	cardiovascular death ; stroke ; heart failure ; myocardial infarction
P-1650	-1.2376 -0.7089 -0.1006 -0.0980 -0.0874 -0.2027 -0.1953 -0.2162 -0.6320 -0.1581 -0.0765 -0.2836 -0.0111 -0.3812 -0.2843 -0.1453 -0.1563
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical treatment ; heart failure
H-336	-0.32589876651763916	▁heart ▁failure ▁; ▁hyper tension ▁; ▁mit ral ▁re gur gi tation ▁; ▁mit ral ▁sten osis ▁; ▁heart ▁failure
D-336	-0.32589876651763916	heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; heart failure
P-336	-0.6184 -0.2837 -0.1407 -0.0920 -0.0672 -0.1122 -0.2421 -0.0235 -0.0093 -0.0338 -0.0952 -0.0192 -0.3087 -0.3255 -0.0325 -0.1530 -0.0200 -0.4088 -3.5640 -0.3206 -0.1659 -0.1333
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization therapy ; crt ; morbidity ; mortality ; chronic systolic heart failure ; wide qrs complex
H-845	-0.40724849700927734	▁Card iac - re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁morbi d ity ▁; ▁mortal ity ▁; ▁chronic ▁sy sto lic ▁heart ▁failure
D-845	-0.40724849700927734	Cardiac-resynchronization therapy ; cRT ; morbidity ; mortality ; chronic systolic heart failure
P-845	-0.8543 -0.0768 -0.0143 -0.1979 -0.0574 -0.0073 -1.0386 -0.2666 -0.0690 -0.1041 -0.6127 -1.3127 -0.1448 -1.5741 -0.0402 -0.2603 -0.1524 -0.0206 -0.1180 -0.1028 -0.1168 -0.1682 -0.1349 -1.5671 -0.4534 -0.4178 -1.4132 -0.1065
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk ; scn5a ; kv4.3 ; mrnas ; transient receptor potential cation channel m7 ; trpm7 ; mrna
H-1086	-0.6540738940238953	▁per k ▁activa tion ▁destabiliz ed ▁s CN 5 a ▁; ▁kv 4.3 ▁channel ▁m RNA s ▁; ▁trans ient ▁receptor ▁potential ▁ cation ▁channel ▁m 7 ▁; TR PM 7) ▁channel ▁m RNA
D-1086	-0.6540738940238953	perk activation destabilized sCN5a ; kv4.3 channel mRNAs ; transient receptor potential cation channel m7 ;TRPM7) channel mRNA
P-1086	-1.9615 -1.3163 -3.5346 -0.0365 -0.7077 -0.1551 -1.7434 -0.3781 -0.2010 -0.3554 -0.1146 -0.2397 -0.1871 -0.7644 -0.0044 -0.0568 -0.1752 -0.1735 -0.0176 -0.1085 -0.0655 -0.6254 -0.9176 -0.0873 -1.4572 -0.2017 -0.7490 -0.2313 -2.4816 -1.7444 -1.4767 -0.5119 -0.0053 -0.0991 -0.5163 -0.1452
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients ; implantable cardioverter-defibrillator ; heart function clinic ; university health network ; toronto ; canada
H-1861	-0.46424317359924316	▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁Heart ▁Fun ction ▁Clinic ▁; ▁University ▁Health ▁Network ▁; Tor onto
D-1861	-0.46424317359924316	implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto
P-1861	-0.0005 -0.0293 -0.2189 -0.1238 -0.0966 -0.0114 -0.0644 -1.7956 -0.7120 -0.0067 -0.0396 -0.3068 -1.2594 -0.2421 -0.0034 -0.1675 -0.3108 -1.0606 -1.0167 -0.3674 -0.4794 -0.2651 -0.0024 -2.9306 -0.0954
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced pasp ; clinical ; prognostic ; pulmonary hypertension ; patients ; right ventricular contractile reserve
H-831	-0.4303814470767975	▁Exerci se - indu ced ▁PAS p ▁; ▁pulmonar y ▁hyper tension ▁; ▁vent ri cular ▁contract ile ▁reserve
D-831	-0.4303814470767975	Exercise-induced PASp ; pulmonary hypertension ; ventricular contractile reserve
P-831	-4.4004 -0.2044 -0.0089 -0.0091 -0.2062 -0.1355 -0.6095 -0.0793 -0.0150 -0.0960 -0.0114 -0.0480 -0.6698 -0.1278 -0.8907 -0.1231 -0.0652 -0.9761 -0.1063 -0.1449 -0.1103
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi ; metoprolol ; elevated ; plasma norepinephrine ; dopamine ; elevated ; epinephrine
H-1550	-0.3682405948638916	▁MI ▁; ▁met o pro lol ▁; ▁plasma ▁no re pine ph rine ▁; ▁dop amine ▁; ▁e pine ph rine
D-1550	-0.3682405948638916	MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
P-1550	-1.2741 -0.8482 -0.6295 -0.1105 -0.0516 -0.2720 -0.0573 -0.6726 -0.0976 -0.1781 -0.2432 -1.4672 -0.1765 -0.2895 -0.0050 -0.1732 -0.2044 -0.0625 -0.0504 -1.1433 -0.1686 -0.1453 -0.1490
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis ; biomedical ; biomedical ; patients ; dcm ; heart failure
H-1264	-0.3149527907371521	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1264	-0.3149527907371521	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
P-1264	-0.0623 -0.0216 -0.0089 -1.1387 -0.2044 -1.6564 -0.1073 -0.2438 -0.0602 -0.0078 -0.0068 -0.5266 -0.5185 -0.5582 -0.1514 -0.2191 -0.2684 -0.1801 -0.2039 -0.1545
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ; hf
H-696	-0.31409406661987305	▁ste 2 ▁; ▁cardio protec tive ▁signal ing ▁; ▁my o car dium ▁; ▁bio mark er ▁in ▁heart ▁failure ▁; HF
D-696	-0.31409406661987305	ste2 ; cardioprotective signaling ; myocardium ; biomarker in heart failure ;HF
P-696	-2.3414 -0.5172 -0.3081 -0.1114 -0.2845 -0.0399 -0.2062 -0.7420 -0.3004 -0.5527 -0.0509 -0.0204 -0.0660 -0.1303 -0.0276 -0.0042 -0.0525 -0.5147 -0.3436 -0.1994 -0.3138 -0.1510 -0.1582 -0.1020
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular outcomes in renal atherosclerotic lesions ; coral ; stenting ; ras
H-1602	-0.30673959851264954	▁Card io vas cular ▁Out com es ▁; ▁Ren al ▁Ath eros cle ro tic ▁Les ions ▁; CO RAL ▁; ▁sten ting ▁; ▁ RAS
D-1602	-0.30673959851264954	Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;CORAL ; stenting ; RAS
P-1602	-0.2872 -0.8010 -0.0312 -0.0580 -0.9699 -0.0436 -0.0478 -0.2439 -0.0165 -0.0440 -0.0241 -0.0351 -0.0466 -0.3801 -0.6135 -0.2975 -0.0234 -0.1107 -1.4226 -0.0152 -0.2228 -0.4916 -1.2690 -0.7806 -0.1306 -0.0100 -0.0836 -0.0886
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality ; heart failure ; hf ; implantable cardioverter defibrillators ; icds
H-60	-0.3701803982257843	▁mortal ity ▁; ▁heart ▁failure ▁; HF ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; IC d s
D-60	-0.3701803982257843	mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
P-60	-1.5614 -0.3929 -0.3274 -0.3997 -0.4841 -0.1028 -0.0793 -0.1618 -0.0006 -0.0507 -0.2738 -0.1184 -0.0680 -0.0263 -1.5402 -0.9597 -0.0124 -1.2068 -0.3581 -0.1829 -0.1465 -0.0153 -0.2822 -0.1330
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic ; interatrial shunting ; patients ; heart failure with reduced ejection fraction
H-1950	-0.3315240442752838	▁ therapeut ic ▁left - to - right ▁inter at rial ▁sh unting ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1950	-0.3315240442752838	therapeutic left-to-right interatrial shunting ; heart failure ; ejection fraction
P-1950	-1.8330 -0.0794 -0.2185 -0.8774 -0.0169 -1.1617 -0.1723 -0.0155 -0.0230 -0.1136 -0.1364 -0.5097 -0.2599 -0.2584 -0.6016 -0.2061 -0.3144 -0.4097 -0.2805 -0.1243 -0.0706 -0.0005 -0.1398 -0.1334
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary approaches to stop hypertension ; dash ; mortality ; postmenopausal ; hf
H-686	-0.35397207736968994	▁Mediterrane an ▁; ▁Diet ary ▁App ro ach es ▁; ▁Stop ▁Hyper tension ▁; DAS h ▁; ▁mortal ity ▁; ▁post meno paus al ▁women ▁; ▁ HF
D-686	-0.35397207736968994	Mediterranean ; Dietary Approaches ; Stop Hypertension ;DASh ; mortality ; postmenopausal women ; HF
P-686	-0.1388 -0.0199 -0.1821 -0.1789 -0.0838 -1.5084 -0.1610 -0.7748 -0.0067 -1.2561 -0.2332 -0.8824 -0.0752 -0.1757 -0.0135 -0.4774 -0.2051 -0.0420 -0.1872 -0.1845 -0.3770 -0.0154 -0.0056 -0.0380 -1.8256 -0.2159 -1.1013 -0.0111 -0.1044 -0.1383
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic ; patients ; reverse remodeling ; crt ; clinical ; outcomes
H-436	-0.2274346649646759	▁multi para metric ▁e cho car dio graphic ▁score ▁; ▁rever se ▁remodel ing ▁; ▁c RT
D-436	-0.2274346649646759	multiparametric echocardiographic score ; reverse remodeling ; cRT
P-436	-0.3755 -0.0520 -0.0996 -0.0357 -0.2338 -0.0357 -0.1523 -0.2435 -0.3044 -0.2219 -0.1855 -0.0063 -0.0171 -0.0454 -0.4793 -0.5106 -0.9657 -0.2408 -0.1162
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire ; implanted ; pacemakers ; ventricularly ; beats ; heart failure
H-1056	-0.34917140007019043	▁York shire ▁s win e ▁; ▁implant ed ▁; ▁pace makers ▁; ▁vent ri cular ly ▁pace d ▁; ▁heart ▁failure
D-1056	-0.34917140007019043	Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; heart failure
P-1056	-0.4855 -0.0142 -0.0582 -0.2970 -0.1070 -0.3279 -0.0584 -0.1844 -0.5437 -0.7002 -0.0783 -0.2575 -0.0171 -0.6049 -0.0114 -0.0380 -0.2116 -0.1615 -0.4681 -2.8947 -0.1680 -0.2227 -0.1206
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; clinical ; outcomes ; chf
H-636	-0.3436615467071533	▁re nin - angi oten sin - al do ster one ▁; ▁sympa the tic ▁ner vous ▁systems ▁; ▁CHF
D-636	-0.3436615467071533	renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
P-636	-0.4613 -0.3198 -0.0207 -0.0061 -0.0132 -0.8548 -0.0646 -0.0144 -0.1408 -0.0558 -0.7922 -0.1908 -0.0605 -0.4621 -1.1322 -0.3560 -0.9576 -0.7200 -0.7974 -0.0087 -0.0411 -0.0903
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf ; hf ; epidemiology ; rheumatic fever
H-1799	-0.4986351430416107	▁ HF ▁; ▁ HF ▁; ▁ HF ▁epidemi ology ▁; ▁SH ▁; ▁c d ▁; ▁rhe u matic ▁fe ver
D-1799	-0.4986351430416107	HF ; HF ; HF epidemiology ; SH ; cd ; rheumatic fever
P-1799	-1.3881 -0.0717 -0.3663 -0.8561 -0.0671 -0.3843 -2.0517 -0.1021 -1.3464 -1.4015 -0.1214 -0.6981 -0.1240 -0.3659 -1.0314 -0.2478 -0.1613 -0.0827 -0.1629 -0.0006 -0.0361 -0.2386 -0.1628
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality ; readmissions ; costs ; patient ; physician ; hospital
H-1725	-0.42065563797950745	▁mortal ity ▁; ▁read missions ▁; ▁costs ▁; ▁patient ▁; ▁physician ▁; ▁hospital
D-1725	-0.42065563797950745	mortality ; readmissions ; costs ; patient ; physician ; hospital
P-1725	-2.1026 -0.1749 -0.1478 -0.5233 -0.0088 -0.2141 -0.1813 -0.7927 -0.5685 -0.6651 -0.0292 -0.4224 -0.0350 -0.3255 -0.1185
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise ; training ; exercise ; exercise capacity ; qol ; obese ; patients ; hfpef
H-1976	-0.4657209813594818	▁calor ic ▁restriction ▁; diet ▁; ▁aero bic ▁exercise ▁training ▁; exe rci se ▁; ▁exercise ▁capacity ▁; ▁Q OL ▁; ▁obes e ▁; ▁h f f
D-1976	-0.4657209813594818	caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese ; hff
P-1976	-0.4316 -0.4774 -0.0888 -0.0595 -0.8115 -0.0726 -0.0718 -0.0277 -0.1571 -1.4904 -0.1194 -0.2291 -0.0110 -0.0115 -0.1135 -2.8550 -0.8296 -0.0842 -0.4690 -0.2825 -0.1257 -1.1825 -0.0681 -0.6658 -0.6159 -0.7728 -0.9486 -0.2726 -0.1604
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic heart failure ; hf ; hemodynamic ; syndrome ; dysfunction ; molecular pathways
H-1472	-0.25508439540863037	▁chronic ▁heart ▁failure ▁; HF ▁; ▁hem o dynamic ▁disorder ▁; ▁syndrome ▁; ▁dys function ▁; ▁inter connect ed ▁molecular ▁path ways
D-1472	-0.25508439540863037	chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction ; interconnected molecular pathways
P-1472	-1.1423 -1.1822 -0.2194 -0.1155 -0.0790 -0.2159 -0.5569 -0.1079 -0.0173 -0.0538 -0.1710 -0.2172 -0.5567 -0.0216 -0.1241 -0.6789 -0.0846 -0.0127 -0.0411 -0.1152 -0.1153 -0.0431 -0.1304 -0.1199
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications ; patients ; heart failure and reduced ejection fraction ; outpatient
H-667	-0.5905563235282898	▁medication s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-667	-0.5905563235282898	medications ; heart failure ; ejection fraction
P-667	-2.3831 -0.0422 -0.2672 -0.7919 -0.2072 -0.1546 -1.5732 -0.6167 -0.0896 -0.1374 -0.0012 -1.1683 -0.2446
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms ; hfpef ; diastolic filling time ; heart rate ; symptoms
H-1172	-0.5826525092124939	▁ HF p EF ▁; ▁dia sto lic ▁fill ing ▁time ▁; ▁heart ▁rate
D-1172	-0.5826525092124939	HFpEF ; diastolic filling time ; heart rate
P-1172	-1.0436 -0.1793 -0.0603 -0.5978 -0.1673 -0.8824 -0.3845 -0.4209 -0.6531 -0.0435 -1.7615 -0.0877 -2.0156 -0.7593 -0.1163 -0.1492
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac ; myocyte-specific mena overexpression ; cardiac ; pathology
H-1813	-0.42254334688186646	▁mi ce ▁; ▁cardiac ▁my o cy te - specific ▁Men a ▁over expression ▁; ▁t g t et Men a ▁; ▁cardiac ▁path ology
D-1813	-0.42254334688186646	mice ; cardiac myocyte-specific Mena overexpression ; tgtetMena ; cardiac pathology
P-1813	-0.8001 -0.0545 -0.1160 -0.0239 -0.6074 -0.1349 -0.0255 -0.0489 -0.5091 -0.0517 -0.4380 -0.1405 -1.6841 -0.1538 -0.1127 -2.0192 -0.0996 -0.1040 -1.6305 -0.1191 -0.0253 -0.4447 -0.0358 -0.5583 -1.1916 -0.1503 -0.1292
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk stratification ; antiplatelet agents ; combination ; anticoagulants ; vascular diseases
H-1355	-0.5460537075996399	▁anti plate let ▁agents ▁; ▁antico a gul ants
D-1355	-0.5460537075996399	antiplatelet agents ; anticoagulants
P-1355	-0.6000 -0.1639 -0.2236 -0.1103 -0.2614 -0.2060 -0.6783 -0.2114 -0.0164 -3.3913 -0.1440
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international right heart foundation working group ; step ; syndrome ; right heart failure
H-1458	-0.8892051577568054	▁international ▁Right ▁Heart ▁Foundation ▁; ▁defect s ▁; ▁syndrome ▁of ▁right ▁heart ▁failure
D-1458	-0.8892051577568054	international Right Heart Foundation ; defects ; syndrome of right heart failure
P-1458	-0.9033 -0.5098 -0.3219 -0.1038 -0.5515 -5.2384 -0.0337 -0.1775 -1.6312 -1.8021 -0.7335 -0.3563 -0.7663 -0.1161 -0.0927
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc ; diagnostic
H-1025	-1.1446534395217896	▁PO c ▁; ▁ NP
D-1025	-1.1446534395217896	POc ; NP
P-1025	-1.5767 -2.5561 -1.3934 -0.9805 -0.0082 -1.3547 -0.1429
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients ; lbbb ; qrs ; implantable
H-890	-0.31713399291038513	LB BB ▁; ▁QR s ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT
D-890	-0.31713399291038513	LBBB ; QRs ; implantable cardioverter defibrillator-CRT
P-890	-0.4723 -0.5718 -0.0750 -0.3807 -0.9224 -0.0443 -0.0025 -0.0286 -0.1604 -0.0995 -0.0360 -0.0283 -0.9504 -0.3598 -0.0055 -0.0309 -0.0510 -1.5333 -0.5258 -0.2964 -0.0849
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography ; cardiac ; cardiac function
H-453	-0.5653222799301147	▁e cho card i ography ▁; ▁cardiac ▁diameter s ▁; ▁cardiac ▁function ▁; ▁b - tre ated
D-453	-0.5653222799301147	echocardiography ; cardiac diameters ; cardiac function ; b-treated
P-453	-0.1322 -0.1400 -0.0638 -0.5224 -0.2753 -0.1230 -0.1567 -0.3828 -0.0682 -0.0978 -0.4085 -3.4149 -0.4109 -0.1252 -0.0468 -0.0365 -0.1381 -4.1095 -0.0885
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline ; embase ; psycinfo
H-151	-0.35259896516799927	▁MED LINE ▁; ▁ EMBA se ▁; ▁Psy c INFO
D-151	-0.35259896516799927	MEDLINE ; EMBAse ; PsycINFO
P-151	-1.6055 -1.2615 -0.1430 -0.2925 -0.0107 -0.4221 -0.0888 -0.1006 -0.0559 -0.0042 -0.1916 -0.0547
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality of life ; functional capacity
H-618	-1.074087381362915	▁life ▁; ▁functional ▁capacity
D-618	-1.074087381362915	life ; functional capacity
P-618	-4.8774 -0.3421 -0.1093 -0.7674 -0.2199 -0.1285
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized ; medical
H-1977	-1.508758544921875	▁urban ▁academic ▁medical ▁center
D-1977	-1.508758544921875	urban academic medical center
P-1977	-6.0637 -1.2317 -0.8507 -0.6433 -0.1648 -0.0984
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients ; systolic hf ; cxl-1020 ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
H-423	-0.6213440895080566	▁sy sto lic ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁; ▁right ▁heart ▁fill ing ▁pressure s ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁cardiac ▁; ▁stroke
D-423	-0.6213440895080566	systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
P-423	-3.5291 -0.1045 -0.2126 -0.2676 -0.0409 -0.0375 -1.2761 -0.2456 -0.4148 -0.1629 -0.4252 -1.0427 -0.5416 -1.6921 -1.7000 -1.7150 -0.0593 -2.1685 -0.0881 -0.1057 -0.6672 -0.2875 -0.1784 -0.2859 -0.1903 -0.0131 -0.2510 -0.0893 -1.2466 -0.0612 -0.6524 -0.1301
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic ; patients ; severe heart failure ; financial
H-1242	-0.7697449922561646	▁ therapeut ic ▁strategy ▁; ▁AF ▁; ▁heart ▁failure ▁; ▁financier ▁burde n
D-1242	-0.7697449922561646	therapeutic strategy ; AF ; heart failure ; financier burden
P-1242	-2.1713 -0.0371 -0.2471 -1.5311 -0.3611 -0.6596 -0.1137 -3.6217 -0.1619 -0.3580 -1.3001 -0.7308 -0.0400 -0.1372 -0.0754
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow up ; ffm ; patients
H-16	-0.9422406554222107	▁body ▁weight ▁; ▁FM ▁; f f ▁; cc
D-16	-0.9422406554222107	body weight ; FM ;ff ;cc
P-16	-3.6297 -0.4968 -0.2393 -0.3961 -0.1399 -1.7028 -0.5415 -0.5567 -1.9625 -0.5552 -0.1441
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential analysis ; cluster analysis
H-1610	-1.0543310642242432	▁r
D-1610	-1.0543310642242432	r
P-1610	-2.1563 -0.9340 -0.0727
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1260	-0.34165677428245544	▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1260	-0.34165677428245544	ventricular ejection fraction ; left ventricular diastolic end diameter
P-1260	-0.2724 -1.1174 -0.2230 -0.3238 -0.5903 -0.1607 -0.1122 -0.0006 -0.1405 -0.4759 -0.0231 -1.5154 -0.1304 -0.3186 -0.1915 -0.3807 -0.3291 -0.0544 -0.2980 -0.1752
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence ; clinical ; outcomes ; concentric left ventricular hypertrophy ; heart failure with preserved ejection fraction
H-1523	-0.3840459883213043	▁ecce n tric ▁; ▁concentr ic ▁left ▁vent ri cular ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1523	-0.3840459883213043	eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
P-1523	-2.3096 -0.0076 -0.1552 -0.2117 -0.3830 -0.0758 -0.5603 -0.0353 -1.8544 -0.2100 -0.0211 -0.0037 -0.0940 -0.5802 -0.1298 -0.2121 -0.2784 -1.3802 -0.3085 -0.0724 -0.0486 -0.0002 -0.1420 -0.1428
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients ; left ventricular ejection fraction ; heart failure with preserved ejection fraction ; hfpef
H-1887	-0.26613858342170715	▁vent ri cular ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1887	-0.26613858342170715	ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
P-1887	-0.4336 -1.3165 -0.2211 -0.1892 -0.3339 -0.1960 -0.1344 -0.0010 -0.1980 -0.4488 -0.3663 -0.2591 -0.3133 -0.0127 -0.1426 -0.0433 -0.4099 -0.1842 -0.1037 -0.0018 -0.3451 -0.7206 -0.0098 -0.0906 -0.2388 -0.2055
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
H-451	-0.2033795267343521	▁β - ad r energi c ▁receptor ▁block er ▁ therapy ▁; ▁my o card ial ▁per fusion ▁; ▁neo angi ogen es is ▁; ▁fail ing ▁heart
D-451	-0.2033795267343521	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
P-451	-0.0580 -0.0412 -0.0560 -0.0894 -0.1496 -0.0491 -0.0153 -0.3097 -0.0646 -0.2615 -0.0166 -0.1490 -1.8853 -0.1643 -0.1607 -0.2956 -0.1861 -0.0388 -0.1701 -0.0584 -0.0322 -0.2148 -0.0549 -0.1226 -0.3657 -0.4990 -0.0854 -0.2040 -0.1609 -0.1423
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
H-1780	-0.3462063670158386	▁cardiac ▁hyper trop hy ▁seconda ry ▁to ▁pressure - over load ▁; ▁abdominal ▁a or tic ▁con stri ction ▁; ▁a ac
D-1780	-0.3462063670158386	cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction ; aac
P-1780	-2.2871 -0.0276 -0.0086 -0.0581 -0.6453 -0.0127 -0.4200 -0.2580 -0.0243 -0.0669 -0.0738 -0.2417 -0.0899 -0.0271 -0.3271 -0.8576 -0.0159 -0.2353 -0.0687 -0.7536 -0.1025 -1.4713 -0.1044 -0.1315
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline ; hgb ; correlated ; baseline ; kccq ; hgb ; exercise ; training ; hrqol
H-839	-0.5583722591400146	▁h gb ▁; ▁k cc q ▁; ▁h gb ▁; ▁HR Qo L
D-839	-0.5583722591400146	hgb ; kccq ; hgb ; HRQoL
P-839	-0.3346 -0.1412 -0.0412 -0.8336 -0.0386 -0.7415 -0.4375 -0.0904 -0.2213 -0.0832 -4.0533 -0.0209 -1.0625 -0.1376 -0.1384
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient ; patients ; heart failure ; hospital ; discharge ; readmissions ; patient ; follow-up
H-722	-0.9718115925788879	▁patients ▁; ▁heart ▁failure ▁; ▁hospital ▁dis charge
D-722	-0.9718115925788879	patients ; heart failure ; hospital discharge
P-722	-3.8342 -1.1651 -0.3596 -0.3504 -0.6010 -0.5379 -0.4081 -0.0168 -2.2637 -0.1814
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; svr ; cardiac index
H-225	-0.3819839060306549	▁Font an ▁failure ▁; ▁hem o dynamic ally ▁; ▁heart ▁failure ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁s VR ▁; ▁cardiac ▁index
D-225	-0.3819839060306549	Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; cardiac index
P-225	-0.0831 -0.4936 -0.1920 -0.1035 -1.1830 -0.0415 -0.0088 -0.0918 -0.2320 -0.6440 -0.1065 -0.0879 -1.8220 -0.5451 -0.3890 -0.4895 -0.1751 -0.0099 -0.1410 -1.4459 -0.4491 -0.2505 -0.6436 -0.1004 -0.0994 -0.1032
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous hf
H-1156	-0.4050864279270172	▁my o fi ber ▁dynamic s ▁; ▁my o fi ber ▁short en ing ▁; ▁em d ▁; ▁dys syn chron ous ▁ HF
D-1156	-0.4050864279270172	myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous HF
P-1156	-2.9056 -0.2447 -0.8320 -0.0881 -0.6368 -0.0192 -0.1657 -0.6671 -0.1126 -0.9108 -0.0690 -0.9026 -0.0568 -0.1940 -0.1073 -1.1766 -0.1952 -0.1192 -0.0626 -0.0030 -0.0015 -0.5265 -0.1466 -0.0295 -0.2061 -0.1533
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial index ; pulse-wave ; coronary artery calcium scores
H-1562	-0.24595673382282257	▁an kle - bra chi al ▁index ▁; ▁puls e - wa ve ▁veloci ty ▁; ▁corona ry ▁arter y ▁calci um ▁score s
D-1562	-0.24595673382282257	ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
P-1562	-1.6336 -0.2546 -0.0336 -0.1099 -0.1186 -0.0584 -0.0639 -0.1385 -0.1631 -0.1415 -0.0055 -0.1015 -0.0257 -0.8549 -0.6649 -0.1710 -0.0372 -0.0743 -0.0517 -0.2463 -0.0694 -0.0203 -0.8815 -0.1788 -0.1582 -0.1379
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate ; unfolded protein response ; upr ; scn5a ; remodeling ; hf
H-1081	-0.2772335708141327	▁tru nca ted ▁na + ▁channel s ▁; ▁un fold ed ▁protein ▁response ▁; ▁u PR ▁; ▁electric ▁remodel ing ▁; ▁ HF
D-1081	-0.2772335708141327	truncated na+ channels ; unfolded protein response ; uPR ; electric remodeling ; HF
P-1081	-0.5804 -0.0131 -0.2375 -0.0791 -1.4368 -0.3025 -0.0353 -0.3087 -0.0349 -0.0008 -0.0195 -0.0776 -0.1331 -0.0835 -0.0365 -0.3491 -0.0550 -1.8954 -0.0362 -0.0211 -0.4400 -0.3935 -0.1108 -0.1657 -0.0848
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary endpoint ; intermacs ; interagency registry for mechanically assisted circulatory support
H-1996	-0.362979918718338	▁inter ma cs ▁; ▁inter age ncy ▁Registr y ▁for ▁Mechanic ally ▁Assist ed ▁Circula tory ▁Support
D-1996	-0.362979918718338	intermacs ; interagency Registry for Mechanically Assisted Circulatory Support
P-1996	-0.2428 -1.2688 -2.0691 -0.1568 -0.4948 -0.1104 -0.0022 -0.1910 -0.0743 -0.3684 -0.0443 -0.4020 -0.1869 -0.0542 -0.2973 -0.2967 -0.1351 -0.3690 -0.1324
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol ; lv contractile function ; xo-mediated ros ; myofilament ; sensitivity
H-477	-0.36446937918663025	▁allo puri nol ▁; ▁LV ▁contract ile ▁function ▁; ▁efficiency ▁; ▁ XO - media ted ▁ ROS ▁; ▁my o fila ment
D-477	-0.36446937918663025	allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS ; myofilament
P-477	-0.2960 -0.0091 -0.1561 -0.0813 -0.2997 -0.0795 -0.8273 -2.0434 -0.2424 -0.7189 -0.0725 -0.3457 -0.0608 -0.0029 -0.0798 -0.1102 -0.0520 -0.1668 -0.7182 -1.8026 -0.0646 -0.0111 -0.0405 -0.7021 -0.1283
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic function ; hfpef ; patients ; long axis function ; exercise
H-1888	-0.6068814992904663	▁implant g ▁techniques ▁; ▁sy sto lic ▁function ▁; ▁ HF p EF ▁; ▁long ▁a xis ▁function
D-1888	-0.6068814992904663	implantg techniques ; systolic function ; HFpEF ; long axis function
P-1888	-1.4204 -0.7272 -0.1221 -0.1055 -1.1708 -0.1191 -1.2696 -1.3953 -0.1397 -1.0879 -0.0369 -0.0307 -0.1347 -0.8189 -0.2970 -0.0337 -0.0375 -1.0996 -1.9471 -0.1438
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians ; patients ; heart failure ; equitable ; therapeutic
H-1823	-0.7326666116714478	▁physician s ▁; ▁patients ▁; ▁advanced ▁heart ▁failure
D-1823	-0.7326666116714478	physicians ; patients ; advanced heart failure
P-1823	-2.2868 -0.0223 -0.3597 -1.7979 -0.7943 -0.3640 -0.3770 -0.1664 -1.0369 -0.1214
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf ; multivariate-adjusted odds ratio ; mortality ; hazard ratio ; mortality
H-1312	-0.6401885747909546	▁ HF ▁; ▁multi varia te - ad just ed ▁odds ▁ratio ▁; ▁28- day ▁mortal ity ▁; ▁hazard ▁ratio
D-1312	-0.6401885747909546	HF ; multivariate-adjusted odds ratio ; 28-day mortality ; hazard ratio
P-1312	-2.3805 -0.1906 -0.2434 -4.6276 -0.1640 -0.1562 -0.0299 -0.0045 -0.0006 -0.0199 -0.0282 -0.1735 -0.2659 -0.6050 -0.0869 -0.0137 -0.2007 -0.1642 -0.0525 -0.0362 -4.4315 -0.2088
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas ; hf ; hyperkalemia ; hypokalemia ; spironolactone ; clinical
H-1708	-0.4847777187824249	▁AA s ▁; ▁ HF ▁; ▁hyper kal emia ▁; ▁hypo kal emia ▁; ▁spi rono lac tone
D-1708	-0.4847777187824249	AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
P-1708	-3.3394 -0.1606 -0.1421 -1.4122 -0.0512 -0.0948 -0.6842 -0.1663 -0.0825 -0.0839 -0.0271 -0.3805 -0.1642 -0.0973 -0.0302 -0.0069 -0.0305 -0.0352 -2.6010 -0.1054
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors ; g-protein-coupled receptor ; kinase-2 ; downregulation
H-1407	-0.28354737162590027	▁g - prote in - co up led ▁receptor ▁kina se -2
D-1407	-0.28354737162590027	g-protein-coupled receptor kinase-2
P-1407	-1.5847 -0.0944 -0.0272 -0.5386 -0.0239 -0.0078 -0.0068 -0.1541 -0.0275 -0.2278 -0.0293 -0.2031 -0.8817 -0.1627
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp ; nonterminal epitopes ; central glycosylated region
H-1522	-0.6231775283813477	▁NT - pro b NP
D-1522	-0.6231775283813477	NT-probNP
P-1522	-0.0971 -0.0176 -0.0043 -0.6430 -0.2050 -3.2769 -0.1183
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a ; angii ; hypoxia ; expression ; upr ; downregulation
H-1085	-0.8174791932106018	▁s CN 5 a ▁; ▁ang II ▁; ▁hypo xia ▁; ▁u PR ▁; ▁down regul ation
D-1085	-0.8174791932106018	sCN5a ; angII ; hypoxia ; uPR ; downregulation
P-1085	-1.8246 -1.1229 -0.2370 -0.4744 -0.1698 -0.6594 -0.7854 -0.1120 -0.0244 -0.0313 -0.1161 -0.2386 -0.9339 -0.3727 -4.4207 -0.0466 -0.0099 -3.7758 -0.1766
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients ; heart transplant ; prospectively ; ecct
H-710	-1.4726285934448242	▁implant
D-710	-1.4726285934448242	implant
P-710	-2.0027 -2.2873 -0.1279
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate logistic regression analysis ; bnp ; patients ; diastolic dysfunction
H-1571	-0.48937347531318665	▁b NP ▁; ▁dia sto lic ▁dys function
D-1571	-0.48937347531318665	bNP ; diastolic dysfunction
P-1571	-0.1013 -0.7959 -0.1654 -0.5852 -0.2222 -2.3703 -0.0080 -0.4481 -0.0837 -0.1136
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate ratio ; therapy ; patient ; comorbidities
H-663	-0.9731749892234802	▁ therapy ▁; ▁como rbi di ties
D-663	-0.9731749892234802	therapy ; comorbidities
P-663	-2.3948 -0.1821 -0.6149 -2.7586 -0.0187 -0.5369 -1.9854 -0.1048 -0.1623
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization ; medicare ; hospital ; medicare ; policy
H-1715	-0.39494675397872925	▁Medica re ▁hospital ▁claims ▁; ▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1715	-0.39494675397872925	Medicare hospital claims ; Medicare ; post-acute care transfer policy
P-1715	-0.2939 -0.0030 -0.8800 -0.7827 -0.0974 -0.0573 -0.0042 -0.3644 -0.3935 -0.0079 -0.1310 -0.0125 -2.7371 -0.1152 -0.4104 -0.2167 -0.2069
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart failure ; compliance ; etidronate ; alendronate
H-1543	-0.35383880138397217	▁heart ▁failure ▁; ▁re fill ▁compliance ▁; ▁et id rona te ▁; ▁ale ndr onate
D-1543	-0.35383880138397217	heart failure ; refill compliance ; etidronate ; alendronate
P-1543	-1.4868 -0.6185 -0.1166 -1.0870 -0.0891 -1.5176 -0.0811 -0.0392 -0.2516 -0.0283 -0.0206 -0.1534 -0.0589 -0.0143 -0.1410 -0.2019 -0.1094
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis ; metabolic exercise ; cardiac ; kidney
H-1762	-0.40801894664764404	▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁score
D-1762	-0.40801894664764404	metabolic exercise ; cardiac ; kidney index score
P-1762	-1.9024 -0.0494 -0.2654 -0.0827 -0.0199 -2.0314 -0.1746 -0.1480 -0.0497 -0.1135 -0.1428 -0.1775 -0.1470
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical ; activity ; crf ; hf ; mortality
H-1776	-0.4791058301925659	▁men ▁; ▁physique ▁activity ▁; ▁c RF ▁; ▁ HF ▁mortal ity
D-1776	-0.4791058301925659	men ; physique activity ; cRF ; HF mortality
P-1776	-2.1018 -0.1966 -1.8880 -0.2939 -0.0809 -0.2934 -0.2698 -0.1278 -0.9466 -0.0898 -0.0838 -0.1222 -0.1012 -0.1117
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular pathways ; patients ; chronic heart failure ; chf
H-249	-0.4633004367351532	▁ET ▁; ▁HD L - media ted ▁protect ive ▁effects ▁; ▁molecular ▁path ways ▁; ▁chronic ▁heart ▁failure ▁; CH f
D-249	-0.4633004367351532	ET ; HDL-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
P-249	-1.2107 -0.2457 -1.5718 -1.4116 -0.0335 -0.0669 -0.3026 -0.6686 -0.0114 -0.2773 -0.1281 -0.3993 -0.1422 -0.0774 -0.2949 -1.9696 -0.6575 -0.2579 -0.2526 -0.3697 -0.1110 -0.1009 -0.0948
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo ; dopamine ; nesiritide ; secondary end points ; renal function ; clinical ; outcomes
H-82	-0.4448363780975342	▁dop amine ▁; ▁nesi riti de ▁; ▁de con gestion ▁; ▁renal ▁function
D-82	-0.4448363780975342	dopamine ; nesiritide ; decongestion ; renal function
P-82	-2.0744 -0.4049 -0.0740 -0.0238 -0.0114 -0.0195 -0.2391 -0.2408 -0.0309 -0.0067 -0.2215 -0.0013 -2.9779 -0.2765 -0.0699
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia ; medline ; cochrane library
H-31	-0.5156628489494324	▁English ▁language ▁; ▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁MED LINE ▁; ▁co ch rane ▁Library
D-31	-0.5156628489494324	English language ; anemia ; iron deficiency ; MEDLINE ; cochrane Library
P-31	-5.7143 -0.7371 -0.5524 -0.2369 -0.1331 -0.7323 -0.0162 -0.0781 -0.0423 -0.0177 -0.4775 -0.1469 -0.4618 -0.2024 -0.7345 -0.1714 -0.2649 -0.0727 -0.0220 -0.1381 -0.2532 -0.1390
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq ; patients ; hfpef
H-790	-0.7084420323371887	▁k cc q ▁; ▁ HF p EF ▁; ▁c ron bach
D-790	-0.7084420323371887	kccq ; HFpEF ; cronbach
P-790	-0.4332 -0.0315 -0.6314 -0.3375 -1.2610 -0.4052 -0.0195 -0.4715 -0.2555 -4.8846 -0.0397 -0.0906 -0.9285 -0.1284
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable ; patients ; qrs duration
H-891	-0.47213003039360046	▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT ▁; LB BB ▁; ▁QR s ▁du ration
D-891	-0.47213003039360046	implantable cardioverter defibrillator-CRT ;LBBB ; QRs duration
P-891	-0.0007 -0.0325 -0.2189 -0.1276 -0.0528 -0.0612 -0.8878 -0.5924 -0.0045 -0.0545 -0.0469 -1.6386 -0.7085 -0.1126 -2.5536 -0.4871 -1.0146 -0.1444 -1.1729 -0.4003 -0.0106 -0.4215 -0.1144
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal ; diagnostic ; clinical
H-1304	-0.7961322069168091	
D-1304	-0.7961322069168091	
P-1304	-1.5388 -0.0535
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up ; patients
H-1538	-0.5900901556015015	▁ale ndr onate - ▁et id rona te - ▁; ▁ra lo xi fen e - tre
D-1538	-0.5900901556015015	alendronate- etidronate- ; raloxifene-tre
P-1538	-0.7915 -0.0336 -0.1455 -0.1031 -3.2256 -0.1084 -0.0182 -0.0153 -0.0505 -2.7299 -0.0137 -0.0773 -0.0404 -0.5494 -0.0552 -0.0445 -0.0219 -3.0339 -0.1538
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy ; trastuzumab ; comorbidities ; chf ; international classification of diseases ; healthcare common procedure coding system codes
H-674	-0.36271530389785767	▁Che mo therapy ▁; ▁tras tuz um ab ▁; ▁CHF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁health care ▁Common ▁Procedur e ▁code s
D-674	-0.36271530389785767	Chemotherapy ; trastuzumab ; CHF ; international Classification of Diseases ; healthcare Common Procedure codes
P-674	-0.9329 -0.0746 -0.0088 -0.1264 -0.0194 -0.0025 -0.0093 -0.0460 -1.0595 -0.1456 -0.1759 -2.1519 -0.2930 -0.0046 -0.1748 -0.0345 -0.0115 -0.1302 -1.6406 -0.0338 -0.1329 -0.1245 -0.0420 -1.9963 -0.0237 -0.2822 -0.1161
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart failure ; hf ; therapies ; outcomes ; patients ; hf ; preserved left ventricular ejection fraction ; lvef
H-111	-0.3437098264694214	▁con tempor ary ▁heart ▁failure ▁; HF ▁; ▁ HF ▁; ▁vent ri cular ▁e je ction ▁ fraction ▁; LV EF
D-111	-0.3437098264694214	contemporary heart failure ;HF ; HF ; ventricular ejection fraction ;LVEF
P-111	-0.8982 -0.0038 -0.0719 -0.4785 -0.1834 -0.1186 -0.1126 -0.1878 -1.1060 -0.4091 -0.0803 -1.1991 -1.3345 -0.1707 -0.1274 -0.4561 -0.3808 -0.1610 -0.0014 -0.3972 -0.0817 -0.0221 -0.1391 -0.1280
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart ; patients ; hfpef ; hf with reduced ejection fraction ; hfref
H-240	-0.5201665163040161	▁h ART ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁ HF ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF
D-240	-0.5201665163040161	hART ; HFpEF ; HF ; HF ; reduced ejection fraction ;HFrEF
P-240	-0.1213 -0.1035 -0.0652 -1.9854 -0.0913 -0.9299 -0.2568 -0.0453 -1.1193 -0.0680 -0.2813 -2.5430 -0.0928 -0.3659 -3.0136 -0.1482 -0.0519 -0.6954 -0.1613 -0.1091 -0.0019 -0.2238 -0.8685 -0.1020 -0.0895 -0.3153 -0.1950
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced hf ; cxl-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
H-421	-0.6026119589805603	▁ conscious ▁; ▁h z ▁; ▁contract ility ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁ve no arte rial ▁di lation
D-421	-0.6026119589805603	conscious ; hz ; contractility ; end-systolic elastance ; venoarterial dilation
P-421	-1.7482 -1.3285 -1.2885 -3.5098 -1.5538 -0.1003 -1.0809 -0.2823 -0.1244 -1.1720 -0.0117 -0.5489 -0.3771 -0.4648 -0.0292 -0.1350 -0.2540 -0.2172 -0.0844 -0.0303 -0.1073 -0.1268 -0.0503 -0.2481 -0.1913
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone morphogenetic protein 4 ; expression ; rrna transcription ; shift ; heterochromatic chromatin
H-98	-0.3853364586830139	▁bone ▁mor pho gene tic ▁protein ▁; ▁r RNA ▁tran scription ▁; ▁hetero ch ro matic ▁chr omat in
D-98	-0.3853364586830139	bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
P-98	-0.6047 -0.2452 -0.3727 -0.6713 -2.0272 -0.2642 -0.1187 -0.1090 -0.0487 -0.0882 -0.0121 -0.5784 -1.9033 -0.1122 -0.0339 -0.0386 -0.0030 -0.0089 -0.5054 -0.1964 -0.1498
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin cytoskeleton ; mitochondrial function ; metabolism ; glycolysis ; gluconeogenesis ; citrate cycle
H-873	-0.2949477434158325	▁act in ▁cy tos kelet on ▁; ▁mito cho ndri al ▁function ▁; ▁intermedi ate ▁metabolism ▁; ▁gly col ysis ▁; glu cone ogen es is ▁; ▁cit rate ▁cycle
D-873	-0.2949477434158325	actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
P-873	-0.0186 -0.8898 -0.6270 -0.1916 -0.0597 -0.2993 -0.1720 -0.0151 -0.6714 -0.0570 -0.0564 -1.5949 -0.1214 -0.5199 -0.1391 -0.0929 -0.1201 -0.0089 -0.9975 -0.1028 -1.1681 -0.2137 -0.0386 -0.2705 -0.0319 -0.0992 -0.3386 -0.0020 -0.0594 -0.2475 -0.0998 -0.1135
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated ; resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
H-939	-0.20659375190734863	▁resist in ▁; ▁an thra cycli ne - indu ced ▁cardio toxic ity ▁; ▁heart ▁failure
D-939	-0.20659375190734863	resistin ; anthracycline-induced cardiotoxicity ; heart failure
P-939	-1.2089 -0.3258 -0.1197 -0.0633 -0.0140 -0.3959 -0.1654 -0.0433 -0.0098 -0.1911 -0.0169 -0.0680 -0.1236 -0.2111 -0.2487 -0.1552 -0.2476 -0.1102
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular matrix ; left ventricular ; biopsies ; tissuefaxs ; correlated ; t1 time
H-741	-0.5215469002723694	▁extra cel lular ▁matri x ▁; ▁left ▁vent ri cular ▁bio psi es ▁; ▁t issue FAX s ▁technology ▁cor related
D-741	-0.5215469002723694	extracellular matrix ; left ventricular biopsies ; tissueFAXs technology correlated
P-741	-1.7905 -0.0707 -0.0532 -0.2683 -0.0268 -0.8368 -0.1404 -0.0474 -1.5313 -0.2866 -0.0686 -0.2057 -0.1230 -0.1084 -1.2658 -0.0188 -0.0729 -1.1349 -1.7104 -0.9984 -0.1155 -0.9782 -0.1430
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients ; systolic hf ; the danish heart failure database ; esrd ; danish registry on dialysis
H-389	-0.45871371030807495	▁sy sto lic ▁ HF ▁; ▁Danish ▁Heart ▁Fail ure ▁database ▁; ▁ES RD ▁; ▁Danish ▁Registr y ▁on ▁Dia lys is
D-389	-0.45871371030807495	systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
P-389	-3.8324 -0.0752 -0.4006 -0.0712 -0.0207 -0.0963 -0.6301 -0.4212 -0.0243 -0.0250 -0.9152 -0.0795 -1.1373 -0.3643 -0.1172 -0.8143 -0.4736 -0.0777 -0.0808 -0.5445 -0.2791 -0.0692 -0.3404 -0.1188
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left ventricular assist devices ; lvads ; patients ; heart failure ; incidence ; pump dysfunction ; pump
H-773	-0.3849238157272339	▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁patients ▁; ▁advanced ▁heart ▁failure ▁; ▁pump ▁dys function ▁; ▁pump ▁replace ment
D-773	-0.3849238157272339	ventricular assist devices ; lVADs ; patients ; advanced heart failure ; pump dysfunction ; pump replacement
P-773	-0.2024 -1.0482 -0.0681 -0.2768 -0.2214 -0.1953 -0.2946 -0.0289 -0.0426 -0.2311 -4.0110 -0.3564 -0.5894 -0.3167 -0.2463 -0.2098 -0.2132 -0.0459 -0.0416 -0.2045 -0.1871 -0.2892 -0.0224 -0.1636 -0.1166
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable models ; st2 ; outcomes ; clinical ; amino-terminal pro-b-type natriuretic peptide
H-704	-0.3602225184440613	▁ST 2 ▁; ▁amino - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de
D-704	-0.3602225184440613	ST2 ; amino-terminal pro-B-type natriuretic peptide
P-704	-1.6251 -0.0946 -0.4896 -0.1947 -0.0137 -0.0040 -0.0056 -0.3528 -0.0116 -0.8179 -0.0569 -0.0186 -0.0118 -0.0605 -0.0478 -3.0660 -0.1826 -0.1629 -0.0983 -0.1266 -0.1230
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular pacing ; bivp ; cardiac output ; cardiac ; surgery ; patients
H-319	-0.4618909955024719	▁bi ven tri cular ▁pa cing ▁; ▁bi VP ▁; ▁cardiac ▁output ▁; co ▁; ▁cardiac ▁surgery
D-319	-0.4618909955024719	biventricular pacing ; biVP ; cardiac output ;co ; cardiac surgery
P-319	-0.5237 -0.1584 -1.7678 -0.4559 -0.1852 -0.8345 -0.1426 -0.4294 -0.1133 -0.1201 -0.0513 -0.8806 -0.1284 -1.5565 -0.5791 -0.0693 -0.0817 -0.5730 -0.1250
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully magnetically levitated lvas ; mortality ; seattle ; heart failure
H-2002	-0.42058369517326355	▁magnet ically ▁le vita ted ▁l VAS ▁; ▁mortal ity ▁risk ▁; ▁Seattle ▁Heart ▁Fail ure ▁Model - pred i cted ▁survival
D-2002	-0.42058369517326355	magnetically levitated lVAS ; mortality risk ; Seattle Heart Failure Model-predicted survival
P-2002	-4.1494 -0.0892 -0.0088 -0.0178 -0.5629 -0.6891 -0.1885 -0.1824 -0.4598 -0.1292 -1.2503 -0.0822 -0.0454 -0.2464 -0.0294 -0.0256 -1.0988 -0.0801 -0.0523 -0.1103 -0.1171 -0.0870 -0.2809 -0.1111
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients ; new york heart association ; nyha ; chronic heart failure ; reduced ejection fraction
H-1952	-0.6944924592971802	▁New ▁York ▁Heart ▁Association ▁; NY ha ▁; ▁chronic ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction ▁; ▁Canadian ▁special ▁access ▁programme
D-1952	-0.6944924592971802	New York Heart Association ;NYha ; chronic heart failure ; reduced ejection fraction ; Canadian special access programme
P-1952	-1.6523 -0.5998 -1.4826 -1.1693 -0.1493 -0.6782 -1.2034 -0.2015 -3.4359 -0.6558 -0.7088 -0.2842 -1.1879 -0.0557 -0.0297 -0.3125 -0.1038 -0.1132 -0.0027 -1.3988 -0.6025 -1.3066 -0.0715 -0.2315 -0.2595 -0.1600
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa ; immunoassays ; antibodies ; c termini ; nt-probnp
H-1518	-0.4936144948005676	▁Alpha LIS a ▁immun o assa ys ▁; ▁anti bo dies ▁; ▁NT - pro b NP
D-1518	-0.4936144948005676	AlphaLISa immunoassays ; antibodies ; NT-probNP
P-1518	-0.0551 -0.2961 -1.3298 -0.0046 -0.1128 -0.0445 -1.0647 -0.0911 -0.0404 -0.0482 -0.3489 -0.1915 -4.8997 -0.0117 -0.0067 -0.6003 -0.0648 -0.0870 -0.0806
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine ; bnp ; furosemide ; dobutamine ; norepinephrine ; outcome
H-587	-0.2235870510339737	▁creati nine ▁; ▁b NP ▁; ▁fur os em ide ▁dose ▁; ▁oxygen ▁flow ▁; ▁dobu tamine ▁; ▁no re pine ph rine
D-587	-0.2235870510339737	creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
P-587	-0.6867 -0.1718 -0.0373 -0.0787 -0.4529 -0.0603 -0.1743 -0.4939 -0.0158 -0.0082 -0.4915 -0.0766 -0.2137 -0.5377 -0.0889 -0.0577 -0.0344 -0.1072 -0.0664 -0.0242 -0.0297 -0.5065 -0.0211 -1.0609 -0.0935
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule ; expression ; regulation ; rad ; q66p ; rgk protein ; in vivo
H-1678	-0.7057844400405884	▁expression ▁; ▁mis tar ge ting ▁; ▁rad ▁; ▁q 66 p ▁; ▁R GK ▁protein ▁; ▁ef fica cy
D-1678	-0.7057844400405884	expression ; mistargeting ; rad ; q66p ; RGK protein ; efficacy
P-1678	-0.7783 -0.1382 -0.0045 -0.0144 -0.0401 -0.9646 -0.1304 -3.1028 -0.7522 -2.6633 -0.2609 -0.1840 -0.0913 -1.6719 -0.1813 -0.7144 -1.7345 -0.0670 -0.0037 -0.1570 -1.7942 -0.0784
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte hypertrophy ; heart failure ; global gene expression ; dna ; genomic
H-89	-0.4989888370037079	▁My o cy te ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁gene ▁expression
D-89	-0.4989888370037079	Myocyte hypertrophy ; heart failure ; gene expression
P-89	-0.4722 -0.0512 -0.0835 -0.1496 -0.0391 -0.0051 -0.0989 -0.1375 -0.3051 -0.4862 -0.2661 -2.7147 -0.0833 -2.4521 -0.1404
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change ; correlation ; hospitals ; longitudinal
H-138	-1.3687840700149536	▁hospital s
D-138	-1.3687840700149536	hospitals
P-138	-3.6121 -0.0764 -1.6620 -0.1247
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical ; biomedical ; patients ; dcm ; heart failure ; pubmed
H-1259	-0.3328174352645874	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1259	-0.3328174352645874	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
P-1259	-0.1598 -0.0142 -0.0050 -0.9453 -0.1886 -0.8660 -0.1546 -0.2319 -0.0342 -0.0042 -0.0050 -0.4333 -0.7353 -0.5697 -0.2578 -0.1656 -0.5681 -0.2601 -0.9567 -0.1007
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 ; sst2 ; odds ratio ; cardiovascular event
H-408	-0.9527265429496765	▁s st 2/ high - dos e ▁BB ▁; ▁s st 2 ▁; ▁b ▁; ▁cardiovascular ▁event
D-408	-0.9527265429496765	sst2/high-dose BB ; sst2 ; b ; cardiovascular event
P-408	-0.5806 -2.4944 -1.7224 -0.5908 -0.0154 -0.3884 -0.0633 -1.0364 -0.2730 -1.7066 -2.4995 -0.0633 -0.3942 -3.6296 -1.1524 -0.4739 -0.8011 -0.0856 -0.1310
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones ; adipokines ; fat free mass ; ffm ; fat mass
H-11	-0.4255887269973755	▁neuro hormon es ▁; ▁adi pok ines ▁; cc ▁; ▁progressive ▁loss ▁; ▁fat ▁free ▁mass ▁; FF m ▁; ▁fat ▁mass ▁; FM
D-11	-0.4255887269973755	neurohormones ; adipokines ;cc ; progressive loss ; fat free mass ;FFm ; fat mass ;FM
P-11	-0.0932 -0.0242 -0.1228 -0.1223 -0.0067 -0.0357 -0.2015 -0.1458 -1.3772 -0.1005 -1.1510 -1.1666 -0.6723 -0.5072 -0.8309 -0.4027 -0.2549 -1.4431 -0.1305 -0.3126 -0.2200 -0.7762 -0.5340 -0.0070 -0.2900 -0.1364
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac plasma membrane ; s1pr1 ; β1ar ; heart failure
H-1411	-0.5396291613578796	▁cardiac ▁plasma ▁membran e ▁; ▁s 1 PR 1 ▁; ▁delete rious ▁β 1 AR ▁over stimul ation ▁; ▁heart ▁failure
D-1411	-0.5396291613578796	cardiac plasma membrane ; s1PR1 ; deleterious β1AR overstimulation ; heart failure
P-1411	-1.5873 -1.8226 -0.0020 -0.0626 -0.2145 -2.2613 -0.0848 -0.2721 -0.2891 -0.4635 -1.9729 -0.0331 -0.3470 -0.0612 -0.3814 -1.0766 -0.0553 -0.0272 -0.8221 -0.0768 -0.2525 -0.1413 -0.1044
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley ; randomized ; acf ; allopurinol
H-473	-0.203642800450325	▁Spr a gue - Da w ley ▁rat s ▁; ▁sham ▁; ▁a CF ▁; ▁allo puri nol
D-473	-0.203642800450325	Sprague-Dawley rats ; sham ; aCF ; allopurinol
P-473	-0.0919 -0.2126 -0.0170 -0.0048 -0.6890 -0.1224 -0.3019 -0.3657 -0.0335 -0.1755 -0.0235 -0.0837 -0.4346 -0.3405 -0.1997 -0.0171 -0.0039 -0.1915 -0.6286 -0.1355
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 ; myocardial collagen ; myocardial
H-1064	-0.6477612257003784	▁my o card ial ▁collage n ▁; ▁my o card ial ▁de lay ed ▁imagin g
D-1064	-0.6477612257003784	myocardial collagen ; myocardial delayed imaging
P-1064	-1.3398 -0.1596 -0.1901 -0.3486 -0.1702 -0.1272 -0.1649 -3.7085 -0.1772 -0.3962 -0.4103 -0.0210 -0.0827 -0.0590 -4.0542 -0.0273 -0.1417 -0.0812
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin ; sitagliptin ; follow-up
H-1833	-0.5485578179359436	▁sax ag lip tin ▁; ▁si tag lip tin
D-1833	-0.5485578179359436	saxagliptin ; sitagliptin
P-1833	-0.0691 -0.3456 -0.3761 -1.3652 -0.5438 -0.5429 -0.0012 -0.1626 -0.8280 -1.6726 -0.1268
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter ablation ; patients ; compensated hfpef ; left ventricular ; ejection fraction
H-944	-0.3939465582370758	▁cat heter ▁ab lation ▁; ▁AF ▁; ▁compensa ted ▁h f f ▁; ▁le ft ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction
D-944	-0.3939465582370758	catheter ablation ; AF ; compensated hff ; left ventricular ;LV ; ejection fraction
P-944	-1.1259 -0.0173 -0.0177 -0.0322 -0.5895 -0.1922 -0.1219 -0.6208 -0.1212 -0.7052 -0.7541 -1.0539 -0.1466 -0.7298 -0.0630 -0.0190 -2.4416 -0.1378 -0.1451 -0.2376 -0.6076 -0.1462 -0.3410 -0.0810 -0.1164 -0.0004 -0.3327 -0.1328
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy ; sst2 ; patients ; chronic heart failure
H-411	-1.066313624382019	▁BB ▁ therapy ▁; ▁patients ▁; ▁chronic ▁heart ▁failure
D-411	-1.066313624382019	BB therapy ; patients ; chronic heart failure
P-411	-0.8394 -0.4736 -0.0488 -0.1988 -6.8553 -0.5219 -0.3568 -0.6194 -0.3891 -1.2835 -0.1429
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths ; crt ; hazard ratio
H-853	-0.7885669469833374	▁c rte ▁; ▁hazard ▁ratio
D-853	-0.7885669469833374	crte ; hazard ratio
P-853	-0.3160 -2.6166 -0.5947 -0.6821 -0.0336 -1.0777 -0.1992
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd ; outpatients ; systolic hf ; patients ; egfr
H-396	-0.542167067527771	▁ES RD ▁; ▁out patient s ▁; ▁sy sto lic ▁ HF ▁; ▁e G FR
D-396	-0.542167067527771	ESRD ; outpatients ; systolic HF ; eGFR
P-396	-1.0361 -0.2778 -0.1382 -2.8052 -0.0158 -0.0227 -0.2821 -0.3429 -0.0617 -0.5142 -0.1976 -0.0441 -0.1270 -0.2955 -2.4726 -0.4205 -0.4953 -0.2099
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse ; pasp ; step ; rv function ; lv dysfunction
H-501	-0.5734366774559021	▁passage ▁; ▁length - force ▁relationship ▁; ▁ RV ▁; ▁LV ▁dys function
D-501	-0.5734366774559021	passage ; length-force relationship ; RV ; LV dysfunction
P-501	-3.8594 -0.3433 -0.7427 -0.0186 -0.0728 -1.0549 -0.1245 -0.1986 -0.1791 -0.9293 -0.3049 -0.4758 -0.0993 -0.0893 -0.1089
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel ; apoptotic cells ; tunel-positive cells
H-172	-0.5095618367195129	▁TU nel ▁; ▁apo pto tic ▁cell s ▁; ▁TU nel - posi tive ▁cell s
D-172	-0.5095618367195129	TUnel ; apoptotic cells ; TUnel-positive cells
P-172	-0.8316 -1.3573 -1.3234 -1.3456 -0.0990 -0.5935 -0.0954 -0.0260 -0.3743 -1.1614 -1.1872 -0.0284 -0.0059 -0.0357 -0.1624 -0.0282 -0.4003 -0.1165
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno donor ; myocardial function ; evidence ; hf
H-425	-0.7517616152763367	▁h no ▁donor ▁; ▁my o card ial ▁function ▁; ▁ HF
D-425	-0.7517616152763367	hno donor ; myocardial function ; HF
P-425	-2.3816 -0.1986 -2.1003 -0.2598 -1.7237 -0.1906 -0.1386 -0.2679 -1.9040 -0.2165 -0.8917 -0.0690 -0.0801 -0.1021
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular support ; rvads ; explanted
H-301	-0.8075183033943176	▁bi ven tri cular ▁support ▁; ▁implant ed
D-301	-0.8075183033943176	biventricular support ; implanted
P-301	-0.4895 -0.1412 -0.4352 -0.1993 -0.6541 -0.3972 -3.6894 -1.4357 -0.4642 -0.1693
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions ; readmission ; patients ; congestive heart failure ; south dakota
H-1583	-0.6336546540260315	▁transition s ▁of ▁care ▁; ▁con ges tive ▁heart ▁failure ▁; ▁non - urban ized ▁Mid we stern ▁state ▁; ▁South ▁da kota
D-1583	-0.6336546540260315	transitions of care ; congestive heart failure ; non-urbanized Midwestern state ; South dakota
P-1583	-0.1393 -0.0137 -0.9577 -2.2244 -1.2083 -3.7845 -0.0776 -0.0852 -0.2732 -0.1246 -0.3349 -2.0137 -0.0175 -0.0096 -0.5934 -0.1533 -0.0247 -0.0336 -0.9518 -0.3048 -0.6143 -1.2674 -0.0081 -0.4040 -0.2218
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes ; myocardium ; conditions
H-990	-0.48961141705513	▁cardio my o cy tes ▁; ▁humor al ▁stimul i ▁; ▁my o car dium
D-990	-0.48961141705513	cardiomyocytes ; humoral stimuli ; myocardium
P-990	-0.1098 -0.1138 -0.2530 -0.1650 -0.1838 -0.3230 -2.6349 -0.1251 -0.0931 -0.1467 -0.2353 -1.1626 -0.0651 -0.0199 -0.2055 -2.3488 -0.1380
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation ; consultation ; consultation ; operation
H-1283	-0.9256523251533508	▁implant ation ▁; ▁MT
D-1283	-0.9256523251533508	implantation ; MT
P-1283	-2.7170 -0.0237 -0.4651 -0.9185 -1.3239 -0.1056
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox proportional hazards models ; death ; transplantation ; lv assist device implantation ; heart failure ; hospitalization ; follow-up
H-431	-0.3127017915248871	▁implant ation ▁; ▁LV ▁assist ▁device ▁implant ation ▁; ▁heart ▁failure
D-431	-0.3127017915248871	implantation ; LV assist device implantation ; heart failure
P-431	-1.6199 -0.0087 -0.0730 -0.1580 -0.4766 -0.2880 -0.0069 -0.0197 -0.2618 -0.1382 -0.4624 -0.4242 -0.1277
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity
H-964	-0.2759740948677063	▁Nico rand il ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁; ▁creati ne ▁kina se ▁activity
D-964	-0.2759740948677063	Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation ; creatine kinase activity
P-964	-0.0059 -0.1559 -0.1773 -0.5898 -0.1637 -0.0511 -0.2192 -0.1812 -0.6847 -0.3830 -0.0139 -0.0103 -0.1347 -0.1355 -0.0177 -0.0647 -0.5695 -0.0348 -0.4745 -0.0402 -0.0663 -0.0496 -0.2847 -0.1037 -0.0196 -0.5478 -1.3091 -0.0154 -2.0464 -0.0579 -0.1076 -0.0199 -0.0203 -0.9086 -0.1356 -0.1351
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass correlation coefficient ; icc ; kappa coefficient ; standard error of measurement ; minimal detectable change ; mdc
H-801	-0.45575204491615295	▁intra class ▁corre lation ▁co e ffi cient ▁; IC c ▁; ▁ka ppa ▁co e ffi cient ▁; ▁change ▁; ▁m d c
D-801	-0.45575204491615295	intraclass correlation coefficient ;ICc ; kappa coefficient ; change ; mdc
P-801	-2.7010 -0.1541 -0.3495 -0.2470 -0.0675 -0.2620 -0.0235 -0.0817 -0.1389 -0.2371 -1.7206 -0.0958 -0.1252 -0.0606 -0.0357 -0.0455 -0.0072 -0.0206 -0.2857 -3.3082 -0.1271 -0.1006 -0.1997 -1.0444 -0.2550 -0.1556
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized ; heart failure ; saxagliptin ; sitagliptin ; antihyperglycemic drugs ; retrospective cohort study
H-1826	-0.27636590600013733	▁Hospital ized ▁Heart ▁Fail ure ▁; ▁Sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁Drug s
D-1826	-0.27636590600013733	Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
P-1826	-1.2940 -0.3591 -0.1365 -0.0174 -0.0301 -0.1349 -0.0379 -0.0977 -0.1352 -1.0719 -0.1826 -0.3956 -0.0003 -0.0299 -0.4992 -0.1912 -0.0545 -0.0412 -0.2518 -1.2292 -0.1040 -0.2302 -0.3962 -0.0130 -0.1447 -0.1073
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise ; training ; outcomes ; chronic heart failure ; heart failure - a controlled trial investigating outcomes in exercise training ; hf-action
H-1629	-0.5471795797348022	▁race ▁; ▁exercise ▁training ▁; ▁chronic ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁Out com es ▁; ▁Exerci se ▁Tra i N ing ▁; HF - AC tion
D-1629	-0.5471795797348022	race ; exercise training ; chronic heart failure ; Heart Failure ; controlled Trial Investigating Outcomes ; Exercise TraiNing ;HF-ACtion
P-1629	-1.8389 -0.5135 -4.4874 -1.2828 -0.1213 -0.5973 -0.1503 -0.1846 -0.3255 -1.7691 -0.1333 -0.0411 -0.0874 -0.5790 -0.0349 -0.2214 -0.0110 -0.0979 -0.7218 -0.9142 -0.0683 -0.0184 -0.8963 -0.3570 -0.0191 -0.2406 -0.2984 -1.2396 -0.0647 -0.3074 -0.3832 -0.0073 -0.3666 -0.9981 -0.1612 -0.1595
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient ; primary end point ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cabg
H-972	-0.20557697117328644	▁Swedish ▁national ▁in patient ▁Registr y ▁; ▁re hospital ization ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca BG
D-972	-0.20557697117328644	Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
P-972	-0.1139 -0.6533 -0.1078 -0.1227 -0.4196 -0.0821 -0.2258 -0.1665 -0.0038 -0.3277 -0.3371 -0.0422 -0.1002 -0.2378 -0.2406 -0.0480 -0.1692 -0.0065 -0.5882 -0.1085 -0.1080 -0.1393 -0.0693 -0.5076 -0.4168 -0.2102 -0.1064 -0.0971
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients ; heart failure with preserved ejection fraction ; hfpef ; heart failure ; obese
H-1974	-0.5166612267494202	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f f ▁; ▁heart ▁failure ▁; ▁over weight ▁; ▁obes e
D-1974	-0.5166612267494202	heart failure ; preserved ejection fraction ; hff ; heart failure ; overweight ; obese
P-1974	-2.1819 -0.3527 -0.1842 -0.3487 -0.0094 -0.2002 -0.0388 -0.8299 -0.1598 -0.1299 -0.0012 -0.2819 -0.0965 -0.3382 -0.7514 -0.2562 -0.5854 -0.4250 -0.3645 -3.8246 -0.0533 -1.5662 -0.0160 -0.0525 -0.2153 -0.1695
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal dialysis ; pd ; diuretic ; volume overload ; heart failure ; hf
H-894	-0.24191638827323914	▁Peri tone al ▁di al ysis ▁; PD ▁; ▁di ure tic ▁resist ant ▁volume ▁over load ▁; ▁heart ▁failure ▁; HF
D-894	-0.24191638827323914	Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
P-894	-0.1517 -0.1400 -0.0428 -0.0867 -0.0406 -0.0941 -0.1145 -0.0287 -0.1256 -0.1491 -0.0137 -1.0713 -0.2944 -0.0188 -0.4708 -0.9219 -0.0576 -0.8293 -0.1396 -0.1787 -0.2020 -0.3222 -0.2224 -0.0894
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal dysfunction ; prognostic ; heart failure ; hf ; dysfunction ; end-stage renal disease ; esrd
H-387	-0.35621845722198486	▁Ren al ▁dys function ▁; ▁heart ▁failure ▁; HF ▁; ▁dys function ▁; ▁end - s tage ▁renal ▁disease ▁; ES RD
D-387	-0.35621845722198486	Renal dysfunction ; heart failure ;HF ; dysfunction ; end-stage renal disease ;ESRD
P-387	-1.0484 -0.2129 -0.0300 -0.3078 -0.1008 -1.2055 -0.2902 -0.1277 -0.0779 -0.0992 -1.8389 -0.0835 -0.1980 -0.0744 -0.0342 -0.1421 -0.0013 -0.0126 -0.4188 -0.1328 -1.6909 -0.1332 -0.1693 -0.1187
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression analysis ; echocardiographic ; lv reverse remodeling ; lv end-systolic volume
H-430	-0.22789925336837769	▁e cho car dio graphic ▁score ▁; ▁LV ▁rever se ▁remodel ing ▁; ▁LV ▁end - sy sto lic ▁volume
D-430	-0.22789925336837769	echocardiographic score ; LV reverse remodeling ; LV end-systolic volume
P-430	-0.3265 -0.3189 -0.0499 -0.1997 -0.1293 -0.1972 -0.0588 -0.0638 -0.1704 -0.0111 -0.0226 -0.1292 -0.1047 -0.5521 -1.1228 -0.0119 -0.3185 -0.2699 -0.2916 -0.3759 -0.1669 -0.1222
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral artery disease ; pad ; heart failure ; hf ; prevalence ; hf ; patients ; pad
H-1567	-0.3315633237361908	▁Peri pher al ▁arter y ▁disease ▁; PAD ▁; ▁heart ▁failure ▁; HF ▁; ▁ HF ▁; PAD
D-1567	-0.3315633237361908	Peripheral artery disease ;PAD ; heart failure ;HF ; HF ;PAD
P-1567	-0.2316 -0.0270 -0.3364 -0.1986 -0.4888 -0.7989 -0.1014 -0.0304 -0.0692 -0.1728 -0.2704 -0.1152 -0.1241 -0.1786 -0.4047 -0.0904 -0.1579 -2.5601 -0.1228 -0.1519
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission ; disease ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia
H-137	-0.5442742705345154	▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia
D-137	-0.5442742705345154	heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
P-137	-6.6790 -0.6101 -0.0968 -0.2187 -0.0484 -0.1958 -0.0037 -0.6135 -0.3745 -0.0768 -0.2106 -0.0062 -0.6808 -0.1428 -0.2673 -0.3367 -0.2773 -0.0003 -0.3094 -0.1648 -0.1163
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; fontan circulation
H-1492	-0.22651635110378265	▁per i pher al ▁muscle ▁pump ▁; ▁cardiac ▁fill ing ▁; ▁sub pul mon ary ▁vent ric le ▁; ▁Font an ▁circulation
D-1492	-0.22651635110378265	peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
P-1492	-0.4159 -0.1960 -0.0213 -0.0378 -0.3075 -0.2877 -0.1269 -0.3770 -0.1490 -0.0445 -0.4527 -0.1825 -0.0198 -0.7873 -0.0548 -0.0043 -0.8318 -0.4662 -0.1580 -0.0966 -0.1132 -0.0088 -0.1908 -0.1060
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological phenotype ; clinically ; deficit index ; medical ; frailty
H-1013	-0.5150813460350037	▁bi ological ▁ph eno type ▁; ▁deficit ▁index ▁; ▁medical ▁records
D-1013	-0.5150813460350037	biological phenotype ; deficit index ; medical records
P-1013	-0.0436 -0.2642 -1.0570 -0.3329 -0.0129 -0.3611 -2.4314 -0.1538 -0.2771 -0.2264 -0.3658 -1.0984 -0.0713
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt ; elevated ; acute ; β-adrenoceptor blockade ; esmolol
H-1444	-0.47126978635787964	▁SD QT ▁; ▁ HF VT ▁; ▁h Nor m ▁; ▁β - ad re no cept or ▁block ade ▁; ▁es mol ol
D-1444	-0.47126978635787964	SDQT ; HFVT ; hNorm ; β-adrenoceptor blockade ; esmolol
P-1444	-0.0259 -0.2807 -0.0369 -2.0043 -0.1598 -0.7425 -0.0652 -0.1651 -3.0828 -0.0028 -0.7286 -1.9268 -0.0046 -0.0183 -0.0261 -0.0373 -0.6927 -0.1726 -0.3221 -0.6949 -0.4993 -0.1716 -0.0292 -0.0092 -0.2433 -0.1103
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology ; national cardiovascular disease registry practice innovation and clinical excellence registry
H-660	-0.5023863315582275	▁Card i ology ▁practice s ▁; ▁national ▁Card io vas cular ▁Disease ▁Registr y ▁practice ▁Innovation ▁; ▁Clinic al ▁Excellence ▁registr y
D-660	-0.5023863315582275	Cardiology practices ; national Cardiovascular Disease Registry practice Innovation ; Clinical Excellence registry
P-660	-0.7830 -0.8795 -0.7994 -0.3493 -0.0154 -0.1331 -1.4737 -0.5541 -1.1151 -0.0245 -0.1818 -0.1246 -0.3116 -0.0345 -1.9389 -0.4966 -0.4825 -0.3043 -0.0047 -0.0335 -1.6669 -0.0660 -0.1785 -0.1055
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts ; hh ; medical ; all-cause mortality ; discharged ; patients ; heart failure
H-162	-1.0305217504501343	▁s ts ▁ HH ▁; ▁TM ▁; ▁medical ▁support ▁; ▁all - ca use ▁mortal ity ▁; ▁dis charge d ▁patients ▁; ▁heart ▁failure
D-162	-1.0305217504501343	sts HH ; TM ; medical support ; all-cause mortality ; discharged patients ; heart failure
P-162	-3.2031 -1.9979 -1.4645 -0.0358 -0.1114 -1.0214 -0.5994 -2.2219 -1.3598 -0.5385 -5.6771 -0.0113 -0.0346 -0.0065 -0.0140 -0.0949 -0.1342 -5.1162 -0.0071 -0.1437 -1.1517 -0.9381 -0.3837 -0.2220 -0.1739 -0.1308
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically ; myocardial infarction ; heart failure ; randomized ; bisoprolol
H-452	-0.26885437965393066	▁sur g ically ▁induc ed ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁bis o pro lol ▁; ▁vehicle
D-452	-0.26885437965393066	surgically induced myocardial infarction ; heart failure ; bisoprolol ; vehicle
P-452	-0.6419 -0.0629 -0.1069 -0.1145 -0.0737 -0.4277 -0.1533 -0.1092 -0.3926 -0.0169 -0.5689 -0.1042 -0.1794 -0.0551 -0.0659 -1.5809 -0.4521 -0.0698 -0.0201 -0.1287 -0.3980 -0.4487 -0.1737 -0.1072
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions ; training ; patients ; out-patient ; follow-up ; patient ; health care
H-1579	-0.8396683931350708	▁transition s ▁of ▁care
D-1579	-0.8396683931350708	transitions of care
P-1579	-0.0033 -0.0319 -0.6776 -1.4291 -2.7713 -0.1248
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf ; phenotype ; cardiac ; explant ; progenitors ; regulation
H-1337	-0.5184791684150696	▁CHF ▁; ▁cardiac ▁ex plant ▁c - K it
D-1337	-0.5184791684150696	CHF ; cardiac explant c-Kit
P-1337	-0.1640 -0.1331 -0.5098 -0.1279 -0.0743 -0.6203 -0.0517 -0.4438 -0.0251 -3.4775 -0.0757
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia ; intravenous ; atropine ; cardiac ; vagal tone
H-1380	-0.5637537240982056	▁a tropi ne ▁; ▁cardiac ▁va gal ▁tone ▁; ▁CHF - DN x ▁; ▁CHF - IN v
D-1380	-0.5637537240982056	atropine ; cardiac vagal tone ; CHF-DNx ; CHF-INv
P-1380	-5.6248 -0.3947 -0.4243 -0.1123 -0.0662 -0.3105 -0.0589 -0.0551 -0.4318 -0.0505 -0.0124 -0.1959 -0.0059 -0.2703 -0.1813 -0.0101 -1.4571 -0.9418 -0.5643 -0.1070
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report ; stable ; hno donor ; cxl-1020 ; myoctyes ; hearts ; patients ; heart failure ; hf
H-415	-0.6115754842758179	▁h no ▁donor ▁; ▁c XL -10 20) ▁my oc ty es ▁; ▁intact ▁heart s ▁; ▁heart ▁failure ▁; HF
D-415	-0.6115754842758179	hno donor ; cXL-1020) myoctyes ; intact hearts ; heart failure ;HF
P-415	-0.4565 -0.3480 -1.0538 -0.0818 -1.0165 -0.4857 -0.1344 -0.2003 -5.6800 -0.3597 -0.4519 -0.1474 -0.3026 -0.1287 -0.3302 -0.0360 -0.2255 -1.6185 -0.1107 -0.3562 -0.2869 -0.1463 -0.1087
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.41299667954444885	▁drug - free
D-947	-0.41299667954444885	drug-free
P-947	-0.9918 -0.2149 -0.1706 -0.5769 -0.1108
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet ; patient ; subvalvular ; annular ms
H-374	-0.4624970853328705	▁ms ▁; ▁sub val vu lar ▁; ▁dynamic ▁; ▁ann ular ▁MS ▁; ▁fixed ▁ring ▁size
D-374	-0.4624970853328705	ms ; subvalvular ; dynamic ; annular MS ; fixed ring size
P-374	-1.5136 -0.1894 -1.0417 -1.1358 -0.0730 -0.1070 -0.1188 -1.4114 -0.1557 -0.1048 -0.0135 -0.2434 -0.2582 -0.5747 -0.3900 -0.7326 -0.1619 -0.0997
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes ; chronic heart failure ; hf ; exercise ; training
H-1630	-0.8558073043823242	▁race ▁; ▁chronic ▁heart ▁failure ▁; HF ▁; ▁exercise
D-1630	-0.8558073043823242	race ; chronic heart failure ;HF ; exercise
P-1630	-1.5554 -0.1679 -3.0446 -0.8546 -0.2103 -0.2009 -0.1570 -0.9524 -1.0534 -1.1114 -0.1061
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological ; capillary ; coronary perfusion
H-457	-0.37123993039131165	▁cap illa ry ▁; ▁corona ry ▁per fusion ▁; ▁b - tre ated ▁; ▁ad - f lk ▁rat s ▁; ▁b - tre ated ▁; ▁ad - c ▁rat s
D-457	-0.37123993039131165	capillary ; coronary perfusion ; b-treated ; ad-flk rats ; b-treated ; ad-c rats
P-457	-1.8428 -0.0067 -0.1164 -0.6026 -0.1795 -0.0913 -0.4055 -0.0350 -0.1660 -1.2221 -0.0361 -0.0166 -0.2522 -0.2318 -0.5644 -0.0364 -0.4841 -0.0448 -0.4947 -0.0171 -0.2674 -0.3206 -0.0219 -0.0155 -0.2532 -0.3415 -0.8644 -0.0216 -1.7514 -1.1937 -0.0180 -0.1810 -0.1547
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician ; mortality ; internists ; cardiologists
H-1730	-0.4427180886268616	▁physician ▁volume ▁; ▁mortal ity ▁; ▁intern ists ▁; ▁cardio logist s
D-1730	-0.4427180886268616	physician volume ; mortality ; internists ; cardiologists
P-1730	-0.4539 -1.2977 -0.7407 -0.0078 -0.3960 -0.4764 -0.1360 -1.6845 -0.2293 -0.3123 -0.1115 -0.0886 -0.1658 -0.0977
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle walk test ; hand ; baseline
H-1322	-0.7163376808166504	▁shu ttle ▁walk ▁test ▁; ▁body ▁mass ▁; ▁hand ▁grip ▁strength
D-1322	-0.7163376808166504	shuttle walk test ; body mass ; hand grip strength
P-1322	-0.4827 -0.0057 -0.1511 -1.6511 -0.1523 -0.5286 -0.4459 -0.1436 -2.5843 -0.9226 -0.9674 -1.0589 -0.2181
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc ; frame ; patient ; consultation ; patients
H-1027	-0.5015094876289368	▁protocol - driv en ▁PO C ▁; ▁ NP ▁; ▁consultation ▁; ▁ED ▁; ▁through put ▁; ▁disposition ▁; ▁at - risk ▁patients
D-1027	-0.5015094876289368	protocol-driven POC ; NP ; consultation ; ED ; throughput ; disposition ; at-risk patients
P-1027	-1.2914 -0.0259 -0.0024 -0.0655 -0.3112 -2.5295 -0.8439 -0.5228 -0.0097 -0.1329 -0.9128 -0.1941 -1.0487 -0.6462 -0.3438 -0.0496 -0.2835 -0.2824 -1.3988 -0.1620 -0.1088 -0.0080 -1.0796 -0.1063 -0.1779
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical ; outcomes ; heart failure ; charm ; candesartan in heart failure assessment of reduction in mortality and morbidity
H-554	-0.4447162449359894	▁heart ▁failure ▁; ▁CHA RM ▁programme ▁; Can des ar tan ▁in ▁Heart ▁Fail ure ▁; ▁Mor t ality ▁; ▁Morbi d ity
D-554	-0.4447162449359894	heart failure ; CHARM programme ;Candesartan in Heart Failure ; Mortality ; Morbidity
P-554	-4.8541 -0.3405 -0.2618 -0.1262 -0.4262 -0.1890 -0.2937 -0.5468 -0.0114 -0.1058 -0.0074 -0.0585 -0.3425 -0.0631 -0.0287 -1.2486 -0.2673 -0.0179 -0.0388 -1.2181 -0.0011 -0.0973 -0.2559 -0.1802 -0.1369
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis risk in communities
H-284	-0.4734586775302887	▁Tro ponin ▁; ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁; ▁bio mark er ▁; ▁heart ▁failure ▁risk ▁; ▁at hero sc ler osis ▁risk
D-284	-0.4734586775302887	Troponin ; N-terminal pro-B-type natriuretic peptide ; biomarker ; heart failure risk ; atherosclerosis risk
P-284	-0.1827 -0.0038 -1.5998 -3.0070 -0.0108 -0.0039 -0.0034 -0.2677 -0.0064 -0.5128 -0.0360 -0.0253 -0.0117 -0.0438 -0.0230 -2.0765 -0.3895 -0.1556 -0.1045 -0.3248 -0.5681 -0.0036 -0.0305 -1.3516 -0.3314 -0.1423 -1.1485 -0.2198 -0.1951 -0.1312 -0.8195 -0.9622 -0.0661 -1.7333 -0.4302 -0.1223
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial shunting ; patients ; heart failure with reduced ejection fraction ; proof-of-principle cohort study
H-1948	-0.7091467380523682	▁inter at rial ▁sh unting ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1948	-0.7091467380523682	interatrial shunting ; patients ; heart failure ; ejection fraction
P-1948	-5.2207 -0.0740 -0.1351 -2.0822 -0.1441 -0.2273 -1.2931 -0.9764 -0.2620 -0.2130 -0.1698 -0.7072 -0.3552 -0.1419 -0.0953 -0.0018 -0.5043 -0.1612
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical examination ; patient ; bmi ; heart rate ; rhythm ; blood pressure ; auscultation ; rule ; valvular disease ; pulmonary congestion
H-1894	-0.4612363576889038	▁b mi ▁; ▁heart ▁rate ▁; ▁ rhythm ▁; ▁ly ing ▁; ▁standing ▁blood ▁pressure ▁; ▁val vu lar ▁disease ▁; ▁pulmonar y ▁con gestion
D-1894	-0.4612363576889038	bmi ; heart rate ; rhythm ; lying ; standing blood pressure ; valvular disease ; pulmonary congestion
P-1894	-0.0966 -1.4129 -0.0937 -3.4653 -0.6805 -0.1356 -0.0986 -0.0573 -0.0884 -0.0457 -0.0859 -0.1861 -0.5672 -0.5070 -0.4207 -0.1156 -2.4264 -0.3648 -0.1853 -0.7081 -0.1952 -0.0030 -0.1264 -0.0206 -0.0069 -0.2118 -0.1480
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial extracellular matrix ; cardiac magnetic resonance ; t1 mapping ; pathobiology ; pathophysiology ; prognosis
H-735	-0.3286430835723877	▁my o card ial ▁extra cel lular ▁matri x ▁; ▁cardiac ▁magnetic ▁res on ance
D-735	-0.3286430835723877	myocardial extracellular matrix ; cardiac magnetic resonance
P-735	-0.5346 -0.1929 -0.1003 -0.2195 -0.1534 -0.1287 -0.0132 -0.2296 -0.0854 -0.1855 -0.0112 -0.0715 -0.5618 -0.1218 -0.0162 -2.8389 -0.1223
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone antagonist ; therapy ; chronic advanced heart failure ; patients ; post-myocardial infarction ; heart failure ; patients
H-1738	-0.5272453427314758	▁al do ster one ▁anta gon ist ▁ therapy ▁; ▁chronic ▁advanced ▁heart ▁failure ▁; ▁post - my o card ial ▁in far ction ▁heart ▁failure
D-1738	-0.5272453427314758	aldosterone antagonist therapy ; chronic advanced heart failure ; post-myocardial infarction heart failure
P-1738	-0.3163 -0.0549 -0.0795 -1.0797 -0.0819 -0.0527 -0.9373 -0.3028 -0.0153 -0.1765 -2.0436 -1.5030 -0.6079 -0.1238 -1.4709 -1.1523 -0.0070 -0.0967 -0.4017 -0.1271 -0.2241 -0.0466 -0.8854 -0.1351 -1.2952 -0.0573 -1.2917 -0.1965
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil ; heart rate ; aortic ; blood flow ; mitochondrial ; oxidative stress ; doxorubicin ; cardiotoxicity
H-963	-0.21759958565235138	▁Nico rand il ▁; ▁heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁mito cho ndri al ▁oxid ative ▁stress ▁; ▁do xor ubi cin ▁cardio toxic ity
D-963	-0.21759958565235138	Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxicity
P-963	-0.0103 -0.0623 -0.0659 -0.2529 -1.8394 -1.3064 -0.0794 -0.0056 -0.0191 -0.2854 -0.1164 -0.2229 -0.0770 -0.0231 -0.4451 -0.0838 -0.0273 -0.0337 -0.1589 -0.3860 -0.1360 -0.0130 -0.0025 -0.0058 -0.1752 -0.1639 -0.1090 -0.1880 -0.1368 -0.0970
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed ; heart failure ; left ventricular ejection fraction ; spironolactone ; kaiser permanente ; northern california
H-440	-0.4253307580947876	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁; ▁spi rono lac tone ▁; ▁Kaiser ▁Permanent e ▁Northern ▁California
D-440	-0.4253307580947876	heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
P-440	-1.4258 -0.3584 -0.1234 -0.2521 -0.0149 -1.6751 -0.3505 -0.0493 -0.2092 -0.1761 -0.9797 -0.0964 -0.0038 -0.0205 -0.0114 -2.0802 -0.3906 -0.1224 -0.1224 -0.7666 -0.0399 -0.3849 -0.1288
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative ; renal dysfunction ; cardiovascular events ; stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
H-968	-0.41448044776916504	▁renal ▁dys function ▁; ▁cardiovascular ▁events ▁; stro ke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure
D-968	-0.41448044776916504	renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure
P-968	-0.8946 -0.0082 -0.1602 -0.0887 -0.0256 -0.1615 -0.0882 -0.8250 -0.3861 -0.3512 -0.1985 -0.2236 -0.0259 -0.0973 -0.0181 -0.5316 -0.0592 -0.1037 -0.0665 -0.0986 -4.5509 -0.1553
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum ; systolic ; lv posterior wall ; lv internal diameter ; metoprolol
H-1549	-0.9050378799438477	▁mis ▁; ▁sept um ▁; sy sto lic ▁; ▁thi ck ness ▁; ▁LV ▁; ▁posterior ▁wall ▁thi ck ness ▁; ▁LV ▁internal ▁diameter ▁; ▁met o pro lol
D-1549	-0.9050378799438477	mis ; septum ;systolic ; thickness ; LV ; posterior wall thickness ; LV internal diameter ; metoprolol
P-1549	-3.2603 -0.4468 -0.2963 -0.0457 -0.9044 -0.1252 -0.5852 -0.4997 -0.9075 -5.2425 -0.2217 -1.0137 -0.0498 -0.6636 -0.7982 -2.7887 -1.3557 -2.3908 -0.1712 -0.3580 -0.0996 -0.2903 -4.0692 -0.0586 -0.8611 -0.0613 -0.0514 -0.0116 -0.1914 -0.0976 -0.1391
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american college of physicians ; acp ; evidence ; clinical ; anemia ; patients ; heart disease
H-30	-0.34336569905281067	▁American ▁College ▁of ▁Physic ians ▁; ▁a CP ▁; ▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁heart ▁disease
D-30	-0.34336569905281067	American College of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
P-30	-1.5733 -0.1688 -0.0625 -0.0302 -0.2161 -0.1272 -0.0756 -0.1028 -0.2674 -1.8542 -0.1295 -0.1593 -0.0280 -0.0674 -0.0326 -0.0378 -0.3970 -0.0938 -0.1852 -0.9304 -1.1166 -0.1382 -0.1037
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese ; patients ; clinically ; stable ; hfpef ; exercise ; training ; peak vo2
H-1990	-0.4232323169708252	▁h f f ▁; ▁calor ic ▁restriction ▁; ▁aero bic ▁exercise ▁; ▁VO 2
D-1990	-0.4232323169708252	hff ; caloric restriction ; aerobic exercise ; VO2
P-1990	-0.9805 -0.1577 -0.4499 -0.1500 -0.4044 -0.3782 -0.0726 -0.0393 -0.3581 -0.0628 -0.3035 -1.2788 -1.7004 -0.0200 -0.2426 -0.1729
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2007	-0.6312436461448669	▁économique ▁Analys is ▁; ▁Patient ▁Management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁Cost - E ff ective ness ▁Model ▁; ▁coût - effect ive ness ▁; ▁disease ▁management ▁; ▁heart ▁failure
D-2007	-0.6312436461448669	économique Analysis ; Patient Management Interventions ; Heart Failure Cost-Effectiveness Model ; coût-effectiveness ; disease management ; heart failure
P-2007	-0.8941 -0.8987 -0.0482 -0.2121 -0.4938 -0.9110 -1.5245 -0.0130 -1.0373 -0.2692 -0.0721 -0.0369 -0.7344 -0.0151 -1.2477 -1.6133 -0.0035 -0.2413 -1.0412 -0.4708 -4.4582 -0.0136 -0.1406 -0.0163 -0.4428 -0.2531 -0.1885 -0.0311 -2.0765 -0.9951 -0.1704 -0.1286 -0.1379
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective ; hf ; patients ; hf with reduced ef ; ef ; hfpef ; ef
H-782	-0.47008663415908813	▁ HF ▁registr y ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-782	-0.47008663415908813	HF registry ; HF ; EF ; HFpEF
P-782	-0.7341 -0.1369 -1.1476 -0.2788 -0.3259 -0.6959 -0.1615 -0.1796 -1.1507 -0.1528 -0.7517 -0.2191 -0.0741 -0.4373 -0.9065 -0.1689
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat ; n-terminal pro-brain natriuretic peptide ; hospitalized ; hf
H-1877	-0.38245734572410583	▁BAT ▁; ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁ HF
D-1877	-0.38245734572410583	BAT ; N-terminal pro-brain natriuretic peptide ; HF
P-1877	-0.3826 -0.3694 -2.6274 -0.0245 -0.0155 -0.0104 -0.0942 -0.0691 -0.0896 -0.2474 -0.0147 -0.0346 -0.0237 -1.4308 -0.3746 -0.1094 -0.0615 -0.6565 -1.4204 -0.1701 -0.0953 -0.0925
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients ; hr variability ; mortality ; ami ; diagnosis ; chf ; lv dysfunction
H-1586	-0.4433038532733917	▁HR ▁variabil ity ▁; ▁mortal ity ▁; ▁ AMI ▁; ▁CHF ▁; LV ▁dys function
D-1586	-0.4433038532733917	HR variability ; mortality ; AMI ; CHF ;LV dysfunction
P-1586	-1.1622 -0.3811 -0.1008 -0.2575 -0.4526 -0.1464 -0.2413 -0.5853 -0.0411 -0.1315 -0.3486 -2.2426 -0.5521 -0.2406 -0.3681 -0.1507 -0.1338
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence ; exercise ; cell senescence ; active ; osteoporosis
H-1901	-0.39667418599128723	▁cell ▁se nesc ence ▁; ▁active ▁; ▁malign a ncies ▁; ▁cancer ▁; ▁prostat e ▁; ▁colon ▁; ▁osteo por osis ▁; ▁depression
D-1901	-0.39667418599128723	cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression
P-1901	-2.2583 -0.0587 -0.0525 -0.0068 -0.1778 -0.1959 -1.0074 -0.1321 -0.6592 -0.0565 -0.1123 -0.1272 -0.4145 -0.0237 -0.0657 -0.0931 -0.9662 -0.5639 -0.0277 -0.0837 -0.0299 -0.2104 -0.5469 -1.9635 -0.0831
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended criteria cardiac transplant ; ecct ; transplant ; donors ; transplant ; comorbidity
H-708	-0.8318822383880615	▁cardiac ▁transplant ▁; EC CT ▁; ▁transplant ▁pool ▁; ▁donor s ▁; ▁transplant
D-708	-0.8318822383880615	cardiac transplant ;ECCT ; transplant pool ; donors ; transplant
P-708	-0.1156 -0.1319 -0.3073 -1.2375 -1.5715 -0.6464 -0.2315 -0.3068 -0.6425 -2.8509 -0.0418 -0.4588 -0.9075 -2.9391 -0.0890
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic ; pediatric fontan ; patients ; catheterization
H-227	-0.5791929960250854	▁pediatr ic ▁Font an ▁; PF
D-227	-0.5791929960250854	pediatric Fontan ;PF
P-227	-1.8383 -0.2364 -0.1750 -0.2867 -0.4891 -0.1414 -1.3160 -0.1507
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ; ventricular assist devices ; cardiac ; nurses ; gastrointestinal bleeding
H-1660	-0.286505788564682	▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse s ▁; ▁gastro inte stin al ▁ble ed ing
D-1660	-0.286505788564682	ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
P-1660	-0.0042 -1.3723 -0.1252 -0.2274 -0.2102 -0.2757 -1.2468 -0.0792 -0.0245 -0.2789 -0.5374 -0.0099 -0.1077 -0.0408 -0.0411 -0.3818 -0.1881 -0.1502 -0.1424
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the lancet ; anoop shah ; air ; heart failure ; morbidity ; mortality
H-1807	-0.3619730770587921	▁Lance t ▁; ▁ano op ▁Shah ▁; ▁air ▁pollution ▁; ▁heart ▁failure
D-1807	-0.3619730770587921	Lancet ; anoop Shah ; air pollution ; heart failure
P-1807	-0.0146 -0.0236 -0.0765 -0.4497 -0.0321 -0.1144 -0.1328 -0.0223 -0.0241 -0.2138 -0.2253 -0.1870 -3.4398 -0.1115
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia ; hf ; health-related quality of life ; hrqol ; hf
H-835	-0.36921682953834534	▁an emia ▁; ▁ HF ▁; ▁health - related ▁quality ▁of ▁life ▁; HR Qo L ▁; ▁ HF
D-835	-0.36921682953834534	anemia ; HF ; health-related quality of life ;HRQoL ; HF
P-835	-0.6482 -0.1050 -0.3197 -1.0634 -0.0434 -0.1346 -0.9918 -0.0335 -0.0423 -0.3443 -0.4291 -0.4675 -0.1211 -0.6282 -0.0331 -0.3813 -0.5949 -0.9556 -0.1389 -0.1560 -0.1217
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell therapy ; chronic heart failure ; chf ; disease ; progenitor cells
H-1336	-0.2318650782108307	▁cell ▁ therapy ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁ex plant - der i ved ▁pro gen itor ▁cell s
D-1336	-0.2318650782108307	cell therapy ; chronic heart failure ;CHf ; explant-derived progenitor cells
P-1336	-1.0869 -0.0800 -0.0165 -0.1912 -0.2606 -0.5200 -0.2819 -0.1171 -0.6661 -0.0930 -0.1685 -0.4693 -0.0482 -0.0164 -0.1347 -0.0994 -0.1736 -0.3379 -0.1076 -0.0630 -0.3399 -0.0228 -0.1620 -0.1082
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous nonfailing ; hf ; combinations ; remodeling
H-1152	-0.27300530672073364	▁m RI - based ▁models ▁; ▁dys syn chron ous ▁non fail ing ▁; ▁ HF ▁can ine ▁electro me chan ics
D-1152	-0.27300530672073364	mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
P-1152	-0.1625 -0.8973 -0.2434 -0.3582 -0.5446 -0.4668 -0.0068 -0.0042 -0.0031 -0.2600 -0.0540 -0.0043 -0.0665 -0.0791 -0.4637 -0.0485 -0.5085 -0.0361 -0.0366 -0.0093 -0.0869 -0.9060 -1.1211 -0.1845
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients ; acute rv failure ; chronic pulmonary arterial hypertension ; pah ; acute ; pulmonary embolism
H-1095	-0.2754270136356354	▁ RV ▁failure ▁; ▁chronic ▁pulmonar y ▁arterial ▁hyper tension ▁; PA h ▁; ▁a cute ▁pulmonar y ▁e mbol ism
D-1095	-0.2754270136356354	RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
P-1095	-1.3260 -0.4415 -0.1786 -0.2705 -0.4714 -0.0052 -0.0341 -0.0201 -0.0269 -0.0325 -0.2114 -0.6113 -0.4097 -0.3760 -0.4721 -0.0140 -0.0052 -0.0536 -0.1082 -0.0041 -0.9640 -0.1741 -0.1242
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute rv failure ; pulmonary embolism ; mortality ; diagnostic
H-1097	-0.383276104927063	▁ RV ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁mortal ity
D-1097	-0.383276104927063	RV failure ; pulmonary embolism ; mortality
P-1097	-0.9788 -0.6527 -0.3810 -0.1097 -0.0226 -0.0360 -0.1156 -0.0106 -0.8766 -1.2240 -0.3465 -0.3762 -0.1120 -0.1237
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin ; chemotherapy ; elevated ; cardiotoxicity
H-937	-0.37222394347190857	▁se rum ▁resist in ▁; ▁an thra cycli ne - conta ining ▁che mo therapy ▁; ▁cardio toxic ity
D-937	-0.37222394347190857	serum resistin ; anthracycline-containing chemotherapy ; cardiotoxicity
P-937	-1.3785 -0.1430 -0.2278 -0.4802 -0.2604 -0.9743 -0.0685 -1.1069 -0.3783 -0.0623 -0.0189 -0.3261 -0.3444 -0.1216 -0.0380 -0.7311 -0.1247 -0.1629 -0.5483 -0.1332 -0.1874
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients ; sst2 ; titrated ; cardiovascular event
H-405	-1.0205622911453247	▁s st 2 ▁; ▁b ▁; ▁cardiovascular ▁event
D-405	-1.0205622911453247	sst2 ; b ; cardiovascular event
P-405	-0.5247 -2.0884 -0.1238 -0.1681 -3.5451 -0.8475 -0.2818 -0.8898 -1.6238 -0.1127
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad ; q66p ; cardiomyopathy
H-1677	-0.856502890586853	▁rad ▁Q 66 p ▁; ▁cardio my o pathy
D-1677	-0.856502890586853	rad Q66p ; cardiomyopathy
P-1677	-0.3785 -4.3071 -0.1093 -0.2169 -0.1676 -0.0855 -0.5274 -0.2391 -0.0283 -3.2377 -0.1241
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular ; wall stiffness
H-1148	-0.5047934055328369	▁vent ri cular ▁structure ▁; ▁ge ometr y ▁; ▁fiber ▁; she et ▁ orientation ▁; ▁handling ▁; ▁slow ed ▁con duction ▁; ▁wall ▁sti ff ness
D-1148	-0.5047934055328369	ventricular structure ; geometry ; fiber ;sheet orientation ; handling ; slowed conduction ; wall stiffness
P-1148	-0.0186 -1.6063 -0.2219 -0.3580 -0.0989 -1.8970 -0.0656 -0.1351 -0.0763 -0.0929 -0.6416 -0.0538 -0.1875 -0.2130 -0.0043 -0.2819 -3.8673 -0.2338 -0.5821 -0.3311 -0.0526 -0.0208 -0.2811 -1.2045 -0.2132 -0.3890 -0.9280 -0.3927 -0.1902
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.6904374957084656	▁SD QT - to - SD RR ▁ratio ▁; ▁ HF VT ▁; ▁h n m
D-1441	-0.6904374957084656	SDQT-to-SDRR ratio ; HFVT ; hnm
P-1441	-0.2338 -0.8571 -0.1255 -1.2534 -0.0159 -0.0251 -0.5263 -0.0518 -0.1108 -1.2258 -0.2738 -0.7263 -0.2608 -0.4246 -4.9709 -0.3008 -0.9133 -0.1316
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration ; renin-angiotensin system blocker ; beta-blocker ; therapy ; patients ; hospitalized ; heart failure ; preserved left ventricular ejection fractions
H-174	-0.27562853693962097	▁re nin - angi oten sin ▁system ▁block er ▁; ▁beta - block er ▁ therapy ▁; ▁heart ▁failure ▁; ▁vent ri cular ▁e je ction ▁ fraction s
D-174	-0.27562853693962097	renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; ventricular ejection fractions
P-174	-0.0165 -0.6311 -0.0299 -0.0545 -0.1132 -0.4715 -0.1941 -0.3337 -0.1312 -0.1764 -0.0672 -0.0113 -0.0398 -0.0350 -0.1810 -0.0163 -0.2067 -0.2717 -0.2924 -0.2714 -1.5559 -1.1261 -0.1533 -0.2305 -0.3596 -0.3705 -0.6857 -0.0011 -0.0471 -0.2433 -0.2267
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use of exercise and medical therapies to improve cardiac function among patients with exertional shortness of breath due to lung congestion
H-1180	-0.560588002204895	▁Exerci se ▁; ▁Medical ▁Therapie s ▁; ▁Card iac ▁Fun ction ▁; ▁Short ness ▁of ▁Breath ▁; ▁Lung ▁Con gestion
D-1180	-0.560588002204895	Exercise ; Medical Therapies ; Cardiac Function ; Shortness of Breath ; Lung Congestion
P-1180	-3.5779 -0.0628 -0.1063 -0.2302 -0.0973 -0.0152 -0.1969 -0.2969 -0.1222 -0.1105 -0.0076 -0.1697 -2.6334 -0.7910 -1.0886 -0.0797 -0.3646 -0.1422 -1.2416 -0.0122 -0.8909 -0.0954
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional electrical stimulation ; peripheral muscles ; endothelial function ; clinical ; heart failure ; patients ; preserved left ventricular ejection fraction
H-1326	-0.3883872926235199	▁electric al ▁stimul ation ▁; ▁per i pher al ▁muscle s ▁; ▁en dot heli al ▁function ▁; ▁heart ▁failure ▁; ▁vent ri cular ▁e je ction ▁ fraction
D-1326	-0.3883872926235199	electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; ventricular ejection fraction
P-1326	-0.8870 -0.0210 -0.1118 -0.0127 -0.3024 -0.1987 -0.3900 -0.0601 -0.1149 -0.7228 -0.0293 -0.2190 -0.1319 -0.5823 -0.0208 -0.0076 -2.4232 -0.1283 -1.3191 -0.2657 -0.4399 -0.7423 -0.9687 -0.0761 -0.3095 -0.3533 -0.5274 -0.2738 -0.0006 -0.2243 -0.1757
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
H-1139	-0.5112358927726746	▁ta chy car dic ▁response ▁; ▁met hy la tropi ne ▁; ▁va gal ▁tone ▁; ▁bra dy car dic ▁response ▁; ▁propra no lol
D-1139	-0.5112358927726746	tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol
P-1139	-3.2716 -1.3474 -0.1883 -0.3133 -1.1316 -0.2836 -0.0583 -0.0880 -0.6452 -0.0176 -0.9103 -0.1994 -0.0750 -0.0318 -0.2968 -0.2459 -0.4467 -0.3090 -0.0327 -0.1496 -1.4045 -0.2281 -0.0675 -0.0054 -0.1129 -1.8293 -0.1135
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac resynchronization therapy ; crt ; mild heart failure ; hf ; patients ; qrs prolongation ; ejection fraction ; ef
H-751	-0.31687524914741516	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁mild ▁heart ▁failure ▁; HF ▁; ▁QR s ▁prolong ation ▁; ▁e je ction ▁ fraction ▁; EF
D-751	-0.31687524914741516	cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs prolongation ; ejection fraction ;EF
P-751	-0.4022 -0.0131 -0.0595 -0.0116 -0.9175 -0.5746 -0.0531 -0.1316 -0.5110 -1.5141 -0.1324 -0.4602 -0.1853 -0.2257 -0.0982 -0.3032 -0.1774 -0.1402 -0.9147 -0.9103 -0.0877 -0.2465 -0.0193 -0.2225 -0.1141 -0.1236 -0.0006 -0.7608 -0.0598 -0.2503 -0.2017
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ; lad
H-509	-0.3579820692539215	▁Fra ction al ▁flow ▁reserve ▁; ▁posi tron ▁e mission ▁tom ography ▁imagin g ▁; ▁ ische mia ▁; ▁bottle ne ck ▁sten ting ▁; ▁left ▁vent ric le ▁; ▁ LAD
D-509	-0.3579820692539215	Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; LAD
P-509	-1.0733 -0.0039 -0.1406 -0.3556 -0.4058 -0.1509 -0.0150 -0.0092 -0.0211 -0.0797 -0.4870 -0.2457 -0.2385 -0.0250 -0.1510 -0.2231 -0.2080 -0.4251 -0.3345 -0.0615 -0.0159 -0.1647 -0.0966 -1.5412 -0.1530 -0.2761 -0.0179 -1.9105 -1.3806 -0.2717 -1.1967 -0.0092 -0.3971 -0.0858
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity ; oxidative stress ; dna fragmentation
H-962	-0.29214897751808167	▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁; ▁creati ne ▁kina se ▁activity ▁; ▁oxid ative ▁stress ▁marker s ▁; ▁DNA ▁fragment ation
D-962	-0.29214897751808167	mitochondrial oxidative phosphorylation ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
P-962	-0.0150 -0.7402 -0.0457 -0.0634 -0.1875 -0.2977 -0.0572 -0.0243 -0.3831 -1.2005 -0.0120 -1.4944 -0.0190 -0.0804 -0.0089 -0.0292 -0.4111 -0.1037 -0.0111 -0.1089 -0.2409 -0.2162 -0.0153 -0.7162 -0.1380 -0.6926 -0.0249 -1.0274 -0.1075
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox regression ; covariates ; spironolactone ; death ; hospitalization ; hyperkalemia ; acute kidney injury
H-442	-0.3627999424934387	▁spi rono lac tone ▁; ▁death ▁; ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury
D-442	-0.3627999424934387	spironolactone ; death ; hyperkalemia ; acute kidney injury
P-442	-0.4032 -0.0151 -0.0607 -0.0491 -1.4178 -3.0807 -0.1066 -0.1240 -0.1060 -0.0852 -0.1975 -0.3588 -0.0059 -0.1658 -0.3097 -0.0463 -0.1040 -0.1168 -0.1401
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes ; mortality ; hospitalization ; mortality ; cardiovascular mortality ; hf ; hospitalization ; cox models ; exercise ; training
H-1633	-0.4777716100215912	▁mortal ity ▁; ▁cardiovascular ▁mortal ity ▁; HF ▁hospital ization ▁; ▁co x ▁models
D-1633	-0.4777716100215912	mortality ; cardiovascular mortality ;HF hospitalization ; cox models
P-1633	-0.8996 -0.1791 -0.1893 -0.0929 -0.0168 -0.1207 -0.1570 -1.1306 -0.7550 -0.5029 -0.8084 -0.3749 -0.0062 -1.3944 -0.8953 -0.1213
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin inhibitors ; natriuretic peptide ; atrial natriuretic peptide ; b-type natriuretic peptide
H-1462	-0.5364768505096436	▁Ne pri ly sin ▁inhibi tors ▁; ▁na tri ure tic ▁pe pti de ▁system ▁; ▁at rial ▁na tri ure tic ▁pe pti de ▁; ▁b - type ▁na tri ure tic ▁pe pti de
D-1462	-0.5364768505096436	Neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; b-type natriuretic peptide
P-1462	-2.8030 -0.0748 -1.3604 -0.4138 -0.1392 -1.0002 -0.1367 -0.0829 -0.1454 -0.0559 -2.1009 -0.3514 -0.1455 -0.1226 -1.0431 -0.2918 -1.8885 -0.1215 -0.0584 -0.1620 -0.0553 -2.1490 -0.2773 -0.0769 -0.1041 -0.4610 -0.5764 -0.0445 -0.0969 -0.0280 -0.1612 -0.0488 -2.8684 -0.3367 -0.1140 -0.1099 -0.1999 -0.1798
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse ; pasp ; downward ; hfref ; hfpef ; prognostic ; resolution
H-500	-0.6057729125022888	▁T AP se ▁; ▁PAS p ▁; ▁non sur viv ors ▁; ▁h Fr EF ▁; ▁ HF p EF
D-500	-0.6057729125022888	TAPse ; PASp ; nonsurvivors ; hFrEF ; HFpEF
P-500	-4.1814 -0.3510 -0.7593 -0.3002 -0.3311 -0.4985 -0.4049 -2.1980 -0.0084 -0.0289 -0.3786 -0.0607 -0.1048 -1.2706 -0.5327 -0.0768 -0.3690 -0.1927 -0.0319 -0.2368 -0.9254 -0.0852
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action ; randomized ; patients ; hf ; ejection fraction ; exercise ; training
H-1632	-0.7778932452201843	▁ HF - AC tion ▁; ▁ HF ▁; ▁ HF ▁; ▁e je ction ▁ fraction
D-1632	-0.7778932452201843	HF-ACtion ; HF ; HF ; ejection fraction
P-1632	-1.4253 -0.0929 -0.0340 -1.3999 -0.8452 -0.2017 -1.7941 -0.1655 -0.3678 -2.4164 -0.1550 -0.4067 -0.6551 -1.2394 -0.1159 -0.2519 -0.0017 -3.0136 -0.1977
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic ; proteins ; histone acetyltransferases ; epigenetic ; histone deacetylases ; cardiac ; disease
H-1041	-0.6127378344535828	▁protein s ▁; hi stone ▁a ce tyl transfer as es ▁; ▁epi gene tic ▁; eras ers ▁; hi stone ▁de ace ty las es ▁; ▁cardiac ▁development
D-1041	-0.6127378344535828	proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac development
P-1041	-5.4944 -0.0233 -0.1509 -0.0575 -0.3490 -0.0119 -0.2524 -0.2659 -0.0263 -0.1041 -0.0597 -0.3217 -1.6640 -0.0560 -0.9673 -2.4608 -0.1417 -0.0737 -0.4541 -0.0646 -0.7071 -0.0230 -0.2434 -1.5911 -0.1105 -0.0265 -0.4830 -0.0269 -0.7778 -1.7897 -0.2168
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated ; nt-probnp ; admission ; all-cause mortality ; patients ; acute hf ; admission
H-270	-0.21762774884700775	▁NT - pro b NP ▁; ▁mortal ity ▁; ▁a cute ▁ HF
D-270	-0.21762774884700775	NT-probNP ; mortality ; acute HF
P-270	-0.0314 -0.0094 -0.0050 -0.5944 -0.1179 -0.4002 -0.6001 -0.2131 -0.2921 -0.4451 -0.0449 -0.1877 -0.0360 -0.0768 -0.2104
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic cell transplantation ; hct ; congestive heart failure ; chf ; anthracyclines
H-1449	-0.3837931156158447	▁ha e mato po ie tique ▁cell ▁transplant ation ▁; ▁h CT ▁; ▁con ges tive ▁heart ▁failure ▁; CH f ▁; ▁h CT ▁; ▁an thra cycli nes
D-1449	-0.3837931156158447	haematopoietique cell transplantation ; hCT ; congestive heart failure ;CHf ; hCT ; anthracyclines
P-1449	-0.8972 -0.1315 -0.0354 -0.0712 -0.2179 -1.4493 -0.2790 -0.0652 -0.0332 -0.1853 -0.1138 -1.6631 -0.2216 -0.6969 -0.0850 -0.1629 -0.3307 -0.1532 -0.1931 -0.3744 -0.0730 -0.1331 -0.3590 -1.8840 -0.8749 -0.3023 -0.0313 -0.4488 -0.0860 -0.1843 -0.1610
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; administration ; doxorubicin
H-956	-0.1904180347919464	▁cardio protec tive ▁effect ▁; ▁nic oran dil ▁; ▁hem o dynamic ▁altera tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁do xor ubi cin
D-956	-0.1904180347919464	cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; doxorubicin
P-956	-0.1345 -0.2618 -0.0296 -0.7096 -0.2388 -0.0691 -0.0242 -0.1654 -0.1074 -0.3976 -0.0896 -0.0168 -0.5394 -0.0199 -0.0885 -0.0027 -0.8012 -0.0277 -0.0373 -0.0044 -0.0828 -0.2703 -0.2349 -0.0146 -0.0160 -0.2573 -0.6130 -0.0773
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in vivo ; mir-25 ; antagomir ; cardiac dysfunction ; murine ; myocardium ; heart failure
H-643	-0.48457998037338257	▁in ▁vivo ▁inhibi tion ▁; ▁mi r -25 ▁; ▁cardiac ▁dys function ▁; ▁mur ine ▁my o car dium ▁; ▁heart ▁failure
D-643	-0.48457998037338257	in vivo inhibition ; mir-25 ; cardiac dysfunction ; murine myocardium ; heart failure
P-643	-1.7557 -0.0764 -0.3114 -0.0378 -0.2758 -0.0988 -0.8936 -0.3822 -0.1978 -2.8392 -0.0441 -0.2015 -0.1442 -0.1294 -0.3621 -1.0357 -0.0891 -0.0249 -0.1590 -1.4901 -0.2599 -0.2579 -0.3333 -0.2299
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine ; patients ; dilated cardiomyopathy ; dcm ; heart failure
H-1258	-0.3108488619327545	▁Chinese ▁herbal ▁medicine ▁; CH m ▁; ▁dil ated ▁cardio my o pathy ▁; DC m ▁; ▁heart ▁failure
D-1258	-0.3108488619327545	Chinese herbal medicine ;CHm ; dilated cardiomyopathy ;DCm ; heart failure
P-1258	-0.8045 -0.1234 -0.1291 -0.0918 -1.2675 -0.1071 -0.1861 -1.5087 -0.2651 -0.0939 -0.4435 -0.4795 -0.0127 -0.1001 -0.1193 -0.1034 -0.2297 -0.0691 -0.0997 -0.1533 -0.1404
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension ; diabetes mellitus ; grade ; systolic ; diastolic murmurs ; apex
H-347	-0.1637309491634369	▁hyper tension ▁; ▁h g ▁; ▁diabetes ▁mell itus ▁; ▁sy sto lic ▁; ▁dia sto lic ▁mur mur s
D-347	-0.1637309491634369	hypertension ; hg ; diabetes mellitus ; systolic ; diastolic murmurs
P-347	-0.1156 -0.0478 -0.0932 -0.0735 -0.0145 -0.0965 -0.0491 -0.0046 -0.0439 -0.2695 -0.7042 -0.0672 -0.2764 -0.4797 -0.0340 -0.1869 -0.4779 -0.1888 -0.0233 -0.0552 -0.1799 -0.1205
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative ; patients ; preoperative ; hypoalbuminemia ; albumin
H-533	-0.8535867929458618	▁hypo album in emia ▁; ▁album in
D-533	-0.8535867929458618	hypoalbuminemia ; albumin
P-533	-3.4786 -0.1025 -0.2459 -0.2525 -0.5185 -1.9152 -0.4078 -0.6285 -0.1329
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left bundle branch block ; remodeling ; dyssynchronous heart failure ; hf ; heart
H-1147	-0.22954130172729492	▁electric al ▁activa tion ▁; ▁dys syn chron ous ▁heart ▁failure ▁; HF ▁; ▁electro me chan ical ▁behavior ▁; ▁heart
D-1147	-0.22954130172729492	electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
P-1147	-0.7855 -0.0121 -0.6492 -0.0249 -0.1823 -0.0097 -0.0021 -0.0025 -0.4553 -0.4076 -0.2101 -0.1497 -0.1173 -0.2195 -0.0153 -0.0066 -0.0492 -0.0628 -0.4583 -0.5094 -0.6381 -0.1844 -0.1276
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients ; heart failure ; heart ; cardiologists ; cardiovascular ; surgeons ; medical ; patient
H-1822	-0.6052981019020081	▁patients ▁; ▁advanced ▁heart ▁failure ▁; heart ▁team ▁; ▁cardio logist s ▁; ▁cardiovascular ▁surge ons
D-1822	-0.6052981019020081	patients ; advanced heart failure ;heart team ; cardiologists ; cardiovascular surgeons
P-1822	-1.6543 -0.9701 -0.9538 -0.5648 -0.7111 -0.3152 -0.5896 -1.2723 -0.3452 -0.2157 -0.0608 -0.0449 -0.2570 -0.1735 -0.1957 -0.2003 -2.2258 -0.1453
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex sensitivity ; heart rate variability ; hrv ; renal dnx
H-1376	-0.4727625846862793	▁Baro re flex ▁ sensitiv ity ▁; ▁time ▁domain ▁heart ▁rate ▁variabil ity ▁; HR V ▁; ▁CHF - IN V ▁; ▁sham - IN v ▁; ▁sham - in v ▁; ▁renal ▁DN x
D-1376	-0.4727625846862793	Baroreflex sensitivity ; time domain heart rate variability ;HRV ; CHF-INV ; sham-INv ; sham-inv ; renal DNx
P-1376	-0.0481 -0.0470 -0.0310 -0.3326 -0.0962 -0.0701 -0.1248 -0.9161 -0.2055 -1.9928 -0.8580 -0.1840 -0.2733 -0.1265 -0.6000 -0.7266 -0.1957 -0.1382 -0.0165 -1.3420 -1.0477 -0.2804 -0.1045 -0.0208 -1.4022 -1.0307 -0.1509 -0.3770 -0.5124 -1.3901 -0.9375 -0.2027 -1.0171 -0.2794 -0.0032 -0.2499 -0.1606
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
H-1542	-0.19157245755195618	▁bis phos phon ates ▁; ▁ale ndr onate ▁; ▁et id rona te ▁; ▁heart ▁failure
D-1542	-0.19157245755195618	bisphosphonates ; alendronate ; etidronate ; heart failure
P-1542	-0.0976 -0.0060 -0.0245 -0.1572 -0.1245 -0.0114 -0.0088 -0.0256 -0.1038 -0.0287 -0.2032 -0.0074 -0.0054 -0.1862 -1.5188 -0.2320 -0.5942 -0.1131
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse ; hospitalization ; physician ; discharge ; patients ; hospitalized ; heart failure
H-206	-0.436165452003479	▁nurse ▁; ▁cognitive ▁im pair ment ▁; ▁physician ▁; ▁dis charge ▁; ▁el der ly ▁patients ▁; ▁heart ▁failure
D-206	-0.436165452003479	nurse ; cognitive impairment ; physician ; discharge ; elderly patients ; heart failure
P-206	-0.1110 -1.0999 -0.1265 -0.0427 -0.0723 -0.0620 -0.5251 -1.1663 -0.3035 -0.9224 -0.0031 -0.2205 -0.1480 -0.1408 -0.2062 -0.6907 -2.0104 -0.8617 -0.1787 -0.1422 -0.1257
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol ; nonselective β-blocker ; selective β-blocker ; metoprolol ; thromboembolic events ; heart failure
H-1111	-0.46226200461387634	▁car vedi lol ▁; ▁β - block er ▁; ▁β - block er ▁met o pro lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure
D-1111	-0.46226200461387634	carvedilol ; β-blocker ; β-blocker metoprolol ; thromboembolic events ; heart failure
P-1111	-1.1738 -0.0087 -0.0773 -0.2650 -1.6043 -0.0184 -0.1078 -0.1266 -0.4033 -3.1531 -0.0107 -0.1269 -0.1414 -1.9373 -0.1548 -0.0227 -0.1393 -0.2684 -0.2080 -0.2802 -0.3634 -0.5250 -0.0079 -0.7367 -0.3845 -0.7725 -0.1877 -0.3664 -0.1567 -0.1392
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline ; cardiac transplant ; ecct
H-716	-0.49282777309417725	▁cardiac ▁transplant ▁survival ▁; ▁EC CT
D-716	-0.49282777309417725	cardiac transplant survival ; ECCT
P-716	-0.5134 -0.1759 -1.1937 -0.9728 -0.3073 -0.4828 -0.1615 -0.1352
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ; ami ; pna ; mortality
H-1700	-0.7594748735427856	▁ HF ▁; ▁ AMI ▁; ▁p na ▁; ▁mortal ity
D-1700	-0.7594748735427856	HF ; AMI ; pna ; mortality
P-1700	-3.3791 -0.2088 -0.0758 -1.4866 -0.5908 -0.1098 -1.1689 -0.4648 -0.5549 -0.9097 -0.2309 -0.5582 -0.1348
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients ; heart failure ; hf ; evidence ; outcomes ; hf
H-685	-0.9184938669204712	▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁ HF
D-685	-0.9184938669204712	patients ; heart failure ;HF ; HF
P-685	-4.6679 -1.0668 -0.3046 -0.3181 -0.1522 -0.1161 -0.4661 -2.3648 -0.0240 -0.4891 -0.1338
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling ; arrhythmia ; ami ; hr variability ; arrhythmia
H-1590	-0.7314258813858032	▁implant ing ▁; ▁ar rhythm ia ▁substrat e ▁; ▁ AMI ▁; ▁HR ▁variabil ity
D-1590	-0.7314258813858032	implanting ; arrhythmia substrate ; AMI ; HR variability
P-1590	-1.8201 -0.6808 -0.3255 -2.8430 -0.1277 -0.7136 -0.0764 -0.1773 -0.1599 -1.8192 -0.0382 -0.1481 -0.1552 -0.7126 -0.0833 -2.4142 -0.1390
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced cardiotoxicity ; resistin ; retn
H-933	-0.372150719165802	▁do xor ubi cin - indu ced ▁cardio toxic ity ▁; ▁Hum - Re t n ▁mi ce ▁; ▁litt er mate ▁; ▁human ▁resist in ▁; ▁re t n
D-933	-0.372150719165802	doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate ; human resistin ; retn
P-933	-0.0027 -0.0055 -0.0188 -0.5249 -0.0401 -0.0117 -0.4681 -0.0387 -0.1410 -0.2014 -0.1452 -0.1306 -0.0299 -1.8388 -0.0607 -0.0383 -2.1783 -0.0698 -0.0876 -0.2429 -0.0048 -0.0272 -0.7434 -2.2934 -0.4681 -0.1721 -0.7104 -0.7904 -0.1807 -0.0161 -0.1377 -0.0896
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients ; hypertension ; compensated hfpef ; dash ; sodium
H-919	-0.569852352142334	▁hyper tension ▁; ▁compensa ted ▁H FP EF ▁; ▁DAS h ▁; ▁s RD ▁; tar get ▁so dium ▁; ▁kcal
D-919	-0.569852352142334	hypertension ; compensated HFPEF ; DASh ; sRD ;target sodium ; kcal
P-919	-0.1363 -0.2053 -0.0900 -0.7282 -0.2326 -1.2503 -0.8880 -0.3067 -0.0874 -0.1371 -0.6544 -0.5501 -2.5861 -2.1657 -0.3224 -0.7757 -0.0056 -0.0780 -0.1758 -0.7888 -0.6648 -0.1661 -0.1112
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd ; dyssynchronous hf ; remodeling ; insignificantly
H-1154	-0.3004220426082611	▁em d ▁; ▁dys syn chron ous ▁ HF
D-1154	-0.3004220426082611	emd ; dyssynchronous HF
P-1154	-1.7863 -0.2756 -0.1330 -0.0183 -0.0039 -0.0030 -0.4105 -0.1134 -0.0245 -0.3950 -0.1411
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic dysfunction ; pathophysiology ; hfpef ; cardiovascular function
H-1302	-0.5091193914413452	▁dia sto lic ▁dys function ▁; ▁pat ho phy si ology ▁; ▁ HF p EF ▁; ▁non - dia sto lic ▁ab normal ities ▁; ▁cardiovascular
D-1302	-0.5091193914413452	diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular
P-1302	-0.2713 -0.2858 -2.3471 -0.0217 -0.2475 -0.0702 -0.4993 -0.0233 -0.0847 -0.7258 -0.9998 -0.2417 -0.6911 -0.1023 -0.0167 -0.1421 -0.2095 -3.1711 -0.0090 -0.1145 -0.3109 -0.4001 -0.0409 -0.0267 -0.4486 -0.3301 -0.0429 -2.7430 -0.1468
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ; ejection fraction ; cardiac index ; inotropes ; medical ; transplant
H-1997	-0.3470258414745331	▁e je ction ▁ fraction ▁; ▁cardiac ▁index ▁; ▁in o trop es ▁; ▁in ot rope - dependent
D-1997	-0.3470258414745331	ejection fraction ; cardiac index ; inotropes ; inotrope-dependent
P-1997	-0.5708 -0.2879 -0.0748 -0.1754 -0.0009 -0.2778 -0.2224 -0.0958 -0.1892 -0.0406 -0.6314 -0.0249 -0.4201 -0.1880 -0.0444 -0.7675 -0.0232 -0.0589 -0.0361 -2.9574 -0.2000
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density lipoprotein ; hdl ; endothelial cell ; nitric oxide
H-246	-0.5007234215736389	▁lipo prote in ▁; HD l ▁; ▁en dot heli al - protec tive ▁effects ▁; ▁en dot heli al ▁cell ▁; EC ▁; ▁ni tric ▁oxid e
D-246	-0.5007234215736389	lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide
P-246	-4.8215 -0.3385 -1.0803 -0.1235 -0.2169 -0.9072 -0.3863 -0.0931 -0.5253 -0.0400 -0.0224 -0.0563 -0.2370 -0.0440 -0.7286 -0.4415 -0.0669 -1.4509 -0.0653 -0.0227 -0.1018 -0.2179 -1.1364 -0.1842 -0.0103 -0.0876 -0.0021 -0.0951 -1.3890 -0.1292
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort study ; saxagliptin ; sitagliptin ; antihyperglycemic agents
H-1840	-0.26948314905166626	▁h HF ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁agents
D-1840	-0.26948314905166626	hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
P-1840	-0.0050 -1.2238 -0.1093 -0.1120 -0.1002 -0.1777 -0.9500 -0.1005 -0.3109 -0.0005 -0.0486 -0.6708 -0.2057 -0.0092 -0.0488 -0.4932 -0.6780 -0.0785 -0.2891 -0.0867 -0.1153 -0.1148
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially expressed genes ; degs ; ischemic heart failure ; healthy ; diagnosis ; heart failure
H-1608	-0.8267689943313599	▁de g s ▁; ▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁healthy ▁control ▁; ▁heart ▁failure
D-1608	-0.8267689943313599	degs ; non-ischemic ; ischemic heart failure ; healthy control ; heart failure
P-1608	-3.4051 -1.3262 -0.0436 -0.2132 -2.4974 -0.0273 -0.7787 -0.0605 -0.9387 -0.2642 -0.4892 -0.2207 -1.0738 -0.1466 -0.4656 -3.9273 -0.0982 -0.3443 -1.3295 -0.2632 -0.1355 -0.1401
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin resistance ; type 2 diabetes ; insulin receptor substrates 1 ; irs1 ; irs2 ; cellular metabolism
H-653	-0.451903373003006	▁in s ulin ▁resist ance ▁; ▁diabetes ▁; ▁insulin ▁receptor ▁substrat es ▁; IR s 1 ▁; ▁i RS 2 ▁; ▁insulin - signal ing ▁; ▁cel lular ▁metabolism
D-653	-0.451903373003006	insulin resistance ; diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling ; cellular metabolism
P-653	-0.3680 -0.4048 -0.0501 -0.4017 -0.0081 -0.1115 -0.3640 -0.0838 -0.0097 -0.0723 -0.0467 -0.1425 -0.2282 -2.4307 -0.0555 -0.1388 -0.2748 -0.7120 -0.9619 -0.9905 -0.4213 -0.1035 -0.0365 -0.0292 -0.0738 -1.9960 -3.0602 -0.0082 -0.0620 -0.2451 -0.1174
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome ; admission ; discharge ; hospitalized ; heart failure ; hf ; nursing outcomes classification ; noc
H-1398	-0.36760371923446655	▁ad mission ▁to ▁dis charge ▁; ▁hospital ized ▁older ▁adults ▁; ▁heart ▁failure ▁; HF ▁; ▁Nur sing ▁Out com es ▁Classifica tion ▁; NO c
D-1398	-0.36760371923446655	admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing Outcomes Classification ;NOc
P-1398	-1.1212 -0.0153 -0.6494 -0.0189 -0.0046 -0.1654 -0.7610 -0.4334 -0.7528 -0.2777 -0.5158 -0.2581 -0.2503 -0.1947 -0.2649 -0.1546 -0.2335 -0.0680 -1.9104 -0.0639 -0.0064 -0.2514 -0.0104 -0.3904 -0.6096 -0.6293 -0.1812 -0.1004
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp ; phosphomimic ; ser77 ; ser83 ; riα ; proteins ; riα
H-1432	-0.7162983417510986	▁8- flu o - c AMP ▁ binding ▁; ▁ phos pho mi mic ▁; ▁ser 77 ▁; ▁ser 83 ▁mu tant ▁; ▁RI α ▁; ▁double ▁mu tant ▁; ▁ WT ▁RI α
D-1432	-0.7162983417510986	8-fluo-cAMP binding ; phosphomimic ; ser77 ; ser83 mutant ; RIα ; double mutant ; WT RIα
P-1432	-3.7729 -0.1256 -0.3009 -0.0487 -0.1359 -0.0462 -0.3260 -0.1713 -0.1294 -0.3542 -0.1141 -0.0452 -0.0476 -0.2406 -1.4319 -1.0842 -0.8333 -0.1081 -0.9356 -1.6072 -1.1307 -0.2819 -0.5786 -3.3405 -0.7095 -1.2958 -1.4492 -0.0176 -0.1684 -0.3570 -1.6384 -0.3568 -1.6191 -0.6703 -0.1980 -0.1159
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate analysis ; preoperative ; albumin ; mortality ; lvad ; implantation ; hazard ratio ; confidence interval
H-535	-0.37048041820526123	▁pre operativ e ▁album in ▁; ▁mortal ity ▁; ▁l VAD ▁implant ation
D-535	-0.37048041820526123	preoperative albumin ; mortality ; lVAD implantation
P-535	-2.5501 -0.0491 -0.0487 -0.2261 -0.3990 -0.1991 -0.1091 -0.2422 -0.3199 -0.7724 -0.0532 -0.0163 -0.0384 -0.3472 -0.1861
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients ; systolic heart failure ; qrs duration ; crt ; death ; hospitalization ; heart failure ; mortality
H-854	-0.7839308977127075	▁sy sto lic ▁heart ▁failure ▁; ▁QR s ▁; ▁c RT ▁; ▁hospital ization ▁; ▁heart ▁failure
D-854	-0.7839308977127075	systolic heart failure ; QRs ; cRT ; hospitalization ; heart failure
P-854	-2.7043 -0.2411 -1.4894 -0.4204 -0.1783 -0.0917 -0.0388 -1.0041 -0.7187 -0.5446 -1.8710 -0.2268 -2.8250 -0.7114 -0.6525 -0.1368 -0.4930 -0.4074 -0.1395
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox regression models ; propensity score ; oral ; glucocorticoid ; hf ; hospitalisations ; loop diuretics
H-605	-0.25709447264671326	▁co x ▁re gression ▁models ▁; ▁pro pens ity ▁score ▁de cile ▁; ▁oral ▁gluco cor tico id ▁; ▁ HF ▁hospital isation s ▁; ▁loop ▁di ure tics
D-605	-0.25709447264671326	cox regression models ; propensity score decile ; oral glucocorticoid ; HF hospitalisations ; loop diuretics
P-605	-0.0706 -0.0199 -0.0118 -0.0269 -0.5466 -0.1370 -0.0472 -0.0155 -0.1308 -0.1207 -0.0829 -0.0306 -0.0941 -0.4920 -0.0125 -0.1822 -0.5142 -0.2895 -1.2038 -0.8442 -0.0111 -1.3064 -0.0449 -0.0567 -0.1542 -0.1385 -0.1541 -0.2363 -0.5719 -0.3002 -0.1225
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional electrical stimulation ; fes ; exercise capacity ; quality of life ; endothelial function ; chronic heart failure ; systolic function
H-1327	-0.5513990521430969	▁fonction al ▁electric al ▁stimul ation ▁; ▁f es ▁; ▁emotional ▁stress ▁; ▁en dot heli al ▁function ▁; ▁chronic ▁heart ▁failure ▁; ▁im pair ed ▁sy sto lic ▁function
D-1327	-0.5513990521430969	fonctional electrical stimulation ; fes ; emotional stress ; endothelial function ; chronic heart failure ; impaired systolic function
P-1327	-1.8375 -0.1704 -0.0542 -0.0096 -0.0439 -0.0200 -0.2624 -2.5009 -0.1429 -0.2381 -3.0099 -0.3605 -0.1211 -0.0749 -0.4514 -0.0438 -0.0044 -1.0288 -0.1484 -1.2753 -0.4304 -0.1705 -0.3567 -1.7633 -0.0065 -0.0322 -0.3965 -0.1599 -1.0330 -1.2568 -0.1531 -0.0873
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis ; patients ; hf ; hospitalization ; all-cause hospitalization ; mortality ; hf ; hospitalization ; death
H-910	-0.9004892110824585	▁Dia lys is ▁; HF
D-910	-0.9004892110824585	Dialysis ;HF
P-910	-1.3858 -0.1392 -0.0475 -1.4123 -1.2174 -1.9255 -0.1758
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse events ; reoperation ; bleeding ; driveline ; infection ; gastrointestinal bleeding ; stroke ; rankin score
H-2003	-0.24323397874832153	▁ble ed ing ▁; ▁drive line ▁infection ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁de bilitat ing ▁stroke
D-2003	-0.24323397874832153	bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
P-2003	-2.2062 -0.3354 -0.3388 -0.1415 -0.1364 -0.0485 -0.3405 -0.1436 -0.0370 -0.0047 -0.1711 -0.1232 -0.0365 -0.3426 -0.1999 -0.1809 -0.0831 -0.0025 -0.0502 -0.0153 -0.2908 -0.1223
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta blockers ; all-cause mortality ; readmissions ; heart failure with reduced ejection fraction ; hfref ; heart rate
H-1936	-0.49884986877441406	▁Beta ▁block ers ▁; ▁read missions ▁in ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁heart ▁rate ▁; HR
D-1936	-0.49884986877441406	Beta blockers ; readmissions in heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
P-1936	-0.5575 -0.7772 -0.0677 -0.2211 -2.7572 -0.0074 -0.8935 -0.2737 -0.2494 -0.0996 -0.5060 -0.5629 -0.0422 -0.0673 -0.0023 -0.2154 -1.1510 -0.0848 -0.3193 -0.1046 -1.6896 -1.0616 -0.7276 -0.0790 -0.2997 -0.1525
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous hf ; electromechanical delay ; emd ; myocyte depolarization ; myofiber shortening
H-1149	-0.3406243324279785	▁dys syn chron ous ▁ HF ▁; ▁electro me chan ical ▁de lay ▁; ▁em d ▁; ▁my o cy te ▁de po lar ization ▁; ▁my o fi ber
D-1149	-0.3406243324279785	dyssynchronous HF ; electromechanical delay ; emd ; myocyte depolarization ; myofiber
P-1149	-0.6392 -0.0052 -0.0011 -0.6262 -0.2191 -0.0233 -0.0463 -0.0024 -0.0170 -0.1288 -0.1707 -0.0408 -0.2786 -0.1690 -1.4804 -0.0848 -0.1399 -2.9681 -0.1410 -0.4126 -0.1615 -0.0461 -0.1166 -0.1011 -0.2236 -0.3160 -0.4133 -0.0976 -0.8308 -0.0346 -0.7320 -0.2322
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs morphology ; outcomes ; cardiac resynchronization therapy ; resynchronization-defibrillation for ambulatory heart failure trial ; raft
H-879	-0.2132309079170227	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁re syn chron ization - Def i bril lation ▁; ▁Amb ulator y ▁Heart ▁Fail ure ▁Tri al ▁; RAF t
D-879	-0.2132309079170227	QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAFt
P-879	-0.0618 -0.4558 -0.3969 -0.0754 -0.8548 -0.1392 -0.5457 -0.0095 -0.0356 -0.0054 -0.3978 -0.9419 -0.0237 -0.3099 -0.2439 -0.0225 -0.0168 -0.3339 -0.0421 -0.0924 -0.2613 -0.0892 -0.0068 -0.3937 -0.0290 -0.0137 -0.0164 -0.2417 -0.0675 -0.0414 -0.3135 -0.0097 -0.5991 -0.0027 -0.5584 -0.1162 -0.1242
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker ; clinical ; therapeutic
H-1478	-0.42336633801460266	▁bio mark er ▁; ▁bio mark er - guide d ▁clinic al ▁trial ▁; ▁multi mark er - based ▁strategy
D-1478	-0.42336633801460266	biomarker ; biomarker-guided clinical trial ; multimarker-based strategy
P-1478	-0.7410 -0.0101 -0.0276 -3.1075 -0.5008 -0.0205 -0.0247 -0.0288 -0.0051 -0.0582 -0.1312 -0.0538 -0.3855 -1.7227 -0.5950 -0.0441 -0.0208 -0.0475 -0.0498 -1.4945 -0.1115 -0.1334
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf ; incidence ; liver ; nodularity
H-231	-0.672171413898468	▁ab normal ▁ liver ▁; ▁no du lar ity
D-231	-0.672171413898468	abnormal liver ; nodularity
P-231	-2.0388 -0.0860 -0.2123 -0.7885 -2.7559 -0.7619 -0.0153 -0.0505 -0.2084 -0.2847 -0.1914
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant ; patients ; pd ; hf ; clinical
H-896	-0.44553834199905396	▁transplant ▁in elig ible ▁patients ▁; ▁PD ▁; ▁ HF ▁volume ▁management ▁; ▁pre - PD ▁initiat ion
D-896	-0.44553834199905396	transplant ineligible patients ; PD ; HF volume management ; pre-PD initiation
P-896	-0.6900 -0.1847 -0.0026 -1.3726 -0.7557 -0.3162 -0.5818 -0.1709 -0.5843 -0.0331 -0.5952 -0.0633 -0.5201 -1.3714 -0.0032 -1.2281 -0.2148 -0.0143 -0.1215 -0.0870
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty ; biological phenotype ; physical ; activity
H-1004	-0.6387986540794373	▁Fra il ty ▁; ▁bi ological ▁ph eno type ▁; ▁we ak ▁grip ▁; ▁physical ▁exhaust ion ▁; ▁slow ness ▁; ▁activity ▁; ▁un inten tional ▁weight
D-1004	-0.6387986540794373	Frailty ; biological phenotype ; weak grip ; physical exhaustion ; slowness ; activity ; unintentional weight
P-1004	-1.2826 -0.2155 -1.6763 -0.2184 -0.0852 -0.2250 -0.8490 -0.3322 -0.0146 -0.4063 -1.9192 -0.0060 -0.0857 -1.0436 -1.5387 -0.1129 -0.0271 -0.2914 -1.2697 -1.7850 -0.2460 -2.1627 -0.2639 -0.5053 -0.0222 -0.2895 -0.3056 -1.2244 -0.1212
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d ; patients ; ic ; crt-d ; ies
H-109	-0.5224149823188782	▁c RT - d ▁; ▁IE ▁; ▁IC ▁; ▁c RT - d ▁; ▁IE s
D-109	-0.5224149823188782	cRT-d ; IE ; IC ; cRT-d ; IEs
P-109	-0.9260 -1.0582 -0.0522 -0.7172 -0.0812 -0.8501 -0.1097 -0.5854 -0.1573 -0.6612 -1.5927 -0.0479 -0.5720 -0.3050 -0.8752 -0.4189 -0.2754 -0.1177
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds ; discharge ; patients ; heart failure ; outcomes ; driven ; readmissions
H-467	-1.1906794309616089	▁ed s ▁; ▁heart ▁failure ▁; ▁low - volu me ▁ED
D-467	-1.1906794309616089	eds ; heart failure ; low-volume ED
P-467	-4.0535 -0.2337 -0.1860 -1.5677 -0.1323 -0.5308 -4.3072 -0.0044 -0.0082 -0.0312 -0.5882 -3.6702 -0.1654
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute right heart failure ; therapy ; refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; ecmo ; cpr ; icu
H-1295	-0.40297919511795044	▁a cute ▁right ▁heart ▁failure ▁; ▁ therapy ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁heart ▁; ▁extra ▁corpore al ▁membran e ▁oxygen ation ▁; ▁e mo ▁; ▁c PR ▁; ▁ ICU
D-1295	-0.40297919511795044	acute right heart failure ; therapy refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; emo ; cPR ; ICU
P-1295	-0.6520 -0.0121 -2.0173 -0.3476 -0.1059 -0.1284 -1.0667 -0.0085 -0.0028 -0.0205 -0.4771 -0.0301 -0.0439 -0.4192 -0.0133 -0.3031 -0.5390 -1.4925 -2.6602 -0.0234 -0.0436 -0.0113 -0.3185 -0.1450 -0.0300 -0.1941 -0.6634 -0.5169 -0.4138 -0.1243 -0.0723 -0.7026 -0.6593 -0.0082 -0.1500 -0.0906
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report ; patient ; right atrial myxoma ; massive embolism ; pulmonary arteries ; surgically ; right atrial ; pulmonary embolectomy
H-595	-0.3624900281429291	▁right ▁at rial ▁my xo ma ▁; ▁massive ▁e mbol ism ▁; ▁pulmonar y ▁arteri es ▁; ▁right ▁at rial ▁mass ▁remo val ▁; ▁pulmonar y ▁e mbol ecto my
D-595	-0.3624900281429291	right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
P-595	-2.9901 -0.0983 -0.1599 -0.8222 -0.0334 -0.0633 -0.1877 -1.3239 -0.0327 -0.0029 -0.8232 -0.2610 -0.0270 -0.0825 -0.0330 -0.1110 -0.4680 -0.4132 -0.1063 -0.2497 -0.3147 -0.0930 -0.9482 -0.2049 -0.0025 -0.0691 -0.0613 -0.0031 -0.1821 -1.1408 -0.1960 -0.0947
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency room ; undiagnosed ; heart disease ; symptoms ; hf ; surgical palliation
H-201	-0.7633265256881714	▁heart ▁disease ▁; ▁ HF ▁; ▁sur g ical ▁palli ation
D-201	-0.7633265256881714	heart disease ; HF ; surgical palliation
P-201	-5.3410 -1.1082 -0.1296 -1.1104 -0.0244 -1.7128 -0.0748 -0.0418 -0.0923 -0.0144 -0.0436 -0.0995 -0.1303
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart magnetic resonance imaging ; chelation ; patient ; compliance ; heart failure ; arrhythmias
H-745	-0.32068654894828796	▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁patient ▁compliance ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-745	-0.32068654894828796	heart magnetic resonance imaging ; chelation choices ; patient compliance ; heart failure ; arrhythmias
P-745	-0.8370 -0.0552 -0.2471 -0.1557 -0.0355 -0.1114 -0.0321 -0.3534 -0.1773 -0.0059 -0.7200 -0.0278 -0.2284 -0.8766 -0.3244 -0.1586 -1.5560 -0.1927 -0.3739 -0.7290 -0.0771 -0.1413 -0.1886 -0.0914
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection fraction ; ef ; patients ; nyha class iiib ; symptoms ; right ventricular dysfunction
H-897	-0.4662475883960724	▁e je ction ▁ fraction ▁; EF ▁; ▁pre - PD ▁; ▁NY HA ▁class ▁III b ▁; ▁vent ri cular ▁dys function
D-897	-0.4662475883960724	ejection fraction ;EF ; pre-PD ; NYHA class IIIb ; ventricular dysfunction
P-897	-0.5615 -0.5580 -0.0678 -0.1269 -0.0008 -0.1159 -0.5332 -0.1012 -0.2474 -0.0095 -0.0741 -0.1748 -1.1502 -0.8453 -0.5445 -0.1524 -0.5793 -0.7987 -2.7265 -1.1391 -0.1920 -0.0242 -0.5881 -0.1961 -0.1489
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs ; early-outgrowth colony-forming units ; eo-cfus ; cells
H-124	-0.4898841977119446	▁c PC s ▁; ▁early - out g row th ▁colon y - form ing ▁unit s ▁; EO - c FU s ▁; ▁circula ting ▁CD 34 ▁; ▁v EG FR 2 ▁; ▁CD 133
D-124	-0.4898841977119446	cPCs ; early-outgrowth colony-forming units ;EO-cFUs ; circulating CD34 ; vEGFR2 ; CD133
P-124	-0.1937 -0.4824 -0.0820 -0.3629 -3.2327 -0.0268 -0.3050 -1.4062 -0.0437 -0.0356 -0.8287 -0.0663 -0.0138 -0.0682 -0.1316 -0.1750 -0.0637 -0.2126 -0.8086 -0.0157 -1.1424 -0.7186 -0.0831 -0.1872 -0.3154 -1.3537 -0.5252 -0.2996 -0.5765 -0.0802 -0.7574 -0.9727 -0.3397 -0.6501 -0.1157 -0.1038 -1.5947 -0.2445
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene expression ; bax ; pacing ; bcl-2 ; mrna ; expression ; heart failure ; bcl-2 ; bax
H-168	-0.440528005361557	▁Gene ▁expression ▁; ▁Bax ▁; ▁b cl -2 ▁m RNA ▁expression ▁; ▁heart ▁failure ▁; ▁b cl - 2/ Ba x
D-168	-0.440528005361557	Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
P-168	-2.6521 -0.0930 -0.2614 -0.0374 -0.0776 -0.3286 -0.1095 -0.3167 -0.0148 -0.0500 -0.6340 -0.1101 -1.7810 -0.5405 -0.3154 -0.1731 -0.2367 -0.0383 -0.0819 -1.8288 -0.0100 -0.3161 -0.1251
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl ; hno ; inotropic ; lusitropic ; vasodilator ; in vivo ; camp
H-413	-0.27405408024787903	▁ni tro x yl ▁; ▁h no ▁; ▁Angeli ▁; ▁salt ▁; ▁in o tropi c ▁; ▁ lusi tropi c ▁; ▁vaso dila tor ▁effects ▁; ▁c AMP
D-413	-0.27405408024787903	nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
P-413	-0.1037 -0.0278 -0.0470 -0.0982 -0.1546 -0.3114 -0.2406 -0.1607 -0.0925 -1.9835 -0.1238 -0.1290 -0.3851 -0.6678 -0.0159 -0.0840 -0.3296 -0.2137 -0.0147 -0.0561 -0.1693 -0.3108 -0.0280 -0.0218 -0.0660 -1.7768 -0.3077 -0.0174 -0.0085 -0.4420 -0.1076
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy ; anticoagulation ; rate control ; cardiovascular ; complications ; stroke ; cardiovascular death ; acute heart failure ; patients ; atrial fibrillation
H-1643	-0.36857494711875916	▁ therapy ▁; ▁cardiovascular ▁complica tions ▁; stro ke ▁; ▁cardiovascular ▁death ▁; ▁a cute ▁heart ▁failure ▁; ▁at rial ▁fi bril lation ▁; AF
D-1643	-0.36857494711875916	therapy ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
P-1643	-3.2261 -0.2124 -0.1679 -1.7759 -0.0218 -0.0425 -0.1377 -0.5806 -0.3394 -0.3610 -0.0313 -0.5317 -0.0654 -0.0198 -0.0056 -0.1708 -0.0689 -0.4037 -0.3622 -0.1992 -0.2860 -0.0178 -0.0350 -0.6139 -0.0402 -0.1334 -0.1012
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence ; clinical ; continuous-flow lvads ; heartmate ii ; hm ii ; heartware ; btt ; dt ; patients
H-309	-0.6476626396179199	▁coût - effect ive ness ▁; ▁continuo us - flow ▁l VAD s ▁; ▁he art Mate ▁II ▁; ▁h m ▁; ▁h m ▁; ▁Heart War e ▁; ▁b t ▁; ▁ DT
D-309	-0.6476626396179199	coût-effectiveness ; continuous-flow lVADs ; heartMate II ; hm ; hm ; HeartWare ; bt ; DT
P-309	-5.9086 -0.1457 -0.0792 -0.0265 -1.0679 -0.1747 -0.3568 -0.0645 -0.0220 -0.0161 -2.5714 -0.0533 -0.0806 -0.1553 -1.5916 -0.8662 -0.1887 -0.9926 -0.0368 -0.5180 -1.1693 -0.5652 -0.5406 -0.9544 -0.4845 -2.0657 -0.1812 -0.0160 -0.1053 -0.1361 -0.3511 -0.1719 -0.9438 -0.2118 -0.3447 -0.1580
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients ; baseline ; ef ; ef ; core
H-753	-0.7642011046409607	▁EF ▁; ▁blind ed ▁core ▁laborator y
D-753	-0.7642011046409607	EF ; blinded core laboratory
P-753	-2.4181 -0.5087 -3.1061 -0.1413 -0.2378 -0.1761 -0.0581 -0.1086 -0.1231
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal muscle ; lean mass ; z-score
H-1499	-0.9331678748130798	▁s kelet al ▁muscle ▁mass ▁; ▁appen di cular ▁lean ▁mass ▁index
D-1499	-0.9331678748130798	skeletal muscle mass ; appendicular lean mass index
P-1499	-3.3386 -0.0525 -0.1357 -1.2228 -0.8078 -0.2674 -4.0007 -0.0348 -0.0990 -0.3353 -0.4109 -0.1544 -2.0339 -0.1706
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash ; mortality ; hf ; nonsignificant
H-693	-0.48466554284095764	▁DAS h ▁; ▁mortal ity ▁; ▁ HF ▁; ▁Mediterrane an
D-693	-0.48466554284095764	DASh ; mortality ; HF ; Mediterranean
P-693	-0.1137 -0.5449 -0.5816 -0.4611 -0.1591 -0.0461 -1.4945 -0.0283 -0.1659 -0.4775 -0.1147 -2.0075 -0.1059
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality of life ; all-cause mortality ; mortality
H-561	-0.6075895428657532	▁Quality ▁of ▁life ▁; ▁all - ca use ▁mortal ity
D-561	-0.6075895428657532	Quality of life ; all-cause mortality
P-561	-0.7487 -1.2797 -0.9102 -0.5600 -0.6037 -0.0171 -0.0421 -0.0094 -0.0650 -0.1735 -2.6808 -0.2010
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef ; bnp ; bnp ; inhospital ; mortality
H-197	-0.6256035566329956	▁b NP ▁; ▁in hospital ▁mortal ity
D-197	-0.6256035566329956	bNP ; inhospital mortality
P-197	-1.8238 -1.4213 -0.3603 -1.5901 -0.0403 -0.1150 -0.0745 -0.1123 -0.0929
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular diseases ; heart failure ; hf ; incidence ; hf
H-285	-0.33331388235092163	▁cardiovascular ▁disease s ▁; ▁heart ▁failure ▁; HF
D-285	-0.33331388235092163	cardiovascular diseases ; heart failure ;HF
P-285	-0.0920 -1.4777 -0.0280 -0.1454 -0.1019 -0.1716 -0.1197 -0.2238 -0.8757 -0.0973
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart failure ; left ventricular systolic dysfunction ; post hoc analysis
H-402	-0.6413195729255676	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁sy sto lic ▁dys function ▁; ▁BB
D-402	-0.6413195729255676	heart failure ; left ventricular systolic dysfunction ; BB
P-402	-1.3688 -0.5671 -0.1270 -1.0525 -0.0306 -2.3151 -0.1461 -0.5447 -0.2622 -1.6707 -0.0174 -0.5481 -1.0196 -0.3662 -0.1126 -0.1126
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka ; polymorphism ; rs10927887 ; p.arg83gly ; heart failure ; estimated glomerular filtration rate ; renastur
H-1801	-0.6093066930770874	▁CL CN KA ▁poly morph ism ▁; ▁heart ▁failure ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁RE NAS TUR
D-1801	-0.6093066930770874	CLCNKA polymorphism ; heart failure ; glomerular filtration rate ; RENASTUR
P-1801	-0.7525 -2.6700 -1.1576 -0.0184 -0.0123 -0.6046 -0.0616 -3.0651 -0.8099 -0.0914 -0.2259 -0.0375 -0.1174 -0.1478 -0.0288 -1.0552 -0.1940 -1.1569 -0.0596 -0.4070 -0.5469 -0.1843
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 ; functional capacity ; outcomes ; ambulatory ; patients ; hf
H-706	-0.6748863458633423	▁ST 2 ▁; ▁functional ▁capacity ▁; ▁well - tre ated ▁; ▁ambula tory ▁patients ▁; ▁ HF
D-706	-0.6748863458633423	ST2 ; functional capacity ; well-treated ; ambulatory patients ; HF
P-706	-2.2921 -0.0853 -0.6554 -0.8706 -0.3099 -0.2024 -3.5903 -0.0160 -0.0655 -0.1799 -2.0932 -0.0565 -0.3941 -0.6565 -0.2101 -0.4498 -0.0170 -0.5235 -0.1548
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac vegf expression ; endothelial no synthase activation ; hearts
H-455	-0.2624618411064148	▁cardiac ▁VE GF ▁expression ▁; ▁Akt ▁; ▁en dot heli al ▁NO ▁synth ase ▁activa tion ▁; ▁drug - un tre ated ▁fail ing ▁heart s
D-455	-0.2624618411064148	cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; drug-untreated failing hearts
P-455	-0.6362 -0.3846 -0.0878 -0.0148 -0.0551 -0.0141 -0.0519 -0.0685 -0.8495 -0.0468 -0.0063 -0.4842 -0.1160 -0.5647 -0.4324 -0.0394 -0.3139 -1.7112 -0.0181 -0.2253 -0.0070 -0.0898 -0.2494 -0.1163 -0.3355 -0.0312 -0.2800 -0.1187
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene expression ; cardiomyocytes ; jq1 ; drug ; genes
H-1046	-0.45530983805656433	▁cardio my o cy tes ▁; ▁j q 1 ▁; ▁drug ▁ab roga ted ▁; ▁ phen yle ph rine - indu ced ▁gene s
D-1046	-0.45530983805656433	cardiomyocytes ; jq1 ; drug abrogated ; phenylephrine-induced genes
P-1046	-4.9011 -0.3914 -0.4431 -0.1870 -0.1477 -0.1233 -0.4365 -1.0547 -0.1746 -0.2330 -0.1191 -0.4450 -0.0035 -0.6656 -0.3099 -0.1192 -0.1052 -0.5387 -0.3769 -0.0544 -0.0546 -0.0011 -0.4285 -0.6032 -0.0183 -0.2439 -0.1136
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced pasp ; right ventricular contractile reserve ; patients ; exercise-induced pasp
H-824	-0.8754208087921143	▁exercise - indu ced ▁PAS p ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve
D-824	-0.8754208087921143	exercise-induced PASp ; right ventricular contractile reserve
P-824	-5.1912 -0.0299 -0.0537 -0.2176 -0.2062 -0.6381 -0.0877 -1.5304 -0.0109 -1.5392 -0.3272 -0.0464 -1.4027 -0.1058 -2.5082 -0.1115
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene expression profile ; gse9128 ; gene expression omnibus ; non-ischemic heart failure ; ischemic
H-1609	-0.533559262752533	▁Gene ▁expression ▁profile ▁; ▁g se 91 28 ▁; ▁Gene ▁Express ion ▁Omni bus ▁; ▁non - ische mic ▁heart ▁failure ▁; ▁ ische mic
D-1609	-0.533559262752533	Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic
P-1609	-0.6258 -0.0359 -1.3411 -1.0629 -2.5856 -0.0739 -0.7894 -0.1598 -0.4591 -0.3663 -0.2108 -0.0124 -0.0095 -0.0197 -0.3481 -1.9878 -0.0133 -0.5461 -0.0638 -0.5176 -0.1178 -1.4943 -0.0957 -0.2828 -0.1685 -0.8811 -0.1371
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac ; insulin-resistance ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose
H-1784	-0.2346695214509964	▁cardiac ▁insulin - re si stance ▁; ▁a ac ▁; ▁insulin - stimul ated ▁rates ▁; ▁gly col ysis ▁; ▁gluco se ▁oxid ation ▁; ▁plasma ▁membran e ▁trans location ▁; ▁gluco se ▁transporter
D-1784	-0.2346695214509964	cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
P-1784	-0.1200 -0.2508 -0.0214 -0.2218 -0.2625 -0.0020 -0.1234 -0.2658 -2.3336 -0.2309 -0.0948 -0.0339 -0.0139 -0.0783 -0.4839 -0.4024 -0.0184 -0.9198 -0.2215 -0.1574 -0.0554 -0.0392 -0.0473 -0.0262 -0.2876 -0.1027 -0.0037 -0.0615 -0.0554 -0.1394 -0.5704 -0.0573 -0.0247 -0.2355 -0.3462 -0.1389
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic ; invasively
H-920	-0.5918818712234497	DAS h ▁; ▁s RD ▁bra chi al ▁; ▁central ▁blood ▁pressure ▁; ▁radi al ▁arterial ▁ton ometr y ▁; ▁cardiovascular ▁; ▁e cho car dio graphic
D-920	-0.5918818712234497	DASh ; sRD brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic
P-920	-0.2026 -0.8874 -0.2173 -2.4341 -0.5910 -3.2937 -0.0169 -0.0231 -0.4178 -0.7551 -0.7824 -1.5853 -0.0650 -0.0365 -0.0336 -0.1575 -0.8221 -0.0677 -0.1411 -0.1311 -0.0432 -2.5599 -0.0870 -0.0962 -0.0249 -0.3564 -0.2679 -0.9281 -0.1395
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial ; exercise ; outcomes ; heart failure ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-1924	-0.4103149473667145	▁Psycho social ▁Factor s ▁; ▁Exerci se ▁Ad her ence ▁; ▁Heart ▁Fail ure ▁Patient s ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga tion ▁; ▁Exerci se ▁Training ▁; HF - AC tion
D-1924	-0.4103149473667145	Psychosocial Factors ; Exercise Adherence ; Heart Failure Patients ; Heart Failure ; controlled Trial Investigation ; Exercise Training ;HF-ACtion
P-1924	-0.7606 -0.0261 -0.3151 -0.0395 -0.1869 -3.8873 -0.0290 -0.4769 -0.2123 -0.0027 -0.0755 -0.4697 -0.0389 -0.0556 -0.6787 -0.0512 -0.2898 -0.6566 -0.0370 -0.0562 -0.2673 -2.2944 -0.0636 -0.2343 -0.0379 -0.1395 -1.2779 -0.2359 -0.4819 -0.0109 -0.0654 -0.2294 -0.3835 -0.0072 -0.3842 -0.8011 -0.1846 -0.1473
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients ; coronary angiography ; diagnosis ; systolic hf ; etiology ; ejection fraction
H-1186	-0.3565791845321655	▁corona ry ▁ang i ography ▁; ▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology
D-1186	-0.3565791845321655	coronary angiography ; systolic HF ; unclear etiology
P-1186	-2.4032 -0.1720 -0.0289 -0.7482 -0.2210 -0.1570 -0.5904 -0.0576 -0.3631 -0.0870 -0.0147 -0.2400 -0.1136 -0.0022 -0.0160 -0.3563 -0.7180 -0.3496 -0.1362
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees ; ea
H-922	-0.3530471920967102	▁arterial ▁elastan ce ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁e es
D-922	-0.3530471920967102	arterial elastance ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees
P-922	-1.2516 -0.5857 -0.1660 -0.0513 -1.1721 -0.0393 -0.2356 -0.0976 -0.6375 -0.0867 -0.1186 -0.0732 -0.5092 -0.0095 -0.1108 -0.0066 -0.4470 -0.0457 -0.0366 -0.0096 -0.0474 -0.0282 -0.9889 -0.3894 -1.4826 -0.0263 -1.0874 -0.1451
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic ; rhythm
H-1653	-0.17534086108207703	▁ rhythm ▁control ▁ therapy ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁cat heter ▁ab lation ▁; ▁electro car dio graphic ▁device
D-1653	-0.17534086108207703	rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device
P-1653	-0.1075 -0.1458 -0.0924 -0.1600 -0.0145 -0.2814 -0.1548 -0.2708 -0.0476 -0.2536 -0.0446 -0.1651 -0.0310 -0.0008 -0.0120 -0.0081 -0.1925 -0.0412 -0.0266 -0.1037 -0.1223 -0.1826 -1.5572 -0.1920
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells ; angiotensin ii ; angii ; hypoxia ; scn5a ; mrna splicing ; scn5a
H-1083	-0.5987682938575745	▁ang io ten sin ▁II ▁; ▁ang II ▁; ▁hypo xia ▁; ▁activa tors ▁; ▁ab normal ▁S CN 5 a ▁m RNA ▁s plic ing
D-1083	-0.5987682938575745	angiotensin II ; angII ; hypoxia ; activators ; abnormal SCN5a mRNA splicing
P-1083	-0.1130 -1.9905 -0.0910 -0.5124 -0.5322 -0.1344 -0.5661 -0.4714 -0.1615 -0.0088 -0.0169 -0.2115 -2.5608 -0.8822 -0.3383 -0.1116 -0.0295 -1.5216 -0.2039 -0.0666 -0.7380 -0.0093 -0.0704 -0.3798 -0.1646 -0.0582 -4.6440 -0.1772
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence ; hf with reduced ejection fraction ; hfref ; hf with preserved ejection fraction ; hfpef
H-1488	-0.4813039302825928	▁ HF ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁ HF ▁; ▁ HF ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h p EF
D-1488	-0.4813039302825928	HF ; reduced ejection fraction ;HFrEF ; HF ; HF ; preserved ejection fraction ; hpEF
P-1488	-1.5470 -0.0509 -0.2631 -2.5803 -0.0556 -0.0641 -1.0571 -0.1798 -0.1668 -0.0032 -0.1875 -1.3246 -0.2082 -0.1320 -0.0790 -1.2214 -0.1332 -0.3329 -2.7476 -0.1591 -0.3447 -0.8601 -0.0088 -0.1441 -0.0737 -0.6280 -0.1445 -0.1469 -0.0018 -0.2103 -1.1145 -0.0257 -0.2875 -0.2466 -0.1152
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal life support ; therapy ; patients ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion ; therapy
H-1298	-0.4042966663837433	▁extra corp o real ▁life ▁support ▁; ▁ brid ging ▁ therapy ▁; ▁a cute ▁ ische mic ▁right ▁heart ▁failure ▁; ▁re frac tory ▁cardio ge nic ▁shock
D-1298	-0.4042966663837433	extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock
P-1298	-1.9540 -0.0028 -0.3712 -0.0107 -0.1571 -0.3797 -0.3748 -0.6049 -0.0258 -0.1018 -0.1315 -0.0140 -0.2580 -1.8184 -0.0392 -0.4852 -0.6416 -0.0938 -1.2628 -0.4860 -0.1260 -0.1600 -0.0087 -0.0165 -0.6002 -0.0308 -0.0691 -0.7018 -0.0227 -1.4655 -0.1186
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart failure ; reduced left ventricular ejection fraction ; fes ; exercise capacity ; quality of life ; endothelial function ; hfpef
H-1332	-0.5541672110557556	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁F es ▁; ▁en dot heli al ▁function ▁; ▁ HF p EF
D-1332	-0.5541672110557556	heart failure ; left ventricular ejection fraction ; Fes ; endothelial function ; HFpEF
P-1332	-0.3723 -0.3189 -0.0464 -0.7749 -0.0254 -1.5863 -0.4662 -0.0899 -0.3609 -0.2523 -0.1894 -0.0008 -0.2562 -2.1031 -0.2620 -0.1430 -3.5737 -1.2772 -0.0584 -0.0057 -1.8280 -0.2533 -0.5908 -0.1932 -0.0253 -0.1921 -0.1474 -0.1236
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures ; hospitalizations ; noncardiovascular ; diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular ; drugs ; rate-control
H-1240	-0.3146987855434418	▁ex pendi tures ▁; ▁non car dio vas cular ▁diagnose s ▁; ▁implant able ▁cardiac ▁ar rhythm ia ▁devices ▁; ▁non car dio vas cular ▁drugs
D-1240	-0.3146987855434418	expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
P-1240	-4.5800 -0.0082 -0.0248 -0.2359 -0.4396 -0.0098 -0.2083 -0.0818 -0.1417 -0.3335 -0.0104 -0.1041 -0.0002 -0.0810 -0.0147 -0.8468 -0.0362 -0.1881 -0.1631 -0.1844 -0.1379 -0.0085 -0.1861 -0.0805 -0.1892 -0.0750 -0.3332 -0.1085
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.3456995189189911	▁in tub ation
D-220	-0.3456995189189911	intubation
P-220	-0.0512 -0.0052 -0.0356 -1.4850 -0.1514
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene ; heart failure
H-1541	-0.757688045501709	▁ra lo xi fen e ▁; ▁cardiovascular ▁failure
D-1541	-0.757688045501709	raloxifene ; cardiovascular failure
P-1541	-0.4700 -0.0474 -0.0463 -0.8582 -0.1392 -0.2650 -3.9300 -1.4092 -0.2866 -0.1252
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts ; heart mass ; transgenic
H-1814	-0.6483892798423767	▁heart s ▁; ▁t g t et Men a ▁mi ce ▁; ▁wild - type ▁litt er mates ▁; ▁heart ▁mass ▁; ▁trans ge nic ▁mi ce
D-1814	-0.6483892798423767	hearts ; tgtetMena mice ; wild-type littermates ; heart mass ; transgenic mice
P-1814	-2.0169 -0.0494 -0.2728 -2.4159 -1.1139 -0.0650 -2.6722 -0.4340 -0.1299 -1.5898 -0.1420 -0.2327 -1.9024 -0.0152 -0.0472 -0.0413 -0.0212 -0.1025 -0.2066 -2.2367 -1.0018 -0.1514 -0.0418 -0.1642 -0.7366 -0.5606 -0.1297 -0.1777 -0.1322
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients ; hfref ; exercise ; respiratory gas analysis ; baseline
H-1938	-0.5407501459121704	▁h fr f ▁; ▁respirator y ▁gas
D-1938	-0.5407501459121704	hfrf ; respiratory gas
P-1938	-0.2835 -2.1309 -0.7906 -0.1465 -0.6769 -0.0540 -0.1471 -0.4880 -0.1493
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients ; drugs ; heart failure ; biomedical ; nonprescribing ; patients
H-1126	-0.5120048522949219	▁drugs ▁; ▁heart ▁failure ▁; ▁bio medic al ▁reasons
D-1126	-0.5120048522949219	drugs ; heart failure ; biomedical reasons
P-1126	-2.5438 -0.4842 -0.2778 -0.1168 -0.4467 -0.0235 -0.0066 -0.0027 -0.0724 -1.5119 -0.1456
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean mass ; adverse outcome ; adipose tissue ; cardioprotective ; hf
H-1169	-0.3563651442527771	▁Was ting ▁; ▁fat ▁; ▁lean ▁mass ▁; ▁fat ▁loss ▁; ▁cata bol ism ▁; ▁adi pose ▁tissu e ▁; ▁cardio protec tive ▁; ▁ HF
D-1169	-0.3563651442527771	Wasting ; fat ; lean mass ; fat loss ; catabolism ; adipose tissue ; cardioprotective ; HF
P-1169	-2.4185 -0.2512 -0.6447 -0.7848 -0.0875 -0.0484 -0.1825 -0.1930 -0.4865 -1.2447 -0.1324 -0.5372 -0.0830 -0.3115 -0.0949 -0.0128 -0.0298 -0.1461 -0.2195 -0.1855 -0.0375 -0.1051 -0.0208 -0.7520 -0.8120 -0.0162 -0.0591 -0.0809
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
H-97	-0.5538598299026489	▁heart s ▁; ▁fish ▁la cking ▁nu cle olin ▁; ▁cha mber ▁pattern ing ▁; ▁functional ▁deficit s ▁; ▁cardiac ▁loop ing ▁; ▁my o cy te ▁differenti ation
D-97	-0.5538598299026489	hearts ; fish lacking nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
P-97	-0.6356 -0.0313 -0.4117 -1.5141 -0.1151 -0.1320 -1.4965 -0.0048 -0.5593 -0.1616 -2.7040 -0.0302 -0.2997 -0.5823 -0.2241 -3.4241 -0.6895 -0.0456 -0.1402 -0.6002 -0.2390 -0.0559 -0.3896 -0.4557 -0.0623 -0.0939 -0.0667 -1.7227 -0.0150 -0.1476 -0.1192
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients ; chronic hf ; prevalence ; exercise ; hf ; hospitalization ; mortality ; exercise ; training
H-1641	-0.9821226596832275	▁black ▁race ▁; ▁ HF ▁; ▁modifi able ▁risk ▁factors ▁; ▁exercise ▁performance ▁; ▁ HF ▁; ▁mortal ity
D-1641	-0.9821226596832275	black race ; HF ; modifiable risk factors ; exercise performance ; HF ; mortality
P-1641	-0.8070 -0.1482 -0.1327 -2.5230 -0.0400 -0.2060 -5.2130 -0.0233 -0.5737 -0.3651 -0.1194 -4.0321 -0.4636 -0.1501 -0.4417 -0.0333 -2.3848 -0.6125 -0.2427 -1.9848 -0.1276
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse event ; acute myocardial infarction ; congestive heart failure ; adverse events
H-4	-0.4458218812942505	▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure
D-4	-0.4458218812942505	acute myocardial infarction ; congestive heart failure
P-4	-3.1822 -0.0314 -1.2963 -0.1985 -0.0912 -0.1799 -0.0156 -0.8588 -0.1166 -0.1343 -0.0324 -0.0130 -0.0307 -0.1289 -0.0595 -1.0763 -0.1334
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages ; cardiomyocytes ; doxorubicin ; in vitro ; resistin ; mrna ; protein expression
H-935	-0.49245086312294006	▁cardio my o cy tes ▁; ▁Hum - re t n ▁mi ce ▁; ▁do xor ubi cin ▁; ▁h re t n ▁; human ▁resist in ▁; ▁m RNA ▁; ▁protein ▁expression
D-935	-0.49245086312294006	cardiomyocytes ; Hum-retn mice ; doxorubicin ; hretn ;human resistin ; mRNA ; protein expression
P-935	-2.2392 -0.1044 -0.2898 -0.0735 -0.0640 -0.2191 -0.3303 -0.0836 -1.4911 -0.2798 -0.0558 -2.7895 -0.1014 -0.2904 -0.1197 -0.0595 -0.0312 -0.1025 -0.4253 -0.0043 -2.7370 -0.1524 -0.0256 -0.2167 -2.0076 -0.5375 -0.1339 -0.3910 -0.0029 -0.0216 -1.2537 -0.1363 -0.0344 -0.2707 -0.1601
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads ; heartmate ii ; thoratec corp ; pleasanton ; calif ; hvad ; heartware ; framingham
H-546	-0.34306493401527405	▁l VAD s ▁; ▁CF ▁devices ▁; ▁Heart Mate ▁II ▁devices ▁; ▁Thor a tec ▁Corp ▁; ▁Ple asan ton ▁; ▁Cali f ▁; ▁h VAD ▁; ▁h VAD ▁devices ▁; ▁Heart War e ▁in t l ▁; ▁in t l ▁; ▁Fram ing ham ▁; ▁Mass
D-546	-0.34306493401527405	lVADs ; CF devices ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD ; hVAD devices ; HeartWare intl ; intl ; Framingham ; Mass
P-546	-1.0163 -0.0745 -0.0891 -0.0929 -0.2656 -0.6054 -0.0368 -2.5256 -0.0361 -0.3319 -0.2371 -0.0651 -0.0600 -0.0499 -0.0066 -0.1726 -0.1883 -0.1799 -0.0025 -0.0153 -1.8190 -0.0576 -0.0013 -0.0275 -0.1561 -0.4866 -0.4502 -0.3499 -0.3815 -1.9015 -0.0719 -0.8658 -0.0900 -0.0240 -0.1392 -0.0145 -0.0042 -0.2562 -1.3080 -0.0338 -0.0068 -0.2337 -0.5269 -0.0158 -0.0041 -0.8997 -0.0175 -0.4987 -0.1167
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma nps ; adiponectin ; baseline ; ffm ; correlate ; nps ; adiponectin ; follow up
H-19	-0.4661431610584259	▁FM ▁; ▁plasma ▁ NP s ▁; ▁adi pon ect in ▁; ▁FM ▁; f f ▁; ▁ NP s ▁; ▁adi pon ect in
D-19	-0.4661431610584259	FM ; plasma NPs ; adiponectin ; FM ;ff ; NPs ; adiponectin
P-19	-0.9059 -0.0912 -1.0832 -0.4344 -0.0087 -0.0270 -0.1627 -1.2121 -0.0245 -0.0252 -0.7736 -0.4860 -1.0674 -0.1423 -2.0302 -0.5620 -0.3221 -1.2412 -0.0717 -0.0237 -0.9495 -0.0649 -0.0591 -0.0406 -0.4579 -0.1831 -0.1355
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic tone ; parasympathetic tone ; heart rate ; intravenous bolus ; metoprolol ; atropine
H-1378	-0.4660162329673767	▁sympa the tic ▁tone ▁; ▁para sy mpa the tic ▁tone ▁; ▁heart ▁rate ▁; ▁met o pro lol ▁; ▁a tropi ne
D-1378	-0.4660162329673767	sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
P-1378	-1.2887 -0.6345 -1.1440 -0.1043 -0.0788 -0.1524 -0.1751 -0.1116 -1.1599 -1.7588 -0.1166 -0.2210 -0.3549 -0.8535 -1.2081 -1.2626 -0.1472 -0.0423 -0.1683 -0.2415 -0.0050 -0.0279 -0.1512 -0.1485 -0.0939
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef ; pathophysiologically ; hf with reduced ef ; hfref ; hfref ; therapy
H-1533	-0.5572332143783569	▁EH ▁; ▁ HF p EF ▁; ▁pat ho phy si ological ly ▁; ▁ HF ▁; ▁h f f ▁ therapy
D-1533	-0.5572332143783569	EH ; HFpEF ; pathophysiologically ; HF ; hff therapy
P-1533	-0.0063 -0.0673 -1.2144 -0.1876 -0.0847 -0.3509 -0.0778 -3.5318 -0.0104 -0.0900 -0.3666 -0.1851 -0.1603 -0.7316 -0.4485 -0.1252 -0.1113 -2.0092 -0.8587 -1.6302 -0.7702 -0.0228 -0.2364 -0.0960
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma ; collected ; hf ; patients ; immunoreactive ; nt-probnp ; c-terminally ; nt-probnp
H-1520	-0.6515313386917114	▁ HF ▁; ▁immun ore active ▁NT - pro b NP ▁; ▁c - termin ally ▁tru nca ted ▁fragment s ▁; ▁NT - pro b NP
D-1520	-0.6515313386917114	HF ; immunoreactive NT-probNP ; c-terminally truncated fragments ; NT-probNP
P-1520	-2.9992 -0.0793 -0.5493 -0.0038 -1.8226 -0.0687 -0.6299 -0.0261 -0.0167 -1.5351 -0.1674 -0.3422 -4.2497 -0.0701 -0.0779 -0.7774 -0.0061 -0.0546 -0.3392 -1.5194 -0.0255 -0.2641 -0.5336 -0.0154 -0.0291 -1.1243 -0.2775 -1.1216 -0.1683
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt interval ; ecgs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine ; infusion
H-1438	-0.36373838782310486	▁beat - to - beat ▁ QT ▁interval ▁; ▁surface ▁E CG s ▁; ▁at rial ▁pa cing ▁; ▁es mol ol ▁; ▁iso pren a line ▁; ▁a tropi ne ▁in fusion
D-1438	-0.36373838782310486	beat-to-beat QT interval ; surface ECGs ; atrial pacing ; esmolol ; isoprenaline ; atropine infusion
P-1438	-1.6245 -0.0167 -0.3866 -0.0495 -0.0957 -0.3395 -0.2132 -0.6884 -0.2945 -0.1854 -1.2687 -0.1184 -0.0829 -0.3633 -2.6231 -0.0743 -0.0727 -1.3100 -0.1437 -0.3222 -0.0888 -0.0078 -0.3160 -0.0300 -0.0309 -0.3223 -0.0697 -0.6751 -0.0185 -0.0425 -0.1347 -0.0096 -0.0958 -0.4072 -0.2084
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence interval
H-803	-0.5084152221679688	
D-803	-0.5084152221679688	
P-803	-0.8985 -0.1183
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power spectral analysis ; hf ; dnx
H-1377	-0.6258036494255066	▁power ▁spec tral ▁analysis ▁; ▁low - fre que ncy ▁; high - fre que ncy ▁; LF ▁; HF ▁; ▁CHF - in v ▁; ▁sham - in v ▁; ▁sham ▁; ▁DN x
D-1377	-0.6258036494255066	power spectral analysis ; low-frequency ;high-frequency ;LF ;HF ; CHF-inv ; sham-inv ; sham ; DNx
P-1377	-1.0542 -1.1337 -0.0095 -2.2459 -0.1400 -0.7501 -0.0441 -0.0298 -0.1621 -0.0228 -0.6946 -1.6522 -0.0704 -0.0157 -0.0616 -0.0310 -0.1522 -0.3996 -0.4739 -0.0909 -0.2488 -1.2339 -0.0407 -1.5110 -1.6478 -0.0631 -0.9417 -0.0516 -1.1947 -1.1835 -0.1943 -0.2282 -2.4016 -2.2933 -0.0069 -0.4751 -0.2044
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ; ventricular-arterial coupling ; patients
H-524	-0.43365901708602905	▁contract ility ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁i va bra dine - tre
D-524	-0.43365901708602905	contractility ; ventricular-arterial coupling ; ivabradine-tre
P-524	-0.8115 -0.4799 -0.0684 -0.0013 -0.6871 -0.1164 -0.0313 -0.0047 -0.0475 -0.0237 -1.4949 -0.3712 -0.7352 -0.0093 -0.1715 -0.0499 -0.0497 -0.0904 -3.2622 -0.1673
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change ; follow-up ; readmissions ; hospital ; follow-up
H-721	-1.0974143743515015	▁hospital ▁quality ▁improvement
D-721	-1.0974143743515015	hospital quality improvement
P-721	-1.4120 -1.9326 -0.1451 -1.8732 -0.1241
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal pro-b-type natriuretic peptide ; nt-probnp ; misdiagnosis ; heart failure ; hf
H-1511	-0.39869409799575806	▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁mis diagnos is ▁; ▁heart ▁failure ▁; HF
D-1511	-0.39869409799575806	N-terminal pro-B-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
P-1511	-4.2748 -0.0273 -0.0158 -0.0201 -0.3505 -0.0207 -0.5218 -0.0614 -0.0104 -0.0049 -0.0868 -0.0349 -2.6527 -0.2439 -0.1426 -0.0778 -0.2154 -0.8215 -0.0026 -0.0061 -0.6191 -0.1108 -0.3795 -0.0128 -0.1221 -0.0626 -0.9008 -0.1302 -0.3252 -0.5305 -0.1230 -0.1252 -0.1232
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac magnetic resonance postcontrast t1 time ; prognosis ; hfpef ; postcontrast t1 ; biomarker ; hfpef
H-743	-0.3201638460159302	▁cardiac ▁magnetic ▁res on ance ▁; ▁h f EF ▁; ▁bio mark er ▁; ▁h f f
D-743	-0.3201638460159302	cardiac magnetic resonance ; hfEF ; biomarker ; hff
P-743	-0.1003 -0.0410 -0.1806 -0.1748 -0.0177 -0.1795 -0.1202 -0.8320 -0.9678 -0.2743 -0.4327 -0.0067 -0.0202 -0.3442 -0.1608 -0.7942 -1.1440 -0.1699 -0.1221
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action ; randomized ; patients ; left ventricular ejection fraction ; new york heart association class ii ; hf ; exercise ; training
H-698	-0.7191298007965088	▁h - ac tion ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁New ▁York ▁Heart ▁Association ▁; ▁ HF
D-698	-0.7191298007965088	h-action ; left ventricular ejection fraction ; New York Heart Association ; HF
P-698	-1.3122 -0.4166 -2.6595 -0.7989 -0.1389 -1.0772 -0.0272 -2.2109 -0.2969 -0.1839 -0.5125 -0.4301 -0.6911 -0.0021 -0.1270 -0.9042 -0.4363 -0.8435 -0.8876 -0.7409 -1.1793 -0.2993 -0.9161 -0.1667
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial dd ; collagen deposition ; titin ; obese ; diabetic ; zsf1 ; heart failure with preserved ejection fraction
H-762	-0.3764173984527588	▁my o card ial ▁ DD ▁; ▁collage n ▁de position ▁; ▁titi n ▁modification ▁; ▁obes e ▁; ▁diabet ic ▁z SF 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-762	-0.3764173984527588	myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; ejection fraction
P-762	-1.6788 -0.1370 -0.0946 -0.1329 -0.7940 -0.0109 -0.2135 -0.0745 -0.0613 -0.0370 -0.0919 -0.1375 -0.0750 -0.0138 -0.7742 -0.2355 -0.3874 -0.0349 -0.1313 -0.0489 -0.0530 -2.0142 -0.1596 -0.0682 -0.1825 -0.0649 -0.7850 -1.4001 -0.2711 -0.9917 -1.3228 -0.1239 -0.0519 -0.3511 -0.0010 -0.7729 -0.1488
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac ; jq1 ; bet ; pathological ; cardiac ; gene expression
H-1049	-0.525948166847229	▁cardiac ▁tissu e ▁; ▁mi ce ▁; ▁ TAC - ▁; ▁sham - opera ted ▁; ▁j q 1 ▁; ▁vehicle ▁; ▁ BET ▁inhibi tion ▁; ▁path ological ▁cardiac ▁expression ▁programme
D-1049	-0.525948166847229	cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac expression programme
P-1049	-0.5852 -2.8094 -0.3134 -0.2388 -0.7708 -0.0838 -0.1617 -0.6202 -0.0130 -0.0416 -2.0288 -0.0381 -0.0129 -0.0188 -0.5647 -0.2451 -0.2843 -1.4065 -0.0814 -0.1552 -0.9461 -0.2208 -0.5836 -0.0501 -2.1100 -0.0401 -0.2883 -0.4003 -0.3013 -0.1752 -1.6644 -0.1036 -0.3443 -0.1804
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional hazard models ; negative binomial regression models ; health
H-1624	-0.29781368374824524	▁co x - propor tional ▁hazard ▁models ▁; ▁negative ▁bi nom ial ▁re gression ▁models
D-1624	-0.29781368374824524	cox-proportional hazard models ; negative binomial regression models
P-1624	-0.3796 -0.0048 -0.0097 -0.0129 -0.1566 -0.2504 -0.3141 -0.1128 -0.3504 -0.0228 -0.1004 -0.0130 -0.0095 -0.0055 -0.3271 -2.8753 -0.1179
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic blood pressure ; elevated ; left ventricular ; hypertrophy
H-277	-0.4623181223869324	▁Sy sto lic ▁blood ▁pressure ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁hyper trop hy ▁; ▁AT ▁; ▁AN ▁; ▁AS ▁; ▁ ANS
D-277	-0.4623181223869324	Systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ; ANS
P-277	-0.4631 -0.2763 -0.9791 -0.4117 -0.9676 -0.1295 -0.3168 -0.0458 -1.5977 -0.4495 -0.4791 -0.1179 -0.6225 -0.0903 -0.0042 -0.0823 -0.3184 -0.6284 -0.2992 -0.1947 -0.4171 -0.0322 -0.3007 -0.9989 -1.0533 -1.0961 -0.1103
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 ; hypertrophy ; fibrosis ; ventricular dysfunction ; gene
H-642	-0.23405860364437103	▁condition al ▁gene - tar get ed ▁Hand 2 ▁mi ce ▁; ▁pressure - over load - indu ced ▁hyper trop hy ▁; ▁fibro sis ▁; ▁vent ri cular ▁dys function ▁; ▁fet al ▁gene ▁program
D-642	-0.23405860364437103	conditional gene-targeted Hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
P-642	-0.0460 -0.0867 -1.2213 -0.0354 -0.0169 -0.1311 -0.0646 -0.2843 -0.0595 -0.8111 -0.0940 -0.1533 -1.2890 -0.0248 -0.0799 -0.1329 -0.2311 -0.0582 -0.2438 -0.0121 -0.0039 -0.1099 -0.1445 -0.0043 -0.3990 -0.1016 -0.0025 -0.5210 -0.1184 -0.0106 -0.0776 -0.1824 -0.1096 -0.0463 -0.4514 -1.2092 -0.1780 -0.1481
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission ; nt-probnp ; patients ; acute hf ; diagnosis
H-264	-0.7035073041915894	▁NT - pro b NP ▁; ▁ED ▁; ▁a cute ▁ HF
D-264	-0.7035073041915894	NT-probNP ; ED ; acute HF
P-264	-1.7361 -0.0142 -0.0080 -0.7143 -0.1363 -0.2039 -3.8010 -0.2927 -1.7338 -0.0264 -0.0820 -0.1305 -0.7828 -0.1869
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak oxygen consumption ; vo2max ; resting hr ; bpm ; p value
H-1943	-0.6288604140281677	▁Peak ▁oxygen ▁consum p tion ▁; VO 2 max ▁; ▁rest ing ▁HR
D-1943	-0.6288604140281677	Peak oxygen consumption ;VO2max ; resting HR
P-1943	-1.5162 -0.3914 -2.2212 -0.0381 -0.2530 -0.1430 -0.1132 -0.0333 -0.0033 -0.3446 -2.1575 -0.1275 -0.6578 -1.3077 -0.1250
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up ; patients ; combined end point ; death ; heart failure ; death ; cardiac transplant
H-1747	-0.8694618940353394	heart ▁failure ▁; ▁non card iac ▁; ▁cardiac ▁transplant
D-1747	-0.8694618940353394	heart failure ; noncardiac ; cardiac transplant
P-1747	-3.5897 -0.2747 -0.7636 -3.9609 -0.0335 -0.1062 -0.2719 -0.0571 -0.1035 -0.2326 -0.1703
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty ; health abc short physical performance battery ; habc battery ; gill index ; hf
H-625	-0.494393527507782	▁fra il ty ▁; ▁Health ▁ABC ▁Short ▁Physic al ▁Performance ▁Bat tery ▁; ▁h ABC ▁Bat tery ▁; ▁Gill ▁index ▁; ▁ HF
D-625	-0.494393527507782	frailty ; Health ABC Short Physical Performance Battery ; hABC Battery ; Gill index ; HF
P-625	-3.8502 -0.3071 -1.8670 -0.0789 -1.3260 -0.2292 -0.9853 -0.2949 -0.0233 -0.1024 -0.1188 -0.0075 -0.0632 -0.1202 -0.2959 -0.2892 -0.0044 -0.0853 -0.9872 -0.1778 -0.0936 -0.6080 -0.0622 -0.2958 -0.0865
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic ; cardiac ; cardiac ; gene ; signal transduction ; pathological ; gene expression ; hf
H-1053	-0.332912415266037	▁epi gene tic ▁readers ▁; ▁cardiac ▁bi ology ▁; ▁cardiac ▁gene ▁control ▁; ▁chr omat in - dependent ▁signal ▁trans duction ▁; ▁a bro gate ▁path ological ▁gene ▁expression ▁; ▁ HF ▁progression
D-1053	-0.332912415266037	epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; abrogate pathological gene expression ; HF progression
P-1053	-1.1703 -0.0433 -0.4554 -0.0613 -1.0045 -0.0342 -0.2503 -0.7547 -0.1603 -2.2736 -1.3924 -0.0911 -0.2119 -0.0453 -0.0110 -0.8683 -0.0253 -0.0137 -0.2987 -0.0754 -0.1167 -0.1999 -0.0491 -0.0008 -0.0026 -0.2872 -0.1787 -0.2687 -0.0294 -0.1572 -0.2926 -0.0138 -0.4595 -0.2163 -0.1384
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical ; rule ; patients ; cad ; angiography ; patients ; systolic hf ; cost
H-1193	-0.6353464126586914	▁clinic al ▁predict ion ▁rule ▁; ▁CAD ▁; ▁ang i ography ▁; ▁sy sto lic ▁ HF
D-1193	-0.6353464126586914	clinical prediction rule ; CAD ; angiography ; systolic HF
P-1193	-4.3051 -0.0230 -0.4194 -0.0060 -0.5683 -0.1546 -0.9389 -0.0803 -0.2541 -0.4050 -0.1891 -0.1191 -2.1083 -0.1397 -0.4802 -0.1060 -0.0158 -1.6169 -0.1418
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic response ; heart rate ; exercise ; baseline ; follow-up ; tests ; heart rate ; exercise
H-1176	-0.877715528011322	▁load - corre cted ▁chr ono tropi c ▁response ▁; ▁heart ▁rate
D-1176	-0.877715528011322	load-corrected chronotropic response ; heart rate
P-1176	-2.2818 -0.0478 -0.0212 -0.2144 -0.0673 -0.0477 -0.0539 -0.1551 -0.9356 -0.1817 -2.1585 -1.5910 -4.3635 -0.1685
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient ; hospital ; gastrointestinal bleeding ; patient ; ventricular tachycardia ; terminal heart failure
H-1961	-0.32045280933380127	▁hospital ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁ta chy car dia ▁storm ▁; ▁terminal ▁heart ▁failure
D-1961	-0.32045280933380127	hospital ; gastrointestinal bleeding ; ventricular tachycardia storm ; terminal heart failure
P-1961	-1.1877 -0.4422 -0.0758 -0.0020 -0.3712 -0.0568 -0.0202 -0.1164 -0.1082 -0.2961 -0.0584 -0.6443 -0.0468 -0.6081 -0.0474 -0.0146 -0.3125 -0.0118 -0.2499 -2.1742 -0.3729 -0.2282 -0.1180 -0.1271
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous ; revascularization ; angioplasty ; stenting ; clinical ; patients ; randomized ; clinical
H-1601	-0.44953885674476624	▁cat heter - based ▁per cuta ne ous ▁re vas cular ization ▁; ▁ang io plast y ▁; ▁sten ting
D-1601	-0.44953885674476624	catheter-based percutaneous revascularization ; angioplasty ; stenting
P-1601	-1.3050 -0.0017 -0.0361 -0.2288 -0.9837 -0.0053 -0.1852 -1.3137 -0.0124 -0.0306 -0.2948 -0.4254 -0.4621 -0.0078 -0.8118 -0.0369 -0.1696 -0.5049 -0.0090 -1.9957 -0.9554 -0.1138
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients ; hf ; t2d ; erc ; vo2max ; maximum oxygen consumption ; skm ; biopsies
H-1251	-0.2847076952457428	▁ HF ▁; ▁t 2 d ▁; ▁ ERC ▁; ▁tre ad m ill ▁testing ▁; VO 2 max ▁; ▁oxygen ▁consum p tion ▁; ▁Sk m ▁bio psi es
D-1251	-0.2847076952457428	HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
P-1251	-1.9289 -0.0661 -0.0364 -0.5118 -0.0356 -0.3181 -0.0501 -0.2499 -0.3010 -0.0728 -0.3822 -0.0069 -0.0289 -0.2947 -1.5116 -0.0310 -0.2711 -0.0142 -0.0056 -0.0835 -0.1836 -1.1580 -0.0215 -0.1113 -0.4144 -0.1131 -0.0778 -0.3482 -0.0835 -0.0425 -0.2188 -0.1376
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild hf ; qrs prolongation ; lvef ; crt ; reverse remodeling ; clinical ; systolic dysfunction
H-758	-0.5403048992156982	▁ HF ▁; ▁QR s ▁prolong ation ▁; ▁LV EF ▁; ▁c rte ▁; ▁rever se ▁remodel ing ▁; ▁clinic al ▁benefit ▁; ▁LV
D-758	-0.5403048992156982	HF ; QRs prolongation ; LVEF ; crte ; reverse remodeling ; clinical benefit ; LV
P-758	-0.6121 -0.0445 -0.0630 -0.0172 -1.3063 -0.2413 -0.0349 -0.0687 -0.3099 -0.2164 -0.0157 -0.6699 -1.4443 -0.1490 -0.0912 -0.0029 -0.0083 -0.0364 -0.1148 -3.2078 -0.0152 -0.8007 -0.1622 -0.8590 -3.4588 -0.0977
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients ; rv support ; lvad ; patients ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
H-295	-0.5253632664680481	▁ RV ▁; ▁l VAD ▁ insertion ▁; ▁cardio ge nic ▁shock ▁; ▁my o card ial ▁in far ction ▁; ▁chronic ▁de com pensa ted ▁heart ▁failure
D-295	-0.5253632664680481	RV ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
P-295	-0.9915 -0.4118 -1.8199 -1.4049 -0.0443 -1.4961 -0.0108 -0.3661 -0.0937 -0.0634 -1.1179 -0.0916 -0.3650 -1.0061 -0.3168 -0.1389 -0.2711 -0.0263 -1.3723 -0.1483 -0.3514 -1.8283 -0.0403 -0.1345 -0.0118 -0.8200 -0.2702 -0.1873 -0.3107 -0.2495
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up ; patients
H-268	-0.7890704870223999	
D-268	-0.7890704870223999	
P-268	-1.4024 -0.1757
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty ; gill index ; hf
H-628	-1.0321389436721802	▁non - fra il ▁; ▁h ▁; ▁severe ▁fra il ty ▁; ▁h ▁; ▁Gill ▁index ▁; ▁ HF
D-628	-1.0321389436721802	non-frail ; h ; severe frailty ; h ; Gill index ; HF
P-628	-3.4949 -0.0212 -0.0051 -0.1448 -0.9043 -2.9257 -0.7517 -4.1611 -0.1954 -0.1769 -2.1852 -0.1293 -2.5746 -1.3743 -0.5487 -0.4354 -0.2804 -0.9583 -0.0940 -0.1447 -0.1690
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence ; hf ; ami ; adjusted odds ratio
H-1310	-0.8371620178222656	▁ HF ▁; ▁ AMI ▁; ▁odds ▁ratio
D-1310	-0.8371620178222656	HF ; AMI ; odds ratio
P-1310	-1.5633 -0.1132 -0.2033 -2.0134 -1.0748 -0.8874 -0.8118 -0.1496 -1.4025 -0.1522
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic heart failure ; chf ; multisystem disease ; comorbidities ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
H-1357	-0.16949881613254547	▁Chro nic ▁heart ▁failure ▁; CH f ▁; ▁multi system ▁disease ▁; ▁an emia ▁; ▁insulin ▁resist ance ▁; ▁autonomi c ▁dys balance ▁; ▁cardiac ▁cache xia
D-1357	-0.16949881613254547	Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
P-1357	-0.4993 -0.2950 -0.5238 -0.1179 -0.0876 -0.8143 -0.0596 -0.1676 -0.0073 -0.1928 -0.4544 -0.1991 -0.0878 -0.0660 -0.1535 -0.0155 -0.2447 -0.0087 -0.1393 -0.0651 -0.1644 -0.0083 -0.0213 -0.1421 -0.0215 -0.0409 -0.0426 -0.1797 -0.0955
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic ; β-ar ; catecholamine ; infusions ; pde2 ; expression ; camp ; activity ; correlated ; cardiac ; β-ar responsiveness
H-1214	-0.34925949573516846	▁β - AR ▁stimul ation ▁; ▁cate chol amine ▁in fusion s ▁; ▁p de 2 ▁expression ▁; ▁c AMP ▁hydro ly tic ▁activity ▁; ▁blu n ted ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.34925949573516846	β-AR stimulation ; catecholamine infusions ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
P-1214	-3.6251 -0.0214 -0.0632 -0.5464 -0.0209 -0.7655 -0.0202 -0.0129 -0.1276 -0.0545 -0.0368 -0.0616 -0.1322 -1.2921 -0.0745 -0.0227 -0.1399 -0.0689 -0.0368 -0.0753 -0.0605 -0.3563 -1.5877 -0.1193 -0.1891 -0.1202 -0.0313 -1.5697 -0.0294 -0.5785 -0.0038 -0.0301 -0.1056 -0.2416 -0.2213 -0.1300
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic pah ; clinical ; hospitalized ; patients ; acute ; rv decompensation ; pharmacologic ; therapies ; rv failure ; pah
H-1096	-0.385810911655426	▁chronic ▁P AH ▁; ▁ RV ▁de com pensa tion ▁; ▁ pharma c ologic ▁ therapie s ▁; ▁ RV ▁failure ▁management ▁; ▁p AH
D-1096	-0.385810911655426	chronic PAH ; RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
P-1096	-0.8437 -1.3829 -0.0115 -0.2863 -1.3908 -0.7412 -0.2636 -0.3570 -0.0116 -0.0242 -0.4316 -0.0670 -0.3053 -0.0437 -0.0715 -0.2667 -0.1098 -0.0241 -0.3798 -0.3898 -0.1408 -0.2592 -0.0890 -1.0217 -1.5373 -0.0134 -0.1521 -0.1871
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese ; zsf1 ; heart failure with preserved ejection fraction ; lung ; preserved left ventricular ejection fraction ; left ventricular dd
H-767	-0.5984259843826294	▁z SF 1 ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁lung ▁weight ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁ DD
D-767	-0.5984259843826294	zSF1 ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular DD
P-767	-1.2499 -1.0743 -0.2960 -1.4826 -2.0011 -0.4410 -0.1069 -1.2836 -0.3827 -0.0840 -0.0769 -0.0012 -0.2051 -0.7339 -0.4104 -0.0643 -2.5152 -0.0329 -1.2734 -0.1229 -0.3381 -0.4712 -0.3289 -0.1641 -0.0017 -0.2536 -0.6025 -0.0482 -1.8200 -0.1514 -1.2923 -0.5169 -0.3618 -0.1576
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine oxidase ; xo ; left ventricular ; myocytes ; volume overload ; vo ; mitral regurgitation ; aortocaval fistula ; acf
H-470	-0.3889736831188202	▁Xan thi ne ▁oxid ase ▁; XO ▁; ▁rat ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁my o cy tes ▁; ▁volume ▁over load ▁; VO ▁; ▁mit ral ▁re gur gi tation ▁; ▁a orto ca val ▁fi stu la ▁; ▁ac f
D-470	-0.3889736831188202	Xanthine oxidase ;XO ; rat ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ; acf
P-470	-0.0013 -0.0158 -0.1290 -0.0009 -0.2009 -0.1173 -0.0161 -0.1682 -1.0119 -0.8345 -2.4312 -0.0424 -0.7950 -0.2648 -0.2467 -0.1785 -0.2517 -1.5861 -0.0530 -0.0161 -0.0356 -0.2382 -3.0824 -0.6565 -0.0691 -0.1603 -0.6813 -0.2553 -0.4834 -0.0988 -0.0068 -0.0138 -0.0897 -0.0177 -0.2035 -0.0065 -0.0174 -0.0054 -0.3867 -0.0353 -0.0039 -0.1244 -0.9642 -1.9723 -0.1071 -0.1128 -0.0920
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse ; myocardial t1 ; heart failure
H-1055	-0.2706654369831085	▁free - bre a thing ▁puls e ▁se que nce ▁; ▁my o card ial ▁t 1 ▁changes ▁; ▁s win e ▁model ▁; ▁ta chy car dia - indu ced ▁heart ▁failure
D-1055	-0.2706654369831085	free-breathing pulse sequence ; myocardial t1 changes ; swine model ; tachycardia-induced heart failure
P-1055	-1.1981 -0.0301 -0.0791 -0.1320 -0.0649 -0.0859 -0.0904 -1.1601 -0.0473 -0.0159 -0.1427 -0.2243 -0.0843 -0.0617 -0.0478 -1.2132 -0.0290 -0.2938 -0.0587 -0.1526 -0.2139 -0.0355 -1.2385 -0.8347 -0.7700 -0.0230 -0.0127 -0.3162 -0.0265 -0.0045 -0.3295 -0.1236 -0.0626 -0.1427 -0.1272
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic ; new york heart association classes ; saf
H-229	-1.1556493043899536	▁ PF ▁co hor t ▁; ▁New ▁York ▁Heart ▁Association
D-229	-1.1556493043899536	PF cohort ; New York Heart Association
P-229	-2.3273 -0.3395 -4.4066 -0.0417 -0.1282 -0.1427 -1.3569 -0.3953 -1.3436 -0.7841 -2.4801 -0.1216
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians ; patients ; patient ; clinician ; medication ; patient
H-1129	-0.753139853477478	▁co management ▁; ▁medication
D-1129	-0.753139853477478	comanagement ; medication
P-1129	-0.7793 -0.1752 -0.6862 -2.3463 -0.3693 -0.1626
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients ; physicians ; mortality ; physicians ; hospitals
H-1727	-0.5305023193359375	▁physician s ▁; ▁mortal ity ▁; ▁low - volu me ▁physician s ▁; ▁low - volu me ▁hospital s
D-1727	-0.5305023193359375	physicians ; mortality ; low-volume physicians ; low-volume hospitals
P-1727	-4.1925 -0.0579 -0.2553 -1.4302 -0.4801 -0.1892 -0.3250 -0.0228 -0.0275 -0.0263 -0.6876 -0.0545 -0.6713 -1.8309 -0.0217 -0.0503 -0.0209 -0.4652 -0.0875 -0.1000 -0.1438
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western ; administrative ; health ; patients ; hf ; hospitalized ; ami
H-1307	-0.7898829579353333	▁Western ▁Australian ▁; ▁administrative ▁health ▁; ▁ HF ▁; ▁ AMI
D-1307	-0.7898829579353333	Western Australian ; administrative health ; HF ; AMI
P-1307	-0.6000 -0.6597 -1.2274 -0.1817 -0.4774 -1.3246 -1.8840 -0.9302 -1.0098 -1.0682 -0.6183 -0.1478 -0.1395
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report ; connection ; patients ; disease ; healthcare ; conditions ; turkey
H-1825	-0.7680271863937378	▁conditions ▁; ▁Turkey
D-1825	-0.7680271863937378	conditions ; Turkey
P-1825	-1.3552 -0.9016 -1.3587 -0.0869 -0.1377
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective cohort ; eds ; diagnosis ; heart failure
H-463	-0.8446641564369202	▁ed s ▁; ▁responsable ▁ diagnos is ▁; ▁heart ▁failure
D-463	-0.8446641564369202	eds ; responsable diagnosis ; heart failure
P-463	-1.7246 -0.2169 -0.2729 -3.7960 -0.6000 -0.3960 -0.0408 -1.0237 -0.2808 -0.2928 -1.2996 -0.1918
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome ; prospective ; hospitalized ; hf ; nursing ; outcomes
H-1403	-1.074035882949829	▁nur sing - sensitiv e ▁; ▁science ▁; ▁ HF
D-1403	-1.074035882949829	nursing-sensitive ; science ; HF
P-1403	-3.7079 -0.0647 -0.0177 -0.0091 -0.1015 -2.8276 -0.4826 -0.1057 -4.6119 -0.2294 -0.6033 -0.1269
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas ; rnas ; expression ; genes ; messenger rna ; repression
H-1482	-0.6146607995033264	▁mi RNA s ▁; ▁ RNA s ▁; ▁ RNA s ▁; ▁ binding ▁; ▁messenger ▁ RNA ▁; ▁degrada tion ▁; ▁re pression
D-1482	-0.6146607995033264	miRNAs ; RNAs ; RNAs ; binding ; messenger RNA ; degradation ; repression
P-1482	-0.8886 -0.0129 -0.0436 -0.4325 -1.3615 -0.0385 -0.0874 -0.2961 -2.3067 -0.2862 -0.2010 -0.3323 -2.4620 -1.2196 -0.3437 -0.9382 -0.1441 -0.0513 -1.2022 -1.0020 -0.0601 -0.5480 -1.4706 -0.0073 -0.1618 -0.0829
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients ; hfpef ; ivabradine ; placebo ; double-blind
H-1173	-0.5317621827125549	▁ HF p EF ▁; ▁i va bra dine
D-1173	-0.5317621827125549	HFpEF ; ivabradine
P-1173	-1.5768 -0.2141 -0.0601 -0.6338 -0.1609 -0.0239 -0.0097 -0.5509 -0.0230 -2.4349 -0.1613
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac ; cells ; cardiac ; cells ; cardiac functions ; myocardial infarction
H-1335	-0.5289366841316223	▁Card iac ▁c - K it ▁; ▁cardiac ▁ex plant - der i ved ▁cell s ▁; ▁cardiac ▁; ▁implant - der i ved ▁cell s ▁; ▁cardiac ▁function s ▁; ▁my o card ial ▁in far ction
D-1335	-0.5289366841316223	Cardiac c-Kit ; cardiac explant-derived cells ; cardiac ; implant-derived cells ; cardiac functions ; myocardial infarction
P-1335	-1.0674 -0.0410 -0.0956 -0.0247 -0.3221 -0.1288 -0.2757 -0.1658 -0.5819 -0.0300 -0.0248 -0.1731 -0.1820 -0.1210 -0.3664 -0.0276 -0.2101 -0.4652 -1.7082 -3.8094 -0.6931 -0.8077 -0.1986 -0.1573 -1.0215 -0.0226 -0.2852 -1.2414 -3.3770 -0.0839 -0.5210 -0.9169 -0.1335 -0.0878 -0.2873 -0.0114 -0.9083 -0.2500 -0.1837 -0.1483
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps ; adverse outcomes ; patients ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
H-1022	-0.5979831218719482	NP s ▁; ▁heart ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁diabetes ▁; ▁che mo therapy
D-1022	-0.5979831218719482	NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
P-1022	-1.6392 -0.0483 -0.5155 -5.5470 -0.3323 -0.2872 -0.0087 -0.0651 -0.0910 -0.0044 -1.2691 -0.1290 -0.0591 -0.8484 -0.1909 -0.0558 -0.0128 -0.1192 -0.1389
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses ; pathophysiology ; hf ; nursing ; medical ; symptoms ; pathophysiologic
H-2022	-0.546914279460907	▁pat ho phy si ology ▁; ▁ HF ▁; ▁medical ▁management ▁; ▁pat ho phy si ologic
D-2022	-0.546914279460907	pathophysiology ; HF ; medical management ; pathophysiologic
P-2022	-2.0901 -0.0743 -0.1063 -0.5397 -0.8753 -0.2912 -0.7045 -0.0316 -0.1978 -1.3501 -0.0556 -0.6636 -1.2775 -0.0603 -0.3809 -0.2750 -0.1018 -1.1826 -0.1331
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia ; pna
H-1691	-0.32963234186172485	▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia ▁; ▁p na
D-1691	-0.32963234186172485	heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pna
P-1691	-2.6355 -0.1289 -0.0540 -0.4094 -0.0324 -0.0923 -0.0048 -0.6707 -0.4786 -0.0564 -0.1330 -0.0082 -0.5633 -0.0768 -0.1670 -0.3866 -0.0498 -0.0003 -0.4179 -0.2969 -0.2845 -0.5928 -0.2161 -0.1549
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
H-1618	-0.2393820732831955	▁mortal ity ▁; ▁health care ▁utiliza tion ▁; ▁tele health ▁; ▁con ges tive ▁heart ▁failure ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁mell itus
D-1618	-0.2393820732831955	mortality ; healthcare utilization ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
P-1618	-0.0759 -0.2113 -0.0771 -0.1051 -0.0277 -0.1087 -0.0132 -0.4179 -3.5649 -0.1624 -0.1918 -0.1038 -0.0142 -0.0598 -0.3204 -0.0637 -0.0744 -0.0387 -0.1694 -0.0524 -0.0126 -0.0042 -0.1880 -0.6724 -0.1207 -0.0503 -0.0062 -0.0102 -0.1746 -0.0895
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 ; bets ; chromatin ; downstream signalling ; rna ; polymerase ii ; pol ii
H-1043	-0.4978456199169159	▁inhibi tor ▁; ▁j q 1 ▁; ▁ BET s ▁; ▁chr omat in ▁; ▁ RNA ▁poly mera se ▁II ▁; Pol ▁II
D-1043	-0.4978456199169159	inhibitor ; jq1 ; BETs ; chromatin ; RNA polymerase II ;Pol II
P-1043	-1.4914 -0.0164 -1.1569 -1.2259 -0.8549 -0.2041 -0.3767 -0.6092 -0.1322 -0.3243 -0.3532 -0.0420 -0.0161 -0.6199 -0.1583 -3.0773 -0.3707 -0.0374 -0.0261 -0.0175 -0.2669 -0.3499 -0.7298 -0.2378 -0.1574 -0.0916
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction ; hfpef
H-942	-0.20234237611293793	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f f
D-942	-0.20234237611293793	catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hff
P-942	-0.0822 -0.0387 -0.0569 -0.0401 -0.4382 -0.0696 -0.1954 -0.4249 -0.0290 -0.0105 -0.2337 -0.1094 -0.0961 -0.4202 -0.1657 -0.1153 -0.2414 -0.0045 -0.0938 -0.0392 -0.4766 -0.2361 -0.1164 -0.0018 -0.4288 -0.1127 -0.2463 -1.0204 -0.3674 -0.1590
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic ; heart failure with preserved ejection fraction ; hfpef ; patients ; health ; symptoms ; quality of life
H-780	-0.4395505487918854	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁patients ▁; ▁health ▁status
D-780	-0.4395505487918854	heart failure ; preserved ejection fraction ;HFpEF ; patients ; health status
P-780	-1.3453 -0.2550 -0.1182 -0.5894 -0.0059 -0.1640 -0.0307 -0.4058 -0.2123 -0.1191 -0.0016 -0.1992 -0.5559 -0.0137 -0.1961 -0.2497 -1.9554 -1.0998 -0.5159 -0.3853 -1.1395 -0.1124
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate cox proportional hazards regression modeling ; hospitalization ; acute coronary syndromes ; coronary interventions ; patients
H-104	-0.4251709580421448	▁co x ▁proportion al ▁hazard s ▁re gression ▁; ▁i ▁; ▁a cute ▁corona ry ▁syndrome s ▁; ▁corona ry ▁intervention s
D-104	-0.4251709580421448	cox proportional hazards regression ; i ; acute coronary syndromes ; coronary interventions
P-104	-0.5913 -0.0110 -0.0348 -0.0373 -0.1040 -0.0841 -0.2083 -0.0037 -1.4696 -2.7076 -1.1469 -2.0541 -0.0073 -0.1808 -0.0786 -0.0570 -0.0490 -0.2623 -0.1082 -0.0769 -0.4384 -0.0510 -0.2869 -0.1548
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic adenosine monophosphate ; camp ; cyclic guanosine monophosphate ; cgmp ; hearts
H-1209	-0.366891473531723	▁ cycli c ▁ad enos ine ▁mono phos pha te ▁; ▁c AMP ▁; ▁aug mente d ▁ cycli c ▁gua no sine ▁mono phos pha te ▁; ▁c g mp ▁; ▁fail ing ▁heart s
D-1209	-0.366891473531723	cyclic adenosine monophosphate ; cAMP ; augmented cyclic guanosine monophosphate ; cgmp ; failing hearts
P-1209	-1.0401 -0.7380 -0.2257 -0.1732 -0.1415 -0.2707 -0.2127 -0.0009 -0.1012 -0.0670 -0.1940 -0.3461 -0.0485 -0.1169 -3.1837 -0.1011 -0.0051 -0.0977 -0.1181 -0.3114 -0.5520 -0.0059 -0.3976 -0.1156 -0.0010 -0.0719 -0.0431 -0.1968 -0.4809 -1.1071 -1.0149 -0.4694 -1.0059 -0.1223 -0.3128 -0.0597 -0.3128 -0.1786
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra ; methotrexate ; tnf antagonist ; non-biological disease modifying antirheumatic drug ; nbdmard
H-604	-0.32953378558158875	▁RA ▁; ▁met ho tre xa te ▁; ▁t NF ▁anta gon ist ▁; ▁non - bi ological ▁disease ▁mod ifying ▁anti r heu matic ▁drug ▁; n b DM ARD
D-604	-0.32953378558158875	RA ; methotrexate ; tNF antagonist ; non-biological disease modifying antirheumatic drug ;nbDMARD
P-604	-0.8854 -0.3898 -0.2897 -0.0532 -0.0209 -0.0462 -0.0596 -0.2224 -1.4694 -0.4059 -0.3703 -0.0327 -0.6185 -0.0990 -0.9344 -0.0152 -0.1633 -0.2309 -0.1070 -0.5387 -0.0085 -0.0195 -0.4339 -0.4632 -0.0761 -0.0572 -0.3824 -0.9304 -0.0043 -0.9078 -0.2305 -0.2129 -0.1955
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal dysfunction ; intestinal ; lead ; chronic ; inflammatory ; catabolic ; anabolic ; cardiac cachexia ; terminal ; chf ; prognosis
H-1360	-0.249164417386055	▁intestinal ▁dys function ▁; ▁disturb ed ▁intestinal ▁barrier ▁; ▁chronic ▁infla mma tory ▁state ▁; ▁cata bo lic / ana bo lic ▁im balance ▁; ▁cardiac ▁cache xia ▁; ▁CHF
D-1360	-0.249164417386055	intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic/anabolic imbalance ; cardiac cachexia ; CHF
P-1360	-0.5203 -0.1184 -0.3782 -0.0678 -1.3279 -0.0346 -0.2684 -0.1531 -0.1966 -0.3767 -0.2666 -0.4448 -0.1096 -0.4650 -0.0987 -0.0181 -0.0098 -0.3353 -1.4135 -0.0307 -0.0756 -0.3297 -0.0282 -0.0142 -0.1401 -0.0252 -0.0299 -0.0114 -0.1900 -0.2196 -0.1763 -0.0989
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report ; patient ; diagnosis ; ischemic-hypertensive cardiomyiopathy ; angina ; myocardial ischemia ; coronary arteries
H-998	-0.34884345531463623	▁ ische mic - hy per tensi ve ▁cardio my io pathy ▁; ▁ang ina ▁; ▁induc ible ▁my o card ial ▁ ische mia ▁; ▁corona ry ▁arteri es
D-998	-0.34884345531463623	ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
P-998	-0.6548 -1.1573 -0.1072 -0.0116 -0.0071 -0.0607 -0.0859 -0.0785 -0.0395 -0.3333 -3.3114 -0.0535 -0.1850 -0.0497 -0.2914 -0.1485 -0.3312 -0.4532 -0.8549 -0.1423 -0.1250 -0.1863 -0.0564 -0.8444 -0.3333 -0.2900 -0.2453 -0.1093 -0.0619 -0.2034 -0.2200 -0.1305
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate receptor 1 ; s1pr1 ; β1-adrenergic receptor ; β1ar ; g-protein-coupled receptors ; heart
H-1405	-0.36233213543891907	▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁β 1- ad r energi c ▁receptor ▁; β 1 AR ▁; ▁g - prote in - co up led ▁receptor s ▁; ▁heart
D-1405	-0.36233213543891907	sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
P-1405	-0.0019 -0.2456 -3.4669 -0.7093 -0.4058 -0.1249 -0.0037 -0.0644 -0.0491 -0.0611 -0.3025 -1.7484 -0.0447 -0.1862 -1.4773 -0.1063 -0.2248 -0.0825 -0.1179 -0.2624 -0.1161 -0.0239 -0.1610 -0.7132 -0.0440 -0.1216 -0.3172 -0.9489 -0.0176 -0.0203 -0.7755 -0.0204 -0.0085 -0.0023 -0.0389 -0.8242 -0.0984 -0.3093 -0.2851 -0.2012 -0.1227
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal ; correlated ; pcwp ; p values
H-484	-0.8215134143829346	sept al ▁; ▁PC WP
D-484	-0.8215134143829346	septal ; PCWP
P-484	-0.2914 -0.1426 -0.3550 -0.3382 -0.2776 -4.0166 -0.3291
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-864	-0.4398116171360016	▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-864	-0.4398116171360016	atrial fibrillation ; carvedilol ; metoprolol
P-864	-3.9330 -0.1799 -0.6929 -0.0440 -0.0530 -0.3145 -0.1923 -0.0391 -0.1671 -0.2596 -0.0693 -0.2529 -0.0241 -0.3911 -0.2585 -0.1659
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia ; intravenous ; metoprolol ; cardiac ; sympathetic tone
H-1379	-0.40672001242637634	▁Brad y car dia ▁induc ed ▁; ▁met o pro lol ▁; ▁cardiac ▁sympa the tic ▁tone ▁; ▁CHF - IN v ▁rabbi ts ▁; ▁sham - IN v ▁; ▁CHF - DN x
D-1379	-0.40672001242637634	Bradycardia induced ; metoprolol ; cardiac sympathetic tone ; CHF-INv rabbits ; sham-INv ; CHF-DNx
P-1379	-0.0249 -0.0727 -0.0459 -0.6975 -1.5337 -0.1339 -0.2974 -2.2889 -0.0812 -0.0201 -0.2068 -0.0735 -0.0285 -0.3645 -0.3346 -1.5840 -0.0291 -0.5543 -0.1691 -0.0090 -1.3029 -1.0160 -0.3168 -0.0589 -0.1574 -0.0519 -0.0134 -1.2333 -0.7108 -0.3388 -0.2881 -0.0152 -0.1177 -0.0090 -0.3142 -0.1480
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized ; walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; severe heart failure
H-569	-0.6301668882369995	▁Nordic ▁walking ▁; ▁standard ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁heart ▁failure
D-569	-0.6301668882369995	Nordic walking ; standard cardiac rehabilitation ; functional capacity ; heart failure
P-569	-1.0648 -0.8168 -0.0838 -1.8371 -0.0409 -0.1184 -0.0282 -0.9952 -0.5499 -0.3869 -0.2771 -2.8982 -0.1528 -0.1113 -0.0911
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes ; patients ; prescribed ; pharmacological ; discharge ; left ventricular function
H-1849	-0.46726730465888977	▁c PG - re com mend ed ▁ pharma c ological ▁treatment ▁; ▁device ▁consideration ▁; ▁self - care ▁education ▁; ▁left ▁vent ri cular
D-1849	-0.46726730465888977	cPG-recommended pharmacological treatment ; device consideration ; self-care education ; left ventricular
P-1849	-0.1803 -0.5948 -0.1013 -0.0407 -0.0265 -0.0022 -0.0289 -0.0302 -0.0097 -0.0992 -0.1448 -0.6150 -0.1903 -0.6292 -0.9110 -0.1753 -2.9023 -0.0034 -0.0416 -0.8178 -0.3931 -1.0264 -0.0132 -0.9881 -0.0769 -2.3494 -0.2248
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls ; lvef ; prognostic ; clinical ; echocardiographic ; systolic
H-820	-0.6417012810707092	▁gr s ▁; ▁LV EF ▁; ▁sa ▁; ▁CV ▁; ▁e cho car dio graphic ▁sy sto lic ▁parameter s ▁; ▁AF
D-820	-0.6417012810707092	grs ; LVEF ; sa ; CV ; echocardiographic systolic parameters ; AF
P-820	-0.3621 -1.3863 -0.0834 -0.1441 -0.3136 -0.0515 -0.4187 -0.1804 -1.5707 -1.0039 -5.2125 -0.1863 -0.0833 -0.2678 -0.2226 -0.4939 -0.0801 -0.4861 -1.5854 -0.0177 -0.6654 -0.3919 -0.0960 -0.0972
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc ; dapc protein ; sarcomeric microstructure ; skm ; myofibre regeneration
H-1254	-0.47806572914123535	ERC ▁; ▁DAP c ▁protein ▁; ▁sar come ric ▁micro structure ▁; ▁Sk m ▁; ▁my o fi bre ▁regenera tion
D-1254	-0.47806572914123535	ERC ; DAPc protein ; sarcomeric microstructure ; Skm ; myofibre regeneration
P-1254	-0.2801 -0.6400 -0.2566 -1.1893 -1.8539 -0.3822 -0.0133 -0.7583 -0.3584 -0.0391 -0.0812 -0.2131 -0.4102 -0.1210 -1.1424 -2.2068 -0.0646 -0.4541 -0.0515 -0.0808 -0.0898 -0.1902 -0.1185
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas ; expression ; bhlh ; transcription factor ; hand2 ; myocardium ; gene ; heart failure
H-644	-0.4021761417388916	▁signal ling ▁casca des ▁; ▁micro RNA s ▁; ▁b HL h ▁tran scription ▁factor ▁Hand 2 ▁; ▁post na tal ▁mamma lian ▁my o car dium ▁; ▁em bry o nic ▁gene ▁programs ▁; ▁heart ▁failure
D-644	-0.4021761417388916	signalling cascades ; microRNAs ; bHLh transcription factor Hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
P-644	-1.5692 -1.1189 -0.0099 -0.0087 -0.3092 -0.0296 -0.0038 -0.0384 -0.2141 -0.0279 -0.2879 -0.4032 -1.2282 -0.0211 -0.5743 -1.7021 -0.0380 -0.1666 -0.2453 -0.0788 -0.0505 -0.0268 -0.4849 -1.7173 -0.2018 -0.0318 -0.1248 -0.2545 -0.1779 -0.0080 -0.0716 -1.5057 -0.4763 -0.3194 -1.1902 -0.1116 -0.4677 -0.2622 -0.1267
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad ; q66p ; rad ; cav1.2 ; cav1.3 ; l-type channel ; isoforms ; heart
H-1674	-0.5291038155555725	▁rad ▁; ▁q 66 p ▁; ▁inhibi tory ▁actions ▁; ▁rad ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁l - type ▁channel ▁iso form s ▁; ▁heart
D-1674	-0.5291038155555725	rad ; q66p ; inhibitory actions ; rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
P-1674	-0.7408 -0.7853 -3.2947 -0.3424 -0.1331 -0.1065 -0.3072 -0.2682 -0.1786 -0.1260 -0.7291 -0.7220 -0.2062 -1.3229 -1.2457 -0.1755 -0.2722 -1.2764 -0.9462 -0.1465 -0.9921 -0.0815 -0.0175 -0.3495 -0.0887 -0.2788 -0.0422 -0.1546 -0.7548 -0.1758 -0.1413
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef ; lcx ; lad ; stenting ; infarcted ; left ventricle ; lcx ; lad
H-512	-0.7286056876182556	▁EF ▁; ▁ LC x ▁; ▁ LAD ▁; ▁ LAD ▁; ▁sten ting ▁; ▁in far cted ▁left ▁vent ric le ▁; ▁ LC x ▁; ▁ LAD
D-512	-0.7286056876182556	EF ; LCx ; LAD ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD
P-512	-0.8438 -0.1675 -1.3858 -0.1473 -0.5862 -0.6397 -0.8454 -0.1558 -0.4747 -3.1122 -0.3329 -0.6313 -1.8790 -2.6520 -0.3336 -0.5514 -0.2774 -0.2518 -0.1816 -0.0276 -1.9579 -1.0505 -0.2726 -0.8514 -0.2818 -0.7585 -0.3682 -0.2866 -0.1591 -0.9707 -0.1525
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv compliance ; lv end-diastolic volume ; lv end-diastolic pressure ; β coefficient
H-1531	-1.0611572265625	▁EH ▁; ▁LV ▁compliance ▁; ▁h z ▁; LV ▁end - dia sto lic ▁volume ▁; ▁h g ▁; ▁co e ffi cient ▁; ▁ml
D-1531	-1.0611572265625	EH ; LV compliance ; hz ;LV end-diastolic volume ; hg ; coefficient ; ml
P-1531	-0.1302 -0.0903 -0.7404 -2.5933 -0.0463 -4.1557 -1.1104 -0.1082 -3.8029 -4.0990 -0.0201 -0.2623 -1.0551 -0.8400 -0.4104 -0.0918 -4.1720 -0.3212 -0.5446 -2.1178 -0.0956 -0.0052 -0.0335 -0.5612 -0.2719 -0.8088 -0.1631
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva ; surgical ; implantation ; leaflet ; leaflet ; edge-to-edge anastomosis
H-360	-0.22958265244960785	▁m va ▁; ▁sur g ical ▁ring ▁implant ation ▁; ▁le a flet ▁motion ▁; ▁le a flet ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is
D-360	-0.22958265244960785	mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
P-360	-0.2751 -0.0884 -0.1231 -1.3722 -0.0403 -0.1340 -0.9371 -0.0012 -0.0103 -0.1036 -0.0669 -0.1101 -0.0053 -0.5716 -0.0863 -0.1345 -0.0662 -0.0305 -1.5442 -0.0032 -0.3175 -0.2081 -0.0067 -0.4321 -0.3837 -0.0401 -0.0250 -0.0508 -0.0021 -0.0406 -0.0897 -0.1477 -0.1279
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart ; patients ; new york heart association ; nyha ; hospitalized ; hf ; primary outcome ; death ; hf ; hospitalization
H-239	-0.5766720175743103	▁h ART ▁; ▁New ▁York ▁Heart ▁Association ▁; NY HA ▁; ▁ HF ▁; ▁self - management ▁counsel ing ▁; ▁death ▁; ▁ HF
D-239	-0.5766720175743103	hART ; New York Heart Association ;NYHA ; HF ; self-management counseling ; death ; HF
P-239	-0.3445 -0.1430 -0.1627 -1.4370 -0.3749 -1.1016 -0.9495 -0.1801 -0.7908 -0.9654 -0.2418 -2.4080 -0.3684 -0.3521 -0.8626 -0.0119 -0.0873 -0.0123 -0.0487 -0.4501 -1.9426 -0.2318 -0.2229 -0.0526 -1.1047 -0.1461
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in vivo ; cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
H-1783	-0.6630001068115234	▁cardiac ▁function ▁; ▁e cho card i ography ▁; ▁dia sto lic ▁dys function ▁; ▁e ▁; ▁e je ction ▁ fraction
D-1783	-0.6630001068115234	cardiac function ; echocardiography ; diastolic dysfunction ; e ; ejection fraction
P-1783	-0.3586 -3.0642 -0.0634 -0.0822 -0.3502 -0.0786 -0.3333 -0.2757 -0.2280 -0.0381 -0.1457 -1.2119 -0.0158 -0.1068 -0.1458 -0.4123 -5.0721 -0.8071 -2.4553 -0.2120 -0.1027 -0.0017 -0.2159 -0.1345
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; hf ; pathogenesis ; hf
H-1038	-0.5327085852622986	▁ BET ▁family ▁bro modo main ▁protein s ▁; BET s ▁; ▁a ce tyl - ly sine ▁reader ▁protein s ▁; ▁ HF
D-1038	-0.5327085852622986	BET family bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF
P-1038	-1.5060 -0.0205 -3.4438 -0.2330 -0.0304 -0.1418 -1.9273 -0.0494 -0.2273 -0.2527 -0.3637 -0.0904 -1.1119 -0.0888 -0.1206 -0.0181 -0.9805 -0.4134 -0.0527 -1.3628 -0.0232 -0.1621 -0.2563 -0.0696 -0.7449 -0.1591
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood transfusions ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
H-42	-0.3675202429294586	▁blood ▁trans fusion s ▁; ▁ir on ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease
D-42	-0.3675202429294586	blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
P-42	-4.4284 -0.0118 -0.0160 -0.0490 -0.1975 -0.0111 -0.0568 -0.2096 -1.7492 -0.1510 -0.2369 -0.1539 -0.1408 -0.0715 -0.1585 -0.0214 -0.4172 -0.0655 -0.2415 -0.4833 -0.0574 -0.1185 -0.1244 -0.0275 -0.0884 -0.2376 -0.1038 -0.1194 -0.0420 -0.0722 -0.3503 -1.1193 -0.9958 -0.1682
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade ; clinical
H-202	-1.1418976783752441	▁guidelines ▁; ▁Grad e
D-202	-1.1418976783752441	guidelines ; Grade
P-202	-3.6265 -0.5655 -1.0094 -0.5593 -1.0195 -0.0712
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf ; hospitalization
H-563	-0.9281373620033264	▁ HF
D-563	-0.9281373620033264	HF
P-563	-2.1345 -0.2179 -1.0366 -0.3236
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right heart circulatory failure ; disease ; right heart
H-1460	-1.2893939018249512	▁vent ▁circula tory ▁failure ▁; ▁mécanisme s ▁of ▁disease ▁; ▁right ▁heart
D-1460	-1.2893939018249512	vent circulatory failure ; mécanismes of disease ; right heart
P-1460	-6.8703 -0.6220 -0.3172 -0.1121 -0.5666 -4.8192 -0.0091 -0.9515 -1.0306 -0.6555 -1.3788 -0.4662 -0.1084 -0.1439
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular action potentials ; excitation-contraction ; myocardium
H-1671	-0.5582101345062256	▁influ x ▁; ▁l - type ▁volta ge - ga ted ▁; ▁vent ri cular ▁action ▁; ▁trigger ▁; ▁excita tion - con traction ▁; EC ▁; ▁coup ling ▁; ▁my o car dium
D-1671	-0.5582101345062256	influx ; l-type voltage-gated ; ventricular action ; trigger ; excitation-contraction ;EC ; coupling ; myocardium
P-1671	-2.6666 -0.0128 -0.2904 -1.6977 -0.1263 -0.0110 -0.3842 -0.0289 -0.0191 -0.0742 -0.3422 -0.4892 -1.4130 -1.8076 -0.2293 -0.0308 -0.2903 -4.2481 -0.9134 -0.1614 -0.0639 -0.0080 -0.1510 -0.0402 -0.1156 -0.2674 -0.3099 -0.0017 -0.5973 -0.8938 -1.4069 -0.0765 -0.0129 -0.3235 -0.3931 -0.1975
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine ; exercise capacity ; left ventricular filling ; patients ; heart failure with preserved ejection fraction ; hfpef
H-1171	-0.31779780983924866	▁i va bra dine ▁; ▁vent ri cular ▁fill ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1171	-0.31779780983924866	ivabradine ; ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
P-1171	-0.0643 -0.0112 -0.4973 -0.0232 -0.4080 -2.1800 -1.2952 -0.0769 -0.3795 -0.0433 -0.1516 -0.7429 -0.1542 -0.1155 -0.2091 -0.0020 -0.0415 -0.0190 -0.3338 -0.1205 -0.0779 -0.0017 -0.5761 -0.9348 -0.0201 -0.0973 -0.1712 -0.1500
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; patients ; systolic dysfunction
H-1733	-0.467852920293808	▁al do ster one ▁anta gon ism ▁; ▁heart ▁failure ▁; ▁al do ster one ▁; ▁neuro hormon e ▁; ▁electro ly tes
D-1733	-0.467852920293808	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes
P-1733	-0.7317 -0.0733 -0.1544 -0.9043 -0.5090 -0.0604 -0.9059 -0.7602 -0.3370 -0.3793 -0.5532 -1.8104 -0.0308 -0.0283 -0.6286 -0.2150 -0.1228 -0.0196 -0.1064 -0.2106 -0.0041 -0.2673 -0.0201 -2.7177 -0.1457
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate analysis ; bnp ; estimated glomerular filtration rate ; hypertension ; transmitral ; e-wave ; diastolic mitral annular velocity
H-1570	-0.3624200224876404	▁b NP ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁hyper tension ▁; ▁transmit ral ▁E - wa ve ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1570	-0.3624200224876404	bNP ; glomerular filtration rate ; hypertension ; transmitral E-wave ; diastolic mitral annular velocity
P-1570	-0.2108 -0.9353 -0.1295 -0.4395 -0.0079 -0.0314 -0.0701 -0.0270 -1.2651 -0.1436 -0.0109 -0.0239 -0.1022 -0.2831 -0.0601 -1.0881 -0.0078 -0.0963 -0.0096 -0.1455 -1.5829 -0.2471 -0.1910 -0.9324 -0.0592 -1.2049 -0.0053 -0.9312 -0.3472 -0.4939 -0.1519
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1 receptors ; neprilysin ; renin-angiotensin-aldosteron ; ras ; vasodilatory ; diuretic ; natriuretic peptides
H-1967	-0.44495484232902527	▁AT 1 ▁receptor s ▁; ▁nepri ly sin ▁block s ▁re nin - angi oten sin - al do ster on ▁; RAS ▁; ▁vaso dila tory ▁; ▁di ure tic ▁pe pti des
D-1967	-0.44495484232902527	AT1 receptors ; neprilysin blocks renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic peptides
P-1967	-2.1734 -0.0813 -0.4753 -0.0607 -0.3108 -0.0724 -0.0527 -0.3813 -0.1606 -0.0285 -0.2814 -0.1654 -0.0114 -0.0036 -0.0527 -1.2334 -0.0366 -0.0178 -0.6065 -0.1384 -0.3677 -0.5483 -0.2114 -0.5603 -2.3013 -0.0926 -0.4799 -0.8226 -0.0747 -0.0173 -1.3168 -2.2403 -0.0971 -0.1110 -0.2224 -0.2104
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade ; halt ; disease ; protein kinase ; pka ; β-adrenergic receptor
H-1425	-0.42521214485168457	▁β - block ade ▁; ▁c AMP - dependent ▁protein ▁kina se ▁; ▁p KA ▁; ▁β - ad r energi c ▁receptor ▁activa tion
D-1425	-0.42521214485168457	β-blockade ; cAMP-dependent protein kinase ; pKA ; β-adrenergic receptor activation
P-1425	-1.2548 -0.0698 -0.4185 -0.8021 -0.1951 -1.2041 -0.0944 -0.0375 -0.0169 -0.2199 -0.0584 -0.0794 -0.2109 -0.6635 -0.6770 -0.3399 -1.8511 -0.0099 -0.0545 -0.1407 -0.1416 -0.0561 -0.0295 -2.0801 -0.0610 -0.5615 -0.1524
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence ; erythropoiesis-stimulating agent ; therapy ; venous thromboembolism
H-47	-0.47636106610298157	▁er y thro po ies is - stimul ating ▁agent ▁ therapy ▁; ▁har ms ▁; ▁ve nous ▁ thro mbo e mbol ism
D-47	-0.47636106610298157	erythropoiesis-stimulating agent therapy ; harms ; venous thromboembolism
P-47	-3.2972 -0.0423 -0.2133 -0.2279 -0.1677 -0.0855 -0.0375 -0.0236 -0.4008 -0.0939 -0.1677 -0.0318 -0.3067 -4.4040 -0.0171 -0.1945 -0.1156 -0.5715 -0.0769 -0.0671 -0.3882 -0.3169 -0.0027 -0.8919 -0.1311 -0.1119
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable adjustment ; mortality ; hospitalization ; hazard ratio ; cardiovascular mortality ; hf ; hospitalization
H-1638	-0.3519671857357025	▁black ▁race ▁; ▁mortal ity ▁; haz ard ▁ratio ▁; ▁cardiovascular ▁mortal ity ▁; HF
D-1638	-0.3519671857357025	black race ; mortality ;hazard ratio ; cardiovascular mortality ;HF
P-1638	-0.3064 -0.8507 -0.2108 -0.5449 -0.3056 -0.7320 -0.5206 -0.0203 -0.0054 -0.2068 -0.1467 -0.0669 -0.2435 -0.3845 -0.6096 -0.5451 -0.2834
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous ; chronic myocardial ischemia ; stent ; polytetrafluoroethylene
H-504	-0.5708935260772705	▁chronic ▁my o card ial ▁ ische mia ▁; ▁sten t ▁; ▁poly te tra flu oro e thy lene ▁tube
D-504	-0.5708935260772705	chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
P-504	-5.7648 -1.6005 -0.2245 -0.1940 -0.2680 -0.0380 -1.4465 -0.5410 -0.2673 -0.0335 -0.0344 -0.5695 -0.0089 -0.0261 -0.0184 -0.0169 -0.0411 -0.7120 -0.0762 -0.0853 -0.5404 -0.5054 -0.1179
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical ; genetic ; chf ; area under the curve ; auc ; genetic ; auc ; clinical ; auc
H-1456	-0.8744964003562927	clin ical ▁; ▁genetic ▁; ▁CHF ▁predict ive ▁model ▁; ▁cur ve ▁; ▁genetic ▁; ▁au c ▁; ▁clinic al
D-1456	-0.8744964003562927	clinical ; genetic ; CHF predictive model ; curve ; genetic ; auc ; clinical
P-1456	-2.6734 -0.2005 -0.5465 -0.1046 -0.2604 -0.0375 -2.0287 -0.0041 -0.8432 -0.2831 -1.6320 -0.0335 -0.2642 -2.6750 -0.2707 -3.8852 -1.8053 -0.3519 -0.1055 -0.0289 -1.0981 -0.1066
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable logistic analysis ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney ; prognostic ; hf index
H-1760	-0.7399197220802307	▁implant ation ▁; ▁oxygen ▁up take ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁; ▁ HF
D-1760	-0.7399197220802307	implantation ; oxygen uptake ; metabolic exercise ; cardiac ; kidney index ; HF
P-1760	-4.0672 -2.1015 -0.2219 -2.1649 -0.2298 -0.2668 -0.0806 -0.3852 -0.0487 -0.2345 -0.0792 -0.0231 -1.5589 -0.3723 -0.1720 -0.0238 -0.7990 -0.9272 -1.7640 -0.0832 -0.5484 -0.1259
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart failure ; hf ; tumor necrosis factor ; tnf ; tnf antagonists ; disease ; severe hf
H-601	-0.3075562119483948	▁heart ▁failure ▁; HF ▁; ▁tumor ▁nec rosi s ▁factor ▁; TN f ▁; ▁t NF ▁anta gon ists ▁; ▁ HF
D-601	-0.3075562119483948	heart failure ;HF ; tumor necrosis factor ;TNf ; tNF antagonists ; HF
P-601	-0.2296 -0.2629 -0.0901 -0.0616 -0.1076 -0.0106 -0.1893 -0.0375 -0.0729 -0.3268 -0.3558 -0.3381 -0.1164 -0.4171 -0.3809 -0.0952 -1.1262 -0.0545 -0.1100 -0.2051 -2.3958 -0.1619 -0.1461 -0.0894
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers for medicare and medicaid services ; cms ; hospital ; outcomes ; reported ; mortality ; readmission ; penalties
H-1031	-0.5207679271697998	▁Center s ▁for ▁Medica re ▁and ▁Medica id ▁services ▁; ▁c ms ▁; ▁hospital ▁quality ▁of ▁care ▁outcome s ▁; ▁mortal ity ▁; ▁read mission ▁rates ▁; ▁penal ties
D-1031	-0.5207679271697998	Centers for Medicare and Medicaid services ; cms ; hospital quality of care outcomes ; mortality ; readmission rates ; penalties
P-1031	-0.2407 -0.0154 -0.2580 -0.0117 -0.0071 -1.3740 -0.0084 -0.0498 -0.5851 -0.1809 -0.2521 -1.4299 -0.4076 -2.1954 -0.8785 -0.3024 -1.4710 -1.0679 -0.0140 -0.2467 -1.8183 -0.1029 -0.1967 -0.2599 -0.0582 -1.4529 -0.7448 -0.0099 -0.2819 -0.0884 -0.1335
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox proportional hazard models ; covariates ; follow-up ; physician ; discharge ; primary outcome ; death ; all-cause readmission
H-1416	-0.635934591293335	▁co x ▁proportion al ▁hazard ▁models ▁; ▁temps - dependent ▁co varia tes ▁; ▁follow - up ▁; ▁physician ▁; ▁dis charge
D-1416	-0.635934591293335	cox proportional hazard models ; temps-dependent covariates ; follow-up ; physician ; discharge
P-1416	-3.6727 -0.0112 -0.0982 -0.0202 -0.0478 -0.3155 -0.2354 -1.1154 -0.0107 -0.0349 -0.6926 -0.1373 -0.0631 -0.5021 -1.1536 -0.0248 -0.0083 -0.2735 -1.4194 -0.3281 -1.2919 -0.0138 -3.6490 -0.1428
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate logistic regression analysis ; rule ; cad ; stenosis ; 3-vessel cad ; 2-vessel cad ; left anterior descending artery
H-1187	-1.5113645792007446	▁techniques ▁re gression ▁analysis ▁; ▁severe ▁CAD ▁; ▁diameter ▁sten osis ▁; ▁left ▁main ▁; ▁3- ves sel ▁CAD ▁; ▁figure ▁; ▁CAD ▁; ▁proxima l ▁left ▁descend ing ▁arter y
D-1187	-1.5113645792007446	techniques regression analysis ; severe CAD ; diameter stenosis ; left main ; 3-vessel CAD ; figure ; CAD ; proximal left descending artery
P-1187	-7.8533 -0.0407 -0.0167 -2.4330 -0.2124 -5.6292 -0.7000 -0.1350 -0.7356 -0.1481 -0.0937 -0.1574 -6.0628 -0.2061 -0.1153 -7.2675 -0.0122 -0.0023 -0.4342 -0.1285 -5.9994 -0.3062 -4.9916 -0.1600 -2.1381 -0.0428 -1.9950 -1.1372 -0.1018 -0.0246 -0.2717 -0.2257 -0.0968
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate ; signal transduction ; transcription factors ; pathological ; cardiomyocytes ; transcription factors ; epigenetic ; chromatin structure
H-1040	-0.49180105328559875	▁signal ▁trans duction ▁casca de ▁; ▁tran scription ▁factors ▁; ▁cardio my o cy tes ▁; ▁tran scription ▁factors ▁; ▁epi gene tic ▁changes ▁; ▁chr omat in ▁structure
D-1040	-0.49180105328559875	signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
P-1040	-0.7061 -0.0344 -0.4006 -0.0325 -0.0125 -0.2549 -1.3350 -0.0447 -0.6143 -0.2214 -1.4650 -0.4801 -0.7721 -0.1864 -0.1775 -0.3664 -1.7885 -0.1794 -0.6263 -0.1918 -1.6040 -0.1539 -1.0243 -0.2883 -0.7295 -0.0339 -0.0273 -0.7919 -0.2782 -0.2292 -0.1953
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients ; hypertensive hfpef ; dash ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
H-926	-0.3279701769351959	▁h f f ▁; ▁so dium - re strict ed ▁DAS h ▁; ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling
D-926	-0.3279701769351959	hff ; sodium-restricted DASh ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
P-926	-0.5285 -0.1508 -0.2783 -0.0516 -1.0227 -0.0224 -0.0028 -0.0143 -0.0190 -0.0328 -0.0878 -0.6778 -0.6335 -0.0121 -0.6892 -0.0500 -0.2124 -0.1519 -0.5928 -2.0711 -0.1208 -0.1486 -0.1932 -0.0363 -0.1151 -0.0031 -1.0620 -0.0653 -0.0454 -0.0256 -0.0599 -0.0053 -1.9165 -0.2319 -0.1479
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular dilatation
H-334	-0.3194151520729065	▁ann ular ▁size ▁re duction ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁papil lar y ▁muscle s ▁; ▁vent ri cular ▁di la tation
D-334	-0.3194151520729065	annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; ventricular dilatation
P-334	-1.2844 -0.0010 -0.5413 -0.0291 -0.0021 -0.1293 -0.0574 -0.0529 -0.0200 -0.1240 -0.4568 -0.6864 -0.0491 -1.1256 -0.1218 -0.3659 -0.0241 -0.0418 -0.1714 -1.9485 -0.0290 -0.1344 -0.0024 -0.2040 -0.1256 -1.3908 -0.1901 -0.1451 -0.2452 -0.0134 -0.1977 -0.9009 -0.8879 -0.0530 -0.0780 -0.2995 -0.0123 -0.1960 -0.1188
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized aldactone evaluation study ; symptomatic chronic advanced heart failure ; patients ; aldosterone antagonist ; spironolactone ; mortality ; placebo
H-1735	-0.40720993280410767	▁al da cto ne ▁Evalua tion ▁Study ▁; ▁chronic ▁advanced ▁heart ▁failure ▁; ▁al do ster one ▁anta gon ist ▁; ▁spi rono lac tone ▁; ▁mortal ity
D-1735	-0.40720993280410767	aldactone Evaluation Study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortality
P-1735	-1.2833 -0.5860 -0.1450 -0.0438 -0.2246 -0.0229 -1.3729 -0.1045 -1.0135 -0.4803 -0.7222 -0.1064 -1.5006 -0.0673 -0.1399 -0.1362 -1.1423 -0.1205 -0.0208 -0.9739 -0.0984 -0.0047 -0.0045 -0.0146 -0.0269 -1.0253 -0.0799 -0.4267 -0.2015 -0.1271
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence ; mortality ; outcomes ; heart failure ; acute myocardial infarction ; patients ; acute myocardial infarction ; western australia
H-1305	-0.7120181322097778	▁heart ▁failure ▁; ▁a cute ▁my o card ial ▁in far ction
D-1305	-0.7120181322097778	heart failure ; acute myocardial infarction
P-1305	-1.7631 -0.2751 -0.2761 -0.7399 -0.0104 -1.2249 -0.5506 -0.2671 -0.4108 -0.0151 -0.7982 -0.2423 -3.2200 -0.1746
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf ; hct ; polymorphisms ; genes ; anthracycline ; metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
H-1450	-0.2239515334367752	▁CHF ▁; ▁h CT ▁; ▁poly morph ism s ▁; ▁an thra cycli ne ▁metabolism ▁; ▁ir on ▁home osta sis ▁; ▁anti - oxid ant ▁de fen ce ▁; ▁my o card ial ▁remodel ling
D-1450	-0.2239515334367752	CHF ; hCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
P-1450	-0.0626 -0.1805 -0.1135 -1.0603 -0.1053 -1.5746 -0.0035 -0.1590 -0.0859 -0.1675 -0.1991 -0.0231 -0.4434 -0.2382 -0.0875 -0.1062 -0.0829 -0.0195 -0.8672 -0.0643 -0.1937 -0.2080 -0.0045 -0.0261 -0.0092 -0.0513 -0.0341 -0.4675 -0.1504 -0.2185 -0.3805 -0.0930 -0.1940 -0.1007 -0.0056 -0.3018 -0.2978 -0.1293
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.0627717971801758	▁medication
D-559	-1.0627717971801758	medication
P-559	-0.1898 -2.7552 -0.2433
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological ; diagnostic ; prognostic
H-1278	-0.659264087677002	▁pat ho phy si ological ▁origin
D-1278	-0.659264087677002	pathophysiological origin
P-1278	-0.3613 -0.1546 -0.1177 -0.6654 -0.3779 -2.0705 -1.4171 -0.1095
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad ; surgery ; patients ; albumin ; hypoalbuminemia ; surgery
H-534	-0.796741247177124	▁l VAD ▁; ▁album in ▁; ▁hypo album in emia
D-534	-0.796741247177124	lVAD ; albumin ; hypoalbuminemia
P-534	-1.4197 -0.0985 -2.3703 -1.9673 -0.5068 -1.8104 -0.0696 -0.0576 -0.3263 -0.2240 -0.5382 -0.1723
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate model ; creatinine ; hazard ratio ; confidence interval ; mortality
H-717	-0.62617427110672	▁creati nine ▁; haz ard ▁ratio ▁; ▁d L
D-717	-0.62617427110672	creatinine ;hazard ratio ; dL
P-717	-0.2445 -0.2820 -0.2498 -0.0517 -0.0047 -0.0030 -0.2542 -0.9841 -0.6272 -4.0051 -0.1816
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death ; patients ; estimated glomerular filtration rate ; odds ratio ; confidence interval
H-977	-0.9978528618812561	▁glo mer ular ▁filtr ation
D-977	-0.9978528618812561	glomerular filtration
P-977	-3.2703 -0.0367 -0.0725 -0.1749 -0.0802 -3.0797 -0.2706
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical ; hm ii ; heartware ; patients ; economic ; hm ii
H-310	-0.757003664970398	▁scientific ▁literature ▁; ▁h ▁II ▁; ▁Heart War e ▁patients ▁; ▁économique ▁evaluation s ▁; HM ▁II
D-310	-0.757003664970398	scientific literature ; h II ; HeartWare patients ; économique evaluations ;HM II
P-310	-1.2284 -0.4981 -0.0969 -0.7087 -3.3356 -0.0841 -1.8915 -0.0432 -0.0270 -0.8011 -0.1053 -1.8047 -0.8189 -0.0328 -0.1422 -1.0067 -0.8825 -0.7124 -0.1630
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine ; nesiritide ; renal function ; patients ; acute heart failure ; renal dysfunction
H-72	-0.4902755916118622	▁dop amine ▁; ▁nesi riti de ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-72	-0.4902755916118622	dopamine ; nesiritide ; renal function ; acute heart failure ; renal dysfunction
P-72	-1.3559 -0.3343 -0.0456 -2.0362 -0.0158 -0.0264 -0.2678 -0.1047 -3.2804 -0.2568 -0.4315 -0.0128 -0.3452 -0.1599 -0.2524 -0.0117 -0.1130 -0.4791 -0.1447 -0.1313
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized ; hr variability ; hr variability ; clinical ; risk stratification ; cardiac ; patients
H-1591	-0.9553059935569763	▁HR ▁variabil ity / tur bul ence ▁; ▁implant ation ▁; ▁cardiac ▁patients
D-1591	-0.9553059935569763	HR variability/turbulence ; implantation ; cardiac patients
P-1591	-2.2634 -0.2112 -0.2627 -1.4624 -0.3194 -0.0104 -0.0672 -0.3585 -5.0490 -1.4929 -0.6621 -0.0940 -1.6976 -0.1283 -0.2505
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications ; implantation ; lvad therapy ; transplantation ; btt ; dt ; medical therapy
H-313	-0.2651413679122925	▁implant ation ▁; ▁l VAD ▁ therapy ▁; ▁implant ation ▁e ligi bility ▁status ▁; ▁device ▁; ▁b t ▁; ▁ DT ▁; ▁medical ▁ therapy
D-313	-0.2651413679122925	implantation ; lVAD therapy ; implantation eligibility status ; device ; bt ; DT ; medical therapy
P-313	-0.1868 -0.0209 -0.4394 -0.8463 -0.0333 -0.4685 -0.0235 -0.3295 -0.5568 -0.0103 -0.7965 -0.0064 -0.0894 -0.2550 -0.1639 -0.1709 -0.4004 -0.0979 -0.3347 -0.0849 -0.8908 -0.2664 -0.4002 -0.1336 -0.0687 -0.0224 -0.1976 -0.1287
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical ; artery tonometry ; prospectively ; admission ; patients ; icu ; clinical
H-580	-0.4806308448314667	▁radi al ▁arter y ▁ton ometr y ▁; ▁PH ▁; ▁ ICU
D-580	-0.4806308448314667	radial artery tonometry ; PH ; ICU
P-580	-0.5835 -0.0389 -0.0540 -0.1317 -0.3091 -0.0254 -0.0751 -0.6608 -2.9310 -0.9568 -0.3985 -0.0273 -0.3998 -0.1370
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully magnetically levitated centrifugal-flow chronic lvas ; adverse event ; quality of life ; functional status
H-2006	-0.3231026232242584	▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic ▁l VAS
D-2006	-0.3231026232242584	magnetically levitated centrifugal-flow chronic lVAS
P-2006	-0.4634 -0.0902 -0.0084 -0.0161 -0.5280 -0.5874 -0.0557 -0.0544 -0.0201 -0.0213 -0.4415 -1.4151 -0.1791 -0.8615 -0.1045
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome complex ; scaffold protein ; drives ; kinases ; phosphorylation ; effector molecules
H-995	-0.723675549030304	▁e RK ▁; ▁signal o some ▁complex ▁; ▁sc af fold ▁protein ▁; ▁kina ses ▁; ▁sequenti al ▁ phos phor y lation
D-995	-0.723675549030304	eRK ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
P-995	-1.9515 -0.0298 -1.4938 -0.4713 -5.0263 -1.3376 -0.3377 -0.1438 -0.2101 -0.1598 -0.0583 -0.6250 -0.2737 -1.7707 -0.2511 -0.3084 -0.2959 -0.0303 -0.0835 -0.1798 -0.5456 -1.3909 -0.0192 -0.9601 -0.1378
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast cancer ; patients ; medicare ; diagnosed ; breast cancer ; chemotherapy ; seer-medicare ; texas ; medicare
H-672	-0.3748130202293396	▁Medica re ▁coverage ▁; ▁stage ▁I - III ▁breast ▁cancer ▁; ▁che mo therapy ▁; ▁s EER - Medic are ▁; ▁Texas ▁Cancer ▁Registr y - Medic are
D-672	-0.3748130202293396	Medicare coverage ; stage I-III breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare
P-672	-0.6425 -0.0074 -0.2157 -0.1859 -1.8808 -0.5985 -0.0385 -0.0595 -0.0264 -0.1025 -0.3201 -0.1374 -0.0390 -0.0193 -0.2740 -1.1440 -0.0541 -0.0076 -0.1481 -0.5207 -0.0972 -0.4160 -1.3850 -0.1883 -0.0138 -0.8899 -0.0581 -0.3853 -1.2385 -0.1505
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection fraction ; b-type natriuretic peptide ; patients ; hospitalized ; heart failure ; inhospital ; outcomes ; get with the guideline-heart failure registry
H-186	-0.34112849831581116	▁e je ction ▁ fraction ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁heart ▁failure ▁; ▁in hospital ▁outcome s ▁; ▁guide line - He art ▁Fail ure ▁Registr y
D-186	-0.34112849831581116	ejection fraction ; b-type natriuretic peptide ; heart failure ; inhospital outcomes ; guideline-Heart Failure Registry
P-186	-1.5234 -0.5307 -0.0289 -0.0555 -0.0006 -0.1146 -0.5595 -0.0451 -0.0478 -0.0072 -0.0930 -0.0163 -0.9679 -0.1225 -0.0234 -0.0444 -0.5066 -1.6741 -0.2419 -0.3812 -0.2489 -0.0690 -2.4158 -0.0393 -0.4111 -0.4942 -0.0391 -0.0084 -0.3884 -0.2125 -0.0477 -0.0174 -0.3624 -0.1341 -0.1662 -0.2419
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased ; cardiomyocytes ; pde2 ; activity ; cgmp synthesis ; nitric oxide ; donors ; pde2 inhibition ; β-ar responsiveness
H-1215	-0.37865957617759705	▁cardio my o cy tes ▁; ▁p de 2 ▁activity ▁; ▁c g MP ▁synth es is ▁; ▁ni tric ▁oxid e ▁; ▁p de 2 ▁inhibi tion ▁; ▁β - AR ▁responsive ness
D-1215	-0.37865957617759705	cardiomyocytes ; pde2 activity ; cgMP synthesis ; nitric oxide ; pde2 inhibition ; β-AR responsiveness
P-1215	-0.5061 -0.3927 -0.6808 -0.1712 -0.1717 -0.0983 -0.7012 -0.0692 -0.0285 -0.5338 -0.0970 -0.0079 -1.0964 -1.1041 -1.4166 -0.0603 -0.1179 -0.4686 -0.1564 -0.0879 -0.0085 -0.1710 -1.7185 -0.7519 -0.0515 -0.0424 -1.6425 -0.0745 -0.2315 -0.1475 -0.0039 -0.0426 -0.1288 -0.3770 -0.1612 -0.1116
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko ; cardiac ; irs1 ; irs2 ; proteins ; heart failure ; cardiac energy metabolism gene expression ; p38α ; mitogen-activated protein kinase ; p38
H-656	-0.5953287482261658	▁l - d KO ▁mi ce ▁; ▁cardiac ▁I RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁heart ▁failure ▁; ▁im pair ed ▁cardiac ▁energy ▁metabolism ▁; ▁protein ▁kina se
D-656	-0.5953287482261658	l-dKO mice ; cardiac IRS1 ; iRS2 proteins ; heart failure ; impaired cardiac energy metabolism ; protein kinase
P-656	-1.9557 -0.4457 -0.6079 -1.2710 -2.0164 -0.0740 -0.1468 -0.3118 -1.7449 -0.0955 -0.2388 -0.3174 -1.0622 -0.4003 -0.0451 -1.7026 -0.0208 -0.1405 -0.2133 -0.2806 -0.1607 -0.4322 -0.0063 -0.0237 -0.1024 -0.3168 -0.0605 -0.1554 -4.8176 -0.1148 -0.0187 -0.2001 -0.1454
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs ; hdl ; phosphorylation
H-251	-0.4205878674983978	▁EC s ▁; ▁HD L ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁e NOS - Th r ▁; ▁PK c - β II - Ser
D-251	-0.4205878674983978	ECs ; HDL ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser
P-251	-0.2956 -0.3256 -0.2272 -0.3859 -2.1440 -0.1993 -0.0804 -0.0512 -0.0558 -0.8275 -0.0218 -0.3292 -0.0181 -0.0979 -0.0255 -0.1858 -0.2280 -0.0747 -0.1599 -0.0172 -2.2891 -0.0057 -0.1586 -0.8480 -0.5021 -0.0246 -0.1667 -0.3833 -0.0253 -0.0871 -2.9853 -0.2326
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp ; 6-minute walking distance ; peak o2
H-829	-1.0237317085266113	▁PAS p ▁; ▁walking ▁distance ▁; ▁kilogram
D-829	-1.0237317085266113	PASp ; walking distance ; kilogram
P-829	-1.5681 -0.5636 -0.4917 -1.9322 -0.7514 -0.6482 -2.2029 -0.9196 -0.1361
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts ; patients ; sts ; hh ; sts
H-155	-1.1619336605072021	▁R CT s ▁; ▁s ts ▁; ▁h ▁; ▁h ▁; ▁h m ▁; ▁TM ▁; ▁s ts ▁; ▁TM
D-155	-1.1619336605072021	RCTs ; sts ; h ; h ; hm ; TM ; sts ; TM
P-155	-4.9178 -0.6579 -0.1791 -0.2974 -1.1371 -0.7273 -0.1311 -0.1947 -2.0728 -0.2581 -1.8580 -0.6575 -2.1530 -0.1714 -3.3143 -1.0052 -0.6159 -1.6706 -0.4452 -2.6021 -0.3456 -0.1506
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular myocytes ; sarcomere ; shortening
H-417	-0.4901418089866638	▁mouse ▁vent ri cular ▁my o cy tes ▁; ▁sar com ere
D-417	-0.4901418089866638	mouse ventricular myocytes ; sarcomere
P-417	-0.7561 -0.0141 -0.6962 -0.1627 -0.7325 -0.0847 -0.0553 -0.1759 -0.1908 -0.1198 -0.2188 -0.1746 -3.3721 -0.1086
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative ; alberta ; discharged ; hospital ; diagnosis ; heart failure
H-1415	-0.46994224190711975	▁administrative ▁database s ▁; ▁province ▁of ▁Albert a ▁; ▁dis charge d ▁ali ve ▁; ▁hospital ▁; ▁heart ▁failure
D-1415	-0.46994224190711975	administrative databases ; province of Alberta ; discharged alive ; hospital ; heart failure
P-1415	-0.0476 -0.9815 -0.0228 -0.2351 -1.5842 -0.8862 -0.0256 -0.1732 -0.6351 -1.0621 -0.0065 -0.2273 -0.1335 -0.0795 -0.6886 -0.1586 -0.4911 -2.0807 -0.1378 -0.1288 -0.0829
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart failure ; histologically ; myocardial collagen ; healthy ; heart failure
H-1062	-0.8044983744621277	▁animals ▁; ▁heart ▁failure ▁; ▁my o card ial ▁collage n ▁; ▁tissu e
D-1062	-0.8044983744621277	animals ; heart failure ; myocardial collagen ; tissue
P-1062	-3.0709 -0.5831 -0.9021 -0.6193 -0.2318 -1.8817 -0.5133 -0.1480 -0.1599 -0.0641 -0.1502 -0.2318 -0.3276 -0.1884 -3.6529 -0.1468
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates ; crt ; death ; hf ; hospitalization ; hazard ratio ; lvef
H-757	-0.6057934761047363	▁c rte ▁; ▁time ▁to ▁death ▁; ▁ HF ▁hospital ization ▁; haz ard ▁ratio ▁; ▁LV EF
D-757	-0.6057934761047363	crte ; time to death ; HF hospitalization ;hazard ratio ; LVEF
P-757	-0.2595 -2.0887 -1.2397 -3.1034 -0.9830 -0.2977 -0.0558 -0.7527 -0.1779 -0.8553 -1.1371 -0.2434 -0.0427 -0.0133 -0.0127 -0.2909 -0.0776 -0.2520 -0.1057 -0.1270
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor 1 ; s1pr1 ; downregulation ; cardiac ; hypertrophic ; heart failure ; s1pr1 ; cardiac ; gene ; therapy
H-1404	-0.3417491614818573	▁beta 1- ad r energi c ▁receptor ▁; ▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁reciproc al ▁down regul ation ▁; ▁cardiac ▁hyper trop hic ▁response ▁; ▁heart ▁failure ▁; ▁s 1 PR 1 ▁cardiac ▁gene ▁ therapy
D-1404	-0.3417491614818573	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 cardiac gene therapy
P-1404	-1.1182 -0.5661 -0.2350 -0.0550 -0.0467 -0.1633 -0.0062 -0.0846 -0.0025 -0.1204 -1.9617 -0.4386 -0.4628 -0.2404 -0.0011 -0.0277 -0.0549 -0.0186 -0.3145 -2.1231 -0.0855 -0.6313 -1.5127 -0.8935 -0.0146 -0.0822 -0.0880 -0.0178 -0.1324 -0.0188 -0.0210 -0.0013 -0.1356 -0.1577 -0.1165 -0.5653 -0.3009 -0.5433 -1.6649 -0.0379 -0.1972 -0.1518 -0.1110 -0.6024 -0.0366 -0.0106 -0.1329 -0.0988
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative risk ; rr ; heart failure ; bisphophonates ; rr ; confidence interval ; hazard ratio
H-1540	-0.8851026892662048	▁relative ▁risk ▁; RR ▁; ▁heart ▁failure ▁; ▁bis pho phon ates ▁; ▁cru de ▁ RR
D-1540	-0.8851026892662048	relative risk ;RR ; heart failure ; bisphophonates ; crude RR
P-1540	-3.4360 -1.8655 -0.2162 -1.2264 -0.3509 -0.6570 -0.5708 -0.2514 -0.6051 -0.0606 -0.0965 -0.9476 -0.6941 -0.1613 -0.0046 -0.8631 -0.1449 -4.4491 -0.2159
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare ; centers for medicare and medicaid services ; clinics ; propensity-score
H-1621	-0.36491987109184265	▁Medica re ▁fee - for - service ▁beneficiar ies ▁; ▁Center s ▁for ▁Medica re ▁; ▁Medica id ▁services ▁; ▁pro pens ity - s core
D-1621	-0.36491987109184265	Medicare fee-for-service beneficiaries ; Centers for Medicare ; Medicaid services ; propensity-score
P-1621	-2.4490 -0.0159 -0.4134 -0.0113 -0.1903 -0.0243 -0.0624 -0.5798 -0.0603 -0.1384 -0.6057 -0.0454 -0.8950 -0.0312 -0.0083 -0.5223 -0.0138 -0.5435 -0.9238 -1.7325 -0.1572 -0.0017 -0.0783 -0.0117 -0.1123 -0.0853 -0.3677 -0.1369
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician ; heart failure ; clinical practice guideline ; cpg ; outcomes ; heart failure ; hf
H-1841	-0.5303976535797119	▁physician ▁ad her ence ▁; ▁guide line ▁recommendations ▁; ▁heart ▁failure ▁; ▁Clinic al ▁Practic e ▁Guide line ▁; CP g ▁; ▁heart ▁failure ▁; HF
D-1841	-0.5303976535797119	physician adherence ; guideline recommendations ; heart failure ; Clinical Practice Guideline ;CPg ; heart failure ;HF
P-1841	-0.8710 -0.1710 -0.1589 -0.0049 -0.2285 -0.3464 -0.0347 -0.5077 -1.0211 -0.4039 -0.2651 -0.3455 -1.7521 -0.0238 -1.5471 -0.0659 -1.0620 -0.0450 -0.2159 -0.2372 -0.4437 -0.2398 -3.5144 -0.4133 -0.2164 -0.4248 -0.1637 -0.1273
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil ; heart failure ; hemodynamic ; mitochondrial dysfunction ; antitumor ; activity
H-967	-0.1236443966627121	▁nic oran dil ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁hem o dynamic ▁perturba tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁anti tum or ▁activity
D-967	-0.1236443966627121	nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
P-967	-0.2874 -0.0040 -0.0704 -0.1358 -0.0160 -0.0037 -0.0100 -0.3494 -0.0328 -0.0067 -0.2676 -0.2414 -0.2240 -0.1403 -0.1411 -0.0195 -0.1870 -0.1554 -0.0459 -0.0225 -0.0408 -0.0097 -0.0931 -0.0084 -0.4521 -0.0200 -0.0311 -0.0102 -0.0577 -0.1977 -0.3954 -0.0778 -0.0195 -0.4686 -0.0922 -0.1160
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq ; new york heart association class ; patients ; hfpef ; hf with reduced ef
H-788	-0.607327938079834	▁k cc q ▁; ▁New ▁York ▁Heart ▁Association ▁class ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁ HF ▁; ▁EF
D-788	-0.607327938079834	kccq ; New York Heart Association class ; HFpEF ; HF ; HF ; EF
P-788	-0.6297 -0.0637 -1.1225 -0.2717 -1.2300 -0.4166 -1.6150 -1.3200 -0.4725 -0.0767 -0.9408 -0.1071 -0.0338 -0.1613 -0.0555 -0.3835 -0.2815 -0.4840 -1.9208 -0.3744 -0.4842 -1.5786 -0.3858 -0.1662
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm control therapy ; diagnosis ; atrial ; sinus rhythm ; rhythm control ; symptoms ; rate control
H-1646	-0.5332603454589844	▁ Rhythm ▁control ▁ therapy ▁; ▁af ▁; ▁at rial ▁structure ▁; ▁ rhythm ▁; ▁de lay ed ▁ rhythm ▁control ▁; ▁rate ▁control
D-1646	-0.5332603454589844	Rhythm control therapy ; af ; atrial structure ; rhythm ; delayed rhythm control ; rate control
P-1646	-1.2636 -1.4089 -0.1575 -0.0719 -0.0182 -0.2027 -0.7265 -0.4848 -0.4476 -0.1532 -0.0451 -0.1597 -1.2613 -1.0689 -0.4139 -1.9386 -0.1031 -0.0244 -0.0253 -0.4665 -0.0970 -0.8776 -2.0494 -0.0365 -0.2589 -0.1034
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic ; therapy
H-83	-0.48032766580581665	▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁dop amine ▁; ▁nesi riti de ▁; ▁renal ▁function ▁; ▁di ure tic ▁ therapy
D-83	-0.48032766580581665	acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic therapy
P-83	-1.4304 -0.0118 -0.2325 -0.0908 -0.1129 -0.0117 -0.0201 -0.1485 -0.1922 -0.5038 -0.3292 -0.0710 -1.7494 -0.0257 -0.0142 -0.1547 -0.3702 -4.1931 -0.6501 -0.0331 -0.0569 -1.6819 -0.0743 -0.0359 -0.1734 -0.1207
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf ; prospective ; dual-energy x-ray absorptiometry ; echocardiography ; blood
H-1161	-0.5425493717193604	▁ HF ▁; ▁body ▁composition ▁; s kin fold ▁thi ck ness ▁; ▁dual - ener gy ▁X - ray ▁ab sor pti ometr y ▁; ▁e cho card i ography ▁; ▁blood ▁testing
D-1161	-0.5425493717193604	HF ; body composition ;skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
P-1161	-1.9960 -0.0899 -0.1528 -3.9472 -0.9363 -0.1679 -3.4824 -1.7501 -0.2568 -1.3513 -0.2444 -0.4095 -0.1344 -0.3040 -0.0152 -0.1061 -0.2425 -1.2059 -0.0131 -0.0536 -0.0384 -0.0341 -0.0294 -0.0686 -0.1816 -0.1407 -0.0571 -0.2028 -0.1185 -0.2991 -0.1862 -0.3580 -0.0410 -0.6019 -0.1313 -0.1835
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients ; heart failure
H-1744	-1.1269285678863525	▁implant ment ▁; ▁heart ▁failure
D-1744	-1.1269285678863525	implantment ; heart failure
P-1744	-3.4574 -0.5016 -1.3605 -0.4268 -0.3251 -1.5579 -0.2594
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp ; red blood cell transfusion ; hemoglobin ; hemoglobin ; hospitalized ; patients ; coronary heart disease
H-36	-0.859502911567688	▁a CP ▁; ▁restrict ive ▁red ▁blood ▁cell ▁trans fusion ▁; tri gger ▁hem o glob in ▁; ▁hem o glob in ▁; ▁corona ry ▁heart ▁disease
D-36	-0.859502911567688	aCP ; restrictive red blood cell transfusion ;trigger hemoglobin ; hemoglobin ; coronary heart disease
P-36	-0.5948 -0.4240 -0.3202 -0.2055 -0.0073 -0.0763 -0.4010 -0.0773 -0.3201 -0.0424 -1.6990 -3.7589 -0.0362 -0.7552 -0.4497 -0.4337 -1.2485 -0.3347 -5.3150 -0.5663 -0.5454 -0.9062 -0.6374 -2.4367 -0.2472 -0.4222 -2.1955 -0.2393 -0.2297
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals ; patients ; hospitalized ; heart failure ; hf ; conditions ; acute myocardial infarction ; pneumonia ; conditions
H-1032	-0.32774439454078674	▁hospital s ▁; ▁heart ▁failure ▁; HF ▁; ▁conditions ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁pneu monia
D-1032	-0.32774439454078674	hospitals ; heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia
P-1032	-2.0123 -0.1097 -0.1912 -1.8865 -0.1362 -0.1547 -0.1328 -0.2315 -0.1135 -0.1492 -0.1321 -0.0010 -0.6488 -0.2546 -0.0580 -0.1019 -0.0056 -0.3322 -0.1247 -0.3596 -0.0002 -0.1337 -0.4244 -0.1714
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted ; interatrial shunt ; clinical ; haemodynamic ; outcomes ; patients ; heart failure with reduced ejection fraction
H-1962	-0.26644840836524963	▁implant ed ▁left - to - right ▁inter at rial ▁shu nt ▁; ▁ha emo dynamic ▁outcome s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1962	-0.26644840836524963	implanted left-to-right interatrial shunt ; haemodynamic outcomes ; heart failure ; ejection fraction
P-1962	-0.0030 -0.0835 -1.1378 -0.0064 -0.6650 -0.2423 -0.0127 -0.0337 -0.1259 -0.3596 -0.1029 -0.0604 -0.1789 -1.0291 -0.1708 -0.0122 -0.7890 -0.0153 -0.1865 -0.3511 -0.1535 -0.3015 -0.7955 -0.3445 -0.1745 -0.0864 -0.0015 -0.1605 -0.1431
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1 time ; correlated ; right ventricular-pulmonary arterial coupling ; pulmonary vascular resistance ; right ventricular ejection fraction
H-742	-0.4763912558555603	▁vent ri cular - pul mon ary ▁arterial ▁coup ling ▁; pul mon ary ▁vas cular ▁resist ance ▁; ▁right ▁vent ri cular ▁e je ction ▁ fraction
D-742	-0.4763912558555603	ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
P-742	-0.3431 -1.1921 -0.1551 -0.1167 -0.1764 -0.7233 -0.1671 -0.3097 -0.1038 -1.4069 -0.1286 -0.7174 -0.5463 -0.1337 -0.2667 -0.2431 -0.2440 -0.0310 -0.4151 -0.7358 -0.0308 -1.4043 -0.2617 -2.4836 -0.3512 -0.4598 -0.6506 -0.0023 -0.3256 -0.1658
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left ventricular assist devices ; lvads ; chronic end-stage heart failure ; bridge to transplantation ; btt ; patients ; destination therapy ; dt
H-308	-0.35728558897972107	▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁chronic ▁end - s tage ▁heart ▁failure ▁; bridge ▁to ▁transplant ation ▁; ▁b t ▁; ▁transplant - ine ligi ble ▁patients ▁; ▁de stin ation ▁ therapy
D-308	-0.35728558897972107	ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy
P-308	-0.6856 -1.4687 -0.1789 -0.2778 -0.2441 -0.2043 -0.1669 -0.0365 -0.0519 -0.2297 -0.9707 -0.2498 -0.0490 -0.2855 -0.0042 -0.7730 -0.3740 -0.1719 -0.9522 -0.1749 -0.3461 -0.0374 -0.6576 -0.0692 -0.4125 -0.2760 -0.2583 -0.0918 -0.2082 -0.0048 -0.1239 -0.6655 -0.3640 -1.6447 -0.0582 -0.0074 -0.0345 -0.0221 -1.3319 -0.1276
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise ; training ; peak oxygen consumption ; quality of life ; obese ; patients ; heart failure with preserved ejection fraction ; randomized ; clinical
H-1973	-0.2797662913799286	▁Cal o ric ▁re stri ction ▁; ▁Aero bic ▁Exerci se ▁Training ▁; ▁Peak ▁o xy gen ▁Consum p tion ▁; ▁Quality ▁of ▁Life ▁; ▁Heart ▁Fail ure ▁; ▁Pres er ved ▁e je ction ▁Fra ction
D-1973	-0.2797662913799286	Caloric restriction ; Aerobic Exercise Training ; Peak oxygen Consumption ; Quality of Life ; Heart Failure ; Preserved ejection Fraction
P-1973	-0.3172 -0.0924 -0.2771 -0.5895 -0.0266 -0.0328 -0.0483 -0.1486 -0.0309 -0.3300 -0.0263 -0.3754 -0.2939 -0.0258 -0.7049 -0.0122 -0.0694 -0.0210 -0.0153 -0.0257 -0.0836 -0.3196 -0.1495 -0.0632 -0.0909 -2.9534 -0.0330 -0.0289 -0.1001 -1.9273 -0.0035 -0.0802 -0.6412 -0.1584 -0.0256 -0.2205 -0.0245 -0.4241 -0.1200
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol ; metoprolol ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-855	-0.3651845455169678	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD it - c rte ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-855	-0.3651845455169678	carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
P-855	-0.3973 -0.0236 -0.0726 -0.2146 -0.0524 -0.0784 -0.0087 -0.1503 -0.3306 -0.0006 -0.0198 -0.7546 -0.0944 -0.1130 -0.0124 -0.2278 -3.9716 -1.6202 -0.0107 -0.1447 -0.2074 -0.0294 -0.2764 -0.0302 -1.0141 -0.0066 -1.0404 -1.2974 -0.5360 -1.3810 -0.0159 -0.5259 -0.0766 -0.4248 -0.0865 -0.0304 -0.0387 -0.1371 -0.0276 -0.2699 -0.3567 -0.0375 -0.7252 -0.0120 -0.0021 -0.3536 -0.1411 -0.3716 -0.1437
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral ; glucocorticoids ; hf
H-610	-0.6502247452735901	▁Oral ▁gluco cor tico ids ▁; ▁ HF
D-610	-0.6502247452735901	Oral glucocorticoids ; HF
P-610	-1.3481 -0.1805 -0.0653 -0.8189 -0.2445 -0.2094 -0.9798 -0.0299 -2.4484 -0.1774
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ; ea ; tac ; placebo
H-523	-0.6550668478012085	▁HR ▁; ▁i va bra dine ▁group ▁; ▁Ea ▁; ▁ TAC
D-523	-0.6550668478012085	HR ; ivabradine group ; Ea ; TAC
P-523	-1.7065 -0.1829 -0.0206 -0.0082 -0.2576 -0.0054 -1.2475 -0.1928 -4.0981 -0.1448 -0.8673 -0.0813 -0.2312 -0.1266
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol ; therapy ; metoprolol ; hazard ratio ; confidence interval
H-862	-0.3199501037597656	▁car vedi lol ▁; ▁in appropria te ▁ therapy ▁; ▁met o pro lol
D-862	-0.3199501037597656	carvedilol ; inappropriate therapy ; metoprolol
P-862	-1.6111 -0.0519 -0.1302 -0.3748 -0.9453 -0.0917 -0.1716 -0.1990 -0.0224 -0.1791 -0.0476 -0.1711 -0.0305 -0.1978 -0.7735 -0.1217
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up ; systemic ; adverse events ; patients ; dcm ; heart failure
H-1265	-0.5043027997016907	▁CH m ▁; ▁ad ju nc tive ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1265	-0.5043027997016907	CHm ; adjunctive treatment ; dCM ; heart failure
P-1265	-4.2946 -0.1949 -0.2303 -0.6733 -0.0090 -0.0276 -0.0096 -0.7729 -0.2013 -0.3844 -0.2084 -0.2848 -0.3480 -0.1944 -0.1319 -0.1036
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone supplementation ; exercise rehabilitation ; health ; outcomes ; patients ; chf ; testosterone
H-1325	-0.9620682597160339	▁testosteron e ▁supplement ation ▁; ▁exercise ▁rehabilita tion
D-1325	-0.9620682597160339	testosterone supplementation ; exercise rehabilitation
P-1325	-0.5019 -0.0293 -2.0508 -0.0529 -0.3995 -2.8791 -0.1439 -0.0338 -3.4413 -0.0882
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change ; peak vo2 ; correlated ; change ; lean body mass ; change ; thigh ; muscle
H-1987	-0.7321550846099854	▁VO 2 ▁; ▁change ▁; ▁lean ▁body ▁mass ▁; ▁change ▁; ▁th igh ▁muscle ▁; inter mus cular ▁fat ▁ratio
D-1987	-0.7321550846099854	VO2 ; change ; lean body mass ; change ; thigh muscle ;intermuscular fat ratio
P-1987	-0.9683 -0.0448 -0.1117 -2.5215 -0.3835 -1.5248 -1.3738 -0.4574 -0.1186 -2.1097 -0.7798 -1.8585 -0.3613 -1.1988 -0.4602 -0.7630 -0.1224 -0.0542 -0.4219 -0.0482 -0.2249 -0.2000
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals ; get with the guidelines-heart failure ; hf ; patients ; ef ; ef ; ef ; ef
H-189	-0.46946772933006287	▁guide lines - He art ▁Fail ure ▁; ▁h f
D-189	-0.46946772933006287	guidelines-Heart Failure ; hf
P-189	-0.9732 -0.1235 -0.0151 -0.3609 -0.0669 -0.0193 -0.0251 -0.1710 -0.7827 -0.5373 -2.4258 -0.1328
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2017	-0.5240182280540466	▁économique ▁Analys is ▁; ▁Patient ▁Management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁Cost - E ff ective ness ▁Model ▁; ▁coût - effect ive ness ▁; ▁disease ▁management ▁programs ▁in ▁heart ▁failure
D-2017	-0.5240182280540466	économique Analysis ; Patient Management Interventions ; Heart Failure Cost-Effectiveness Model ; coût-effectiveness ; disease management programs in heart failure
P-2017	-0.7921 -0.8845 -0.0472 -0.1902 -0.3868 -0.7330 -1.1045 -0.0100 -0.8514 -0.2422 -0.0617 -0.0403 -0.7821 -0.0146 -1.1370 -1.3265 -0.0039 -0.1272 -0.4487 -0.2194 -4.5524 -0.0186 -0.0419 -0.0166 -0.5037 -0.4582 -0.2734 -0.0266 -0.7721 -0.7784 -0.5200 -0.1563 -0.1598 -0.1355
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi ; death ; medical ; hospitalization ; hf ; clinic ; outpatients ; hf ; health
H-385	-0.8819409608840942	▁ HF PSI ▁; ▁risk ▁of ▁death ▁; ▁medical ▁hospital ization ▁; ▁ HF ▁clinic ▁out patient s ▁; ▁ HF ▁resources ▁; ▁health ▁systems
D-385	-0.8819409608840942	HFPSI ; risk of death ; medical hospitalization ; HF clinic outpatients ; HF resources ; health systems
P-385	-1.2964 -0.2257 -0.3636 -0.2063 -5.7280 -2.3854 -0.3779 -0.0735 -1.6242 -0.3777 -0.3229 -0.1544 -0.7777 -0.0484 -2.7409 -0.6814 -0.0151 -0.0314 -0.3410 -1.0586 -0.1192 -2.2739 -0.6026 -0.4160 -1.1846 -0.2323 -0.1533
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; hypertrophy ; heart failure
H-1787	-0.23471373319625854	▁cardiac ▁insulin - re si stance ▁; ▁mito cho ndri al ▁oxid ative ▁metabolism ▁; ▁metabol ic ▁changes ▁; ▁cardiac ▁hyper trop hy ▁; ▁energy ▁deficit ▁; ▁hyper trop hy ▁; ▁heart ▁failure
D-1787	-0.23471373319625854	cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
P-1787	-0.2040 -0.4064 -0.0199 -0.1256 -1.4493 -0.0009 -0.0426 -0.2281 -0.3874 -0.0209 -0.0516 -0.0081 -0.1725 -0.0550 -0.1553 -2.2219 -0.0336 -0.5302 -0.1068 -0.1485 -0.0343 -0.0032 -0.1135 -0.1280 -0.1185 -0.0683 -0.1836 -0.1320 -0.0115 -0.1291 -0.4101 -0.1607 -0.1469 -0.0973 -0.1095
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate cox model ; pasp ; exercise ; peak o2 ; prognostic ; hazard ratio ; peak o2 ; pasp
H-830	-1.6845420598983765	▁co x ▁model ▁; ▁gain ▁; ▁PAS p ▁; ▁figure
D-830	-1.6845420598983765	cox model ; gain ; PASp ; figure
P-830	-0.1401 -0.0198 -1.3643 -0.7669 -6.7299 -0.3128 -3.1399 -0.6695 -0.6228 -5.9485 -0.3776 -0.1223
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology ; heart failure with preserved ejection fraction ; hfpef ; myocardial extracellular matrix
H-734	-0.2256859689950943	▁pat ho phy si ology ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f f ▁; ▁my o card ial ▁extra cel lular ▁matri x ▁accumula tion
D-734	-0.2256859689950943	pathophysiology ; heart failure ; preserved ejection fraction ; hff ; myocardial extracellular matrix accumulation
P-734	-1.2385 -0.1061 -0.0712 -0.8582 -0.6614 -0.5737 -0.0995 -0.1610 -0.1056 -0.1154 -0.0052 -0.0870 -0.0378 -0.3524 -0.0817 -0.1212 -0.0012 -0.1649 -0.0689 -0.1903 -0.3476 -0.2853 -0.6715 -0.0565 -0.1193 -0.1127 -0.2099 -0.2033 -0.0161 -0.1071 -0.0648 -0.0232 -0.0664 -0.3525 -0.1619
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular ; dilatation
H-338	-0.3279602825641632	▁ann ular ▁size ▁re duction ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁; LV
D-338	-0.3279602825641632	annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV
P-338	-1.3920 -0.0010 -0.5223 -0.0317 -0.0019 -0.1333 -0.0624 -0.0572 -0.0213 -0.1197 -0.5034 -0.6854 -0.0479 -1.3489 -0.1121 -0.3874 -0.0252 -0.0455 -0.1676 -1.5614 -0.0283 -0.1219 -0.0020 -0.1935 -0.1327 -1.2019 -0.1713 -0.1166 -0.2256 -0.0121 -0.1581 -0.2921 -0.0156 -0.8547 -0.0363 -0.9795 -0.0615 -0.8276 -0.1314
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ; pvf ; implanted ; cardioverter-defibrillator device
H-1346	-0.26139551401138306	▁breath ing ▁control ▁; ▁cardiac ▁arrest ▁; ▁puls e less ▁vent ri cular ▁fi bril lation ▁; PV f ▁; ▁implant ed ▁cardio ver ter - de fi br illa tor ▁device
D-1346	-0.26139551401138306	breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVf ; implanted cardioverter-defibrillator device
P-1346	-1.0074 -0.1318 -0.0494 -0.2873 -0.2209 -0.0389 -0.1302 -1.0747 -0.1349 -0.0417 -0.0081 -0.8091 -0.1329 -0.6002 -0.0788 -0.0427 -0.1548 -0.0229 -0.1441 -0.1273 -0.0082 -0.0917 -0.2646 -0.0692 -0.0522 -0.0104 -0.1120 -1.7537 -0.5335 -0.0084 -0.0746 -0.3191 -0.2255 -0.1258
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad ; rgk ; rem ; rem2 ; rad ; monomeric g proteins ; ventricular action potential ; gain ; cardiac ; l-type channel ; activity
H-1672	-0.48220688104629517	▁rad ▁; ▁rem ▁; ▁rem 2 ▁; ▁rad ▁; ▁Gem ▁; Kir ▁; ▁mono me ric ▁g ▁protein s ▁; ▁vent ri cular ▁action ▁; ▁EC ▁coup ling ▁gain ▁; ▁cardiac ▁l - type ▁channel ▁activity
D-1672	-0.48220688104629517	rad ; rem ; rem2 ; rad ; Gem ;Kir ; monomeric g proteins ; ventricular action ; EC coupling gain ; cardiac l-type channel activity
P-1672	-0.3974 -0.1501 -0.3848 -0.2510 -0.0448 -0.1758 -0.0929 -0.1297 -0.1016 -0.3296 -0.7500 -1.1446 -0.2091 -3.6519 -0.0175 -0.1089 -1.8879 -0.8090 -0.0183 -0.2179 -0.0342 -1.0348 -0.2024 -0.0400 -0.4117 -0.3198 -0.0076 -0.1538 -0.3608 -0.1428 -1.4154 -2.8076 -0.0468 -0.0164 -0.0529 -0.0359 -0.2013 -0.1670
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase inhibitor ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hf ; myocardial infarction
H-1136	-0.3306373655796051	▁a ce tyl cho line ster ase ▁inhibi tor ▁py rido stig mine ▁; ▁sympa t hova gal ▁balance ▁; ▁cardiac ▁remodel ing ▁; ▁cardiac ▁function ▁; ▁ HF ▁; ▁my o card ial ▁in far ction
D-1136	-0.3306373655796051	acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; HF ; myocardial infarction
P-1136	-0.1098 -0.1711 -0.1721 -0.5150 -0.1508 -0.2578 -0.4742 -0.0245 -0.0422 -1.0482 -0.0112 -0.0003 -0.1423 -0.2457 -0.2255 -0.1043 -0.1315 -0.0905 -0.0674 -0.1547 -0.0200 -0.0576 -0.0560 -0.1558 -0.1381 -2.3539 -0.1486 -0.9839 -0.0307 -0.2471 -1.3731 -0.5132 -0.2021 -0.8526 -0.0089 -0.7054 -0.6055 -0.1542 -0.1493
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac sympathetic activity ; β-blocker
H-1112	-0.4356568157672882	▁cardiac ▁sympa the tic ▁activity ▁; ▁i - meta - i odob enz yl guan i dine ▁; ▁i - mi BG ▁; ▁β - block er
D-1112	-0.4356568157672882	cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
P-1112	-0.9386 -0.7651 -0.7259 -1.4488 -0.0617 -0.1502 -0.6014 -0.2003 -0.0107 -0.0437 -0.8436 -0.0916 -0.0506 -0.9584 -0.0050 -0.4712 -0.0094 -0.0855 -0.1541 -0.2154 -1.4366 -1.3141 -0.5802 -0.7438 -0.0185 -0.1183 -0.1016 -0.2680 -0.2216
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based ; heart disease ; therapies ; patients ; cabg ; sweden
H-971	-0.5193884372711182	▁Swedish ▁web - system ▁; ▁e viden ce - based ▁care ▁; ▁Heart ▁disease ▁; ▁Reco mmende d ▁Therapie s ▁registr y ▁; ▁ca BG
D-971	-0.5193884372711182	Swedish web-system ; evidence-based care ; Heart disease ; Recommended Therapies registry ; caBG
P-971	-0.1884 -1.2836 -0.0192 -0.1377 -1.0848 -2.0506 -0.0307 -0.0348 -0.0088 -0.0034 -1.3262 -0.6430 -0.4144 -0.5131 -0.2707 -1.2555 -0.0002 -0.0672 -0.1402 -0.0082 -0.9999 -0.0393 -0.3945 -1.3434 -0.4309 -1.2427 -0.0922
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef ; clinical ; reverse remodeling ; death ; hf ; hospitalization ; hazard ratio
H-756	-0.45530813932418823	▁LV EF ▁; ▁rever se ▁remodel ing ▁parameter s ▁; ▁time ▁to ▁death ▁; ▁ HF
D-756	-0.45530813932418823	LVEF ; reverse remodeling parameters ; time to death ; HF
P-756	-0.0320 -0.2176 -0.0755 -0.5705 -0.0034 -0.0090 -0.0608 -0.8821 -0.0245 -0.1969 -1.8510 -0.9346 -0.2943 -0.0589 -0.9250 -0.0812 -1.8198 -0.1584
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients ; brain natriuretic peptide ; bnp ; bnp ; patients ; bnp ; bnp
H-1569	-0.47011423110961914	▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁b NP ▁; ▁b NP ▁; ▁b NP
D-1569	-0.47011423110961914	brain natriuretic peptide ; bNP ; bNP ; bNP ; bNP
P-1569	-0.4498 -0.0110 -0.0855 -0.0179 -3.1643 -0.1349 -0.2172 -0.2125 -0.1976 -0.1609 -0.2791 -0.3793 -0.1054 -0.5531 -0.5077 -0.0815 -0.4901 -0.9038 -0.0999 -0.5662 -1.5600 -0.1647
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes ; coprimary end points ; end point ; change ; serum cystatin c ; renal function ; end point
H-79	-0.5419226884841919	▁co prima ry ▁end ▁points ▁; ▁cum ul ative ▁urin e ▁volume ▁; ▁de con gestion ▁end ▁point ▁; ▁change ▁in ▁se rum ▁cyst atin ▁C ▁; ▁en roll ment ▁; ren al ▁function ▁end ▁point
D-79	-0.5419226884841919	coprimary end points ; cumulative urine volume ; decongestion end point ; change in serum cystatin C ; enrollment ;renal function end point
P-79	-0.8007 -0.0112 -0.0452 -0.3221 -0.1213 -0.1972 -0.8461 -0.0139 -0.0645 -0.7860 -0.0697 -0.9698 -0.1671 -0.3182 -0.0287 -0.0078 -0.6485 -0.0490 -0.4200 -0.1925 -0.6861 -0.0967 -0.1440 -0.0915 -0.2433 -1.8585 -0.2714 -3.1986 -0.0717 -0.0410 -0.3758 -3.5482 -0.0353 -1.7418 -1.5090 -0.0322 -0.4530 -0.1151
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse ; longitudinal rv fiber shortening ; pasp ; rv ; in vivo ; rv ; prognosis
H-493	-0.6257460713386536	▁t AP se ▁; long itud in al ▁ RV ▁fiber ▁short en ing ▁; ▁PAS p ▁; force ▁generate d ▁; ▁ RV ▁; ▁in ▁vivo ▁ RV ▁length - force
D-493	-0.6257460713386536	tAPse ;longitudinal RV fiber shortening ; PASp ;force generated ; RV ; in vivo RV length-force
P-493	-4.0013 -1.1033 -0.5166 -0.0550 -1.3907 -0.2284 -0.5124 -0.1898 -0.1063 -0.3179 -1.4414 -0.5760 -0.1046 -0.1887 -0.1423 -0.5066 -0.4771 -0.0634 -0.6628 -1.0404 -0.1261 -0.4446 -0.3031 -0.2464 -0.1709 -0.1630 -0.0280 -0.8109 -0.2803 -2.3425 -0.0113 -0.0842 -2.4745 -0.1645
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde ; pde2 ; cgmp ; leading ; camp hydrolysis ; cross talk ; cgmp ; camp signaling
H-1210	-0.39356791973114014	▁p de ▁super family ▁; ▁p de 2 ▁; ▁c g mp ▁; ▁c AMP ▁hydro lys is ▁; ▁c g mp ▁; ▁c AMP ▁signal ing
D-1210	-0.39356791973114014	pde superfamily ; pde2 ; cgmp ; cAMP hydrolysis ; cgmp ; cAMP signaling
P-1210	-0.2752 -0.0208 -0.3683 -0.0416 -0.1423 -0.2467 -0.0271 -0.0359 -0.1620 -0.0747 -1.6107 -0.7806 -0.1420 -0.0488 -1.5966 -0.0717 -0.2245 -0.0330 -0.1783 -1.0317 -1.7069 -0.7859 -0.3139 -0.0215 -0.6839 -0.3978 -0.1007 -0.1714 -0.1189
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal probnp ; nt-probnp ; midregional proanp ; mr-proanp ; adiponectin ; elevated ; chf ; correlated ; bmi
H-14	-0.5412405133247375	▁n - termin al ▁pro B NP ▁; NT - pro b NP ▁; ▁mid region al ▁pro AN p ▁; MR - pro an p ▁; ▁adi pon ect in ▁; ▁CHF ▁; ▁b mi ▁; ▁FM
D-14	-0.5412405133247375	n-terminal proBNP ;NT-probNP ; midregional proANp ;MR-proanp ; adiponectin ; CHF ; bmi ; FM
P-14	-4.1785 -0.0519 -0.0917 -0.0072 -0.0596 -1.4996 -0.0736 -0.0810 -1.6170 -0.0017 -0.0068 -1.0882 -0.1771 -0.0517 -0.3966 -0.0605 -0.0151 -0.0228 -3.6084 -0.5195 -0.0700 -0.1746 -0.0027 -0.0026 -1.9632 -0.2440 -0.1222 -2.1724 -0.0075 -0.0031 -0.1794 -0.1397 -0.1014 -0.0848 -0.4471 -1.2604 -0.1048 -0.6600 -0.1787 -0.1223
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization ; admissions ; patient
H-900	-0.3480016887187958	▁re - hospital ization
D-900	-0.3480016887187958	re-hospitalization
P-900	-0.0605 -0.1671 -0.0166 -0.6000 -1.1330 -0.1108
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides ; szeto-schiller ; ss ; ss20 ; cardiac function ; proteomic remodeling ; signaling pathways
H-870	-0.3367764353752136	▁mito cho ndri al - tar get ed ▁antioxidant ▁; ▁protect ive ▁pe pti des ▁; ▁Sze to - Sch iller ▁; SS ▁; ▁SS 20 ▁; ▁cardiac ▁function ▁; ▁prote om ic ▁remodel ing ▁; ▁signal ing ▁path ways
D-870	-0.3367764353752136	mitochondrial-targeted antioxidant ; protective peptides ; Szeto-Schiller ;SS ; SS20 ; cardiac function ; proteomic remodeling ; signaling pathways
P-870	-0.9080 -0.2829 -0.0429 -0.0418 -0.0113 -0.0053 -0.0659 -0.0092 -0.0233 -0.1434 -1.3710 -0.0092 -0.0648 -0.0495 -0.0501 -0.3960 -0.0054 -0.0183 -0.0036 -0.4927 -0.0228 -0.4717 -0.3227 -0.3748 -2.5410 -0.4309 -0.4935 -0.0690 -2.1916 -0.2835 -0.1805 -0.2434 -0.8436 -0.0051 -0.0277 -1.0338 -0.0362 -0.2118 -0.0863 -0.0374 -0.1389 -0.1038
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical ; cardiac arrest ; cardiopulmonary resuscitation ; cpr ; diagnosis ; posterior wall infarction ; hospitalized ; cardiac
H-1291	-0.341161847114563	▁cardiac ▁arrest ▁; ▁cardio pul mon ary ▁res uscita tion ▁; ▁c PR ▁; ▁posterior ▁wall ▁in far ction ▁; ▁cardiac ▁centre
D-1291	-0.341161847114563	cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
P-1291	-1.8048 -0.0867 -0.0756 -0.0393 -0.0271 -1.9429 -0.2606 -0.1023 -0.0203 -0.0899 -0.2746 -0.1441 -0.0556 -0.2603 -0.1324 -0.2308 -0.0120 -0.4015 -0.1024 -0.8085 -0.1186 -0.8798 -0.1947 -0.1231
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence ; hyperkalemia ; mineralocorticoid receptor antagonists ; mineralocorticoid receptor antagonists ; heart failure ; hf
H-1702	-0.47864818572998047	▁hyper kal emia ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁race ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁heart ▁failure ▁; HF
D-1702	-0.47864818572998047	hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
P-1702	-0.1590 -0.2849 -0.2851 -0.3164 -0.2025 -0.1499 -0.4409 -0.9439 -0.3571 -0.1088 -0.3087 -0.1065 -0.3909 -0.2208 -1.8967 -0.1383 -2.4712 -0.2083 -0.5484 -1.2190 -0.3277 -0.3519 -0.8955 -0.1790 -0.6646 -0.5233 -0.4033 -0.3114 -0.3530 -0.3152 -0.1009 -0.1338
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade ; evidence ; acp ; erythropoiesis-stimulating agents ; patients ; anemia ; congestive heart failure ; coronary heart disease
H-37	-0.507881224155426	▁a CP ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease
D-37	-0.507881224155426	aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
P-37	-2.2229 -0.8005 -0.3324 -3.0591 -0.1256 -0.7142 -0.3557 -0.4685 -0.2259 -0.2635 -0.0296 -0.6732 -0.2058 -0.2040 -1.5660 -0.0905 -0.1077 -0.2066 -0.0304 -0.1520 -0.2803 -0.1698 -0.1214 -0.0192 -0.1370 -0.4320 -1.3026 -0.2056 -0.2266
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients ; patients ; type 2 diabetes ; therapy ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; insulin
H-1831	-0.2600743770599365	▁diabetes ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁second - genera tion ▁sul fon yl ure as ▁; ▁long - ac ting ▁insulin ▁products
D-1831	-0.2600743770599365	diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; long-acting insulin products
P-1831	-1.1931 -0.2588 -0.2303 -0.0776 -0.1397 -0.8899 -0.2294 -0.0802 -0.0003 -0.0461 -0.7698 -0.1908 -0.0013 -0.5110 -0.0219 -0.1192 -0.2477 -0.2223 -0.0165 -0.1739 -0.0208 -0.0936 -0.0244 -0.2351 -0.0255 -0.0328 -0.2461 -0.2108 -0.0031 -0.0826 -0.3746 -0.0253 -1.8542 -0.2443 -0.2099
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr ; scn5a ; ventricular systolic hf ; human induced pluripotent stem cell-derived cardiomyocytes ; hipsc-cms
H-1082	-0.3210549056529999	▁u PR ▁; ▁s CN 5 a ▁; ▁vent ri cular ▁sy sto lic ▁ HF ▁; ▁implant ed ▁pluri potent ▁stem ▁cell - der i ved ▁cardio my o cy tes ▁; hi PS c - CM s
D-1082	-0.3210549056529999	uPR ; sCN5a ; ventricular systolic HF ; implanted pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
P-1082	-0.0808 -0.3955 -0.0713 -0.8196 -1.0123 -0.0736 -0.2001 -0.1597 -0.1305 -1.1855 -0.1130 -0.2371 -0.0756 -0.2891 -0.1685 -0.1703 -0.9726 -3.7529 -0.0747 -0.0008 -0.0027 -0.0690 -0.0646 -0.0266 -0.0529 -0.0637 -0.0640 -0.1383 -0.4829 -0.4169 -0.0717 -0.1022 -0.2038 -0.1843 -0.5858 -0.2354 -0.0105 -0.0098 -0.0148 -0.2788 -0.1013
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory ; patients ; heart failure ; hf ; reduced ejection fraction ; renin-angiotensin system ; ras ; β-blockers ; all-cause mortality ; readmissions
H-175	-0.44769954681396484	▁ambula tory ▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁e je ction ▁ fraction ▁; r EF ▁; ▁re nin - angi oten sin ▁system ▁; RAS ▁; ▁β - block ers
D-175	-0.44769954681396484	ambulatory patients ; heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; β-blockers
P-175	-2.0886 -0.1155 -0.7575 -0.4509 -0.3949 -0.2183 -0.1311 -0.0476 -0.1011 -0.6189 -0.4620 -0.1005 -0.0998 -0.0017 -0.1944 -0.2325 -0.1114 -0.0468 -0.0107 -3.6781 -0.0323 -0.0188 -0.1081 -0.9147 -0.2787 -0.6963 -0.3585 -0.3464 -0.3783 -0.0030 -0.0397 -0.0337 -1.9268 -0.2242
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial ; cochrane effective practice and organisation of care taxonomy
H-1847	-0.3236520290374756	▁co ch rane ▁Effective ▁Practic e ▁; ▁organisation ▁of ▁Care ▁Tax ono my
D-1847	-0.3236520290374756	cochrane Effective Practice ; organisation of Care Taxonomy
P-1847	-0.7315 -0.1055 -0.0456 -1.3027 -0.8633 -0.0159 -0.1097 -0.1775 -0.0597 -0.2285 -0.7250 -0.0289 -0.1631 -0.1818 -0.1160
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd ; chf ; crf ; icc ; kappa coefficients
H-802	-0.4304908812046051	▁co PD ▁; ▁CHF ▁; ▁c RF ▁; ▁ICC ▁; ▁ka ppa ▁co ef fici ents
D-802	-0.4304908812046051	coPD ; CHF ; cRF ; ICC ; kappa coefficients
P-802	-1.5497 -2.3282 -0.2101 -0.0438 -0.1136 -0.2737 -0.7208 -0.2260 -0.2165 -0.6757 -0.1362 -0.0464 -0.4143 -0.0185 -0.0094 -0.3695 -0.2877 -0.1088
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients ; stable heart failure ; left ventricular ejection fraction ; training ; training
H-1913	-0.8572204113006592	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁aero bic ▁training ▁; ▁dynamic ▁resist ance ▁training ▁; ▁lower ▁lim bs
D-1913	-0.8572204113006592	heart failure ; left ventricular ejection fraction ; aerobic training ; dynamic resistance training ; lower limbs
P-1913	-2.3798 -0.4354 -0.0944 -0.3670 -0.0292 -2.0265 -0.3935 -0.0720 -0.3594 -0.1696 -1.6278 -0.0137 -0.3538 -3.6916 -0.1704 -1.2964 -0.6558 -4.4034 -0.5430 -0.0246 -1.7909 -0.4165 -0.2487 -0.5047 -0.5762 -0.3281 -0.1725
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient ; implantable cardioverter-defibrillator ; implant ; change ; clinical
H-1865	-0.4230548143386841	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant ▁; ▁implant
D-1865	-0.4230548143386841	implantable cardioverter-defibrillator deactivation ; implant ; implant
P-1865	-0.0013 -0.0523 -0.3002 -0.0868 -0.0463 -0.0164 -0.0639 -2.2033 -1.1881 -0.0045 -0.0525 -0.0418 -0.0411 -0.1084 -0.4798 -0.0012 -0.7242 -0.9864 -1.9559 -0.1065
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients ; heart failure ; myocardial function ; dilated ; contracting ; ventricles ; aetiologies
H-987	-0.7781825065612793	▁heart ▁failure ▁; ▁poor ▁my o card ial ▁function ▁; ▁vent ric les
D-987	-0.7781825065612793	heart failure ; poor myocardial function ; ventricles
P-987	-1.2492 -0.1447 -0.0915 -3.3303 -0.7904 -0.3031 -0.2271 -0.3044 -1.3349 -0.2506 -1.9130 -1.3974 -0.0334 -0.1545 -0.1483
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients ; implantable cardioverter-defibrillator ; patients ; implantable cardioverter-defibrillator
H-1866	-0.48167937994003296	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant able ▁implant able ▁cardio ver ter - de fi br illa tor ▁shock s
D-1866	-0.48167937994003296	implantable cardioverter-defibrillator deactivation ; implantable implantable cardioverter-defibrillator shocks
P-1866	-0.0006 -0.0595 -0.5015 -0.1025 -0.0791 -0.0119 -0.0566 -3.0617 -1.3821 -0.0052 -0.0760 -0.0490 -0.0394 -0.1294 -0.9197 -0.2429 -0.0947 -1.3017 -0.1038 -0.5818 -0.1281 -0.0678 -0.0094 -0.0345 -2.3513 -0.7817 -0.0081 -0.0712 -2.5935 -0.0649 -0.3554 -0.1487
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global left ventricular longitudinal systolic strain ; gls ; left ventricular ; cardiovascular ; atrial fibrillation
H-809	-0.4125753343105316	▁global ▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁gr s ▁; ▁left ▁vent ri cular ▁mechanic s ▁; ▁cardiovascular ▁; CV ▁; ▁at rial ▁fi bril lation ▁; AF
D-809	-0.4125753343105316	global left ventricular longitudinal systolic strain ; grs ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ;AF
P-809	-1.1015 -0.5859 -0.0570 -1.1892 -0.3997 -0.1028 -0.1146 -0.0406 -0.6184 -0.0879 -0.3014 -0.0697 -0.2508 -0.3973 -1.1180 -0.1421 -2.1545 -0.0487 -1.5105 -0.2380 -0.2318 -0.0180 -0.1472 -0.3861 -0.4193 -0.0094 -0.0767 -1.7513 -0.0640 -0.4671 -0.0296 -0.0315 -0.4383 -0.0236 -0.1172 -0.1131
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad ; q65p ; murine ; rad ; q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type rad
H-1675	-0.966524064540863	▁mouse ▁rad ▁; ▁mur ine ▁; ▁rad ▁; ▁rad ▁; ▁q 66 p ▁; ▁l - type ▁current s ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁rad
D-1675	-0.966524064540863	mouse rad ; murine ; rad ; rad ; q66p ; l-type currents ; cav1.2 ; cav1.3 ; rad
P-1675	-0.2093 -2.3154 -0.4211 -0.5679 -0.3855 -0.2246 -2.2446 -0.3061 -4.0337 -0.3420 -4.6468 -0.6335 -0.1371 -0.1774 -3.7969 -0.1192 -0.0471 -0.4339 -0.1182 -0.4976 -0.2422 -1.1018 -1.1650 -0.2446 -0.4897 -0.7740 -1.0234 -1.3504 -0.8520 -0.9621 -0.0995
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient ; mi ; hazard ratios ; hf
H-1108	-1.154582142829895	▁MI ▁; ▁hazard ▁ratio s ▁; ▁ HF
D-1108	-1.154582142829895	MI ; hazard ratios ; HF
P-1108	-2.2606 -0.5290 -2.7491 -0.3145 -0.1216 -0.3447 -4.0538 -0.7269 -0.1773 -0.2685
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare ; patients ; acute ; hospital ; hf ; ami ; pna
H-1693	-0.7625818252563477	▁national ▁Medica re ▁; ▁patients ▁; ▁a cute ▁care ▁hospital ▁; ▁ HF ▁; ▁ AMI ▁; ▁p na
D-1693	-0.7625818252563477	national Medicare ; patients ; acute care hospital ; HF ; AMI ; pna
P-1693	-2.1120 -0.0593 -0.0090 -0.4814 -3.5203 -0.5301 -0.0543 -0.0698 -1.4633 -0.2363 -0.2743 -2.4879 -0.3048 -0.1547 -0.6567 -1.9395 -0.2326 -0.5342 -0.5653 -0.1937 -0.1348
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular events ; baseline ; sst2 ; metoprolol succinate
H-404	-0.9808400273323059	▁cardio vas cular ▁events ▁; ▁s st 2 ▁status ▁; ▁h z ▁; ▁ms ▁; ▁met o pro lol ▁suc cina te
D-404	-0.9808400273323059	cardiovascular events ; sst2 status ; hz ; ms ; metoprolol succinate
P-404	-3.6446 -0.1996 -0.1940 -0.5041 -0.2991 -0.1171 -2.2572 -0.0622 -0.6704 -0.1481 -3.9634 -0.7493 -1.1725 -4.8283 -1.7802 -1.9185 -0.1919 -0.0784 -0.3885 -0.0738 -0.0097 -0.0478 -0.1704 -0.0709
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt ; nt-probnp ; aric ; hf ; aucs ; nris
H-289	-0.45903560519218445	▁c t n t ▁; ▁NT - pro b NP ▁; ▁a RIC ▁ HF ▁model ▁; ▁au c s ▁; ▁continuo us ▁NR Is
D-289	-0.45903560519218445	ctnt ; NT-probNP ; aRIC HF model ; aucs ; continuous NRIs
P-289	-0.0413 -0.1135 -0.0943 -0.2364 -0.0357 -0.1105 -0.0087 -0.0028 -0.5640 -0.0616 -0.0397 -0.0944 -2.1222 -0.2293 -0.2645 -1.2119 -0.1656 -2.2820 -0.9601 -0.2118 -0.1031 -0.4249 -0.0211 -0.0836 -1.0240 -1.7291 -0.1575
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf ; hf with reduced ef ; hf with preserved ef ; change ; hf ; mi
H-1109	-0.6702934503555298	▁ HF ▁; ▁ HF ▁; ▁EF ▁; ▁ HF ▁; ▁ HF ▁; ▁ HF ▁; ▁MI
D-1109	-0.6702934503555298	HF ; HF ; EF ; HF ; HF ; HF ; MI
P-1109	-2.0372 -0.4115 -0.0969 -2.4902 -0.1421 -0.0664 -0.5964 -0.0511 -0.4544 -0.1366 -0.0839 -1.4838 -0.1886 -0.0991 -2.2955 -0.3989 -0.1156 -1.0308 -1.0921 -0.1347
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl ; nyha-iiib ; phosphorylation ; phosphorylation ; hdl ; healthy
H-255	-0.5201830267906189	▁EC ▁; ▁HD L ▁; NY ha - III b ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁ phos phor y lation ▁; ▁e NOS - Th r ▁; ▁HD L
D-255	-0.5201830267906189	EC ; HDL ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDL
P-255	-0.5890 -0.0928 -2.1334 -1.8962 -0.0729 -1.0756 -0.6589 -0.0596 -0.0436 -0.0065 -0.1783 -0.2535 -0.2465 -0.2985 -1.1704 -0.0255 -0.3251 -0.0983 -0.0385 -0.0243 -0.0872 -0.2478 -0.4177 -0.3807 -0.5084 -1.0003 -0.0556 -0.2896 -0.2733 -0.1263 -0.0394 -1.9762 -0.0094 -0.3810 -1.8562 -1.9232 -0.7191 -0.1883
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol ; von willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
H-1118	-0.42480871081352234	▁car vedi lol ▁; ▁Will e brand ▁factor ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1118	-0.42480871081352234	carvedilol ; Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
P-1118	-3.3701 -0.1073 -0.3788 -0.2077 -1.9284 -0.0953 -0.0147 -0.8863 -0.1782 -0.1270 -0.1432 -0.0252 -0.4529 -0.2724 -0.8467 -0.4135 -0.1253 -0.1791 -0.3069 -0.0509 -0.0349 -0.3962 -0.0704 -0.0926 -0.2004 -0.1408
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart failure ; hf ; hypertensive heart disease ; hhd ; pathophysiology ; therapeutic ; hhd ; stable ; phenotypes
H-274	-0.47264429926872253	▁mouse ▁heart ▁failure ▁; HF ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁h HD ▁; ▁pat ho phy si ology ▁; ▁h HD
D-274	-0.47264429926872253	mouse heart failure ;HF ; hypertensive heart disease ; hHD ; pathophysiology ; hHD
P-274	-0.0377 -1.0449 -0.0887 -0.0657 -0.0818 -0.0606 -0.0546 -0.0887 -0.0877 -1.0334 -0.7355 -0.0874 -0.2194 -1.7473 -0.4604 -1.6865 -0.0177 -0.0854 -0.3860 -0.5210 -0.1008 -0.3012 -1.9666 -0.7656 -0.0916
2021-01-18 16:51:49 | INFO | fairseq.logging.progress_bar | :    101 / 142 wps=211
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic reticular ; protein ; phospholamban ; infarcted ; hearts ; metoprolol
H-1551	-0.3146791160106659	▁sar co plas mic ▁reti cular ▁; SR ▁; ▁ca (2 +) - up take ▁; ▁protein ▁; ▁SR ▁; ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁in far cted ▁heart s ▁; ▁met o pro lol
D-1551	-0.3146791160106659	sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
P-1551	-0.0300 -0.1921 -0.2431 -1.8710 -0.0138 -0.4289 -0.2721 -0.1204 -0.2774 -0.6929 -0.5253 -0.0046 -0.0632 -0.1156 -0.2228 -0.0678 -0.8338 -0.3694 -0.8169 -0.8995 -1.4362 -0.4192 -0.0041 -0.0129 -0.0081 -0.0984 -0.1624 -0.0951 -0.1116 -0.1940 -0.0378 -0.1675 -0.0316 -0.6433 -0.7952 -0.2173 -0.0286 -0.1851 -0.7456 -0.0541 -0.0261 -0.1182 -0.0930 -0.0996
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug ; patients ; chronic obstructive pulmonary disease ; copd ; chronic heart failure ; chf ; chronic renal failure ; crf
H-794	-0.5921773910522461	▁temps d ▁up ▁; ▁go ▁; ▁tu g ▁; ▁patients ▁; ▁advanced ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; CO PD ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁chronic ▁renal ▁failure ▁; CR f
D-794	-0.5921773910522461	tempsd up ; go ; tug ; patients ; advanced chronic obstructive pulmonary disease ;COPD ; chronic heart failure ;CHf ; chronic renal failure ;CRf
P-794	-1.1367 -1.5063 -0.1430 -2.1977 -2.5022 -0.0770 -0.2845 -0.5307 -0.1580 -3.2868 -0.3394 -0.5903 -0.3082 -0.3236 -0.0876 -0.0689 -0.0049 -0.0864 -0.5943 -0.0909 -1.5044 -0.3850 -0.0441 -0.9140 -0.5048 -0.1408 -0.1007 -1.1118 -0.0893 -0.0497 -0.8389 -0.1125 -0.2871 -0.2345 -1.2573 -0.2713 -0.1531 -0.1860
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise ; intramuscular testosterone supplementation ; patients ; chronic heart failure ; chf ; testosterone ; collected ; health ; outcomes
H-1317	-0.9380468726158142	▁in mus cular ▁testosteron e ▁supplement ation ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁low ▁testosteron e
D-1317	-0.9380468726158142	inmuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone
P-1317	-6.5062 -0.3023 -0.1175 -0.0687 -0.0350 -2.0429 -0.0243 -0.1248 -3.6019 -0.8527 -0.2211 -0.0946 -1.2303 -0.0686 -0.1474 -1.4071 -0.0859 -0.0491 -1.6687 -0.1117
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients ; hospitalized ; hf ; preserved lvef ; mortality ; patients ; lvef ; lvef ; mortality
H-117	-0.4807690978050232	▁ HF ▁; ▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁LV EF ▁; ▁long - term ▁mortal ity
D-117	-0.4807690978050232	HF ; LVEF ; long-term mortality ; LVEF ; long-term mortality
P-117	-2.6994 -0.0500 -0.1088 -1.0517 -0.1439 -0.1464 -0.4248 -0.0465 -0.6445 -0.0466 -0.1611 -0.4383 -0.4230 -0.0616 -0.7411 -1.6935 -0.0335 -1.0905 -0.0496 -0.2114 -0.1662 -0.1444
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls ; left ventricular ejection fraction ; lvef ; systolic mitral annulus velocity ; multivariate models
H-818	-0.6485590934753418	▁gr s ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; LV EF ▁; ▁sy sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁sa ▁; ▁CV
D-818	-0.6485590934753418	grs ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; CV
P-818	-0.3926 -1.6696 -0.2644 -0.6799 -0.0476 -1.7725 -0.4558 -0.2612 -0.4510 -0.4891 -0.1739 -0.0026 -0.2018 -0.1294 -0.2212 -0.0829 -0.3714 -0.1308 -0.5539 -0.7043 -0.0851 -2.1900 -0.9141 -4.0056 -0.3707 -0.1641 -0.2118 -0.7511 -1.1700 -1.0475 -0.1395
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart failure ; hf ; plasma b-type natriuretic peptide ; bnp ; preserved ejection fraction ; ef ; hf
H-187	-0.5065276026725769	▁heart ▁failure ▁; HF ▁; ▁plasma ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁e je ction ▁ fraction ▁; EF ▁; ▁ HF
D-187	-0.5065276026725769	heart failure ;HF ; plasma ; b-type natriuretic peptide ; bNP ; ejection fraction ;EF ; HF
P-187	-0.3950 -0.2734 -0.1000 -0.1873 -0.0658 -0.6671 -0.9044 -1.1445 -1.7211 -0.0388 -0.0148 -0.1668 -0.0441 -3.0573 -0.1231 -0.2287 -0.2503 -0.2767 -0.1466 -0.5340 -0.2141 -1.3803 -0.5161 -0.1128 -0.0921 -0.0016 -0.2638 -1.2344 -0.2357 -0.5410 -0.1025 -1.5662 -0.1151
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm ; telemonitoring ; implanted ; medical ; structured telephone support ; sts ; human-to-human contact ; hh ; human-to-machine interface
H-153	-0.5567774772644043	▁RM ▁; ▁implant ed ▁monitoring ▁devices ▁; ▁medical ▁support ▁; ▁telephone ▁support ▁; ▁st s ▁; ▁human - to - human ▁contact ▁; HH ▁; ▁human - to - machine ▁interface ▁; HM
D-153	-0.5567774772644043	RM ; implanted monitoring devices ; medical support ; telephone support ; sts ; human-to-human contact ;HH ; human-to-machine interface ;HM
P-153	-0.2875 -0.7628 -0.5897 -0.0770 -0.4123 -0.4160 -0.3039 -1.4201 -0.5629 -0.3261 -2.7922 -0.6865 -0.2187 -1.4736 -0.2053 -0.3874 -2.0960 -0.0185 -0.1301 -0.1884 -0.0162 -0.0032 -0.2352 -2.1306 -0.2880 -1.7820 -0.0124 -0.1799 -0.0225 -0.0566 -0.0232 -0.5859 -0.3329 -0.3750 -0.0889
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox regression analysis ; patients ; beta-blockers ; beta-blockers ; primary endpoint ; therapy ; antitachycardia pacing ; atp ; shock therapy
H-859	-0.3255132734775543	▁co x ▁re gression ▁; ▁beta - block ers ▁; ▁beta - block ers ▁; ▁anti ta chy car dia ▁pa cing ▁; ▁a TP ▁; ▁shock ▁ therapy
D-859	-0.3255132734775543	cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
P-859	-0.8235 -0.0183 -0.0936 -0.0198 -1.5386 -1.6497 -0.0277 -0.2314 -0.0696 -0.0765 -0.3241 -0.0238 -0.2164 -0.0788 -0.1326 -0.8067 -0.2317 -0.1527 -0.0153 -0.4541 -0.1716 -0.8561 -0.1996 -0.2822 -0.6159 -0.6033 -0.0359 -0.0642 -0.0129 -0.1287 -0.1354
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically ; legal ; decisions
H-1680	-0.5165612101554871	▁et h ically ▁complex ▁situations ▁; ▁pediatr ics ▁; ▁families ▁; ▁religious ▁belief s ▁; ▁life - s usta ining ▁treatment
D-1680	-0.5165612101554871	ethically complex situations ; pediatrics ; families ; religious beliefs ; life-sustaining treatment
P-1680	-0.3107 -0.0851 -0.3915 -0.6077 -0.2894 -0.3442 -0.0326 -0.2165 -0.2291 -0.7449 -0.3387 -0.1613 -0.3530 -0.0281 -0.1399 -2.3636 -0.0187 -0.6762 -0.1865 -0.1757 -0.6309 -3.4546 -0.1020
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient ; prescribing ; medications ; medical
H-1122	-0.4418236315250397	▁patient ▁preference s ▁; ▁priorit ies ▁; ▁guide line - re com mend ed ▁medication s
D-1122	-0.4418236315250397	patient preferences ; priorities ; guideline-recommended medications
P-1122	-3.5245 -0.2196 -0.0319 -0.0989 -0.8776 -0.0622 -0.1702 -0.1110 -0.0557 -0.0097 -0.0147 -0.1477 -0.0254 -0.0756 -0.0722 -0.0252 -2.3429 -0.0877
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost ; patient ; rhythm-control ; rate-control
H-1241	-0.6030347347259521	▁coût ▁; ▁ rhythm - control ▁; ▁rate - control
D-1241	-0.6030347347259521	coût ; rhythm-control ; rate-control
P-1241	-1.1543 -0.4459 -0.1260 -0.9772 -0.1778 -0.2487 -0.4056 -2.0375 -0.1469 -0.2932 -0.8281 -0.3952
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left ventricular ejection fraction ; egfr
H-393	-1.1280927658081055	▁media n ▁age ▁; ▁women ▁; ▁media n ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁media n ▁e g FR ▁; ▁m l
D-393	-1.1280927658081055	median age ; women ; median left ventricular ejection fraction ; median egFR ; ml
P-393	-4.8443 -0.0277 -1.1922 -0.1353 -2.2173 -0.1425 -2.7497 -0.0234 -1.2432 -0.0268 -1.7843 -0.2814 -0.1973 -0.6711 -0.6721 -0.3512 -0.0054 -0.4520 -4.2472 -0.0203 -0.0948 -3.8326 -1.4764 -0.6806 -0.2587 -2.2486 -1.4255 -0.2846
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf ; hazard ratios ; body mass index ; obese
H-1773	-0.6763688325881958	▁fit ▁; ▁un fit ▁; ▁c RF ▁distribution ▁; ▁hazard ▁ratio s ▁; ▁fit ▁; ▁un fit ▁; ▁obes e ▁men
D-1773	-0.6763688325881958	fit ; unfit ; cRF distribution ; hazard ratios ; fit ; unfit ; obese men
P-1773	-0.3820 -0.4437 -0.2070 -0.2158 -0.1027 -0.1658 -0.2467 -0.7203 -0.3978 -1.2839 -0.0405 -0.1338 -0.3699 -2.5972 -0.1171 -0.3215 -0.1631 -0.5820 -5.9096 -0.1208 -0.7442 -0.1645 -0.1266
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary outcome ; patients ; crt ; hazard ratio ; confidence interval
H-852	-0.7549371123313904	▁c rte ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
D-852	-0.7549371123313904	crte ; hazard ratio ; confidence interval
P-852	-0.4678 -1.8538 -0.6827 -1.0879 -0.0648 -0.9862 -1.3133 -0.4093 -0.5101 -0.1737
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi ; blood urea nitrogen ; b-type natriuretic peptide ; new york heart association class ; diabetes ; atrial fibrillation ; all-cause hospitalization
H-382	-0.43896394968032837	▁ HF PSI ▁; ▁blood ▁u rea ▁nit rogen ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁New ▁York ▁Heart ▁Association ▁class ▁; ▁diabetes ▁; ▁at rial ▁fi bril lation ▁; flu tter
D-382	-0.43896394968032837	HFPSI ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart Association class ; diabetes ; atrial fibrillation ;flutter
P-382	-2.2894 -0.2727 -1.0019 -0.4074 -1.0482 -0.0112 -2.4047 -0.1298 -0.0239 -0.0540 -0.8430 -0.0197 -0.0267 -0.0023 -0.0291 -0.0113 -1.6807 -0.0742 -0.0890 -0.0959 -0.1063 -0.1626 -0.3651 -1.2702 -1.0543 -0.5035 -0.0851 -0.0523 -0.3922 -0.1070 -0.0804 -0.1707 -0.0719 -0.0402 -1.5159 -0.0937 -0.0046 -0.3683 -0.1602
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare patient safety monitoring system ; mpsms ; adverse event ; patients ; hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
H-2	-0.3697557747364044	▁Medica re ▁Patient ▁Safety ▁Monitor ing ▁System ▁; ▁mp SMS ▁; ▁advers e ▁event ▁rates ▁; ▁patients ▁hospital ized ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁pneu monia ▁; ▁surgery
D-2	-0.3697557747364044	Medicare Patient Safety Monitoring System ; mpSMS ; adverse event rates ; patients hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
P-2	-0.0343 -0.0019 -0.1700 -0.1163 -0.2472 -0.0388 -1.1184 -0.2365 -1.1586 -0.2311 -0.4302 -0.5396 -0.0355 -0.1274 -2.5493 -0.3123 -1.2324 -0.8994 -1.0630 -0.3730 -0.0572 -0.0029 -0.9080 -0.2763 -0.0977 -0.1809 -0.0138 -0.5674 -0.1019 -0.1504 -0.0584 -0.0124 -0.0477 -0.1953 -0.0460 -0.1803 -0.0023 -0.1717 -0.5396 -0.7713 -0.1317 -0.1012
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells ; functional capacity ; cells ; peak vo2
H-127	-1.3182621002197266	▁CD 34 + ve g FR 2 + ▁cell s ▁; ▁functional ▁capacity ▁; ▁CD 34 + ve g FR 2 ▁; ▁cell s ▁; ▁VO 2
D-127	-1.3182621002197266	CD34+vegFR2+ cells ; functional capacity ; CD34+vegFR2 ; cells ; VO2
P-127	-1.5823 -0.2827 -3.2579 -1.1008 -1.5222 -2.3856 -0.2670 -2.9511 -0.4614 -0.0664 -0.2379 -2.5691 -0.7280 -0.0899 -3.2204 -0.3923 -2.5930 -2.0789 -1.8487 -2.5374 -0.1450 -1.8636 -0.7754 -0.0793 -0.2486 -4.4853 -0.1637 -0.1385 -0.1569
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients ; heart failure and reduced ejection fraction ; patient
H-659	-0.6187937259674072	▁implant s ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-659	-0.6187937259674072	implants ; heart failure ; reduced ejection fraction
P-659	-4.3197 -0.7006 -0.4117 -1.0262 -0.1803 -0.0871 -0.8425 -0.0153 -0.0214 -0.2437 -0.0530 -0.0610 -0.0004 -1.1799 -0.1390
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality rate ; patients ; hf ; hf ; case-fatality rate
H-1311	-0.9123614430427551	▁cru de ▁28- day ▁case - fat ality ▁rate ▁; ▁ HF
D-1311	-0.9123614430427551	crude 28-day case-fatality rate ; HF
P-1311	-2.4877 -0.0111 -1.6280 -0.1009 -1.2177 -0.0499 -0.0304 -0.0615 -1.3649 -0.1264 -1.5376 -0.0774 -3.9339 -0.1457
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame ; chf ; anthracycline ; stem cell ; allogeneic ; autologous ; follow-up
H-1453	-0.689117968082428	▁CHF ▁; ▁an thra cycli ne ▁exposure ▁; ▁stem ▁cell ▁source ▁; allo gene ic
D-1453	-0.689117968082428	CHF ; anthracycline exposure ; stem cell source ;allogeneic
P-1453	-0.7312 -0.4241 -5.0598 -0.2674 -0.3648 -0.1517 -0.7370 -0.2521 -0.0289 -0.0527 -0.4491 -1.1208 -0.0101 -0.1190 -0.8337 -1.0100 -0.1025
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting tension ; fpassive ; muscle ; kcl-ki ; titin ; titin ; extracellular matrix ; fpassive
H-765	-0.6049903631210327	▁tension ▁; f pass ive - sar com ere ▁length ▁relations ▁; ▁muscle ▁strip s ▁; ▁k c l - KI ▁treatment ▁; ▁titi n ▁; ▁extra cel lular ▁matri x ▁; ▁F pass ive
D-765	-0.6049903631210327	tension ;fpassive-sarcomere length relations ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix ; Fpassive
P-765	-0.1840 -0.1524 -4.6786 -0.2594 -0.0064 -1.9409 -0.1204 -0.0586 -0.1591 -0.9038 -0.2736 -0.3199 -2.9002 -0.4469 -0.0104 -0.2663 -1.0418 -0.5933 -0.0800 -0.0242 -0.0462 -3.0613 -0.3024 -0.1858 -0.0157 -0.1546 -1.0505 -0.1584 -0.0125 -0.0265 -0.0074 -0.7663 -1.7306 -0.1352 -0.0040 -0.2047 -0.1023
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart failure ; myocardial infarction ; mi ; β-adrenoceptor blockade ; infarcted ; metoprolol
H-1547	-0.31945371627807617	▁rever si bility ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction ▁; MI ▁; ▁β - ad re no cept or ▁block ade ▁; ▁in far cted ▁rat s ▁; ▁met o pro lol
D-1547	-0.31945371627807617	reversibility ; heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
P-1547	-0.7566 -0.1822 -0.0569 -0.9245 -0.2179 -0.1842 -0.1954 -0.5823 -0.4098 -0.1694 -0.5745 -0.0557 -1.4520 -0.1567 -0.1474 -1.2304 -0.1047 -0.1738 -0.0035 -0.0125 -0.0150 -0.0451 -1.0411 -0.0793 -0.2853 -0.2616 -0.1928 -0.1141 -0.6700 -0.6326 -0.1045 -0.0325 -0.3410 -0.1817 -0.1114 -0.0296 -0.2306 -0.3735 -0.1266
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training ; exercise capacity ; muscle ; quality of life ; cardiac ; nt-probnp ; inflammatory ; il6 ; hscrp ; biomarkers
H-1922	-0.7277663946151733	▁aero bic ▁; ▁resist ance ▁training ▁; ▁benefits ▁; ▁exercise ▁capacity ▁; ▁muscle ▁strength ▁; ▁cardiac ▁; NT - pro b NP ▁; ▁infla mma tory ▁; ▁i 6 ▁; ▁h s CR p
D-1922	-0.7277663946151733	aerobic ; resistance training ; benefits ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ; i6 ; hsCRp
P-1922	-0.3590 -0.1348 -0.7084 -0.0670 -0.0168 -2.1787 -0.3450 -3.9443 -0.1057 -0.9894 -0.6152 -0.1468 -0.1387 -0.3723 -0.2153 -2.4283 -0.3707 -1.8908 -0.0082 -0.6858 -1.0445 -0.2112 -0.3878 -0.8129 -0.3742 -0.1969 -0.5959 -2.1881 -2.1480 -0.2543 -0.0005 -0.0222 -1.3954 -0.1820 -0.4686 -0.1958
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital ; readmission ; all-cause readmission ; acr ; potential preventable readmission ; ppr ; medicare ; medicaid ; readmission ; cms
H-135	-0.4844278395175934	▁hospital ▁performance ▁; ▁all - ca use ▁read mission ▁; ▁a CR ▁; ▁Potential ▁Prev en table ▁Read mission ▁; ▁p PR ▁; ▁Center s ▁for ▁Medica re ▁; ▁Medica id ▁30- day ▁read mission ▁; ▁c MS
D-135	-0.4844278395175934	hospital performance ; all-cause readmission ; aCR ; Potential Preventable Readmission ; pPR ; Centers for Medicare ; Medicaid 30-day readmission ; cMS
P-135	-1.8196 -0.8242 -0.1482 -3.2833 -0.0050 -0.0069 -0.0086 -0.6068 -0.0406 -0.1521 -0.0504 -1.4900 -0.0371 -2.1999 -0.0998 -0.0189 -0.0367 -0.2062 -0.0293 -0.0988 -0.1819 -0.2059 -0.0752 -0.5987 -0.0171 -0.2500 -0.0089 -0.0036 -0.8554 -0.0119 -0.0461 -3.1954 -0.0296 -0.8135 -0.0716 -0.1825 -0.0904 -1.2551 -0.2019 -0.1198
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive heart failure ; correlation coefficient
H-218	-0.7871818542480469	▁con ges tive ▁heart ▁failure ▁; ▁ed
D-218	-0.7871818542480469	congestive heart failure ; ed
P-218	-1.0367 -0.0080 -0.0857 -0.6178 -0.2229 -1.3234 -0.8116 -2.8208 -0.1576
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise ; rehabilitation ; walking ; minnesota quality of life ; exercise
H-1882	-1.8713444471359253	▁rehabilita tion ▁; ▁distance ▁; ▁walking
D-1882	-1.8713444471359253	rehabilitation ; distance ; walking
P-1882	-4.8442 -0.0898 -0.3371 -2.9227 -1.2709 -1.3969 -3.9679 -0.1413
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine vasopressin ; avp ; physiologic ; chf ; avp ; vasopressin receptor antagonist ; therapy ; therapeutic ; chf
H-637	-0.4197579324245453	▁argi nine ▁vaso press in ▁; ▁a VP ▁; ▁physio logic ▁process es ▁; ▁CHF ▁; ▁a VP ▁; ▁vaso press in ▁receptor ▁anta gon ist ▁ therapy ▁; ▁CHF
D-637	-0.4197579324245453	arginine vasopressin ; aVP ; physiologic processes ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
P-637	-3.2688 -0.2341 -0.1216 -0.0286 -0.8361 -0.2374 -0.1912 -0.0728 -0.2726 -0.8082 -0.1689 -2.4584 -0.0160 -0.5944 -0.0093 -0.5892 -0.4811 -0.2032 -0.1560 -0.3726 -0.0326 -0.4070 -0.1326 -0.0993 -0.0175 -0.4816 -0.1945 -0.0196 -0.4667 -0.1270 -0.1611 -0.1723
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; β-blockers ; patients ; heart failure and reduced ejection fraction
H-661	-0.34074515104293823	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-661	-0.34074515104293823	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
P-661	-1.3482 -1.1619 -0.1393 -0.7845 -0.1199 -0.0202 -0.0312 -1.5026 -0.0516 -0.0817 -0.0411 -1.8226 -0.2601 -0.3455 -0.0133 -0.6074 -0.0335 -0.4908 -0.0529 -0.1282 -0.0688 -0.0073 -0.0612 -0.0413 -0.2039 -0.8489 -0.3946 -0.2438 -0.1776 -0.1782 -0.0953 -0.1043 -0.0013 -0.2622 -0.2009
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies ; medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; risk stratification ; patient ; heart failure ; therapies ; disease
H-1205	-0.43692532181739807	▁implant able ▁de fi br illa tors ▁; ▁circula tory ▁support ▁; ▁transplant ation ▁; ▁heart ▁failure
D-1205	-0.43692532181739807	implantable defibrillators ; circulatory support ; transplantation ; heart failure
P-1205	-0.0861 -0.0761 -0.0254 -1.4078 -1.0831 -0.0103 -1.1172 -0.3686 -0.0393 -0.0768 -0.1067 -0.3545 -0.3111 -0.0109 -0.2625 -1.6234 -0.1427 -1.0481 -0.1510
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary approaches to stop hypertension ; dash ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hfpef
H-918	-0.46005159616470337	▁so dium - re strict ed ▁dieta ry ▁; ▁hyper tension ▁die t ▁; DAS h ▁; ▁s RD ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁H FP EF
D-918	-0.46005159616470337	sodium-restricted dietary ; hypertension diet ;DASh ; sRD ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
P-918	-3.4094 -0.0418 -0.0038 -0.0357 -0.0345 -0.0497 -2.0458 -0.1210 -0.6467 -0.1831 -0.0597 -2.2576 -0.0536 -0.0774 -0.0161 -0.5179 -0.1771 -1.5763 -1.1188 -0.1593 -1.1244 -0.0118 -1.0623 -0.0736 -0.2610 -0.1256 -0.6343 -1.9686 -0.1559 -0.0977 -0.1647 -0.0270 -0.1123 -0.0031 -0.7412 -0.0556 -0.0500 -0.0225 -0.0474 -0.0035 -0.5491 -0.4743 -0.0884 -0.0890 -0.0471 -1.4809 -0.5285 -0.1102 -0.1636 -0.1439
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right ventricular pacing ; gene expressions ; bax ; bcl-2 ; caspase-3 ; rtq-pcr ; interventricular septum ; biopsies ; heart failure
H-166	-0.3206356167793274	▁rapid ▁vent ri cular ▁pa cing ▁; ▁Bax ▁; ▁b cl -2 ▁; ▁Cas pas e -3 ▁; ▁RT q - PC r ▁; ▁interven tri cular ▁sept um ▁bio psi es ▁; ▁beag le ▁dog s ▁; ▁heart ▁failure
D-166	-0.3206356167793274	rapid ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
P-166	-2.2272 -1.3969 -1.1012 -0.2088 -0.1338 -0.6648 -0.1586 -0.7479 -0.0513 -0.0205 -0.0400 -0.4142 -0.1393 -0.4080 -0.0813 -0.1211 -0.1934 -0.1630 -0.2054 -1.3041 -0.0169 -0.1487 -0.2480 -0.2413 -0.0807 -0.0458 -0.0370 -0.0471 -0.0108 -0.0493 -0.0265 -0.0482 -0.2430 -0.0251 -0.2945 -0.5416 -0.0435 -0.5945 -0.3162 -0.3674 -0.1446 -0.1151
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; bax ; caspase 3 ; expression
H-961	-0.25818607211112976	▁rat s ▁; ▁heart s ▁; ▁cas pas e -3 ▁activity ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁cy to ch rom e ▁c ▁; ▁b cl 2 ▁; ▁Bax ▁; ▁cas pas e
D-961	-0.25818607211112976	rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase
P-961	-0.9115 -0.0648 -0.2169 -1.1625 -0.0433 -0.1685 -0.0130 -0.2060 -0.3434 -0.3937 -0.3369 -0.1261 -0.1434 -0.0365 -0.4846 -0.1716 -0.3563 -0.3593 -0.0123 -0.0393 -0.1057 -0.3805 -0.0154 -0.0333 -0.2510 -0.4414 -0.0362 -0.1522 -0.0108 -0.0528 -0.9584 -0.5322 -0.0481 -0.0419 -0.0543 -0.2424 -0.0047 -0.2327 -0.0065 -0.3037 -0.2090 -1.1885 -0.2102
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol ; carvedilol ; sympathetic activity ; von willebrand factor
H-1119	-0.6716561913490295	▁met o pro lol ▁; ▁car vedi lol ▁; ▁sympa the tic ▁activity
D-1119	-0.6716561913490295	metoprolol ; carvedilol ; sympathetic activity
P-1119	-0.4369 -0.1578 -0.0191 -0.1696 -0.1226 -0.0429 -0.1015 -0.2774 -0.2774 -0.3191 -0.6457 -1.3179 -0.1628 -5.9028 -0.1213
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute hf ; relax-ahf ; astronaut ; pronto ; patient ; patients ; end points
H-1017	-0.431269109249115	▁a cute ▁ HF ▁; ▁RELA x - a HF ▁; ▁ AST RON AUT ▁; ▁PR ONTO ▁; ▁patient ▁en roll ment
D-1017	-0.431269109249115	acute HF ; RELAx-aHF ; ASTRONAUT ; PRONTO ; patient enrollment
P-1017	-0.4505 -0.0316 -0.1833 -0.0374 -0.2762 -0.6971 -0.3514 -0.0029 -0.7208 -0.3691 -0.0473 -1.8966 -0.1287 -0.9924 -0.0856 -0.0753 -0.4563 -0.0094 -0.8008 -1.4004 -0.0723 -0.0335 -0.0309 -1.5281 -0.1035
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized ; hf ; international classification of diseases ; clinical ; principal ; discharge ; diagnosis
H-1832	-0.20944008231163025	▁Hospital ized ▁ HF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁Clinic al ▁Modifica tion ▁code s ▁; ▁principal ▁dis charge ▁ diagnos is
D-1832	-0.20944008231163025	Hospitalized HF ; international Classification of Diseases ; Clinical Modification codes ; principal discharge diagnosis
P-1832	-1.4288 -0.2832 -0.2899 -0.0293 -0.0956 -0.2538 -0.4246 -0.0062 -0.3025 -0.0443 -0.0151 -0.1184 -0.5939 -0.0041 -0.0400 -0.0222 -0.0706 -0.0190 -0.5348 -0.1279 -0.0575 -0.0043 -0.4723 -0.1529 -0.0367 -0.1073 -0.1193
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
H-1959	-0.5010621547698975	▁Pul mon ary ▁cap illa ry ▁we dge ▁pressure ▁; ▁h g ▁; ▁h g ▁; ▁h g ▁; ▁right ▁at rial ▁pressure ▁; ▁pulmonar y ▁arterial ▁pressure ▁; ▁pulmonar y ▁resist ance
D-1959	-0.5010621547698975	Pulmonary capillary wedge pressure ; hg ; hg ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
P-1959	-0.6215 -1.6334 -0.2922 -0.6627 -0.0270 -0.0271 -2.0617 -0.0080 -1.1346 -0.1554 -0.0907 -0.0292 -0.0959 -0.2472 -0.0264 -0.1127 -3.3359 -0.0279 -0.1138 -1.7244 -0.2852 -0.4204 -1.4274 -0.1126 -0.0337 -0.0358 -0.0536 -1.6383 -0.3054 -0.0016 -0.1337 -0.3377 -0.0395 -0.1667 -0.1177
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad ; q65p ; movement ; wild-type rad ; q65p ; l-type channel ; rgk proteins
H-1676	-0.882835328578949	▁rad ▁; ▁Q 65 p ▁; ▁ga ting ▁movement ▁; ▁rad ▁; ▁wild - type ▁rad ▁; ▁Q 65 p ▁; ▁implant ion ▁; ▁l - type ▁channel ▁inhibi tion ▁; ▁R GK ▁protein s
D-1676	-0.882835328578949	rad ; Q65p ; gating movement ; rad ; wild-type rad ; Q65p ; implantion ; l-type channel inhibition ; RGK proteins
P-1676	-0.4766 -0.2757 -4.6526 -0.6413 -0.2976 -0.2099 -4.4379 -0.6108 -0.3184 -0.1433 -2.7914 -0.1563 -1.6068 -0.0051 -0.0095 -1.1454 -0.1338 -2.0126 -0.1874 -0.2778 -0.4060 -5.3417 -0.4035 -0.1100 -2.2035 -0.1095 -0.0222 -0.5332 -0.1954 -0.0573 -0.1908 -1.2611 -0.1623 -0.9489 -0.0243 -0.1790 -0.1259
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 ; heart failure ; proteomics ; actin cytoskeleton ; ss20 ; mitochondrial ; metabolic pathways
H-876	-0.7220402359962463	▁heart ▁failure ▁; ▁prote o mics ▁; ▁act in ▁cy tos kelet on ▁path ways ▁; ▁SS 20 ▁; ▁mito cho ndri al ▁; ▁metabol ic ▁path ways
D-876	-0.7220402359962463	heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
P-876	-3.7769 -0.6996 -0.1754 -1.8774 -0.8929 -0.0081 -3.3570 -0.2036 -0.2441 -1.1891 -0.2751 -0.0726 -0.1735 -1.5369 -0.0987 -0.5433 -1.6463 -0.3481 -0.8674 -0.3476 -0.4460 -0.0144 -0.0518 -1.4225 -0.0950 -0.1581 -0.5916 -0.1163 -0.2438 -0.1882
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic insufficiency ; mechanical circulatory support ; continuous flow ; left ventricular assist devices ; lvads ; pulsatile devices
H-542	-0.2899100184440613	▁a or tic ▁insu ffi cie ncy ▁; AI ▁; ▁mechanic al ▁circula tory ▁support ▁; ▁continuo us ▁flow ▁; CF ▁; ▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁pulsa tile ▁devices
D-542	-0.2899100184440613	aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
P-542	-0.3828 -0.1113 -1.0389 -0.1350 -0.1282 -1.0134 -0.0238 -0.1419 -1.8087 -0.1927 -0.1998 -0.0146 -0.1112 -0.3487 -0.1921 -0.1750 -0.6883 -0.2202 -0.6740 -0.0560 -0.3234 -0.1085 -0.1831 -0.0137 -0.7640 -0.0822 -0.3015 -0.3025 -0.1605 -0.3264 -0.0305 -0.0458 -0.2444 -0.0110 -0.0117 -0.1097 -0.1937 -0.1476
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration ; pyridostigmine ; coronary artery ligation ; cardiac ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hf
H-1145	-0.261799693107605	▁py rido stig mine ▁; ▁corona ry ▁arter y ▁liga tion ▁; ▁cardiac ▁va gal ▁; ▁sympa the tic ▁tone ▁; ▁cardiac ▁remodel ing ▁; ▁vent ri cular ▁dys function ▁; ▁ HF
D-1145	-0.261799693107605	pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; ventricular dysfunction ; HF
P-1145	-2.1837 -0.0157 -0.0006 -0.0760 -0.1672 -0.2848 -0.0591 -0.0722 -0.1709 -0.5838 -0.1227 -0.1160 -0.0521 -0.0795 -0.0154 -0.1343 -0.7181 -0.2109 -0.7224 -0.0479 -0.1305 -0.1135 -0.0222 -0.0718 -0.1348 -0.6159 -0.6566 -0.0799 -0.0060 -0.0917 -0.1753 -0.3993 -0.0487 -0.6986 -0.0850
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge ; patients ; follow-up ; physician ; physician
H-1418	-0.8713992834091187	▁dis charge
D-1418	-0.8713992834091187	discharge
P-1418	-1.7726 -0.0274 -1.5690 -0.1166
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life expectancy ; heart failure ; patients ; disease ; terminal heart failure
H-1665	-1.1117724180221558	▁heart ▁failure ▁; ▁re frac tory ▁; ▁terminal ▁heart ▁failure
D-1665	-1.1117724180221558	heart failure ; refractory ; terminal heart failure
P-1665	-5.1657 -0.4092 -0.3421 -3.4578 -0.0268 -0.2868 -0.8349 -1.0515 -1.2192 -0.2729 -0.1148 -0.1596
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart failure ; discharges ; university of connecticut health center ; patients ; follow-up
H-723	-0.6771866083145142	▁heart ▁failure ▁dis charge s ▁; ▁University ▁of ▁Connect i cut ▁health ▁Center
D-723	-0.6771866083145142	heart failure discharges ; University of Connecticut health Center
P-723	-1.4750 -0.2208 -0.4290 -0.0043 -0.0366 -0.1821 -0.4513 -0.0690 -1.0458 -0.0831 -0.2869 -1.6933 -0.5275 -3.5293 -0.1240
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes ; patients ; new york heart association ; nyha ; heart failure ; eplerenone ; placebo ; heart failure ; medicines ; emphasis-hf
H-1229	-0.7845762372016907	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁class ▁II ▁Heart ▁Fail ure ▁; ▁e pler en one ▁; ▁place bo ▁; ▁standard ▁Heart ▁Fail ure ▁Medicine s ▁; EMP ha SIS - HF ▁Study
D-1229	-0.7845762372016907	New York Heart association ;NYha ; class II Heart Failure ; eplerenone ; placebo ; standard Heart Failure Medicines ;EMPhaSIS-HF Study
P-1229	-5.2579 -1.1400 -3.1511 -1.1894 -0.0597 -1.5078 -1.0829 -0.1218 -0.9185 -0.2272 -0.6420 -0.1248 -0.0758 -0.1159 -0.2357 -0.1113 -0.1335 -1.1895 -0.0513 -1.8934 -0.0072 -0.0449 -2.5293 -0.8361 -0.0930 -0.0328 -0.0618 -0.0195 -0.1427 -1.3241 -1.4524 -1.3289 -0.0043 -0.0281 -1.0476 -0.6993 -0.1478
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; ivc occlusion ; bivp ; ste ; rs
H-324	-0.40845009684562683	▁vent ri cular ▁base ▁; ▁mid pap illa ry ▁; ▁ap ex ▁; ▁IV c ▁oc clusi on ▁; ▁bi VP ▁; ▁ste ▁; ▁twist ▁; ▁ap ical ▁; ▁bas al ▁rota tions ▁; ▁CS ▁; ▁RS ▁; ▁synchron y
D-324	-0.40845009684562683	ventricular base ; midpapillary ; apex ; IVc occlusion ; biVP ; ste ; twist ; apical ; basal rotations ; CS ; RS ; synchrony
P-324	-0.8202 -1.3263 -0.0932 -0.0827 -0.2079 -0.6379 -0.0712 -0.0104 -0.0187 -0.2972 -1.3877 -0.0268 -0.2790 -0.0904 -0.7329 -0.1815 -0.0076 -0.1203 -0.1210 -0.7413 -0.3542 -0.3524 -1.9153 -0.6688 -0.7714 -0.1038 -1.6040 -0.0439 -0.9455 -0.0032 -0.0066 -0.0599 -0.0102 -0.1609 -0.1255 -0.2700 -0.0920 -1.9601 -0.0003 -0.1169 -0.1527 -0.1831
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence ; drugs ; drugs ; raas ; renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
H-1490	-0.3241749107837677	▁drugs ▁; ▁RA as ▁; ▁direct ▁re nin ▁inhibi tors ▁; ▁neutral ▁en dop ep tida se ▁inhibi tors ▁; ▁vaso pe pti das e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers
D-1490	-0.3241749107837677	drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
P-1490	-1.3144 -0.1288 -1.1597 -0.4660 -0.1547 -0.0018 -0.0067 -1.3804 -0.1666 -0.2573 -0.1001 -1.5675 -0.0206 -0.0098 -0.9108 -0.0105 -0.0130 -0.0567 -0.6584 -0.1438 -0.0262 -0.0872 -0.1414 -0.6603 -0.1088 -0.0699 -1.0498 -0.1639 -0.0171 -0.2823 -0.0719 -0.2506 -0.0100 -0.1450 -0.0144 -0.2309 -0.1369
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute heart failure ; hf ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
H-1015	-0.24335037171840668	▁a cute ▁heart ▁failure ▁; HF ▁; ▁ pharma c ologic ▁studies ▁; ▁calci um - sensi t izing ▁agents ▁; ▁en do the lin ▁; ▁vaso press in ▁; ▁ad enos ine
D-1015	-0.24335037171840668	acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
P-1015	-0.2772 -0.0604 -0.7007 -0.1624 -0.1769 -0.0509 -0.3007 -0.4318 -0.0303 -0.1023 -0.1195 -0.8792 -0.2969 -0.1398 -0.0183 -0.0141 -0.0023 -0.9608 -0.1684 -0.0462 -0.1436 -0.1236 -0.0750 -0.2789 -1.3146 -0.2481 -0.0093 -0.0270 -0.4325 -0.4455 -0.0038 -0.0203 -0.0595 -0.2065 -0.1903
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in vivo ; hf ; phenylephrine ; haemodynamic ; surgical ; transverse aortic constriction ; tac ; jq1 ; pathological ; cardiac hypertrophy
H-1047	-0.4454750418663025	HF ▁; ▁ HF ▁; ▁ phen yle ph rine ▁; ▁ha emo dynamic ▁stress ▁; ▁sur g ical ▁method ▁of ▁trans verse ▁a or tic ▁con stri ction ▁; TAC ▁; ▁j q 1 ▁; ▁cardiac ▁hyper trop hy
D-1047	-0.4454750418663025	HF ; HF ; phenylephrine ; haemodynamic stress ; surgical method of transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
P-1047	-2.2071 -0.4795 -1.5673 -0.5382 -0.3148 -1.2846 -2.3046 -0.1884 -0.1378 -0.0708 -0.2029 -0.1033 -0.0574 -0.0118 -0.2869 -0.0613 -0.2918 -0.0952 -0.0399 -0.7588 -0.7704 -0.0007 -0.0980 -0.0153 -0.1256 -0.6059 -0.0350 -0.1251 -0.0482 -0.2675 -0.5050 -0.3580 -0.3908 -0.9050 -0.0890 -1.1024 -1.7663 -0.1098 -0.0029 -0.1196 -0.1501 -0.1170
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; fontan
H-1502	-0.33500730991363525	▁Mus cle ▁aero bic ▁capacity ▁; ▁poste xer ci se ▁ phos pho creati ne ▁re syn the sis ▁; ▁Font an
D-1502	-0.33500730991363525	Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
P-1502	-0.2643 -0.2432 -0.3352 -0.3033 -0.7049 -0.1160 -0.0161 -0.0283 -0.0994 -0.2270 -0.1437 -0.0219 -0.2149 -0.3407 -0.5086 -0.0144 -0.0352 -0.8707 -1.5214 -0.4796 -0.0952 -0.0949 -1.2450 -0.1162
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
H-1117	-0.591662585735321	▁i - mi g ▁cardiac ▁was hout ▁; ▁car vedi lol ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1117	-0.591662585735321	i-mig cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
P-1117	-0.1209 -1.6331 -0.8271 -3.6530 -0.4000 -4.0463 -0.0427 -0.1326 -0.1860 -0.0458 -0.1189 -0.1761 -0.0778 -0.1540 -0.0217 -0.3089 -2.1147 -0.9244 -0.4416 -0.1161 -0.1505 -0.4244 -0.0492 -0.0979 -0.4307 -0.0479 -0.0782 -0.1747 -0.1630
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute myocardial infarction ; ami ; incidence ; deaths ; heart failure ; hf ; ami
H-1306	-0.40514442324638367	▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁heart ▁failure ▁; HF ▁; ▁complicat ing ▁ AMI
D-1306	-0.40514442324638367	acute myocardial infarction ;AMI ; heart failure ;HF ; complicating AMI
P-1306	-0.9550 -0.0325 -1.3793 -0.3198 -0.1071 -0.3565 -0.0297 -0.5033 -0.1364 -0.2355 -1.1046 -0.2356 -2.3456 -0.1367 -0.1570 -0.3294 -0.2459 -0.1226 -0.1624 -0.1717 -0.0161 -0.1348 -0.1010
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; cardiac metabolic gene expression ; atp
H-655	-0.5519914031028748	▁h - d KO ▁; ▁vent ri cular ▁mass ▁; ▁cardiac ▁apo pto sis ▁; ▁fibro sis ▁; ▁failure ▁; ▁Akt ▁; ▁for k head ▁box ▁; ▁im pair ed ▁cardiac ▁metabol ic ▁gene ▁expression ▁; ▁ATP
D-655	-0.5519914031028748	h-dKO ; ventricular mass ; cardiac apoptosis ; fibrosis ; failure ; Akt ; forkhead box ; impaired cardiac metabolic gene expression ; ATP
P-655	-0.3354 -1.1985 -0.3636 -0.9700 -0.8783 -0.0895 -1.7331 -0.3550 -0.3460 -0.0317 -0.2958 -0.2990 -0.1525 -0.8252 -0.2295 -0.0040 -0.1696 -0.3207 -3.5608 -0.1731 -0.4827 -0.5176 -1.8520 -0.1285 -0.0677 -0.2719 -0.2787 -1.1653 -0.0098 -0.0172 -0.1365 -0.1184 -0.1889 -2.3819 -0.0156 -0.0985 -0.5554 -0.7614 -0.1485
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck stent ; implanted ; lad ; circumflex artery ; lcx ; lcx ; lad
H-505	-0.4871956706047058	▁bottle ne ck ▁sten t ▁; ▁proxima l ▁left ▁anterior ▁descend ing ▁; LAD ▁; ▁proxima l ▁circum flex ▁arter y ▁; LC x ▁; ▁proxima l ▁ LC x ▁; ▁ LAD
D-505	-0.4871956706047058	bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCx ; proximal LCx ; LAD
P-505	-0.1730 -0.0084 -0.1809 -0.1913 -0.0536 -0.2752 -3.9070 -0.0286 -0.8078 -1.0591 -0.0064 -0.0525 -0.2467 -0.1114 -0.1501 -0.5467 -0.0576 -0.3340 -0.0410 -0.0576 -0.3082 -0.4082 -0.6690 -0.6572 -0.1542 -1.6964 -0.0249 -0.2386 -0.2022 -0.3578 -0.2291 -1.2836 -0.0956 -2.3129 -0.1250
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized ; heart failure ; dipeptidyl peptidase-4 ; dpp-4 ; antihyperglycemic agents
H-1827	-0.440640926361084	▁hospital ized ▁heart ▁failure ▁; ▁h HF ▁; ▁di pe pti dy l ▁pep tida se -4 ▁; ▁d p -4 ▁; ▁anti hy per gly ce mic ▁agents
D-1827	-0.440640926361084	hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; antihyperglycemic agents
P-1827	-3.0213 -0.6152 -1.0044 -0.3400 -0.1136 -0.3834 -0.1716 -0.0599 -0.0178 -0.0120 -0.0177 -3.1570 -1.4075 -0.0110 -0.0339 -0.1297 -0.0649 -0.1490 -0.2227 -0.7167 -0.0828 -0.3863 -0.0194 -0.0389 -0.1324 -0.7275 -0.0576 -0.2279 -0.0644 -0.1225 -0.1511
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox modeling ; heart failure patient severity index ; hfpsi ; university of michigan ; hf ; clinic ; primary outcome
H-380	-0.774684727191925	▁quality ▁improvement ▁database ▁; ▁multi vari able ▁co x ▁model ing ▁; ▁Heart ▁Fail ure ▁Patient ▁Sever ity ▁Index ▁; HF PSI ▁; ▁University ▁of ▁Michigan ▁; ▁h f ▁; ▁h p ▁; ▁u e ▁; ▁h p
D-380	-0.774684727191925	quality improvement database ; multivariable cox modeling ; Heart Failure Patient Severity Index ;HFPSI ; University of Michigan ; hf ; hp ; ue ; hp
P-380	-4.4531 -0.1186 -1.7659 -0.1124 -0.0078 -0.0016 -0.0148 -0.6748 -0.0173 -0.5038 -0.1096 -0.1524 -0.8770 -0.0854 -0.0458 -0.2664 -0.2966 -0.0843 -1.2502 -0.1280 -1.2076 -0.3120 -0.0733 -0.4946 -0.0657 -0.0240 -0.5799 -1.4739 -1.9164 -1.2188 -2.0913 -1.5510 -0.8439 -2.5789 -0.6909 -1.1245 -1.6384 -1.1041 -0.9093 -0.1234
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 ; healthy ; cardiomyocytes ; camp ; inotropic effect ; acute ; β-ar ; contractility
H-1216	-0.33570826053619385	▁p de 2 ▁; ▁cardio my o cy tes ▁; ▁c AMP ▁; ▁ca 2 ▁; ▁in o tropi c ▁effect ▁; ▁a cute ▁β - AR ▁stimul ation ▁; ▁bas al ▁contract ility
D-1216	-0.33570826053619385	pde2 ; cardiomyocytes ; cAMP ; ca2 ; inotropic effect ; acute β-AR stimulation ; basal contractility
P-1216	-0.5115 -0.0249 -0.0678 -0.7760 -1.5384 -0.2693 -0.3893 -0.2458 -0.2715 -0.0467 -0.0312 -0.1473 -0.2579 -0.8487 -0.0938 -0.1301 -0.2137 -0.4854 -0.0429 -0.0780 -0.7668 -0.0979 -1.5770 -0.0298 -0.2751 -0.0020 -0.0703 -1.2188 -0.0741 -0.3009 -0.0009 -0.0453 -0.0699 -0.7218 -0.2048 -0.1598
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp ; shock therapy
H-863	-0.5368273258209229	▁ATP ▁; ▁in appropria te ▁shock ▁ therapy
D-863	-0.5368273258209229	ATP ; inappropriate shock therapy
P-863	-0.8247 -0.2909 -1.0323 -0.0508 -0.1408 -2.3702 -0.0542 -0.0160 -0.4048 -0.1835
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac resynchronization therapy ; crt ; patients ; heart failure ; hf ; outcomes ; crt ; dialysis ; reported
H-904	-0.4096156656742096	▁Card iac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁c RT ▁; ▁di al ysis
D-904	-0.4096156656742096	Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF ; cRT ; dialysis
P-904	-0.5339 -0.0929 -0.0096 -0.0356 -0.0033 -1.2377 -0.2811 -0.0408 -0.1153 -0.7133 -1.1329 -0.1883 -0.2967 -0.0990 -0.1308 -0.0539 -0.0709 -1.1819 -0.3515 -0.2291 -0.3243 -0.2685 -0.2732 -0.6428 -1.0255 -1.6014 -0.7042 -0.8507 -0.1490 -0.2106 -0.1130 -0.1463
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ; hf ; mortality ; cardiovascular ; hf ; mortality
H-1766	-0.3036118149757385	▁cardio re spira tory ▁fitness ▁; CR f ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁; HF ▁; ▁cardiovascular ▁risk ▁factors ▁; ▁ HF ▁mortal ity ▁; ▁fit ▁; ▁un fit ▁men
D-1766	-0.3036118149757385	cardiorespiratory fitness ;CRf ; body mass index ; heart failure ;HF ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
P-1766	-0.3971 -0.0323 -0.0621 -0.1443 -0.3577 -0.0709 -1.3138 -0.0882 -0.0413 -0.0765 -0.3484 -0.0080 -0.0610 -0.2977 -0.6827 -0.1067 -0.4151 -0.3776 -0.2486 -1.0610 -0.5813 -0.1267 -0.4351 -0.0899 -0.3029 -0.1179 -0.2200 -0.4771 -0.8050 -0.0295 -0.0218 -0.5476 -0.2578 -0.1192
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; eplerenone ; patients ; hospitalization ; heart failure
H-1221	-0.5424512028694153	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁EM PHA SIS - HF ▁; ▁e pler en one ▁in ▁Mil d ▁Patient s ▁Hospital ization ▁; ▁sur v I val ▁Study ▁in ▁Heart ▁Fail ure
D-1221	-0.5424512028694153	eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone in Mild Patients Hospitalization ; survIval Study in Heart Failure
P-1221	-0.5397 -1.5589 -0.5463 -3.0161 -0.1637 -0.0900 -0.3660 -0.1296 -0.0949 -0.3807 -2.5651 -0.3391 -0.2294 -0.0322 -0.3853 -0.0052 -0.0094 -0.6460 -0.3010 -0.7469 -0.2781 -2.3597 -2.4964 -1.3392 -0.0299 -0.1471 -0.0253 -0.1514 -0.7059 -0.1610 -0.3021 -0.0542 -0.7464 -0.1033 -0.1299 -0.2960 -0.3026 -0.0310 -0.0452 -0.1776 -0.2125
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart rate ; cardiac ; patients ; patients ; acute myocardial infarction ; ami ; patients ; congestive heart failure ; chf ; left ventricular ; dysfunction
H-1585	-0.4305088520050049	▁Heart ▁rate ▁; HR ▁; ▁cardiac ▁patients ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁con ges tive ▁heart ▁failure ▁; CH f ▁; ▁left ▁vent ri cular ▁; LV
D-1585	-0.4305088520050049	Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
P-1585	-1.0596 -1.5400 -0.2483 -0.4723 -0.5301 -0.2100 -0.8887 -0.1916 -0.1621 -0.0174 -1.1523 -0.4805 -0.1338 -0.5488 -0.0316 -0.9649 -0.3342 -0.3490 -0.0878 -0.3277 -0.8549 -0.0308 -0.0714 -0.2191 -0.1057 -0.1353 -0.7593 -0.1121 -0.1195 -0.1068 -0.0224 -1.5133 -0.1319 -0.9664 -0.0360 -0.8419 -0.1713
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular cardiomyocytes ; chronic ; insulin ; irs1 ; irs2 ; proteins ; insulin ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
H-657	-0.3512158691883087	▁ne ona tal ▁rat ▁vent ri cular ▁cardio my o cy tes ▁; ▁chronic ▁insulin ▁exposure ▁; ▁i RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁insulin ▁action ▁; ▁cardiac ▁dys function ▁; ▁insulin ▁resist ance ▁; ▁diabetes
D-657	-0.3512158691883087	neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; cardiac dysfunction ; insulin resistance ; diabetes
P-657	-1.6941 -0.0261 -0.0558 -0.1238 -0.0282 -0.8411 -0.2930 -0.0510 -0.2292 -0.2870 -0.0587 -0.1907 -0.1383 -0.5797 -0.3980 -0.8757 -0.0439 -1.1825 -0.0521 -0.0866 -0.3394 -0.9226 -0.4201 -0.0278 -0.7753 -0.0136 -0.1629 -1.1296 -0.4198 -0.1415 -0.7206 -0.0406 -0.0451 -0.1759 -0.0554 -0.4630 -0.0094 -0.1561 -0.8378 -0.1838 -0.1242
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms ; left ventricular ; midpapillary ; atrioventricular delay ; avd ; interventricular delay ; vvd ; ste ; circumferential strain ; radial strain ; rs
H-323	-0.3274197578430176	▁vent ri cular ▁mid pap illa ry ▁; ▁at rio ven tri cular ▁de lay ▁; ▁av d ▁; ▁interven tri cular ▁de lay ▁; VV d ▁; ▁ste ▁; ▁circum fer ential ▁strain ▁; CS ▁; ▁radi al ▁strain ▁; RS
D-323	-0.3274197578430176	ventricular midpapillary ; atrioventricular delay ; avd ; interventricular delay ;VVd ; ste ; circumferential strain ;CS ; radial strain ;RS
P-323	-0.2943 -1.6153 -0.1926 -0.4976 -0.0605 -0.0127 -0.0321 -0.6983 -0.6930 -0.1374 -0.0296 -0.3797 -0.1181 -0.0306 -0.1615 -0.2841 -0.8477 -0.1168 -0.0989 -0.0597 -0.3838 -0.0303 -0.0215 -0.2942 -0.2941 -0.2187 -0.1001 -0.1386 -0.7430 -0.4443 -2.7542 -0.1812 -0.1832 -0.0162 -0.3535 -0.4641 -0.1665 -0.0016 -0.0252 -0.1217 -0.6187 -0.0264 -0.3101 -0.1548
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients ; new york heart association ; nyha ; functional class ; hf ; ejection fractions ; chronic ; stable ; guideline-directed medical therapy ; gdmt ; united states ; canada ; europe
H-1870	-0.4585215747356415	▁New ▁York ▁Heart ▁Association ▁; NY HA ▁; ▁ HF ▁; ▁e je ction ▁ fraction s ▁; ▁chronic ▁stable ▁guide line - direct ed ▁medical ▁ therapy ▁; GD MT
D-1870	-0.4585215747356415	New York Heart Association ;NYHA ; HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
P-1870	-1.8251 -0.5747 -1.2855 -1.0654 -0.1469 -0.6877 -0.9619 -0.1263 -1.8467 -0.2900 -0.0634 -0.0708 -0.2499 -0.0520 -0.0847 -0.0012 -0.0355 -0.0624 -0.6293 -2.7657 -0.3342 -0.0423 -0.0146 -0.0210 -0.0831 -0.1025 -0.0408 -0.0180 -0.1426 -0.2205 -0.1282 -1.0678 -0.0904
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients ; qrs ; hazard ratio ; primary outcome ; patients ; qrs ; hazard ratio
H-889	-0.8896051645278931	▁non - LB BB ▁; ▁QR s ▁; ▁hazard ▁ratio
D-889	-0.8896051645278931	non-LBBB ; QRs ; hazard ratio
P-889	-4.6303 -0.0368 -0.0661 -0.5472 -0.0810 -0.0642 -1.1409 -0.4026 -1.4421 -0.0331 -2.0385 -0.1926
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous hf ; myofiber shortening ; septum ; myofiber shortening ; stretch ; wall
H-1155	-0.6784148216247559	▁dys syn chron ous ▁ HF ▁; ▁my o fi ber ▁; ▁sept um ▁; ▁de press es ▁; ▁my o fi ber ▁short en ing ▁; ▁stretch ▁rate ▁; ▁late - activa ted ▁lateral ▁wall
D-1155	-0.6784148216247559	dyssynchronous HF ; myofiber ; septum ; depresses ; myofiber shortening ; stretch rate ; late-activated lateral wall
P-1155	-4.3779 -0.0072 -0.0030 -0.6581 -0.2848 -0.0574 -0.1534 -2.2289 -0.2021 -0.7779 -0.1245 -0.6932 -2.3123 -0.0408 -0.1563 -1.2351 -0.0493 -0.1294 -0.1596 -1.1763 -0.0958 -0.5794 -0.0850 -2.0638 -0.1151 -0.2759 -0.7765 -0.6072 -1.3171 -0.3870 -3.2978 -0.0101 -0.0132 -0.5846 -0.0945 -0.2576 -0.2027 -0.1891
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics ; proteomics ; transverse aortic constriction ; tac ; heart failure ; signaling pathway ; ingenuity pathway analysis
H-871	-0.40223032236099243	▁label - free ▁shot gun ▁prote o mics ▁; ▁global ▁prote o mics ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC - indu ced ▁heart ▁failure ▁; ▁signal ing ▁path way ▁changes ▁; ▁ingen u ity ▁path way
D-871	-0.40223032236099243	label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC-induced heart failure ; signaling pathway changes ; ingenuity pathway
P-871	-0.1685 -0.0124 -0.1060 -0.0797 -0.0507 -0.6469 -0.5409 -0.0033 -0.3353 -1.7909 -0.3678 -0.6865 -0.0030 -1.5054 -0.0049 -0.0954 -0.0173 -0.0857 -0.9062 -0.0433 -0.5443 -0.0415 -0.1735 -0.7078 -2.3673 -0.0130 -0.1480 -0.0984 -0.1616 -0.4372 -1.0157 -0.1625 -0.3337 -0.1574 -1.4220 -0.5930 -0.0183 -0.0553 -0.0769 -0.3459 -0.0549 -0.8386 -0.0791
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells ; transforming growth factor-β ; tgf-β ; epithelial ; mesenchymal ; transition ; expression ; pluripotency markers
H-1342	-0.3463236093521118	▁CHF ▁; ▁transform ing ▁growth ▁factor - β ▁; ▁t GF - β ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker s ▁; ▁sham s
D-1342	-0.3463236093521118	CHF ; transforming growth factor-β ; tGF-β ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
P-1342	-0.0728 -0.8574 -2.9343 -0.1141 -1.7172 -1.4683 -0.1857 -0.0327 -0.1273 -0.3196 -1.5900 -0.0438 -0.0228 -0.2727 -0.0511 -0.1066 -0.0958 -0.0336 -0.5864 -0.0178 -0.1510 -0.0418 -0.2205 -0.0056 -0.2874 -0.0217 -0.1861 -0.0037 -0.0209 -0.0160 -0.2093 -0.0100 -0.6574 -0.0019 -0.0335 -0.1571 -0.1401
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka ; change ; riiα ; cα ; expression ; riiα ; ser96 ; cα ; thr197 ; phosphorylation ; hf
H-1428	-0.6332935690879822	▁p ka ▁; ▁regulator y ▁; RI i α ▁; ▁cata ly tic ▁; ▁c α ▁; ▁r II α ▁; ▁ser 96) ▁; ▁c α ▁; ▁ phos phor y lation ▁; ▁ HF
D-1428	-0.6332935690879822	pka ; regulatory ;RIiα ; catalytic ; cα ; rIIα ; ser96) ; cα ; phosphorylation ; HF
P-1428	-0.4360 -1.1368 -0.2072 -2.3811 -0.1141 -0.2530 -0.6136 -1.8207 -0.3837 -0.1386 -0.0050 -0.1630 -0.2129 -0.3699 -0.3730 -0.6454 -0.4400 -1.9471 -3.1386 -1.2751 -0.1395 -0.9648 -1.0052 -0.4669 -0.8771 -1.0780 -0.1520 -0.2049 -0.1078 -0.2339 -0.5374 -0.0177 -0.4621 -0.7966 -0.0875 -0.1284 -0.1171
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients ; hfref ; left ventricular ejection fraction ; hfpef ; left ventricular ejection fraction ; β-blocker ; hf ; hospitalization
H-178	-0.692853569984436	▁h f ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁h f p EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ RAS - ▁; ▁β - block er
D-178	-0.692853569984436	hf ; left ventricular ejection fraction ; hfpEF ; left ventricular ejection fraction ; RAS- ; β-blocker
P-178	-0.0754 -1.2254 -0.2727 -0.9088 -0.0956 -2.7045 -1.2371 -0.3241 -0.7179 -0.8897 -0.7822 -0.0047 -0.1280 -0.9355 -0.3378 -0.2890 -0.3613 -0.1191 -0.4400 -0.0977 -3.8218 -1.0520 -0.3622 -0.9481 -1.4121 -0.8057 -0.0090 -0.3263 -0.4084 -0.2704 -0.1466 -1.3196 -0.1937 -0.0186 -0.0451 -0.0238 -2.8768 -0.3419
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross talk ; g-protein-coupled receptors ; physiological ; significance ; regulation ; hearts ; chronic ; β-adrenergic receptor ; postischemic heart failure
H-1410	-0.4717932641506195	▁g - prote in - co up led ▁receptor s ▁; ▁reciproc al ▁regula tion ▁; ▁mouse ▁heart s ▁; ▁β - ad r energi c ▁receptor ▁stimul ation ▁; ▁rat ▁; ▁post ische mic ▁heart ▁failure
D-1410	-0.4717932641506195	g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; β-adrenergic receptor stimulation ; rat ; postischemic heart failure
P-1410	-1.2414 -0.0996 -0.0822 -0.8027 -0.0222 -0.0070 -0.0060 -0.0892 -0.1348 -0.0900 -0.2296 -3.5013 -0.0203 -0.8003 -0.0285 -0.1879 -0.1115 -0.6615 -0.0624 -0.1116 -3.2101 -0.0094 -0.0856 -0.1475 -0.0976 -0.0416 -0.0499 -1.2150 -0.0210 -0.0813 -0.6868 -0.5080 -1.1308 -1.8800 -0.0782 -0.4397 -0.1196 -0.1778 -0.1298
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric remodeling ; concentric hypertrophy ; left ventricular ; remodeling ; heart failure with preserved ejection fraction ; hfpef ; eccentric hypertrophy ; patients
H-1524	-0.1913299709558487	▁concentr ic ▁remodel ing ▁; CR ▁; ▁concentr ic ▁hyper trop hy ▁; CH ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁remodel ing ▁in ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁ecce n tric ▁hyper trop hy ▁; EH
D-1524	-0.1913299709558487	concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling in heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
P-1524	-0.2585 -0.0461 -0.1563 -0.0963 -0.1640 -0.6252 -0.1062 -0.0732 -0.0184 -0.0112 -0.0043 -0.0238 -0.1744 -0.2534 -0.2038 -0.2763 -0.0281 -1.2647 -0.2025 -0.3999 -0.0410 -0.2174 -0.8619 -0.0390 -0.5510 -0.6088 -0.2364 -0.1074 -0.1940 -0.0022 -0.0426 -0.0195 -0.2220 -0.0846 -0.0860 -0.0016 -0.2091 -0.7983 -0.0157 -0.1053 -0.0658 -0.0460 -0.0065 -0.0365 -0.0102 -0.0030 -0.0350 -0.1787 -0.0172 -0.3210 -0.2074
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise ; exercise
H-1989	-1.6189944744110107	▁weight ▁; ▁die t ▁group ▁; ▁exercise
D-1989	-1.6189944744110107	weight ; diet group ; exercise
P-1989	-2.3211 -0.4060 -3.4293 -0.1328 -1.9537 -0.5221 -2.6500 -2.9515 -0.2044
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv dysfunction ; hazard ratio ; confidence interval ; cachexia ; hazard ratio ; multivariate analyses
H-1166	-0.7419025301933289	▁ RV ▁dys function ▁; haz ard ▁ratio ▁; ▁confidence ▁interval ▁; ▁CI ▁; ▁cache xia ▁; haz ard ▁ratio
D-1166	-0.7419025301933289	RV dysfunction ;hazard ratio ; confidence interval ; CI ; cachexia ;hazard ratio
P-1166	-1.7706 -0.3652 -0.0757 -0.4707 -0.2119 -4.6820 -0.0238 -0.6279 -0.4904 -1.2674 -0.4123 -0.2522 -2.1941 -0.3542 -0.0562 -0.4046 -1.0985 -0.3118 -0.0240 -0.3037 -0.7000 -0.2246
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients ; resting hr ; follow-up ; baseline ; vo2max ; patients ; resting hr ; p value
H-1945	-1.2564153671264648	▁rest ing ▁HR ▁; ▁VO 2 max
D-1945	-1.2564153671264648	resting HR ; VO2max
P-1945	-3.0486 -0.1523 -0.2812 -0.3757 -3.5673 -0.0832 -0.0066 -3.5831 -0.2097
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β ; cell ; phenotype ; in vitro ; cardiac progenitor function ; cell ; clinical
H-1344	-0.5894918441772461	▁t GF - β ▁inhibi tion ▁; ▁c - K it + ▁cell ▁; ▁implant ation ▁; ▁cardiac ▁pro gen itor ▁function ▁; ▁cell ▁exp an sion
D-1344	-0.5894918441772461	tGF-β inhibition ; c-Kit+ cell ; implantation ; cardiac progenitor function ; cell expansion
P-1344	-1.1797 -2.0233 -0.0371 -0.0349 -0.6531 -0.0928 -0.0453 -0.0191 -0.0643 -1.1599 -0.0215 -2.1231 -0.3500 -1.1865 -2.7701 -0.5844 -0.2134 -0.1479 -0.4476 -0.2703 -0.1877 -1.8724 -0.5532 -0.0248 -0.1019 -0.1122 -0.1162 -0.6342 -0.0681
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp ; inflammatory ; biomarkers ; hscrp ; il6 ; patients ; hscrp
H-1920	-0.497457355260849	▁NT - pro b NP ▁; ▁infla mma tory ▁bio mark ers ▁; ▁h s CR p ▁; ▁il 6 ▁; ▁h s CR p
D-1920	-0.497457355260849	NT-probNP ; inflammatory biomarkers ; hsCRp ; il6 ; hsCRp
P-1920	-0.0266 -0.0459 -0.5796 -0.8026 -0.1985 -0.0651 -0.4697 -0.1747 -0.2026 -0.0337 -0.0052 -0.0496 -0.1595 -0.0412 -0.0225 -1.5392 -0.2564 -0.1182 -2.4019 -2.0204 -0.9673 -0.0994 -0.0278 -1.9506 -0.1355 -0.8507 -0.1869
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets ; in vitro ; neurohormonally ; heart disease ; nanomolar ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological ; gene induction
H-1044	-0.24808965623378754	BET s ▁; ▁neuro hormon ally ▁induc ed ▁heart ▁disease ▁; ▁j q 1 ▁; ▁ phen yle ph rine - media ted ▁hyper trop hy ▁; ▁cardio my o cy tes ▁; ▁path ological ▁gene ▁in duction
D-1044	-0.24808965623378754	BETs ; neurohormonally induced heart disease ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
P-1044	-0.7480 -0.3479 -0.1612 -0.4425 -0.0146 -0.2799 -0.3093 -0.0604 -0.4642 -0.8097 -0.1921 -0.5700 -1.5620 -0.3182 -0.3176 -0.6581 -0.1073 -0.1012 -0.1348 -0.0281 -0.0213 -0.0351 -0.1731 -0.0035 -0.0012 -0.0754 -0.2933 -0.0306 -0.1824 -0.3871 -0.0748 -0.0969 -0.3169 -0.1031 -0.1297 -0.0388 -0.0106 -0.0034 -0.1733 -0.1462
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat ; functional status ; quality of life ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; heart failure ; hospitalizations ; patients ; nyha functional class iii ; hf
H-1878	-0.6239078044891357	▁BAT ▁; ▁implant al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁burde n ▁; ▁heart ▁failure ▁; ▁GD MT - tre ated ▁NY HA ▁functional ▁class ▁III ▁ HF
D-1878	-0.6239078044891357	BAT ; implantal pro-brain natriuretic peptide ; burden ; heart failure ; GDMT-treated NYHA functional class III HF
P-1878	-0.5503 -0.4826 -3.8531 -2.7307 -0.4369 -0.0595 -0.0919 -0.2149 -0.0059 -0.0448 -0.0190 -1.5398 -0.2011 -0.0593 -0.0227 -0.2023 -2.1150 -0.0121 -0.9576 -0.1615 -0.1415 -0.5135 -0.5808 -0.6399 -0.1385 -0.0045 -0.4459 -0.7371 -0.3751 -2.9963 -0.0982 -1.2178 -0.3684 -0.0102 -0.3072 -0.1246
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated ; p70s6k ; pkc-βii ; hdl ; nyha-iiib ; malondialdehyde ; bound ; hdl ; nyha-iiib ; hdl ; healthy
H-257	-0.7600046396255493	▁p 70 s 6 K ▁; ▁PK c - β II ▁; ▁HD l ▁; ny ha - III b ▁; ▁malo ndi alde hy de ▁ bound ▁; ▁HD l ▁; NY ha - III b ▁; ▁HD l ▁; health y
D-257	-0.7600046396255493	p70s6K ; PKc-βII ; HDl ;nyha-IIIb ; malondialdehyde bound ; HDl ;NYha-IIIb ; HDl ;healthy
P-257	-0.7374 -0.8286 -0.6851 -0.5691 -3.6130 -0.0706 -0.0245 -0.7527 -0.0548 -0.0842 -0.3679 -0.0502 -2.4812 -1.5508 -0.1202 -4.5428 -0.4096 -0.0729 -0.2940 -0.0216 -0.1178 -0.0152 -0.0358 -0.0706 -0.1693 -0.0186 -2.0062 -0.0580 -0.3311 -1.6664 -1.5373 -0.1714 -3.0451 -0.8345 -0.0539 -0.3180 -0.0127 -0.3674 -1.5909 -2.0256 -0.7152 -1.3500 -0.0282 -0.1869 -0.1431
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change ; exercise ; exercise
H-1986	-0.9089215993881226	▁ ML HF ▁; ▁exercise ▁; ▁die t
D-1986	-0.9089215993881226	MLHF ; exercise ; diet
P-1986	-1.4297 -0.1209 -0.8633 -0.4039 -3.4577 -0.2241 -1.5317 -0.0859 -0.7610 -0.2111
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx ; dnx
H-1374	-1.1024127006530762	▁non pa ce ▁; ▁non - DN x ▁; ham - I nner vat ed ▁; ▁s ham - in v ▁; ▁non pa ce ▁DN x ▁; ▁h z - DN x ▁; ▁pace ▁non - DN x ▁; ▁ch f - in v ▁; ▁pace ▁; ▁DN x ▁; ▁h f - DN x
D-1374	-1.1024127006530762	nonpace ; non-DNx ;ham-Innervated ; sham-inv ; nonpace DNx ; hz-DNx ; pace non-DNx ; chf-inv ; pace ; DNx ; hf-DNx
P-1374	-6.3781 -0.0941 -0.1267 -0.5379 -3.9023 -0.2203 -0.4644 -0.0541 -0.3015 -4.2921 -0.0141 -1.2667 -0.0012 -0.0302 -0.0689 -0.4700 -4.4184 -0.5147 -0.0105 -1.7145 -0.8256 -0.4490 -2.4019 -0.0889 -0.0679 -2.1770 -0.0054 -0.1698 -4.1057 -2.7908 -0.2509 -2.3099 -0.0059 -0.1331 -3.4491 -0.4927 -0.0052 -0.9033 -0.0131 -0.1221 -3.5565 -0.2201 -0.0161 -1.1716 -0.5867 -0.2247 -3.4673 -1.1350 -1.7074 -0.0080 -0.2612 -2.9696 -0.7278 -0.0254 -1.3065 -0.0078 -0.7043 -0.1960
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc battery ; hf ; health abc hf model ; death
H-629	-0.861430823802948	▁h ABC ▁Bat tery ▁score ▁; ▁ HF ▁risk ▁; ▁Health ▁ABC ▁ HF ▁Model ▁; ▁h z ▁; ▁SD ▁; ▁death
D-629	-0.861430823802948	hABC Battery score ; HF risk ; Health ABC HF Model ; hz ; SD ; death
P-629	-0.1565 -1.0402 -2.1734 -0.0109 -0.7428 -0.0764 -0.6719 -0.0257 -2.3608 -0.0594 -1.3315 -0.0983 -0.7362 -0.0384 -1.5450 -0.1143 -1.2698 -1.6287 -0.3579 -0.5824 -0.2863 -3.8156 -1.4140 -0.1381
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection fraction ; patients ; frail ; biological phenotype ; death ; frailty ; deficit index ; death
H-1010	-0.6912117004394531	▁age ▁; ▁sex ▁; ▁e je ction ▁ fraction ▁; ▁fra il ▁; ▁bi ological ▁ph eno type ▁; ▁risk ▁of ▁death ▁; ▁fra il ty ▁; ▁deficit ▁index
D-1010	-0.6912117004394531	age ; sex ; ejection fraction ; frail ; biological phenotype ; risk of death ; frailty ; deficit index
P-1010	-5.0629 -0.0894 -1.3714 -0.1127 -0.0179 -0.2386 -0.0406 -0.1466 -0.0002 -0.2098 -1.1610 -0.1677 -0.1857 -0.0273 -0.2739 -0.4797 -0.0935 -0.0113 -0.2317 -3.2477 -1.6023 -0.5331 -0.5564 -0.8227 -0.2101 -2.1798 -0.4369 -0.1176 -0.1127 -1.5578 -0.1287
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin ; hgb ; hrqol ; hrqol ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-836	-0.42341965436935425	▁hem o glob in ▁; ▁h gb ▁; ▁HR Qo L ▁; ▁training - indu ced ▁changes ▁; ▁HR Qo L ▁; ▁patients ▁in ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - AC TION
D-836	-0.42341965436935425	hemoglobin ; hgb ; HRQoL ; training-induced changes ; HRQoL ; patients in Heart Failure ; controlled Trial Investigating Outcomes of Exercise Training ;HF-ACTION
P-836	-0.7735 -0.0778 -0.0495 -0.6805 -0.1508 -0.1172 -0.0142 -0.1002 -0.3478 -0.0440 -0.9799 -0.1204 -4.0021 -0.0234 -0.0094 -0.0460 -0.1315 -0.2271 -0.2178 -0.0223 -0.5594 -0.1171 -0.8097 -0.7676 -0.4244 -0.0361 -0.0178 -0.1496 -3.7961 -0.0641 -0.1691 -0.0134 -0.0254 -1.2836 -1.3710 -0.0649 -0.0288 -0.4660 -0.1498 -0.0072 -0.0521 -0.2000 -0.3051 -0.0053 -0.1579 -0.8905 -0.1287 -0.1282
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial fibrillation ; congestive heart failure ; health care ; expenditures ; patients ; québec ; randomized ; rhythm ; rate-control
H-1234	-0.5461989641189575	▁at rial ▁Fi bril lation ▁; ▁con ges tive ▁Heart ▁Fail ure ▁trial ▁; ▁health ▁care ▁ex pendi tures ▁; ▁patients ▁; ▁Québec ▁; ▁ rhythm ▁; ▁rate - control ▁treatment ▁; ▁coût - mini m ization
D-1234	-0.5461989641189575	atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; patients ; Québec ; rhythm ; rate-control treatment ; coût-minimization
P-1234	-0.6814 -0.0185 -1.3338 -0.0191 -0.0108 -0.2090 -0.2518 -0.0231 -0.0526 -0.1732 -0.0284 -0.0354 -1.8774 -0.2057 -0.4876 -2.6834 -0.0326 -0.0030 -0.0503 -0.1621 -1.5246 -0.4199 -0.6936 -0.1811 -0.1098 -0.3324 -0.5160 -0.2131 -0.0562 -0.2110 -1.1189 -1.6118 -2.9012 -0.0434 -0.0514 -0.0761 -1.5859 -1.0891 -0.2270
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart failure ; patient ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
H-1668	-0.46937569975852966	▁heart ▁failure ▁; ▁my o card ial ▁is cha emia ▁; ▁ta chy - ▁; ▁bra dy ar rhythm ias ▁; ▁val vu lar ▁re gur gi tation ▁; ▁pulmonar y ▁e mbol ism ▁; ▁renal ▁dys function
D-1668	-0.46937569975852966	heart failure ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; renal dysfunction
P-1668	-3.8793 -0.2033 -0.1747 -1.1474 -0.1245 -0.1814 -0.1820 -0.4377 -0.0320 -0.1087 -0.2484 -2.7474 -0.0424 -0.0088 -4.2418 -0.1052 -0.3983 -0.0799 -0.0517 -0.2272 -0.2032 -0.1635 -0.2069 -0.0920 -0.0073 -0.0262 -0.0802 -0.0312 -0.3046 -0.0036 -0.0398 -0.0470 -0.0021 -0.7844 -0.2380 -1.5473 -0.0127 -0.0620 -0.1570 -0.1441
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report ; calcineurin ; nfat ; mir-25 ; expression ; basic helix-loop-helix ; bhlh ; transcription factor ; dhand ; hand2 ; diseased ; myocardium
H-640	-0.5591567754745483	▁calci ne uri n / n fat ▁signal ling ▁; ▁mi R -25 ▁expression ▁; ▁heli x - loop - heli x ▁; ▁b HL h ▁; ▁Hand ▁; ▁disease d ▁human ▁; ▁mouse ▁my o car dium
D-640	-0.5591567754745483	calcineurin/nfat signalling ; miR-25 expression ; helix-loop-helix ; bHLh ; Hand ; diseased human ; mouse myocardium
P-640	-0.0472 -0.1729 -0.1553 -0.0858 -2.9281 -1.8011 -0.0950 -0.8375 -0.6020 -0.0670 -0.4292 -1.3097 -0.0806 -0.0320 -0.2199 -1.2706 -0.0842 -0.0150 -0.0546 -0.0811 -0.0072 -0.0330 -0.2064 -0.3469 -0.5541 -0.3209 -0.1252 -2.7879 -0.8509 -1.9998 -0.0367 -0.4327 -0.5665 -0.0751 -2.7655 -0.1433 -0.0116 -0.2660 -0.3296 -0.1384
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise ; correlated ; psss ; btes ; exercise ; psss ; btes
H-1929	-1.1145069599151611	▁Exerci se ▁time ▁; ▁PS SS ▁; ▁b tes
D-1929	-1.1145069599151611	Exercise time ; PSSS ; btes
P-1929	-3.8646 -0.1579 -2.5827 -0.0777 -0.4646 -0.4670 -0.0521 -0.1690 -0.2261 -4.0703 -0.1275
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp ; admission ; sensitivity ; specificity ; confidence interval ; area under the curve
H-269	-0.7232120037078857	▁NT - pro b NP
D-269	-0.7232120037078857	NT-probNP
P-269	-0.2131 -0.0224 -0.0216 -0.6678 -0.2934 -3.7008 -0.1434
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic ; r-r interval ; hr variability ; short-term fractal scaling exponent ; prognostic
H-1588	-0.5459200143814087	▁prognos tic ▁power ▁; ▁r - R ▁interval ▁os cilla tions ▁; ▁HR ▁variabil ity ▁; ▁short - term ▁fra c tal ▁scal ing ▁ex ponent
D-1588	-0.5459200143814087	prognostic power ; r-R interval oscillations ; HR variability ; short-term fractal scaling exponent
P-1588	-2.2809 -0.3800 -0.1586 -0.1436 -0.9623 -0.1095 -1.2296 -0.5052 -1.5764 -0.0049 -0.0342 -0.1280 -2.5831 -0.7680 -0.1172 -0.1193 -0.5353 -0.0136 -0.2806 -1.0069 -0.1795 -0.1573 -0.1351 -0.0769 -1.2441 -0.1152 -0.3248 -0.1157
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic function ; diastolic filling formalism ; relaxation ; doppler mitral inflow velocity ; e-wave
H-921	-0.32196488976478577	▁dia sto lic ▁fill ing ▁formal ism ▁; ▁relax ation ▁; vis co ela stic ▁; ▁passiv e / sti ff ness ▁; ▁do pp ler ▁mit ral ▁in flow ▁veloci ty ▁; ▁e - wa ve
D-921	-0.32196488976478577	diastolic filling formalism ; relaxation ;viscoelastic ; passive/stiffness ; doppler mitral inflow velocity ; e-wave
P-921	-0.9033 -0.0724 -0.1796 -1.0835 -0.0540 -1.1095 -0.2151 -0.1124 -0.0396 -0.0097 -1.1215 -0.0380 -0.0074 -0.0101 -0.0070 -0.2705 -0.0830 -0.0316 -1.4747 -0.1616 -0.2126 -0.1047 -0.1177 -0.3703 -0.0596 -0.6866 -0.9367 -0.0782 -0.0304 -0.2690 -1.3639 -0.4354 -0.1506 -0.2492 -0.0131 -0.0987 -0.0241 -0.2185 -0.1531
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart failure ; hf ; patients ; spontaneous ventricular tachycardia ; hf ; patients ; spontaneous vt ; hearts
H-1437	-0.6849306225776672	▁heart ▁failure ▁; HF ▁; ▁vent ri cular ▁ta chy car dia ▁; HF VT ▁; ▁ HF ▁; ▁ VT ▁; ▁h n m
D-1437	-0.6849306225776672	heart failure ;HF ; ventricular tachycardia ;HFVT ; HF ; VT ; hnm
P-1437	-0.8769 -0.4337 -0.1488 -0.1467 -0.2147 -0.1701 -1.7476 -0.2167 -1.5527 -0.2691 -0.0369 -0.4303 -0.1212 -1.2747 -0.8952 -0.1436 -1.0577 -0.4379 -0.6901 -1.6429 -1.0935 -0.1003 -0.5901 -3.2624 -0.0559 -0.7341 -0.1491
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke ; estimated glomerular filtration rate ; lvef
H-819	-0.39770644903182983	▁gr s ▁; ▁co x ▁model ▁; ▁chronic ▁heart ▁failure ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁prior ▁stroke ▁score ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁LV EF ▁; ▁CV
D-819	-0.39770644903182983	grs ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; CV
P-819	-0.4092 -1.8089 -0.1063 -0.2050 -0.0104 -0.3634 -0.1886 -0.5588 -0.5566 -0.2695 -0.1235 -0.0049 -0.0686 -0.0838 -0.1611 -0.0460 -1.5907 -0.1067 -0.3346 -0.0646 -0.0691 -0.0101 -0.1109 -0.1300 -0.0349 -0.5859 -0.1130 -0.1146 -0.0788 -0.1509 -3.8876 -0.6739 -0.1033
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient ; vad ; patients ; ventricular assist device ; ecmo ; patients ; extracorporeal membrane oxygenation ; ecmo ; vad ; patients ; ecmo ; vad
H-1387	-0.6136260032653809	▁vent ri cular ▁assist ▁device ▁support ▁; ▁EC mo ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁membran e ▁support ▁; ▁ VAD
D-1387	-0.6136260032653809	ventricular assist device support ; ECmo ; extracorporeal membrane oxygenation membrane support ; VAD
P-1387	-0.4961 -1.0608 -0.1213 -0.3125 -0.1995 -0.8309 -0.0744 -0.9398 -1.6009 -0.4867 -1.5261 -0.0591 -0.9120 -0.2985 -0.0082 -0.1791 -0.2503 -0.1288 -0.0171 -0.1546 -1.5393 -0.2290 -3.1119 -0.1233 -0.9993 -0.2947
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic events ; ies ; patients ; ischemic cardiomyopathy ; ic ; cardiac resynchronization therapy ; defibrillator ; crt-d
H-102	-0.40620848536491394	▁ ische mic ▁events ▁; IE s ▁; ▁ ische mic ▁cardio my o pathy ▁; IC ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁c rte - d ▁; ▁device
D-102	-0.40620848536491394	ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; crte-d ; device
P-102	-1.5651 -0.8401 -0.1513 -0.5002 -0.2017 -0.5956 -0.0521 -0.2234 -0.8503 -0.6445 -0.1661 -0.0669 -0.7176 -1.1068 -0.0276 -0.1614 -0.1539 -0.2280 -0.0300 -0.0204 -0.0240 -0.0063 -0.5758 -0.5610 -0.0143 -0.1664 -0.0986 -0.6266 -0.1907 -0.0117 -0.0884 -0.2719 -0.6066 -2.0220 -0.0413 -0.5250 -1.3454 -0.4519 -0.1225 -0.1948
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart failure ; disease ; evidence-based ; health care
H-2016	-0.83050936460495	▁coût - effect ive ness ▁; ▁heart ▁failure ▁disease ▁management
D-2016	-0.83050936460495	coût-effectiveness ; heart failure disease management
P-2016	-1.2473 -0.1576 -0.2977 -0.0764 -1.8483 -0.3998 -0.2320 -0.2448 -1.2095 -0.2011 -3.9117 -0.1398
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin ; heart failure ; murine ; resistin ; transgenic ; retn ; gene ; resistin
H-930	-0.543556809425354	▁human ▁resist in ▁in ▁heart ▁failure ▁; ▁human ized ▁mouse ▁; ▁mur ine ▁resist in ▁; ▁trans ge nic ▁; ▁human ▁Ret n ▁gene ▁; ▁h um - re t n ▁mi ce ▁; ▁bas al ▁; ▁ inflammation - stimul ated ▁resist in
D-930	-0.543556809425354	human resistin in heart failure ; humanized mouse ; murine resistin ; transgenic ; human Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin
P-930	-3.2024 -2.3115 -0.3848 -0.4876 -0.1849 -0.0785 -0.1664 -2.3654 -0.7656 -0.1189 -1.1665 -0.1627 -0.2462 -0.4902 -0.3850 -0.0884 -0.8205 -0.0196 -0.0699 -0.3050 -3.2139 -0.0924 -0.0074 -0.3825 -0.1118 -0.3175 -0.1425 -0.0050 -1.4863 -0.0385 -0.0059 -0.6793 -0.0651 -0.3373 -0.0335 -0.0073 -1.5322 -0.0443 -0.1606 -0.0183 -0.0113 -0.5182 -0.3618 -0.2075 -1.2397 -0.1636
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients ; angiotensin-converting enzyme inhibitors ; angiotensin receptors blockers ; β-blockers
H-1745	-0.4358659088611603	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor s ▁block ers ▁; ▁β - block ers ▁; ▁devices
D-1745	-0.4358659088611603	angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers ; devices
P-1745	-0.5027 -1.2550 -0.2519 -1.1222 -0.1545 -0.0259 -0.0518 -2.2630 -0.0738 -0.0986 -0.0507 -1.6865 -0.4733 -0.0990 -0.0064 -0.6481 -0.0319 -0.0861 -1.2414 -0.1454 -0.2271 -0.0490 -0.0056 -0.0357 -0.0595 -1.0861 -0.4214 -0.2644 -0.2232
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ; tac
H-1815	-0.3632010817527771	▁t t t Men a ▁mi ce ▁; ▁cardiac ▁injury ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁heart ▁di la tation ▁; ▁hyper trop hy ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC
D-1815	-0.3632010817527771	tttMena mice ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
P-1815	-1.9692 -0.2436 -0.6547 -3.5997 -0.2735 -1.1687 -0.1136 -0.1667 -0.1629 -0.1330 -0.1887 -0.5355 -0.1648 -0.0644 -0.1099 -0.0018 -0.1801 -0.3268 -0.0009 -0.3549 -1.0360 -0.0736 -0.1704 -0.1261 -0.3255 -0.4760 -0.7447 -0.0072 -0.2137 -0.0424 -0.0061 -0.0666 -0.1384 -0.0009 -0.1201 -0.0201 -0.2226 -0.6520 -0.0125 -0.1907 -0.1011 -0.8342 -0.0606 -0.1381 -0.1513
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation for ambulatory heart failure trial ; implantable ; primary end point ; all-cause mortality ; heart failure ; hospitalization
H-882	-0.3212567865848541	▁re syn chron ization - Def i bril lation ▁; ▁Amb ulator y ▁Heart ▁Fail ure ▁Tri al ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT ▁; ▁heart ▁failure
D-882	-0.3212567865848541	resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-CRT ; heart failure
P-882	-0.4682 -0.0066 -0.0031 -0.3557 -0.0129 -0.0714 -0.3483 -0.0850 -0.0033 -1.1803 -0.0136 -0.0120 -0.0186 -0.0751 -0.0159 -0.0245 -0.6580 -0.0232 -0.1171 -0.0002 -0.0232 -0.1115 -0.0795 -0.0285 -0.0104 -1.0151 -0.3288 -0.0026 -0.0436 -0.0426 -1.0608 -0.7108 -0.1761 -3.2134 -0.4080 -1.0516 -0.0869
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart failure ; patients ; italy ; confirmatory factor analysis ; cfa ; schfi v.6.2 ; self-care maintenance ; self-care management ; self-care confidence
H-1505	-0.5024418830871582	▁heart ▁failure ▁; ▁Italy ▁; ▁c fa ▁; ▁ SCH FI ▁; Sel f - Car e ▁Main ten ance ▁; ▁Self - Car e ▁Management ▁; ▁Self - Car e ▁Confi den ce
D-1505	-0.5024418830871582	heart failure ; Italy ; cfa ; SCHFI ;Self-Care Maintenance ; Self-Care Management ; Self-Care Confidence
P-1505	-2.3837 -0.2205 -1.1430 -0.6952 -0.1470 -1.2946 -0.4737 -0.1140 -1.4683 -0.3040 -2.4932 -0.1050 -0.3969 -0.0698 -0.0188 -1.2826 -0.0369 -0.1532 -0.1229 -0.0114 -0.1297 -0.1608 -0.0057 -0.9589 -0.0255 -0.9888 -0.1214 -0.1143 -0.0038 -0.8221 -0.0299 -1.2700 -0.1028 -0.0200 -0.2487 -0.1505
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional status ; 6-mwt ; nyha class ; patients ; hfpef ; hfref ; prescribed ; therapy ; patients ; hfpef ; death ; hf ; hospitalization
H-244	-0.593693733215332	▁mw t ▁; ▁NY ha ▁class ▁; ▁ HF p EF ▁; ▁h Fr EF ▁; ▁ therapy ▁; ▁h f p EF ▁; ▁ HF p EF
D-244	-0.593693733215332	mwt ; NYha class ; HFpEF ; hFrEF ; therapy ; hfpEF ; HFpEF
P-244	-1.0472 -0.0876 -0.0762 -0.1127 -0.5744 -1.0894 -0.2998 -1.1935 -0.2676 -0.0568 -0.0999 -0.0584 -0.1178 -1.4106 -0.3566 -0.1923 -1.5473 -0.4906 -0.2524 -1.4050 -0.8908 -0.0835 -0.2628 -0.2431 -1.5065 -0.1503 -0.5355 -0.2529 -2.9631 -0.1862
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; follow-up ; mortality ; ischemic cardiomyopathy
H-69	-0.1942555457353592	▁renal ▁dys function ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i CD ▁shock s ▁; ▁mortal ity ▁; ▁ ische mic ▁cardio my o pathy
D-69	-0.1942555457353592	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
P-69	-0.1957 -0.0072 -0.0969 -0.0646 -0.0590 -0.1193 -0.0416 -0.0391 -0.0035 -0.0892 -0.7148 -0.0592 -0.0477 -0.0474 -0.0361 -0.1319 -0.0257 -0.2000 -0.0997 -0.0888 -0.2621 -0.0903 -0.5458 -0.0118 -1.2087 -0.1366 -0.1015 -0.1742 -0.2385 -0.3440 -0.0014 -0.2462 -0.3448 -0.1497 -0.2369 -0.0147 -0.2377 -0.1593 -0.2867 -0.0745 -0.2641 -0.1770 -0.1249 -0.0260 -0.3684 -0.2572 -0.0320 -1.0408 -0.1958
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold proteins ; cardiac remodelling ; field ; therapeutic
H-996	-0.31722766160964966	▁Raf - MEK 1/2 - ER k 1/2 ▁sc af fold ▁protein s ▁; ▁adapt ive ▁; ▁mal adapt ive ▁cardiac ▁remodel ling
D-996	-0.31722766160964966	Raf-MEK1/2-ERk1/2 scaffold proteins ; adaptive ; maladaptive cardiac remodelling
P-996	-0.1323 -0.0382 -0.0164 -0.6242 -0.0912 -0.7752 -0.4848 -0.3002 -0.9916 -0.1556 -0.0414 -0.6157 -0.0167 -0.1952 -1.3609 -0.0083 -0.8431 -0.1710 -0.0417 -0.0084 -0.0181 -0.0178 -0.1609 -0.7686 -0.0535
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients ; chf ; testosterone ; exercise ; testosterone ; placebo
H-1318	-0.5925512909889221	▁CHF ▁; ▁SD ▁testosteron e ▁; ▁testosteron e
D-1318	-0.5925512909889221	CHF ; SD testosterone ; testosterone
P-1318	-0.2101 -0.1529 -0.7954 -0.4535 -0.0643 -0.4541 -2.8350 -0.0870 -0.7543 -0.1188
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional ms ; lv dilatation ; heart failure ; hf ; functional ms ; hf ; prolapse ; degenerative mitral valve
H-341	-0.47602951526641846	▁functional ▁MS ▁; ▁LV ▁di la tation ▁; ▁heart ▁failure ▁; HF ▁; ▁LV ▁; ▁functional ▁MS ▁; ▁ HF ▁; ▁MR ▁; ▁de genera tive ▁mit ral ▁val ve
D-341	-0.47602951526641846	functional MS ; LV dilatation ; heart failure ;HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
P-341	-2.5050 -0.0935 -0.1320 -0.2162 -0.5174 -0.1506 -0.0026 -0.1063 -2.5809 -0.1002 -0.0848 -1.2597 -0.0497 -0.1799 -0.2482 -1.8273 -0.1867 -0.2987 -1.0363 -0.1634 -0.0522 -0.9314 -0.1361 -1.1694 -0.2207 -0.0188 -0.3005 -0.0625 -0.0929 -0.0371 -0.3885 -0.0835
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new york heart association class ; kccq ; symptom ; spearman correlations ; 2-way anova ; patients ; hf with reduced ef ; hfpef
H-783	-0.8074030876159668	▁New ▁York ▁Heart ▁association ▁class ▁; ▁k cc q ▁; ▁symptom ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-783	-0.8074030876159668	New York Heart association class ; kccq ; symptom ; HF ; EF ; HFpEF
P-783	-2.9556 -0.3822 -0.9372 -1.0896 -0.6863 -0.1226 -0.2725 -0.0422 -0.6844 -0.1603 -3.4859 -0.3168 -2.0151 -0.9340 -0.1206 -3.2547 -0.0958 -0.2168 -0.1951 -0.0411 -0.1591 -0.2569 -0.1456
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; patients ; heart failure ; medications ; medical
H-1130	-0.4228033423423767	▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure
D-1130	-0.4228033423423767	angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure
P-1130	-1.3544 -2.1443 -0.2101 -0.3762 -0.0038 -0.2488 -0.0636 -0.0641 -0.0519 -0.2262 -0.0912 -0.0771 -1.1187 -0.2994 -0.5395 -0.0991 -0.0055 -0.2159 -1.2766 -0.1062 -0.1537 -0.2811 -0.0060 -0.0470 -0.0537 -0.3348 -1.4054 -0.3164 -1.3141 -0.1992
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang ii infusion ; ang ii infusion ; uninephrectomy ; ang ii infusion ; salt loading ; ang ii infusion ; uninephrectomy ; salt loading
H-276	-0.9560413956642151	▁c 57 bl ▁; ▁ANG ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁ang ▁; ▁salt ▁load ing ▁; as ▁; ▁ANG ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁salt ▁load ing ▁; ANS
D-276	-0.9560413956642151	c57bl ; ANG II infusion ; uninephrectomy ; ang ; salt loading ;as ; ANG II infusion ; uninephrectomy ; salt loading ;ANS
P-276	-1.2213 -1.9341 -2.6261 -0.2698 -3.4688 -2.2716 -0.0307 -0.2486 -0.1338 -1.6119 -0.2301 -2.0677 -0.1628 -0.1021 -0.4302 -0.2112 -3.6370 -2.1155 -1.1834 -0.0440 -0.0176 -0.3425 -3.8097 -0.2859 -2.3807 -1.8347 -0.0326 -0.2393 -0.2417 -0.1093 -0.1937 -1.8816 -0.1491 -0.1721 -0.5130 -0.3732 -0.5166 -0.0929 -0.0228 -1.4165 -1.9869 -0.3321 -0.1645
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral blood flow velocity ; tissue doppler ; diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcwp ; patients ; decompensated systolic heart failure ; hf
H-480	-0.8021625876426697	▁early ▁transmit ral ▁blood ▁flow ▁; ▁tissu e ▁; ▁do pp ler ▁; ▁dia sto lic ▁mit ral ▁ann ulus ▁; ▁pulmonar y ▁cap illa ry ▁we dge ▁pressure ▁; PC WP ▁; ▁de com pensa ted ▁sy sto lic ▁heart ▁failure ▁; HF
D-480	-0.8021625876426697	early transmitral blood flow ; tissue ; doppler ; diastolic mitral annulus ; pulmonary capillary wedge pressure ;PCWP ; decompensated systolic heart failure ;HF
P-480	-5.4786 -1.8367 -0.4781 -0.8800 -0.2117 -0.6519 -3.1743 -0.2359 -0.6899 -0.4458 -0.0156 -0.4091 -0.5877 -5.7717 -1.2445 -0.6387 -1.5044 -0.0590 -0.9721 -0.4728 -1.6707 -0.3148 -0.0214 -0.1653 -0.0044 -0.0282 -0.9518 -0.0131 -0.9200 -0.1096 -0.5982 -0.3907 -0.0985 -2.3255 -0.0210 -0.0083 -0.3558 -0.2473 -0.4154 -1.5150 -0.2376 -0.1028 -0.2940 -0.0729 -0.1678 -0.0910
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic ; lv ejection fraction ; lv strain ; strain ; systole ; diastolic ; lv strain rate ; diastole ; transmitral flow ; patients ; sinus rhythm ; follow-up
H-951	-0.7426064014434814	▁LV ▁; ▁e je ction ▁ fraction ▁; ▁LV ▁; ▁strain ▁; ▁stra in ▁rate ▁; ▁sy stol e ▁; ▁dia sto lic ▁indice s ▁; ▁LV ▁; ▁strain ▁rate ▁; ▁dia stol e ▁; ▁early ▁transmit ral ▁flow ▁; ▁sinus ▁ rhythm
D-951	-0.7426064014434814	LV ; ejection fraction ; LV ; strain ; strain rate ; systole ; diastolic indices ; LV ; strain rate ; diastole ; early transmitral flow ; sinus rhythm
P-951	-0.3622 -1.4718 -1.2581 -1.0756 -0.1202 -0.0658 -0.0005 -0.1016 -0.1054 -1.0618 -1.1017 -0.8751 -3.2504 -0.3466 -0.1935 -0.5148 -2.3560 -0.0706 -0.1584 -0.2813 -0.7655 -1.3383 -0.1376 -0.0382 -0.0107 -0.0896 -0.6233 -0.8680 -3.1790 -1.7814 -0.2410 -1.0865 -0.0248 -0.1696 -0.3282 -3.5357 -1.4080 -0.2435 -0.5934 -0.8671 -0.7250 -0.0522 -0.1437 -0.2287 -0.1672
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak vo2 ; exercise
H-1984	-1.3869168758392334	▁VO 2 ▁; ▁exercise ▁; ▁body ▁mass
D-1984	-1.3869168758392334	VO2 ; exercise ; body mass
P-1984	-2.6842 -0.0834 -0.4589 -3.0929 -0.3388 -3.4478 -0.3660 -1.6880 -0.3224
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard ratios ; confidence interval ; hf ; hf
H-1107	-0.9136106967926025	▁age - ▁; ▁sex - ad just ed ▁risk ▁; ▁hazard ▁ratio s ▁; ▁cim ▁; ▁early - ons et ▁ HF
D-1107	-0.9136106967926025	age- ; sex-adjusted risk ; hazard ratios ; cim ; early-onset HF
P-1107	-0.5273 -0.0555 -3.6959 -0.6695 -0.0267 -0.0086 -0.0019 -0.0328 -0.4613 -0.1175 -2.6461 -0.2794 -0.0621 -0.1689 -5.2335 -0.1461 -1.8614 -0.0614 -0.2144 -0.6830 -0.4768 -0.0936 -4.2073 -0.1957
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami ; patient ; hospital ; hospital compare ; p-value
H-1698	-0.9781389236450195	▁ AMI ▁; ▁hospital ▁; ▁hospital ▁; ▁odds ▁; ▁dy ing
D-1698	-0.9781389236450195	AMI ; hospital ; hospital ; odds ; dying
P-1698	-1.1483 -0.0387 -1.4883 -0.2404 -0.4511 -3.0371 -0.6095 -3.3639 -1.2265 -0.2715 -0.1209 -0.5519 -0.1677
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass spectrometry ; c-terminally ; nt-probnp ; physiological ; proteolysis
H-1517	-0.4982830584049225	▁Mass ▁spec tro met ry ▁; ▁N - ▁; ▁c - termin ally ▁process ed ▁form s ▁; ▁circula ting ▁NT - pro b NP ▁; ▁physio logic al ▁prote ol ysis ▁; ▁le u 3 ▁; ▁gr ly 4 ▁; ▁figure
D-1517	-0.4982830584049225	Mass spectrometry ; N- ; c-terminally processed forms ; circulating NT-probNP ; physiological proteolysis ; leu3 ; grly4 ; figure
P-1517	-1.8723 -0.4380 -0.0295 -0.0426 -0.1168 -0.1310 -2.2891 -0.0425 -1.3459 -0.3245 -0.0480 -0.0160 -0.3429 -1.0308 -0.1045 -0.2660 -0.0588 -0.5984 -0.0259 -1.2222 -0.0944 -0.0096 -0.0197 -1.0377 -0.1421 -0.1642 -0.0285 -0.2268 -0.0103 -0.1130 -0.0694 -0.1490 -0.2687 -0.9075 -0.0204 -0.7867 -0.4341 -1.6760 -1.0743 -0.7602 -0.2596 -2.5170 -0.6910 -0.1186
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt ; nt-probnp ; report ; ctnt ; nt-probnp ; clinical ; hf
H-292	-0.42026108503341675	▁c t n t ▁; ▁NT - pro b NP ▁; ▁laborator y ▁report ▁; ▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF
D-292	-0.42026108503341675	ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF
P-292	-3.7666 -0.1299 -0.0560 -0.2890 -0.0630 -0.2579 -0.0216 -0.0124 -0.8349 -0.1622 -0.1589 -1.7829 -0.0296 -0.0980 -0.4064 -0.0726 -0.1845 -0.0216 -0.3201 -0.0783 -0.6440 -0.0165 -0.0367 -0.5799 -0.2354 -0.2900 -0.3243 -0.2311 -1.2977 -0.2058
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef ; patients ; new york heart association class ii ; ejection fraction ; fes ; placebo
H-1329	-0.8486785888671875	▁ HF p EF ▁; ▁New ▁York ▁Heart ▁Association ▁class ▁II ▁; ▁mean ▁e je ction ▁ fraction
D-1329	-0.8486785888671875	HFpEF ; New York Heart Association class II ; mean ejection fraction
P-1329	-0.4882 -0.1603 -0.0922 -0.3568 -0.6326 -2.7339 -0.6160 -1.1909 -0.8731 -0.9233 -0.7445 -0.2018 -3.1888 -0.0527 -0.4485 -0.1029 -0.2443 -0.0026 -3.7606 -0.1597
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left ventricular ; systolic pressure ; ejection fraction ; fractional shortening ; cardiac output ; lv end-diastolic pressure ; mi ; metoprolol
H-1548	-0.4830823242664337	▁de press ed ▁left ▁vent ri cular ▁; LV ▁; ▁pressure ▁; ▁pressure ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁cardiac ▁output ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; ▁mis ▁; ▁met o pro lol
D-1548	-0.4830823242664337	depressed left ventricular ;LV ; pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV ; end-diastolic pressure ; mis ; metoprolol
P-1548	-0.4700 -0.0094 -0.1235 -0.4287 -0.0257 -1.4351 -0.2481 -0.2656 -0.1747 -0.2560 -2.9102 -0.0797 -2.2409 -0.2675 -0.2077 -0.2726 -0.0332 -0.0705 -0.0016 -0.1212 -0.4878 -0.0010 -0.4419 -0.2781 -0.0852 -0.2292 -0.1323 -0.8838 -0.3490 -0.1323 -0.2023 -0.3827 -2.8555 -0.0087 -0.1589 -0.3299 -0.5013 -0.9875 -0.0892 -2.3233 -0.9605 -0.8490 -0.0703 -0.0149 -0.0717 -0.1111 -0.1255
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction ; clinical ; carotid ; baroreflex activation therapy ; bat ; heart failure ; hf
H-1867	-0.5251480937004089	bar ore flex ▁Activ ation ▁Therapy ▁; ▁Heart ▁Fail ure ▁; ▁Red u ced ▁e je ction ▁Fra ction ▁; ▁caro tid ▁baro re flex ▁activa tion ▁ therapy ▁; BAT ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1867	-0.5251480937004089	baroreflex Activation Therapy ; Heart Failure ; Reduced ejection Fraction ; carotid baroreflex activation therapy ;BAT ; advanced heart failure ;HF
P-1867	-5.4329 -1.8910 -0.0855 -0.9881 -0.0176 -0.0817 -0.0888 -0.4323 -0.0849 -0.0429 -0.1163 -0.4861 -0.0194 -0.7658 -0.5653 -0.0639 -0.0192 -0.2896 -0.0077 -0.5309 -1.7458 -0.0867 -1.4087 -0.2347 -0.0629 -1.4363 -0.0614 -0.2726 -0.0310 -0.1126 -0.0979 -0.1555 -1.9333 -0.1735 -0.1321 -0.3067 -0.0360 -0.1012 -0.0819
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome ; hazard ratio
H-1748	-1.205002784729004	▁en roll ment
D-1748	-1.205002784729004	enrollment
P-1748	-2.8455 -0.0193 -0.0822 -2.8843 -0.1936
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf ; blood glucose ; obesity ; systemic hypertension ; rheumatic fever ; disease
H-1793	-0.46743911504745483	▁ HF ▁; ▁ HF ▁; ▁raised ▁blood ▁gluco se ▁; ▁obes ity ▁; ▁to ba cco ▁; ▁ aging ▁; ▁system ic ▁hyper tension ▁; SH ▁; ▁rhe u matic ▁fe ver ▁; ▁Cha gas ' ▁disease ▁; ▁c d
D-1793	-0.46743911504745483	HF ; HF ; raised blood glucose ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; Chagas' disease ; cd
P-1793	-2.0366 -0.0278 -0.2360 -3.6950 -0.0776 -0.1661 -1.3674 -0.4998 -0.0084 -0.0186 -0.6892 -0.7828 -0.3839 -0.0835 -0.0934 -0.0760 -0.0237 -0.1373 -0.0180 -0.0534 -0.1742 -0.7767 -0.3622 -0.0072 -0.0280 -0.0975 -0.1259 -0.0303 -0.0441 -0.0391 -0.0963 -0.0007 -0.0272 -0.0825 -0.5629 -0.0315 -2.4451 -0.1243 -0.1227 -0.9195 -2.0248 -1.3455 -0.1574
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard ratios ; crf ; obese ; body mass index
H-1772	-0.7986047863960266	▁c RF ▁; ▁normal ▁; ▁over weight ▁; ▁obes e ▁body ▁mass ▁index
D-1772	-0.7986047863960266	cRF ; normal ; overweight ; obese body mass index
P-1772	-2.1048 -1.4574 -0.3676 -2.5684 -1.2022 -0.4882 -0.0792 -0.2356 -0.0630 -0.0812 -1.7073 -0.5671 -0.1269 -0.7383 -0.1917
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq ; patients ; hfpef ; log rank ; ef
H-789	-0.959764838218689	▁k cc q ▁; ▁ HF p EF
D-789	-0.959764838218689	kccq ; HFpEF
P-789	-1.0897 -0.0264 -1.1038 -0.3473 -1.5450 -0.3742 -0.0240 -0.7817 -4.0718 -0.2338
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline ; egfr ; egfr ; egfr ; hypertension ; diuretics ; esrd
H-395	-0.6175497174263	▁e g FR ▁; ▁e g FR ▁; ▁e g FR ▁; ▁un control led ▁hyper tension ▁; ▁di ure tics ▁; ▁temps ▁; ▁ES RD
D-395	-0.6175497174263	egFR ; egFR ; egFR ; uncontrolled hypertension ; diuretics ; temps ; ESRD
P-395	-0.3316 -1.5732 -1.1995 -0.8261 -0.1430 -1.6903 -0.9873 -1.0491 -0.3889 -1.5980 -0.7747 -1.1666 -0.8563 -0.1328 -0.2308 -0.0171 -0.0926 -0.0749 -0.3555 -0.0968 -0.4691 -0.1726 -1.7844 -0.5750 -0.2934 -0.0664 -0.1752 -0.1705
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial ; phosphodiesterase-2 ; pde2 ; heart failure ; hf ; beta-adrenergic receptor ; β-ar ; healthy ; diseased ; cardiomyocytes
H-1208	-0.35787850618362427	▁my o card ial ▁ phos pho dies tera se -2 ▁; ▁p de 2 ▁; ▁heart ▁failure ▁; HF ▁; ▁p de 2- media ted ▁effects ▁; ▁beta - ad r energi c ▁receptor ▁; β - AR ▁; ▁cardio my o cy tes
D-1208	-0.35787850618362427	myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
P-1208	-0.9579 -0.1344 -0.0860 -1.0082 -0.1103 -0.0324 -0.7849 -0.7439 -0.0756 -0.8222 -0.5252 -0.1672 -0.2639 -0.0334 -1.2684 -0.1158 -0.2482 -0.1420 -0.1272 -0.1467 -0.0910 -0.3009 -0.0374 -0.3004 -2.5634 -0.1099 -0.2607 -0.5092 -0.1684 -0.0082 -0.0569 -0.0994 -0.2868 -0.1011 -0.0086 -0.3482 -0.4146 -0.0031 -0.0666 -0.5407 -1.5841 -0.2591 -0.2621 -0.1266 -0.1730 -0.1842 -0.1618
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart failure ; patients ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator ; carvedilol ; atp ; shock therapy ; metoprolol
H-866	-0.33882585167884827	▁heart ▁failure ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁device ▁; ▁car vedi lol ▁; ▁ATP ▁; ▁shock ▁ therapy ▁; ▁met o pro lol
D-866	-0.33882585167884827	heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
P-866	-0.8731 -0.2292 -0.5440 -0.0527 -0.0135 -0.0363 -0.0040 -0.5302 -0.9376 -0.0415 -0.1319 -0.0433 -1.7745 -1.5465 -0.0290 -0.1922 -0.1089 -0.0007 -0.0143 -0.1803 -0.1158 -0.1207 -0.0143 -0.0839 -2.4107 -1.3556 -0.0188 -0.2062 -1.0306 -0.1716 -0.0425 -0.0144 -0.0652 -0.1507 -1.2065 -0.2291 -0.1078 -0.0817 -0.0168 -0.2436 -0.0307 -0.0656 -0.0093 -0.0887 -0.2636 -0.1577
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich cocoa ; skm ; mitochondrial structure ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; murphy ; naviaux ; hogan ; ceballos ; maisel ; henry
H-1245	-0.26332005858421326	ERC ▁; ▁e pica tech in - rich ▁coco a ▁; ▁Sk m ▁mito cho ndri al ▁structure ▁; ▁ram i rez - s anche z ▁; ▁ci ar aldi ▁; ▁per kin s ▁; ▁Murphy ▁; ▁na vi aux ▁; ▁Hoga n ▁; ▁ce ball os ▁; ▁mais el ▁; ▁Henry
D-1245	-0.26332005858421326	ERC ; epicatechin-rich cocoa ; Skm mitochondrial structure ; ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; maisel ; Henry
P-1245	-0.6977 -0.2778 -0.1547 -0.0035 -0.0364 -0.4867 -0.0449 -0.0005 -0.0648 -0.0289 -0.1712 -0.2091 -0.1592 -0.2117 -0.6201 -0.0953 -0.0200 -0.1143 -0.2321 -3.1557 -0.3363 -0.0697 -0.0018 -1.5803 -0.0092 -0.0013 -0.1268 -0.4252 -0.0136 -0.0014 -0.1401 -0.5408 -0.0514 -0.0070 -0.1938 -0.0201 -0.1175 -0.1497 -0.0160 -0.0067 -0.3220 -0.0050 -0.0044 -0.2630 -0.0531 -0.0259 -0.4721 -0.2477 -0.9301 -0.0008 -0.3954 -0.6707 -0.1150 -0.1208
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up ; death ; readmission ; patients ; physician ; physicians
H-1420	-1.319238543510437	▁death ▁; ▁urgent ▁read mission
D-1420	-1.319238543510437	death ; urgent readmission
P-1420	-6.1341 -0.1627 -0.2277 -0.8363 -0.0797 -1.6626 -0.1315
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena overexpression ; tac ; surgery ; mena ; cardiac hypertrophy ; cardiac
H-1816	-0.8334038257598877	▁men a ▁over expression ▁; ▁ TTA ▁; ▁t g t et Men a ▁mi ce ▁; ▁ TAC ▁surgery ▁; ▁cardiac ▁hyper trop hy ▁; ▁ TTA ▁; ▁t g t et Men a ▁; ▁ TAC ▁cardiac ▁functional ▁deteriora tion
D-1816	-0.8334038257598877	mena overexpression ; TTA ; tgtetMena mice ; TAC surgery ; cardiac hypertrophy ; TTA ; tgtetMena ; TAC cardiac functional deterioration
P-1816	-1.2645 -0.6379 -3.4958 -0.1265 -0.0860 -3.3409 -0.4439 -0.3332 -4.1395 -0.4321 -0.1312 -2.8170 -0.3596 -0.1986 -0.5420 -0.1041 -0.0715 -1.2590 -0.1570 -1.6317 -0.1054 -3.0059 -0.1275 -0.0046 -0.0752 -0.0979 -1.6835 -0.5031 -0.3872 -0.7592 -0.0490 -0.0603 -0.9443 -0.2802 -0.0856 -1.1882 -1.7153 -0.6537 -1.8906 -0.8920 -0.2008 -0.0815 -0.1309 -0.1758
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography ; lv end-diastolic volume ; mitral valve opening ; mva
H-357	-0.4789165258407593	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁; ▁ml ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁m va ▁; ▁pression ▁gradi ent ▁; ▁h g
D-357	-0.4789165258407593	echocardiography ; LV ; end-diastolic volume ; ml ; MR ; mitral valve opening ; mva ; pression gradient ; hg
P-357	-0.1004 -0.3396 -0.0434 -0.3659 -0.2448 -0.1343 -1.0949 -0.5560 -2.3830 -0.0091 -0.0729 -0.3444 -0.3045 -0.2365 -0.2293 -0.8276 -1.9294 -1.1648 -0.1806 -0.9948 -0.0592 -0.1242 -0.0641 -0.5583 -0.2769 -0.4154 -0.2954 -0.1509 -2.2077 -0.2527 -0.1192 -0.5617 -0.0486 -0.0160 -0.4111 -0.1234
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd ; diuretic ; hf ; outcomes ; clinical ; hospitalizations ; pdrelated ; complications
H-901	-0.5414062142372131	▁p ▁; ▁di ure tic ▁re frac tory ▁severe - end - s tage ▁ HF
D-901	-0.5414062142372131	p ; diuretic refractory severe-end-stage HF
P-901	-2.6557 -0.1681 -0.2453 -0.0091 -1.4028 -0.0080 -0.0192 -0.3304 -1.0355 -0.0279 -0.2908 -0.0187 -0.1365 -0.0013 -0.5173 -0.0241 -2.7558 -0.0987
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial ; glycolysis
H-1785	-0.34065696597099304	▁ATP ▁production ▁; ▁a ac ▁; ▁mito cho ndri al ▁oxid ation ▁; ▁gluco se ▁; ▁lac tate ▁; ▁fa tty ▁acid s ▁; ▁my o card ial ▁gly col ysis
D-1785	-0.34065696597099304	ATP production ; aac ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
P-1785	-0.1041 -0.4492 -1.8778 -0.7556 -2.1912 -0.1557 -0.0680 -0.3339 -0.0347 -0.0216 -0.0174 -0.0165 -0.1943 -0.0379 -0.0233 -0.2098 -0.0254 -0.0502 -0.1626 -0.1109 -0.2099 -0.0197 -0.0155 -0.2365 -1.0488 -0.1364 -0.1614 -0.5980 -0.0860 -0.9101 -0.0602 -0.7563 -0.1628
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients ; eplerenone ; potassium ; potassium ; hospitalization ; hyperkalemia ; medication ; adverse events
H-1226	-0.36005136370658875	▁e pler en one ▁; ▁po tas s ium ▁; ▁po tas s ium ▁; ▁hyper kal emia ▁; ▁medication
D-1226	-0.36005136370658875	eplerenone ; potassium ; potassium ; hyperkalemia ; medication
P-1226	-1.0224 -0.3946 -0.2091 -2.3474 -0.1524 -0.0186 -0.2359 -0.1963 -0.2389 -0.0942 -0.0316 -0.2615 -0.0765 -0.5284 -0.1523 -0.2484 -0.1157 -0.0895 -0.1858 -0.9519 -0.2419 -0.1278
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient ; new york heart association class iii ; heart failure ; hf ; left ventricular ejection fraction ; periodic breathing ; pb ; report
H-1347	-0.6099972128868103	▁New ▁York ▁Heart ▁Association ▁class ▁III ▁heart ▁failure ▁; HF ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁permanent ▁periodic ▁breath ing ▁; PB
D-1347	-0.6099972128868103	New York Heart Association class III heart failure ;HF ; left ventricular ejection fraction ; permanent periodic breathing ;PB
P-1347	-4.8358 -0.5861 -1.4193 -0.8420 -0.3085 -0.0947 -0.6038 -1.0131 -0.1193 -0.3961 -0.1002 -1.5564 -0.2579 -0.0165 -1.8010 -0.2285 -0.0512 -0.1962 -0.0929 -1.3781 -0.0024 -0.3860 -0.4384 -0.2969 -0.3208 -0.0912 -0.2430 -0.3092 -0.2023 -0.1122
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation ; bottleneck stent ; lad ; lcx ; myocardial ischemia ; stent ; ischemic heart failure ; stent ; therapeutic
H-514	-0.32096484303474426	▁implant ation ▁; ▁bottle ne ck ▁sten t ▁; ▁proxima l ▁ LAD ▁; ▁ LC x ▁; ▁por cine ▁model ▁of ▁rever sible ▁my o card ial ▁ ische mia ▁; open ▁sten t ▁; ▁ ische mic ▁heart ▁failure ▁; ▁sten t
D-514	-0.32096484303474426	implantation ; bottleneck stent ; proximal LAD ; LCx ; porcine model of reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
P-514	-0.0018 -0.0064 -0.4591 -1.3987 -0.0119 -0.1666 -0.1600 -0.0569 -0.2505 -0.1939 -0.0124 -0.2511 -0.0047 -0.1547 -0.5839 -0.2677 -0.5880 -0.2482 -3.0624 -0.1232 -0.1703 -0.6556 -0.0028 -0.0029 -0.6702 -0.3074 -0.1320 -0.1760 -0.1021 -0.9686 -0.4628 -0.2311 -0.3341 -0.0815 -0.0192 -0.1473 -0.1787 -0.4581 -0.0932 -0.1984 -0.0628 -0.3082 -0.6506 -0.0184 -0.2317 -0.0983
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium ; spironolactone ; aas
H-1705	-0.4568621814250946	▁po tas s ium ▁; ▁spi rono lac tone ▁; ▁AA s ▁; ▁race
D-1705	-0.4568621814250946	potassium ; spironolactone ; AAs ; race
P-1705	-0.2080 -0.1224 -0.1895 -0.1472 -0.0906 -0.1382 -0.0127 -0.0599 -0.0621 -0.1137 -1.3241 -0.1975 -0.2106 -0.3668 -3.8790 -0.1875
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese ; body mass index ; chronic ; stable ; hfpef
H-1978	-1.0344268083572388	▁obes e ▁; ▁d SD ▁; ▁body ▁mass ▁index ▁; ▁h f f
D-1978	-1.0344268083572388	obese ; dSD ; body mass index ; hff
P-1978	-2.4953 -0.0796 -0.6674 -3.6958 -1.6022 -0.1283 -0.7836 -0.4576 -0.0336 -0.1641 -2.2164 -0.8414 -1.1075 -1.0778 -0.1658
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic ; vegf pathway ; intravenously ; injected ; adenoviral ; vegf receptor ; adenovirus
H-456	-0.36796075105667114	▁pro angi ogen ic ▁effects ▁; ▁b ▁; ▁VE GF ▁path way ▁; ▁a den ovi ral ▁ve ctor ▁; ▁de co y ▁VE GF ▁receptor ▁; ▁ad - f lk ▁; ▁ade no virus ▁; ▁ad - c ▁; ▁b
D-456	-0.36796075105667114	proangiogenic effects ; b ; VEGF pathway ; adenoviral vector ; decoy VEGF receptor ; ad-flk ; adenovirus ; ad-c ; b
P-456	-0.4855 -0.0558 -0.1565 -0.3811 -0.4389 -0.2071 -0.1705 -0.6194 -2.7865 -0.2283 -0.7922 -0.0410 -0.1648 -1.2244 -0.0485 -0.6119 -0.0757 -0.2199 -0.2627 -0.1383 -0.0587 -0.0041 -0.1621 -1.9042 -0.3166 -0.2413 -0.1853 -0.4550 -0.0515 -0.1349 -0.0200 -0.1328 -0.8116 -0.0151 -0.0046 -0.1800 -0.3777 -0.0077 -0.2690 -0.4755 -0.5408 -0.2551 -0.1099
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical ; post-lvad ai ; aortic valve ; leaflet ; bioprosthetic aortic valve replacement ; functional capacity ; lvad ; patients ; symptomatic
H-552	-0.6413968801498413	▁sur g ical ▁treatment ▁; ▁post - L VAD ▁AI ▁; ▁a or tic ▁val ve ▁; ▁le a flet ▁repair ▁; ▁bio pro sthetic ▁a or tic ▁val ve ▁replace ment ▁; ▁CF ▁l VAD ▁; ▁AI
D-552	-0.6413968801498413	surgical treatment ; post-LVAD AI ; aortic valve ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD ; AI
P-552	-3.6059 -0.6993 -0.1091 -1.4403 -0.3659 -1.3044 -0.0103 -2.3678 -0.0157 -1.0991 -0.1599 -0.0554 -0.0938 -0.9881 -0.5371 -0.0756 -1.5949 -0.0198 -0.0589 -0.0084 -0.1989 -0.0324 -0.0119 -0.0020 -0.0062 -0.0632 -0.0560 -0.9710 -0.4191 -0.0574 -0.3349 -0.0158 -0.2014 -1.3922 -2.4116 -0.0539 -0.6343 -3.3420 -0.7370 -0.1049
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced pulmonary artery systolic pressure ; pasp ; stress doppler echocardiography ; right ventricular contractile reserve ; patients ; pulmonary hypertension ; right heart failure
H-822	-0.38691285252571106	▁exercise - indu ced ▁pulmonar y ▁arter y ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁stress ▁; ▁do pp ler ▁e cho card i ography ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension ▁; ▁right ▁heart ▁failure
D-822	-0.38691285252571106	exercise-induced pulmonary artery systolic pressure ;PASp ; stress ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
P-822	-2.1656 -0.0334 -0.0220 -0.1830 -0.0188 -0.0722 -0.1555 -0.1148 -2.4826 -0.2983 -1.0177 -0.5523 -0.1418 -0.0532 -0.4975 -0.1277 -0.8700 -0.3670 -1.0739 -0.0186 -0.1257 -0.0361 -0.5545 -0.0908 -0.1147 -0.1456 -0.1273 -0.4769 -0.0103 -1.5350 -0.1284 -0.0742 -1.0208 -0.0990 -0.1334 -0.4247 -0.0777 -0.0389 -0.0995 -0.1189 -1.1272 -0.1697 -0.1629 -0.1577 -0.0954
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline ; embase ; healthstar ; cinahl ; cochrane library ; campbell collaboration ; joanna briggs institute evidence based practice ; centre for reviews and dissemination ; evidence based practice centres
H-1844	-0.421924352645874	▁MED LINE ▁; ▁ EMBA se ▁; ▁HE al th STAR ▁; ▁c INA HL ▁; ▁co ch rane ▁Library ▁; ▁Campbell ▁Col labora tion ▁; ▁Joan na ▁Brig gs ▁Institute ▁E viden ce ▁Base d ▁Practic e
D-1844	-0.421924352645874	MEDLINE ; EMBAse ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs Institute Evidence Based Practice
P-1844	-0.3952 -1.1511 -0.1377 -1.5898 -0.0071 -0.3630 -0.0639 -0.6215 -0.5697 -0.8571 -0.7143 -0.1453 -0.7506 -1.7401 -0.6729 -0.1245 -0.1764 -0.0273 -0.0105 -0.1573 -0.1087 -0.0153 -0.6131 -0.0580 -0.0060 -0.0817 -0.0092 -0.0070 -0.0646 -0.0390 -0.0684 -2.3341 -0.0292 -0.0069 -0.6817 -0.0160 -0.3521 -0.0692 -1.9358 -0.1057
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods study ; health care ; systolic heart failure ; prescribed ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
H-1123	-0.4919165074825287	▁VA ▁health care ▁systems ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁β - block er ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block er
D-1123	-0.4919165074825287	VA healthcare systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
P-1123	-2.9233 -1.2931 -3.0577 -1.5634 -0.3630 -0.3548 -0.0718 -1.4101 -0.3722 -0.2692 -0.1483 -0.6871 -0.0085 -0.1077 -0.1238 -0.0810 -0.2239 -1.0362 -0.2998 -0.4848 -0.0067 -0.1169 -0.0718 -0.0618 -0.0689 -0.0276 -0.1066 -0.0411 -1.1765 -0.3865 -0.5530 -0.0609 -0.0074 -0.0766 -0.4710 -0.0718 -0.3454 -0.1626
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ; angiotensin receptor blockers ; angiotensin converting enzyme inhibitors ; beta receptor blockers ; mineralocorticoid receptor antagonists
H-647	-0.3491494655609131	▁heart ▁failure ▁; ▁neuro - hormon al ▁system ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁in tolerance ▁; ▁beta ▁receptor ▁block ers ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists
D-647	-0.3491494655609131	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
P-647	-1.7456 -0.4518 -0.1572 -0.8583 -0.0476 -0.0107 -0.0362 -0.3579 -0.3573 -0.0602 -0.5808 -0.2307 -0.8534 -0.0107 -0.2652 -0.0856 -0.1187 -0.0947 -1.3150 -0.1985 -0.4314 -0.0313 -0.5220 -0.2792 -0.5190 -0.0376 -0.1042 -0.0532 -0.6606 -0.1373 -0.4472 -0.0268 -0.2744 -0.2183 -0.1452 -0.1274 -2.0856 -0.5701 -0.0551 -0.1585 -0.5541 -0.0271 -0.5501 -0.0157 -0.1227 -0.0297 -0.0613 -0.6603 -1.3021 -0.3156 -0.0129 -0.1436 -0.0346 -0.5091 -0.3219 -0.1709
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest ; rs ; rs synchrony ; ste ; noninvasive ; rvpo ; rs synchrony ; strain ; bivp
H-330	-0.5302512645721436	▁open ▁che st ▁model ▁; ▁twist ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁ rte ▁; ▁CO ▁; ▁ RV PO ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁bi VP ▁; ▁CO
D-330	-0.5302512645721436	open chest model ; twist ; RS ; RS synchrony ; CS ; rte ; CO ; RVPO ; RS synchrony ; CS ; biVP ; CO
P-330	-0.4680 -0.4841 -0.0499 -0.3342 -0.0781 -0.0041 -0.0546 -0.0449 -0.1731 -0.1750 -0.0027 -0.1547 -0.1250 -0.4897 -0.1545 -2.3616 -0.9956 -0.1169 -3.1779 -0.9136 -1.0331 -0.4670 -1.4975 -0.0864 -1.6949 -0.0059 -0.2594 -0.1136 -1.2192 -0.1165 -0.8224 -0.4940 -0.2989 -0.2523 -0.2096 -0.1599
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse ; pasp ; tapse ; pasp ; cox regression ; kaplan-meier analyses ; tapse ; pasp
H-498	-0.605960488319397	▁t AP se ▁; ▁PAS p ▁; ▁t AP se - to - PAS p ▁ratio ▁; TA PS e ▁; PAS p ▁; ▁co x ▁re gression ▁; ▁Ka plan - me ier ▁; ▁t AP se ▁; ▁PAS p
D-498	-0.605960488319397	tAPse ; PASp ; tAPse-to-PASp ratio ;TAPSe ;PASp ; cox regression ; Kaplan-meier ; tAPse ; PASp
P-498	-2.8422 -1.4075 -0.7369 -0.1868 -1.4113 -1.0272 -0.1127 -1.5870 -0.8033 -0.3667 -0.0362 -0.2335 -0.0153 -0.1327 -0.4971 -0.1091 -0.1912 -0.9514 -1.3415 -0.8885 -0.4309 -0.2622 -0.3977 -0.4345 -0.1719 -0.0140 -0.0125 -0.0278 -0.2051 -0.3635 -0.0999 -0.0053 -0.4204 -0.0796 -1.3769 -3.1798 -1.2548 -0.2522 -0.2787 -0.9004 -0.4204 -0.4452 -0.1445
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom ; cpet ; patients ; chf ; patients ; exercise ; exercise ; patients ; exercise ; rehabilitation
H-1880	-0.8261688947677612	▁c PET ▁; ▁CHF ▁; ▁exercise ▁; ▁exercise ▁; ▁rehabilita tion
D-1880	-0.8261688947677612	cPET ; CHF ; exercise ; exercise ; rehabilitation
P-1880	-0.7153 -0.4182 -0.1177 -0.0662 -0.4212 -3.0556 -0.2385 -4.3468 -0.5311 -0.3403 -0.0295 -0.3208 -0.1391
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart failure ; hf ; mrna splicing ; cardiac ; scn5a ; endoplasmic reticulum
H-1080	-0.5697396397590637	▁Human ▁heart ▁failure ▁; HF ▁; ▁m RNA ▁s plic ing ▁; ▁v ▁; ▁volta ge - ga ted ▁cardiac ▁; ▁na + ▁channel ▁α - sub un it ▁; ▁s CN 5 a ▁; ▁tru nca ted ▁; ▁non function al ▁channel s ▁; ▁en do plas mic ▁reti culum
D-1080	-0.5697396397590637	Human heart failure ;HF ; mRNA splicing ; v ; voltage-gated cardiac ; na+ channel α-subunit ; sCN5a ; truncated ; nonfunctional channels ; endoplasmic reticulum
P-1080	-3.8837 -0.4372 -0.1653 -0.1100 -0.1908 -0.1217 -0.0450 -0.0246 -0.9579 -0.0052 -0.0574 -0.1551 -1.0735 -0.3973 -0.4854 -0.0136 -0.0235 -0.1426 -0.6703 -0.1668 -1.6307 -0.4458 -2.2144 -1.0796 -3.8597 -0.0032 -0.0061 -0.0161 -0.0156 -0.1983 -1.2910 -1.6740 -0.1346 -0.4026 -0.2320 -0.0384 -0.0680 -0.1628 -1.4437 -3.0497 -0.0298 -0.0141 -0.3093 -0.0185 -0.3248 -0.8114 -0.3137 -0.0618 -0.7839 -0.0077 -0.0049 -0.2656 -0.1573
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart failure ; diagnosis ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; disease
H-988	-0.5589536428451538	▁pa e dia tric ▁heart ▁failure ▁; ▁my o card itis ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure ▁; ▁an thra cycli ne ▁; ▁child hood ▁malign ant ▁disease
D-988	-0.5589536428451538	paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; anthracycline ; childhood malignant disease
P-988	-1.2162 -0.0638 -2.8243 -1.0725 -0.6576 -0.1145 -0.1694 -1.6171 -0.3152 -0.3347 -0.2125 -0.2042 -0.2347 -0.0531 -0.0505 -0.1917 -0.2393 -0.0226 -0.2066 -1.4988 -0.1425 -0.3464 -2.0516 -0.1012 -0.8779 -0.1728 -0.5859 -0.9159 -0.9860 -0.0195 -0.0658 -0.2874 -1.0151 -0.1372
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; clinical ; evidence-based ; medications ; costs ; outcomes
H-2010	-0.5662108659744263	▁économique ▁Analys is ▁; ▁Patient ▁Management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁Cost - E ff ective ness ▁Model ▁; ▁web - based ▁simula tion ▁; ▁clinic al ▁; ▁laborator y ▁character istic s ▁; ▁evidence - based ▁medication s ▁; ▁costs
D-2010	-0.5662108659744263	économique Analysis ; Patient Management Interventions ; Heart Failure Cost-Effectiveness Model ; web-based simulation ; clinical ; laboratory characteristics ; evidence-based medications ; costs
P-2010	-1.0845 -0.5909 -0.0520 -0.3111 -0.2875 -0.8388 -0.8227 -0.0079 -0.9721 -0.1988 -0.0397 -0.0298 -0.4334 -0.0193 -1.2270 -1.9211 -0.0141 -0.1114 -0.4114 -0.2364 -3.9129 -0.0042 -0.0286 -0.1264 -0.0239 -1.0114 -5.5109 -0.0475 -0.8238 -1.3425 -0.0388 -0.6960 -0.0784 -0.0141 -0.0554 -0.7830 -0.0013 -0.0071 -0.0653 -0.0121 -0.1594 -0.3235 -0.1388 -0.0983
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic peptides ; nps ; b-type np ; n-terminal pro-b-type np ; diagnosis ; acute heart failure ; patients ; emergency department ; acute dyspnea
H-1020	-0.2927778959274292	▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁b - type ▁ NP ▁; ▁n - termin al ▁pro - B - type ▁ NP ▁; ▁a cute ▁heart ▁failure ▁; ▁Emer gen cy ▁Department ▁; ▁ed ▁; ▁a cute ▁dys pne a
D-1020	-0.2927778959274292	natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-B-type NP ; acute heart failure ; Emergency Department ; ed ; acute dyspnea
P-1020	-0.0021 -0.0891 -0.0284 -1.8542 -0.0978 -0.0595 -0.1354 -0.1936 -0.0262 -0.0211 -0.0514 -1.4820 -0.0761 -0.1692 -0.2294 -0.0062 -0.1146 -2.9930 -0.0227 -0.0029 -0.0020 -0.0439 -0.0074 -1.3362 -0.0706 -0.0260 -0.1072 -0.0049 -0.2622 -0.6420 -0.0505 -0.3993 -0.0584 -0.1162 -0.2412 -0.0369 -0.0356 -0.1368 -0.4233 -0.8533 -0.5958 -0.1534 -0.0234 -0.0550 -0.0177 -0.1461 -0.3815 -0.1716
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak oxygen consumption ; peak vo2 ; exercise ; exercise oscillatory ventilation ; eov ; partial pressure of end-tidal co2 ; petco2 ; gain ; cardiopulmonary exercise testing
H-1275	-0.40744900703430176	▁pe ak ▁oxygen ▁consum p tion ▁; ▁VO 2 ▁; ven ▁; ▁v co 2 ▁s lope ▁; ▁exercise ▁os cilla tory ▁ventilation ▁; ▁e OV ▁; ▁pressure ▁; ▁end - ti dal ▁CO 2 ▁; PET co 2 ▁; ▁cardio pul mon ary ▁exercise ▁testing
D-1275	-0.40744900703430176	peak oxygen consumption ; VO2 ;ven ; vco2 slope ; exercise oscillatory ventilation ; eOV ; pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
P-1275	-2.7127 -0.0084 -0.4111 -0.7187 -0.0288 -0.1021 -0.0683 -1.2167 -0.9054 -0.0829 -1.7189 -0.6383 -0.2152 -0.8178 -0.0187 -0.2809 -0.0567 -0.2392 -1.8775 -0.1046 -0.0009 -0.1429 -0.0219 -0.1202 -0.1396 -0.1715 -0.1130 -0.9319 -0.1185 -0.3408 -0.0212 -0.0214 -0.0670 -0.2605 -0.0170 -0.0890 -0.3548 -0.8469 -0.9734 -0.3211 -0.0297 -0.0169 -0.3859 -0.1782 -0.6976 -0.6506 -0.1457 -0.1565
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective cohort study ; denmark ; bisphosphonates ; raloxifene
H-1536	-0.8507817983627319	▁Denmark ▁; ▁bis phos phon ates ▁; ▁ra lo xi fen e
D-1536	-0.8507817983627319	Denmark ; bisphosphonates ; raloxifene
P-1536	-6.3321 -0.2887 -0.4983 -0.0080 -0.0545 -0.5775 -0.5172 -0.0714 -0.1983 -0.0855 -1.2570 -0.2052 -1.6799 -0.1373
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension ; lv dilatation ; lv dysfunction ; mitral valve ; organic ; lesion ; systolic ; diastolic tethering ; etiology
H-365	-0.3842765688896179	▁hyper tension ▁; ▁LV ▁di la tation ▁; ▁LV ▁dys function ▁; ▁MR ▁; ▁MS ▁; ▁mit ral ▁val ve ▁; ▁ closure ▁; ▁les ion ▁; ▁sy sto lic ▁; ▁dia sto lic ▁te ther ing ▁; ▁MR ▁; ▁MS
D-365	-0.3842765688896179	hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; closure ; lesion ; systolic ; diastolic tethering ; MR ; MS
P-365	-0.1825 -0.0499 -0.0372 -0.0375 -0.3301 -0.2144 -0.0066 -0.0919 -0.0131 -0.0073 -0.0622 -0.0403 -0.4665 -0.0817 -1.3309 -0.6866 -1.3380 -0.0624 -0.4027 -0.0640 -0.2015 -2.2749 -0.1136 -0.2388 -4.5491 -0.0310 -0.1223 -0.3332 -0.0612 -0.2471 -0.7406 -0.0148 -0.3225 -0.3344 -0.0962 -0.0196 -0.0181 -0.0880 -0.6754 -0.2356 -0.1319 -0.0999 -0.0683
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; patients ; diuretic ; therapy ; serum sodium ; systolic function
H-1196	-0.5079695582389832	▁to lv ap tan ▁; ▁hypo na trem ia ▁; ▁Japan ▁; ▁con ges tive ▁heart ▁failure ▁; ▁di ure tic ▁ therapy ▁; ▁se rum ▁so dium ▁levels ▁; ▁sy sto lic ▁function
D-1196	-0.5079695582389832	tolvaptan ; hyponatremia ; Japan ; congestive heart failure ; diuretic therapy ; serum sodium levels ; systolic function
P-1196	-1.5394 -0.4955 -0.0519 -0.0469 -0.2017 -0.5011 -0.0357 -0.0398 -0.7722 -0.1707 -4.3155 -0.2015 -0.2213 -0.0285 -0.0780 -0.2640 -0.0533 -0.8287 -0.6881 -0.0781 -1.6646 -0.1486 -0.0234 -0.4470 -0.2632 -0.0602 -0.1459 -0.0122 -1.2970 -0.2487 -0.0593 -0.0984 -0.6436 -2.2428 -0.2086 -0.1118
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal ; strain ; left ventricle ; echocardiographic ; patients ; baseline ; echocardiography ; crt ; follow-up ; echocardiograms
H-429	-0.8309928178787231	▁longitud in al ▁strain ▁; ▁left ▁vent ric le ▁; ▁e cho car dio graphic ▁; ▁c RT ▁; ▁e cho card i ogram s
D-429	-0.8309928178787231	longitudinal strain ; left ventricle ; echocardiographic ; cRT ; echocardiograms
P-429	-4.9839 -0.1586 -0.0392 -0.5148 -0.8254 -0.2363 -0.0669 -2.3176 -1.8547 -0.2102 -0.1499 -0.1768 -0.0763 -0.3581 -0.1971 -1.9039 -1.4600 -1.8205 -0.5916 -0.8311 -0.2030 -0.0793 -0.7019 -2.0152 -0.3560 -0.2035 -0.1048
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating factor ; paf ; metabolic ; enzymes ; follow-up ; patients ; diagnosed ; heart failure ; hf ; healthy
H-1267	-0.6015349626541138	▁plate let - activa ting ▁factor ▁; PA f ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure ▁; ▁h z ▁; ▁b mi - match ed
D-1267	-0.6015349626541138	platelet-activating factor ;PAf ; metabolic enzymes ; heart failure ; hz ; bmi-matched
P-1267	-0.8584 -0.1895 -0.0807 -0.0108 -2.8352 -0.4452 -0.3008 -1.0904 -0.1261 -0.1281 -0.0399 -0.0701 -0.0994 -0.0362 -0.2808 -2.4764 -0.3755 -0.4519 -1.0283 -0.9263 -0.4416 -1.5547 -1.1461 -0.3015 -0.0097 -0.0732 -1.3291 -0.1371
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute care surgery ; acs ; consultations ; oht ; transplantation ; medical therapy ; intravenous ; inotropes ; ventricular assist devices ; vads
H-1281	-0.38061872124671936	▁a cute ▁care ▁surgery ▁; AC s ▁; ▁o HT ▁; ▁transplant ation ▁; ▁medical ▁ therapy ▁; MT ▁; ▁intra ven ous ▁in o trop es ▁; ▁vent ri cular ▁assist ▁devices ▁; VAD s
D-1281	-0.38061872124671936	acute care surgery ;ACs ; oHT ; transplantation ; medical therapy ;MT ; intravenous inotropes ; ventricular assist devices ;VADs
P-1281	-0.0184 -0.0178 -2.9534 -0.2303 -0.1708 -1.6614 -0.7180 -0.2282 -0.1827 -1.0700 -0.1222 -0.3365 -0.0140 -0.1979 -0.3178 -0.0438 -0.0075 -0.1174 -1.7910 -0.1157 -0.1044 -0.0119 -1.8909 -0.0086 -0.3366 -0.0183 -0.1987 -0.1295 -0.0007 -0.4029 -0.0285 -0.1680 -0.0295 -0.3027 -0.0153 -0.1028 -0.2597 -0.1399
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients ; hfpef ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1178	-1.261836051940918	▁ HF p f ▁; ▁i va bra dine ▁; ▁vent ri cular ▁fill ing ▁pressure ▁; ▁exercise ▁; ▁implant ation ▁; ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1178	-1.261836051940918	HFpf ; ivabradine ; ventricular filling pressure ; exercise ; implantation ; diastolic mitral flow velocity ; diastolic mitral annular velocity
P-1178	-1.8766 -0.2155 -0.4398 -1.0293 -0.0874 -0.0813 -0.0161 -0.6655 -0.0231 -0.1397 -1.7981 -1.6560 -0.0814 -1.8694 -0.0400 -1.1896 -0.5729 -5.1228 -0.3301 -5.2924 -2.0482 -0.6586 -4.1978 -0.5203 -0.4752 -0.9317 -0.0801 -5.7842 -2.7566 -0.7347 -0.2188 -2.8198 -0.7945 -1.2019 -1.9032 -0.2167 -3.1826 -0.0027 -0.8704 -0.7991 -0.1647 -0.1086
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone system ; raas ; hfref ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hfpef
H-1489	-0.3526630699634552	▁re nin - angi oten sin - al do ster one ▁system ▁; ra as ▁; ▁h fr EF ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁al do ster one ▁block ade ▁; ▁ HF p EF
D-1489	-0.3526630699634552	renin-angiotensin-aldosterone system ;raas ; hfrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
P-1489	-0.0164 -0.3995 -0.0589 -0.0246 -0.0314 -2.5479 -0.0819 -0.0218 -0.3853 -0.1811 -1.4032 -0.2169 -0.3456 -0.9464 -0.2281 -0.1077 -0.4281 -1.3698 -0.9740 -0.0931 -0.0302 -0.7243 -0.1596 -0.5454 -0.0473 -0.0095 -0.0388 -1.2448 -0.0282 -0.0524 -0.0336 -0.8840 -0.0938 -0.0174 -0.9066 -0.1603 -0.3703 -0.5226 -0.3086 -0.0342 -0.0757 -0.0083 -0.1282 -0.0952 -0.5344 -0.1902 -0.4843 -0.4165 -0.2969 -0.2052 -0.0224 -0.2309 -0.1659 -0.1162
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission ; lvet ; patients ; outcome ; tonometric
H-583	-1.1329795122146606	▁l VET ▁; ▁un favor able ▁outcome
D-583	-1.1329795122146606	lVET ; unfavorable outcome
P-583	-0.9473 -3.2744 -0.4544 -2.7050 -0.0058 -0.0220 -0.4048 -2.1340 -0.2491
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart rate ; blood pressure ; renal function ; spironolactone ; ras blockers ; β-blockers
H-182	-0.7222498059272766	▁heart ▁rate ▁; ▁blood ▁pressure ▁; ▁renal ▁function ▁; ▁spi rono lac tone ▁; ▁ RAS ▁block ers ▁; ▁β - block ers
D-182	-0.7222498059272766	heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
P-182	-4.4365 -1.2649 -0.1759 -0.8662 -1.7331 -0.1234 -0.1628 -3.0827 -0.1456 -0.0064 -0.0041 -0.0466 -0.0198 -1.0581 -0.4163 -0.1064 -1.9797 -0.0610 -0.4772 -1.2000 -0.0103 -0.0792 -0.1037 -0.3111 -0.1850
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac ; β-adrenoceptor blockade ; heart failure ; reverse ; cardiac remodeling ; elevated ; plasma catecholamines
H-1553	-0.3833063840866089	▁cardiac ▁performance ▁; ▁β - ad re no cept or ▁block ade ▁; ▁heart ▁failure ▁; ▁SR ▁ca (2 +) - pump ▁; ▁rever se ▁cardiac ▁remodel ing ▁; ▁plasma ▁cate chol amine s
D-1553	-0.3833063840866089	cardiac performance ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump ; reverse cardiac remodeling ; plasma catecholamines
P-1553	-1.4765 -0.5933 -0.1057 -0.1258 -0.0117 -0.0197 -0.0291 -0.0758 -0.4758 -0.1325 -0.2969 -0.4984 -0.1659 -0.3997 -0.3481 -0.2018 -2.6210 -1.2550 -0.7931 -0.0057 -0.0169 -0.0135 -0.8207 -1.6527 -0.0054 -0.2117 -0.0248 -0.0801 -0.3534 -0.3245 -0.0694 -0.0073 -0.2210 -0.0590 -0.1735 -0.1335
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate ratio ; confidence interval ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; therapy ; confidence interval ; β-blockers ; therapy
H-666	-0.34298285841941833	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁ therapy ▁; ▁β - block ers ▁ therapy
D-666	-0.34298285841941833	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; β-blockers therapy
P-666	-1.5407 -1.4012 -0.0984 -0.5883 -0.0930 -0.0144 -0.0545 -1.2227 -0.0293 -0.0844 -0.0306 -1.1416 -0.4354 -0.1497 -0.0070 -0.2788 -0.0346 -0.4681 -0.0391 -0.8309 -0.0217 -0.2582 -0.2002 -0.0070 -0.0618 -0.0243 -0.4519 -0.0582 -0.4100 -0.2536
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 ; congestive heart failure ; phenotypes ; mitochondrial ; tac ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein
H-874	-0.43918919563293457	▁con ges tive ▁heart ▁failure ▁; ▁mito cho ndri al ▁damage ▁; ▁ TAC ▁; ▁mito cho ndri al ▁prote ome ▁changes ▁; ▁mito cho ndri al ▁; ▁non mi to cho ndri al ▁protein ▁changes
D-874	-0.43918919563293457	congestive heart failure ; mitochondrial damage ; TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
P-874	-4.3613 -0.0398 -0.0916 -0.4056 -0.1172 -0.2703 -0.1291 -0.8060 -0.1477 -0.0268 -0.4849 -0.3985 -0.6484 -0.0159 -0.1963 -0.5033 -0.7330 -0.1287 -0.0242 -0.8428 -0.4014 -0.6899 -0.2996 -0.6903 -0.6525 -0.1202 -0.0142 -0.8230 -0.7758 -0.0350 -0.0913 -0.3866 -0.1007 -0.0066 -0.4118 -0.5346 -0.2079 -0.0764
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar ; atpase ; activity ; mrna ; phospholamban ; α-myosin heavy chain ; mrna ; β-myosin heavy chain ; metoprolol
H-1552	-0.5552000403404236	▁my o fi bril lar ▁ca (2 +) - stimul ated ▁ATP ase ▁activity ▁; ▁m RNA ▁levels ▁; ▁SR ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁α - my os in ▁heavy ▁chain ▁; ▁m RNA ▁; ▁β - my os in ▁heavy ▁chain ▁; ▁met o pro lol
D-1552	-0.5552000403404236	myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA ; β-myosin heavy chain ; metoprolol
P-1552	-4.3579 -0.4243 -1.1945 -0.0944 -0.5095 -0.4355 -0.9098 -0.0298 -0.1508 -0.0828 -0.2036 -0.4194 -1.0058 -0.1008 -0.0993 -0.0105 -0.0320 -2.1875 -0.0751 -1.8751 -1.4261 -0.4419 -0.0071 -0.0196 -0.0330 -0.1162 -0.4187 -0.1817 -0.1764 -0.1957 -0.0306 -0.2735 -1.5930 -0.0073 -0.0598 -1.7957 -0.7708 -0.3068 -0.0088 -0.3526 -0.0058 -0.0965 -0.4259 -3.8368 -0.0045 -0.1385 -2.2133 -0.5361 -0.4488 -0.0385 -0.6182 -0.2401 -0.0673 -0.0248 -0.1871 -0.1829 -0.1679
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl ; healthy ; hdl ; healthy ; patients ; chf-nyha-iii ; hdl ; nyha-iiib ; patients ; chf-nyha-ii ; hdl ; nyha-ii
H-250	-0.8881269097328186	▁HD L ▁; HD L ▁; health y ▁; ▁CHF - NY HA - III ▁; HD l ▁; NY HA - III b ▁; ▁ET ▁; ▁CHF - NY HA - II ▁; HD l ▁; NY HA - II
D-250	-0.8881269097328186	HDL ;HDL ;healthy ; CHF-NYHA-III ;HDl ;NYHA-IIIb ; ET ; CHF-NYHA-II ;HDl ;NYHA-II
P-250	-1.4924 -2.0386 -0.2304 -3.8134 -2.5849 -0.2581 -2.3012 -0.0190 -0.5970 -0.1974 -0.0439 -0.1952 -0.7976 -0.0884 -0.0778 -0.1716 -1.2759 -1.3614 -0.2765 -5.3618 -0.8936 -0.0271 -0.2153 -0.7741 -0.2357 -0.7426 -0.2808 -0.3548 -0.0420 -0.2834 -1.0504 -0.0483 -0.1193 -0.1295 -2.2070 -1.5674 -0.5699 -3.1210 -1.1434 -0.0419 -0.2562 -0.7910 -0.1123
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized ; coronary microembolization-induced hf ; cxl-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; maximal ventricular power index
H-420	-0.38457241654396057	▁in est het ized ▁dog s ▁; ▁corona ry ▁micro e mbol ization - indu ced ▁ HF ▁; ▁c XL -10 20 ▁; ▁vent ri cular ▁end - dia sto lic ▁pressure ▁; ▁my o card ial ▁oxygen ▁consum p tion ▁; ▁e je ction ▁ fraction ▁; ▁vent ri cular ▁power ▁index
D-420	-0.38457241654396057	inesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
P-420	-1.7944 -0.0291 -1.9190 -0.6179 -0.3216 -0.0207 -0.1772 -0.0666 -0.0360 -0.0446 -0.1987 -0.0005 -0.2629 -0.1355 -0.0017 -0.0960 -0.2146 -0.0248 -0.0446 -2.0618 -0.5403 -0.4258 -0.2113 -0.6048 -1.1892 -1.0276 -0.0815 -0.7660 -0.0159 -0.1146 -0.2160 -0.4782 -0.9133 -0.0762 -0.8265 -0.0878 -0.0917 -0.1098 -0.2094 -1.2906 -0.0097 -0.2030 -0.1800 -0.1762 -0.1786 -0.0599 -0.4883 -0.0027 -0.3126 -0.0794 -1.1456 -0.1404 -0.4557 -0.2075 -0.3952 -0.1566
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard error of measurement ; mdc ; mdc
H-805	-0.8163080811500549	▁m d ▁; ▁m d ▁; ▁m d
D-805	-0.8163080811500549	md ; md ; md
P-805	-0.5118 -0.4126 -0.2967 -0.7454 -0.2161 -0.8215 -0.9511 -0.1509 -3.8454 -0.2116
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline ; heart failure ; t1-mapping ; administration ; administration
H-1061	-0.8480992317199707	▁base line ▁; ▁heart ▁failure ▁; ▁t 1- ma pping ▁; ▁administration ▁; ▁contrast ▁agent
D-1061	-0.8480992317199707	baseline ; heart failure ; t1-mapping ; administration ; contrast agent
P-1061	-1.4201 -0.2777 -0.9348 -0.2318 -0.4896 -0.5336 -4.5803 -0.3552 -0.0939 -0.0731 -0.6493 -1.2058 -1.2337 -0.4328 -0.1152 -1.6251 -0.1657
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies ; hf ; idiopathic dilated cardiomyopathy ; ischemic ; valvular
H-1794	-0.54095458984375	▁ HF ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁c ' d ▁; ▁ ische mic ▁; ▁SH ▁; ▁val vu lar ▁; ▁alcohol
D-1794	-0.54095458984375	HF ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
P-1794	-1.4940 -0.2544 -0.2663 -3.1111 -1.4139 -0.0129 -0.2583 -0.1826 -0.1598 -0.2048 -0.2738 -0.3642 -0.0113 -0.1309 -0.1979 -3.8992 -0.1826 -0.1880 -0.1598 -0.4913 -0.0486 -0.3629 -0.8662 -0.2586 -0.0310 -0.0369 -0.1503 -0.4492 -0.1992 -0.9748 -0.1347
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 ; functional capacity ; clinical ; outcomes ; ambulatory ; patients ; hf ; heart failure ; outcomes ; exercise ; training ; hf-action ; randomized ; exercise ; training ; hf
H-697	-0.41122305393218994	▁ST 2 ▁; ▁functional ▁capacity ▁; ▁ambula tory ▁patients ▁; ▁ HF ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - AC tion ▁; ▁multi center ▁; ▁exercise ▁training ▁; ▁ HF
D-697	-0.41122305393218994	ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; controlled Trial Investigating Outcomes of Exercise Training ;HF-ACtion ; multicenter ; exercise training ; HF
P-697	-0.2887 -0.0863 -0.6444 -0.6784 -0.2554 -0.1405 -0.9418 -0.2178 -0.3913 -0.1908 -0.2714 -0.0372 -0.1077 -1.1230 -0.0452 -0.0242 -0.1563 -2.8977 -0.0597 -0.2327 -0.0126 -0.0188 -1.2358 -0.6053 -0.2042 -0.0355 -0.9652 -0.2111 -0.0192 -0.0308 -0.1692 -1.0441 -0.0149 -0.3907 -1.0282 -0.2581 -0.7381 -0.0092 -0.3179 -0.9398 -0.3359 -0.9153 -0.2428 -0.0708 -0.1588 -0.1537
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ; exercise rehabilitation ; patient ; chronic heart failure ; chf ; clinical ; cardiopulmonary exercise testing ; cpet ; exercise rehabilitation ; china
H-1879	-0.6134834885597229	▁cardio pul mon ary ▁exercise ▁testing ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁Card io P ul mon ary ▁Exerci se ▁Test ing ▁; ▁c PET ▁; ▁exercise ▁rehabilita tion ▁; ▁China
D-1879	-0.6134834885597229	cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ;CHf ; CardioPulmonary Exercise Testing ; cPET ; exercise rehabilitation ; China
P-1879	-0.1986 -0.0582 -1.3850 -0.2928 -0.7494 -1.7573 -0.1534 -4.2913 -0.1874 -0.0318 -0.3198 -0.9399 -0.7748 -0.3027 -0.6306 -0.3489 -0.1963 -2.3219 -0.1089 -0.1747 -0.6787 -0.2594 -0.8885 -0.0695 -1.3761 -0.0597 -0.5294 -0.0238 -0.2492 -0.0562 -0.1212 -0.2027 -0.1401 -0.3972 -1.3524 -0.1200 -0.0293 -1.3878 -1.4925 -0.3254 -0.1701
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ; ischemic hf ; pathogenesis ; nyha functional class iv ; estimated glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
H-1704	-0.3344108760356903	▁ ische mic ▁ HF ▁; ▁NY HA ▁functional ▁class ▁IV ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁heart ▁rate ▁; ▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁my o card ial ▁in far ction
D-1704	-0.3344108760356903	ischemic HF ; NYHA functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
P-1704	-1.3109 -0.9794 -0.0402 -0.0776 -0.0408 -0.6583 -0.1907 -0.5748 -0.6284 -0.0456 -0.1244 -0.2149 -0.1232 -0.0054 -0.0736 -0.0878 -0.0229 -1.3870 -0.1313 -0.3037 -1.7259 -0.0551 -0.0180 -0.0249 -0.0603 -0.0382 -0.0076 -0.0093 -0.0595 -0.9773 -0.2449 -0.0738 -0.2671 -0.0108 -0.5742 -0.3491 -1.0232 -0.1674
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action ; randomized ; exercise ; training ; patients ; hf ; left ventricular ejection fractions ; hrqol ; kansas city cardiomyopathy questionnaire ; kccq ; baseline
H-837	-0.5080941915512085	▁ HF - AC tion ▁; ▁ HF ▁; ▁vent ri cular ▁e je ction ▁ fraction s ▁; ▁HR Qo L ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁k cc q
D-837	-0.5080941915512085	HF-ACtion ; HF ; ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
P-837	-2.0775 -0.0811 -0.0213 -0.8498 -0.6747 -0.1104 -2.6250 -0.1332 -0.2304 -2.8322 -1.3260 -0.2640 -0.1096 -0.4867 -0.2867 -0.6860 -0.0016 -0.0412 -0.0813 -0.1717 -0.0130 -0.7363 -0.1238 -0.0210 -0.1542 -0.5358 -0.2626 -0.2096 -1.6755 -0.0984 -0.3946 -0.0024 -0.2190 -0.2871 -0.0982 -0.9098 -0.2939 -0.1820
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt ; systolic dysfunction ; outcomes ; resynchronization reverses remodeling in systolic left ventricular dysfunction ; reverse ; patients ; left ventricular ; ejection fraction ; lvef
H-752	-0.4854048490524292	▁c RT ▁; ▁sy sto lic ▁dys function ▁; ▁re syn chron ization ▁re VE rse s ▁re model ing ▁; ▁Sy sto lic ▁left ▁v ▁en tri cular ▁dys function ▁; ▁re VERS e ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; LV EF
D-752	-0.4854048490524292	cRT ; systolic dysfunction ; resynchronization reVErses remodeling ; Systolic left v entricular dysfunction ; reVERSe ; left ventricular ;LV ; ejection fraction ;LVEF
P-752	-0.4014 -1.9453 -0.0894 -2.9371 -0.1201 -1.8205 -0.2016 -0.2222 -0.0943 -0.4870 -0.0788 -0.0042 -0.5130 -0.0038 -0.7001 -0.0051 -0.0109 -0.3709 -0.4871 -0.0465 -0.9100 -0.2680 -0.0435 -0.9127 -0.1833 -0.2317 -2.5394 -0.7464 -0.1642 -0.0182 -0.1641 -0.1046 -1.9019 -0.8764 -0.0754 -0.3555 -2.2111 -0.0232 -0.9649 -0.1103 -0.3603 -0.4147 -0.3234 -0.0975 -0.2952 -0.1681 -0.1059 -0.0030 -0.1711 -0.0562 -0.0588 -0.1672 -0.1605
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated glomerular filtration rate ; egfr ; type 2 diabetes ; cholesterol ; ldl-cholesterol ; clcnka ; genotype
H-1803	-0.5365183353424072	▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR ▁; ▁diabetes ▁; ▁cholesterol ▁; ▁l DL - ch olesterol ▁; ▁CL CN KA ▁ GG ▁geno type
D-1803	-0.5365183353424072	glomerular filtration rate ; egFR ; diabetes ; cholesterol ; lDL-cholesterol ; CLCNKA GG genotype
P-1803	-0.3737 -0.0401 -0.0653 -0.2552 -0.0468 -1.1220 -0.1748 -0.0635 -2.3465 -1.2145 -0.1352 -0.7869 -0.0512 -0.8178 -0.0727 -1.1082 -0.6502 -0.0513 -0.7479 -0.0016 -0.1318 -0.6072 -1.2354 -0.7134 -0.5840 -0.5996 -1.7679 -0.0099 -0.1731 -0.1482
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography ; lv end-diastolic dimension ; lv end-diastolic pressure ; wall stress ; lung ; acf
H-474	-0.637854814529419	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁; ▁LV ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight ▁; ▁a CF ▁; ▁sham ▁group
D-474	-0.637854814529419	echocardiography ; LV ; end-diastolic dimension ; LV end-diastolic pressure ;wall stress ; lung weight ; aCF ; sham group
P-474	-0.2644 -0.5911 -0.1288 -0.4406 -0.1802 -0.1395 -1.0654 -1.0842 -0.9009 -0.0309 -0.3983 -0.6942 -1.4475 -0.8296 -0.0263 -0.0807 -0.3910 -1.4206 -0.0351 -0.5208 -0.8206 -1.5183 -2.3484 -0.3744 -0.7262 -0.6851 -0.0695 -0.4728 -0.3568 -0.0742 -1.7375 -0.7834 -1.7427 -0.0331 -0.8306 -0.2271 -0.1296
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic ; patients ; auc ; auc
H-488	-1.8073030710220337	
D-488	-1.8073030710220337	
P-488	-3.1386 -0.4760
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients ; follow-up ; patients ; spironolactone ; hospitalization ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval
H-443	-0.6789261102676392	▁spi rono lac tone
D-443	-0.6789261102676392	spironolactone
P-443	-0.7164 -0.0154 -0.0492 -0.0912 -2.9972 -0.2041
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control ; patients ; cardiac ; driven ; cardioversions ; costs ; antiarrhythmic drugs ; cad ; patient ; confidence interval ; patient
H-1239	-0.728698194026947	▁Rate - control ▁patients ▁; ▁cardiac ▁procedure s ▁; ▁cardio version s ▁; ▁costs ▁; ▁anti ar rhythm ic ▁drugs
D-1239	-0.728698194026947	Rate-control patients ; cardiac procedures ; cardioversions ; costs ; antiarrhythmic drugs
P-1239	-2.1267 -0.1393 -0.1260 -1.8572 -0.3066 -1.0060 -3.6554 -0.0337 -0.1357 -1.0976 -0.0110 -0.0471 -0.1398 -1.9258 -0.1656 -0.0190 -0.3364 -0.0864 -0.1283 -0.1753 -2.3840 -0.1283
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients ; bundle branch morphology ; diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin ii receptor blocker
H-906	-0.27571776509284973	▁diabetes ▁mell itus ▁; ▁cardio my o pathy ▁; ▁β - block er ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin ▁II ▁receptor ▁block er
D-906	-0.27571776509284973	diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
P-906	-1.8597 -0.0157 -0.1262 -0.0773 -0.0093 -0.2130 -0.4249 -0.0196 -0.8646 -0.2700 -0.0075 -0.0725 -0.0622 -0.1039 -0.0506 -0.4588 -0.1410 -0.3480 -0.0628 -0.0125 -0.0468 -0.8674 -0.0424 -0.0660 -0.0338 -0.0389 -0.0895 -0.0463 -0.7119 -0.2245 -0.3359 -0.6589 -0.0376 -0.2849 -0.0452 -1.3114 -0.1603
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone post myocardial infarction heart failure efficacy and survival study ; ephesus ; post-myocardial infarction ; patients ; heart failure ; mortality ; hospitalizations ; patients ; randomized ; aldosterone antagonist ; eplerenone
H-1737	-0.5804395079612732	▁e pler en one ▁Post ▁my o card ial ▁in far ction ▁Heart ▁failure ▁Ef fica cy ▁; ▁su rvi val ▁Study ▁; ▁e he SUS ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁mortal ity ▁; ▁al do ster one ▁anta gon ist ▁e pler en one
D-1737	-0.5804395079612732	eplerenone Post myocardial infarction Heart failure Efficacy ; survival Study ; eheSUS ; post-myocardial infarction ; heart failure ; mortality ; aldosterone antagonist eplerenone
P-1737	-0.3606 -0.1987 -0.5122 -1.8232 -2.8104 -1.1067 -0.6452 -0.2689 -0.6329 -0.0402 -0.6771 -0.1164 -1.2902 -0.0891 -2.4185 -0.0024 -0.0353 -0.1945 -1.3990 -0.0503 -0.0959 -0.1298 -0.1016 -0.5369 -3.9310 -0.6797 -0.0757 -0.4765 -0.0165 -0.2585 -0.4956 -0.5454 -0.4866 -0.0291 -1.0364 -0.1197 -1.2166 -0.5209 -0.1027 -0.2956 -0.3697 -0.2814 -0.1053 -0.3104 -0.0760 -0.0571 -0.8959 -0.0350 -0.0143 -0.5922 -0.0445 -0.4005 -0.1787 -2.8766 -0.2194 -0.2251
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol ; metoprolol ; endpoint ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-856	-0.3447924852371216	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD it - c rte ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-856	-0.3447924852371216	carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
P-856	-2.8277 -0.0393 -0.1257 -0.1830 -0.0613 -0.0688 -0.0094 -0.1549 -0.1154 -0.0069 -0.0264 -0.2575 -0.0947 -0.1221 -0.0139 -0.1710 -2.6614 -1.1100 -0.0090 -0.1127 -0.1853 -0.0208 -0.0798 -0.0641 -1.3540 -0.0058 -0.9513 -1.4535 -0.0776 -0.6488 -0.0241 -0.5643 -0.0609 -0.4597 -0.2021 -0.0531 -0.0287 -0.1461 -0.0221 -0.3108 -0.4253 -0.0379 -0.7188 -0.0084 -0.0017 -0.3126 -0.1763 -0.2277 -0.1023
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence interval ; heart ; mortality ; death
H-1749	-0.5697370767593384	▁risk ▁re duction ▁; ▁h ▁; ▁heart ▁failure - related ▁mortal ity ▁; ▁sud den ▁death
D-1749	-0.5697370767593384	risk reduction ; h ; heart failure-related mortality ; sudden death
P-1749	-2.5918 -0.1720 -0.0163 -0.2276 -1.0066 -0.9154 -2.2403 -1.0892 -0.1112 -0.0395 -0.0774 -0.1209 -0.3788 -0.0029 -0.0246 -0.5750 -0.5189 -0.1467
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash ; clinic ; brachial systolic pressure ; central end-systolic pressure
H-924	-0.7507860660552979	▁DAS h ▁; ▁s RD ▁; ▁bra chi al ▁sy sto lic ▁pressure ▁; ▁h g ▁; ▁central ▁end - sy sto lic ▁pressure ▁; ▁h g
D-924	-0.7507860660552979	DASh ; sRD ; brachial systolic pressure ; hg ; central end-systolic pressure ; hg
P-924	-0.0265 -0.2999 -0.4463 -1.6297 -0.7670 -0.0965 -3.5019 -0.0574 -0.1514 -0.5761 -0.3471 -1.3287 -0.9456 -0.0725 -3.6886 -0.0416 -0.0605 -0.9053 -1.6113 -0.0824 -0.9774 -0.5048 -0.8878 -0.9691 -0.9470 -0.1250 -0.0413 -0.5211 -0.1628
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients ; hf ; obese ; body mass index ; idiopathic-dilated cardiomyopathy
H-558	-0.5231325030326843	▁h f ▁; ▁obes e ▁; ▁body ▁mass ▁index ▁; ▁black ▁et hni city ▁; ▁ idio pathi c - dila ted ▁cardio my o pathy
D-558	-0.5231325030326843	hf ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
P-558	-1.7970 -1.3410 -0.1903 -0.8597 -0.0818 -0.1283 -3.0445 -0.8022 -0.1057 -0.2161 -1.8126 -0.1026 -0.1211 -0.8677 -0.1378 -0.3710 -0.0753 -0.0227 -0.4634 -0.0509 -0.0033 -0.4648 -0.1262 -0.4964 -0.3936 -0.0226 -0.3742 -0.1749
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause mortality ; hospitalization ; hf ; lvef ; patients ; heart failure survey ; israel
H-113	-0.5294128060340881	▁all - ca use ▁mortal ity ▁; ▁ HF ▁; ▁LV EF ▁; ▁heart ▁Fail ure ▁Survey ▁; ▁IS ra el
D-113	-0.5294128060340881	all-cause mortality ; HF ; LVEF ; heart Failure Survey ; ISrael
P-113	-3.9455 -0.0472 -0.0710 -0.0295 -0.0207 -0.2041 -0.1779 -0.8530 -0.1074 -0.1751 -0.0668 -0.1877 -0.1018 -3.4888 -0.2839 -0.0544 -0.2297 -0.8502 -0.8761 -0.0132 -0.0076 -0.2183 -0.1664
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients ; left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography ; followed up
H-1743	-0.3341386318206787	▁vent ri cular ▁e je ction ▁ fraction ▁; ▁World ▁Health ▁Organization ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁negative ▁corona ry ▁ang i ography
D-1743	-0.3341386318206787	ventricular ejection fraction ; World Health Organization ; idiopathic dilated cardiomyopathy ; negative coronary angiography
P-1743	-0.7205 -1.3113 -0.1705 -0.0857 -0.2194 -0.1272 -0.2905 -0.0005 -0.1348 -0.5534 -1.2574 -0.2530 -0.9224 -0.3063 -0.0287 -0.0416 -0.2113 -0.3517 -0.3035 -0.1198 -0.7208 -0.4347 -0.0358 -0.0687 -0.1371 -0.2937 -0.1343 -0.0186 -0.6786 -0.2425 -0.3531 -0.1647
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european society of cardiology ; hfpef ; symptoms ; heart failure ; preserved lv ejection fraction ; non-dilated left ventricle ; evidence ; diastolic dysfunction ; lv relaxation ; lv diastolic stiffness ; elevated ; lv filling pressures
H-27	-0.5253889560699463	▁european ▁Society ▁of ▁Card i ology ▁guidelines ▁; ▁h f f ▁; ▁heart ▁failure ▁; ▁LV ▁e je ction ▁ fraction ▁; ▁non - dila ted ▁left ▁vent ric le ▁; ▁dia sto lic ▁dys function ▁; ▁in impa i red ▁LV ▁relax ation ▁; ▁LV ▁dia sto lic ▁sti ff ness ▁; ▁LV ▁fill ing ▁pressure s
D-27	-0.5253889560699463	european Society of Cardiology guidelines ; hff ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ; inimpaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
P-27	-2.5254 -1.1353 -0.1615 -0.3259 -0.3539 -0.6345 -1.0975 -0.0868 -0.1654 -0.3699 -0.4580 -0.1788 -0.4258 -0.1706 -0.0858 -2.1621 -0.3171 -0.1263 -0.0232 -1.4672 -0.0024 -0.2437 -2.9860 -0.0071 -0.0048 -0.1190 -0.2179 -0.0216 -1.2259 -0.7741 -0.2003 -0.2627 -0.2438 -0.9678 -0.0195 -0.0314 -0.1009 -2.6470 -0.9699 -0.1123 -0.1382 -0.0310 -0.4443 -0.0067 -0.0336 -0.4750 -1.6835 -0.5093 -0.6382 -0.0564 -0.6093 -0.3366 -0.1834 -1.0794 -0.7388 -0.0131 -0.7432 -0.0238 -0.2143 -0.1362
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars ; s1pr1s ; myocyte ; camp ; report ; receptors ; g-protein-coupled receptor ; kinase-2
H-1408	-0.5637568235397339	▁β 1 AR s ▁; ▁s 1 PR 1 s ▁; ▁my o cy te ▁; ▁action ▁on ▁c AMP ▁production ▁; ▁receptor s ▁; ▁g - prote in - co up led ▁receptor ▁kina se -2
D-1408	-0.5637568235397339	β1ARs ; s1PR1s ; myocyte ; action on cAMP production ; receptors ; g-protein-coupled receptor kinase-2
P-1408	-3.0373 -0.3600 -0.4064 -0.3420 -0.1675 -2.2458 -0.1141 -0.1834 -0.0946 -0.1435 -0.2153 -0.8902 -0.1395 -0.1731 -0.0495 -0.0850 -1.0670 -1.0296 -0.0111 -0.0536 -0.5344 -0.3569 -4.3635 -0.1338 -0.1948 -3.2123 -0.0566 -0.0544 -0.6295 -0.0224 -0.0238 -0.0060 -0.1035 -0.0666 -0.2261 -0.0160 -0.6272 -0.3971 -0.1534
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up ; paf-cpt ; paf ; lyso-paf-at ; downregulated ; paf-ah ; lp-pla2 ; elevated
H-1270	-0.5471786856651306	▁PA f - c p ▁; ▁PA f ▁; ▁lys o - pa f - AT ▁; ▁PA f - AH ▁; ▁l p - PLA 2
D-1270	-0.5471786856651306	PAf-cp ; PAf ; lyso-paf-AT ; PAf-AH ; lp-PLA2
P-1270	-2.0131 -0.1985 -0.0804 -0.9975 -1.6424 -0.0729 -0.7784 -0.2592 -0.3361 -0.8767 -0.0467 -0.0147 -0.4843 -0.2907 -0.2806 -0.5622 -0.1299 -3.9561 -0.3166 -0.0852 -0.3415 -0.1038 -1.0099 -0.0046 -0.0293 -0.0201 -0.1052 -0.6595 -0.1724
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients ; heart failure ; ejection fraction ; cardiac rehabilitation ; walking ; exercise
H-570	-0.5831905007362366	▁heart ▁failure ▁; me an ▁e je ction ▁ fraction ▁; ▁cardiac ▁rehabilita tion ▁; ▁Nordic ▁walking
D-570	-0.5831905007362366	heart failure ;mean ejection fraction ; cardiac rehabilitation ; Nordic walking
P-570	-2.0048 -0.4451 -0.1519 -0.2585 -0.6954 -0.0256 -0.2005 -0.0751 -0.2134 -0.0006 -0.2401 -1.9388 -0.1051 -0.0699 -2.4245 -0.3582 -0.4705 -1.1914 -0.2114
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
H-1836	-0.494844526052475	▁d RS - stra t ified ▁hazard ▁ratio s ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁si tag lip tin ▁; ▁sul fon yl ure as ▁; ▁si tag lip tin ▁; ▁insulin
D-1836	-0.494844526052475	dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
P-1836	-0.2021 -1.2574 -0.0540 -0.0174 -0.0265 -0.0487 -0.2347 -0.1754 -0.0638 -0.2465 -1.0679 -0.0030 -0.3680 -2.1597 -0.5076 -0.0041 -1.5901 -0.0423 -0.0781 -0.2370 -0.8602 -0.0073 -0.2883 -2.0721 -0.4601 -0.2829 -0.0257 -0.2952 -0.0371 -0.0920 -0.2859 -2.2193 -0.0128 -0.4035 -2.5172 -0.5804 -0.0651 -0.1889 -0.2205
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal muscle ; t-score ; fontan ; sarcopenic range muscle wasting ; t-score ; clinically ; t-score
H-1501	-0.8390434980392456	▁skelet al ▁muscle ▁mass ▁; ▁t - s core ▁; ▁figure ▁; ▁sar co pen ic ▁range ▁muscle ▁was ting ▁; ▁t - s core
D-1501	-0.8390434980392456	skeletal muscle mass ; t-score ; figure ; sarcopenic range muscle wasting ; t-score
P-1501	-0.1439 -0.0725 -1.5709 -0.6705 -0.6431 -0.5717 -0.0566 -0.2062 -0.1542 -0.0936 -4.2513 -0.2078 -0.4040 -0.0465 -1.2798 -1.1542 -0.4509 -2.4106 -3.6634 -1.2836 -0.2971 -0.9132 -0.0252 -0.1176 -0.1957 -1.6867 -0.0835
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise ; testosterone ; baseline ; peak oxygen uptake ; beck depression inventory ; leg ; medical outcomes study short-form ; quality of life ; exercise ; placebo
H-1323	-0.40720051527023315	▁testosteron e ▁group ▁; ▁oxygen ▁up take ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁leg ▁strength ▁; ▁Medical ▁Out com es ▁; ▁Short - Form ▁quality ▁of ▁life
D-1323	-0.40720051527023315	testosterone group ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes ; Short-Form quality of life
P-1323	-0.8464 -0.0295 -1.6846 -0.1871 -0.4119 -0.2358 -0.1587 -0.0550 -0.0502 -0.2625 -0.0113 -0.5163 -0.1512 -0.0090 -0.1207 -0.3990 -0.9429 -0.0917 -0.6263 -0.6414 -0.1115 -0.0057 -0.2551 -1.0953 -0.0088 -0.1243 -0.2221 -0.2957 -0.1855 -2.7404 -0.1474
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker ; uptitrations ; composite end-point ; all-cause mortality ; hf ; readmissions ; hfref ; hazard ratio ; confidence interval
H-181	-0.6059354543685913	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁all - ca use ▁mortal ity ▁; ▁ HF ▁read missions ▁; ▁h Fr EF ▁; haz ard ▁ratio ▁; ▁h f
D-181	-0.6059354543685913	RAS- ; β-blocker uptitrations ; all-cause mortality ; HF readmissions ; hFrEF ;hazard ratio ; hf
P-181	-1.1041 -0.0424 -0.1400 -1.7681 -0.1033 -0.0089 -0.0264 -0.0187 -0.8325 -0.0964 -0.0593 -0.0321 -0.1636 -3.3044 -0.0036 -0.0133 -0.0064 -0.0305 -0.1154 -0.0433 -1.7401 -0.0637 -2.4998 -0.0301 -0.1174 -0.0489 -1.6593 -0.9552 -0.4629 -0.9636 -0.0347 -0.0333 -0.3242 -0.7183 -1.2405 -3.3344 -0.2803
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients ; heart failure ; outcomes ; exercise ; training ; hf-action ; exercise ; perceived social support score ; psss ; barriers to exercise score ; btes
H-1927	-0.4851281940937042	▁patients ▁en roll ed ▁in ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - AC tion ▁; ▁social ▁support ▁; ▁barrier s ▁to ▁exercise ▁; ▁social ▁support ▁score ▁; PS s ▁; ▁barrier s ▁to ▁exercise ▁score ▁; ▁b tes
D-1927	-0.4851281940937042	patients enrolled in Heart Failure ; controlled Trial Investigating Outcomes of Exercise Training ;HF-ACtion ; social support ; barriers to exercise ; social support score ;PSs ; barriers to exercise score ; btes
P-1927	-3.9097 -0.6154 -0.0113 -0.2649 -0.3983 -0.3449 -0.0222 -0.0262 -0.1635 -2.3249 -0.0616 -0.1667 -0.0299 -0.0169 -0.9024 -0.7893 -0.1685 -0.0273 -1.2651 -0.4669 -0.0325 -0.0632 -0.2044 -0.3125 -0.0053 -0.5464 -0.6257 -0.1270 -0.0328 -0.4072 -0.1872 -1.4364 -0.0049 -0.2564 -0.3165 -0.2436 -0.4715 -0.7733 -0.0428 -0.0971 -1.5758 -0.9414 -0.1450 -1.4561 -0.0061 -0.2964 -1.6523 -0.2916 -0.2624 -0.4526 -0.1748 -0.1817 -0.1132
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable analysis ; st2 ; death ; hospitalization ; hazard ratio ; cardiovascular death ; hf ; hospitalization ; hazard ratio ; all-cause mortality ; hazard ratio ; hazard ratios
H-703	-0.8664503693580627	▁ST 2 ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁all - ca use ▁mortal ity
D-703	-0.8664503693580627	ST2 ; cardiovascular death ; HF hospitalization ; all-cause mortality
P-703	-1.5242 -0.2371 -0.4810 -1.6037 -1.2921 -0.0586 -1.3896 -0.0503 -1.3746 -1.6072 -0.1597 -3.7947 -0.0152 -0.0183 -0.0096 -0.0105 -0.2085 -2.3227 -0.3049
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients ; new york heart association class i ; fontan ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dxa ; calf ; muscle ; magnetic resonance spectroscopy ; healthy
H-1495	-0.5446581840515137	▁New ▁York ▁Heart ▁Association ▁; ▁cardio pul mon ary ▁exercise ▁; ▁lean ▁mass ▁; ▁dual ▁x - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁cal f ▁muscle ▁; ▁magnetic ▁res on ance ▁spec tros copy
D-1495	-0.5446581840515137	New York Heart Association ; cardiopulmonary exercise ; lean mass ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
P-1495	-2.5314 -0.6086 -1.6721 -1.1623 -0.4803 -0.4645 -0.1043 -1.8057 -0.4913 -0.6208 -0.4122 -0.0158 -1.0726 -0.4556 -3.5283 -0.1615 -0.0429 -0.1773 -0.0460 -0.0602 -0.0595 -0.1241 -0.3054 -0.2251 -0.3236 -0.6603 -0.0672 -0.1252 -0.0039 -0.6427 -0.0766 -0.3325 -0.3672 -0.2935 -0.0372 -0.2771 -0.0343 -0.1170 -1.6805 -0.1198
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo ; dopamine ; nesiritide ; bolus ; diuretic ; therapy ; renal function ; patients ; acute heart failure ; renal dysfunction
H-73	-0.6352999210357666	▁dop amine ▁; ▁nesi riti de ▁; ▁di ure tic ▁ therapy ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure
D-73	-0.6352999210357666	dopamine ; nesiritide ; diuretic therapy ; renal function ; acute heart failure
P-73	-1.9903 -0.3968 -0.0646 -0.6778 -0.0111 -0.0148 -0.0719 -0.1847 -0.0803 -1.4719 -0.0929 -0.0311 -0.2480 -0.0811 -3.1573 -0.2544 -0.4135 -0.0224 -0.2457 -0.1495 -4.1896 -0.1269
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized ; crt ; patients ; new york heart association class iii ; heart failure ; left ventricular ejection fraction ; qrs duration ; echocardiographic ; evidence ; left ventricular dyssynchrony
H-847	-0.6438817977905273	▁c rte ▁; ▁New ▁York ▁Heart ▁Association ▁class ▁III ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁; ▁QR s ▁; ▁e cho car dio graphic ▁evidence ▁; ▁left ▁vent ri cular ▁dys syn chron y
D-847	-0.6438817977905273	crte ; New York Heart Association class III ; heart failure ; left ventricular ejection ; QRs ; echocardiographic evidence ; left ventricular dyssynchrony
P-847	-1.1939 -1.9040 -0.1045 -2.4367 -0.8288 -0.6261 -0.8129 -0.9483 -0.2904 -0.3531 -2.5541 -1.1015 -0.0963 -0.2031 -0.0648 -2.1594 -0.3895 -0.2088 -0.4132 -0.2142 -0.6049 -0.0317 -0.7729 -0.6122 -0.2454 -0.1097 -0.0254 -0.1485 -0.1726 -1.6059 -0.3515 -0.3091 -0.0657 -2.9610 -0.2407 -0.0305 -0.0094 -0.0017 -0.6258 -0.3953 -0.1757
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients ; left ventricular ; ejection fraction ; stable hf ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
H-482	-0.4262324571609497	▁left ▁vent ri cular ▁; LV ▁; ▁ HF ▁; ▁right - side d ▁cardiac ▁cat heter ization ▁; ▁trans t hora cic ▁e cho card i ography ▁; ▁transmit ral ▁flow ▁; ▁mit ral ▁ann ulus ▁veloci ties ▁; ▁sy stol e ▁; ▁dia stol e
D-482	-0.4262324571609497	left ventricular ;LV ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
P-482	-1.0693 -0.0285 -1.6849 -0.3330 -0.2456 -0.0428 -0.2150 -1.6469 -0.2176 -0.1094 -2.8531 -0.0103 -0.0377 -0.1445 -0.0229 -0.0746 -0.0061 -0.5162 -0.0695 -0.0016 -0.0738 -0.0143 -0.0527 -0.0399 -0.2484 -0.0343 -0.1288 -0.1708 -0.1407 -0.2197 -0.5040 -0.7204 -0.8062 -1.1754 -0.1064 -0.1279 -0.1866 -3.0320 -0.3393 -0.2716 -1.7129 -0.0077 -0.2719 -0.4776 -0.0198 -0.0054 -0.2099 -0.3275 -0.1304
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients ; acute coronary syndromes ; patients ; stable ; cad ; bnp ; nt-probnp ; cad ; prognostic ; clinical ; outcome
H-1367	-0.35257598757743835	▁a cute ▁corona ry ▁syndrome s ▁; ▁CAD ▁; ▁b NP ▁; ▁NT - pro b NP ▁; ▁CAD
D-1367	-0.35257598757743835	acute coronary syndromes ; CAD ; bNP ; NT-probNP ; CAD
P-1367	-0.2604 -0.0062 -0.1060 -0.0682 -0.0391 -0.0306 -0.3082 -1.4225 -0.4418 -0.2561 -0.3231 -0.1212 -0.4776 -0.0218 -0.0069 -0.9895 -0.3967 -0.5985 -0.8835 -0.5021 -0.1441
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline ; patients ; hf ; lyso-paf-at ; paf-cpt ; paf ; paf-ah ; lp-pla2
H-1269	-0.5555804967880249	▁ HF ▁; ▁lys o - pa f - AT ▁; ▁PA f - c p ▁; ▁PA f ▁; ▁PA f - AH ▁; ▁l p - PLA 2
D-1269	-0.5555804967880249	HF ; lyso-paf-AT ; PAf-cp ; PAf ; PAf-AH ; lp-PLA2
P-1269	-1.7831 -0.0532 -0.2039 -1.1483 -0.0645 -0.0340 -0.6229 -0.2419 -0.2103 -0.3818 -0.0817 -0.5737 -0.2425 -0.0519 -1.5372 -1.1789 -0.1155 -0.7185 -0.3436 -1.1510 -0.7412 -0.3588 -0.2517 -3.0314 -0.1212 -1.5587 -0.0051 -0.0407 -0.0120 -0.0709 -0.6410 -0.2077
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical therapy ; patients ; redo sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; patients ; transcatheter aortic valve procedure ; surgery ; aortic valve
H-549	-0.40927210450172424	▁ster no to my ▁; ▁a or tic ▁val ve ▁; ▁bio pro sthetic ▁val ve ▁replace ment ▁; ▁da cro n ▁patch ▁ closure ▁; ▁a or tic ▁val ve ▁repair s ▁; ▁trans cat heter ▁a or tic ▁val ve ▁; ▁surgery ▁; ▁a or tic ▁val ve ▁replace ment
D-549	-0.40927210450172424	sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve ; surgery ; aortic valve replacement
P-549	-3.5218 -0.0149 -0.1290 -0.6412 -0.3123 -0.0147 -0.0574 -2.3940 -0.5877 -0.0640 -1.4713 -0.0268 -0.0125 -0.0358 -0.6144 -0.0716 -1.0744 -0.0222 -0.1458 -0.4036 -0.0295 -0.0044 -0.0228 -0.0306 -0.0061 -0.1442 -0.0141 -0.0696 -0.9190 -0.3354 -0.0917 -0.1962 -0.1317 -0.2000 -0.0024 -0.0274 -0.0028 -0.0357 -0.0464 -1.1521 -0.2815 -0.0646 -1.6760 -2.3200 -0.2915 -0.0204 -0.0770 -1.3055 -0.3087 -0.1092 -0.1539 -0.0179 -0.2666 -0.1306
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma n-terminal pro-b-type natriuretic peptide ; nt-probnp ; patients ; acute heart failure ; hf ; admission ; emergency department
H-263	-0.5125925540924072	▁cut off ▁value ▁; ▁plasma ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁a cute ▁heart ▁failure ▁; HF ▁; ▁emergency ▁department ▁; ▁ed
D-263	-0.5125925540924072	cutoff value ; plasma N-terminal pro-B-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ; ed
P-263	-4.6720 -0.1239 -1.1730 -0.0590 -0.2565 -2.4599 -0.0162 -0.0056 -0.0072 -0.0591 -0.0109 -0.7064 -0.0776 -0.0137 -0.0055 -0.0831 -0.0239 -2.2077 -0.2533 -0.0928 -0.0403 -0.1602 -0.8352 -0.0029 -0.0070 -0.6475 -0.1477 -0.2726 -1.9094 -0.1433 -0.3594 -0.1309 -0.1632 -0.6421 -0.4117 -0.6521 -0.1306 -0.4544 -0.9346 -0.5388 -0.1251
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac troponin t ; ctnt ; n-terminal pro-b-type natriuretic peptide ; nt-probnp ; biomarkers ; hf ; hf ; atherosclerosis risk in communities ; aric
H-286	-0.46265465021133423	▁cardiac ▁trop onin ▁t ▁; ▁c t n t ▁; ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁ HF ▁; ▁ HF ▁; ▁ HF ▁; ▁Ath eros cle rosi s ▁Risk ▁in ▁communauté s ▁; ARI c
D-286	-0.46265465021133423	cardiac troponin t ; ctnt ; N-terminal pro-B-type natriuretic peptide ;NT-probNP ; HF ; HF ; HF ; Atherosclerosis Risk in communautés ;ARIc
P-286	-0.0436 -0.0250 -0.0829 -0.9675 -0.1065 -0.7106 -0.0730 -0.0106 -0.4161 -0.1511 -5.1910 -0.0078 -0.0101 -0.0021 -0.0944 -0.0098 -0.8372 -0.0583 -0.0194 -0.0042 -0.0914 -0.0201 -2.1963 -0.1075 -0.1789 -0.0524 -0.1594 -1.4492 -0.0022 -0.0093 -0.5118 -0.1725 -0.0811 -0.9323 -0.5442 -0.0776 -0.4300 -0.1925 -0.2976 -2.2876 -0.7146 -0.4651 -0.6418 -0.0452 -0.5118 -0.6270 -0.0218 -0.1424 -0.6777 -1.7211 -0.1837 -0.2288 -0.4349 -0.4283 -0.2915 -0.1579
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body mass index ; fat mass ; fat-free mass
H-1167	-1.163350224494934	▁body ▁mass ▁index ▁; HR ▁; ▁fat - free ▁mass ▁index
D-1167	-1.163350224494934	body mass index ;HR ; fat-free mass index
P-1167	-3.6648 -1.6939 -0.1614 -0.3262 -2.0816 -0.4129 -4.2674 -0.7696 -0.3126 -0.6633 -0.3064 -0.3061 -0.1573
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile range ; body mass index ; interquartile range ; copd ; chf ; crf
H-797	-1.374342441558838	▁p d ▁; ▁CHF ▁; ▁c RF
D-797	-1.374342441558838	pd ; CHF ; cRF
P-797	-6.5737 -0.1852 -0.1895 -2.6651 -0.2031 -0.2513 -1.4308 -0.5687 -0.3016
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse remodeling ; ejection fraction ; mortality ; all-cause hospitalizations ; hf ; hospitalizations ; dialysis ; patients
H-911	-0.34036800265312195	▁rever se ▁remodel ing ▁; ▁e je ction ▁ fraction ▁; ▁mortal ity ▁; ▁ HF ▁; ▁di al ysis
D-911	-0.34036800265312195	reverse remodeling ; ejection fraction ; mortality ; HF ; dialysis
P-911	-0.1424 -0.0282 -0.0270 -0.0827 -0.1238 -0.0275 -0.3295 -0.0634 -0.0910 -0.0008 -0.2248 -0.0420 -0.3815 -0.1856 -1.7395 -0.1839 -1.4676 -0.3764 -0.0203 -0.0732 -1.7038 -0.1731
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates ; lv contractility ; lvef ; β coefficient ; confidence interval ; systolic blood pressure ; end-systolic volume ; β coefficient
H-1530	-0.870008111000061	▁EH ▁; ▁LV ▁contract ility ▁; ▁LV EF ▁; ▁LV EF ▁; ▁ratio ▁of ▁sy sto lic ▁blood ▁pressure ▁; ▁end - sy sto lic ▁volume ▁; ▁h g
D-1530	-0.870008111000061	EH ; LV contractility ; LVEF ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ; hg
P-1530	-0.4353 -0.1093 -0.7505 -0.3786 -0.1582 -0.0653 -3.7555 -0.7478 -0.0855 -3.7190 -0.6763 -0.0956 -4.3833 -0.4974 -0.7218 -0.5545 -1.1439 -0.6638 -1.4141 -0.1886 -0.6160 -0.0228 -0.3888 -1.5923 -0.7398 -0.4430 -0.8476 -0.2364 -0.0264 -1.3569 -0.1559
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography ; dilated lv ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mva
H-348	-0.5964556336402893	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁m L / m 2 ▁; ▁LV ▁e je ction ▁ fraction ▁; ▁mild ▁MR ▁; ▁ms ▁; ▁ms ▁; ▁m va ▁; ▁pressure ▁gradi ent ▁; ▁h g
D-348	-0.5964556336402893	echocardiography ; LV ; end-diastolic volume index ; mL/m2 ; LV ejection fraction ; mild MR ; ms ; ms ; mva ; pressure gradient ; hg
P-348	-0.6652 -0.8340 -0.2123 -0.4572 -0.1211 -0.0785 -4.4228 -0.0748 -0.3967 -0.0115 -0.1886 -0.4032 -0.2384 -0.1472 -0.3022 -0.1044 -0.5645 -1.1079 -3.5865 -0.0269 -0.0502 -0.1057 -0.3909 -0.5334 -0.1636 -0.0512 -0.4093 -0.0035 -0.1327 -0.7504 -0.0744 -0.1441 -3.5244 -0.1404 -2.3447 -0.1263 -0.9947 -0.3516 -0.1218 -2.3735 -0.1318 -0.0863 -0.5389 -0.0837 -0.0220 -0.3347 -0.1051
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind ; clinical ; renal optimization strategies evaluation ; rose ; hospitalized ; patients ; acute heart failure ; renal dysfunction ; estimated glomerular filtration rate ; randomized ; admission
H-74	-0.36885371804237366	▁double - blind ▁; ▁place bo - control led ▁clinic al ▁trial ▁; ▁re nal ▁Optim ization ▁Strategie s ▁Evalua tion ▁; ROS e ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁glo mer ular ▁filtr ation
D-74	-0.36885371804237366	double-blind ; placebo-controlled clinical trial ; renal Optimization Strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration
P-74	-5.1294 -0.0102 -0.0090 -0.4815 -0.2488 -0.0276 -0.0072 -0.0975 -0.5650 -0.1172 -0.0441 -0.1699 -0.1178 -0.6643 -0.0271 -0.2522 -0.1799 -0.2913 -0.0054 -0.5195 -0.0495 -0.2255 -0.0568 -0.0966 -0.1585 -1.0326 -0.0112 -0.2808 -0.1122 -0.1408 -0.0227 -0.0359 -0.2337 -0.2494 -0.0686 -0.0207 -0.0662 -0.0818 -0.0339 -2.9983 -0.1827
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets ; signal transduction ; pol ii ; transcription factor ; hf ; pathogenesis ; nuclear factor of activated t cells ; nfat ; nuclear factor-κb ; nf-κb ; transcription factor ; gata4
H-1051	-0.5986119508743286	▁ BET s ▁; ▁chr omat in - media ted ▁signal ▁trans duction ▁; ▁Pol ▁II ▁; ▁co - activa ting ▁tran scription ▁factor ▁network s ▁; ▁ HF ▁path ogen es is ▁; ▁nuclear ▁factor ▁of ▁activa ted ▁T ▁cell s ▁; ▁n FAT ▁; ▁nuclear ▁factor - κ b ▁; NF - κ b ▁; ▁tran scription ▁factor
D-1051	-0.5986119508743286	BETs ; chromatin-mediated signal transduction ; Pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; nFAT ; nuclear factor-κb ;NF-κb ; transcription factor
P-1051	-2.2201 -0.0528 -0.4039 -0.2146 -0.1047 -0.0072 -0.6561 -0.0254 -0.0187 -0.2882 -0.1291 -0.0289 -0.0938 -0.4122 -0.3578 -0.3776 -0.2490 -1.8281 -0.0036 -0.0058 -1.2601 -0.2562 -0.0781 -0.2483 -3.0357 -0.0487 -0.3024 -0.6168 -0.2813 -2.0989 -0.2911 -0.0461 -0.1002 -0.2031 -0.5478 -0.3989 -1.2002 -0.2895 -0.2977 -0.6154 -0.1046 -0.0262 -0.1942 -4.5306 -0.2909 -0.0605 -1.2082 -1.1268 -0.1247 -2.2139 -0.4540 -0.0830 -1.5636 -0.0558 -1.5191 -0.2486 -0.3332 -0.9216 -0.1366 -0.3502 -1.6396 -0.2336
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes ; mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
H-33	-0.3658687472343445	▁mortal ity ▁; ▁hospital ization ▁; ▁cardiovascular ▁events ▁; ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ar rhythm ia ▁; ▁cardiac ▁death ▁; ▁hyper tension ▁; ▁ve nous ▁ thro mbo e mbol ic ▁events ▁; ▁ ische mic ▁cerebro vas cular ▁events
D-33	-0.3658687472343445	mortality ; hospitalization ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
P-33	-1.0801 -0.2737 -0.0624 -1.3636 -0.8264 -0.0858 -1.7592 -0.8571 -0.0633 -0.4518 -0.2279 -0.0740 -0.2520 -0.0232 -0.9672 -0.1155 -0.1177 -0.0550 -0.0201 -0.0335 -0.2256 -0.0485 -0.4064 -0.5608 -0.1540 -0.4063 -0.1346 -0.0406 -0.6432 -0.2480 -0.1674 -0.1081 -0.0882 -0.3078 -0.2999 -0.1166 -0.1214 -1.1871 -1.1549 -0.0016 -0.6185 -0.5248 -0.1573 -0.3641 -0.3136 -0.1681 -0.0582 -0.0167 -0.1818 -1.0950 -0.2415 -0.1552
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular mortality ; multivariable adjustment ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-562	-0.43278104066848755	▁all - ca use ▁; ▁cardiovascular ▁mortal ity
D-562	-0.43278104066848755	all-cause ; cardiovascular mortality
P-562	-0.8789 -0.0991 -0.0565 -0.0140 -0.4504 -0.0246 -0.0683 -0.2767 -2.2615 -0.1980
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus ; diabetes ; patients ; diabetes ; peak vo2 ; patients ; diabetes ; eo-cfus ; peak vo2
H-128	-1.1501413583755493	▁ EO - c FU s ▁; ▁diabetes ▁; ▁ EO - c FU ▁; ▁diabetes ▁; ▁ EO - c FU ▁; ▁VO 2 ▁; ▁diabetes ▁; ▁ EO - c FU s
D-128	-1.1501413583755493	EO-cFUs ; diabetes ; EO-cFU ; diabetes ; EO-cFU ; VO2 ; diabetes ; EO-cFUs
P-128	-2.2717 -0.0920 -0.0459 -2.0031 -1.3901 -0.2103 -0.3512 -0.0734 -0.1573 -4.6417 -0.2261 -0.0516 -2.4699 -0.8579 -0.5314 -2.5638 -0.1681 -4.2334 -0.2779 -0.0480 -2.2592 -0.8114 -0.9339 -4.3622 -0.0872 -0.8832 -1.1907 -0.6484 -2.4195 -0.2584 -0.0455 -2.3635 -0.7587 -0.2622 -1.2436 -0.2127
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting ; video edge detection ; epifluorescence microscopy ; myocardial tissues ; cardiomyocytes ; hf
H-1212	-0.2526523172855377	▁immun o blo tting ▁; ▁radio en zy matic - ▁; ▁fluor esc ence ▁res on ance ▁energy ▁transfer - based ▁as say s ▁; ▁video ▁edge ▁det ection ▁; ▁epi flu o resc ence ▁micro s copy ▁; ▁ca 2 ▁; ▁my o card ial ▁tissu es ▁; ▁cardio my o cy tes ▁; ▁ HF
D-1212	-0.2526523172855377	immunoblotting ; radioenzymatic- ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; cardiomyocytes ; HF
P-1212	-0.1005 -0.0714 -0.0163 -0.2112 -0.0799 -0.0776 -0.1353 -0.0032 -0.0740 -0.0547 -2.7807 -0.0083 -0.4152 -0.0059 -0.3069 -0.1042 -0.0394 -0.5760 -0.1763 -0.0995 -0.0740 -1.0506 -0.0125 -0.0352 -0.0806 -0.7746 -0.0864 -0.5870 -0.0066 -0.1142 -0.0688 -0.0175 -0.4519 -0.0968 -0.0132 -0.0517 -0.0405 -0.0544 -0.0943 -0.5387 -0.0891 -0.1574 -0.7349 -0.1324 -0.0688 -0.3736 -0.2289 -0.1424 -0.0655 -0.1114 -0.1927 -0.2975 -0.1680 -0.0838 -0.1746 -1.8381 -0.1662 -0.1882 -0.1071
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east ; early treatment of atrial fibrillation for stroke prevention trial ; randomize ; patients ; stroke ; rhythm control therapy ; prospective ; randomized ; outcome
H-1649	-0.5496945977210999	▁e AST ▁; ▁at rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁Tri al ▁; ▁AF ▁; ▁stroke ▁; ▁guide line - manda ted ▁usual ▁care ▁; ▁ rhythm ▁control ▁ therapy
D-1649	-0.5496945977210999	eAST ; atrial fibrillation ; Stroke prevention Trial ; AF ; stroke ; guideline-mandated usual care ; rhythm control therapy
P-1649	-1.2089 -0.4387 -0.0872 -1.1968 -0.1525 -0.1875 -0.0147 -0.0128 -0.4685 -0.3504 -0.2978 -0.0561 -0.0039 -0.6527 -0.0175 -0.6969 -1.3797 -0.1902 -1.2112 -0.3606 -4.0995 -0.0130 -0.0175 -0.0018 -0.2155 -1.2740 -1.3320 -0.0864 -1.7612 -0.3028 -0.0296 -0.0973 -0.0112 -0.8817 -0.1313
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes ; exercise capacity ; peak oxygen consumption ; vo2 ; co-primary outcome ; qol ; minnesota ; heart failure ; heart ; qol ; co-primary outcome
H-1980	-0.7543862462043762	▁Exerci se ▁capacity ▁; ▁pe ak ▁oxygen ▁consum p tion ▁; VO 2 ▁; ▁m l / kg / min ▁; ▁Q OL ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁; ▁ml HF ▁; ▁heart ▁failure - related ▁Q OL
D-1980	-0.7543862462043762	Exercise capacity ; peak oxygen consumption ;VO2 ; ml/kg/min ; QOL ; Minnesota Living with Heart Failure ; mlHF ; heart failure-related QOL
P-1980	-3.5660 -0.1652 -0.3005 -0.0952 -1.7696 -0.0131 -0.2679 -0.3938 -0.0142 -0.0977 -0.0730 -0.1029 -0.0420 -0.1050 -2.5975 -0.7945 -3.1921 -0.3185 -2.4139 -0.8326 -0.0599 -2.5347 -0.4907 -0.0791 -0.1053 -0.2276 -1.0370 -0.2107 -0.0947 -0.1011 -0.1033 -0.6067 -1.5837 -0.3472 -3.7650 -0.7770 -0.2330 -0.1482 -0.8786 -0.6096 -0.3970 -0.1388
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic ; mitochondrial-targeted peptide ; ss31 ; mitochondrial function ; tac ; clinical ; mitochondrial-targeted peptide ; drugs ; heart failure
H-878	-0.48066720366477966	▁ TAC - indu ced ▁prote om ic ▁altera tions ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁SS 31 ▁; ▁per tur bed ▁mito cho ndri al ▁function ▁; ▁path way ▁altera tions ▁; ▁ TAC ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁drugs ▁; ▁heart ▁failure
D-878	-0.48066720366477966	TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
P-878	-0.6029 -0.0390 -0.2096 -0.1853 -0.5293 -0.2098 -0.3343 -0.3238 -2.0408 -0.0244 -0.0900 -0.7452 -1.0238 -0.2479 -0.0893 -0.0267 -0.0319 -0.3481 -0.0219 -0.4325 -0.1126 -0.0436 -2.7520 -0.2371 -0.3069 -1.1610 -0.1129 -0.0453 -0.4724 -0.8121 -0.1451 -0.0403 -3.1087 -0.2323 -2.9294 -0.0433 -0.6082 -0.0246 -0.1769 -0.0854 -0.0997 -0.0920 -2.1037 -0.7176 -0.4536 -0.0573 -0.0193 -0.0388 -0.2101 -0.0073 -0.4856 -0.0598 -0.0457 -0.8209 -0.1746 -1.6028 -0.1274 -0.1180 -0.1183
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients ; left ventricular ejection fraction ; patients ; hf ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient ; epidemic ; medical ; financial costs
H-55	-0.81075119972229	▁vent ri cular ▁e je ction ▁ fraction ▁; ▁patients ▁; ▁ HF ▁; ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁hospital ▁; ▁physician s ▁; ▁a cute ▁; ▁out patient ▁setting s ▁; ▁financier ▁costs
D-55	-0.81075119972229	ventricular ejection fraction ; patients ; HF ; ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient settings ; financier costs
P-55	-3.4489 -1.5576 -0.4520 -0.3198 -0.5439 -0.2389 -0.3820 -0.0009 -0.1312 -2.6840 -0.3293 -1.2109 -0.0368 -0.1655 -2.5764 -2.1913 -0.3053 -0.1700 -0.5315 -0.2054 -0.4235 -0.0017 -0.3688 -0.6090 -0.2276 -1.0309 -0.0219 -1.0394 -0.6909 -0.0036 -1.9902 -0.2197 -0.0192 -3.3837 -0.0124 -0.5421 -2.9416 -1.1141 -0.1862 -0.1218
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf ; patients ; hfref ; left ventricular ; ejection fraction ; hfpef ; echo-doppler ; n-terminal pro-brain-type natriuretic peptide ; adverse events
H-494	-0.4771205484867096	▁h f ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; ▁h f ▁; ▁e cho - D opp ler ▁studies ▁; ▁pro - bra in - type ▁na tri ure tic ▁pe pti de
D-494	-0.4771205484867096	hf ; left ventricular ;LV ; ejection fraction ; hf ; echo-Doppler studies ; pro-brain-type natriuretic peptide
P-494	-1.5310 -0.4668 -0.1781 -2.0868 -0.0404 -1.9087 -0.4734 -0.2312 -0.1639 -0.2767 -0.1669 -0.4907 -0.0793 -0.1201 -0.0024 -0.1456 -0.8647 -1.2752 -0.3732 -0.2951 -0.3531 -0.0186 -1.7853 -0.0008 -0.0627 -0.7095 -0.0892 -0.8471 -0.0354 -0.1064 -0.2025 -0.0184 -0.0074 -0.0140 -0.0476 -0.0397 -2.9584 -0.2694 -0.0497 -0.1198 -0.7995 -0.3344
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds ; comorbidities ; hospitalized ; adjusted odds ratio ; aor ; confidence interval ; eds ; aor
H-464	-1.130934715270996	▁low - volu me ▁ED s ▁; ▁hospital ized ▁; ▁medium ▁; ▁high - volu me ▁ED s
D-464	-1.130934715270996	low-volume EDs ; hospitalized ; medium ; high-volume EDs
P-464	-3.4617 -0.0466 -0.0273 -0.0458 -0.8669 -0.1232 -0.2901 -1.3128 -2.4538 -0.1805 -3.9757 -0.7266 -5.6170 -0.0218 -0.0570 -0.0210 -1.3697 -0.0841 -1.7151 -0.2217
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients ; cardiac transplant ; ecct ; patients ; diabetes mellitus ; chronic kidney disease ; estimated glomerular filtration rate
H-715	-0.39353147149086	▁cardiac ▁transplant ▁; ▁EC CT ▁; ▁diabetes ▁mell itus ▁; ▁chronic ▁ki dne y ▁disease ▁; ▁glo mer ular ▁filtr ation
D-715	-0.39353147149086	cardiac transplant ; ECCT ; diabetes mellitus ; chronic kidney disease ; glomerular filtration
P-715	-0.0876 -0.1172 -0.2409 -0.2009 -0.4643 -0.8708 -0.4400 -0.0151 -0.0838 -0.1064 -0.5571 -0.3550 -0.3059 -0.2596 -1.5164 -0.2566 -0.0782 -0.0174 -0.0607 -0.2384 -0.0889 -2.4148 -0.2754
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc battery ; health abc hf risk model ; change ; c-index ; net-reclassification-improvement ; hf
H-631	-0.4031303822994232	▁h ABC ▁Bat tery ▁score s ▁; ▁Health ▁ABC ▁; ▁ HF ▁Risk ▁Model ▁; ▁discrimina tion ▁; ▁c - index ▁; net - re class ification - improv ement ▁; ▁ HF
D-631	-0.4031303822994232	hABC Battery scores ; Health ABC ; HF Risk Model ; discrimination ; c-index ;net-reclassification-improvement ; HF
P-631	-0.1320 -1.0538 -0.6989 -0.0027 -1.1512 -0.0290 -0.0504 -1.2511 -0.1486 -0.6133 -1.8929 -0.0369 -2.2411 -0.3608 -0.3061 -0.2951 -0.0948 -0.1357 -0.2486 -0.0496 -0.0493 -0.2248 -0.6943 -0.0122 -0.1201 -0.0713 -0.0127 -0.0181 -0.0386 -0.0293 -0.1757 -0.9911 -0.4630 -0.2645 -0.1517
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi ; rmsea ; self-care maintenance ; cfi ; rmsea ; self-care management ; cfi ; rmsea ; self-care confidence
H-1507	-0.8882646560668945	▁c f ▁; ▁RM se a ▁; ▁Self - Car e ▁Main ten ance ▁Scal e ▁; ▁c f ▁; ▁RM se a ▁; ▁Self - Car e ▁management ▁Scal e ▁; ▁c f ▁; ▁RM se a ▁; ▁Self - Car e ▁Confi den ce ▁scale
D-1507	-0.8882646560668945	cf ; RMsea ; Self-Care Maintenance Scale ; cf ; RMsea ; Self-Care management Scale ; cf ; RMsea ; Self-Care Confidence scale
P-1507	-2.7934 -3.5996 -0.0414 -1.4708 -0.5022 -1.3699 -0.0432 -1.1221 -0.0374 -2.1164 -0.2040 -0.9778 -0.6609 -0.0155 -0.1789 -0.0820 -0.0337 -0.2490 -3.6707 -0.0211 -1.4649 -0.3722 -0.9659 -0.0328 -0.8962 -0.0326 -2.1740 -0.1413 -0.4454 -0.3885 -0.0388 -0.0375 -0.1715 -3.6235 -0.0238 -1.8346 -0.2743 -1.0730 -0.0472 -2.7664 -0.0212 -2.7162 -0.1722 -3.1788 -0.2280 -0.0309 -0.6778 -0.2760 -0.2291
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients ; bat ; patients ; quality-of-life ; nyha functional class ; change
H-1876	-0.64888596534729	▁BAT ▁; ▁distance ▁walked ▁; ▁quality - of - life ▁score ▁; ▁NY ha ▁functional ▁class ▁ranking
D-1876	-0.64888596534729	BAT ; distance walked ; quality-of-life score ; NYha functional class ranking
P-1876	-0.2959 -0.5118 -1.9291 -0.9483 -0.2959 -1.0282 -0.1038 -0.5963 -0.3707 -0.1668 -0.4119 -0.2067 -1.2366 -1.2139 -1.7649 -0.0186 -0.3635 -0.6424 -0.2238
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients ; preoperative ; hypoalbuminemia ; postoperative ; albumin ; hypoalbuminemia ; albumin ; lvad
H-537	-0.7477349042892456	▁hypo album in emia ▁; ▁post operativ e ▁normal ization ▁; ▁album in ▁levels ▁; ▁hypo album in emia ▁; ▁de cre as ing ▁album in ▁; ▁l VAD
D-537	-0.7477349042892456	hypoalbuminemia ; postoperative normalization ; albumin levels ; hypoalbuminemia ; decreasing albumin ; lVAD
P-537	-1.0885 -0.1976 -0.4501 -0.1101 -0.1324 -3.3144 -0.1014 -0.1242 -0.8788 -0.5850 -0.7208 -0.2199 -0.7333 -2.8119 -0.2537 -0.5793 -0.2309 -0.8388 -0.3330 -0.1633 -3.1691 -0.1620 -0.2207 -0.5540 -1.7688 -0.8432 -1.0150 -0.8701 -0.0383 -0.5370 -0.1345
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization ; confidence interval ; acute myocardial infarction ; ami ; complications ; kidney infection ; urinary tract infection ; uti ; complications
H-1717	-0.5186039805412292	▁re hospital ization ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁complica tions ▁; ▁ki dne y ▁infection ▁; ▁urin ary ▁tract ▁infection ▁; UTI
D-1717	-0.5186039805412292	rehospitalization ; acute myocardial infarction ;AMI ; complications ; kidney infection ; urinary tract infection ;UTI
P-1717	-4.5643 -0.0061 -0.7082 -0.1570 -0.3453 -0.0438 -0.8218 -0.2916 -0.1108 -0.2159 -0.0259 -0.6718 -0.3319 -0.2520 -0.4372 -0.2622 -3.9831 -0.0450 -0.1352 -0.5297 -0.1426 -0.0854 -0.6021 -0.0494 -0.0100 -0.1725 -0.0614 -0.6534 -0.3440 -0.0428 -0.2489 -0.2438
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients ; heart failure ; hf ; ischemic ; nonischemic cardiomyopathies ; pharmacological ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; right ventricular assist devices
H-54	-0.41237255930900574	▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁ ische mic ▁; ▁non ische mic ▁cardio my o pathi es ▁; ▁ pharma c ological ▁arma ment arium ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cardiac ▁transplant ation ▁; ▁vent ri cular ▁assist ▁devices
D-54	-0.41237255930900574	patients ; heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; ventricular assist devices
P-54	-1.8584 -1.3070 -0.4976 -0.1426 -0.1392 -0.0682 -0.1085 -0.6472 -0.4333 -0.0552 -1.4680 -0.5392 -1.1551 -0.1736 -0.0540 -0.3375 -0.9361 -0.0255 -0.2248 -0.4812 -1.9579 -0.0371 -0.1229 -0.1680 -0.0947 -0.0080 -0.0109 -0.2944 -0.0012 -0.0575 -0.5664 -0.1333 -0.0707 -0.0325 -2.6146 -1.3709 -0.0117 -1.5429 -0.3248 -0.0288 -0.0228 -0.0223 -0.0040 -0.4560 -0.3055 -0.0187 -0.1754 -0.1841 -0.2365 -0.0194 -0.2109 -0.9748 -0.4912 -0.0235 -0.1560 -0.1075 -0.2839 -0.1238
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf ; catheterization ; central venous pressure ; svr ; cardiac index
H-230	-1.5888328552246094	▁ SAF ▁; ▁p f ▁; ▁figure ▁; ▁central ▁ve nous ▁pressure ▁; ▁h g ▁; ▁h g ▁; ▁s vr ▁; ▁h g ▁; ▁h g ▁; ▁cardiac ▁index
D-230	-1.5888328552246094	SAF ; pf ; figure ; central venous pressure ; hg ; hg ; svr ; hg ; hg ; cardiac index
P-230	-2.7526 -0.6603 -0.3011 -2.6405 -0.6498 -0.4028 -5.6753 -0.8127 -1.0458 -1.5798 -2.2503 -2.8477 -0.2703 -0.0994 -0.0833 -0.2214 -2.1229 -0.1058 -0.2541 -2.1673 -2.0879 -0.7883 -5.6791 -0.7476 -0.3459 -5.2815 -1.0235 -0.3673 -5.3910 -1.6015 -0.2923 -0.2936
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission ; bnp ; reduced ef ; preserved ef ; bnp ; ef
H-193	-1.162685513496399	▁ad mission ▁media n ▁b NP ▁; ▁EF ▁; ▁EF ▁; ▁b NP ▁; ▁b NP
D-193	-1.162685513496399	admission median bNP ; EF ; EF ; bNP ; bNP
P-193	-1.8611 -0.0579 -2.0460 -0.0169 -0.3553 -0.4140 -0.1815 -1.4998 -0.0827 -5.1629 -0.1022 -1.6492 -1.0599 -0.1992 -1.1752 -1.3374 -3.4656 -0.2618
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart failure ; admission ; heart transplantation ; lv assist device ; death ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval ; ischemic ; functional class
H-435	-0.6760566830635071	▁heart ▁failure ▁ad mission ▁; ▁heart ▁transplant ation ▁; LV ▁assist ▁device ▁; ▁death ▁; ▁ ische mic ▁cause
D-435	-0.6760566830635071	heart failure admission ; heart transplantation ;LV assist device ; death ; ischemic cause
P-435	-1.2225 -0.7389 -1.8802 -0.0189 -0.1011 -0.9193 -0.6278 -0.0482 -0.1911 -0.2510 -1.2418 -0.1186 -0.2988 -0.4930 -0.3499 -3.0693 -1.1266 -0.0445 -0.2485 -1.0266 -0.1806
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv ejection fraction ; shortening ; systolic elastance ; contractile efficiency ; acf ; acf ; allopurinol ; cardiomyocytes ; extracellular flux analyzer
H-475	-0.3504616916179657	▁LV ▁e je ction ▁ fraction ▁; ▁vitesse ▁; ▁circum fer ential ▁short en ing ▁; ▁elastan ce ▁; ▁contract ile ▁efficiency ▁; ▁a CF ▁; ▁a CF ▁; ▁allo puri nol ▁rat s ▁; ▁o 2 ▁consum p tion ▁rate ▁; ▁cardio my o cy tes ▁; ▁extra cel lular ▁flux ▁anal y zer
D-475	-0.3504616916179657	LV ejection fraction ; vitesse ; circumferential shortening ; elastance ; contractile efficiency ; aCF ; aCF ; allopurinol rats ; o2 consumption rate ; cardiomyocytes ; extracellular flux analyzer
P-475	-0.3567 -0.5012 -0.2239 -0.0640 -0.1902 -0.0019 -0.1200 -2.2455 -1.9663 -1.2426 -0.3423 -0.0594 -0.2198 -0.0758 -0.1820 -0.1058 -1.8000 -0.1603 -0.0769 -0.0213 -1.4718 -0.2058 -0.0925 -0.2489 -0.6692 -0.0417 -0.8079 -0.8811 -0.0554 -0.1242 -0.0172 -0.1378 -0.1910 -0.0364 -0.1299 -0.3155 -0.0721 -0.9224 -0.0246 -0.0844 -1.1759 -0.0644 -0.0900 -0.2465 -0.2118 -0.0858 -0.1725 -0.1549 -0.0771 -0.2463 -0.0074 -0.0059 -0.5197 -0.0946 -0.0162 -0.1922 -0.1293
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively ; patients ; hfpef ; lv hypertrophy ; lvh ; relative wall thickness ; rwt ; lvh ; rwt ; lvh ; rwt ; lvh ; rwt
H-1526	-0.7638736367225647	▁ HF p EF ▁; ▁LV ▁structure ▁; ▁normal ▁ge ometr y ▁; ▁LV ▁hyper trop hy ▁; LV h ▁; ▁relative ▁wall ▁thi ck ness ▁; RW t ▁; ▁CR ▁; ▁LV h ▁; ▁r WT ▁; ▁h z
D-1526	-0.7638736367225647	HFpEF ; LV structure ; normal geometry ; LV hypertrophy ;LVh ; relative wall thickness ;RWt ; CR ; LVh ; rWT ; hz
P-1526	-1.8576 -0.1672 -0.0326 -0.3639 -0.1846 -0.6722 -3.0156 -0.5121 -0.5412 -0.7736 -0.1667 -0.4147 -0.1148 -0.8720 -0.3950 -0.0218 -0.0816 -0.0421 -1.1118 -1.0874 -0.0729 -0.7451 -0.6893 -0.6440 -0.1554 -0.4871 -0.1332 -2.1301 -0.1013 -0.1081 -1.3004 -0.0486 -0.7879 -0.7493 -0.0573 -1.8606 -0.5441 -0.1495 -2.8016 -2.0668 -3.8274 -0.1941
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 ; angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist ; valsartan ; hypertension ; heart failure with preserved ejection fraction ; outcomes ; heart failure with reduced ejection fraction
H-1463	-0.438167542219162	▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁; ▁nepri ly sin ▁inhibi tor ▁pro drug ▁; ▁ang io ten sin ▁receptor ▁anta gon ist ▁val sar tan ▁; ▁hyper tension ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1463	-0.438167542219162	angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction
P-1463	-0.9981 -2.0849 -0.5294 -1.2545 -0.0674 -0.7232 -0.1357 -0.4879 -0.0685 -0.0398 -0.1408 -0.0580 -0.1839 -0.5415 -0.1190 -0.0623 -0.2725 -0.0119 -0.0513 -0.0643 -0.8699 -0.3899 -0.7700 -0.0706 -0.2414 -0.0273 -1.0083 -0.1163 -0.0754 -0.0110 -0.1708 -0.0173 -0.1029 -0.1718 -2.3659 -0.2045 -0.2813 -1.7302 -0.0024 -0.1219 -0.0435 -0.3275 -0.1318 -0.0671 -0.0006 -3.1471 -0.2321
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood pressure ; mitral valve plasty ; degenerative mr ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; physio ring 30 ; edwards lifesciences ; irvine
H-343	-0.27684101462364197	▁blood ▁pressure ▁; ▁h g ▁; ▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁p 3 ▁pro lapse ▁; ▁chor dal ▁rup tures ▁; ▁tri ang ular ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is ▁; ▁ring ▁ann ulo plast y ▁; ▁Ph y sio ▁Ring ▁; ▁ed ward s ▁Life science s ▁; ▁ir vine ▁; ▁ca
D-343	-0.27684101462364197	blood pressure ; hg ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ; edwards Lifesciences ; irvine ; ca
P-343	-0.5895 -0.2755 -0.0580 -2.7258 -0.0090 -0.0993 -0.3979 -0.0273 -0.1654 -0.0430 -0.0175 -0.2487 -0.2865 -0.0179 -0.1128 -0.0171 -0.0461 -0.2116 -1.1938 -0.0204 -0.6033 -0.0166 -0.2570 -0.0075 -0.0602 -0.0073 -0.0431 -0.1304 -1.4176 -0.0164 -0.0020 -0.1679 -0.0026 -0.2456 -0.2542 -0.0038 -0.3030 -0.1966 -0.0363 -0.0192 -0.0310 -0.0045 -0.1676 -0.0318 -0.2065 -0.1166 -0.0524 -0.4209 -0.0123 -0.0832 -0.0918 -1.6115 -0.0077 -0.0073 -0.1388 -0.3465 -0.1643 -0.0169 -0.0015 -0.7407 -0.0107 -0.0011 -0.3945 -0.3278 -0.0080 -2.1010 -0.6892 -0.8533 -0.1089
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes ; incremental shuttle walk test ; peak oxygen uptake ; muscular ; echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory ; beck depression inventory ; health-related quality of life ; minnesota living with heart failure questionnaire ; medical outcomes study short-form
H-1320	-0.28906962275505066	▁shu ttle ▁walk ▁test ▁; ▁oxygen ▁up take ▁; ▁muscular ▁strength ▁; ▁e cho car dio graphic ▁measure s ▁; ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s ▁; ▁depression ▁; ▁be ck ▁de pression ▁in ven tory ▁; ▁health - related ▁quality ▁of ▁life ▁; Min nes ota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁Medical
D-1320	-0.28906962275505066	shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic measures ; pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; health-related quality of life ;Minnesota Living with Heart Failure Questionnaire ; Medical
P-1320	-0.2611 -0.0011 -0.0831 -0.8463 -0.0904 -0.3542 -0.2569 -0.0952 -0.1009 -0.0189 -0.7580 -0.0824 -0.0153 -0.0912 -0.0202 -0.1045 -0.1329 -1.4006 -0.0100 -0.1435 -0.1850 -0.0136 -0.0807 -0.1416 -0.0100 -0.0260 -0.0153 -1.3095 -0.2879 -0.0532 -0.0250 -0.1535 -0.3153 -0.4884 -0.1692 -0.0272 -0.0077 -0.1133 -0.1499 -0.0832 -0.8826 -0.1376 -0.1270 -0.0598 -0.2531 -0.1724 -0.0167 -0.3961 -2.0932 -0.0088 -0.1026 -0.7078 -0.2479 -0.4472 -0.2345 -1.3078 -0.0260 -0.1188 -0.2537 -0.7921 -0.5086 -0.0498 -0.0748 -0.8355 -0.0012 -0.5242 -0.2141 -0.6465 -0.1830
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction term analysis ; lvef ; patients ; patients ; mortality ; lvef ; p value
H-116	-0.7059292197227478	▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁LV EF ▁; ▁age - by - LV EF
D-116	-0.7059292197227478	LVEF ; long-term mortality ; LVEF ; age-by-LVEF
P-116	-3.6923 -0.1379 -0.1275 -0.8955 -0.0344 -0.6207 -0.0382 -0.1293 -0.1958 -4.3618 -0.0785 -1.1368 -1.6328 -0.0136 -0.2198 -0.0128 -0.0873 -0.0774 -0.4756 -0.1506
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto ; zsf1 ; obese ; zsf1 ; obese ; zsf1 ; followed up ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
H-763	-0.6560230255126953	▁rat s ▁; Wi star - K yo to ▁; ▁lean ▁Z SF 1 ▁; ▁obes e ▁Z SF 1 ▁; ▁obes e ▁Z SF 1 ▁; ▁high - fat ▁die t ▁; ▁metabol ic ▁; ▁renal ▁; ▁e cho car dio graphic ▁evaluation s ▁; ▁hem o dynamic ally
D-763	-0.6560230255126953	rats ;Wistar-Kyoto ; lean ZSF1 ; obese ZSF1 ; obese ZSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic evaluations ; hemodynamically
P-763	-6.2384 -0.0375 -0.1720 -2.0191 -0.0333 -0.0094 -2.7470 -0.0762 -0.0390 -0.0994 -0.1298 -1.5398 -0.2932 -1.0411 -0.0943 -0.2661 -0.0390 -0.9416 -0.2930 -0.5741 -0.1374 -1.0898 -0.0408 -0.8005 -0.3410 -0.5337 -0.1542 -2.4192 -0.0112 -0.1985 -1.9670 -0.1262 -0.2633 -0.7632 -0.0401 -0.7545 -0.0072 -0.4463 -0.0271 -0.0794 -0.0198 -0.1223 -0.2326 -3.0434 -0.0500 -0.3048 -1.1900 -0.0658 -0.0780 -0.5739 -1.4002 -0.1485
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier curves ; log-rank testing ; risk stratification ; patients ; patients
H-384	-0.7429708242416382	▁Ka plan - me ier ▁cur ves ▁; ▁log - rank ▁testing ▁; ▁risk ▁strat ification
D-384	-0.7429708242416382	Kaplan-meier curves ; log-rank testing ; risk stratification
P-384	-0.2988 -0.0395 -0.0051 -0.7436 -0.1727 -1.6771 -0.1179 -0.1402 -0.1193 -0.0170 -0.0033 -1.0073 -0.1672 -2.1255 -0.8498 -0.0719 -5.5715 -0.2457
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate cox regression analyses ; hypertension ; sinus rhythm ; hazard ratio ; confidence interval
H-950	-0.6548376083374023	▁af ▁type ▁; ▁long - standing ▁persist ent ▁AF ▁; ▁hyper tension ▁; ▁maintenance ▁; ▁sinus ▁ rhythm ▁; haz ard ▁ratio
D-950	-0.6548376083374023	af type ; long-standing persistent AF ; hypertension ; maintenance ; sinus rhythm ;hazard ratio
P-950	-1.5591 -2.6703 -0.0991 -2.8202 -0.0161 -0.0127 -0.0215 -0.2490 -0.9888 -0.1037 -0.0528 -0.0691 -0.1150 -1.8442 -0.8767 -0.1191 -0.0715 -0.1789 -0.7565 -0.0419 -0.0089 -0.0085 -2.8080 -0.2246
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients ; chronic ; hf-ref ; nyha functional class ii ; egfr ; potassium ; eplerenone ; hyperkalemia
H-1228	-0.43476879596710205	▁ HF - re f ▁; ▁NY HA ▁functional ▁class ▁II ▁; ▁e g FR ▁; ▁po tas s ium ▁; ▁e pler en one ▁; ▁hyper kal emia ▁; ▁w RF
D-1228	-0.43476879596710205	HF-ref ; NYHA functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wRF
P-1228	-1.2712 -0.2143 -0.0200 -0.4944 -0.1753 -0.0624 -0.0884 -0.6900 -0.2305 -0.0144 -0.6675 -0.3038 -0.4113 -3.0611 -1.6665 -0.0479 -0.0818 -0.2755 -0.1069 -0.0561 -0.0776 -0.0851 -0.4696 -0.0785 -0.9652 -0.7119 -0.3899 -0.1579 -0.1439 -0.2452 -0.7868 -0.3925 -0.1561 -0.1829
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm ; dual energy x-ray absorptiometry ; dxa ; patients ; chronic heart failure ; chf ; non-cachectic chf ; myocardial
H-12	-0.5128865838050842	▁f f ▁; ▁FM ▁; ▁body ▁fat ▁distribution ▁; ▁dual ▁energy ▁X - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁non - dia be tic ▁patients ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; cc ▁; ▁CHF ▁; ▁my o card ial ▁in far ction - bo th
D-12	-0.5128865838050842	ff ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; CHF ; myocardial infarction-both
P-12	-1.2738 -0.1656 -0.2161 -1.3261 -0.1202 -1.2291 -0.2127 -0.0571 -0.3099 -0.7647 -0.1670 -1.2092 -0.0390 -0.1142 -0.0301 -0.0715 -0.0524 -0.2155 -0.4707 -0.3447 -0.5239 -0.5126 -0.2285 -4.0445 -0.0135 -0.0431 -0.0529 -0.7479 -0.4883 -0.2574 -0.7943 -0.8267 -0.2889 -0.1419 -2.6807 -0.0719 -0.0600 -0.6013 -0.1194 -1.0876 -0.1288 -2.9173 -0.3501 -0.0651 -0.1145 -0.0086 -0.6805 -0.2187 -0.1508 -0.0048 -0.0108 -0.4345 -0.1237
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline ; drug ; spironolactone ; combined end point ; death ; hospitalization ; hf ; hazard ratio ; confidence interval ; aas ; hazard ratio ; confidence interval ; p value
H-1707	-0.5804054141044617	▁drug ▁dose ▁; ▁spi rono lac tone ▁; ▁end ▁point ▁of ▁death ▁; ▁hospital ization ▁; ▁ HF ▁; ▁AA s ▁; haz ard ▁ratio
D-1707	-0.5804054141044617	drug dose ; spironolactone ; end point of death ; hospitalization ; HF ; AAs ;hazard ratio
P-1707	-1.3880 -0.9382 -0.1387 -0.0090 -0.0066 -0.0393 -0.1117 -0.1294 -0.9422 -0.0498 -1.2537 -0.5289 -0.0584 -1.4194 -0.9575 -0.1262 -1.3112 -0.0420 -0.0960 -2.1605 -0.1739 -0.9907 -0.8214 -0.1402 -0.4859 -1.1588 -0.1934
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective study ; patients ; invasively ; diagnosed ; pulmonary arterial hypertension ; inoperable ; chronic thromboembolic pulmonary hypertension ; right ventricular ; pump ; stable ; pulmonary arterial hypertension ; medication ; noninvasive ; stress echocardiography ; cardiopulmonary exercise testing
H-823	-0.24129407107830048	▁pulmonar y ▁arterial ▁hyper tension ▁; ▁in opera ble ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y ▁hyper tension ▁; ▁im pair ed ▁right ▁vent ri cular ▁pump ▁; ▁pulmonar y ▁arterial ▁hyper tension ▁medication ▁; ▁stress ▁e cho card i ography ▁; ▁cardio pul mon ary ▁exercise
D-823	-0.24129407107830048	pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump ; pulmonary arterial hypertension medication ; stress echocardiography ; cardiopulmonary exercise
P-823	-0.5860 -0.0294 -0.0304 -0.0192 -0.0502 -0.0335 -0.6743 -0.0852 -0.0606 -0.0362 -0.0646 -0.0166 -0.4252 -0.1451 -0.0033 -0.2344 -0.0079 -0.0892 -0.0492 -0.0812 -0.0735 -0.9138 -0.0068 -0.0216 -0.7695 -0.0098 -1.1006 -0.0550 -0.4313 -1.0515 -0.8336 -0.0339 -0.0271 -0.0284 -0.0541 -1.0538 -0.2457 -0.3853 -0.0155 -0.1021 -0.0570 -0.1641 -0.2105 -0.1912 -0.0177 -0.0430 -0.2272 -0.2207 -0.1952 -0.9524 -0.0922
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular death ; hf ; hospitalization ; randomization ; btes ; btes ; cardiovascular death ; hf ; hospitalization ; exercise ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-1930	-0.7259172797203064	▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁b tes ▁; ▁b tes ▁; ▁b tes ▁; ▁cardiovascular ▁death ▁; ▁ HF
D-1930	-0.7259172797203064	cardiovascular death ; HF hospitalization ; btes ; btes ; btes ; cardiovascular death ; HF
P-1930	-0.9568 -1.1577 -0.0831 -0.7223 -0.0253 -1.4947 -1.0970 -0.2307 -0.1503 -0.4402 -0.0956 -0.4043 -0.3912 -0.0954 -3.2070 -0.3952 -0.1035 -0.2700 -1.0776 -0.0851 -0.4449 -0.0568 -4.2967 -0.1406
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients ; hospitalized ; death ; all-cause readmission ; aor ; eds ; aor
H-466	-1.0923943519592285	▁index ▁ED ▁visit ▁; ▁low - volu me ▁ED ▁; ▁30- day ▁death ▁; ▁all - ca use ▁read mission ▁; ▁ed s
D-466	-1.0923943519592285	index ED visit ; low-volume ED ; 30-day death ; all-cause readmission ; eds
P-466	-0.1191 -2.0181 -3.1816 -0.1197 -0.8608 -0.0155 -0.0122 -0.0325 -1.3758 -0.9699 -5.9956 -0.0623 -1.6514 -0.6092 -2.4595 -0.0108 -0.0258 -0.0048 -0.5277 -0.0732 -0.1396 -5.5087 -0.1659 -1.1896 -0.1806
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients ; implantable cardioverter-defibrillator ; implantation ; engage ; patients ; decisions ; implantable cardioverter-defibrillator
H-1863	-0.4049345552921295	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant ation ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1863	-0.4049345552921295	implantable cardioverter-defibrillator deactivation ; implantation ; implantable cardioverter-defibrillator deactivation
P-1863	-0.0005 -0.0658 -0.3074 -0.1153 -0.1217 -0.0189 -0.0419 -3.7784 -1.7117 -0.0063 -0.0598 -0.0323 -0.0422 -0.1548 -0.6286 -0.0072 -0.2773 -0.4249 -0.1586 -0.8196 -0.4151 -0.1694 -0.1076 -0.0125 -0.0243 -2.3105 -0.9574 -0.0067 -0.0648 -0.0534 -0.1203 -0.1408 -0.4907 -0.1212
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac magnetic resonance ; t1 time ; hazard ratio ; confidence interval ; left atrial area ; hazard ratio ; confidence interval ; pulmonary vascular resistance ; hazard ratio ; confidence interval ; cardiac events
H-739	-0.7048308849334717	▁Card iac ▁magnetic ▁res on ance ▁; ▁left ▁at rial ▁area ▁; ▁pulmonar y ▁vas cular ▁resist ance ▁; ▁cardiac
D-739	-0.7048308849334717	Cardiac magnetic resonance ; left atrial area ; pulmonary vascular resistance ; cardiac
P-739	-0.8533 -0.2322 -0.1596 -0.6162 -0.9357 -0.1306 -0.5044 -2.0808 -0.1331 -0.2499 -1.9325 -0.1919 -0.5147 -0.0960 -0.3407 -0.5280 -1.0881 -0.0497 -0.3770 -0.6563 -3.6275 -0.2078
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively ; followed up ; hf ; patients ; systolic ; left ventricular ejection fraction ; hf ; stable ; clinical ; conditions ; new york heart association class i ; clinical ; echocardiographic ; cardiopulmonary exercise test
H-1755	-0.5242608785629272	▁ HF ▁unit s ▁; ▁sy sto lic ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁New ▁York ▁Heart ▁Association ▁; ▁e cho car dio graphic ▁; ▁cardio pul mon ary ▁exercise
D-1755	-0.5242608785629272	HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart Association ; echocardiographic ; cardiopulmonary exercise
P-1755	-1.2558 -0.2022 -4.2491 -0.0355 -0.1951 -1.1705 -0.0550 -0.1333 -0.2770 -0.9663 -0.1938 -0.0433 -1.3166 -0.1916 -0.1438 -0.3213 -0.3656 -0.4194 -0.0009 -0.1112 -0.5965 -0.0958 -0.0681 -1.5109 -0.2863 -0.5993 -0.9053 -1.9636 -1.6557 -0.0786 -0.0217 -0.2413 -0.1299 -0.2165 -0.0495 -0.0591 -0.3064 -0.1738 -0.1915 -0.5916 -0.1061
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients ; end stage heart failure ; abcd classification ; american college of cardiology ; acc ; american heart association ; aha ; new york heart association ; nyha ; heart disease ; symptoms ; heart failure ; physical ; medical treatment
H-1666	-0.8365676403045654	▁heart ▁failure ▁; ▁ABC d ▁classifica tion ▁; ▁American ▁College ▁of ▁Card i ology ▁; ▁a cc ▁; ▁a cc ▁; American ▁Heart ▁association ▁; AHA ▁; ▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁structura l ▁heart ▁disease ▁; ▁heart ▁failure
D-1666	-0.8365676403045654	heart failure ; ABCd classification ; American College of Cardiology ; acc ; acc ;American Heart association ;AHA ; New York Heart association ;NYHA ; structural heart disease ; heart failure
P-1666	-6.3848 -0.6362 -0.1641 -0.3633 -0.3168 -0.9467 -0.0108 -0.1597 -0.7768 -0.2042 -0.2584 -0.3126 -0.3232 -0.3305 -0.1337 -0.0431 -0.0830 -0.1497 -2.5917 -0.0788 -0.0942 -1.3365 -1.1599 -0.8382 -0.2287 -0.2576 -0.0370 -3.2176 -0.5044 -1.4052 -0.9175 -0.2141 -1.7502 -0.6560 -0.3042 -4.3143 -0.0915 -0.2352 -1.4525 -0.1704 -1.5898 -0.5814 -1.0265 -0.1581
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva ; continuity equation ; lv end-diastolic volume ; lv end-systolic volume ; mitral filling flow ; mva ; mitral filling flow ; continuous wave doppler echocardiography ; mitral valve plasty
H-345	-0.43175074458122253	▁m va ▁; ▁continu ity ▁e qu ation ▁; LV ▁; ▁end - dia sto lic ▁volume ▁; ▁LV ▁; ▁end - sy sto lic ▁volume ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁m va ▁; ▁veloci ty ▁time ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁continuo us ▁wa ve ▁do pp ler ▁e cho card i ography ▁; ▁MR ▁; ▁mit ral ▁val ve ▁plast y
D-345	-0.43175074458122253	mva ; continuity equation ;LV ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow ; mva ; velocity time ; mitral filling flow ; continuous wave doppler echocardiography ; MR ; mitral valve plasty
P-345	-1.6310 -0.0794 -0.1736 -0.0246 -0.0674 -0.2543 -0.0380 -0.1125 -0.1189 -1.0564 -0.4876 -2.0076 -0.0101 -1.0241 -0.4885 -0.2688 -0.2714 -0.0593 -0.3194 -0.9279 -0.6000 -0.0078 -0.3123 -0.1932 -0.1250 -0.2840 -0.0844 -1.2065 -0.0551 -0.3947 -0.0452 -0.6522 -0.5259 -0.2502 -0.1853 -0.0904 -1.6481 -0.1136 -1.4669 -0.2446 -1.0457 -0.0717 -0.3983 -0.0276 -0.6230 -0.1138 -2.3885 -0.0753 -0.2436 -0.0097 -1.7558 -0.1230 -0.1464 -0.0610 -0.1986 -0.0459 -0.0786 -0.1455 -0.1047 -0.0493 -0.9280 -2.1259 -0.0368 -0.2894 -0.0453 -0.0348 -0.4346 -0.1402 -0.1437
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance ; rm ; all-cause mortality ; sts ; hh ; cri ; cri ; cri
H-157	-0.8926287889480591	▁stati tis tical ▁significa nce ▁; ▁RM ▁; ▁all - ca use ▁mortal ity ▁; ▁s ts ▁ HH ▁; ▁ms ▁; ▁office ▁hours
D-157	-0.8926287889480591	statitistical significance ; RM ; all-cause mortality ; sts HH ; ms ; office hours
P-157	-2.3170 -0.2720 -1.2459 -0.0724 -0.0201 -0.3166 -0.1440 -0.1929 -1.8483 -0.0085 -0.0133 -0.0032 -0.0180 -0.1194 -0.1096 -1.0423 -0.8744 -1.4032 -0.1336 -0.1625 -4.8198 -0.4773 -2.0617 -0.6425 -4.7101 -0.1799
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi ; hf ; clinic ; outcomes ; hfpsi ; outcomes ; tracking ; patients ; hfpsi
H-381	-0.9210206270217896	▁ HF PSI ▁; ▁Ann ▁Ar bor ▁Veteran s ' ▁Affairs ▁; ▁ HF ▁clinic ▁; VA - RT ▁; ▁VA ▁; ▁ HF PSI ▁; ▁ HF PSI ▁; ▁ HF PSI
D-381	-0.9210206270217896	HFPSI ; Ann Arbor Veterans' Affairs ; HF clinic ;VA-RT ; VA ; HFPSI ; HFPSI ; HFPSI
P-381	-0.8078 -0.7748 -0.4793 -0.0955 -0.0508 -0.2337 -0.0278 -0.2138 -0.0268 -4.3828 -0.0512 -1.1519 -0.9497 -0.2338 -2.5483 -0.0704 -1.2879 -1.1770 -1.3304 -0.3367 -1.4892 -1.7524 -1.3448 -0.7757 -0.5056 -0.3863 -1.6458 -0.7885 -0.5603 -0.6284 -2.3873 -0.8782 -0.8642 -1.8235 -0.1750
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas ; spironolactone ; hyperkalemia ; potassium ; hypokalemia ; potassium
H-1706	-0.4187150299549103	▁AA s ▁; ▁spi rono lac tone ▁dose ▁; ▁hyper kal emia ▁; ▁po tas s ium ▁; ▁hypo kal emia
D-1706	-0.4187150299549103	AAs ; spironolactone dose ; hyperkalemia ; potassium ; hypokalemia
P-1706	-0.2558 -0.2315 -0.2439 -1.2039 -0.0156 -0.0773 -0.0885 -0.8156 -0.1023 -0.2058 -0.3307 -0.2051 -0.2534 -0.8632 -0.4470 -0.1473 -0.4528 -0.5274 -0.5676 -0.7561 -0.2695 -1.3727 -0.1974
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate analysis ; patients ; preserved lvef ; mortality ; patients ; lvef ; hazard ratio ; lvef ; preserved lvef
H-115	-0.6190375685691833	▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁LV EF ▁; haz ard ▁ratio ▁; ▁LV EF
D-115	-0.6190375685691833	LVEF ; long-term mortality ; LVEF ;hazard ratio ; LVEF
P-115	-4.6253 -0.2083 -0.1286 -0.2635 -0.0428 -0.5656 -0.0401 -0.1464 -0.1933 -1.1457 -0.1058 -0.2320 -0.3007 -0.0080 -0.0016 -0.2759 -1.2580 -0.1413 -2.4787 -0.2192
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients ; hfpef ; primary outcome ; odds ratio ; nyha class iii ; 6-minute walk test ; 6-mwt ; feet ; prescribed ; medications
H-242	-1.245643973350525	▁ HF p EF ▁; ▁ HF p EF ▁; ▁gender ▁; ▁NY ha ▁class ▁III ▁; ▁distance ▁covered ▁; ▁mw t ▁; ▁ml t ▁; ▁ad her ence ▁; ▁medication s
D-242	-1.245643973350525	HFpEF ; HFpEF ; gender ; NYha class III ; distance covered ; mwt ; mlt ; adherence ; medications
P-242	-2.3448 -0.0898 -0.0426 -0.6105 -0.2189 -4.9069 -0.5668 -0.0538 -0.6920 -0.1750 -5.7145 -0.1962 -3.2692 -0.5301 -1.4554 -0.7209 -0.3021 -2.4009 -1.7371 -0.8059 -3.3444 -0.1513 -0.4978 -4.9433 -0.1229 -0.9833 -3.4830 -0.1949 -0.0045 -0.9062 -0.3336 -0.0530 -0.3150 -0.1852
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived pulmonary arterial systolic pressure ; pasp ; right ventricular ; rv ; tricuspid annular plane systolic excursion ; tapse ; diastole ; end-systole ; clinical ; follow-up ; heart failure ; hf ; patients ; cardiac
H-492	-0.35371193289756775	▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁right ▁vent ri cular ▁; RV ▁; ▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; TA PS e ▁; ▁dia stol e ▁; ▁end - sy stol e ▁; ▁heart ▁failure ▁; HF ▁; ▁cardiac ▁risk
D-492	-0.35371193289756775	pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
P-492	-0.9086 -0.0427 -0.0813 -0.4201 -0.0806 -0.8550 -0.5165 -0.0549 -0.0410 -0.6477 -0.0455 -0.6680 -0.0129 -1.2414 -0.1166 -0.2651 -0.6838 -0.1352 -1.2747 -0.0161 -0.0021 -0.0824 -0.0166 -0.1962 -0.0738 -0.2078 -0.9606 -0.1050 -0.0080 -0.1528 -0.4427 -1.1237 -1.0461 -0.0578 -0.9549 -0.0092 -0.1191 -0.8583 -0.0442 -0.0133 -0.1741 -0.0114 -0.0697 -0.2517 -1.0871 -0.1755 -0.0696 -0.2870 -0.5325 -0.1408 -1.0476 -0.1609 -0.1567
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad ; diabetes ; odds ratio ; electrocardiographic q waves ; left bundle branch block ; odds ratio ; nondiabetes ; dyslipidemia ; hypertension ; odds ratio
H-1190	-0.5528908371925354	▁CAD ▁; ▁electro car dio graphic ▁Q ▁wa ves ▁; ▁left ▁bund le ▁bran ch ▁block ▁; ▁non dia bete s ▁; ▁dys li pide mia ▁; ▁hyper tension ▁; ▁to ba cco ▁use
D-1190	-0.5528908371925354	CAD ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes ; dyslipidemia ; hypertension ; tobacco use
P-1190	-4.6100 -0.0877 -0.5001 -0.0165 -0.0591 -0.0995 -2.1871 -0.3637 -0.0628 -0.1098 -0.5248 -0.1950 -0.6408 -0.1672 -0.1822 -0.5390 -0.3038 -1.8542 -0.3345 -0.0198 -0.0354 -0.8179 -1.0365 -0.0333 -0.0320 -0.5706 -0.2118 -0.0080 -0.0406 -0.3445 -0.1936 -0.0681 -0.1116 -2.9650 -0.3505 -0.2269
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area under the receiver operating characteristic curve ; auc ; pcwp ; confidence interval ; septal ; p values
H-485	-1.1341058015823364	▁receive r ▁operating ▁character istic ▁cur ve ▁; ▁au c ▁; ▁ratio s ▁; ▁PC WP ▁; sept al ▁; ▁e - e lateral ▁; ▁e - eme an
D-485	-1.1341058015823364	receiver operating characteristic curve ; auc ; ratios ; PCWP ;septal ; e-elateral ; e-emean
P-485	-4.4074 -0.0109 -0.9115 -0.4750 -0.1428 -1.3130 -0.1055 -0.1611 -1.5485 -2.1413 -0.0649 -3.9458 -0.0224 -0.0801 -0.3098 -0.3512 -0.1992 -5.4748 -0.0181 -0.1149 -0.8068 -5.5457 -0.2043 -0.7792 -0.5456 -0.6682 -4.3552 -0.0259 -0.0582 -0.1424 -0.2275
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients ; coronary artery disease ; hypertension ; trastuzumab ; administration ; chf
H-680	-0.7775676846504211	▁tras tuz um ab - tre ated ▁patients ▁; ▁corona ry ▁arter y ▁disease ▁; ▁h ▁; ▁hyper tension ▁; ▁h
D-680	-0.7775676846504211	trastuzumab-treated patients ; coronary artery disease ; h ; hypertension ; h
P-680	-0.4596 -0.0154 -0.0684 -0.8725 -0.2534 -0.1199 -1.1734 -1.2125 -0.1502 -1.7176 -0.0579 -0.0213 -0.2500 -0.7838 -0.0773 -2.8145 -0.5961 -0.1325 -0.0353 -0.1414 -1.7543 -4.9449 -0.2317
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef ; clinical ; crt ; crt ; systolic volume index ; lv mass
H-754	-0.7737961411476135	▁LV EF ▁; ▁clinic al ▁com posit e ▁response ▁; ▁c RT ▁ON ▁; ▁c RT ▁OFF ▁; ▁LV ▁end ▁sy sto lic ▁volume ▁index ▁; ▁m L / m ▁; ▁LV ▁mass
D-754	-0.7737961411476135	LVEF ; clinical composite response ; cRT ON ; cRT OFF ; LV end systolic volume index ; mL/m ; LV mass
P-754	-0.2358 -0.2351 -0.0390 -1.2704 -0.0231 -0.0069 -0.0055 -0.0192 -0.5101 -0.1122 -0.2732 -1.2064 -1.7306 -0.1385 -0.2428 -1.7618 -0.4327 -0.0890 -0.7472 -2.8124 -1.0549 -0.1792 -0.4235 -0.3941 -0.3888 -0.0945 -1.5170 -2.0059 -2.7030 -0.0280 -1.0298 -2.1978 -2.5868 -0.4956 -0.0921
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β signaling ; tgf-β receptor type i ; cell ; yield ; epithelial ; mesenchymal ; transition ; pluripotency marker ; nanog ; cell ; cells ; in vitro
H-1343	-0.3343925476074219	▁T GF - β ▁signal ing ▁; ▁T GF - β ▁receptor ▁; ▁s mad ▁; ▁small - mo le cule ▁inhibi tors ▁; ▁c - K it + ▁cell ▁yi eld ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker ▁na nog ▁; ▁c - K it + ▁cell ▁differenti ation ▁; ▁cardio my o cy te - like ▁cell s
D-1343	-0.3343925476074219	TGF-β signaling ; TGF-β receptor ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
P-1343	-1.9504 -0.2675 -0.0601 -0.0604 -0.5700 -0.1973 -0.0887 -2.4100 -0.3955 -0.0638 -0.1931 -0.5604 -0.6057 -0.9945 -0.0111 -0.1006 -1.4052 -0.0076 -0.0937 -0.7474 -0.1069 -0.0585 -0.8265 -0.0679 -0.0639 -0.0661 -0.7888 -0.0449 -2.2242 -0.4780 -0.4261 -0.0019 -0.0889 -0.0748 -0.1092 -0.0471 -0.0260 -1.3288 -0.0121 -0.1569 -0.0924 -0.4295 -0.0027 -0.0613 -0.0119 -0.0863 -0.0039 -0.0303 -0.0069 -0.0232 -0.2868 -0.0181 -0.1723 -0.1241 -0.0180 -0.3346 -0.0457 -1.5270 -0.1888 -0.2658 -0.0143 -0.3422 -0.0255 -0.2996 -0.1710 -0.0755 -0.1562 -0.2463 -0.4714 -0.0687 -0.0112 -0.8945 -0.1239
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients ; hfref ; diuretics ; co-morbidities ; 6-mwt ; feet ; nyha class iii
H-243	-0.7110355496406555	▁h fr f ▁; ▁di ure tics ▁; ▁co - mor bid ities ▁; ▁mw t ▁; ▁NY ha ▁class ▁III
D-243	-0.7110355496406555	hfrf ; diuretics ; co-morbidities ; mwt ; NYha class III
P-243	-0.1726 -1.1545 -0.6613 -0.1008 -0.2377 -0.2448 -1.0109 -0.2361 -0.2185 -0.0321 -0.0914 -0.0247 -0.7602 -0.3207 -3.3695 -0.2499 -0.2755 -3.1703 -0.8048 -0.2777 -0.3828 -2.3417 -0.2155
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery ; hf ; postoperative ; echocardiography ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mitral valve area ; mva
H-344	-0.5722659230232239	▁surgery ▁; ▁ HF ▁; ▁post operativ e ▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁LV ▁; ▁e je ction ▁ fraction ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁mit ral ▁val ve ▁; ▁m va ▁; ▁pression ▁gradi ent ▁; ▁h g
D-344	-0.5722659230232239	surgery ; HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve ; mva ; pression gradient ; hg
P-344	-1.8599 -0.0798 -1.2580 -0.0198 -0.2179 -3.0682 -0.0986 -0.0296 -0.0418 -0.3070 -0.0671 -0.3150 -0.1537 -0.1054 -1.6624 -0.0891 -0.2099 -0.0145 -0.2352 -0.2438 -0.2668 -0.2406 -0.6999 -0.1252 -3.2714 -0.3805 -2.7295 -0.5284 -0.0620 -0.3382 -0.0025 -0.2271 -0.1181 -0.1097 -2.7897 -0.1221 -0.2786 -0.0930 -0.7358 -0.1370 -1.2427 -0.2676 -0.2247 -0.0801 -2.2504 -0.3831 -0.2036 -0.3110 -2.4967 -0.2496 -0.0398 -0.5155 -0.0356 -0.0131 -0.3006 -0.1000
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients ; systolic heart failure ; ejection fraction ; randomized ; placebo ; ivabradine ; shift ; systolic heart failure treatment with the if inhibitor ivabradine trial ; patients ; placebo ; ivabradine ; echocardiographic
H-519	-0.4743839502334595	▁sy sto lic ▁heart ▁failure ▁; ▁i va bra dine ▁; ▁SHI FT ▁; Sy sto lic ▁Heart ▁Fail ure ▁Treatment ▁; ▁If ▁in hib itor ▁i va bra dine ▁Tri al ▁; ▁i va bra dine ▁; ▁e cho car dio graphic ▁sub stu dy
D-519	-0.4743839502334595	systolic heart failure ; ivabradine ; SHIFT ;Systolic Heart Failure Treatment ; If inhibitor ivabradine Trial ; ivabradine ; echocardiographic substudy
P-519	-4.1901 -0.2085 -1.3331 -0.5979 -0.1362 -0.0925 -2.4084 -0.0587 -0.9565 -0.0434 -0.1268 -0.1031 -0.7343 -0.0811 -1.4866 -0.0626 -0.7553 -0.2600 -0.0575 -0.0245 -0.3573 -0.1199 -2.3690 -0.3434 -0.0306 -0.0298 -1.0335 -0.0066 -0.2290 -0.0102 -0.8736 -0.0070 -0.2130 -0.2452 -0.0195 -0.5122 -0.0338 -0.2734 -0.2335 -0.2077 -0.0372 -0.5880 -0.6069 -0.0485 -0.0012 -0.3975 -0.1260 -0.0996
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard ratios ; multivariate regression ; tapse ; pasp ; hazard ratio ; tapse ; new york heart association functional class
H-499	-1.0861878395080566	▁Hazard ▁ratio s ▁; ▁multi varia te ▁re gression ▁; ▁t AP se / PAS p ▁; ▁h g ▁; haz ard ▁ratio ▁; ▁t AP se ▁; ▁New ▁York ▁Heart ▁Association ▁functional ▁class
D-499	-1.0861878395080566	Hazard ratios ; multivariate regression ; tAPse/PASp ; hg ;hazard ratio ; tAPse ; New York Heart Association functional class
P-499	-5.7529 -0.3616 -0.1303 -0.1799 -4.1447 -0.1220 -0.3265 -0.0295 -0.0594 -0.4029 -2.0756 -1.2782 -0.8464 -2.2677 -0.1412 -0.3354 -0.1299 -1.1231 -0.3997 -0.1321 -3.4369 -0.0677 -0.0500 -0.2026 -2.4350 -1.8169 -0.5208 -0.0860 -3.4980 -0.6509 -2.2840 -1.2881 -1.2932 -0.0568 -0.9638 -0.2129
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal function ; the chronic kidney disease epidemiology collaboration ; patients ; estimated glomerular filtration rate ; egfr
H-390	-0.788416862487793	▁Ren al ▁function ▁; ▁Chro nic ▁Kid ney ▁Disease ▁Epidemi ology ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR
D-390	-0.788416862487793	Renal function ; Chronic Kidney Disease Epidemiology ; glomerular filtration rate ; egFR
P-390	-1.1550 -0.1850 -3.1346 -0.3118 -0.0114 -0.4775 -0.0505 -0.2283 -0.0951 -0.0547 -0.7776 -0.4881 -1.7670 -0.1225 -0.3142 -0.2148 -0.0863 -1.0618 -0.3540 -0.0722 -2.1878 -2.5727 -2.8637 -0.3355
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective ; randomized ; paradigm-hf ; chronic heart failure ; systolic dysfunction ; lv ef ; functional class ; nyha ; elevated ; bnp ; nt-pro bnp ; primary endpoint ; cardiovascular death ; hospitalization ; heart failure ; arni ; lcz696 ; sacubiltril ; valsartan
H-1968	-0.6430742740631104	▁para DIG m - HF ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁; LV EF ▁; ▁functional ▁class ▁NY HA ▁II - III ▁; ▁b NP ▁; ▁b NP ▁; car dio vas cular ▁death ▁; ▁hospital ization ▁for ▁heart ▁failure ▁; ▁AR NI ▁; ▁sa cubi lt ril ▁; ▁val sar tan
D-1968	-0.6430742740631104	paraDIGm-HF ; chronic heart failure ; systolic dysfunction ;LVEF ; functional class NYHA II-III ; bNP ; bNP ;cardiovascular death ; hospitalization for heart failure ; ARNI ; sacubiltril ; valsartan
P-1968	-4.5705 -0.9366 -0.1356 -0.0160 -0.0837 -0.1767 -2.3293 -0.7339 -0.2613 -0.3766 -0.6069 -0.1790 -1.4402 -0.0074 -0.0576 -0.1241 -0.0940 -4.9491 -0.0699 -3.9585 -0.0443 -0.6437 -0.3859 -0.7562 -0.0182 -0.0112 -0.0988 -0.0743 -0.3319 -0.1724 -0.1885 -0.3014 -0.1159 -3.4966 -0.0452 -0.2801 -0.1266 -0.5663 -0.0527 -0.4143 -0.7478 -1.0116 -0.2582 -0.2364 -0.3875 -1.6547 -1.0229 -0.1198 -1.0288 -0.2280 -0.0898 -0.0276 -0.5438 -0.0316 -0.0318 -0.0081 -0.5040 -0.1346
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv reverse remodeling ; lv end-diastolic dimension ; longitudinal ; strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial ; right ventricular fractional area ; change
H-432	-1.4230153560638428	▁LV ▁rever se ▁remodel ing ▁; ▁pre - C RT ▁; ▁vent ric le ▁; ▁left ▁at rial ▁; ▁vent ri cular ▁end - dia sto lic ▁ dimension ▁; ▁vent ri cular ▁ fraction al ▁area ▁change
D-432	-1.4230153560638428	LV reverse remodeling ; pre-CRT ; ventricle ; left atrial ; ventricular end-diastolic dimension ; ventricular fractional area change
P-432	-1.6432 -0.3704 -0.0062 -0.0127 -0.0943 -0.0878 -1.8900 -0.0044 -2.4129 -1.3633 -0.2285 -5.5446 -3.3518 -2.4196 -0.1177 -2.0835 -2.1065 -0.4071 -1.5815 -2.0699 -1.9191 -0.1848 -4.3164 -0.0277 -0.2263 -0.9458 -1.1316 -5.3824 -0.3152 -0.3467 -2.3032 -3.1973 -0.3063 -5.0645 -0.0263 -0.0905 -2.0701 -0.3174 -0.7476 -0.2054
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia ; outcomes ; african americans ; aas ; new york heart association ; nyha ; hf ; left ventricular dysfunction ; randomized ; spironolactone ; titrated ; placebo ; randomized aldactone evaluation study ; rales
H-1703	-0.4830813407897949	▁hyper kal emia ▁; ▁African ▁American s ▁; ▁AA s ▁; ▁non - AA s ▁; ▁New ▁York ▁Heart ▁Association ▁; NY HA ▁; ▁ HF ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁spi rono lac tone ▁; ▁al da cto ne ▁Evalua tion ▁Study ▁; RAL es
D-1703	-0.4830813407897949	hyperkalemia ; African Americans ; AAs ; non-AAs ; New York Heart Association ;NYHA ; HF ; left ventricular dysfunction ; spironolactone ; aldactone Evaluation Study ;RALes
P-1703	-0.2312 -0.2190 -0.1696 -0.1280 -1.2244 -0.7303 -0.0921 -0.0629 -1.6004 -0.0644 -0.0303 -1.4303 -0.0091 -0.0358 -0.0162 -0.0402 -4.7498 -0.5838 -1.2531 -0.9249 -0.1687 -1.3180 -1.3859 -0.0999 -1.1844 -0.4037 -0.0489 -0.1723 -0.0202 -2.2922 -0.3721 -0.0171 -0.3404 -0.1307 -0.0418 -0.0047 -0.0200 -0.0195 -0.1236 -1.0185 -0.0488 -0.0375 -0.0742 -0.1995 -0.0164 -0.5802 -0.4524 -0.0194 -0.1816 -0.1453 -0.1035
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 ; irs2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; irs1 ; irs2 ; heart-specific irs1 and irs2 gene double-knockout ; h-dko ; liver-specific irs1 and irs2 double-knockout ; l-dko
H-654	-0.519512414932251	▁i RS 1 ▁; ▁i RS 2 ▁; ▁hyper insu line mia ▁; ▁my o card ial ▁insulin ▁resist ance ▁; ▁cel lular ▁dys function ▁; ▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart - specific ▁; ▁i RS 1 ▁; ▁i RS 2 ▁gene ▁double - k no ckou t ▁; ▁h - d KO ▁; ▁ liver - specific ▁i RS 1 ▁; ▁i RS 2 ▁double - k no ckou t ▁; ▁l - d KO
D-654	-0.519512414932251	iRS1 ; iRS2 ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS1 ; iRS2 ; heart-specific ; iRS1 ; iRS2 gene double-knockout ; h-dKO ; liver-specific iRS1 ; iRS2 double-knockout ; l-dKO
P-654	-1.0219 -0.4016 -0.5847 -0.7927 -0.8800 -0.8835 -0.1526 -0.4547 -0.5613 -0.0212 -0.5027 -1.4500 -0.2072 -1.0757 -0.2027 -0.2984 -0.5395 -0.1581 -0.8763 -0.0253 -0.1527 -0.7509 -0.0112 -0.0083 -0.1294 -0.2000 -0.6180 -0.1711 -0.7654 -0.4254 -0.7889 -0.6506 -0.0772 -0.3934 -1.8447 -0.0546 -0.1666 -1.4663 -1.2435 -0.2870 -0.2792 -0.2602 -1.4224 -1.0704 -0.1191 -2.7096 -0.0133 -0.0193 -0.9805 -0.0808 -0.0112 -0.0103 -0.2405 -0.3005 -0.1705 -0.4033 -0.2690 -0.3097 -0.4734 -0.8608 -0.0449 -0.3069 -2.0978 -0.6057 -0.2845 -0.3495 -1.8335 -2.0152 -0.1276 -0.0350 -0.0139 -0.7151 -0.0344 -0.0167 -0.0108 -0.3229 -0.7110 -0.0860 -0.3493 -0.4153 -0.6927 -0.2315
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; diagnostic ; stable ; coronary artery disease ; b-type natriuretic peptide ; bnp ; nt-probnp ; ventricular cardiomyocytes ; ventricular ; wall stress ; myocardial ischemia
H-1364	-0.6045098900794983	▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁n - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁; ▁corona ry ▁arter y ▁disease ▁; ▁b NP ▁; ▁vent ri cular ▁cardio my o cy tes ▁; ▁vent ri cular ▁wall ▁stress ▁; ▁my o card ial ▁ ische mia
D-1364	-0.6045098900794983	b-type natriuretic peptide ; n-terminal pro-B-type natriuretic peptide ; coronary artery disease ; bNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
P-1364	-0.8849 -1.0787 -0.7318 -0.0829 -0.4389 -0.0455 -1.9487 -0.4934 -0.0974 -0.1058 -0.1014 -5.0888 -0.0152 -0.0100 -0.0033 -0.3480 -0.0173 -0.7798 -0.0708 -0.0585 -0.0311 -0.1707 -0.0486 -2.0203 -0.6198 -0.1207 -0.0833 -0.1896 -3.5703 -0.1013 -0.0814 -0.2906 -0.6897 -0.4110 -0.7467 -1.6584 -0.2392 -2.7847 -0.6346 -0.3033 -0.1312 -0.1701 -0.2972 -0.0718 -0.2273 -0.1860 -0.0168 -1.4679 -0.3350 -2.0165 -0.4775 -0.0964 -1.2070 -0.2051 -0.1641 -0.5016 -0.0747 -0.9411 -0.6775 -0.2526 -0.1614
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range ; interquartile range
H-665	-0.3769896924495697	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁β - block ers
D-665	-0.3769896924495697	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers
P-665	-1.0818 -1.2790 -0.0897 -0.6192 -0.0567 -0.0227 -0.0676 -1.1067 -0.0331 -0.0812 -0.0276 -1.0268 -0.6450 -0.1853 -0.0064 -0.2798 -0.0228 -0.5173 -0.0547 -0.3794 -0.9500 -0.0045 -0.0600 -0.0708 -0.8879 -0.2457
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ; ivabradine ; change ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; correlates ; exercise capacity ; therapy ; ivabradine ; correlated ; peak oxygen uptake
H-1177	-1.3252924680709839	▁i va bra dine ▁; ▁ therapy ▁; ▁i va bra dine
D-1177	-1.3252924680709839	ivabradine ; therapy ; ivabradine
P-1177	-0.7756 -0.0122 -0.5799 -0.0385 -0.1564 -4.7521 -0.2599 -0.2973 -5.2070 -0.0804 -0.8226 -0.2680 -5.1374 -0.1669
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence ; transfusion ; mortality ; relative risk ; mortality ; patients ; acute coronary syndrome
H-45	-0.580815315246582	▁liberal ▁trans fusion ▁protocol s ▁; ▁mortal ity ▁; ▁aggressiv e ▁protocol s ▁; ▁a cute ▁corona ry ▁syndrome
D-45	-0.580815315246582	liberal transfusion protocols ; mortality ; aggressive protocols ; acute coronary syndrome
P-45	-1.0801 -0.0249 -0.1136 -0.7014 -0.0230 -0.2418 -3.4038 -0.2718 -1.5253 -1.9995 -0.0432 -0.2928 -0.0149 -0.2275 -1.7346 -0.0211 -0.0915 -0.0532 -0.0172 -0.1724 -0.1436
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death ; readmission ; patients ; physician ; hazard ratio ; confidence interval ; physician ; follow-up ; patients ; follow-up
H-1419	-1.1223596334457397	▁death ▁; ▁un plan ned ▁read mission
D-1419	-1.1223596334457397	death ; unplanned readmission
P-1419	-5.5917 -0.1222 -0.0964 -0.0463 -0.3471 -0.4852 -0.1125 -3.1180 -0.1817
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek ; human embryonic kidney ; cells ; β1ar ; s1pr1 ; β1ar ; downregulation ; sphingosine-1-phosphate ; s1pr1 agonist ; s1pr1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
H-1409	-0.6081641316413879	▁h EK ▁; ▁em bry o nic ▁ki dne y ▁; ▁sp hing os ine -1 - phos pha te ▁; ▁s 1 PR 1 ▁ago nist ▁; ▁iso prot eren ol ▁; ▁β - ad r energi c ▁receptor ▁ago nist
D-1409	-0.6081641316413879	hEK ; embryonic kidney ; sphingosine-1-phosphate ; s1PR1 agonist ; isoproterenol ; β-adrenergic receptor agonist
P-1409	-0.5800 -1.9627 -0.0986 -1.1527 -0.0524 -0.0861 -0.8426 -0.3618 -0.2209 -0.0842 -0.1931 -4.5862 -0.5587 -1.7804 -0.2228 -0.5595 -0.0463 -0.0024 -0.0485 -0.0230 -0.0655 -1.8802 -0.0789 -0.2294 -0.2649 -2.0628 -0.0472 -0.2658 -4.0236 -0.0400 -1.7905 -0.0347 -0.1570 -0.6533 -0.0294 -0.0764 -0.2317 -0.4905 -0.0974 -0.0691 -0.1052 -0.0202 -0.4578 -0.1249
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline ; training ; 6-minute walked distance ; quality of life ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; symptoms ; beck depression inventory ; zung self-rated depression scores ; b-type natriuretic peptide ; endothelial function ; flow-mediated dilatation ; left ventricular diastolic function
H-1330	-0.4089393615722656	Kan sas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁ depressiv e ▁symptoms ▁; ▁be ck ▁de pression ▁in ven tory ▁; ▁depression ▁; ▁na tri ure tic ▁pe pti de ▁; ▁en dot heli al ▁function ▁; flow - media ted ▁di la tation ▁; ▁vent ri cular ▁dia sto lic ▁function
D-1330	-0.4089393615722656	Kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; depression ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; ventricular diastolic function
P-1330	-2.8055 -0.0105 -0.2943 -0.5565 -0.0877 -0.1003 -0.8871 -0.0564 -1.3674 -0.0034 -0.0378 -0.0189 -0.3772 -0.8439 -0.1585 -0.0214 -0.0424 -0.9029 -0.0034 -0.0769 -0.3799 -0.0122 -0.0406 -0.2503 -0.0451 -0.8160 -0.1177 -0.1830 -0.0273 -0.5056 -0.1329 -0.0050 -0.1061 -1.2636 -0.7834 -0.4226 -0.0573 -0.0243 -0.8699 -0.0847 -0.0259 -0.0166 -0.1301 -0.1858 -2.0764 -0.1025 -0.0056 -2.3024 -0.1527 -1.0673 -0.0124 -0.0782 -0.7089 -0.0322 -0.1495 -0.0098 -0.2630 -0.2294 -0.4421 -0.0737 -0.1335 -0.0864 -0.6060 -2.8605 -0.2681 -0.1908
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds ratios ; confidence intervals ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; patients ; estimated glomerular filtration rate ; nonsignificant ; acute kidney injury
H-976	-0.3323889970779419	▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁diabetes ▁mell itus ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁stroke ▁; ▁glo mer ular ▁filtr ation
D-976	-0.3323889970779419	cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration
P-976	-2.5025 -0.4260 -0.1791 -1.1478 -0.0747 -0.2526 -0.0109 -0.0203 -0.1549 -0.1480 -0.0151 -1.3160 -0.2436 -0.0701 -0.1389 -0.2059 -0.3261 -0.0008 -0.1163 -0.0312 -0.0060 -0.0278 -0.0641 -0.0970 -0.0854 -0.1142 -0.0549 -0.2411 -0.0786 -0.3143 -0.1005 -0.2441 -0.1619 -0.1156 -0.2513 -0.0127 -0.9817 -0.1408 -0.1233 -0.1549 -0.1107 -0.0708 -0.0578 -0.3407 -0.2762 -0.0132 -0.0513 -0.1240 -0.0347 -4.9527 -0.1687
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic function ; ea ; ventricular-arterial coupling ; ees ; ea
H-925	-0.6841274499893188	▁in ▁con jun ction ▁; ▁dia sto lic ▁function ▁; ▁vent ri cular - arte rial ▁coup ling
D-925	-0.6841274499893188	in conjunction ; diastolic function ; ventricular-arterial coupling
P-925	-2.0557 -0.5920 -0.1858 -0.0521 -0.3641 -0.0815 -0.2587 -0.7466 -2.5017 -0.1913 -0.6003 -1.5223 -0.0849 -0.0745 -0.0130 -0.0715 -0.0644 -1.9762 -1.9766 -0.2693
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard ratios ; disease risk score ; drs ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
H-1835	-0.7470893859863281	▁disease ▁risk ▁score ▁; ▁d RS ▁; ▁si tag lip tin ▁; ▁sax ag lip tin ▁; ▁pi og lita zone ▁; ▁sax ag lip tin ▁; ▁sul fon yl ure as ▁; ▁sax ag lip tin ▁; ▁insulin
D-1835	-0.7470893859863281	disease risk score ; dRS ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
P-1835	-1.3809 -0.7973 -0.1747 -0.1943 -0.1425 -0.5031 -0.3703 -4.6691 -0.0059 -0.3978 -1.2636 -0.2648 -1.8482 -0.4397 -0.6123 -1.6227 -0.2651 -0.0268 -1.2100 -0.0423 -0.0740 -0.2187 -1.5437 -1.1141 -0.7699 -2.0206 -0.3575 -0.5213 -0.0233 -0.2298 -0.0573 -0.1076 -0.4020 -2.0461 -1.3046 -0.7449 -1.8451 -0.5276 -0.1768 -0.1314 -0.1828
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients ; revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline ; electrocardiogram
H-106	-0.4015949070453644	▁re vas cular ization ▁; ▁co ron ary ▁arter y ▁by pass ▁surgery ▁; ▁hazard ▁ratio ▁; ▁per cuta ne ous ▁corona ry ▁intervention ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁left ▁bund le ▁bran ch ▁block ▁pattern ▁; ▁base line ▁electro card i ogram
D-106	-0.4015949070453644	revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram
P-106	-2.3551 -0.0166 -0.0799 -0.2643 -0.1754 -1.3369 -0.1096 -0.5420 -0.0335 -0.0947 -0.7858 -0.1212 -0.1342 -0.3013 -0.1797 -0.0027 -0.0928 -0.1554 -0.0012 -0.0679 -0.3238 -0.1996 -0.0857 -0.2962 -0.1778 -2.0108 -0.0633 -0.6564 -0.1981 -0.9681 -0.1199 -1.7383 -0.0350 -0.2087 -0.2304 -0.1133 -0.4899 -0.4880 -0.2613 -0.2317 -0.0454 -0.0086 -0.0210 -0.1598 -0.0229 -2.6970 -0.1736
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical ; biomedical ; relative risk ; confidence interval ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1262	-0.7310288548469543	▁bio medic al ▁treatment ▁; ▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1262	-0.7310288548469543	biomedical treatment ; biomedical treatment ; CHm ; ventricular ejection fraction ; left ventricular diastolic end diameter
P-1262	-0.0195 -0.0157 -0.0099 -1.3522 -0.3910 -0.9871 -0.0171 -0.0118 -1.6128 -0.1841 -1.6576 -0.1455 -0.1771 -2.7394 -1.1411 -0.2716 -0.8110 -0.6665 -0.3001 -0.5183 -0.0033 -0.1563 -2.4184 -0.0656 -1.7984 -0.3587 -1.6805 -0.3009 -0.6658 -0.4262 -0.4747 -2.4828 -0.2632
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective ; randomized ; crossover study ; outcome ; stable heart failure ; patients ; left ventricular ejection fraction ; homozygous ; haplotype ; β2-receptor ; randomized ; carvedilol ; metoprolol
H-1114	-0.6815520524978638	▁heart ▁failure ▁patients ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁Ar g 16 ▁; ▁gr n 27 ▁; ▁g ly 16 ▁; ▁figure ▁; ▁β 2- recept or ▁; ▁car vedi lol ▁; ▁met o pro lol
D-1114	-0.6815520524978638	heart failure patients ; left ventricular ejection fraction ; Arg16 ; grn27 ; gly16 ; figure ; β2-receptor ; carvedilol ; metoprolol
P-1114	-3.3021 -0.2533 -1.3244 -0.0799 -1.3110 -0.2520 -0.0272 -1.5514 -0.3691 -0.0647 -0.5604 -0.3235 -0.6343 -0.0013 -0.1162 -2.9559 -0.0163 -0.2372 -1.0371 -0.6292 -1.4662 -0.2210 -0.0849 -2.4776 -1.1034 -0.1314 -0.6132 -4.1093 -0.2276 -1.4077 -0.2460 -0.0037 -0.0730 -0.3422 -0.7565 -0.1255 -0.4322 -0.1428 -0.2300 -0.1646 -0.0318 -0.3066 -0.1132 -0.1312
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients ; death ; hospitalization ; aor ; aor ; aor ; aor
H-465	-1.2995058298110962	▁low - volu me ▁ED ▁; ▁death ▁; hospital ization ▁; ▁ed
D-465	-1.2995058298110962	low-volume ED ; death ;hospitalization ; ed
P-465	-4.6412 -0.0451 -0.0282 -0.0484 -1.3533 -1.1398 -3.9108 -0.9017 -0.9982 -0.9854 -0.8731 -0.5140 -2.5330 -0.2208
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health buddy program ; all-cause mortality ; hazard ratio ; confidence interval ; inpatient ; admissions ; baseline
H-1625	-0.48543399572372437	▁Health ▁Budd y ▁Program ▁; ▁risk - ad just ed ▁all - ca use ▁mortal ity ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁CI ▁; ▁quarter ly ▁in patient ▁ad missions
D-1625	-0.48543399572372437	Health Buddy Program ; risk-adjusted all-cause mortality ;hazard ratio ;HR ; confidence interval ; CI ; quarterly inpatient admissions
P-1625	-2.3082 -0.0348 -0.0333 -1.1793 -0.1901 -3.3132 -0.0141 -0.0089 -0.0008 -0.0193 -0.0270 -0.0124 -0.0092 -0.0071 -0.0073 -0.0682 -0.2206 -0.0026 -0.0105 -0.0005 -0.3230 -0.2215 -0.1728 -1.6489 -0.1196 -0.3371 -3.4751 -0.3137 -1.2008 -0.0466 -0.0136 -0.0714 -0.2671 -0.0095 -1.6200 -0.1676
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted hazard ratios ; dash
H-691	-0.5425463318824768	▁multi vari able - ad just ed ▁hazard ▁ratio s ▁; ▁Mediterrane an ▁die t ▁score ▁; ▁DAS h
D-691	-0.5425463318824768	multivariable-adjusted hazard ratios ; Mediterranean diet score ; DASh
P-691	-0.0747 -0.0019 -0.0663 -0.0532 -0.0140 -0.0047 -0.0459 -0.2151 -0.1191 -0.1040 -0.2368 -2.2758 -0.3154 -3.3103 -0.1476 -0.3057 -0.3432 -1.7627 -0.4609 -1.2871 -0.2491
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt ; nt-probnp ; report ; aric ; hf ; systolic blood pressure ; antihypertensive medication ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hf ; area under the receiver operating characteristic curve ; auc ; integrated discrimination improvement ; net reclassification improvement ; nri
H-287	-0.4949277639389038	▁c t n t ▁; ▁NT - pro b NP ▁; ▁a RIC ▁ HF ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁anti hy per tensi ve ▁medication ▁; ▁smoking ▁; ▁diabetes ▁; ▁body ▁mass ▁index ▁; ▁corona ry ▁heart ▁disease ▁; ▁heart ▁rate ▁; ▁ HF ▁; ▁receive r ▁operating ▁character istic ▁cur ve ▁; ▁au c ▁; ▁discrimina tion ▁; ▁net ▁re class ification ▁improvement ▁; ▁n RI ▁; ▁model ▁fit
D-287	-0.4949277639389038	ctnt ; NT-probNP ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver operating characteristic curve ; auc ; discrimination ; net reclassification improvement ; nRI ; model fit
P-287	-0.0507 -0.0626 -0.2861 -0.1657 -0.0519 -0.0889 -0.0087 -0.0035 -0.3799 -0.1043 -0.1015 -2.6428 -2.5660 -1.9613 -0.9029 -0.1503 -4.2659 -0.2699 -0.5786 -0.1829 -0.9959 -0.0811 -0.0556 -0.0251 -0.0784 -0.0406 -0.0333 -0.0607 -0.6510 -0.1633 -0.0308 -0.0813 -0.0225 -1.6180 -0.3566 -0.0231 -0.0368 -0.1650 -0.0236 -0.1270 -0.7867 -0.0620 -0.2196 -0.9195 -0.1660 -1.0254 -0.3183 -0.0406 -1.1123 -0.0034 -0.1909 -0.0890 -0.0206 -0.1923 -0.0161 -0.1696 -1.6522 -2.1951 -0.0386 -0.0329 -0.0171 -1.1195 -1.2077 -0.0177 -0.0626 -0.0071 -1.3818 -0.1213 -1.8800 -0.0902 -1.4401 -0.7188 -0.0188 -0.1932 -0.0981
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; patients ; heart failure and reduced ejection fraction ; hf-ref ; new york heart association ; nyha ; functional class ; estimated glomerular filtration rate ; egfr ; serum potassium
H-1222	-0.5014333128929138	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁w RF ▁; ▁EM PHA SIS - HF ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF - re f ▁; ▁New ▁York ▁Heart ▁Association ▁; NY HA ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR ▁; ▁se rum ▁po tas s ium
D-1222	-0.5014333128929138	eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart Association ;NYHA ; glomerular filtration rate ; egFR ; serum potassium
P-1222	-0.3323 -0.4771 -0.2860 -2.1075 -0.0931 -0.0326 -0.3192 -0.0525 -0.0622 -0.8063 -1.7256 -0.1267 -0.8206 -0.2237 -0.1190 -1.8257 -0.0358 -0.5761 -0.0030 -0.0318 -0.0853 -0.9414 -0.3846 -0.0408 -1.6623 -0.0188 -0.0058 -0.5486 -0.0429 -0.0566 -0.0015 -0.0908 -1.4295 -0.0078 -0.3973 -0.2729 -0.0230 -0.5786 -0.2036 -0.4376 -1.0138 -0.1468 -1.5282 -0.6236 -0.1999 -2.0343 -0.0219 -0.1733 -0.0364 -0.0321 -0.8513 -0.1729 -0.0506 -3.4491 -1.1222 -0.2959 -1.8167 -0.1981 -0.0269 -0.2967 -0.1856 -0.0637 -0.3208 -0.1446
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide ; nesiritide ; placebo ; change ; cystatin c ; nesiritide ; placebo
H-81	-1.297425627708435	▁low - dos e ▁nesi riti de ▁; ▁72 - ho ur ▁cum ul ative ▁urin e ▁volume ▁; nesi riti de ▁; ▁figure ▁; ▁cyst atin ▁C ▁; nesi riti de
D-81	-1.297425627708435	low-dose nesiritide ; 72-hour cumulative urine volume ;nesiritide ; figure ; cystatin C ;nesiritide
P-81	-7.8141 -0.1151 -1.9938 -0.5094 -0.6519 -0.0489 -0.0522 -0.1739 -5.9329 -0.1101 -0.0988 -0.0741 -1.5778 -0.0089 -0.0425 -1.6417 -0.2565 -0.7089 -0.3297 -1.0481 -0.2445 -0.0534 -0.3164 -7.7814 -0.2611 -0.9687 -0.2975 -2.4394 -1.0104 -4.1501 -0.2904 -0.0381 -2.8241 -0.2476
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking ; functional capacity ; 6mwt ; physical ; activity ; symptoms ; hospital anxiety and depression scale
H-572	-1.0508840084075928	▁Nordic ▁walking ▁; ▁functional ▁capacity ▁; ▁mw t ▁; ▁physical ▁activity ▁; ▁ depressiv e ▁symptoms ▁; Hospital ▁an xie ty ▁; ▁de pression
D-572	-1.0508840084075928	Nordic walking ; functional capacity ; mwt ; physical activity ; depressive symptoms ;Hospital anxiety ; depression
P-572	-0.8382 -0.7307 -0.2373 -1.0544 -0.4501 -0.2027 -3.1532 -0.1345 -0.1195 -2.3534 -0.0954 -0.2762 -5.7228 -1.1732 -0.1857 -2.0941 -0.3350 -1.0739 -1.5872 -0.0690 -1.0077 -2.2370 -0.2991 -0.0773 -1.5430 -0.2725
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients ; hyperkalemia ; patients ; diabetes ; egfr ; systolic blood pressure ; potassium ; hyperkalemia ; leading ; hospitalization ; hospitalization ; primary outcome ; hospitalization ; hf ; cardiovascular mortality
H-1225	-0.42989999055862427	▁hyper kal emia ▁; ▁w RF ▁; ▁diabetes ▁; ▁e g FR ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁h g ▁; ▁po tas s ium ▁; ▁hyper kal emia ▁; drug ▁dis continu ation ▁; ▁hospital ization ▁; ▁w RF ▁; hospital ization ▁; ▁ HF ▁; ▁cardiovascular ▁mortal ity
D-1225	-0.42989999055862427	hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ; potassium ; hyperkalemia ;drug discontinuation ; hospitalization ; wRF ;hospitalization ; HF ; cardiovascular mortality
P-1225	-0.2613 -0.3807 -0.1610 -0.0881 -0.7545 -0.7119 -0.1213 -0.2552 -0.0486 -0.0569 -1.7475 -1.1135 -0.0429 -2.6041 -0.2267 -0.7713 -0.2333 -1.1267 -0.0451 -0.0838 -0.0435 -0.1456 -0.7936 -0.0926 -0.1052 -0.0603 -0.0510 -0.6451 -0.4654 -0.1502 -0.1703 -1.6396 -0.0762 -0.0002 -0.0333 -0.0937 -1.3360 -0.5840 -0.2169 -0.8436 -0.9472 -0.3151 -1.3171 -0.5030 -0.4498 -0.2240 -0.0463 -0.1617 -0.0461 -0.0139 -0.1242 -0.1256 -0.1298
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf ; biosynthetic enzymes ; lyso-paf acetyltransferase ; lyso-paf-at ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; paf-cpt ; catabolic isoenzymes ; paf-acetylhydrolase ; paf-ah ; lipoprotein-associated phospholipase a2 ; lp-pla2 ; leukocytes
H-1268	-0.47988107800483704	▁PA f ▁; ▁bio syn the tic ▁enzym es ▁; lys o - pa f ▁a ce tyl transfer ase ▁; lys o - pa f - AT ▁; ▁di thi oth rei tol ▁; ▁d t - in sensitiv e ▁CD p ▁cho line ▁; ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁cho line phos pho transfer ase ▁; ▁p f - c p ▁; ▁cata bo lic ▁iso en zy mes ▁; pa f - ace tyl hydro lase ▁; ▁p f - abb ▁; ▁lipo prote in - as soci ated ▁ phos pho lipa se ▁a 2 ▁; ▁l p - PLA 2
D-1268	-0.47988107800483704	PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt-insensitive CDp choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; pf-cp ; catabolic isoenzymes ;paf-acetylhydrolase ; pf-abb ; lipoprotein-associated phospholipase a2 ; lp-PLA2
P-1268	-0.7176 -0.2698 -0.3412 -0.5533 -0.0030 -0.4626 -0.9990 -0.0441 -0.0506 -0.1689 -0.4816 -0.0588 -0.0232 -0.4881 -0.2812 -0.0864 -0.3791 -0.5731 -0.0601 -0.9462 -0.1336 -2.2430 -0.0352 -0.0103 -0.2342 -0.2318 -0.3910 -0.3739 -0.1028 -0.0207 -0.0223 -0.6531 -0.0599 -0.4774 -0.1090 -0.3599 -0.1349 -2.1813 -0.3557 -0.0344 -0.0387 -0.3773 -0.1704 -3.1508 -0.0398 -0.5959 -3.2063 -0.0432 -0.0464 -0.3713 -0.0272 -0.2963 -0.1696 -0.0126 -0.1680 -0.0419 -0.0253 -0.2228 -0.3222 -0.0219 -3.9664 -0.1157 -0.3748 -0.6095 -1.2681 -0.5390 -0.1387 -2.4420 -0.6475 -0.0464 -0.9038 -1.3594 -0.2085 -0.0862 -0.0660 -0.0807 -0.0150 -0.1431 -0.0038 -0.0297 -0.2363 -2.5468 -0.3466 -0.0273 -0.0655 -0.3574 -0.3614 -0.1762 -0.2549 -2.1300 -0.7690 -0.0287 -2.0284 -0.7662 -0.2915 -0.1882 -0.6556 -0.0309 -0.0287 -0.0014 -0.2831 -0.0856 -0.2171 -0.1065 -0.0828 -0.0711 -1.4646 -0.0179 -0.3021 -0.7031 -0.0046 -0.0258 -0.0377 -2.4437 -0.8063 -0.1786
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine ; baseline ; follow-up ; exercise capacity ; mets ; mets ; peak oxygen uptake ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1175	-1.1174577474594116	▁i va bra dine ▁group ▁; ▁base line ▁; ▁follow - up ▁exercise ▁capacity ▁; ▁ MET s ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁exercise - indu ced ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1175	-1.1174577474594116	ivabradine group ; baseline ; follow-up exercise capacity ; METs ; peak oxygen uptake ; exercise-induced ; peak early diastolic mitral flow velocity ; early diastolic mitral annular velocity
P-1175	-0.0243 -0.0127 -0.4123 -0.0174 -1.5306 -0.1532 -1.4059 -0.1122 -1.3698 -0.1726 -0.0275 -0.0058 -0.6792 -1.0572 -0.1496 -5.6901 -0.6188 -0.0316 -0.1413 -3.2575 -0.0145 -1.4904 -0.2030 -0.3408 -0.1448 -4.4179 -0.0405 -0.0064 -0.1958 -1.0873 -5.3666 -0.0184 -1.0934 -0.1205 -0.7736 -0.6274 -1.3679 -0.0977 -5.9897 -2.8899 -0.6882 -0.2160 -3.8685 -0.1942 -1.4235 -1.3363 -1.4718 -0.1352 -5.9196 -0.0045 -0.9367 -0.7495 -0.1271 -0.1156
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate analysis ; chf ; odds ratio ; chest ; hypertension ; genes ; rac2 ; doxorubicin efflux transporter ; abcc2
H-1455	-0.902149498462677	▁CHF ▁; ▁implant s ▁; ▁h t ▁che st ▁radi ation ▁; ▁hyper tension ▁; ▁gene s ▁co ding ▁; ▁ NAD ▁; ▁p h - oxid ase ▁sub un it ▁ RAC 2 ▁; ▁h f ▁; ▁h f ▁; ▁do xor ubi cin ▁ eff lux ▁transporter ▁ABC c 2
D-1455	-0.902149498462677	CHF ; implants ; ht chest radiation ; hypertension ; genes coding ; NAD ; ph-oxidase subunit RAC2 ; hf ; hf ; doxorubicin efflux transporter ABCc2
P-1455	-1.1231 -0.1943 -5.0436 -0.3618 -1.4395 -0.9365 -2.5335 -2.6628 -0.1222 -0.0490 -0.0851 -0.1138 -0.0325 -0.0725 -0.1450 -3.0072 -0.0279 -0.3361 -0.2802 -0.6098 -0.5005 -0.0169 -3.5470 -3.0604 -3.1492 -0.4867 -0.0451 -1.9347 -0.1506 -0.2143 -0.1310 -0.7635 -0.1694 -0.1914 -0.1216 -0.2065 -3.0974 -0.1213 -0.3607 -3.0936 -0.1198 -1.4828 -0.2073 -0.0390 -0.1878 -0.2075 -0.0784 -0.3597 -0.7007 -1.7453 -1.0785 -0.3890 -1.2182 -0.3634
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline ; follow-up ; nyha classification ; patients ; patient ; change ; patient ; quality of life ; duke activity status index ; kansas city cardiomyopathy questionnaire ; 6 min walk test
H-1958	-0.9575996398925781	▁NY ha ▁classifica tion ▁; ▁class ▁III ▁; ▁class ▁II ▁; ▁implant ation ▁Status ▁; ▁Duke ▁Activ ity ▁Status ▁Index ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁walk ▁test ▁distance
D-1958	-0.9575996398925781	NYha classification ; class III ; class II ; implantation Status ; Duke Activity Status Index ; Kansas City Cardiomyopathy Questionnaire ; walk test distance
P-1958	-0.7313 -0.5511 -0.4782 -0.0304 -0.1996 -1.4367 -1.2697 -0.6090 -0.9124 -1.2486 -0.1498 -6.3510 -1.2824 -1.3758 -1.5720 -0.5516 -1.2418 -0.0566 -0.2095 -1.7847 -0.1290 -0.5493 -0.3738 -0.6079 -0.1296 -0.0923 -0.7230 -0.0753 -2.0677 -0.0037 -0.3651 -3.9409 -1.2015 -0.7706 -1.1250 -0.2768
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo ; dopamine ; dopamine ; placebo ; change ; cystatin c ; dopamine ; placebo
H-80	-1.2898364067077637	▁low - dos e ▁dop amine ▁; ▁72 - ho ur ▁cum ul ative ▁urin e ▁volume ▁; dop amine ▁; ▁ml l ▁; ▁cyst atin ▁c ▁level ▁; dop amine
D-80	-1.2898364067077637	low-dose dopamine ; 72-hour cumulative urine volume ;dopamine ; mll ; cystatin c level ;dopamine
P-80	-5.5699 -0.0597 -0.5677 -0.4412 -0.4401 -0.3383 -0.1235 -4.3025 -0.1001 -0.0890 -0.0693 -1.4954 -0.0154 -0.0658 -1.5596 -0.2813 -0.6020 -0.1684 -1.3340 -0.6854 -0.1648 -4.9774 -3.0872 -0.0708 -2.1466 -0.5409 -2.3327 -3.3196 -0.2119 -3.3793 -0.6286 -3.2005 -0.1956
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard ratio ; confidence interval ; baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; new york heart association class ; atrial fibrillation ; congestive hf ; mortality
H-66	-0.6688828468322754	▁implant ation ▁; ▁base line ▁glo mer ular ▁filtr ation ▁rate ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i CD ▁shock s ▁; ▁New ▁York ▁Heart ▁Association ▁class ▁; ▁at rial ▁fi bril lation ▁; ▁con ges tive ▁ HF
D-66	-0.6688828468322754	implantation ; baseline glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; ventricular ejection fraction ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart Association class ; atrial fibrillation ; congestive HF
P-66	-7.2808 -0.0798 -0.8875 -3.0404 -0.0895 -0.3563 -0.0187 -0.1331 -0.2595 -0.0345 -2.5511 -0.2006 -5.6693 -0.6518 -0.1613 -0.0239 -0.0085 -0.1632 -1.0695 -0.1615 -0.3100 -0.0728 -2.1753 -1.5084 -0.2290 -0.2296 -0.1807 -0.1345 -0.5117 -0.0022 -0.2070 -1.5471 -0.3302 -0.5079 -0.2093 -0.4852 -0.3789 -0.8400 -0.1707 -2.5079 -0.0381 -2.0853 -0.2674 -0.1376 -0.2229 -0.2066 -0.7877 -0.0036 -0.2502 -1.6485 -1.0761 -0.3036 -0.0369 -0.0920 -1.3064 -0.4678 -0.3927 -1.0572 -0.5621 -0.1106 -0.0188 -0.2952 -0.1737 -0.0326 -0.0543 -0.1081 -0.3911 -0.0493 -0.0520 -0.1462 -0.0641 -0.6842 -0.3262
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable analysis ; end point ; peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
H-1761	-0.7586742639541626	▁pe ak ▁oxygen ▁up take ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁ventilator y ▁efficiency ▁s lope ▁; ▁hem o glob in ▁; ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁renal ▁function ▁; ▁renal ▁disease ▁; ▁so dium
D-1761	-0.7586742639541626	peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; ventricular ejection fraction ; renal function ; renal disease ; sodium
P-1761	-5.2786 -0.0301 -0.2406 -0.2334 -0.5530 -0.0940 -0.8290 -0.0146 -0.1272 -1.0916 -0.4985 -0.1544 -0.4448 -0.3351 -0.2712 -0.1849 -0.0355 -0.1107 -1.4495 -0.1394 -0.0780 -1.1197 -0.1757 -1.5088 -1.4132 -0.1977 -0.1003 -0.2241 -0.1924 -0.3031 -0.0012 -0.1462 -0.7406 -4.7378 -0.1654 -1.8920 -3.8252 -0.5820 -0.7770 -0.3172 -0.9994 -0.2512
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute walked distance ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; beck depression inventory ; flow-mediated dilatation ; fes ; placebo ; b-type natriuretic peptide ; mitral
H-1331	-0.5430463552474976	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁z ung ▁; ▁flow - media ted ▁di la tation ▁diameter ▁; ▁F es ▁; ▁na tri ure tic ▁pe pti de ▁; ▁mit ral ▁e / e ▁; ▁wa ve ▁ratio
D-1331	-0.5430463552474976	Kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; Fes ; natriuretic peptide ; mitral e/e ; wave ratio
P-1331	-0.1414 -0.4668 -1.1620 -0.1031 -0.1262 -0.3350 -0.0544 -3.2057 -0.0032 -0.7107 -0.1939 -0.4027 -0.6989 -0.2036 -0.0191 -0.0791 -0.9360 -0.0025 -0.1345 -0.1760 -0.3121 -0.0362 -0.3706 -0.3383 -0.0142 -0.1296 -0.5343 -0.3209 -0.1065 -2.1128 -0.0154 -0.1912 -0.9797 -0.0399 -0.2259 -0.0138 -0.1066 -0.0987 -2.6868 -0.4943 -0.3734 -2.3377 -0.0476 -0.0351 -1.0186 -0.1795 -0.0456 -0.0268 -0.2257 -3.2495 -0.1095 -1.5857 -1.1353 -0.0245 -2.7326 -0.6650 -0.0171 -0.0266 -0.2597 -0.2051
2021-01-18 16:53:06 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-18 16:53:06 | INFO | fairseq_cli.generate | Translated 2,024 sentences (35,578 tokens) in 182.2s (11.11 sentences/s, 195.29 tokens/s)
2021-01-18 16:53:06 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 44.63, 67.6/53.5/44.8/37.6 (BP=0.898, ratio=0.903, syslen=35578, reflen=39387)
